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Published: 22 August 2018Table 1 (abstract O01). The top 8 variables in the final prediction
model (full model uses 18 variables)
Variable Adjusted Hazard Ratio for time to
remission on medications (95% CI)
P-value
Physician global (0-10) 0.933 (0.888-0.981) 0.005
Weeks from onset to diagnosis 0.997 (0.995-0.999) 0.003
RF+ Polyarthritis 0.383 (0.150-0.978) 0.041
Systemic arthritis 0.550 (0.308-0.983) 0.039
Subtalar joint involved 0.670 (0.482-0.931) 0.015
Symmetric joints involved 0.777 (0.616-0.979) 0.029
Pain intensity (0-10) 0.927 (0.874-0.983) 0.010
No. enthesitis sites 0.960 (0.921-1.001) 0.050Updates in JIA management
O01
PREDICTING WHICH CHILDREN WITH JUVENILE IDIOPATHIC
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Introduction: Accurate estimates of the likelihood of attaining early
remission with conventional treatment escalation may help target
aggressive treatment to children with juvenile idiopathic arthritis
(JIA) who have a low chance of remission.
Objectives: To develop a clinical prediction tool to estimate the
chance of early clinical remission with conventional treatment for
each child at the time of JIA diagnosis.
Methods: Prediction models were developed using data from 1074
subjects in the Research in Arthritis in Canadian Children emphasiz-
ing Outcomes (ReACCh-Out) cohort diagnosed 2005-2010. Treatment
was compatible with the 2011 recommendations of the American
College of Rheumatology. The predicted outcome was clinical in-
active disease for 6 or more months starting within one year of the
diagnosis in patients who did not receive early biologic agents or
triple DMARD therapy. Models were developed in 200 random splits
of 75% of the cohort, and tested on the remaining 25% of subjects,
calculating expected and observed frequencies of remission and c-
index values.
Results: A Cox-logistic model combining 18 clinical variables at a median
of 2 days after diagnosis had a c-index of 0.69 (95%CI: 0.67-0.71) and
performed better than JIA category alone (0.59, 0.56-0.63). Table 1 lists
the top 8 variables included in the final model. Using the model, an on-
line calculator (https://andrew-j-henrey.shinyapps.io/JIA_Remission_Calc/)© The Author(s). 2018 Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zeproduces estimates of the chance of remission for each child with JIA at
diagnosis. Children in the lowest decile of probability of remission accord-
ing to the model had a 20% chance of remission and 21% of them remit-
ted; children in the highest decile had a 69% chance of remission and
73% remitted. Compared to 5% of subjects identified by JIA category
alone, the model identified 14% of the cohort as having a low chance of
remission (<0.25 probability of remission), of whom 77% failed to attain
remission within one year of diagnosis.
Conclusion: Although the model did not meet our a priori perform-
ance threshold (c-index>0.70), it identified three times more subjects
with low chance of remission than JIA category alone, and it may
serve as a benchmark for judging the value added by future
biomarkers.
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Introduction: Immune cells are constantly confronted with intracellu-
lar and extracellular radical oxygen species (ROS) under steady-state
and even more under inflammatory and pathogenic conditions. To
investigate the effects of oxidative stress and ROS molecules in regu-
latory T cells (Tregs), we deciphered the role of Nuclear factorle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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found to be more resistant to ROS than effector T cells and activated
Treg cells show higher expression of genes, which belong to the Nrf2-
mediated oxidative stress response compared to activated ef-
fector T cells.
Objectives: To analyze the specific role of Nrf2 in Tregs.
Methods: To define the role of Nrf2 in Tregs, we generated mice with a
knock out of Keap in all hematopoietic cells (VAVCRE-Keapfl/fl) with a Treg
specific knockout of Keap 1, which is the constitutive binding partner of
Nrf2 (Foxp3CRE-Keap1fl/fl) and characterized the mice using flow cytome-
try, T cell suppression assays and metabolomics.
Results: While mice bearing a constitutive activation of Nrf2 activa-
tion in all immune cells (VavcreKeapfl/fl) accumulate high percentages
of Foxp3-positive Tregs in the spleen, lymph nodes and thymus, their
suppressive capacity seems to be defective. Interestingly, a Treg specific
activation of Nrf2 (Foxp3creKeapfl/fl) results in an auto-inflammatory
phenotype with immune cell infiltrates in the lungs, enhanced effector
T cell activation and high percentages of IFN-γ producing effector T
cells. Moreover, the constitutive Nrf2 activation in Tregs increases their
in-vitro proliferation, glucose uptake and mTOR activity, while the differ-
entiation and Foxp3 expression in Tregs declines
Conclusion: We demonstrate for the first time that constitutive Nrf2
activation specific to Tregs affects Treg lineage stability and metabol-
ism and might thereby induce an auto-inflammatory phenotype.
Our results therefore may have implications for diseases associated
with oxidative stress and dysregulated Treg responses.
Disclosure of Interest
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Introduction: An atlas of the developing immune system is key to
understanding its normal maturation and identifying disease-
associated cell subsets. The availability of high dimensional mass cy-
tometry, in comparison to traditional oligo-dimensional approach
such as fluorescence-based flow cytometry, provides an opportunity
for the creation of this reference. However to date, the power avail-
able from these big data has not been fully harnessed due to the ab-
sence of clinically relevant and standardised datasets. This results in
issues of fragmentation by focusing on individual cell subsets and
lack the ability to transverse the whole developmental gradient from
neonatal to adult age. There is a critical unmet need for standardised
datasets depicting at single cell level and with high dimensionality
the entire human immune system. These limitations hamper transla-
tional and clinical research.
Objectives: To address this need, we aim to construct a mass cytome-
try based immune atlas from healthy peripheral blood mononuclear
cells (PBMC) samples ranging from cord blood to adult age and make
this dataset available to the research community via an interactive web
portal to enable its mining and comparison with diseased dataset.
Methods: The mass cytometry data from 113 healthy individuals
(cord blood, newborn to adult) using 63 immune markers encom-
passing the major immune lineages were obtained. Quality control
was performed before dimensional reduction and clustering toidentify the cell subsets using our in-house analysis and visualisation
pipeline. Their frequencies across the ages were presented as 3-D fre-
quency histograms to create the immune landscape. This database
and the analytic pipeline were incorporated into a web-based portal
allowing users to interact and upload their own data for comparison.
Results: Here, we described EPIC with examples of its potential by
exploring the evolution of some representative immune subsets over
the full gradient of ages. Three developmental trajectories made up
the healthy immune landscape with the most distinct being an in-
crease or decrease in the cell populations with age. The last trajec-
tory constituted an increase in population size in early childhood
followed by a region of levelling. There was a distinct segregation of
the naive T cell subset enriched in the cord blood/newborn period
with the memory T cell subset enriched in adulthood. The naive IL8+
and TNFα+ CD4+ T cells were prominent peaks in the landscape and
were found in higher frequency in the cord blood/newborn period.
In contrast, the memory IFNɣ+ and TNFα+ CD4+ T cells were
enriched in adulthood.
For specific cell subsets, transition developmental milestones were
observed in the TNFα+ CD4+ T cells where the size of its memory
subset would exceed its naive subset at 8 year old. There was a sig-
nificant reduction and increase with age in the frequency of the
naive and memory TNFα+ CD4+ T cells with a Spearman’s correlation
coefficient, rho, of -0.4662 and 0.4164 respectively (p<0.0001). A simi-
lar intersection was present for the naive and memory regulatory T
cell (CD4+, CD25+, Foxp3+, CD152+) subsets at 14 year old with a
rho of -0.537 and 0.5034 respectively (p<0.0001).
Conclusion: A holistic description of the developing immunome was
obtained with key developmental milestones in the T cell compart-
ment identified. This atlas has the translational potential of helping
us define the stage of immune maturity and identify the pathological
cell subset in both paediatric and adult immune mediated diseases
by the direct comparison with this reference atlas using the web-
based portal that will be made freely available.
Disclosure of Interest
None Declared
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Introduction: Provisional Eurofever evidence-based classification cri-
teria for the 4 inherited recurrent fever (FMF, CAPS, TRAPS, MKD) have
been published and other diagnostic criteria are available in the litera-
ture for FMF, CAPS and PFAPA. Despite a significant increase of accur-
acy of the recent Eurofever classification criteria in respect to the
previous ones, none of them combine the clinical criteria with the re-
sults of molecular analysis. This is a major limitation considering the
fact that the genetic analysis might be considered per se
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of a confirmatory genotype. Recently new evidence-based classifi-
cation criteria for hereditary recurrent fevers (HRF) and PFAPA have
been identified during a Consensus Conference held in Genoa in
March 2017. For each of the monogenic recurrent fever new classi-
fication criteria based on genetic and clinical variables were devel-
oped. For PFAPA novel classification criteria based on positive and
negative clinical variables were also approved by experts (Gattorno
et al. PRES 2017, submitted).
Objectives: To evaluate the performance of the final set of classifi-
cation criteria, in discriminating patients with the different HRF and
PFAPA in a separate set of real patients coming from the Eurofever
Registry and to compare their accuracy with respect to existing
criteria.
Methods: We selected those patients with recurrent HPF coming
from the Eurofever Registry excluding patients belonging to the ori-
ginal dataset of 360 patients used for the development of the criteria
themselves. Patients with inherited periodic fever (TRAPS, FMF, MKD
and CAPS), PFAPA and undefined periodic fevers were considered
and classified according to the indication of each center, without any
process of validation by expert. Sensitivity, specificity, accuracy, nega-
tive and positive predictive values and AUC-ROC of the new criteria
were calculated.
Results: A total of 1018 new patients coming from the Eurofever
Registry were included. The performance of the criteria coming
from the Consensus conference in comparison with the criteria of
the literature is listed in Table 1. Overall, their performance was su-
perior (accuracy ranging from 0.81 to 0.98) to the already pub-
lished literature’s criteria (accuracy 0.56-0.94) with a very high
specificity and a variable sensitivity. Most of the patients not clas-
sified with the new criteria were negative for genetic analysis or
carriers of low-penetrance mutations with an inconsistent clinical
phenotype.
Conclusion: The validation of the new Eurofever classification criteria
in a large group of unselected patients coming from the registry con-
firms their high specificity and overall better performance in com-
parison to other criteria available in the literature. It is recommended
to use them as classification rather that diagnostic criteria, for clinical
trials and pathogenic studies.
Disclosure of Interest
None DeclaredTable 1 (abstract O04). See text for description
Sensitivity Specificity Accuracy AUC
New CAPS criteria (clinical + genetics) 0.72 1 0.96 0.86
Kuemmerle CAPS criteria 0.88 0.82 0.83 0.85
New FMF criteria (clinical + genetics) 0.89 1 0.96 0.94
Livneh criteria 0,9 0,58 0,7 0,74
Tel Hashomer 0,59 0,95 0,64 0,77
Pediatric FMF criteria 0,61 0,94 0,83 0,77
New MKD criteria (clinical + genetics) 0.74 1 0.98 0.87
Clinical guideline 0.77 0.53 0.56 0.65
New TRAPS criteria (clinical + genetics) 0.74 1 0.97 0.87
New PFAPA clinical criteria 0.66 0.97 0.9 0.82
Modified Marshall criteria 0.46 0.91 0.81 0.69O05
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Introduction: AIDAI is a novel and unique, validated patient (pt)-re-
ported assessment tool to evaluate disease activity in familial Medi-
terranean fever (FMF), hyper-IgD syndrome/mevalonate kinase
deficiency (HIDS/MKD) and TNF receptor-associated periodic syn-
drome (TRAPS).1
Objectives: To perform an external validation of AIDAI, we calculated
scores over 40 weeks (wks) of canakinumab (CAN) treatment in pts
enrolled into the CLUSTER trial and assessed correlation between
AIDAI and disease/response characteristics.
Methods: CLUSTER consisted of one cohort per disease (crFMF, HIDS/
MKD and TRAPS).2 AIDAI was calculated as the sum of 12 items
(Yes=1; No=0)1 for 30 consecutive days. AIDAI score was calculated if
the first score was recorded before ≥29 days. Missing items beyond
last evaluable measurement were imputed by last observation car-
ried forward (LOCF). Inactive disease (ID) was defined as AIDAI score
<9. Correlation analysis of AIDAI with Sheehan disability score (SDS),
child health questionnaire–psychological/physical (CHQ–PsCS/PCS),
physician global assessment (PGA), short form 12–physical/mental
component summaries (SF12–PCS/MCS), C-reactive protein (CRP) and
serum amyloid A (SAA) were performed. Significance was set at
p<0.05.
Results: Overall, 167 (crFMF: N=59; HIDS/MKD: N=66; TRAPS: N=42)
pts were randomized to CAN 150 mg or placebo every 4 wks. Me-
dian AIDAI scores in all 3 cohorts decreased from baseline (BL) to
Wk 16 (crFMF: 22.5 to 5.0; HIDS/MKD: 41.5 to 12.0; TRAPS: 89.0 to
13.0) and through Wk 40 (crFMF: 1.0; HIDS/MKD: 5.0; TRAPS: 20.5).
In all 3 cohorts, the proportion of pts with ID (AIDAI score <9) was
higher at Wk 40 versus BL (crFMF: 69.5% vs 5.1%; HIDS/MKD:
56.1% vs 6.1%; TRAPS: 42.9% vs 2.4%). AIDAI at Wk 40 correlated
significantly with: SDS in all 3 cohorts; CHQ-PsCS in crFMF and
HIDS/MKD; CHQ-PCS in crFMF; PGA in TRAPS; SF12–PCS in crFMF
and TRAPS. SF12-MCS, CRP and SAA did not correlate with AIDAI
(Table 1).
Conclusion: AIDAI scores decreased markedly over 40 weeks of
treatment with canakinumab in crFMF, HIDS/MKD and TRAPS, with
a relevant percentage of patients having inactive disease score.
AIDAI improvements at Week 40 correlated with patient- and
physician-driven evaluations. AIDAI is a validated patient-reported
tool to assess disease activity and appears to have good sensitivity
to change to be used in comparative trials. Patient’s experience on
disease activity does not strictly correlate with CRP and SAA, as
these reflect more closely biological inflammation than clinical
symptoms.
1Piram M, et al. Ann Rheum Dis. 2014;73:2168-73. 2De Benedetti F,
et al. N Engl J Med. 2018 (in press).
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variables at Week 40
Correlation coefficient (95% CI)
SDS CHQ-PsCS CHQ PCS PGA SF12-PCS SF12-MCS SAA CRP
crFMF 0.54*
(0.20;
0.76)
-0.83*
(-0.95;
-0.49)
-0.67*
(-0.90;
-0.16)
0.24
(-0.08;
0.51)
-0.47*
(-0.77;
0.0)
-0.43
(-0.75;
0.05)
-0.07
(-0.38;
0.25)
-0.07
(-0.38;
0.24)
HIDS/
MKD
0.39*
(0.05;
0.65)
-0.47*
(-0.76;
-0.03)
-0.32
(-0.67;
0.14)
0.24
(-0.03;
0.47)
-0.09
(-0.71;
0.61)
-0.19
(-0.76;
0.54)
0.06
(-0.22;
0.32)
0.08
(-0.19;
0.34)
TRAPS 0.41*
(0.02;
0.69)
-0.07
(-0.62;
0.53)
-0.02
(-0.59;
0.56)
0.37*
(0.02;
0.63)
-0.60*
(-0.86;
-0.11)
-0.13
(-0.62;
0.43)
-0.17
(-0.50;
0.20)
-0.18
(-0.51;
0.18)
*p<0.05
Table 1 (abstract O06). See text for description
MRI characteristics Kappa values (95% CI) of
tibial lesions (n=100)
Kappa values (95% CI) of
femoral lesions (n=100)
Max signal intensity 0.46 (0.44,0.48) 0.48 (0.46,0.5)
Size of proximal epiphyseal
lesion
0.46 (0.44,0.49) 0.34 (0.32,0.36)
Size of proximal metaphyseal
lesion
0.54 (0.52,0.55) 0.28 (0.25,0.3)
Size of diaphyseal lesion 0.46 (0.44,0.48) 0.44 (0.42,0.46)
Size of distal metaphyseal
lesion
0.58 (0.57,0.6) 0.47 (0.46,0.49)
Size of distal epiphyseal
lesion
0.48 (0.45,0.5) 0.49 (0.46,0.51)
Soft tissue inflammation 0.6 (0.57,0.63) 0.63 (0.6,0.65)O06
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Introduction: CNO is an inflammatory bone disease that can result in
bone destruction, persistent bone pain and pathological fractures.
For clinical and research purposes, serial MRI exams are needed to
determine the objective response to treatment. A previously devel-
oped MRI scoring tool for CNO in a single center showed sensitivity
to detect imaging change after aggressive treatment.
Objectives: To use a nominal group technique to develop a practical
and consensus-based MRI scoring tool for clinical and research use inCNO. Furthermore, inter-rater reliability were evaluated using whole
body (WB) MRI from children with CNO.
Methods: Eleven pediatric radiologists, each with at least 5 years of
experience reading musculoskeletal MRI from seven different
pediatric hospitals in North America and Europe, discussed defini-
tions and grading of signal intensity, extent of signal abnormality
within bone marrow and surrounding tissue, physis damage and
vertebral fracture on MRI through monthly conference calls and an
in-person meeting (Seattle, July 2017). Nine sets of whole body
MRIs were used as a pilot reading session at the conference that
demonstrated greater than 70% of agreement among the radiolo-
gist attendees. Fifty sets of pre-existing WB MRI scans between Jan
2013 and August 2016 from children with CNO at the University of
Iowa Children’s Hospital were anonymized and used for an inter-
rater reliability study. Inter-rater agreement of presence of abnor-
mal signal and severity were assessed using Fleiss kappa analysis.
Results: Signal intensity was rated as absent, < fluid signal or similar
to fluid signal within bone marrow. Extent of abnormal signal inten-
sity within bone or surrounding tissues were scored according to
the relative affected proportion. Long bones were divided into
proximal epiphysis, proximal metaphysis, diaphysis, distal metaphy-
sis and distal epiphysis. Complex bony regions such as the pelvis
were divided into easily identifiable anatomical subareas. The
agreement among 11 radiologists in readings of femur and tibia
were shown in Table 1. There was moderate to substantial agree-
ment (0.44-0.63) in all parameters except the sizes of femoral prox-
imal epiphyseal and femoral proximal metaphyseal lesions (0.28-
0.34). There were 38 tibias and 30 femurs identified as active in-
flammation by at least 9 of 11 radiologists. Data from other bones
are being analyzed.
Conclusion: A comprehensive standardized scoring tool for MRI in
children with CNO was developed. There was moderate to substan-
tial agreements among radiologists in majority of parameters of
femur and tibia. If proven reproducible, this tool can be validated in
a prospective study and will become a key element of disease activity
assessment in CNO.
This study was funded by CARRA-AF small grant.
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Table 1 (abstract O07). See text for description
Domains Cronbach’s items
Disease impact on:
- Social 0.42 13
- Economic 0.43 13
- Familiar 0.19 4
- Relationship 0.26 2
II. Disease knowledge 0.28 8
III. Discrimination 0.68 4
IV. Use of social networks 0.55 10
V. Future 0.31 2
VI. Religion 0.004 2
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Introduction: Most common pediatric rheumatic disease (PRD) is ju-
venile idiopathic arthritis (JIA), this influence affects quality of life
(QoL) of children and families. Caregiver is a cornerstone to achieve
disease control however, there are no information on how this condi-
tions affects them; neither a tool to assess this impact was reported.
Objectives: To develop and validate psycho-social impact and finan-
cial burden questionnaire in caregivers of JIA patients (CAREGIVERS
Questionnaire).
Methods: We development and validate the CAREGIVERS Question-
naire in two phases. Phase 1.Design the questionnaire based in non-
systematic review and qualitative study: First version (1stQ), explora-
tory and open questions, was constructed based on literature review
by an expert group (pediatric rheumatologists and methodologist). A
qualitative study of pragmatic type was conducted on 15 caregivers
to identify areas affected after JIA diagnosis. Interviews were
reviewed using thematic analysis with Atlas-ti software. Question-
naire was adapted based on qualitative study and second version
(2ndQ) was tested on 10 participants to evaluate comprehensibility.
Changes in structure were made after pediatric rheumatologists, an-
thropologist/methodologist, psychologist, and pedagogue analyzed
the answers (3rdQ).
Phase 2. Validation of questionnaire. 3rdQ was evaluated for face,
content, reliability, internal consistency, convergent, and divergent
validity. Construct validity was tested for anxiety/depression (Beck),
coping strategies (Reyes-Lagunes), QoL (EuroQol), and social and eco-
nomic factors (Socioeconomic burden). Correlation matrix to assess
the construct validity using Cohen’s kappa, and internal consistency
tests using Cronbach’s alpha were performed.
Results: Qualitative study (1stQ) identified topics like socioeco-
nomic burden, family interactions, alternative medicine, religion, in-
formation access, and prognosis. 2ndQ was conformed by 75
items. After pilot study, six items were confuse and modified, 11
were eliminated for being redundant. Items were organized in five
domains to develop 3rdQ: disease impact (social, economic, family
and relationship), knowledge, future, alternative medicine, and reli-
gion (13, 27, 2, 2, and 2 items, respectively). Validity analysis included
32 participants (93% women). Mean age 39 (SD 8.5) years, mean
EuroQol VAS 82, minimal depression in 90%. Socioeconomic tool
demonstrated family income above 14 minimum wages (65 USD) in
68% and 59% have remunerated job. Reyes-Lagunes describes “life
coping” with emotional-negative strategies in 31 caregivers and
straight strategies in “children´s health coping” in 100%. Finally, in
3rdQ, 22% felt sadness at diagnosis, 84% change initial feeling and
currently 43% are relief. Sixty two percent mention disease has influ-
enced in their financial situation and 72% feel anxiety about their
children future. Statistical analysis show adequate inter-item reliabil-
ity in all domains except for religion, consequently items were
adapted to create new dimensions (Table 1). Correlation matrix
shown good results in all domains, except for social and economic
due to redundant items. After changes, CAREGIVERS Questionnaire
was created.
Conclusion: We design CAREGIVERS Questionnaire, a specific multidi-
mensional tool to assess burden in caregivers of patients with PRD,
and validated in JIA. Further efforts will be performed to validated in
other PRD.
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Introduction: Systemic onset JIA (sJIA) is a multifactorial autoinflam-
matory disease. Historically, the prognosis of sJIA was very poor. The
use of interleukin (IL)-1 and IL-6 blockade improved outcome, but
still most studies report inactive disease in only 30-50% of patients
within one year. It is hypothesized that innate immune activation is
most prominent in the early phase of sJIA. To make use of this ‘win-
dow of opportunity’, we started a prospective cohort with recombin-
ant IL-1 receptor antagonist (rIL-1RA) as first-line monotherapy in
new-onset sJIA patients (Vastert et al. AR 2014).
Objectives: To analyse the long-term efficacy of this therapeutic
strategy and to separately analyse a subset of sJIA patients without
arthritis at disease onset.
Methods: In this single centre, prospective cohort study, new-onset
sJIA patients with an unsatisfactory response to NSAIDs received rIL-
1RA 2mg/kg. Inactive disease (ID) was defined according to the Wal-
lace criteria. In patients reaching ID, rIL-1RA was tapered after 3
months and subsequently stopped. In patients with an incomplete
response to rIL-1RA, our protocol directed to increase rIL-1RA dose,
add prednisolone or switch to alternative therapy. Clinical data in-
cluding damage (JADI) and patient reported outcomes (CHAQ and/or
JAMAR) were completed in a standardized way. Cytokine profiling
was performed using Luminex multiplex immunoassay.
Results: Forty-two patients were analysed, with a median follow-up of
5.8 years. At 3 months, 30/42 patients (71%) had ID with rIL-1RA mono-
therapy and another 6 had ID with rIL-1RA and prednisone. At one year,
32 patients (76%) had ID, of which 22 (52%) were off medication.
Twelve patients had no arthritis at onset; 4 of them developed arth-
ritis during flares. The clinical phenotype, inflammatory parameters
and cytokine profile of patients without arthritis at onset was similar
to patients with arthritis. Hence, after extensive ancillary investiga-
tions to exclude other diseases, these non-arthritic patients also re-
ceived rIL-1RA as first-line therapy. After 3 months, 11/12 non-
arthritic patients had ID (10 on rIL-1RA monotherapy), at 1 year all 12
had ID (8/12 off medication).
Table 1 (abstract O09). Comparison of clinical parameters and SLICC-
SDI scores following MMF vs CYC treatment
Time post
biopsy*
Outcome
parameter
MMF induction CYC induction p
10-14 Renal BILAG score A=1, B=5, C=3,
D=18
A=1, B=3, C=2,
D=8
1.00
UACR** 13[4-42] 21[3–56] 0.99
Serum creatinine 59[51-69] 62[50-73] 0.32
ESR 12[5–21] 20[4–49] 0.62
dsDNA 44[24-95] 20[6-440] 0.84
C3 0.98[0.81-1.18] 1.04[0.92–1.34] 0.20
Patient global 4.5[0–9.3] 3.0[0.5–52.0] 0.98
Physician global 7.0[1.3–14.0] 9.9[3.0–24.0] 0.66
13*** SLICC SDI 0[0-1] 0[0–2.5] 0.67
*Months. **Urinary albumin/creatinine ratio. ***SLICC SDI score after a median
of 13 months post renal biopsy (range 10-18)
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95% of all patients had ID and 72% had ID off medication at 3 and 5
years follow-up, only 5% reported articular damage and 5% extra-
articular damage, no patient developed growth failure and only one
developed obesity during follow-up. Moreover, around 60% of pa-
tients reported complete absence of pain and disease, no limitations
in daily life and the highest possible score on well-being. One patient
died due to MAS. In total, 24 patients (57%) never used other medi-
cation besides rIL-1RA and NSAIDs and only 14 patients (33%) used
glucocorticoids.
Patients who achieved ID at one year were younger and had a sig-
nificantly shorter disease duration, less active joints and higher neu-
trophil and leukocyte count before start of rIL-1RA. Multivariate
analysis confirmed high neutrophil count as a significant predictor
for ID at one year. Furthermore, ID at one year was highly associated
with a good response at 1 month.
Conclusion: First-line, short course monotherapy with rIL-1RA is a
highly efficacious strategy to induce and sustain inactive disease and
to prevent disease- and glucocorticoid-related damage. Our data on
sJIA patients without arthritis plea for leaving out arthritis as a pre-
requisite criterion in future disease classification criteria.
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Introduction: Treatment of proliferative class III/IV lupus nephritis
(LN) in children is largely based upon adult studies. The largest study
demonstrated a similar renal response rate with mycophenolate mo-
fetil (MMF) or cyclophosphamide (CYC) induction treatment in adult
patients with LN [1]. A further smaller study showed MMF to be more
effective than CYC [2]. In both, MMF had a better safety profile [1,2].
Objectives: Within a predominantly Caucasian JSLE cohort, to com-
pare efficacy of MMF vs. CYC in patients with LN, monitoring 1) re-
sponse to treatment, 2) damage accrual, 3) time to achievement of
inactive LN, and 4) time to subsequent LN flare, following MMF or
CYC LN induction treatments.
Methods: Participants of the UK JSLE Cohort Study (2006-2018), <18
years at the time of diagnosis, with ³4 ACR criteria for SLE, were eli-
gible for inclusion if they had ISN/RPS class III or IV LN. Median values
and interquartile ranges quoted. Mann-Whitney U tests for continu-
ous data and Fishers exact test for categorical data.
Results: 69/411 UK JSLE Cohort Study patients met the inclusion cri-
teria; 18/61 were excluded due to insufficient follow-up. 34/51 (67%)
received MMF (13/34 (38%) class III, 21/34 (62%) class IV LN), and 17/
51 (33%) received CYC (8/17 (47%) class III, 9/17 (53%) class IV LN).
No statistically significant differences were identified between treat-
ment groups at 4-8, 10-14 months post renal biopsy, and last follow-
up, in terms of the renal-BILAG score, urine albumin/creatinine ratio,
serum creatinine, ESR, anti-dsDNA antibody, C3 levels and patient/
physician global scores (all p>0.05, see Table 1). Standardised Dam-
age Index (SLICC-SDI) scores did not differ between treatment groups
at a median of 13 months, or last follow-up (all p>0.05, see Table 1).
Inactive LN, following the definition of renal BILAG, was attained at
262 days [141–390] after MMF treatment, and 151 days [117-305] fol-
lowing CYC (p=0.17). Time to subsequent renal flare did not differ;
451 days [157–1266] for MMF, and 343 days [198–635] for CYC
(p=0.47)).Conclusion: This is the largest study to date investigating induction
treatments for proliferative LN in children. In Caucasian JSLE popula-
tions, MMF and CYC may be comparably efficacious in regards to
treatment response, damage accrual, and time to next flare. Remis-
sion may be reached quicker in patients treated with CYC. Future
prospective comparison is warranted to inform LN treatment, given
CYC’s poor safety profile.
References
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2. Ginzler E, et al. NEJM 2005, 353:2219-28.
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Introduction: Long-standing debate continues on the factors and po-
tential etiological agents of vasculitides and rheumatic diseases, such
as Kawasaki disease (KD). Together with the genetic predisposition to
suffer the condition, hitherto undefined environmental factors have
been suggested to contribute to the onset of autoimmune vasculitis
in susceptible individuals. A combined approach integrating research
on atmospheric circulation and wind dynamics with a time-series
study on Kawasaki disease epidemiology in Japan and the US led to
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 7 of 243a publication firmly pointing to the role of winds and large-scale cir-
culation in the propagation of the potential aetiologic agent of this
disease (Rodó et al., 2011).
Objectives: The hypothesis of a windborne role in the generation of
KD etiology is further tested in this study for a series of other world
locations where the disease is also prevalent and along the suspicion
that the interaction between bioaerosols, the air chemistry and pre-
disposed or genetically susceptible patients might similarly be associ-
ated with KD incidence there. Recovery of land source regions is
attempted with the aim of exploring similarities/differences with
those found for Japan. Exploration of the phenological status of
vegetation in each of those region is performed to seek further
mechanistic explanations on the epidemiological links to KD.
Methods: In this study, a retrospective time series analysis of histor-
ical daily hospital admissions of KD and reconstruction of air move-
ments and source regions is presented for several locations in all
continents (US and Canada, Chile, France, the United Kingdom, Cata-
lonia, South Korea, India and Thailand). The FLEXPART v9 atmos-
pheric particle dispersion model is used and land-surface cover and
high-resolution vegetation data employed to explore relationships to
stages of vegetation development.
Results: Source regions and their land-cover typology is reconstructed
for all major KD world sites in terms of disease incidence. Similar strong
relationships emerge to cereal croplands in all the different continents.
The phenological cycle of vegetation in those areas shows a link to the
stages where vegetation is decaying, indicating that a relationship be-
tween the major KD season and some kind of agricultural byproducts
or remnants might play a role in the onset or exacerbation of this dis-
ease. An application of a statistical model integrating the air physics
ssociated to the movement of winds from these sources further dem-
onstrates predictive capacity to anticipate peaks in KD incidence.
Conclusion: Long-standing debate continues on the factors and po-
tential etiological agents of vasculitides and rheumatic diseases, such
as Kawasaki disease (KD) in susceptible children. Together with the
genetic predisposition to suffer the condition, hitherto undefined en-
vironmental factors are now suggested to contribute to the onset of
autoimmune vasculitis in susceptible individuals. The role of bioaero-
sols and air chemistry and physics is presented pointing to a much
clearer combination of factors ultimately appearing to be crucial to
the manifestation of epidemiological clusters of this pediatric vascu-
litis. A computational model integrating all this new environmental
information in combination with epidemiological dynamics proves
successful in predicting KD incidence in Japan.
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Pediatric Rheumatology 2018, 16(Suppl 2):O11Introduction: Juvenile dermatomyositis (JDM) is a rare, severe auto-
immune disease characterised by proximal muscle weakness and skin
rash. While JDM and adult-onset dermatomyositis (DM) share similar
clinical and biological features, there are differences in prevalence of
these features, including cancer, calcinosis and myositis-specific auto-
antibodies, suggesting a possible influence of age on pathogenesis.
Objectives: To investigate genetic risk factors for JDM and age of dis-
ease onset.
Methods: Caucasian JDM cases from the UK (n=312) were genotyped
(Illumina HumanCoreExome). Caucasian control data (n=2808) were ob-
tained from the Wellcome Trust Case Control Consortium (Affymetrix
500K). Following quality control, classical human leukocyte antigen
(HLA) alleles and HLA amino acids were imputed using SNP2HLA. Logis-
tic, linear and Cox regression were performed using PLINK and R pack-
age GenABEL, with adjustment for the first two principal components.
Genome-wide association was set at P<5×10-8 and suggestive associ-
ation at P<1×10-5. We subsequently built an international consortium
to create a replication cohort of Caucasian cases (n=479). Genotyping
of the replication cohort is ongoing using the HumanCoreExome array.
Results: Case-control analyses confirmed involvement of HLA includ-
ing multiple loci within HLA-C (p=1.35×10‑8, OR=2.49, 95% CI = 1.82-
3.42) and HLA-DRB1 (p=2.73×10-8, OR=0.56, 95% CI=0.46-0.69). Out-
side the HLA region there was suggestive evidence of association at
ZNF337 (p=7.49×10-6, OR=1.81, 95% CI=1.40-2.34). Analyses of associ-
ation with age of disease onset did not implicate HLA involvement, sug-
gesting age does not influence the association between HLA and JDM/
DM. Analysis of age of onset as a quantitative trait revealed suggestive
associations at PDE1A (p=1.56×10‑6, β=-1.61, 95% CI = -2.26–0.97) and
AGPAT3 (p=2.26×10-6, β=1.63, 95% CI = 0.97-2.30), genes involved in
regulating intracellular cyclic nucleic acid concentrations and phospho-
lipid biosynthesis/Golgi-to-endoplasmic reticulum retrograde transport,
respectively. In addition, we now have a replication cohort via our inter-
national consortium to validate these findings. Genotyping of the repli-
cation cohort is ongoing using the HumanCoreExome array.
Conclusion: This study confirms previous findings regarding HLA in-
volvement. Analyses of associations with age of JDM onset identified
novel loci, PDE1A and AGPAT3, which if validated in an independent
replication cohort could suggest novel processes involved in patho-
genesis. Together with the replication cohort, this study will be the
largest GWAS of JDM to date.
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Introduction: Interferons (IFNs) seem to play an important role in the
pathogenesis of juvenile dermatomyositis (JDM). We previously reported
that expression of both type I and type II IFN related genes is increased
in muscle biopsies of JDM patients and correlates with histological and
clinical features of the disease. Interferon regulated genes (IRGs) have also
been reported to be upregulated in peripheral blood of JDM patients
and could represent valuable biomarkers of disease activity.
Objectives: The aim of this study was to investigate expression of
IRGs (measured as type I IFN score), as well as serum levels of two
type I and type II IFN induced chemokines (CXCL9, CXCL10) in
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 8 of 243peripheral blood of JDM patients and to assess their correlations with
clinical and laboratory findings.
Methods: We collected 125 blood samples from 28 JDM patients at
different time points during follow-up. We measured expression of
IRGs (IFI27, IFI44L, IFIT1, ISG15, RSAD2, SIGLEC1) by quantitative PCR
(qPCR) and calculated the type I IFN score; serum levels of CXCL9
and CXCL10 were analyzed by ELISA. At each visit, the following
clinical data were recorded: physician’s global assessment of disease
activity VAS (Visual Analogue Scale), cutaneous VAS, Cutaneous As-
sessment Tool (CAT) activity score, Childhood Myositis Assessment
Score (CMAS), serum levels of creatine phosphokinase (CK, IU/l), anti-
nuclear antibody (ANA) status, presence of myositis specific or myo-
sitis associated antibodies (MSA/MAA), prednisone (or equivalent)
dose (mg/kg/daily), ongoing immunosuppressive medications.
Results: Type I IFN score was significantly higher in patients with features
of active disease (physician’s global VAS >0.2, CAT activity score≥1,
CK>150 IU/l). CXCL10 levels were significantly higher in patients with fea-
tures of active muscle disease (CMAS<46, CK>150 IU/l) whereas CXCL9
levels were significantly higher only in patients with abnormal CK levels. In
a multilevel mixed effect approach, type I IFN score was significantly asso-
ciated with physician’s global VAS, cutaneous VAS, CAT activity score,
CMAS and CK levels; CXCL9 showed no significant association with the
evaluated clinical features; CXCL10 levels were significantly associated
with CK levels and CMAS. Including time from disease onset to sampling
did not change the results. Immunosuppressive medications negatively
modulated expression of IRGs and IFN induced chemokines.
Conclusion: Our findings indicate that expression of IRGs, measured
as type I IFN score, and serum levels of CXCL10 reflect specific fea-
tures of disease activity in JDM, further supporting their role as valu-
able disease biomarkers.
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Introduction: Patients with Juvenile Idiopathic Arthritis (JIA) experi-
ence more pain than normal population. Pain has become an import-
ant outcome measure in JIA.
Objectives: To measure the level of pain during the first year of early
aggressive treatment in JIA and at three years from disease onset.
Methods: This study was performed along with Acute-JIA study, in which
60 new-onset patients with polyarticular JIA were randomized to receive
either infliximab plus methotrexate (IFX), combination of hydroxychloro-
quine, sulphasalazine, and methotrexate (Triple) or methotrexate mono-
therapy (MTX). Disease activity and quality of life were measured at 7
study visits during the first year from onset, and at 3 years’ follow-up visit
during open-label extension. Pain VAS (0-100) was utilized. Patients con-
tinued on their originally randomized treatment until they failed the strat-
egy or achieved inactive disease (ID) on medication for at least 6 months.
Results: All 60 patients in the original trial completed the 3-year follow-
up and 56 pain surveys. 50 (83%) switched treatment strategies be-
tween 1 to 3 years. Pain-VAS decreased from 37.0 (SD 24.3) at onset to8.5 (15.6) at 1 year (Wilk’s Lambda p<0.005). During the open-label ex-
tension, the level of pain increased to 10.1 (15.4) at 3 years (p=0.068,
compared with 1 year). No differences between treatment groups were
detected (p=0.21). CHAQ and JADAS at each time point associated with
level of pain. Cumulative time spent in inactive disease (ID) associated
with lower level of pain at 3 years (coefficient beta -0.63, p=0.004)
Conclusion: During one-year early aggressive treatment, pain de-
creased as disease activity diminished. Small, although not statistically
different increase in pain was noted during open-label extension. The
treatment strategy seemed to have no influence on pain.
Trial registration identifying number: Trial registration: ClinicalTrials.gov
NCT01015547
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Introduction: The availability of methotrexate (MTX) and the intro-
duction of multiple biological agents have revolutionized the treat-
ment of juvenile idiopathic arthritis (JIA). Several international and
national drug registries have been implemented to monitor accur-
ately the long-term safety/efficacy of these agents.
Objectives: This study aims to present the combined data coming from
“Pharmacovigilance in JIA patients treated with biologic agents and/or
MTX” (Pharmachild)/Pediatric Rheumatology International Organization
(PRINTO) registry and the national registries from Germany (BiKeR) and
Sweden.
Methods: Descriptive statistics for demographic, clinical data, drug ex-
posure, adverse events (AE) and events of special interest (ESI) were re-
ported. For the Swedish register, AE data were not available.
Results: A total of 15,284 patient’s data were reported, 8,274 (54%)
from the Pharmachild registry, 3,990 (26%) and 3,020 (20%) from the
Germany and the Swedish registries, respectively. Pharmachild children
showed a younger age (median of 5.4 years versus 7.6) at JIA onset
and shorter disease duration (5.3 versus 6.1-6.8) when compared to the
other registries. The most frequent JIA category was the rheumatoid
factor negative polyarthritis (range 24.6-29.9%). Methotrexate (61-84%)
and etanercept (24%>61.8%) were the most frequently used synthetic
and biologic disease-modifying anti-rheumatic drug (DMARD), respect-
ively. There was a wide variability in glucocorticoid use (16.7-42.1%).
Serious AE were present in 572 (6.9%) patients in Pharmachild versus
297 (7.4%) in BiKeR. Infection and infestations were the most frequent
AE (29.4-30.1%) followed by gastrointestinal disorders (11.5-19.6 %).
The most frequent ESI were infections (75.3-89%),(Table 1).
Conclusion: Sharing of data from national and international regis-
tries represents the most powerful tool for future analysis of
safety and effectiveness of immunosuppressive therapies in JIA.
Trial registration identifying number: NCT01399281
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Pharmachild
N = 2,022 (%)
BiKeR
N=1,697 (%)
Infections: 1523 (75.3) 1509 (89)
Serious/targeted infections
(Epstein‐Barr virus, cytomegalovirus,
papilloma virus, herpes zoster primary
and reactivation, and opportunistic infections)
674 (33.3) 171 (10.1)
Tuberculosis 27 (1,3) 0
Other infections 822 (40.6) 1338 (78.8)
Infusion/injection related reactions: 218 (10.8) 24 (1.4)
Infusion related reaction 144 (7.1) 11 (0.6)
Injection related reaction 74 (3.7) 13 (0.8)
Blood cells related ESI: 188 (9.3) 90 (5.3)
Pancytopenia 6 (0.3) 65 (3.8)
Neutropenia 107 (5.3) 14 (0.8)
Macrophage activation syndrome 75 (3.7) 11 (0.6)
Aplastic anemia 0 0
Autoimmune ESI: 50 (2.5) 50 (2.9)
Inflammatory Bowel Disease (IBD) 21 (1.1) 23 (1.3)
Other autoimmune diseases excluding
IBD, uveitis and demyelinisation disorders
18 (0.9) 24 (1.4)
Lupus erythematosus systemic/lupus-like
syndrome
4 (0.2) 1 (0.1)
Optic neuritis 4 (0.2) 0
Multiple sclerosis 2 (0.1) 0
Demyelination 1 (0.05) 2 (0.2)
Malignancies: 16 (0.8) 13 (0.8)
Leukaemias 3 (0.1) 2 (0.2)
Lymphomas 2 (0.1) 5 (0.3)
Haematopoietic neoplasms (excluding
leukaemias and lymphomas)
1 (0.05) 2 (0.2)
Neoplasm (other) 10 (0.5) 4 (0.2)O15
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Introduction: Innovative changes towards targeted treatment have
improved the outcome dramatically for juvenile idiopathic arth-
ritis (JIA) during the last two decades. The question remains how
well these children perform during long-term follow-up.
Objectives: To study the disease activity, remission rate and damage
18 years after JIA onset.
Methods: 510 consecutive cases of JIA with disease onset in 1997 to
2000 from Denmark, Norway, Sweden and Finland were prospect-
ively included in a longitudinal, close to population-based 18-year
(mean 17.5 years; range 14.2-20.2) follow-up study. The last follow-up
visit included an update on the family history, medication and clin-
ical data such as a clinical joint examination and remission status ac-
cording to the preliminary Wallace criteria.
Results: 434 (85%) out of 510 eligible JIA participants with a mean
age (S.D) of 24.0 (± 4.4) years were included. 76 patients (15%) were
lost to follow-up. Out of the included patients 329 (76%) attended a
follow-up visit, and 105 patients (24%) were evaluated by a tele-
phone interview.
The distribution of the JIA categories was as follows: 3% systemic,
27% persistent oligoarticular, 20% extended oligoarticular, 16%
polyarticular RF negative, 1% polyarticular RF positive, 7% psori-
atic, 10% enthesitis-related arthritis (ERA) and 15% undifferenti-
ated JIA.
For all 329 patients attending a clinical visit the median active joint
count was 0 (range 0-15), however during the 18 years of disease
course the median cumulative joint count was 8 (range 1-59). 66 par-
ticipants (15 %) received disease-modifying anti-rheumatic drugs
(DMARDS) and 84 patients (19%) were treated with biologics at the
last follow-up.
At the final study visit the median composite juvenile arthritis dis-
ease activity score JADAS71 was median 1.5 (range 0-31.6) with the
ERA category having the highest median score of 4.5 (range 0-16.5)
(p=0.003). In the follow-up cohort 48% had a JADAS71 score <1 indi-
cating inactive disease.
Articular damage (JADI-A) was found in 20% of the patients who had
a follow-up visit and 12.5% had developed extra-articular damage
(JADI-E), most commonly ocular damage, found in 26/41 (63%). The
highest JADI-A and JADI-E scores were found in the polyarticular RF
negative and psoriatic categories.
Less than half (44%) of the participants were in remission off
medication 18 years after disease onset, but 39.8% had active
disease. Achievement of remission off medication was observed
in the following order: persistent oligoarticular 39/72 (54%), sys-
temic 7/13 (54%), psoriatic 9/22 (41%), undifferentiated 21/55
(38%), extended oligoarticular 19/66 (29%), RFneg poly 16/59
(27%), RFpos poly 1/5 (20%), and ERA 4/37 (11%), the latter being
significantly different from the other categories (p<0.001).
Conclusion: A significant proportion of the JIA cohort do not reach
remission despite new treatment options and notably more than one
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 10 of 243third receive systemic treatment even 18 years after disease onset.
The worst outcome was evident in the ERA category and in general
the JIA disease burden in adulthood remains extensive.
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Introduction: Reaching early inactive disease is the goal in Juvenile
Idiopathic Arthritis (JIA) patients. How to proceed after reaching in-
active disease is subject of ongoing research. Tapering and stopping
disease modyfying anti-rheumatic drug (DMARD) therapy, including
observation of subsequent flares, was applied in all three arms of the
BeSt for Kids study.
Objectives: The aim of the BeSt for Kids study was to investigate,
which of three treatment strategies was most effective and safe, by
comparing them directly. The therapeutic target, in all arms, was in-
active disease. If inactive disease was reached and maintained for a
specific period of time, medication was tapered and stopped.
Methods: We conducted a randomized, single-blinded, multicenter,
treatment strategy study with 24 months of follow-up. DMARD-naive
JIA (oligoarticular, rheumatoid factor negative polyarticular, and ju-
venile psoriatic arthritis patients) were randomized to 1) sequen-
tial DMARD monotherapy, 2) combination therapy: MTX and
prednisolone-bridging, 3) combination therapy MTX with etaner-
cept. For all arms, the treatment protocol described a number of sub-
sequent treatment steps in case medication failed. After reaching
inactive disease for 3 (oligoarticular) or 6 (polyarticular) months,
medication was tapered and stopped according to protocol. Flare fre-
quency was observed.
Missing data were imputed. In case of drug-free clinically inactive dis-
ease often intentionally no blood was drawn causing non-random
missing ESR, and here ‘0’ was imputed for the analysis of inactive
disease.
Primary outcome was time to inactive disease and time to flare after
tapering and stopping DMARD therapy calculated using Kaplan Meier
curve with log rank test. Secondary outcomes are adjusted ACRPedi
30/50/70/90 scores, toxicity, functional ability and quality of life. Gen-
eralised Estimated Equations were used for longitudinal data
analyses.
In this abstract we share time-to-flare, flare frequencies and flare
characteristics in all three arms.
Results: During 24 months 59% (19 (3 oligo)/31 (61%) of patients in
arm 1, 16 (1 oligo)/32 (50%) in arm 2 and 19 (1 oligo)/29 (65%) in
arm 3) had tapered and stopped all DMARDs (drug-free inactive dis-
ease) after median 15.0 (IQR 12.0-18.0) months (arm 1), 19.5 (12.0-
24.0) months (arm 2) and 18.0 (12.0-21.0) months (arm 3) of therapy.
However, 26% (6 (1 oligo) patients in arm 1, 3 in arm 2 and 5 in arm
3) subsequently had to restart treatment before end of study, after
median time-to-flare 18.0 (15.0-21.0) months (p=0.7).Flares were characterised by JADAS-10 of 9.7 (8.1-11.3), which improved
3 months after restart of treatment to JADAS-10 of 3.9 (1.8-6.0).
Conclusion: During 24 months of treatment to target inactive dis-
ease, including tapering and stop-strategies, flare frequency was 26%
after median 18 months. After 24 months, 71% of patients had in-
active disease and 39% were in drug-free inactive disease.
It is feasible to incorporate strategies for tapering and stopping
DMARD-therapy in juvenile idiopathic arthritis patients, when tight
control is maintained.
Trial registration identifying number: Trial registration number:
Dutch trial register 1574
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Introduction: The measurement of disease activity plays a pivotal
role in the care of patients with juvenile idiopathic arthritis (JIA). To
serve this purpose, the Juvenile Arthritis Disease Activity Score
(JADAS) and its clinical version excluding the acute phase reactant
(cJADAS) were developed.
Cutoffs for the state of remission, low disease activity (LDA), moder-
ate disease activity (MDA) and high disease activity (HDA) are neces-
sary to interpret the scores and are ideally suited for pursuing tight
disease control in a treat-to-target strategy.
Aiming to obtain cutoffs suitable for any clinical setting, new values
were recently developed for JADAS10 and cJADAS10 in oligoarthritis
and polyarthritis, based on a large multinational dataset of JIA pa-
tients (Consolaro A, et al. Arthritis Rheumatol. 2017;69s10).
Objectives: To externally validate the new cutoffs for JADAS10 and
cJADAS10 disease activity states.
Methods: Four not selected for cutoffs development JIA patients
dataset were considered: 1) 4397 oligoarthritis and polyarthritis pa-
tients from the EPOCA study; 2) 148 oligoarthritis patients from the
TRIMECA trial; 3) 172 polyarthritis patients from the Abatacept trial,
4) 113 oligoarthritis and polyarthritis patients first starting methotrex-
ate from a monocentric retrospective cohort (Swart et al, Ann Rheum
Dis. 2018;77:336-342).
Face validity was assessed in dataset 1) by plotting the proportion of
patients in remission and LDA against the values of the 6 parameters
in the ACR JIA core set.
Discriminative ability was assessed in datasets 2) and 3) by compar-
ing the percentage of patients below the cutoff values in the differ-
ent ACR pediatric categories of response. In dataset 1) we compared
in each disease activity state, the level of pain (0-10 VAS), functional
ability impairment, and number of restricted joints and the frequency
of patients satisfied with disease outcome, starting a new medication
for JIA, and having morning stiffness.
Predictive ability was assessed in dataset 4) by calculating the sensi-
tivity and specificity of the cutoffs for remission and LDA after 3
months for treatment response after 12 months.
Results: Only most relevant results are described. JADAS10 and cJA-
DAS10 cutoffs for remission allowed up to 1 active joint for polyar-
thritis and 0 for oligoarthritis.
In dataset 2), 42% and 63% of patients achieving an ACRp70 re-
sponse met the JADAS10 cutoffs for remission and LDA, respectively.
In dataset 3), these percentages were 48% and 82%, respectively. In
dataset 1), the median level of pain was 0, 1.5, 3, and 5.5 for
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 11 of 243polyarthritis patients in cJADAS10 remission, LDA, MDA, and HDA, re-
spectively (Kruskal-Wallis p<0.001). The frequency of satisfaction with
disease outcome was 94%, 76%, 56%, and 24% for oligoarthritis pa-
tients in cJADAS10 remission, LDA, MDA, and HDA, respectively (Chi2
test p <0.001).
In dataset 4), 100% and 71% of patients with oligoarthritis classified
as non-responders after 12 months had JADAS levels after 3 months
above the cutoffs for remission and LDA, respectively. For polyarthri-
tis, 90% and 80% of non-responders had JADAS levels after 3 months
above the cutoffs for remission and LDA, respectively.
Conclusion: New JADAS cutoffs showed good face and content val-
idity; achievement of remission and LDA defined by the cutoffs pre-
dicted the response to therapy. Cutoffs were developed and
validated in a large multinational dataset and they are ready for use
in clinical trials and routine practice.
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Introduction: Juvenile dermatomyositis (JDM) and overlap myositis
(OM) represent heterogeneous subtypes of juvenile inflammatory
myopathy (JIM). Chronic evolution may occur in 60% of cases, and
morbidity/mortality is substantial (gastro-intestinal; pulmonary; organ
failure).
Objectives: Clinico-biological description of JDM and OM with posi-
tive MDA5 auto-antibodies in comparison to other JIM.
Methods: Retrospective and prospective study of patients fulfilling
Bohan and Peter criteria for JDM and Troyanov for OM, aged less
than 16 years at diagnosis, ascertained from 3 French paediatric
rheumatology reference centres between 2013 to 2018. Severe forms
were defined as requiring ICU management, and/or more than 3
treatment lines and/or with fatal outcome. Muscle biopsies were
reviewed. Type I interferon pathway activity was assessed by dosage
of interferon alpha (IFNa) through digital elisa (Simoa) with a Pan-
IFNa antibody in patient sera and myoblast lysate, mRNA expression
of interferon stimulated genes (ISGs) by RTqPCR and phosphorylation
of STAT by flow cytometry on whole blood.
Results: 67 patients were included, 12 (group 1) and 54 (group 2)
with and without anti-MDA5 antibodies respectively. Group 1 dem-
onstrated more arthritis (100% vs 24%), cutaneous ulcerations (42%
vs 26%), interstitial lung disease (ILD) (33% vs 14%) and a milder
muscular involvement (median of CK: 96 vs 149 UI/l), with better pre-
served muscular function (MMT and C-MAS, respectively 79/80 vs 70/
80 and 50/52 vs 38/52). Total muscle biopsy scores were lower for
group 1 than group 2 (respectively 5.5 vs 20). Group 1 included more
severe forms (36% vs 19%). 133 IFN signatures (ISGs) and 210 IFNa
Simoa measurements were assessed. Correlation between ISG expres-
sion and protein at 79 simultaneous data points was high (Pearson: r
= 0,74 ****). ISGs and IFNa (signature and dosage) were higher in
group 1 than 2 (median of ISGs 21 vs 7.4 and median of Simoa
3807.5 vs 49.6 fg/ml). In contrast, IFNa levels in patient myoblasts
were similar to controls for group 1 (1 patient), whilst those in group
2 were higher (10 patients). A constitutive phosphorylation of STAT1
and STAT3 was observed in T and B lymphocytes and monocytes of5 patients, including one from group 1. Treatment with steroids, ta-
crolimus, rituximab and immunoadsorption in one group 1 patient
correlated with the disappearance of MDA5 auto-antibodies, the nor-
malisation of IFNa levels and the induction of complete remission
(normalisation of clinical, laboratory and radiological parameters).
Conclusion: This study indicates a higher frequency of cutaneous ul-
cerations, arthritis and ILD, and milder muscular involvement in JIM
with positive MDA5 auto-antibodies compared to other JIM. These
data suggest an important role of systemic IFNa in the pathology of
the disease. In severe and refractory forms, IFNa may be a potential
therapeutic target.
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Introduction: Patients with Juvenile Idiopathic Arthritis (JIA) who fail
to reach a state of clinically inactive disease might start biological
treatment (TNFa-blockers) [3]. Currently little is known in relation to
which patients will respond or not to specific biologicals, potentially
leading to a delay in achieving acceptable clinical state [4].
Objectives: To investigate the possible predictive value of serum pro-
teins on therapeutic (non-)response prior to start of biological therapy.
Methods: This study presents a retrospective analysis of a prospect-
ively collected and followed cohort of non-systemic JIA patients from
a single pediatric rheumatology center. Non-response to biological
was defined as a necessity to switch biological or when criteria for
clinically relevant improvement (a change of ≤-5.5 in JADAS27 [5]
while not achieving clinically inactive disease i.e. a JADAS27 ≤1 [6])
were not met and was evaluated 6 months after start of biological
therapy. Serum protein concentration was analysed by Luminex®
multiplex assay (44-plex including cytokines, chemokines and growth
factors). We performed basic statistics, including univariate analysis
(Mann-Whitney U test) to assess whether protein concentrations as-
sociate with response to therapy. Proteins associating with a p<0.1
were included for further analysis later on whereas proteins with a
p<0.05 were considered significant. If proteins correlated with a
Spearman’s rho >0.6 the more significant protein was included.
Results: 67 Patients were included (Table 1). 36 patients received eta-
nercept, 30 adalimumab and 1 golimumab. Of the oligo articular JIA
patients 14 (60.9%) were persistent oligo articular and 13 (56.5%)
were ANA+. At t=6 months 15 patients were non-responsive (34.1%
of cases with JADAS27 available). We found a significant association
with non-response for TNF-ligand-1a (TL1a) and haptoglobin. With a
p<0.1 interleukine-8 (IL-8) and vascular endothelial growth factor
(VEGF) were of interest for further analysis.
Conclusion: This preliminary analysis yielded various proteins of which
the serum concentration relates to non-response to biological therapy.
These proteins might serve as biomarkers predicting therapeutic re-
sponse. Further research and analyses, including a planned validation
in a separate prospective cohort, is required to predict non-response.
Disclosure of Interest
None Declared
Table 1 (abstract O19). See text for description
Total n 67 42
Female n (%) 42 32.7%
Age at sampling years median (1st;3rd quartile) 12.7 (8.52;15.6)
JIA subtype
Oligo articular JIA n (%) 23 34.3%
Poly articular JIA RF- n (%) 25 37.3%
Poly articular JIA RF+ n (%) 3 4.5%
Enthesitis related JIA n (%) 12 17.9%
Psoriatic JIA n (%) 4 6.0%
JADAS27 t=0 median (1st;3rd quartile) 10.5 (6.1;15.4)
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Introduction: Rituximab in combination with glucocorticoids (GC) is
approved to treat adult patients with GPA or MPA; however, limited
data exist on the safety and efficacy of rituximab in pediatric patients
with these potentially life- and organ-threatening diseases.
Objectives: To report the interim safety, pharmacokinetics (PK) and
exploratory efficacy data from the 6-month remission induction
phase of a Phase IIa international, open-label, 18-month clinical study
of rituximab in pediatric patients with GPA or MPA.
Methods: Patients aged ≥2 to ≤18 years with newly diagnosed or re-
lapsing GPA/MPA received 4 intravenous (IV) rituximab infusions of
375 mg/m2 body surface area (BSA) on Days 1, 8, 15 and 22 with
concomitant GC 1 mg/kg/day (max 60 mg/day) tapered to 0.2 mg/
kg/day minimum (max 10 mg/day) by Month 6. All patients received
3 doses of pulse IV methylprednisolone (30 mg/kg/day, max 1g/day)
prior to first rituximab infusion and mandatory prophylaxis for
Pneumocystis jiroveci infection. Patients were also pre-medicated with
acetaminophen and an antihistamine, 1 hour before each rituximab
infusion. Adverse events (AEs) and laboratory data were measured at
each study visit (1, 2, 4 and 6 months). Plasma samples for PK ana-
lysis were collected throughout the study; clearance and area under
the curve (AUC) were calculated using population PK modeling from
the RAVE study of rituximab in adult patients with GPA/MPA (Stone
et al. NEJM. 2010;363:221-32). For exploratory efficacy assessment,
the Pediatric Vasculitis Activity Score (PVAS) was measured at each
study visit.
Results: Of the 25 patients enrolled, 19 (76%) had GPA and 6 (25%)
had MPA (median [range] age 14 [6-17] years; 80% female). Median
(range) disease duration was 0.5 (0.2-0.7) months; 2 patients had re-
ceived prior cyclophosphamide therapy. All received 4/4 rituximabinfusions and completed the 6-month induction phase. By Month 6,
all patients had experienced ≥1 AE. The most common AEs by sys-
tem organ class were infections and infestations in 16 patients (64%).
Eleven serious AEs occurred in 7 patients (28%), including 3 serious
infections (viral gastroenteritis, one lower and one upper respiratory
tract infection). 32% of patients had ≥1 infusion related reaction
(IRR). No serious IRRs or deaths were reported. The relationship be-
tween AUC and BSA was flat and comparable to adult patients. A
total of 13 patients (52%) achieved remission by 6 months, defined as
PVAS of 0 and GC dose 0.2 mg/kg/day (max 10 mg/day) or PVAS of 0
on 2 consecutive readings ≥4 weeks apart irrespective of GC dose.
Conclusion: In the initial 6 months of this first global clinical trial of
rituximab in pediatric patients with GPA/MPA, rituximab was gener-
ally safe and well tolerated. The overall safety profile and PK parame-
ters were comparable to rituximab-treated adults with GPA/MPA. No
new safety signals were observed. However, the study size and in-
terim nature of the analysis limit firm conclusions. The clinical trial
and additional efficacy, PK and safety analyses are ongoing.
Trial registration identifying number: NCT01750697
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Introduction: Juvenile onset systemic lupus erythematosus (jSLE) is
characterised by a type 1 interferon (IFN) transcription signature. Up
to 80% of patients with jSLE of varying severity express a predomin-
ant IFN signature which correlates with disease activity, and is abro-
gated by steroids. Investigating the IFN signature outside of a flare
may provide insight into the true prevalence of high IFN signature
disease, and underlying differences in disease pathogenesis, that
may be masked by steroid or disease activity.
Objectives: To investigate the prevalence of high IFN signature in
low disease activity jSLE, and to assess whether toll like receptor
(TLR) 7 or 9 dependent IFNα production pathways differ between
high and low IFN signature patients.
Methods: Blood was collected, with consent, from healthy volunteers
(n=24:10 female; 14 male, age=12-19) and young people with jSLE
(n=29:20 female; 9 male, age=14-21). Clinical data were recorded.
Peripheral blood mononuclear cells (PBMC) were separated by
Ficoll gradient centrifugation. Ex vivo RNA was assessed by Nano-
string Plex Set. IFN score was calculated from counts of 5 IFN indu-
cible genes (MX1+BST2+MCP1+ISG15+ IFIT1/5). Samples were
classed as IFN positive (IFN+) if >2SD from the healthy mean. Separ-
ately, PBMC were stimulated with TLR7 agonist, R848, or TLR9
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 13 of 243agonist, CPGODN2216, before assessing for secretion of IFNα and
TNFα by luminex. Statistical analysis was performed using SPSS with
linear regression.
Results: There was a significantly higher IFN score in jSLE than
healthy controls (p=0.001). 14/29 (48.27%) jSLE patients were IFN+ vs
1/23 (0.04%) healthy controls (p=0.005). Patients with jSLE had a
mean SLEDAI of 3.0 (range=0-12); 15 (52%) were on prednisone
(mean= 6.9mg). In patients with jSLE, the only autoantibody that sig-
nificantly predicted IFN score was towards RNP (p=0.018). There was
no association between any specific organ involvement and IFN
score. Four patients with jSLE were B cell depleted (<2%), with no ef-
fect of B cell depletion on IFN score. There were no significant differ-
ences in markers of disease activity (SLEDAI, CRP, ESR, C3, C4 and
double stranded DNA antibodies) between IFN+ and IFN- jSLE pa-
tients. Only jSLE patients who were IFN+ produced significantly more
IFNα (p=0.046) and TNFα (p=0.031) than healthy controls after TLR7
stimulation. After TLR9 stimulation, however, IFNα production was
decreased in jSLE compared to healthy, regardless of IFN score. IFN+
patients with jSLE had significantly higher PBMC RNA expression of
TLR7 than those who were IFN- (p=0.001), and healthy controls
(p=0.04). IFN+ patients with jSLE showed a significant decrease in
TLR9 expression when compared to healthy controls (p=0.023). We
confirmed that TLR7 was not an IFN inducible marker, by assessing
expression in healthy controls with and without IFNα pre-stimulation,
which showed no significant difference.
Conclusion: We present novel data, showing that, in non-flaring pa-
tients with jSLE on low doses of steroid, half are IFN signature posi-
tive. This is lower than reported in studies that include flaring
patients and may better represent prevalence of high IFN signature
disease at baseline. In jSLE, IFN signature score associates with auto-
antibodies to RNP. PBMC from IFN+ patients produce more IFNα after
TLR7 stimulation, and have a significantly higher expression of TLR7,
along with a decrease in TLR9 expression compared to samples from
patients with a negative IFN signature, and healthy controls.
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Introduction: The granulocytic protein S100A12 is expressed at high
levels in Kawasaki Disease (KD) but it is unclear whether S100A12
does actively participate in KD pathology or is a bystander of neutro-
phil activation.
Objectives: Kawasaki disease (KD) is an acute vasculitis of childhood,
predominantly affecting coronary arteries. S100A12 is an endogenous
pattern recognition receptor (PRR) ligand, which is strongly upregu-
lated in KD and S100A12 serum levels track with KD disease activity
and response to intravenous immunoglobulin (IVIG) treatment. While
S100A12 was originally described as agonist of the multi-ligand re-
ceptor for glycation endproducts (RAGE), we described human
monocytes to respond to S100A12-stimulation in an exclusively
TLR4-dependent manner. Here, we aimed to investigate whether and
how serum S100A12 might be actively involved in inflammatory pro-
cesses in KD.Methods: Serum samples (n=75) from patients with KD at different
stages pre- and post-intravenous immunoglobulin (IVIG) treatment
were analyzed for S100A12, cytokines, chemokines and soluble
markers of endothelial activation. Primary human coronary artery
endothelial cells (HCAECs) were analyzed for responsiveness follow-
ing direct stimulation with S100A12 or lipopolysaccharide (LPS). Al-
ternatively, HCAEC were cultured in conditioned medium obtained
from primary human monocytes stimulated with LPS or S100A12 in
the absence or presence of IVIG or cytokine antagonists.
Results: Multiple correlation analyses revealed, that in KD patients’
sera in course of IVIG-therapy soluble vascular cell adhesion
molecule-1 (sVCAM-1) titers as indicator of endothelial activation ex-
clusively associated with pre-treatment S100A12 levels. Yet, in con-
trast to stimulations with LPS, HCAECs were not responsive to direct
treatment with S100A12, despite the presence of appropriate recep-
tors (RAGE, TLR4). Unresponsiveness of HCAECs to S100A12 was due
to lack of membrane CD14 expression. Addition of recombinant sol-
uble CD14 or human serum benefitted LPS- but could not establish
response to S100A12. Instead, HCAECs strongly responded to super-
natants obtained from S100A12-stimulated primary human mono-
cytes, as evidenced by expression of inflammatory cytokines and
adhesion molecules. Inflammatory activation of HCAECs by S100A12-
stimulated monocytes required monocyte-co-stimulation with ATP.
Endothelial cell stimulation was completely abrogated upon IL-1β
blockade but remained unaffected by treatment with IVIG or anti-
TNFa and IL-6 receptor blocking antibodies.
Conclusion: We identified IL-1β-signaling in coronary artery endothe-
lium as particularly relevant in course of sterile inflammation as in-
duced by damage associated molecular pattern (DAMP) molecules
such as S100A12. These data are in support of a potential key role
for IL-1 in KD pathology but also highlight the coronary artery endo-
thelium, which is critically involved in early KD pathology and
aneurysm formation as particularly sensitive to IL-1β blockade during
DAMP-induced sterile inflammation.
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Introduction: Canakinumab (CAN) has demonstrated efficacy and
safety in patients with colchicine-resistant familial Mediterranean
fever (crFMF), TNF receptor-associated periodic syndrome (TRAPS),
and hyper-IgD syndrome (HIDS)/mevalonate kinase deficiency (MKD)
in epoch 2 and 3 (E2 and E3 up to week 40) of the pivotal, rando-
mised CLUSTER study.1
Objectives: To assess long-term maintenance of optimal control of
disease activity (median of no or 1 flare, and no uptitration) and
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 14 of 243safety of CAN dosing regimens of every 4 weeks (q4w) and every 8
weeks (q8w) in patients with crFMF, TRAPS or HIDS/MKD from the
epoch 4 (E4 up to week 112) of CLUSTER.
Methods: CLUSTER comprised 4 epochs (E1-E4). After lead-in E1, effi-
cacy of CAN 150/300 mg q4w to induce complete response was
assessed in E2, a 16-week randomised, double-blind, placebo (PBO)-
controlled epoch. E3, a 24-week randomised withdrawal epoch, eval-
uated whether responders to CAN 150/300 mg q4w in E2 could
maintain clinical efficacy on 150/300 mg q8w or PBO. In E4, a 72-
week, open-label epoch, the long-term maintenance of efficacy and
safety of CAN 150/300 mg q4w or q8w in patients with crFMF, TRAPS
or HIDS/MKD was evaluated. Patients who did not maintain clinical
response on q8w could be uptitrated to 150/300 mg q4w. Safety
assessments included incidence of adverse events (AEs) and
serious AEs.
Results: Five patients discontinued from the study in E4 (one TRAPS
patient discontinued due to AE). A substantial proportion of patients
maintained optimal control of disease activity following treatment
with 150/300 mg q4w or q8w in all 3 cohorts at week 112 (Table 1).
HIDS/MKD patients more often required uptitration to 300 mg q4w.
Majority of patients had 1 or no new flare (crFMF: 96.6%, TRAPS:
94.3%, HIDS/MKD: 83.3%). In all 3 cohorts, the median SAA levels de-
creased rapidly from baseline and remained suppressed through E4
(crFMF: 618 to 21 mg/L, TRAPS: 243 to 12 mg/L and HIDS/MKD: 2061
to 16 mg/L). No new safety findings were reported in CAN-treated
patients through week 112.
Conclusion: Long-term treatment with canakinumab 150/300 mg
q4w in epoch 4 of the CLUSTER study showed that optimal control
of disease activity can be maintained in patients with crFMF, TRAPS
or HIDS/MKD. There were no new or unexpected safety issues re-
ported over 112 weeks of treatment.
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Cohort 150 mg q8w
n (%)
150 mg q4w
n (%)
300 mg q8w
n (%)
300 mg q4w
n (%)
crFMF (N=57) 23 (40.4) 20 (35.1) 5 (8.8) 9 (15.8)
TRAPS (N=50) 25 (50.0) 5 (10.0) 9 (18.0) 11 (22.0)
HIDS/MKD (N=64) 14 (21.9) 7 (10.9) 11 (17.2) 32 (50.0)
*Optimal control of disease activity was defined as median of no or 1 flare,
and no uptitrationEpigenetic in inflammation and
autoimmunity
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Introduction: Regulation of IL-18 gene expression by primary human
monocytes is poorly understood but may provide insights into the
cytokine’s still unclear role in autoinflammation.
Objectives: The interleukin (IL) 1 family cytokine IL-18 is overabun-
dant in plasma and serum of familial mediterranean fever (FMF) and
systemic juvenile idiopathic arthritis (sJIA) patients and its levels coin-
cide with hypersecretion of the damage associated pattern (DAMP)
proteins S100A8/A9 and S100A12. Comparable to IL-1b it is thought
to require caspase-dependent processing to render an immature
pro-form into bioactive mature IL-18. Yet, in stark contrast to IL-1b, it
seems largely unknown whether and how IL-18 gene expression is
regulated.
Methods: Primary human monocytes isolated from healthy donors
were analyzed for kinetics of cytokine expression on gene and pro-
tein level following different stimulations and drug treatments.
Results: Initially, we performed endotoxin desensitization experi-
ments on primary human monocytes, which suggested TNFa, IL-6
and IL-1b but not IL-18 gene expression to be subjected to LPS-
tolerance. However, when studying time kinetic gene expression of
cytokines, we found that IL-1b and IL-18 followed identical secretion
but completely different gene expression patterns. In contrast to IL-
1b, we observed human monocytes to maintain a cytoplasmic store
of mature, bioactive IL-18 from which it could be readily secreted
upon LPS stimulation and, following the observed attenuated IL-18
gene expression, this intracellular bioactive IL-18 store replenished.
Importantly, colchicine as the mainstay of todays FMF-therapy, as
well as the the microtubule polymerisation inhibitor nocodazole ab-
rogated IL-18 expression, while IL-1b gene expression was massively
enhanced.
Conclusion: We propose monocytic IL-18 transcription to be sub-
jected to negative feedback regulation by an intracellular store of IL-
18 protein. The cellular efforts to maintain such a store may suggest
IL-18 to rather operate as DAMP than classical cytokine. This may ex-
plain the orchestrated hypersecretion of IL-18, S100A8/A9 and A12 in
diseases such as FMF or sJIA.
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Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 15 of 243Introduction: Juvenile Idiopathic Arthritis is hallmarked by a dis-
turbed immunological balance between regulatory T-cells (Treg) and
effector T-cells (Teff). Restoring this balance by either enhancing the
suppressive function of Treg or inhibiting activation and proliferation
of pro-inflammatory T-eff is therefore a promising therapeutic
strategy. Previously we demonstrated that inhibition of the lysine
deacetylase SIRT1 resulted in an increase in FOXP3 positive cells in vi-
tro. Since the transcription factor FOXP3 is essential for Treg differen-
tiation and function, this approach could positively influence
immunological tolerance. Interestingly, SIRT1 can be inhibited by the
well known food additive, Vitamin B3, also known as Nicotinamide
(NAM). We therefore aim to translate these laboratory findings into clin-
ical practice and envision a role for NAM as a novel therapeutic strategy
in maintaining the immunological balance in patients with JIA. We
demonstrated a distinctive effect of NAM on Treg, however the effect
of NAM on the other side of the balance; Teff cells is still unexplored.
Objectives: To investigate the effect of SIRT1 inhibition on prolifera-
tion, activation and cytokine production of Teff cells.
Methods: T-cells were isolated from the blood of healthy controls
and JIA patients as well as the synovial fluid from JIA patients. Cells
were stimulated with aCD3/aCD28 and cultured in the presence of
increasing concentrations of NAM (0-9mM) for 1-4 days. Proliferation
and expression of activation makers were determined using flow cy-
tometry. Cytokine production was determined by qPCR, luminex and
flow cytometry. The specific SIRT1 inhibitor EX-527 was used as a
control to determine the pathway involved.
Results: In vitro NAM treatment of human CD4+ T-cells significantly
decreased the production of the pro-inflammatory cytokines IL-2 and
IFNy measured both on mRNA and protein level. In line with this, sur-
face activation markers were downregulated after NAM incubation.
Furthermore proliferation of both CD4+ and CD8+ T-cells was inhib-
ited with NAM treatment in a dose dependent manner in both PBMC
from HC and SFMC from JIA patients. Results were verified by using
another SIRT 1 inhibitor; EX-527.
Conclusion: In addition to the previously demonstrated increase of
Treg numbers and function, these data demonstrate that NAM treat-
ment in vitro inhibits proliferation and activation of Teff cells. There-
fore NAM treatment could modulate the immunological balance by
both increasing tolerance and suppressing immune activation. We
envision that NAM treatment as an adjuvant therapy has the poten-
tial to benefit JIA patients and potentially other autoimmune dis-
eases. To translate these findings to clinical practice and determine if
NAM treatment is useful as a strategy to maintain disease remission
after stopping DMARD or biologicals we are in preparation of a
phase III clinical trial.
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Introduction: Macrophage activation syndrome (MAS), a severe com-
plication of paediatric rheumatic disease, is currently classified among
the secondary forms of HLH (sHLH). Primary HLH (pHLH) are caused bymutation of genes coding for proteins involved in cytotoxic functions.
Mice carrying heterozygous mutations in more than 1 pHLH gene carry
a higher risk to develop HLH following viral infection, suggesting that
accumulation of partial genetic defects may be relevant in HLH.
Objectives: To analyse, with next generation sequencing (NGS),
genes involved in pHLH in MAS in the context of different rheumatic
diseases and in sHLH.
Methods: We performed Targeted resequencing on all patients using a
panel including the 7 principal HLH-related genes (PRF1, UNC13d,
STX11, STXBP2, Rab27a, XIAP, SH2D1A) on MiSeq® and NextSeq550® plat-
forms (Illumina, San Diego, CA); all variants identified were confirmed
by Sanger. We took into account variants with an allelic frequency in
the global population up to 5% in the dbSNP and Ensembl databases.
Results: We analysed 125 patients: 47 MAS (40 developed this com-
plication in the context of systemic Juvenile Idiopathic Arthritis (sJIA)
and 7 in the context of different rheumatic diseases), 32 sHLH, 22
sJIA (without history of MAS) and 24 with different autoinflammatory
diseases (AID). sJIA and AID patients were used as control groups.
We identified at least 1 heterozygous variant in one of the pHLH-
related genes in 41 patients with a detection rate of 52%, 45% of
MAS and 62% of sHLH patients. More than one variant was identified
in 37% patients from both groups, with 19% of both MAS and sHLH
patients carrying polygenic variants. In control groups, 54% of sJIA
and 33% of AID patients carry at least a variant in the analysed
genes, while polygenic variants have been detected in 14% and 8%
of control patients, respectively. The most involved genes in both
MAS and sHLH groups were PRF1 and UNC13d, while variants in
RAB27a and XIAP have been found only in sHLH patients. The most
frequent variants identified in both groups were A91V in PRF1 gene
and R928C in UNC13d gene. The A91V variant in PRF1 gene was iden-
tified in 19% of both MAS and sHLH patients, while this variant was
present, respectively, in only 5% of sJIA and 4% of AID patients. The
R928C variant in UNC13d gene was identified in 32% of MAS and
18% of sHLH patients, and in the control group in 9% of sJIA and
17% of AID patients. Considering the patients’ clinical characteristics,
relapse, CNS involvement, ICU admission and death, in sHLH we ob-
served that three of the 6 patients (50%) carrying multiple variants
had recurrent episodes of HLH and that two of them (33%) pre-
sented a severe disease with exitus.
Conclusion: Monoallelic variants in pHLH-related genes are more fre-
quent in MAS, sHLH and sJIA and less in AID patients, suggesting dif-
ferent molecular mechanisms involved in the diseases.
Re-occurrence and severity of disease seem to be more frequent and
more severe in patients who carry mutations in two genes in sHLH
group. These data may support a polygenic model of sHLH.
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Introduction: Macrophage Activation Syndrome (MAS) is a severe,
life-threatening, complication of rheumatic diseases in childhood,
particularly of systemic Juvenile Idiopathic Arthritis (sJIA), occurring
in approximately 25% of the patients with sJIA. The mortality rate of
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 16 of 243MAS is still significantly high. A score that identify sJIA patients who
are at high risk to develop MAS would be useful in clinical practice.
There are no parameters available to identify from onset sJIA patients
with high risk to develop MAS in their disease course.
Objectives: To evaluate whether routine laboratory parameters at
disease onset may predict the development of MAS in patients with
active sJIA. To define a risk score of MAS for sJIA patients using these
parameters.
Methods: Laboratory parameters of disease activity and severity (WBC,
N, PLT, Hb, ferritin, AST, ALT, gGT, LDH, TGL, fibrinogen, D-dimer and
CRP), were retrospectively evaluated in 56 sJIA patients referred to our
Division of Rheumatology from 1998 to 2016 with at least one year of
follow-up. Laboratory parameters were evaluated during active sJIA,
without MAS, at time of hospitalization (T1) and before treatment for
sJIA was started (T2). Patients were divided in two groups: group 1 (pa-
tients without history of MAS), group 2 (patients with at least one MAS
episode during disease course). To calculate a MAS risk score, labora-
tory parameters, collected at T2, with a statistical significant difference
between the two groups of patients were selected.
Results: Fourteen patients, that fulfilled the 2016 classification criteria
for MAS [1] at time of sampling, were excluded from the analysis.
Therefore, we analyzed laboratory parameters of 42 patients with
sJIA, 27 of whom without history of MAS (group 1) and 15 who devel-
oped at least one episode of MAS during disease course (group
2). Levels of ferritin, AST, LDH, gGT and TGL, collected at T2, were statis-
tically significant higher in patients with a history of MAS compared to
those without a history of MAS. For each of these parameters an arbi-
trary cut-off was defined. In order to define the final score an arbitrary
rate was attributed to each parameter. Sensitivity (Se), specificity (Sp),
positive predictive value (PPV) and negative predictive value (NPV)
were calculated to define the best scoring system. The scoring system
with the best sensitivity was chosen (Table 1). A MAS risk score >3 iden-
tified 14 out of 15 sJIA patients with a history of MAS and 3 out of 27
sJIA patients without history of MAS.
Conclusion: In conclusion we developed a MAS risk score based on
routine laboratory parameters that are available worldwide, that can
help clinicians to identify these patients early in the disease course.
Our results need to be validated in a larger population.
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Laboratory parameters Cut-off Rate
Ferritin (ng/ml) >900 1
AST (UI/L) >35 1
LDH (UI/l) >550 1
gammaGT (UI/L) >30 2
Triglycerides (mg/dl) >150 2
Sensitivity (Se) 0.933 CI95% 0.680-0.998
Specificity (Sp) 0.889 CI95% 0.708-0.977
Positive predictive value (PPV) 0.824 CI95% 0.566-0.962
Negative predictive value (NPV) 0.96 CI95% 0.797-0.999P003
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Introduction: The efficacy and safety of intravenous (IV) tocilizumab
(TCZ) were demonstrated in patients (pts) with systemic juvenile idio-
pathic arthritis (sJIA) in the phase 3 TENDER study.1
Objectives: To investigate dosing regimens of subcutaneous (SC)
TCZ in pts with sJIA by bridging from TENDER data for TCZ IV to
identify the optimal SC regimen through characterization of the
pharmacokinetics (PK), pharmacodynamics (PD), and safety of TCZ SC
in pts with sJIA; efficacy was an exploratory objective.
Methods: This was a multicenter, open-label, phase 1b study to
evaluate the PK, PD, and safety of TCZ SC in pts aged 1-17 years with
sJIA and inadequate response to glucocorticoids. Interim analysis was
conducted after 24 pts had received TCZ SC for 14 weeks. Pts could
be TCZ naive or could switch from TCZ IV to SC. TCZ SC was adminis-
tered for 52 weeks according to body weight: pts <30 kg received ei-
ther 162 mg every 10 days before interim analysis or 162 mg every 2
weeks (Q2W) after interim analysis; pts ≥30 kg received 162 mg
every week (QW).
Results: We enrolled 51 pts, including 25 weighing <30 kg (8 before
and 17 after interim analysis) and 26 weighing ≥30 kg. Twenty-six
pts (51%) were TCZ naive and 25 (49%) switched from TCZ IV. Me-
dian steady state Cmin was similar for pts <30 kg receiving TCZ 162
mg Q2W and pts ≥30 kg receiving TCZ 162 mg QW; the ranges
largely overlapped (Table 1). More than 95% (49/51) of pts treated
with TCZ SC had steady state Cmin higher than the 5th percentile
achieved with TCZ IV. The median and range of AUC2weeks were simi-
lar for both body weight groups (Table 1). Changes in interleukin-6,
C-reactive protein, and erythrocyte sedimentation rate were similar
for both body weight groups. Almost all pts had ≥1 adverse event
(AE; n = 50; 98.0%). Injection site reactions (ISRs) occurred in 21 pts
(41.2%); most were mild, and none led to treatment interruption or
withdrawal. The AE rate was 1200.3/100 pt-years (PY) (909.3/100 PY,
excluding ISRs). The most common AEs were viral upper respiratory
tract infection (13; 25.5%), neutropenia (13; 25.5%), and cough (12;
23.5%). Nine serious AEs occurred in 7 pts (13.7%; 19.3/100 PY); 5
were infections, all in the <30 kg group. Two deaths occurred, both
in the <30 kg group. Median JADAS-71 improved from baseline to
week 52 for TCZ-naive pts (<30 kg, –13.9; ≥30 kg, –12.4) and was
maintained or improved further for pts who switched from TCZ IV
(<30 kg, –0.7; ≥30 kg –0.2). At week 52, 29/43 pts (67.4%) had in-
active disease (JADAS-71 <1.0).
Conclusion: A PK-based strategy was successful in bridging TCZ SC
to TCZ IV in pts with sJIA. Dosing regimens of 162 mg Q2W in pts
<30 kg and 162 mg QW in pts ≥30 kg provided adequate exposure
to support efficacy comparable to that of TCZ IV. Except for ISRs,
safety results were consistent with the known safety profile of TCZ
in sJIA.
Reference
1. De Benedetti F et al. N Engl J Med. 2012;367:2385-95.
Trial registration identifying number: ClinicalTrials.gov NCT01904292
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TCZ SC TCZ IV
<30 kg TCZ
162 mg Q2W
n = 25
≥30 kg TCZ
162 mg QW
n = 26
<30 kg TCZ
12 mg/kg Q2W
n = 46
≥30 kg TCZ
8 mg/kg Q2W
n = 43
Model-computed steady state PK parameters, median (range)
Cmin,ss
μg/mL
64.2 (16.6-135.9) 72.4 19.5-157.8) 65.9 (19.0-135.5) 70.7 (5.3-126.6)
Cmax,ss
μg/mL
126.6 (51.7-265.8) 89.8 (26.4-190.2) 274.4 (148.8-444.0) 253.0 (119.6-404.3)
AUC2weeks,ss
μg/mL×day
1298 (539-2792) 1154 (334-2370) 1734 (840-2712) 1631 (526-2779)
Table 1 (abstract P004). Patient characteristics
Patients with
pulmonary
complications
Patients without
pulmonary
complications
P-value
Patient number 65 849
Observation years
total (IQR)
7.6 (4.3-10.2) 5.1 (2.4-9.1) 0.002
Age diagnosis
SJIA (IQR)
3.7 (2.3-5.6) 5.3 (2.9-9.3) <0.001
Patients with non-
pulmonary AE/ESI
56 (86.2%) 287 (33.8%) <0.001
Synthetic DMARDs
ever
52 (80.0%) 690 (81.3%) 0.745
Anti-TNF ever 25 (38.5%) 307 (36.2%) 0.691
Anti-IL1 ever 29 (44.6%) 332 (39.1%) 0.430
Tocilizumab ever 36 (55.4%) 345 (40.6%) 0.026
Rituximab ever 20 (30.8%) 49 (5.8%) <0.001
Values are the number of patients, unless stated otherwise. Continuous
variables are analysed by a Mann-Witney-U test, asymp. Sig. (2-tailed). For
dichotomous variables Fisher’s exact sig. (2-sided) is usedP004
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ARTHRITIS PATIENTS IN THE PHARMACHILD REGISTRY
Jelle De Groot, Bas Vastert, Gabriella Giancane, Michael Hofer,
Ekaterina Alexeeva, Violeta Panaviene, Susan Nielsen, Jordi Anton,
Florence Uettwiller, Valda Stanevicha, Maria Trachana, Denise P. Marafon,
Constantin Ailioaie, Elena Tsitsami, Troels Herlin, Pavla Dolezalova,
Gordana Susic, Berit Flato, Flavio Sztajnbok, Angela Pistorio, Francesca
Bagnasco, Alberto Martini, Nico Wulffraat, Nicola Ruperto, Joost Swart
PRINTO, Genova, Italy
Correspondence: Jelle De Groot
Pediatric Rheumatology 2018, 16(Suppl 2):P004
Introduction: Lung disease might be an underreported complication
in patients with systemic juvenile idiopathic arthritis (SJIA). Recently
a study describing 25 patients with interstitial lung disease (ILD), pul-
monary arterial hypertension (PAH) and alveolar proteinosis (AP)
emerged. To what extent these complications occur in the SJIA
population is still uncertain.1
Objectives: This study will investigate how often pulmonary compli-
cations occur in children with SJIA in the Pharmachild registry. Pos-
sible associated factors and/or complications of lung disease will also
be investigated.
Methods: Data of the Pharmachild registry, the world's largest phar-
macovigilance database, was used. 914 Patients with SJIA were in-
cluded. Focus lied primarily on pulmonary complications reported in
these children. Secondarily, possible correlated events like the macro-
phage activation syndrome (MAS), death and adverse drug reactions
will be analysed.
Results: Eighty pulmonary complications were found in 65/914 pa-
tients suffering from SJIA (7%). Complications highly suspect for ILD
were found in only 9 children (1%). Patients with pulmonary compli-
cations had significantly longer follow-up (7.6 years versus 5.1), were
younger at diagnosis (3.7 years versus 5.3 years), had significantly
more often non-pulmonary complications and were more likely tohave ever used Tocilizumab (55.4% to 40.6%) and/or Rituximab
(30.8% to 5.8%) (see Table 1).
MAS occurred more often in patients with pulmonary complications
(20.0% to 11.5% P=0.050) and they had significantly more adverse
drug reactions, especially to Tocilizumab (9.2% to 2.7% p=0.013) and
Rituximab (12.3% to 1.2% P<0.001). Fatal disease occurred more
often in patients with pulmonary complications compared to those
without it (4.6% to 0.6% p= 0.006).
Conclusion: Pulmonary complications were found in 7% of the SJIA
population. Pulmonary complications are also associated with signifi-
cant more non-pulmonary comorbidities like MAS, adverse drug reac-
tions and even death. More adequate monitoring of pulmonary
function and consistent documentation of lung disease might be
helpful especially in patients at highest risk of ILD.
References
1) Kimura Y, Weiss JE, Haroldson KL, Lee T, Punaro M, Oliveira S, et al.
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(Hoboken). 2013 May;65(5):745-52. doi: 10.1002/acr.21889.
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Introduction: An increasing body of evidence obtained both in pa-
tients and experimental models of secondary hemophagocytic lym-
phohistiocytosis (sHLH), including macrophage activation syndrome
(MAS), supports the pathogenic role of Interferon-gamma (IFNγ).
Nevertheless, to date, few data demonstrating the activation of the
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 18 of 243IFNγ pathway in target tissues of patients with sHLH during the ac-
tive phase of the disease are available.
Objectives: In this study, in order to further clarify the involvement
of IFNγ in the pathogenesis of sHLH, we investigated the activation
of the IFNγ pathway in the affected liver of patients with active sHLH.
In addition, we evaluated the circulating levels of IFNγ inducible che-
mokines CXCL9 and CXCL10 and assessed the activation of the IFNγ
pathway in peripheral blood mononuclear cells (PBMCs) of patients
collected during the course of the disease.
Methods: We analysed by real-time PCR the mRNA expression levels
of IFNγ and IFNγ-inducible genes in the liver and in peripheral blood
mononuclear cells (PBMCs) from two patients with active sHLH and
one patient with active MAS, in which the disease was limited to the
liver, without systemic involvement. Moreover, both in liver and
PBMCs protein lysates, we evaluated by Western Blot analyses the
levels of total and Tyrosine (701)-phosphorylated Signal transducer
and activator of transcription 1 (STAT1), the transcription factor
mainly involved in the activation of the IFNγ signaling pathways. Cir-
culating CXCL9 and CXCL10 have been measured by ELISA.
Results: The expression levels of IFNγ and IFNγ-inducible genes were
markedly up-regulated in livers from all three patients, compared to
control livers. Conversely, slight differences in the expression levels
of Type I IFN-inducible genes and other classical pro and anti-
inflammatory cytokines were found. Further supporting the activa-
tion of the IFNγ pathway, higher protein levels of phosphorylated
and total STAT1 were detected in patient livers. Accordingly, we
found that mRNA levels of IFNγ-regulated genes and phosphorylated
STAT1 protein levels were markedly increased in patient PBMCs col-
lected during the active phase of the disease. Finally, circulating
levels of IFNγ-inducible CXCL9 and CXCL10 were markedly increased
during the active phase of the disease, paralleling the ferritin’s trend.
Conclusion: Our data provide evidence of selective and marked up-
regulation of the IFNγ pathway in liver tissue as well as in PBMCs
and blood of patients with active sHLH, further supporting the key
role of IFNγ in the pathogenesis of the disease, and provide the ra-
tionale for the therapeutic use of an anti-IFNγ antibody in sHLH.
Disclosure of Interest
G. Prencipe: None Declared, C. Bracaglia: None Declared, A. Pascarella: None
Declared, I. Caiello: None Declared, P. Francalanci: None Declared, M. Pardeo:
None Declared, A. Meneghel: None Declared, G. Martini: None Declared, A.
Insalaco: None Declared, G. Marucci: None Declared, F. Zulian: None
Declared, F. De Benedetti Grant/Research Support from: Novartis,
Novimmune, Hoffmann- La Roche, SOBI, AbbVie, Pfizer
P006
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Introduction: Although not known to be a manifestation of sJIA, high
mortality lung disease, including alveolar proteinosis (AP) and pul-
monary hypertension (PH), have been increasingly noted.
Objectives: To describe clinical, radiologic and biopsy findings in
children with sJIA as they develop life threatening parenchymal lung
disease.Methods: This retrospective observational case series included chil-
dren diagnosed until age 18 with sJIA or sJIA-like illness and lung dis-
ease. Chest CT and/or lung biopsy was required for inclusion and
underwent expert review.
Results: 61 included cases were contributed by 52 case reporters
(Abulaban,K, Baszis,K, Behrens, E, Birmingham, J, Canna, S, Casey, A,
Cidon,M, Cron,R, De, A, DeBenedetti,F, Deterding, R, Ferguson, I, Fish-
man, M, Goodman, S, Graham, B, Grom,A, Haines, K, Hazen, M, Hen-
derson, L, Ibarra, M, Inman, CJ, Jerath,R, Kingsbury, D, Klein-
Gitelman,M, Khawaja, K, Lai, K, Liptzin,DR, Lin, C, Lin, J, Lapidus,S,
Milojevic, D, Mombourquette,J, Onel,K, Ozen,S, Perez, M, Phillippi,K,
Prahal,S, Radhakrishna,S, Reinhardt, A, Riskalla, M, Rosenwasser,N,
Roth, J, Schneider, R, Schonenberg-Meinema,D, Schulert,G, Shenoi,S,
Smith,J, Sonmez,E, Stoll, M,Towe, C, Vehe,R, Young, L). 45 sJIA and 16
sJIA-like cases from the United States (54), Europe, the Middle East
and Asia were studied. Median age of sJIA onset was 2 years; median
time to lung disease was 2 years. Onset characteristics matched re-
ported cohorts with the exception of younger onset age (p<.0001)
and a 50x increased odds of Trisomy 21. Prior to lung disease, 46
cases were exposed to one or more inhibitors of IL-1 or IL-6. This
pre-exposed group demonstrated unusual clinical and radiologic fea-
tures including acute erythematous clubbing, a non-evanescent rash,
and CT features not typical for the pathology observed. Respiratory
symptoms, if present, were subtle. Lung pathology was primarily AP
and PH and did not distinguish those pre-exposed from those who
were not. Systemic inflammation typically occurred immediately prior
to or with lung disease detection. Extent of evaluation for infectious
causes varied and did not reveal a consistent pathogen. Of 6 cases
with PCR for pneumocystis pneumonia (PCP) on BAL fluid, 4 cases
were positive, and these children exhibited PCP compatible disease.
Overall fatality rate was 37% and, of those surviving, only 3 report
resolution of lung disease.
Conclusion: This study is the first to describe a set of unusual clinical
and CT features in children with sJIA who developed lung disease
during treatment with inhibitors of IL-1 or IL-6. However, this group
shared (rare) lung pathologic diagnoses with subjects unexposed to
these drugs. Further work is urgently needed as fatality rate is high,
incidence appears to be increasing, mechanisms remain unknown
and appropriate treatment is yet to be defined.
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Introduction: Systemic juvenile idiopathic arthritis (sJIA) is the most
severe and a rather distinct subtype of JIA. It is common view that
sJIA is the most severe form of childhood arthritis and the most diffi-
cult to treat. Recently the use of interleukin(IL)-1 antagonists has led
to a significant improvement of the disease’s long-term evolution
and has confirmed this cytochin’s key-role in the pathogenesis of
sJIA. A number of potential predictors of the therapeutic effective-
ness of IL-1 inhibitors have been reported, which include less severe
joint disease and increased white blood cell count, shorter disease
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 19 of 243duration, older age at disease onset and use of IL-1 blockade as first-
line therapy. However, because the experience gained so far is still
limited, there is a need of further data to better characterize the pro-
file of sJIA patients who are more susceptible to respond to IL-1
blockade.
Objectives: To seek for predictors of therapeutic response to inter-
leukin (IL)-1 inhibitors in children with systemic juvenile idiopathic
arthritis (sJIA).
Methods: The clinical charts of all patients with sJIA who were newly
treated with anakinra or canakinumab at our center between 2004
and 2017 were reviewed retrospectively. Predictors included baseline
demographic, clinical and laboratory variables as well as previous or
concomitant therapies. The effectiveness of IL-1 antagonists was
assessed at 1 year after treatment start. Complete clinical response
(CCR) was defined as absence of fever, physician’s global assessment
≤ 1, count of active joints ≤ 1, negative C-reactive protein (CRP), and
≥ 75% reduction of corticosteroid dose. According to the intention-to-
treat principle, patients who had IL-1 antagonists discontinued before 1
year for any reasons other than disease remission were classified as non-
responders. Statistics included univariate and multivariable analyses.
Results:
Of the 65 patients included in the study, 25 (39%) met the criteria
for CCR at 1 year, whereas 40 (61%) did not. On multivariable ana-
lysis, independent correlations with achievement of CCR were identi-
fied for shorter disease duration, lower active joint count, higher
ferritin level, and greater activity of systemic manifestations (Table 1).
The area under the curve (AUC) of the model was 83%.
Conclusion: Our findings help to delineate the clinical profile of sJIA pa-
tients who are more likely to benefit from IL-1 blockade. They also under-
score the critical need of randomized controlled trials aimed to explore
the therapeutic role of IL-1 inhibition early in the disease course.
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Explanatory variable OR (95% CI) P£
Disease duration ≤ 3.9 years 7.15 (1.36-37.52) 0.009
Active joint count ≤ 10 10.25 (1.59-65.93) 0.004
Ferritin > 444 ng/dL 5.69 (1.42-22.88) 0.009
Systemic manifestation score > 3 5.83 (1.38-24.62) 0.011P008
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Pediatric Rheumatology 2018, 16(Suppl 2):P008Introduction: Systemic onset juvenile idiopathic arthritis (SoJIA) is a
potentially severe disease with both systemic and joint inflammation;
different evolutive forms were described (monophasic, polyphasic or
persistent), but the outcome is hardly predictable at diagnosis.
Objectives: This study aims to identify early predictors of disease
evolution within the SoJIA population enrolled in the Juvenile Inflam-
matory Rheumatism cohort (JIRcohorte), an international prospective
cohort study.
Methods: 152 SoJIA patients with a minimum of two-year follow-up
were enrolled. 5 patients were excluded due to missing data on diag-
nostic visit. Demographics and clinical data were collected (retro-
spectively if diagnosis < 2015 and prospectively if diagnosis ≥ 2015)
and described for 147 patients. At diagnosis, median age and disease
duration was 5.3 years and 1.9 months, respectively, male to female
ratio was 1:1.2. Median follow-up was 6.7 years. 123 and 98 patients
were treated with biologics and DMARDs, respectively. Monophasic
evolution is determined by the occurrence of active disease (systemic
symptoms and/or arthritis) followed by inactive disease. No recur-
rence of active disease is observed, and remission is obtained. The
polyphasic course is defined by the recurrence of active disease at
any time after having achieved remission. A persistent evolution is
characterized by the persistence of systemic symptoms and/or arth-
ritis and/or abnormal laboratory results (for at least 24 months).
We present the preliminary results in 30 patients with complete data
for disease activity and medication use.
Results: Corresponding to their evolution, patients were classified in
the monophasic (n=10; MONO), polyphasic (n=14; POLY) or persist-
ent group (n=6; PER). Females were predominant in the MONO and
POLY group with 80% and 79%, respectively. No female patient was
in the PER group. At diagnosis, all patients in the PER and POLY
group had arthritis; only 80% did in the MONO group. Hepatomegaly
and splenomegaly was present in 30% and 50% of MONO patients
versus 17% and 0% of PER patients, respectively. Joint count during
first 6 months was ≥ 5 joints for 83% of the PER population com-
pared to 30% for the MONO. Four patients in the MONO group
(40%) did not have any biologics, whereas all patients from the other
groups had one or more (POLY: 7 patients had one, 5 patients had
two and 2 patients had three different biologics). Disease Modifying
Anti-Rheumatic Drugs (DMARDs) were used in 4 patients of the
MONO (40%), 13 of the POLY (93%) and 5 of the PER group (83%).
Median duration of corticoid-use for the MONO group and the POLY
group was 0.3 years and 2.68 years, respectively.
Conclusion: Systemic presentation seems to be more prevalent in
the MONO group whereas arthritis in the POLY and PER groups.
Polyarticular arthritis at 6 months is suggesting persistent disease
evolution. Biologics, DMARDs and corticoids are more often and
longer used in the POLY and PER groups correlating with a more
severe disease course. Early recognition of a monophasic evolution
could help the physician to limit the use of treatments, in particular
steroids.
Data are under completion for all 152 patients. Precise description of
disease evolution and deep phenotypic analysis will be performed.
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Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 20 of 243Introduction: Systemic juvenile idiopathic arthritis (sJIA) is a severe
childhood immune-inflammatory disorder with unknown etiology.
Objectives: One of the concepts is that the disease results from an in-
appropriate control of immune responses to an initially harmless trig-
ger. In the current study, we investigated whether sJIA may be caused
by defects in IL-10, a key cytokine in controlling inflammation.
Methods: IL-10 production was analyzed in a sJIA mouse model,
which relies on injection of Complete Freund’s Adjuvant (CFA) in IFN-
γ deficient mice. Corresponding wild type (WT) mice develop a subtle
and transient inflammatory reaction and were used to study the ef-
fect of IL‑10 neutralization. Cytokines and CRP were analyzed in
plasma of sJIA patients (active: n=10; inactive: n=8) and healthy con-
trols (n=15). Their PBMCs were used to study cell-specific defects in
IL-10.
Results: Diseased IFN-γ deficient mice showed a defective IL-10 pro-
duction in Treg cells, B cells and NK cells, with B cells as the major
source of IL-10. Neutralization of IL-10 in WT mice resulted in a
chronic immune-inflammatory disorder clinically and hematologically
reminiscent of sJIA. In sJIA patients, IL-10 plasma levels were strik-
ingly low as compared to pro-inflammatory mediators. In addition, B
cells from sJIA patients showed a decreased IL-10 production, both
ex vivo and after stimulation.
Conclusion: Cell-specific IL-10 defects in sJIA mice and patients result
in an insufficient IL‑10 production to counterbalance their pro-
inflammatory cytokines. IL-10 neutralization in CFA-challenged WT
mice converts a transient inflammatory reaction into a chronic dis-
ease and represents a model for sJIA in IFN-γ competent mice.
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Introduction: Systemic juvenile idiopathic arthritis (SJIA) accounts for 10-
20% of all JIA patients. It is characterized by findings of systemic inflam-
mation such as fever, rash, serositis, lymphadenopathy, and hepatosple-
nomegaly, and arthritis. Arthritis may develop later in life with variable
clinical features. Macrophage activation syndrome is the most life threat-
ening complication. Progress in the understanding of pathogenesis has
led to the development of cytokine-targeted therapies, biologics.
Objectives: This study aims to evaluate the treatment options in SJIA,
particularly effect of methotrexate prior to biologics.
Methods: A retrospective review of 52 cases of systemic JIA in the
last 20 years was performed.
Results: Thirty one (59.6%) of the patients were female. The mean
age of diagnosis was 89.8 ± 7.88 months and the mean follow-up
was 32 ± 18.5 months. Twenty seven (51.9%) had monocyclic, 9
(17.3%) had polycyclic and 16 (30.8%) had polyarticular course. All of
the patients had intermittant fever at onset, followed by rash and
arthritis, and the least common symptom was serous involvement.
Ten (19.2%) cases had macrophage activation syndrome (MAS). Four
of them presented with MAS as the initial diagnosis. The laboratory
values of MAS cases were significantly lower in ESR, platelet and fi-
brinogen levels and higher in ferritin and triglyceride levels when
compared with other cases. Eight of the MAS cases (80%) had mono-
cyclic, 1 (10%) had polycyclic and 1 had polyarticular course. In 8 of
the MAS cases (80%) the disease was controlled by pulse steroid
followed by methotrexate alone.
Fifty (96.2%) cases received pulse steroids. Methotrexate (MTX) treat-
ment was added in 47 (88.5%) cases. Thirty two (61.5%) cases werein remission with methotrexate treatment, whereas 14 (27%) cases
required an additional biological agent. Majority of patients with bio-
logics (56.3%) had polyarticular course. Adalimumab (1), anakinra (3),
tocilizumab (6), etanercept (8) and canakinumab (9) were the bio-
logics. In 4 cases, cyclosporin was added to control the disease.
Eight patients (15.4%) were transferred to adult rheumatology clinic
for persisting arthritis. Two (4.3%) of the patients died due to sepsis
and MAS, respectively. Seventeen (32.7%) were in remission under
medication, and 25 (48.1%) were in remission without medication.
Conclusion: Randomized controlled trials have evidence about ef-
fectiveness of biologics, particularly IL-1 and IL-6 inhibitors, in treat-
ment of SJIA. However, this study shows that methotrexate could
control the disease in about two thirds of patients, particularly in
“monocyclic” SJIA. Biologics such as anakinra, canakinumab, or toci-
lizumab could be preferred in cases with systemic onset and polyarti-
cular course. Multicentered studies with more patients are needed to
support this “real-world data”.
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Introduction: Monogenic primary HLH (pHLH) are caused by muta-
tions of genes coding for proteins involved in cytotoxic activity or
occur in the context of immunodeficiency.
Objectives: To demonstrate that the evidence of unusual clinical and
laboratory findings in a well-known condition needs further investi-
gations to rule out a different diagnosis.
Methods: Serum CXCL9, CXCL10 and IL-18 levels measured using ELI-
SA.T cell proliferation was assessed stimulating PBMCs with either
anti-CD3 or PMA/ionomycin for five days.
Results: A 14 months old Caucasian male was admitted with a his-
tory of persistent fever, small palpable cervical lymphnodes, rash,
pericardial effusion and arthralgia. He developed overt swelling of
wrists and ankles. Laboratory findings showed: elevated CRP and
ESR, neutropenia, lymphopenia and anaemia, with normal platelet
count. Serum ferritin levels were markedly elevated and lactate de-
hydrogenase aspartate aminotransferase and triglyceride were also
elevated. Fibrinogen was normal. Bone marrow biopsy showed hae-
mophagocytosis. Based on the presence of arthritis in a child with
fever and rash a diagnosis of sJIA was made with onset complicated
by MAS. Treatment with glucocorticoid was started. Functional tests
and genetic analysis of pHLH related genes were negative. After two
weeks the patient presented normalization of laboratory parameters
except for persistent anaemia and profound lymphopenia. Moreover,
a mild muscle hypotone became apparent. These features, unusual
in sJIA, triggered additional investigations. These revealed: reduced
aptoglobin, high reticulocyte count and positive Coombs test, all sug-
gestive of haemolytic anaemia. Immunological phenotyping revealed
a reduced number of B cells, CD4+T cells, CD8+T cells and a defective
proliferative response of T cells to phytohemagglutinin (PHA) and
anti-CD3 (OKT3). A metabolic screening showed an increase in urine
orotic acid, with normal citrulline serum level and low serum level of
uric acid. Based on the presence of haemolytic anaemia, T lympho-
cyte defect and increase in urinary orotic acid, purine nucleoside
phosphorylase (PNP) deficiency was suspected. The diagnosis was
confirmed by marked reduction of enzymatic activity of PNP and by
genetic analysis. The patient received an haplohydentical bone
Table 1 (abstract P012). Demographic, clinical features of sJIA
Female/male (n:168) 87(51.8)/81 (48.2)
Mean age at disease onset 76.7±54.5 months (IQR: 28-118)
Mean age at diagnosis 79,7±54.5 months (IQR: 33-121)
Mean delay of diagnosis 3.9 ± 8.7 months (IQR:1-3)
Clinicalfeatures, n (%)
Typical fever 160(95.2)
Typical rash 99(59)
Lymphadenopathy 45(26.8).
Hepatosplenomegaly 70(41.7)
Arthritis/arthralgia 143(85.1), 25(14.9)
Pericarditis, pleuritis 12(7.1), 3(1.8)
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 21 of 243marrow transplantation (BMT) with a subsequent progressive clinical
improvement. Serum levels of CXCL9 and CXCL10, two chemokines
directly induced by IFNgamma (IFNγ) and of IL-18, were found mark-
edly elevated at disease onset during active phase of MAS. Cytokines
levels decreased progressively during disease course and completely
normalized after the BMT.
Conclusion: This patient with a clinical presentation highly suggest-
ive for sJIA onset complicated by MAS was later diagnosed with PNP
deficiency with HLH. The diagnostic process was driven by some un-
usual features that became apparent when HLH clinical and labora-
tory features were controlled with glucocorticoids. Low T cells and
profoundly defective response to mitogens suggested an immuno-
deficiency, low haptoglobin with positive Coombs test suggested an
haemolytic anemia and increased urinary orotic acid suggested an al-
teration of the pyrimidine biosynthetic pathway. These findings were
consistent with a diagnosis PNP-deficiency. CXCL9, CXCL10 and IL-18
levels suggested that patients with PNP-deficiency may have a sub-
clinical activation of the IFNγ pathway and indeed they are predis-
posed to develop sHLH. Informed consent to publish had been
obtained from the parents.
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Introduction: Juvenile idiopathic arthritis (JIA) is the most common
chronic rheumatic disease in childhood, divided into several sub-
groups. The sJIA could be presented by monocyclic, polycyclic or
persistent polyarticular clinical course. Macrophage activation syn-
drome (MAS) represents the most devastating complication that
could appear during the disease course. Studies on follow up, treat-
ment response and disease complications of the sJIA patients are
spare and rare.
Objectives: To evaluate demographic and clinical characteristics and
to explore the long-term treatment response and disease complica-
tions in a large cohort of sJIA patients from the single center.
Methods: Demographic and clinical features of the sJIA patients were
reached from the patient’s recrods. The frequency of disease flares,
treatment response and side effects were recorded for each patient.
Results: A total of 168 sJIA patients were included in the study: 87
(51.8) female, 81 (48.2) male. The clinical features are shown in Table 1.
Fifty-three (31.5) patients had monocyclic while 23 (13.7) patients had
polycyclic clinical course (mean recurrency of attacks 2.5±2 (IQR:1-4)): in
38 (42). Polyarticular course was present in 92 (54.8) patients. Initially
diagnosis of patients were: infection in 86 (51.1), sJIA in 34 (20.4), acute
rheumatic fever in 19 (11.3), urticaria in 10 (5.9), Kawasaki disease in
4(2.4) and juvenile systemic lupus erythematosus in 2 patients.
The most common disease complications were: MAS in 20 (11.9),
growth retardation in 19 (11.3) and vertebral fracture due to osteo-
porosis in 3 (1.9) patients. Gastrointestinal symptoms secondary to
methotrexate intolerance that led to cessation of treatment were
present in 9 (7.1) patients. Among 5 (2.9) patients that developed tu-
berculosis, 4 (2.3) were under etanercept treatment.
All of the patients were treated with corticosteroids: a doses of 2 mg/
kg/day in 118 (70.2) patients and pulse steroids in 50 (29.8) patients
with severe clinical presentation. The methotrexate was used in 126
(75), leflunomide in 5(3), cyclosporine A in 29 (17.3), intravenousimmunoglobulin in 19 (11.3), anakinra in 27 (16.1), canakinumab in 27
(16.1), tocilizumab in 18 (10.7), etanercept in 50 (29.8) and adalimumab
in 7(4.2) patients. The median time to remission after the initial treat-
ment with corticosteroids was 4 (IQR:2-4) months. The remission off
medications was achieved in 82 (48.8) while remission on medications
was achieved in 83 (49.4) of patients.
Conclusion: Systemic JIA is a subtype of JIA characterized by signifi-
cant morbidity and mortality rate with macrophage activation syn-
drome being the most severe disease complication. Corticosteroids
represent the main treatment modality. Biological agents should be
considered in the steroid-resistant patients. The clinical remission
could be achieved and chronic arthritis sequelae could be prevented
in a majority of patients with biological agents.
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Introduction: The optimal initial treatment for systemic juvenile idio-
pathic arthritis (sJIA) is unclear. Uncontrolled reports suggest that
early treatment with biologic agents likely produces superior short-
term clinical outcomes, but many patients may respond well to non-
biologic therapies. To further study the initial treatment of sJIA, the
Childhood Arthritis and Rheumatology Research Alliance (CARRA)
developed Consensus Treatment Plans (CTPs) to formalize and
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 22 of 243standardize current treatment practices. Subsequently, 4 CTPs were
developed: initial systemic glucocorticoid (GC); initial methotrexate
(MTX) +/- GC; initial IL-1 inhibition (IL-1i) +/- GC; and initial IL-6 inhib-
ition (IL-6i) +/- GC.
Objectives: The FiRst Line Options for Systemic JIA Treatment
(FROST) is an observational study designed to assess the effective-
ness and safety of each of the 4 CTPs and to the compare the CTPs
containing initial biologic therapy (IL-1i and IL-6i) to those that do
not contain initial biologic therapy (GC and MTX).
Methods: Patients with recent onset sJIA who are initiating therapy
are considered for enrollment in FROST. In order to be eligible for
FROST, participants must have fever for ≥2 weeks, arthritis for ≥ 10
days, and at least 1 of the following: evanescent rash, generalized
lymphadenopathy, hepatomegaly, splenomegaly, or serositis. Treat-
ment assignment is at the discretion of the treating physician and
family. All data are collected in the CARRA Registry. To date, 43
CARRA Registry sites have been activated to enroll FROST patients.
Biosamples are collected at baseline and at 6 months. Patient re-
ported outcomes (PRO) of presence of fever and rash and pain
scores are collected at home using mobile devices every 2 days dur-
ing the first 2 weeks of the study. The primary study outcome is clin-
ical inactive disease (Wallace ACR provisional definition) and
cessation of glucocorticoid therapy at 9 months.
Results: Enrollment in the FROST study began in November 2016. As
of April 2018, 26 patients have been enrolled at 13 sites, and their
baseline characteristics are shown in Table 1. The proportion of pa-
tients with specific SJIA disease manifestations was: rash 89%, lymph-
adenopathy 31%, hepatomegaly 15%, splenomegaly 23%, serositis
8%, polyarthritis 46%. Overall, 15 participants (58%) have completed
every requested home PRO during the first 2 weeks of the study,
and 19 (73%) have completed ≥50% of the requested home PRO.
Study follow-up continues to accrue. Eight patients (31%) have com-
pleted the 9-month study visit when the primary study outcome is
assessed.
Conclusion: Enrollment in the FROST study has begun. Participants
enrolled thus far appear to be representative of the general popula-
tion of patients with sJIA. Home PRO collection is feasible through
the CARRA Registry. Additional time is needed to enroll and observe
a sufficient number of patients to assess the comparative effective-
ness of initial treatments for sJIA.
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Characteristic (N=25)
Age (Mean (SD)) 7.2 (5.1)
Female (%) 13 (52%)
Elapsed Days Since Onset of Symptoms (Mean (SD)) 45 (55)
Elapsed Days Since Diagnosis (Mean (SD)) 7 (8)
Physician Global Assessment (Mean (SD)) 6.0 (2.1)
Parent Global Assessment (Mean (SD)) 4.7 (3.2)
Number of Active Joints (Median (IQR)) 3 (2-7.5)
ESR (Median (IQR)) 65 (44-96)
Ferritin (Median (IQR)) 891 (284-2350)P014
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Introduction: Systemic juvenile idiopathic arthritis (sJIA) is a multisys-
temic disease characterized by fever, rash, arthritis and polyserositis.
The most dreadful complication of sJIA is macrophage activation syn-
drome (MAS) that is seen in 10-25% of the cases. sJIA cases may fol-
low monocyclic, polycyclic and chronic polyarticular course.
Objectives: The aim of this study was to demonstrate the frequency
of MAS in sJIA cases and to see whether sJIA cases complicated with
MAS follow a more severe course in the long term.
Methods: Files of sJIA cases that were followed in our clinic between
May 2010 and September 2017 were reviewed. To be included in the
study, the patient had to be coming regularly to follow-up visits and
had to be completed the first six months of the disease.
Results: The cohort consisted of 53 sJIA cases. Mean duration of
follow-up was 39.0 ± 24.1 months. Mean age at the time of diagnosis
was 7.9 ± 4.5 years. There was a female predominance in the cohort
(32 females, 21 males). The frequency of MAS was 33.9% (18 cases).
MAS was observed much more common in male patients than fe-
male patients; 42% vs 28%, respectively.
Bone marrow aspiration was performed to all patients to exclude ma-
lignancy. In 27.7% of MAS cases hemophagocytosis was not ob-
served and hemophagocytosis was observed in 8.5% of cases
without MAS. Initial laboratory test at the time of diagnosis of sJIA
(leukocyte, hemoglobin, platelet, ferritin, triglyceride, ESR, CRP, fi-
brinogen, AST, ALT, albumin, and LDH) were compared in between
patients with MAS and without MAS. Only ferritin and fibrinogen
levels showed significant difference in between the groups (p<0.01).
Patients that developed MAS had higher ferritin (4482 mg/dl) and
lower fibrinogen (371 mg/dl) values than patients without MAS (fer-
ritin 2060 mg/dl, fibrinogen 466 mg/dl) at the time of diagnosis of
sJIA. When these laboratory parameters were compared at the time
of diagnosis of sJIA and at the time of diagnosis of MAS, all parame-
ters showed significant differences except CRP.
Long term follow-up results showed that monocyclic course was ob-
served in 45%, polycyclic course in 32% and chronic polyarticular
course in 23% of the cases. We have observed that patients with
MAS segregated equally into three groups.
All MAS patients were initially treated with high-dose methylprednis-
olone and intravenous immunoglobulin. Additional treatments in
MAS were cyclosporine (12 cases), anakinra (7 cases) and plasma-
pheresis (4 cases).
Biologics were used in 38.8% of all cases. Biologic treatments were
needed in 12.5% of monocyclic cases, in 50% of polycyclic cases and
in 77% of chronic polyarticular cases. At the time of enrollment, 58%
of patients were under remission without medication and 38% were
under remission with medication. Only two cases were active and
both cases were in the group of chronic polyarticular course.
Conclusion: All sJIA patients should be followed for the development
of MAS. High ferritin and relatively lower fibrinogen levels at the time
of diagnosis of sJIA may be early warning signs of impending MAS.
sJIA patients that develop MAS do not seem to portend more
guarded prognosis in the long term follow-up. sJIA patients that fol-
low a chronic polyarticular course are possibly one of the hardest
group of patients to treat in pediatric rheumatology.
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Table 1 (abstract P015). See text for description
MAS sJIA without MAS
Systemic-onset 13 14
Male/Female 7/6 5/9
Age at onset (yrs) 6 (1.1-15.9) 6 (3.1-12.5)
Bone marrow biopsy 13 14
Ferritin >648mg/mL 1,481 (14.9-29970) 587 (73.6-10021)
Platelet count <181k 403 (126-807) 346 (140-923)
AST >48 u/L 43 (17-4613) 99 (15-479)
Triglycerides > 156 mg/dL 150 (57-264) 138 (66-493)
Fibrinogens <360 mg/dL 302 (123-602) 482 (195-820)
CRP (mg/L), 102 (8.4-218.6), 23 (2.0-147.7)
ESR (mm/hr), 73 (4-108), 50 (3-90)
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Introduction: The diagnosis of MAS is difficult. A fall in platelet
count and ESR, in combination with high CRP, are early signs of
impending MAS in a febrile patient with an active rheumatologic
condition. Other features indicative of MAS are hyperferritinemia,
cytopenia involving other cell lines (WBC and RBC), liver dysfunc-
tion, coagulopathy, decreasing serum fibrinogen and increasing
triglycrides.
2016 criteria for classification of MAS in patients with systemic JIA
was conducted of real patient data. These data are based on clinical
and laboratory features at the time of disease onset.
Objectives: The patient with a condition that could potentially be
confused with MAS and active systemic JIA without evidence of
MAS. To evaluate the diagnostic convenience and efficiency of
the 2016 EULA/ACR/PRINTO classification for MAS in patients with
systemic JIA, it will be compared with confirmed MAS by BM
biopsy.
Total 13 MAS is confirmed by BM biopsy. All of these patients are ap-
plied 2016 EULA/ACR/PRINTO classification for MAS in patients with
systemic JIA.
Methods: 2016 new criteria was simplified the diagnostic process
for the convenience. The MAS diagnosis tools are Ferritin, Platelet
count, Aspartate aminotransferase, Triglycerides and Fibrinogen.
This study was a retrospective chart review conducted in the
pediatric department of a tertiary level teaching hospital from 2002
through 2016. The ILAR criteria were identified in each patient at
the time of first presentation to our hospital. Seventy-four patients
were diagnosed with sJIA. 12 boys and 15 girls formed this study
cohort. A comparison of the baseline laboratory characteristics of
patients who fulfilled the ILAR criteria and those with suspected
sJIA has been shown in Table 1.
Results: Diagnosis of MAS is confirmed by presence of haemophago-
cytic histiocytes in bone marrow. Bone marrow biopsy confirmed ac-
tivated histiocytes engulfing a band neutrophil.
Conclusion: A cytokine storm is a consistent feature in patients with
MAS, and it is a potentially life-threatening complication of rheumatic
diseases. The fact that highly effective treatment is needed in the
early stage. So do that, early diagnosis is necessary. The conduct of
the new 2016 classification critieria for MAS also underscored poten-
tial limitations. Additional validation of these criteria will be neces-
sary. The BM biopsy will make up the weakness of limitation and
early diagnosis will be more possible.
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Introduction: The influenza (Flu) is one of the most prevalent infec-
tions in the world and the vaccination is recommended for the pa-
tients treated with immunosuppressive therapy and there is some
immunological research on the Flu vaccination in the patients with
juvenile idiopathic arthritis (JIA). However, the morbidity of Flu in the
patient with JIA in the real-world is unknown.
Objectives: We aimed to evaluate Flu morbidity and side effect of
vaccination in patients with JIA in comparison with the general
population in Japan. And clarify the risk factor of Flu infection for the
patient with JIA.
Methods: From October 2016 to May 2017, a total of 13 participating
medical institutions collected questionnaires from patients with JIA.
The questionnaires focused on the incidence of Flu infection and Flu
vaccination, and the efficacy and side effects of Flu vaccination. The
frequency of each item was compared to that in the general popula-
tion. Multivariable logistic regression analysis was performed to de-
termine the risk factor on the Flu infection.
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males [66%]) were enrolled (mean age, 13.3 years; range, 2.4-37.3
years). Two hundred sixty-eight (57%) patients got the Flu vaccine;
side effects were observed in 58 patients (22%), with no severe
cases. Patients were treated with methotrexate (n=235 [50%];
mean dose, 7.35 mg/m^2/week), prednisolone (n=110 [23%];
mean dose, 0.14 mg/kg/day), and biological disease-modifying
anti-rheumatic drugs (n=327 [69%]). Seventy-four patients (15.6%)
had a Flu infection and the influenza morbidity was significantly
smaller in patients with JIA compared to that in the general
population in Japan (21%)(p=0.005). JIA disease activity flared in
one patient after Flu infection, but no one flared after Flu vaccin-
ation. In logistic regression analysis, the patients with systemic
JIA were high risk for Flu infection (odds ratio:2.666, 95% confi-
dence interval: 1.321-5.475, p=0.007).
JIA: juvenile idiopathic arthritis, MTX: methotrexate, PSL: prednisol-
one, bDMARDs: biological disease-modifying anti-rheumatic drugs,
OR: odds ratio; CI: confidence interval
Conclusion: Influenza vaccination is safe and effective for patients
with JIA treated with glucocorticoids and disease-modifying antirheu-
matic drugs. The risk of Flu infection is significantly high in the pa-
tient with systemic JIA.
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Systemic JIA 2.666 1.321-5.475 0.007
MTX 0.750 0.398-1.419 0.373
PSL 0.766 0.386-1.454 0.428
bDMARDs 0.622 0.310-1.213 0.170
vaccine 0.836 0.490-1.429 0.510P017
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Introduction: Juvenile idiopathic arthritis (JIA) is the most common
chronic rheumatic disease in the pediatric population. These patients
coexist with the chronic disease, and present to a greater extent
negative outcomes such as osteoporosis and cardiovascular diseases.
Objectives: To describe the biomarkers of lipid metabolism related
to the cardiovascular risk of children and adolescents with JIA and to
relate them to variables of the disease, lipid and glucose profile, nu-
tritional status and food consumption.
Methods: Cross-sectional study with 62 JIA patients. The following
were evaluated: disease activity and medications used, body mass
index, height for age (z score), food intake (24 hour recall), lipid pro-
file (total cholesterol - CT, low density lipoprotein - LDL, high density
lipoprotein – HDL, triglycerides - TG and non - HDL), lipid markers
such as apolipoproteins A-I and B (Apo A-I and Apo B). Theassociation analyses were stratified as follows: HDL-c and Apo A-I
into adequate and borderline/low; LDL-c, CT, TG, NHDL-c and Apo B
into adequate and borderline/high; levels of C-reactive protein (CRP)
and erythrocyte sedimentation rate (ESR). For statistical analysis:
Exact Fischer, Chi-square, Mann-Whitney and Spearman Correlation
tests; p <0.05.
Results: The mean age and time since diagnosis were 7.7 years (±
4.3) and 5.0 years (± 3.4), respectively. Active disease was observed
in 33.9% of the patients and the prevalence of dyslipidemia was
62.9% overall when we considered lipid profile alone (CT, LDL-c,
HDL-c, non-HDL-c and TG) and 82.3% when we included altered apo-
lipoproteins (Apo A-I and Apo B). HDL-c and Apo A-I were the most
frequently altered lipid markers. When comparing the subtypes, the
systemic subtype had a higher value and higher frequency of altered
LDL-c and NHDL-c and increased Apo B/Apo A ratio, when compared
to the polyarticular subtype (p = 0.017, 0.042 and 0.03, respectively).
When we cross-referenced the adequate or borderline/low HDL-c
variable against other variables, patients with borderline/low HDL-c
presented lower values and higher frequency of altered Apo A-I
(p<0.001 and 0.001, respectively). There was no significant correlation be-
tween us-CRP and variables related to lipid metabolism. However, ESR
showed a negative correlation with Apo A-I levels (r = -0.25, p = 0.047).
Conclusion: We conclude that dyslipidemia and alteration of lipid
biomarkers are common in patients with JIA. The systemic subtype
and elevated ESR were associated with lower concentrations of Apo
A-I, indicating the participation of the inflammatory process in this al-
teration. Furthermore, the systemic subtype presented higher value
and frequency of atherogenic particles, suggesting that patients with
this subtype are at increased risk for the development of cardiovas-
cular disease.
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Introduction: Increased ferritin is considered biomarker highly sug-
gestive of primary and secondary HLH and it is one of the HLH-2004
diagnostic and MAS guidelines (1, 2), nevertheless it could also be el-
evated in other inflammatory conditions. Interferon-gamma (IFNγ)
and IFNγ induced chemokines, particularly CXCL9, have been demon-
strated to be markedly elevated in patients with primary and second-
ary HLH.
Objectives: To describe eight patients with hyperferritinemia who
fully or partially met the HLH-2004 diagnostic guideline, but in which
the subsequent clinical course and further investigations led to differ-
ent diagnosis that required different therapies and to investigate the
CXCL9 levels in identify diseases that may mimic HLH. To be noted
that soluble CD25 was not measured in these patients.
Methods: Serum CXCL9 levels were analyzed by DuoSet ELISA KIT
DY392 (R&D Systems, Minneapolis, Minn). Normal values of CXCL9
are lower than 700 pg/ml.
Results: We identified 8 patients with laboratory features suggestive
of HLH, included high ferritin levels (>500 ng/ml). Three of these pa-
tients met five of the HLH-2004 criteria, two of them met four criteria
and the others two met three criteria. One patient presented only
high serum ferritin level and cytopenia. CXCL9 levels were <300 pg/
ml in seven of them and approximately 600 pg/ml in one patient.
The clinical disease course and the other investigations ruled out the
diagnosis of HLH and every patient received a different diagnosis.
None of them received treatment for HLH (Table 1).
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tion and promptly therapy are essential to modify the disease course.
One of the most typical feature of primary and secondary HLH is
high ferritin levels. Due to the severity of the disease, sometimes pa-
tients need to be treated before all criteria are fulfilled. The eight pa-
tients reported had features highly suggestive of HLH and met the
HLH-2004 criteria, or part of them. However they all received a differ-
ent final diagnosis. Despite all presented with high ferritin levels,
CXCL9 was low in all. CXCL9 is a chemokine specifically induced by
IFNγ, and has been demonstrated to be markedly elevated in pa-
tients with primary and secondary HLH due to the activation of the
IFNγ pathway. In these cases CXCL9 was able to differentiate diseases
with high ferritin that mimics HLH. High CXCL9 levels appear to be a
potential specific biomarker for HLH diagnosis. Early dosage of CXCL9
levels in patients with hyperferritinemia and with clinical suspicion of
HLH may be helpful for a timely differential diagnosis.
Reference
1. Henter JI et al. HLH-2004: diagnostic and therapeutic guidelines for hemo-
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Collaborative Initiative. Ann Rheum Dis. 2016 Mar;75(3):481-9.
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Pt Gender Months at
onset
HLH-2004
Criteria
Ferritin
ng/ml
CXCL9
pg/ml
Final Diagnosis
1 M 1 5 9.849 <300 Osteopetrosis
2 M 6 5 800 <300 Vitamin B12 deficiency
3 M 1 5 543 <300 Chronic granulomatous
disease
4 M 1 4 15.629 <600 Short bowel syndrome
5 M 3 4 4.378 <300 Cobalamin deficiency
6 F 2 3 37.232 656 Shaken baby syndrome
7 M 165 3 1.400 <300 Ghosal hematodiaphyseal
dysplasia
8 M 172 2 1.184 <300 Primitive myelofibrosis
Table 1 (abstract P020). See text for description
Patient 1 Patient 2 Patient 3 Patient 4
Hemoglobin, g/dl 6.5 11.1 6.9 9.5
Platelet count, x 109/l 32 63 10 90
Aspartate aminotransferase, U/l 77 1015 119 322
Lactic dehydrogenase, U/l 4,852 5,358 4,877 4,683
Fibrinogen, mg/dl 296 < 70 N/A 259
Ferritin, ng/ml 7,122 138,360 3,3250 > 15,000
BUN, mg/dl 86 161 69 157
Creatinine, mg/dl 0.49 2.32 0.9 1.12
Haptoglobin, mg/dl < 2 <2 < 5 3
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Introduction: Macrophage activation syndrome (MAS) is part of the
spectrum of hemophagocytic disorders and is a serious complication
of rheumatologic conditions, mainly systemic juvenile idiopathic arth-
ritis (sJIA). Thrombotic microangiopathy (TMA) is a heterogeneous
group of life-threating diseases characterized by microangiopathic
hemolytic anemia, thrombocytopenia and organ injury. The associ-
ation between TMA and hemophagocytic syndromes has been de-
scribed only in single reports in adult renal transplant recipients andin two pediatric cases of virus-induced hemophagocytic lymphohis-
tiocytosis. TMA complicating MAS has never been reported so far
Objectives: To describe clinical and laboratory features, treatment
and outcome of a cohort of patients with MAS complicated by TMA
Methods: The clinical charts of patients with MAS and TMA seen at 3
Italian tertiary-care pediatric rheumatologic centers were reviewed
retrospectively. Demographic, clinical and laboratory data at the time
of TMA diagnosis were collected. Therapeutic intervention and out-
come were also recorded
Results: Five patients who met the criteria for MAS and developed TMA
during the course of MAS were identified; one patient was excluded due
to insufficient data. The underlying disease was sJIA or a sJIA-like disease
in all patients. The median age at MAS onset was 8.6 years (4.2–12.8 yr),
and the median interval between onset of MAS and occurrence of TMA
was 13.5 days. TMA was characterized in all patients by renal failure with
hematuria, and presence of schistocytes in blood smear. Three of the 4
patients experienced severe CNS involvement, with lethargy, seizures, or
coma. The main laboratory features at TMA onset are shown in Table 1.
For the management of MAS, all patients received high-dose corticoste-
roids and cyclosporine; in 3 cases anakinra was added. All TMA episodes
were treated with plasma-exchange; two patients were also given bio-
logics (rituximab or eculizumab) with good results. During the course of
TMA, aggressive and prolonged management in the Intensive Care Unit
was required in all cases. All patients survived
Conclusion: TMA is a dreadful complication of MAS, which is likely
under-recognized. If not diagnosed timely and treated appropriately,
TMA may precipitate the course of MAS and lead to a fatal outcome.
Clues to suspect TMA in a patient with MAS are the increase in lactic
dehydrogenase and decrease in platelet count out of proportion of the
other laboratory abnormalities, the drop in haptoglobin level, the find-
ing of schistocytes in blood smear, and the new onset of hematuria.
Biologic medications, particularly rituximab and eculizumab may offer
an adjunctive therapeutic option for refractory cases
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Scleroderma overlap’ in children and little data on the clinical charac-
teristics, laboratory features and outcome in this specific group of
JDM have been published. The goal of this survey is to achieve con-
sensus on a meaningful definition of JDM-Scleroderma overlap in
paediatric population and to determine whether overlap features
affect outcome and management.
Objectives: To develop criteria for the diagnosis of JDM-Scleroderma
overlap using an international consensus process.
Methods: A survey was circulated to all investigators in the Juvenile
Dermatomyositis Cohort and Biomarker Study and Repository
(JDCBS) and extended to other members of the Network for JDM in
Paediatric Rheumatology European Society (PReS JDM working party)
through a Delphi survey. Each individual was asked to identify those
clinical manifestations that were felt to be most characteristic to en-
able them to make the diagnosis of JDM-Scleroderma overlap. The
opinions on the importance of identification this subtype of JDM
ware collected and the role of myositis autoantibodies has been
mentioned in the questionnaire.
Results: The survey had a response rate of 26.9% (41 individuals)
from both JDCBS and PReS JDM working party. The most common
clinical features identified by survey responders as found in JDM pa-
tients with scleroderma overlap were sclerodactyly, sclerodermatous
skin change proximal to MCP joints, Raynaud phenomenon and ul-
ceration at the tip of fingers, respectively. 95.1% of responders
though the scleroderma overlap presentations influence the outcome
of JDM, while 86.4% agreed that these features influence the choice
of treatment. Interestingly, all of responders (100%) thought that
negative myositis autoantibodies could not exclude the diagnosis
JDM-Scleroderma overlap, but almost 11% used positive myositis
autoantibodies to diagnose this subgroup of JDM. Myositis associ-
ated autoantibodies occurring in systemic sclerosis overlap (anti PM-
Scl, anti U1-RNP and anti Ku) were thought to be the most com-
monly associated autoantibodies with JDM-Scleroderma overlap
(78%), followed by systemic sclerosis specific autoantibodies (anti
Scl70, anti RNA polymerase III) (44%). Although 83% felt that autoanti-
body profile influences the outcome, only 49% thought that autoanti-
body profile would influence the choice of medication. 89% of
participants in this survey have seen patients with JDM-Scleroderma
overlap.
Conclusion: This process identified clinical features that clinicians felt
to be helpful or important in the diagnosis of JDM-Scleroderma over-
lap. A further process of secondary survey is necessary to agree an
internationally acceptable, clinically usable set of classification criteria.
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Introduction: About 10-20% of patients with Kawasaki disease (KD)
are resistant to intravenous immunoglobulin (IVIg) and are at in-
creased risk of coronary artery abnormalities (CAAs). Early identifica-
tion is critical to initiate aggressive therapies, but available scoring
systems lack sensitivity in non-Japanese populations.Objectives: We investigated the accuracy of 2 Japanese scoring sys-
tems and studied factors associated with IVIg resistance in a large
multiethnic French population of children with KD to build a new
scoring system.
Methods: Children admitted for KD between 2011-2014 in 65 centers
were enrolled. For patients fulfilling American Heart Association
(AHA) criteria, we identified factors predicting resistance to IVIg by
multivariate regression analysis. The performance of our score and
the Kobayashi and Egami scores were compared in our population
and in ethnic subgroups.
Results: Overall, 465 children were reported by 84 physicians; 355
(76%) fulfilled AHA criteria (55% European Caucasian, 12% North Afri-
can/Middle Eastern, 10% African/Afro-Caribbean, 3% Asian and 11%
mixed). Eighty patients (23%) needed second-line treatment. Japa-
nese scores had poor performance in our whole population (sensitivity
52-44.5%). Predictors of IVIg resistance were ALT≥30 IU/L, hemoglobin
level <10 g/dl, lymphocyte count <1500/mm3, modification of extrem-
ities, CAAs at initial echocardiography, and time to treatment <5 days.
The best sensitivity (80%) and specificity (65%) of this model was with
weighted variables and cut-off ≥ 17.5/50 points. The sensitivity remained
good in our 3 main ethnic subgroups (78-83%).
Conclusion: We identified predictors of IVIg resistance and built a
new score with good sensitivity and specificity in a non-Asian
population.
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Introduction: Persistent fever and inflammation after infusion of 2g/
kg of IVIG, the standard treatment of KD represents a high-risk situ-
ation for coronary aneurysms in Kawasaki disease. Identifying pa-
tients at risk for IVIG resistance is difficult outside the Asian
population, and there remains a critical unmet need to identify an
anti-inflammatory treatment that is efficacious in all KD patients. Re-
cent evidence from studies in animals and humans suggest a critical
role for interleukin-1 (IL-1) α and β in the pathogenesis of KD.
Objectives: To identify the clinical characteristics, reasons for use and
response to treatment with anakinra in a retrospective series of pa-
tients with Kawasaki Disease (KD).
Methods: A retrospective chart review of patients treated with ana-
kinra for KD diagnosed according to the AHA criteria. We compared
clinical, biological and echocardiographic characteristics of KD before
and after anakinra use. We analysed reasons for use of anakinra, and
compared treatment regimens used in 7 European KD referral
centres.
Results: Eight boys and 3 girls with treatment-refractory KD, aged 4
months to 9 years old, received at least 2 different KD treatments
prior to anakinra, which was given on mean at 25 days after disease
onset (8 to 87 days). The main reasons for use of anakinra were clin-
ical and biological inflammation, progression of coronary dilatations,
and severe myocarditis with cardiac failure. Doses of anakinra ranged
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 27 of 243from 2 to 8 mg/kg and duration varied from 6 to 81 days. On ana-
kinra treatment, fever disappeared within hours (<24 h) in 3 patients,
and within 2 and 6 days in two patients respectively. Six others pa-
tients were not febrile at onset of anakinra. In addition, CRP levels fell
two to three fold within 48 hours in 7/9 evaluable patients. In terms
of its effect on coronary artery dilatation, Z scores decreased in 10/
11 patients and increased in one who died suddenly of pericardial
hemorrhage.
Conclusion: Anakinra used late in the disease course led to a rapid
and sustained improvement in clinical and biological inflammation.
However, our retrospective analysis did show neither a striking nor a
rapid decrease of coronary dilatations and we cannot determine if
anakinra itself had an effect on coronary artery dimensions. More ro-
bust data will be available soon from the two Phase II ongoing trials,
KAWAKINRA using anakinra treatment early after one failure of IVIG
treatment (European Clinical Trials no. 2014-002715-41) and ANAKID
(ClinicalTrials.gov identifier: NCT02179853), focused on patients with
coronary giant aneurysms.
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Introduction: Takayasu arteritis (TA) is a chronic large-vessel vascu-
litis affecting the aorta and its major branches. Glucocorticoids (GCs)
can achieve remission in most patients with TA. As most patients suf-
fer relapse after reducing GCs, additional therapy such as methotrex-
ate, azathioprine and intravenous cyclophosphamide (IVCY) has been
applied. Recently, the efficacy of TNF-α inhibitors or tocilizumab
(TCZ) has been reported. However, there remain insufficient data on
clinical characteristics and outcomes of patients with childhood-
onset TA, including recent therapeutic advances.
Objectives: We aimed to retrospectively analyse the characteristics
and outcomes of patients with childhood-onset TA in two tertiary
centres in Japan.
Methods: Subjects were 24 patients with TA diagnosed when youn-
ger than 18 years. Follow-up duration was more than 2 years. Diag-
nosis of TA was based on the EULAR/PRINTO/PRES criteria. We
divided the subjects into two groups: those who did and did not ex-
perience relapse. Relapse was defined as NIH criteria for active dis-
ease in TA.
We analysed the patients’ background, treatment and complications.
We additionally compared two groups according to prednisolone
(PSL) reduction rate and whether or not they carried HLA-B52.
Binary data were analysed by Fisher’s exact test, and quantitative
data by Mann-Whitney U test. The cumulative relapse rates after the
diagnosis were estimated using the Kaplan-Meier method; differ-
ences between two groups were assessed by the log-rank test.
Results: Median age at onset was 13.0 (range; 0.5-18.0) years old
(male:female, 11:13). Thirteen patients (54%) had HLA-B52. Period
from onset to diagnosis was 1 (0-66) months. Angiographic classifica-
tions were I, IIa, IIb, III, IV and V (n=3, 2, 4, 1, 2 and12), respectively.
Four patients and one patient had pulmonary artery involvement
and coronary involvement, respectively.
Three patients achieved drug-free remission. Median dose of prednis-
olone (PSL) was 0.8 (0.4-2.4) mg/kg/day at initiation of treatment and
0 (0-0.3) mg/kg/day at the last visit. Immunosuppressants were used
in 13 (54%) from the onset and in 21 (88%) at the last visit. IVCY was
used in 10 patients (42%) from the onset, and 4 after the relapse.Some biologics were used in 4 (17%) from the onset, and in 12
(50%) at the last visit.
Twelve patients (50%) experienced relapse, and median number of
relapses was 3 (1-6) times. The ratio of relapse was not significantly
different between the HLA-B52 positive and negative patients (69%
vs 27%, P=0.099). However, median duration from diagnosis to the
first relapse was significantly shorter in HLA-B52 positive patients
than negative patients (6 vs 51months, P=0.016). The reduction pace
of PSL was significantly greater in relapsed patients than non-
relapsed patients (0.058 vs 0.025 mg/kg/month, P=0.017). The cumu-
lative relapse rates after the started IVCY or TCZ were not signifi-
cantly difference between the patient who introduced IVCY (n=14)
and TCZ (n=12) (P=0.10).
Nine patients (38%) had cardiovascular complications (aortic valve re-
gurgitation (AR) (n=4), annuloaortic ectasia (AAE) (n=1) and AR+AAE
(n=4)). Two patients underwent cardiac surgery. Ten patients had
osteoporosis, 2 had surgery for glaucoma and 5 had some mental
disorders in their clinical coarse.
Conclusion: Approximately half of the patients with childhood-onset
TA experienced relapse despite using immunosuppressants and/or
biologics. HLA-B52 positivity and rapid reduction rate of PSL signifi-
cantly increased risk of early relapse. Furthermore, cardiovascular in-
volvement and GCs-related complications were common. Our study
suggests the outcome of childhood-onset TA remains unfavourable.
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Introduction: International Myositis Assessment and Clinical Stud-
ies Group (IMACS) developed the Myositis Damage Index (MDI)
structured separately for pediatrics and adults, to provide
consistency in myositis outcomes. The MDI documents persistent
changes in 11 organ systems thought to be related to damage.
There is a dearth of studies on damage caused by Juvenile Derm-
atomyositis (JDM) especially from less resourced countries and
hence our study.
Objectives: Primarily to assess the myositis damage index in a cohort
of children with JDM from a single centre in Mumbai, India and sec-
ondarily to study associations of factors leading to long term damage
in these children.
Methods: After ethics approval and consents, a total of 23 patients
with JDM under regular treatment and at least a 2 year follow up, at
first study visit were identified. Specifically excluded were children
with overlap syndromes eg scleromyositis. The MDI was assessed as
severity of damage and extent of damage at the first study visit and
reassessed at a second visit at least six months later and only damage
present at both visits were scored to give a final severity and extent
of damage score. There were no drop outs.
Results: 23 children with age range at disease onset 1y - 17.9 y
(mean 6.9 y, median 6.8 y, IQR 3.5-8.8) were diagnosed as JDM after
a duration of symptoms ranging 1m-30 m (mean 6.8 m, median 5 m,
IQR 3-8.5). Their age at the study visit ranged from 5.5 y - 24.8 y
(mean 13.4 y, median 12.9 y, IQR 10.4-15.3) after a follow up duration
ranging from 2 y - 20.1 y (mean 5.9 y, median 4.2 y, IQR 2.6-8.5, Total
136.5 patient years). The disease course was monocyclic in 14, con-
tinuous in 6 and polycyclic in 3. The total MDI extent of damage score
ranged from 0- 8 / 35 (children) or 37 (adolescents) (mean 2.04, me-
dian 2.0, IQR 0.5-2.5) and severity of damage score ranged from 0-
24.7 /110 (mean 4.7, median 3.5, IQR 1.3-6.4). 17/23 children had
damage in one or more organ systems, with 9 showing damage in
one organ system, 4 in two organ systems, 3 in three organ systems
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 28 of 243and 1 child showed damage in six systems. Cutaneous (16/23), endo-
crine ie growth retardation (6/23) and muscle (5/23) were the most
commonly damaged organ systems with 2 children showing skeletal
damage while ocular, gastrointestinal and cardiac domains were in-
volved in one each. Importantly, over this duration of follow up there
were no children with infection, pulmonary, peripheral vascular dis-
ease or malignancy. Correlation between age at onset, gender, time
to diagnosis, course of disease and duration of follow up did not
yield statistically conclusive results.
Conclusion: This is amongst the earliest studies to report damage
due to JDM from less resourced countries. Over the median follow
up period of 4.2 years about 75% of the children suffer damage in
one or more domains, cutaneous damage being the commonest.
Uniquely despite high infection rates in the community, this domain
was unaffected in our population. Continued enrolment with longer
duration of follow up are needed to shed light on factors influencing
damage.
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Introduction: The first composite disease activity score for juvenile
dermatomyositis (JDM), named JDMAI, has recently been developed
and validated in retrospective patient datasets. It is composed of 4
domains and takes into account the parents’ perception of disease
status. The 6 preliminary versions of the tool performed similarly in
previous validation analyses.
Objectives: To test prospectively the validity of the JDMAI in a sam-
ple of JDM patients seen in daily practice.
Methods: A total of 53 JDM patients seen consecutively at 2
tertiary-care paediatric rheumatology centers, either at disease
onset or at a follow-up visit, a median of 2.3 years after disease
onset, were enrolled. Each patient received a retrospective assess-
ment and a cross-sectional evaluation at study entry. Twenty-two
patients also underwent a second (prospective) assessment after
a median of 3.5 months from study entry. Physician-centered
evaluations included assessment of muscle, skin and overall dis-
ease activity on a visual analogue scale (VAS) or through the Dis-
ease Activity Score (DAS), rating of disease state and course and
measurement of disease damage with the Myositis Damage Index
(MDI). Laboratory data comprised muscle enzymes and ESR.
Parent-reported outcomes were collected through the administra-
tion of the Juvenile Dermatomyositis Multidimensional Assess-
ment Report (JDMAR). Validation analyses included assessment of
construct validity, internal consistency (with Cronbach’s α), dis-
criminant ability, and responsiveness to change in disease state
over time (with standardized response mean, SRM).
Results: All JDMAI versions showed strong (r>0.7) correlations with
muscle disease activity VAS (0.85-0.87), muscle section of DAS (0.81-
0.83), total DAS (0.89-0.92), pain VAS (0.72-0.75), and fatigue VAS
(0.92-0.93). The correlations of the different JDMAI versions with the
skin index not contained in the specific version (skin disease activity
VAS or skin section of DAS) were strong (0.74-0.79). As expected,
JDMAI correlations were moderate (r=0.4-0.7) or low (r<0.4) with la-
boratory parameters (CK, LDH, AST, ALT, and ESR) and with the MDI
(0.1-0.11). The SRM was greater in patients judged as improved by
the physician or the parent (1.26-1.56) than in those judged as not
improved (0.88-1.11). Cronbach’s α was very high (0.89-0.91) for all
JDMAI versions. All JDMAI versions discriminated strongly betweenpatients classified in different disease activity states by the physician
(p<0.0001) or by the parent (p=0.002-0.005), and between patients
whose parents were satisfied or not satisfied with their children’s dis-
ease status (Mann-Whitney U test, p=0.0005-0.0008).
Conclusion: Validation analyses in this prospective patient sample
confirmed that the JDMAI possesses good measurement properties
and is a suitable and reliable tool for the assessment of disease activ-
ity in children with JDM both in clinical practice and research. Im-
portantly, the new tool revealed a strong capacity to capture the
improvement of disease activity over time.
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Introduction: Juvenile dermatomyositis (JDM) is the most common
of the pediatric inflammatory myopathies characterized by inflam-
matory microvasculopathy.
Nailfold videocapillaroscopy (VCP) is an in vivo, rapid, and inexpen-
sive imaging technique that allows quantitative assessment of micro-
circulation. VCP has demonstrated a key role in diagnosis and
disease monitoring. The most severe videocapillaroscopy semi-quan-
titative changes previously reported as loss of capillaries, enlarged
loops and brushy capillaries are associated with longer disease dur-
ation1. There is a lack of specific quantitative measures of the capil-
laries during disease curse.
Objectives: To describe qualitative and semi-quantitative VCP as-
sessment in Mexican patients with JDM
.
Methods: The present study was a cross-sectional observational
study that analyzed 192 images from 24 patients with JDM during dif-
ferent of the disease course, form 3 diferent centers in Mexico. VCP
was performed by the same examiner (AVT), images were ob-
tained from all fingers except thumbs of both hands using a videoca-
pillaroscope with a 200x optical probe. The images were collected,
coded, and stored using OptiPix software (version 1.7.16).Semi-quanti-
tative assessment for architecture were scoredfollowing the inter-
national definitions for the capillary abnormalities.2 Quantitative
assessment consist in the measurement of the number of capillaries
per millimeter, capillary loop length, capillary width, intercapillary dis-
tance in micron (μm)3.
Results: Twenty four patients with JDM were included, 62.5% fe-
male. The qualitative assessment reveal only 4 images with normal
capillaroscopy pattern, nonspecific alterations were found in 31.2%.
Conclusion: VCP is a noninvasive image method that’s provides a
window to microcirculation and allows quantitative assessment of
nailfold capillaries with a grave reliability and gave reproducible
results. This study found more quantitative alterations than previ-
ously reported. A combination of qualitative and quantitative
measures can be used for JDM diagnosis, monitoring and re-
sponse to treatment.
To our knowledge this study is the first in measuring quantitative,
semi-quantitative and qualitative parameters of the microvascula-
ture in juvenile dermatomyositis.
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Table 1 (abstract P027). See text for description
R2 R3 R4 R5
Median (range)
L2 L3 L4 L5
Fingers (n=24)
Bizarre 2
(0-5)
2
(0-5)
2
(0-5)
2
(0-4)
2
(0-5)
2
(0-7)
2 (0-5) 3
(0-4)
Giant
capillary
3
(0-6)
3
(0-7)
3
(0-5)
3
(0-6)
2
(0-6)
3
(0-7)
2 (0-6) 2
(0-6)
Enlarged
capillary
3
(0-6)
3.5
(0-7)
4
(0-7)
3.5
(0-8)
3
(0-6)
3.5
(0-7)
4.5 (0-8) 5
(0-8)
Mean in n/mm and in μm (S.D)
Quantitative
Density 4.92
(1.79)
5.20
(1.91)
5.08
(2.06)
5.21
(1.28)
5.00
(1.50)
5.71
(2.01)
5.43 (1.67) 6
(2.24)
Total
width
75.87 94.02 85.64 71.24 65.55 64.01 72.27 58.9
Total
length
299.21 276.05 286.05 284.14 282.41 261.41 291.73 270.99
Intercapillary
distance
111.23 104.04 125.62 110.93 109.88 107.66 117.58 98.43
*R2:Right hand second finger, R3:Right hand third finger, R4:Right hand fourth
finger, R5:Right hand fifth finger, L2:Left hand second finger, L3:Left hand third
finger, L4:Left hand fourth finger, L5:Left hand fifth finger
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Introduction: The inflammatory idiopathic myopathies (IIM) are a rare
group of myopathic autoimmune diseases diagnosed in both adults
and children. Patients’ present with proximal muscle weakness with
associated skin changes in dermatomyositis. Immunohistochemical
analysis of muscle tissue from these patients has identified immune
cell infiltrate and the expression of pro-inflammatory cytokines how-
ever, little is known about the peripheral immunological profile in ju-
venile and adult patient groups.
Objectives: To identify specific immune cell signatures and cytokine
profiles for disease subtypes and correlate this data with measure-
ments of disease activity.
Methods: 44 adult myositis (AM) patients, 15 Adolescent-onset ju-
venile dermatomyositis (JDM) patients, 25 age-matched adult healthy
controls (AHC), and 15 age-matched teenage healthy controls (THC)
were recruited with appropriate ethical approval after obtaining writ-
ten informed consent. Peripheral blood mononuclear cells (PBMC)
were isolated from patient and control samples. PBMC from all
groups were analysed by flow cytometry to quantify 32 lymphocyte
populations including; T-cell, B-cell and monocyte subsets. The AM
patients were grouped according to myositis subtype; 19 dermato-
myositis (DM), 9 polymyositis (PM), 7 DM + overlap, 4 DM + cancer
and 5 PM + overlap). Disease activity was determined by MITAX
score and clinicians’ decision on treatment; remission off treatment,
remission/mildly active/active on treatment. Cell populations were
analysed by group for differences in fold change/adjusted p value
(1-way ANOVA with Tukey’s multiple comparison).
Results: There was an idenified T cell signature in ADM (increased
Th17, Tregs and CD4+ naïve), a B cell signature in APM (CD27+/- B
cell ratio) and a T cell signature in JDM (CD4/CD8+ T cell ratio). A de-
crease in CD8+ central memory T-cells was observed in both AM and
JDM patients compared to healthy controls, this reduction was most
significant in active disease. AM patients also had reduced CD27+
memory B-cells compared to both JDM patients and healthy controls.AM patients in remission off treatment had increased non-classical
monocyte subset frequencies, whereas JDM patients off treatment
had elevated CD8+ EMRA T-cells. Th17 cells were significantly in-
creased in ADM compared to JDM samples (mean = 3.68 vs. 0.64, ad-
justed p value = 0.0032). More specifically increased Th17 cells were
found in ADM but not APM (mean = 3.67 vs. 0.68, adjusted p value =
0.0019). However, the Th17 population was highest in AM patients
that were in remission on treatment (remission on treatment vs AHC,
mean = 2.68 vs. 0.84, adjusted p value = 0.038).
Conclusion: This group of diseases are notably heterogeneous both
clinically and immunologically as shown by the complex immuno-
phenotyping patterns identified within myositis subgroups. This
study identified signatures unique to adult compared to juvenile
disease, and between AM patients on treatment and during re-
mission. The Th17 signature concurs with studies pinpointing
these cells within the muscle tissue. This data supports the need
for further investigation for the use of IL-17A inhibitors in the
treatment of the IIM.
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Introduction: There are various diagnostic and classification criteria
for myositis, but they are not always suitable for juvenile idiopathic
inflammatory myositis (JIIM). To establish standard diagnostic criteria,
the International Myositis Classification Criteria Project (IMCCP) pub-
lished the EULAR/ACR classification criteria for idiopathic inflamma-
tory myositis (IIM) in 2017.
Objectives: To evaluate the validity of the EULAR/ACR classification
criteria with JIIM cases in Japan.
Methods: We used clinical and laboratory data from a group of JIIM
patients and a comparator group comprised of non-JIIM patients
with mimicking conditions collected at seven major pediatric
rheumatology centers in Japan between 2008 and 2015. A diagnostic
confirmation made at least 6 months prior to the study by a pediatric
rheumatologist was used as the inclusion criterion for this study.
Results: The total of 117 patients (68 JIIM patients and 49 non-JIIM
patients) were included to the study. For the validation analysis, we
applied 55% probability cutoff, which corresponds to “probable IIM”,
based on the IMCCP study. The IMCCP’s diagnostic standard gave us
an almost equivalent sensitivity (86.7% without muscle biopsies;
92.1% with muscle biopsies) and a higher specificity (100% without/
with muscle biopsies) compared to the data reported in the IMCCP
study. We also confirmed an improved sensitivity with the EULAR/
ACR classification criteria, compared to other traditional diagnostic
criteria (e.g. 86.7 % with the EULAR/ACR criteria vs 80.9% with the
Bohan and Peter criteria). In terms of the diagnostic accuracy, the
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EULAR/ACR criteria and the physician-diagnosed subgroups in our
dataset were 100% for Juvenile amyopathic dermatomyositis (DM) and
Juvenile hypomyopathic DM. The proportions were 93.2% for JDM and
43.2% for Juvenile polymyositis (JPM), for seven cases (3 JDM patients
and 4 JPM patients) were not properly classified as JIIM.
Conclusion: Our validation study with Japanese JIIM cases indicates
that the EULAR/ACR classification criteria for IIM generally perform bet-
ter than existing diagnostic criteria for myositis in diagnosing JIIM.
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Introduction: Juvenile dermatomyositis (JDM) is a rare and heteroge-
neous inflammatory myopathy. Clinical features may be severe and
disease course refractory to standard treatment with corticosteroids
and methotrexate (MTX). Evidence for a critical role of the type I
interferon (IFN) pathway in the pathophysiology of dermatomyositis
exists in both childhood and adult forms of the disease.
Objectives: To report the first case of severe vasculopathic JDM suc-
cessfully treated with the JAK 1/2 selective inhibitor ruxolitinib.
Methods: Retrospective chart review from initial presentation to last
follow-up. We assessed type I IFN status by IFNα digital-ELISA quanti-
fication in serum, STAT1 phosphorylation and RNA expression of IFN-
stimulated genes in whole blood.
Results: A previously healthy 13-year-old girl presented with cutane-
ous lesions and a severe proximal muscle weakness (Childhood Mus-
cular Assessment Score, CMAS 2/52, and Manual Muscle Testing,
MMT 38/80) characteristic of JDM. CK level was elevated and anti-
NXP2 antibodies positive. Muscle biopsy revealed severe vasculo-
pathic lesions. Despite treatment with prednisone (1.2mg/kg/day)
and MTX, she developed tetraplegia, dysphonia, dysphagia, intestinal
involvement, and new skin lesions. Treatment escalation with IVIG,
plasma exchange (5/week), rituximab, and increased prednisone re-
sulted in clinical improvement. Thus, plasma exchanges were subse-
quently spaced out and discontinued 6 months after diagnosis.
However, three weeks later, recurrent muscle weakness necessitated
the restart of plasma exchanges, increase of prednisone, a 4th dose
of rituximab, and initiation of mycophenolate mofetil (MMF). While
prednisone and the frequency of plasma exchanges were slowly ta-
pered, she developed two further muscular, cutaneous and intestinal
relapses, as well as a diffuse fascia calcinosis, at 12 and 18 months
after diagnosis. High levels of IFNα protein in the serum (238, 75, and
46 fg/mL, normal < 10 fg/mL) and an increased expression of ISGs
were documented. A constitutive phosphorylation of STAT1 and
STAT3 was recorded in T lymphocytes and monocytes from the pa-
tient compared with controls. Considering these results, ruxolitinibwas started (10mg x 2/day). Rituximab and MMF were discontinued.
Within 2 months, CMAS and MMT scores increased from 47 to 52
and from 57 to 79, respectively. Plasma exchanges were discontinued
and prednisone decreased. Eight months post initiation of ruxolitinib,
JDM was clinically inactive according to the PRINTO criteria and pred-
nisone was tapered (0.15mg/kg/day). Ruxolitinib was well tolerated.
Serum levels of IFNα stabilized and STAT1 phosphorylation in mono-
cytes was comparable to a control 4 hours after drug intake. In-
formed parental consent was obtained for the use of ruxolitinib on a
compassionate basis and for conducting the experiments.
Conclusion: Efficacy of JAK1/2 inhibitors has previously been re-
ported for severe dermatomyositis in adults and for certain mono-
genic interferonopathies in children. Our findings suggest that JAK
inhibition may also represent an efficacious and well-tolerated thera-
peutic option in a subset of patients with recalcitrant JDM. Informed
consent for publication had been obtained from the parents.
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Introduction: Juvenile Dermatomyositis (JDM) is a rare, potentially
life threatening condition. Beginning with mild fatigue and weakness,
the condition can occur at any age, and currently there is no known
cure. Some children and young people can experience fluctuations
between remission and relapse throughout their childhood, into ado-
lescence and beyond. There is very little evidence about the psycho-
logical impact this condition has on children and young people, and
none that has asked them directly, however, through experience
from clinical practice and conversations with those affected, we
know the effects can be profound.
Objectives: The aim of this study was to identify the lived experience
of children and young people between the ages of 8 and 19 years of
age diagnosed with JDM. This study constitutes the first part of a lar-
ger mixed-methods study.
Methods: Ethical approval was gained to interview children and
young people who were enrolled in a wider cohort study. Young
people were interviewed either using creative arts based methods,
such as drawing in a comic book and parallel discussion, or with a
standard verbal interview. Young people were all asked: ‘what it is
like to have JDM?’ Further questions were used to probe or to add
clarity. Interviews took place when attending a specialist Rheumatol-
ogy clinic or the inpatient Rheumatology Ward of a tertiary specialist
Rheumatology Centre or during a specially arranged home visit.
Results: Fifteen young people offered to share their story, their
demographics are shown in Table 1. The interviews lasted between
18 to 130 minutes and all, with permission, were audio recorded.
They were transcribed verbatim and analysed using Interpretive
Phenomenology.
The overarching metaphor of a ‘Rollercoaster’ was developed from
the interview transcripts, to depict the ups and downs of having
JDM. From initial difficulties with diagnosis by local health profes-
sionals of a rare disease to feeling comfort at getting a diagnosis, to
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start to work and some improvement is felt. The ‘Rollercoaster’ meta-
phor is visual, easy to explain and understand, and will allow young
people to feel some support from seeing the journey ahead.
Within this overarching construct, there are five themes which
emerged from the data. These are: being-confused in the beginning;
being-different; sick-steroidal-and-scared of the medicines; being-
uncertain; and having-acceptance, as the JDM journey continues for
many years.
Conclusion: This study is the first to ask children and young people
what it is like to have JDM, and to recount the ‘ups and downs’ of
their lives and describe the ways that JDM affects them. The results
from this study will lead to a wider study asking young people all
over the United Kingdom to share their story through surveys exam-
ining aspects which have been highlighted so far, this will lead into
dissemination workshops to share the results found not only with
children, young people and their families, but also with health
professionals.
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interviewed
Gender 6 males, 9 females
Ethnicity 12 White British, 3 other
Age at interview 8 – 18 years (median 12 years)
Age diagnosed 2 – 16 years (median 8 years)
Disease duration 3 weeks – 16 years (median 5 years)
Disease severity From acute inpatients to remission off medicines
Table 1 (abstract P032). Clinical characteristics of children with JDM
and adults with DM
Clinical Characteristics JDM (n=13) Adult DM (=10) P value
MMT 80 median [IQR] 78 [73-80] 78 [67-80] ns
DAS skin median [IQR] 2 [0.5-2] 0.5 [0-2.5] ns
PGA median [IQR] 0.8 [0-3.5] 2 [0-7] ns
Presence of Calcinosis (%) 7 (54%) 2 (20%) ns
Arthritis (%) 6 (48%) 3 (30%) ns
Interstitial lung disease (ILD) (%) 1 (8%) 7 (70%) p=0.002
ANA positivity (%) 6 (46%) 10 (100%) p=0.02
CK U/L median [IQR] 93 [70.5-668] 46 [43-134] ns
Monotherapy/ Biologic agents
with other DMARDs
4 (31%)/3 (23%) 3 (30%)/1 (10%) ns/ nsP032
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Introduction: Adult and juvenile patients share several hallmark
features of dermatomyositis (DM) but important clinical differ-
ences may reflect different disease triggers between children and
adults.
Objectives: We aimed to compare the disease characteristics be-
tween children with juvenile dermatomyositis (JDM) and adults with
DM and to explore the presence of nailfold capillaroscopy (NFC)
changes abnormalities between the two populations.
Methods: Data were analyzed from children and adults who met
Bohan-Peter criteria for DM. Childhood Myositis Assessment Scale
(CMAS), Manual Muscle Testing (MMT8), muscle enzymes and physi-
cians global assessment (PGA) were recorded at the time of last clin-
ical appointment. Skin disease was assessed using modified skin
disease activity score (DAS). By NFC was assessed nailfold capillary
density, capillaries shape, presence of hemorrhage and neovascular
pattern. Fisher's test was used to test differences between categoricalvariables and Mann-Whitney U test for continuous not-normally dis-
tributed variables.
Results: In total 23 patients were analyzed and compared (13 JDM
and 10 adult DM). The female:male ratio was 9:4 in JDM and 9:1 in
DM. The median age at disease onset was 5.6 years [2.7-10.1] for
JDM and 50.6 years [43.3-60.4] for adult DM, the median disease
duration was 8.4 years [4.4-15.38] for JDM and 2.3 years [1.2-12.5]
for adult DM (p=0.1) and the median time of disease follow-up was
6.7 years [4.3-9.3] for JDM and 2.3 years [1.3-11.3] for adult DM.
Table 1 reports the clinical characteristics for both groups. Adult
DM had a significantly higher proportion of lung involvement and
ANA positivity compared with JDM (p=0.002 and p=0.02, respect-
ively). Dilated capillaries, giant capillaries, hemorrhage and neovas-
cular pattern were found in 86%, 0%, 29% and 14% of JDM
patients, respectively, and in 71%, 26%, 43% and 29% of adult pa-
tients, respectively, but with no statistically significant difference
between children and adults. Clinically inactive disease was found
in 38% and 10% of JDM and adult DM patients, respectively. All of
those children have stopped medication. There was one case of
malignancy in an adult DM patient.
Conclusion: Nailfold microvascular abnormalities were found in
most of the NFC parameters, in JDM patients assessed for after a
median of 8 years of disease, which might reflect the long-term
microangiopathy associated with this disease. Regarding the stud-
ied clinical features, in our cohort, the adult DM patients have
higher lung involvement when compared to JDM.
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Introduction: Idiopathic myopathies are heterogeneous disorders
characterized by muscle weakness and inflammation. Dermato-
myositis is the most frecuent subgroup in pediatrics. Juvenile
Dermatomyositis (JDM) in addition to muscle involvement is char-
acterized by typical skin rashes (Gottron´s sign and heliotrope
rash). Recently, a new proposal of diagnostic criteria was
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 32 of 243presented but patients at debut may had a great variety of mani-
festations due to the multisystemic nature of this condition. Close
to the diagnosis and in the long term, a great variety of compli-
cations can occur and affect the survival and the quality of life
of patients
Objectives: To descrive debut and course of a group of Colombian
patients with Juvenile dermatomyositis
Methods: Multi-center, retrospective, descriptive, case series study.
The review of medical records with a unique format was carried out
in Bogotá, Cali, Cartagena and Barranquilla. The data analysis was
performed with SPSS 20
Results: N = 94 patients. 67% female with an average age at diag-
nosis of 7,78 years (range of 1-18 years) and follow-up time of 46
months (SD 39 months). The average time between the onset of
symptoms and the definitive diagnosis was 7,6 weeks (1-60). In
37% of patients, skin manifestations preceded muscle involvement
and was moderate-severe in 67%. Clinical manifestationts at de-
but: 88% heliotrope rash, 90% Gottron´s sing, malar erythema
78%, periungueal erythema 67%, skin ulcers 25%, 37% arthritis
(31% polyarticular), pulmonary compromise 4%, vasculitis 14%
fever 19% and 25% calcinosis (22% mild-moderate). Seventy five
percent of patients had CPK < 5000 at debut and 49% had positive
antinuclear antibodies. Monocyclic course in 53% of patients. Dur-
ing the follow-up 33% presented calcinosis, 44% muscular atrophy,
52% persistent muscular weakness, 14% osteoporosis and 14%
short stature. 99% of patients received steroid at debut (44% intra-
venous) and 86% during follow-up. 97% received methotrexate
and 13% required a biological medication (92% Rituximab). 70% of
the patients were classified by the treating rheumatologist as ad-
herent to the treatment and 14% of patients had associated other
autoimmune diseases. Patients with mild skin involvement at de-
but had a higher frequency of monocyclic course (p 0,009)
Conclusion: The skin involvement can be the initial manifestation in
an important percentage of patients with JDM. The severity of skin
involvement can be variable and related to the type of course. JDM
requires an intensive, dynamic and monitored management that al-
lows a rapid control of the disease, monitor the appearance of short
and long term complications and the association with other auto-
immune diseases
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Introduction: Post-streptococcal syndrome consists of a wide
spectrum of non-suppurative disorders: erythema nodosum, uveitis
and/or scleritis, post-streptococcal glomerulonephritis, periostitis, vas-
culitis, rheumatic fever and post-streptococcal reactive arthritis. It can
also include an entity with myalgia as the solitary presenting symp-
tom called post-streptococcal polymyalgia (PSPM).
Objectives: To alert to clinical features of PSPM and present Coimbra
classification criteria.
Methods: Retrospective study. Selection of the patients with post-
streptococcal reactive polymyalgia followed in Coimbra’s pediatric
rheumatology department in the last 30 years.
Patients were included based on the following criteria (all):
1) Diffuse myalgia – acute onset, incapacitating and severe pain;
2) Palpation induced muscle pain;
3) Normal serum creatine kinase (CK);
4) Supporting evidence of a recent preceding streptococcal infection
(elevated streptococcal antibodies, or (+) cultures or rapid antigen
tests for streptococcus groups;5) No Exclusion criteria: a) > 1. major manifestations of the revised
Jones criteria for rheumatic fever (2015); b) periostitis.
Results: The unit followed 119 children with poststreptococcal react-
ive musculoskeletal symptoms: 61 rheumatic fever, 55 poststrepto-
coccal reactive arthritis and 3 had only diffuse myalgia - acute onset,
incapacitating and severe pain (one girl and two boys).
The mean age at diagnosis was 5,7 years. Tonsillitis was the previ-
ous streptococcal infection in all patients (one scarlet fever). The
time span between the infection and myalgia presentation had a
variation between 25 and 30 days. The longest myalgia duration
was nine weeks and the shortest was one week and four days.
Lower limbs were involved in all patients and upper limbs in two.
Arthralgia without arthritis was present in two patients. At diagno-
sis visual analog score (VAS) of muscle pain was ≥ 80 mm and all
patients had elevation of inflammatory markers (erythrocyte sedi-
mentation rate between 86 and 102mm/h and C-reative protein be-
tween 4,9 and 6 mg/dl) and normal creatine kinase (CK) values. The
antistreptolysin O titre (ASLO) performed in all patients were
strongly positive (≥ 800 U/l and ≤ 1820 U/I) and echocardiog-
raphy was normal. Two patients had full recovery with NSAIDs
but one refractory patient also needed prednisolone (1mg/kg)
during four weeks.
Conclusion: Severe diffuse pain and tenderness of skeletal muscles
without accompanying arthritis is an under-recognized feature of
post-streptococcal disease. High ASLO titre with normal CPK in a
child with myalgia should alert PSPM diagnosis. We propose the Co-
imbra diagnostic criteria for PSPM.
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Introduction: Juvenile dermatomyositis (JDM) is a systemic auto-
immune capillary vasculopathy that predominantly affects the mus-
cles and cutaneous tissues. In JDM cases, myosonography can
reportedly be used to evaluate disease activity and perform follow-
up monitoring. However, the effectiveness of myosonography in clin-
ically amyopathic JDM (CA-JDM) is undetermined.
Objectives: To investigate the myosonographic findings in patients
with CA-JDM.
Methods: Myosonography was performed in three patients with
CA-JDM. Case 1 was a 2-year-old male with full range of motion
in manual muscle testing (MMT), positive anti-TIF-1γ antibody re-
sults, and superficial perivascular dermatitis; case 2 was a 4-year-
old male with full range of motion in MMT, negative myositis-
specific autoantibody results, and superficial perivascular dermatitis;
case 3 was a 14-year-old female with full range of motion in MMT, posi-
tive anti-MDA5 antibody results, interstitial pneumonia, and superficial
perivascular dermatitis. Case 3 had minimal evidence of myositis on
MRI and in a biopsied specimen. Laboratory testing revealed normal
creatinine kinase concentration in all three cases. The ultrasonographic
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 33 of 243assessment was performed in the bilateral biceps brachii and quadri-
ceps femores.
Results: In case 1, the right biceps and quadriceps had increased
echo intensity compared with the left side, and the power Doppler
signal was positive on the perimysium in the left biceps and quadri-
ceps. In case 2, the echo intensity was increased in the bilateral bi-
ceps and quadriceps, and there was a positive power Doppler signal
on the perimysium in all muscles. In case 3, there was a high echo in-
tensity and positive power Doppler signal on the perimysium in the
left quadriceps, and there was a suspected positive power Doppler
signal on the epimysium in the left quadriceps.
Conclusion: Myosonography detected muscle abnormalities in CA-
JDM. Myosonography may be effective for JDM screening in patients
with no clinical muscular abnormalities who are suspected of having
JDM due to skin characteristics. Informed consent to publish had
been obtained from the parents.
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Introduction: Children with Kawasaki disease (KD) and pyuria have
been misdiagnosed with urinary tract infection (UTI).
Objectives: We compared clinical and laboratory features at admis-
sion between two groups of infants under 6 months of age, who
showed initial pyuria, to find useful clinical clues to the initial suspi-
cion of KD.
Methods: We reviewed the medical records of febrile infants under 6
months of age with pyuria over a 10-year period (2007-2017). We in-
cluded infants with sterile pyuria who were finally diagnosed with
KD and those with UTI.
Results: During the 10-year study period, a total of 121 patients
under aged 6 months were diagnosed as KD. 41 (33.9%) of the 121
KD children had pyuria. Of the 41 pyuria patients, 12 had sterile py-
uria, 7 had concomitant UTI, and 16 had combined bacterial growth
which had to be excluded. The other 6 patients were unidentified
because they did not perform the urine culture tests. Two patients
satisfied the diagnostic criteria of complete Kawasaki disease,
whereas the others were diagnosed with incomplete Kawasaki
disease.
During the same period, 378 infants under 6 months of age were
diagnosed with UTI. We compared the clinical and laboratory fea-
tures between the 12 KD infants with sterile pyuria and the 378
UTI infants. The median age of the KD group (5.2 months;
range,2.5-5.9 months) was higher than that of the UTI group (3.6
months; range 0.9-6 months) (P =.002). The male/female ratios in
the KD and UTI infants were 1.4 (7/5), and 2.8 (277/101),
respectively.
The days of fever before admission and total duration of fever were
longer in the KD group than in the UTI group (P < 0.01). Compared
with the UTI group, the KD group demonstrated a significantly
higher platelet count (P = .04), level of C-reactive protein (CRP) (P <
0.01) and erythrocyte sedimentation rate (ESR) (P < 0.01). UTI group
showed higher presence of positive urine nitrite test (P < 0.01). No
significant differences were evident in blood leukocyte count, abso-
lute neutrophil count, haemoglobin, alanine transaminase, aspartate
aminotransferase, albumin, sodium, total bilirubin and urine β2-
microglobulin (β2-MG)Conclusion: Our study can provide early clues to suspect KD in fe-
brile infants with pyuria.
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Introduction: Henoch Schönlein purpura (HSP) and Kawasaki dis-
ease (KD) are the most common childhood vasculitis. Rare condi-
tions like pancreatitis, aseptic menengitis, pneumonia do not
belong to the classical criteria of KD and defined as atypical KD.
Similarly gastrointestinal involvement are excepted features
of HSP. Few cases of HSP and KD related pancreatitis have been
reported. Herein, we report two acute pancreatitis cases associ-
ated with KD and HSP.
Objectives: A 10-year-old boy consulted with a 6-days history of
fever, abdominal pain, vomiting and a scarlatiniform rash. Initial
blood tests showed Hb 9.7 g/dl, WBC 14.2 × 10 9/L, platalet count
442 ×10 9/L, C-reactive protein 68.8 mg/L, erythrocyte sedimentation
rate 65 mm/hr, albumine: 2.8 g/dL, increased amylase of 639 U/L and
lipase 2056 U/L. In echocardiographic examination myocarditis was
seen and pro-BNP level was 11418 pg/ml. Intravenous immünoglobu-
lin (IVIG) at a dose of 2 g/kg and aspirin 40 mg/kg/day was given
with a preliminary diagnosis of atypical Kawasaki disease. The patient
became afebrile 24 hours later. In the second week of the disease
thrombocytosis (platelet count, 780 ×10 9/L) and periungual des-
quamation of his fingers and toes were observed. Coronary arteries
were normal and cardiac contractions were good in echocardiog-
raphy. His pancreatitis had resolved with a normal amylase of 97 U/L
and lipase of 29 U/L within two weeeks.
Methods: A 6-year-old girl was referred with a 4-days history of
vomiting and abdominal pain. Her physicial examination was nor-
mal except abdominal tenderness. Initial investigations showed
Hb 14.4 g/dl, WBC 41.8 × 10 9/L, platalet count 443 ×10 9/L, C-
reactive protein 50.6 mg/L, erythrocyte sedimentation rate 1mm/
hr, albumin: 1.9 g/dL. In abdominal ultrasonograpy hydrops of
gallbaldder was detected. Few days later purpuric rash on her
legs was observed. She was diagnosed as HSP and prednisolone
at a dose of 2 mg/kg/day was given to her. Despite steroid treat-
ment, back and chest pain added to abdominal pain. Increased
amylase of 344 U/L and lipase 294 U/L levels were detected at
the seventh day of disease, but ultrasonographic pancreatitis was
not observed. In addition to fat free diet intravenous fluids and
pulse steroid treatment (30 mg/kg, for 3 days) was given. In the
second week of the disease proteinüria was detected in 24 hour
urine testing, and mesengioproliferative glomerulonephritis was
diagnosed in renal biopsy. Pulse cyclophosphamide treatment
was started her for HSP nephritis. Her pancreatitis resolved within
a month
Results: HSP and KD are most common types of vasculitis in children.
But, HSP and KD associated pancreatitis is uncommon. There are aut-
opsy studies about KD associated pancreatitis. The association be-
tween pancreatitis and HSP is rare.
Conclusion: In conclusion HSP and KD related pancreatitis is rare.
HSP-related pancreatitis should be considered when abdominal pain
is prolonged and present with changing character of pain. KD should
be considered in the presence of acute pancreatitis and prolonged
fever even the patient does not meet all the criteria. Informed con-
sent to publish had been obtained.
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Introduction: Kawasaki disease (KD) is one of the most common vas-
culitis of childhood. Coronary artery involvement is the most import-
ant complication of the disease and the major cause of the mortality.
IVIG resistance is defined as persisting or recurring fever at least 36
hours after the end of intravenous infusion of immunoglobulin (IVIG).
Although there are some scoring systems trying to predict, it is not
always possible to forsee the IVIG resistance and coronary artery
involvement.
Objectives: The aim of this study is to assess the success of the
Kobayashi scores and other parameters in predicting IVIG resistance
and coronary artery involvement in Turkish population.
Methods: Patients who were diagnosed in the acute phase of
Kawasaki disease at Hacettepe University Faculty of Medicine
(Ankara,Turkey) between June 2007- January 2016 were retro-
spectively and January 2016- February 2018 were prospectively
reviewed and included in this study. Clinical findings, laboratory
parameters, echocardiographic findings, response to IVIG treat-
ment, Kobayashi, Egami, Formosa, Harada scores were evaluated.
The diagnosis of Kawasaki disease was made using the criteria of
the American Heart Association.
Results: A total of 100 patients with Kawasaki disease were in-
cluded in this study. Of the patients with KD, 61 (61 %) were
male and 39 (39%) were female. The mean age at diagnosis of
Kawasaki disease was 48.9 ± 34.9 months, with an age range of
4–164 months. All of the patients had fever while, 77 (77%) of
them had conjunctival congestion, 74 (74%) of them had muco-
sal, 72 (72%) of them had rash, 69 (69%) of them had lymph-
adenopathy and 68 (68%) of them had extremity changes. Fifty
two (52%) patients had complete KD and 48 (48%) patients had
incomplete KD.
Patients younger than 1 year (p<0,001) were found to be associated
with a significantly higher risk for coronary artery involvement. No
significant differences were found between the IVIG-resistant and
IVIG-responsive groups in terms of age (p:0.215).
Significant differences were found between the coronary artery le-
sions (CAL) and non-CAL groups in terms of age, white blood cell
and erythrocyte sedimentation rate.
Compared with the IVIG-responsive group, the IVIG-resistant group
had higher C-reactive protein (CRP) and gamma glutamyl transferase
(GGT) levels.
Of the 100 patients who were administered IVIG, 85 (85%)
responded to IVIG treatment, whereas 15 (15%) were IVIG resist-
ant. Coronary artery involvement was detected in echocardiog-
raphy at diagnosis in 38 patients. Twenty patients had Kobayashi
high-risk scores, 9 patients had Egami high risk scores. The For-
mosa score assigned 45 patients as high-risk. The Harada score
assigned 54 patients as high-risk. Only the Egami score predicted
IVIG resistance in the Turkish population, none predicted coronary
artery involvement.
Conclusion: Studies from different countries revealed that the risk
scores were incapable of defining the IVIG resistance in KD. This may
be atributed to ethnic differences. The Kobayashi score, Harada
score, Formosa score in Turkish population did not predict the IVIG
resistance and coronary artery involvement, but high white blood
cell count, high erythrocyte sedimentation rate and age ≤1 were as-
sociated with coronary artery involvement; high CRP, high GGT, and
Egami score are associated with IVIG Resistance in Turkish
population.
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Introduction: Eosinophilic granulomatosis with polyangiitis (EGPA) is
a rare small and medium-sized-vessel vasculitis characterized by the
presence of vasculitis manifestations and eosinophilia in a previously
asthmatic patient.
Objectives: Increase awareness for the diagnosis of EGPA and discuss
possible treatment strategies.
Methods: Description of a patient with EGPA.
Results: 13-year-old male with allergic rhinitis, asthma and history
of dust mite allergy, under therapy with montelukast and inhaled
and nasal corticosteroid, with multiple episodes of wheezing and
shortness of breath in the last year. The patient presented to the
emergency department after seven days of arthralgias, myalgias
and asthenia and two days of fever. On physical exam a diffuse
petechial rash with hemorrhagic suffusions was detected. Blood
tests revealed hemoglobin 15.9g/dL, leukocytes 34990/μL, neutro-
phils 27.4%, eosinophils 63.2%(23160/μL), platelets 202000/μL, C-
reactive protein (CRP) 10.56mg/dL, ALT 129UI/L, AST 92UI/L, LDH
529UI/L and CK 515UI/L. Ceftriaxone and doxycycline were started
and the patient was admitted to the hospital. Blood cultures
were negative, as well as the aspergillus galactomannanantigen
and serologies for Rickettsia conori, erlichia, brucella, leptospira,
cytomegalovirus, Ebstein Barr virus, parvovirus, adenovirus, cocsakie
and echovírus. Within 72 hours a deterioration of the clinical sta-
tus was observed. The patient had dyspnea, chest pain, signs of
respiratory distress, hypoxemia, tachycardia, hipotension and oly-
guria. It was detected leukocytosis 48390/μL, eosinophilia 30000/
μL and elevated CRP 16.5mg/dL, CK 962 mg/dL, troponin
1686ng/L and NT-proNBP 14800pg/mL. Tryptase was normal
(3.9mcg/L). Bilateral pulmonary insterstitial infiltrates with bilateral
pleural effusion were identifed on chest x-ray and ECG and echo-
cardiogram were suggestive of myopericarditis. The patient was
admitted to the pediatric intensive care unit. Antibiotherapy was
switched to vancomicin plus meropenem and anti-inflammatory
drugs, furosemide, espironolactone and immunoglobulin were
started. Due to hemodinamic instability, mechanic ventilation
and aminergic support were needed. Further exams were per-
formed: bronchoalveolar lavage was negative for bacteria and
fungi; myelogram showed hypercellular medulla with increased
non-clonal eosinophils (41%); skin biopsy revelead leukocytoclas-
tic vasculitis with eosinophils and direct immunofluorescence
compatible with vasculitis. Anti-myeloperoxidase (MPO) antineu-
trophil cytoplasm antibodies (ANCA) were negative. The genetic
analysis for hypereosinophilia syndrome mutations was negative.
The pediatric rheumatology team was called to observe the pa-
tient and, according to the clinical presentation and laboratory
results, the diagnosis of EGPA was made. The patient was started
on methylprednisolone i.v. 1 g per day for three days. A fast clin-
ical, laboratory and radiological improvement occurred, including
complete regression of eosinophilia. Currently, more than six
months after this episode, the patient is followed at the pediatric
rheumatology outpatient clinic and there are no signs of disease
activity under therapy with azathioprine (2mg/kg) and prednisol-
one in progressively lower doses.
Conclusion: We present a patient with EGPA, fulfilling 5 of 6 cri-
teria (asthma, eosinophilia exceeding 10% of the total white
blood cell count, history of allergy, pulmonary infiltrates, extravas-
cular eosinophils), associated with musculoskeletal and cardiac
abnormalities and negative anti-MPO ANCA. In conclusion, EGPA
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 35 of 243is a potentially life-threatening condition, clinical suspicion and
early treatment of these patients are thereby crucial.
For this case submission written informed consent was obtained
from the patient and family.
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Introduction: Henoch-Schönlein purpura nephritis (HSPN) is the
most severe complication of Henoch-Schönlein purpura (HSP) that
can occur at any time of the disease process and includes iso-
lated microscopic or macroscopic hematuria, mild or heavy pro-
teinuria with or without nephrotic syndrome, renal failure and
hypertension.
Objectives: To determine a possible prognostic factor for earlier
HSPN onset, to explore indications for kidney biopsy according to
urine analysis and the correlation between 24-h urinary protein levels
and biopsy findings, as well as biopsy findings and patient outcome.
Methods: The cross-sectional study included all children with HSPN
diagnosed by EULAR/PRES/PRINTO criteria from 2009 to 2017 at 5
tertiary care centres in Croatia.
Results: Out of 540 patients diagnosed with HSP, 91 children who
developed HSPN (16.85%) were included. The patient population
with HSPN included 52 boys (57.14%) and 39 girls (42.86%). Median
(range) age of HSP diagnosis was 8 years (1.5-17.5) and from the HSP
diagnosis to HSPN onset was 1.5 (0-60) months. Median (range)
follow-up time was 44 (4-167) months. Nephritis was present in
18.68% of cases at the HSP onset. No statistically significant differ-
ence or correlation was found between the time of HSP diagnosis to
HSPN onset and gender, age, purpura distribution, joint and gastro-
intestinal involvement. Kidney biopsy was done in 26 patients
(28.57%). Among them, 3 patients had isolated persistent hematuria,
3 had isolated proteinuria and 20 patients had both hematuria and
proteinuria. Median (range) 24-h urinary protein levels in patients
who underwent biopsy was 1.28 (0-7.46) g/dU. The leading indication
for biopsy was simultaneous hematuria and proteinuria (p<0.001),
while isolated proteinuria was not a determining factor (p=0.592).
Isolated hematuria was a statistically significant factor in detecting
patients who were not likely to have a biopsy (p<0.001). Biopsy find-
ings were graded with different classifications: 7 with Oxford classifi-
cation, 6 with Haas, 1 with ISKDC, while 4 were classified
simultaneously with Oxford and ISKDC. Only descriptive findings
were available for 8 biopsy specimens. No statistically significant dif-
ference was found in 24-h urinary protein levels between different
biopsy findings. 68% of HSPN patients were treated with corticoste-
roids out of which 17.6% patients took immunosuppressive or/and
antihypertensive drugs in addition to corticosteroids. Most patients
had good outcome, with normal physical exam findings and no signs
of renal disease in laboratory tests (78%), or with microhematuria
and proteinuria <1g/dU (17.6%), while only 4 patients (4.4%) had a
more severe outcome with proteinuria >1g/dU. No significantdifference was found in patient outcome for different biopsy findings
(p=0.214).
Conclusion: Simultaneous hematuria and proteinuria was a statisti-
cally significant factor for kidney biopsy. However, while isolated pro-
teinuria was not the sole determining factor, excessive levels of 24-h
urinary proteins should be taken in consideration. Due to the small
number of patients and no uniform classification generally used in
grading biopsy findings, a statistically significant difference in regard
to outcome could not be confirmed, indicating the need for both in
future research.
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Introduction: Polyarteritis nodosa (PAN) is a necrotizing vasculitis of
predominantly medium size vessels.
Objectives: The present study aimed to summarize the characteris-
tics of PAN patients, and also analyse the trend of decreasing PAN
frequency in the last 25 years, in Turkey.
Methods: Paediatric and adult PAN patients followed up in Hacet-
tepe University and Istanbul University Cerrahpasa Faculty of Medi-
cine between 1990 and 2015, were included. The demographics,
clinical findings and outcomes were evaluated retrospectively.
Results: One hundred thirty-three patients, including 66 children,
were enrolled in the study. The median (minimum-maximum) age at
symptom onset and diagnosis were 16 (2-75) years and 17 (3-75)
years, respectively. The mean follow-up duration was 13 (2-27) years.
Among 133 patients, 86 (64.7%) had fever, 108 (81.2%) had skin in-
volvement, 54 (40.6%) had renal involvement, 43 (32.3%) had neuro-
logical involvement, 32 (24.1%) had gastrointestinal involvement, 10
(7.5%) had cardiac involvement, 6 (4.5%) had pulmonary involve-
ment. The median (minimum-maximum) leukocyte count, erythro-
cyte sedimentation rate and C-reactive protein levels at the time of
diagnosis were 10400 (6100-32000)/mm3, 58 (2-132) mm/h and 5.22
(0-46) mg/dL, respectively. All patients were ANCA negative. Hepatitis
serology was analyzed in 121 patients and found positive in 13 of
them. MEFV mutations were screened among 65 patients, 24 of them
had mutations in at least one allele. Biopsy was performed in 109 pa-
tients and computerized tomography (CT) angiography was per-
formed in 92 patients. Myalgia and skin involvement were
significantly more frequent in children whereas neurologic involve-
ment was much more common among adults (Table 1). The number
of PAN patients declined significantly after 2010. 9 patients were re-
categorized as DADA2 after 2014 and no patient were diagnosed
with FMF+PAN after 2008.
Conclusion: Our results suggest a decrease in PAN in our country
which may be due to improved healthcare and dissecting mimicking
diseases. Further prospective studies with prolonged follow-up could
help us to better understand the disease characteristics.
Trial registration identifying number:
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Table 1 (abstract P041). Characteristics of paediatric and adult PAN
patients
Features, n (%) Patients
(n=133)
Paediatric patients
(n=66)
Adult patients
(n=67)
P value
Fever 86 (64.7) 50 (75.7) 36 (52,9) 0.06
Myalgia 79 (59.4) 48 (72.7) 31 (46.2) 0.01
Abdominal pain 65 (48.9) 40 (60.6) 25 (37.3) 0.05
Skin involvement 108 (81.2) 63 (95.5) 45 (67.2) <0.001
GIa involvement 32 (24.1) 17 (25.7) 15 (22.3) 0.64
Renal involvement 54 (40.6) 22 (33.3) 32 (47.7) 0.09
Cardiac involvement 10 (7.5) 8 (12) 2 (2.9) 0.04
Neurologic involvement 43 (32.3) 14 (21.2) 29 (43.2) 0.007
Exitus 6 (4.5) 0 (0) 6 (8.9) 0.007
aGI, gastrointestinal
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Introduction: Deficiency of adenosine deaminase type 2 (DADA2)
is an autosomal recessive genetic disease causing systemic in-
flammation and vasculitis resembling polyarteritis nodosa,
caused by loss of function mutations in the ADA2 gene. Treat-
ment of DADA2 with biologic agents targeting TNF-alpha is par-
ticularly effective, but has side effects, is expensive and is
required to be given by injection for life. We are curently explor-
ing an alternative treatment strategy for DADA2 using gene
therapy. Since there is no rodent orthologue of ADA2 an import-
ant first objective for this programme of work was to develop a
cell line model to explore if it is possible to correct in vitro the
defects associated with DADA2 using gene transfer strategies.
Objectives: To develop an ADA2 knockout (KO) monocyte cell line
(THP-1) derived using Clustered Regularly-Interspersed Small Palin-
dromic Repeats (CRISPR)/CAS9 and to confirm that this KO has com-
parable immunophenotype to macrophages from DADA2 patients as
indicated by reduced ADA2 expression and M1/M2 skewing and pro-
inflammatory cytokine production.
Methods: A plasmid delivered CRISPR/CAS9 system was used to gen-
erate the ADA2 KO THP-1 cell line. ADA2 enzyme activity was
assessed using a modified commercially available assay and ADA2
protein expression using immunoblotting. THP-1 cells were treated
with PMA to induce differentiation into macrophages before polarisa-
tion into M1 through LPS/INF-γ stimulation; and M2 polarisation
through IL-4, IL-10 and Il-13 stimulation. Immunophenotyping was
assessed using qPCR.
Results: We first confirmed effective knockout of ADA2 at both gen-
etic sequencing and protein expression level. We further established
reduction of ADA2 enzyme activity by almost 50% in culture super-
natants when compared to scramble control THP-1 cells
(p<0.01). There was significant upregulated gene expression for sev-
eral proinflammatory molecules: TNF-α (p<0.001), CXCL-10 (p<0.001),
STAT-1 (p<0.01), CCL2 (p=0.05) and IL-1β (p<0.001) in M1 polarised
ADA2 KO THP-1 cells when compared to control THP-1 cells. M2 po-
larisation of ADA2 KO THP-1 cells did not affect expression of
CD200R and CD206 compared to control cells.
Conclusion: We have successfully generated an ADA2 genetic KO
myeloid cell line using the CRISPR/Cas9 system. We confirmed that
ADA2 KO THP-1 cells have a comparable immunophenotype tomacrophages from DADA2 patients and exhibit reduced ADA2 en-
zyme activity. This in vitro cell line model can now be used to exam-
ine the possibility of reversing the defects associated with DADA2
using gene editing strategies.
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Introduction: Kawasaki disease (KD) is an acute vasculitis occurring
mainly in children under 5 years of age. The central issue is the pre-
vention of cardiac damage that may occur early and be life-
threatening, requiring admission in intensive care unit (ICU). At ad-
mission in ICU, clinical features of KD may be incomplete or atypical;
especially difficult to distinguish from a severe sepsis. In this context,
the criteria defined by the American Heart Association (AHA) are not
always conclusive to guide the management in acute phase, includ-
ing initiation of appropriate treatment, such as intravenous immuno-
globulin (IVIG).
Objectives: The aim was to compare phenotype and evolution of KD
hospitalized in ICU (KD-ICU) with complete AHA criteria (cKD-ICU) or
incomplete criteria (iKD-ICU).
Methods: Complete criteria of KD were defined as: ≥5 days of fever
and ≥4 main clinical items. Incomplete criteria were defined as: ≥5
days of fever and ≥2 main clinical items (or ≥7 days of unexplained
fever) and inflammatory syndrome with either ≥3 evocative bio-
logical abnormalities or coronary dilatation. All patients had to be
hospitalized in ICU. We collected retrospectively KD-ICU cases be-
tween 2001 and 2018, from a national appeal of French medical
societies (SOFREMIP, GRFUP). Data regarding clinical, biological, ultra-
sound and therapeutic features were recorded. Statistics were per-
formed with Fischer test (PRISM 5.0); averages were compared with
significance defined as p <0.05 (MedCalc).
Results: 25 patients met the criteria of cKD-ICU, 23 patients met the
criteria of iKD-ICU. Patients were hospitalized in ICU for: shock
(37.5%), unstable hemodynamics (16.7%), acute neurological disorder
(10.4%), myocarditis (8.3%), large coronary artery aneurysm (6.2%);
ICU hospitalization duration was 7.8 ± 6.2 days, intubation rate of
45.8%, amines / cardiotropes of 45.8%, vascular filling 33.3% (all simi-
lar in both groups). 2 patients died of myocardial infarction. Differen-
tial diagnoses initially suggested were: unexplained fever / poorly
tolerated bacteremia (45.8%), peritonitis / severe colitis (25%), toxin
shock (12.5%); the diagnostic delay was 4.4 ± 1 days (similar in both
groups). No significant differences were found concerning age at
baseline (3.6 ± 0.6 vs. 2.1 ± 0.5 years old), sex ratio (0.9 vs 0.5 M / F,
p> 0.05) respectively in cKD-ICU and iKD-ICU patients; total duration
of fever, initial biology or extreme values (hemoglobin, platelets, leu-
cocytes, CRP, ASAT, ALAT, natremia) were also similar in both groups.
iKD-ICU patients were more frequently hospitalized in ICU before on-
set of fever (43.4 vs 8%, p = 0.01). The delays between onset of signs
or hospitalization in ICU and the first course of IGIV were similar in
both groups. Intravenous corticosteroid therapy was used in 36% of
cKD-ICU vs 20% of iKD-ICU patients (p = 0.2); a second course of IGIV
was used in 52% of cKD-ICU vs 47% of iKD-ICU patients (p = 0.7). All
patients received a broad-spectrum antibiotic. Other therapeutics
and evolution features were not significantly different between 2
groups.
Conclusion: KD-ICU patients had no initial or evolutive differences
whether they met complete or incomplete AHA criteria. The strong
suspicion of KD is therefore enough to initiate specific therapeutics
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 37 of 243even in severe complicated forms. An upcoming study will precise
the phenotype of patients with KD-ICU to target them earlier, com-
paring them to KD patients who did not need ICU stay, via the
KAWANET French database.
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Introduction: We present the case of a five year old male presenting
with fever, abdominal pain and rectal bleeding. He had a history of
rash and arthralgia, diagnosed as Henoch Schonlein Purpura (HSP).
Objectives: To illustrate the life threatening complications that can
infrequently occus with HSP
Methods: He had a widespread purpuric rash with necrotic lesions and
swollen extremities (figure 1). He was anaemic. Urine dipstick detected
proteinuria and erythrocytes. Renal biopsy showed proliferative glomer-
ulonephritis with strong deposition of IgA (figure 2). Anti-neutrophil
antibodies, Anti- nuclear antibodies and double stranded DNA were
negative with normal complement. IV methyl-prednisolone was com-
menced. He continued to deteriorate with worsening renal function
and respiratory deterioration. Chest X Ray showed bilateral focal abnor-
malities (figure 3). During intubation, he bled secondary to pulmonary
haemorrhage. He required high frequency oscillation ventilation.
Results: He received cyclophosphamide and plasmapheresis followed
by prednisolone and enalapril. He made slow improvement. He continued
to have heavy proteinuria and haematuria but his renal function gradually
improved. He made good recovery. Within two weeks he was mobile, off
oxygen, with no cutaneous scars and no gastrointestinal symptoms.
Conclusion: Henoch-Schönlein purpura (HSP) is the most common
type of IgA vasculitis in childhood. It usually runs a benign and self-
limiting course [1]. Pulmonary-Renal involvement is a rare but life-
threatening complication requiring early recognition and aggressive
treatment [2]. In the deteriorating child with HSP, one must be aware
of this serious complication.
(1) Petty R, Laxer RM, Lindsley CB, Wedderburn LR (eds): Textbook of
Pediatric Rheumatology, ed 7. Philadelphia, Elsevier, 2016.
(2) Aeschlimann FA, Yeung RSM, Laxer RM, et al. A toddler presenting
with pulmonary renal syndrome. Case Rep Nephrol 2017; 7:73-80
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Introduction: Kawasaki Disease (KD) is an acute and self-limited vas-
culitis, potentially leading to severe complications such as coronary
artery aneurysms (CA). Patients with giant aneurysms (z score> 10 or
> 8 mm) are at high risk of complications such as thrombosis and
stenosis. Young infants and those with refractory KD have a high riskof developing CA. These patients would likely benefit from an early
and aggressive treatment, although the most appropriate treatment
strategy remains unknown. To date 3 cases of pediatric patients with
giant aneurysms have been published showing a good response to
anti IL-1 (anakinra). In addition, 3 clinical trials with antiIL-1 are cur-
rently ongoing. Abciximab (monoclonal antibody against the GPIIb /
IIIa glycoprotein receptor located on the surface of platelets) has
been used in cases with giant aneurysms and preliminary data sug-
gests a positive effect on the vascular remodeling.
Objectives: We highlight the favorable medium term outcome and
suggest the potential benefit of anti-Il-1 therapy and abciximab in
this clinical setting.
Methods: We report the case of KD with a severe clinical course and
the development of multiple, large CA despite an early and aggres-
sive treatment.
Results: A 6 months-old male Asian infant was admitted with high
fever for 4 days, submandibular adenopathy, conjunctival injection,
red lips and macular rash. He was initially treated as a bacterial infec-
tion but lack of clinical improvement despite empirical intravenous
antibiotic therapy and the development of clinical symptoms sug-
gestive of KD lead to the performance of a trans-thoracic echocardio-
gram revealing a dilatation of the left coronary artery and an
aneurysm of the anterior descending coronary artery. Treatment with
intravenous immunoglobulins (IVIG) 2 mg/kg and ASA 50 mg/kg/d
was initiated (day 6). Due to the persistence of fever and raised acute
phase reactants a second IVIG dose was administered at day 8. Given
the severity of symptoms, laboratory tests (49160/mcl leukocytes,
PCR 295 mg/l, proBNP 1261pg/ml), the patients’ age and the echo-
cardiographic findings, corticosteroids (30mg/kg/dose) were pre-
scribed (day 8, 9 and 10) without clinical improvement and the
patient was therefore transferred to our center.
Because of the refractory clinical picture and the remarkable coron-
ary findings(multiple CA, the highest in right coronary artery:14mm,
z-score: 39.89) anakinra(4mg/kg/day) was started on day 11. The
dose was increased to 8mg/kg/day, and abciximab(initial dose of 2
mg/kg/day followed by a 12 hour intravenous infusion of 1.6 mg
with ICU monitoring) was added to the treatment plan on day 14
with resolution of the clinical symptoms and normalization of the la-
boratory parameters (except trombocytosis 1295000/mm3). He was
discharged 1 month after the onset of symptoms and managed as
an outpatient with anakinra (8mg/kg/day), ASA, heparin and ta-
pered corticosteroids. At discharged the ecocardiogram showed a
significant dilation of the coronary aneurysms, with 2 giant aneu-
rysms of 9.7 mm, z-score 26.17 and 12 mm, z-score 33.59 in the
right coronary artery. Anakinra was stopped one month after discharge.
Subsequent echocardiographic controls (seven months later), showed a
significant improvement (largest aneurysm 2.5 mm, z-score: 2.93).
Current treatment is limited to AAS and heparin.
Conclusion: Despite adequate initial KD management, there remains
a group of patients which develop serious cardiac complications. The
identification of these high risk patients and the establishmentof
guidelines forrisk-adjusted therapy are needed in order to optimize
the management and subsequently the outcome of these patients.
Informed consent had been obtained from the parent.
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Introduction: Kawasaki disease (KD) is a systemic vasculitis of
medium-sized arteries in young children. KD has various complica-
tions, including arthritis, which is a common complication. Arthritis in
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 38 of 243the febrile acute phase of KD is likely to resolve following improve-
ment of systemic symptoms. However, some patients have persistent
or new-onset arthritis in the subacute phase of KD. There have been
few studies of arthritis in the subacute phase of KD.
Objectives: This study aimed to evaluate the clinical characteristics,
laboratory findings, imaging findings, treatment, and prognosis of
arthritis in the subacute phase of KD.
Methods: We assessed patients with arthritis in the subacute phase
of KD in our institute, a tertiary medical facility in Yokohama city,
from April 2008 to January 2018. We retrospectively examined the
treatment for KD, coronary artery lesions (CALs), affected joints, C-
reactive protein (CRP) levels, matrix metalloproteinase-3 (MMP-3)
levels, imaging findings, treatment for arthritis, and outcome of arth-
ritis using the patients’ electronic medical records.
Results: Fifteen patients were enrolled. The median age of patients
was 46 months (range, 10–116 months) and most were boys (60%).
Five (33%) patients had arthritis in the acute phase of KD, and the
arthritis resolved once with acute treatment of KD, except for one pa-
tient. Four (27%) patients were treated with single administration of
intravenous immunoglobulin (IVIG) and 11 (73%) required additional
IVIG. Infliximab (IFX) was administrated to seven (47%) patients and
plasma exchange was performed in one because of IVIG resistance.
One patient developed CALs. Arthritis was detected most in the
knees (67%), followed by the ankles (47%) and hip joints (40%). Six
(40%) patients had a consistent fever. At diagnosis of arthritis, CRP
levels increased again in 14 (97%) patients and MMP-3 levels were el-
evated in 14 (97%) patients. Ultrasound showed joint fluid in all pa-
tients, but none showed synovial proliferation accompanied by a
positive power Doppler signal. Nonsteroidal anti-inflammatory drugs,
steroids, and methotrexate were administered for arthritis in 13
(87%), 11 (73%), and one (6.7%) patient, respectively. Among these
treatments, steroids promptly improved arthritis without developing
CALs. The median administration period of steroids was 46 days
(range, 12–249 days). The arthritis resolved without sequelae in all of
the patients, and they successfully discontinued treatment.
Conclusion: Arthritis in the subacute phase of KD is relatively com-
mon, and the arthritis does not cause destruction of joints and cartil-
age. However, some patients suffer from persistent arthritis for
several weeks. For persistent arthritis, short-term steroid therapy can
help to ensure rapid improvement without a new complication of
CALs. The pathogenesis of arthritis in the subacute phase of KD remains
unclear, but arthritis occurs, despite administration of IFX. Therefore,
this condition appears to be unrelated to tumor necrosis factor-α.
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Introduction: Background:Acute hemorrhagic edema of infancy (AHEI)
is an immune complex-mediated leukocytoclastic vasculitis and rare dis-
ease that age of onset for it usually is 4-24 months. Clinical findings such
as low grade fever,edema of face, upper and lower limbs and general-
ized petechiae,purpura or ecchymosis develop rapidly over 24-48 hours.
Upper respiratory tract infection, gastroenteritis, or vaccination have
been reported to cause of this disease. AHEI was reported after heptava-
lent vaccination ( Hemophilus influenza type B, diphtheria, tetanus,
acellular pertussis, hepatitis B, polio, and conjugate pneumococcal vacci-
nes).To our knowledge there is’nt any report of post pentavalent vaccin-
ation ( Hemophilus influenza type B, diphtheria, tetanus, acellular
pertussis and hepatitis B)AHEI. asystemic involvement such as arthritis/
arthralgia,abdominal pain,intussusception and scrotal pain and testicular
torsion are rare.Diagnosis of AHEI is clinical and routine laboratory testsare nondiagnostic, although leukocytosis and thrombocytosis ,eleva-
tion of erythrocyte sedimentation rates((ESR), c-reactive protein(CRP) and
liver function test may be occured. No effective therapy need for AHEI.
The use ofantihistamines and steroids has been controversial . systemic
corticosteroids may be used to sever conditions or systemic involvement
such as abdominal pain,intussusception ,nephritis ,scrotal pain and tes-
ticular torsion. Monitor patients for rare systemic involvement such as
renal involvementhas been controversial.
Objectives: Case report:Our patient was a 6-month boy injected by
pentavalent vaccine 5days ago.since 3 days ago he had low grade fever,-
edema of face, upper and lower limbs and generalized petechiae,pur-
pura and ecchymosis. His condition was good.Mild scrotal swelling was
seen. Other review of system and physical examinations were normal.
Labratoary findings showed only high ESR,CRP.Abdominal-pelvic and
testicular ultrasonographies were normal. We treated this patient with
supportive treatment and after ruled out of infectious diseases single
dose 10mg/kg methlprednisolon infusion. There were no complica-
tions in follow up. Informed consent for publication had been obtained.
Methods: case report
Results: case report
Conclusion: Conclusion: Pentavalent vaccination can induced AHEI.
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Introduction: Fever of unknown origin (FUO) in children is defined as
fever >38.3°C (101°F) at least once per day for ≥8 days with no ap-
parent diagnosis after initial outpatient or hospital evaluation that in-
cludes a detailed history, thorough physical examination, and initial
laboratory assessment. The most common causes are infectious dis-
eases, rheumatologic diseases and malignant diseases. This case is
presented to emphasize that Takayasu Arteritis should be considered
in patients examined for FUO.
Objectives: An 11-year-old girl presented with a fever increasing up
to 38.3°C 1-2 times a day for one month, and up to 39°C for the last
five days, despite continued antibiotic therapy. It has been learnt that
she had a pain in the upper abdominal region for a week and she
had lost 10 kilograms in the last two months after using a teeth re-
tainer. On physical examination, body weight was under 3th percent-
ile, while height was at 25-50 percentile. Vitals were normal except a
fever reaching up to 38.5°C. There was no finding in systemic exam-
ination except general sensitivity in the abdomen. Hemoglobin was
8.1 g/dL. Biochemical values, immunoglobulin levels, and comple-
ments were normal. C-reactive protein (14.9 mg/dL) and erythrocyte
sedimentation rate (140 mm/h) were high. Rheumatoid factor and
viral serology were negative. No microorganism was yielded in the
blood, throat or urine cultures. There was no sign of active tubercu-
losis on chest X-ray and PPD evaluation. Anti-nuclear antibody, anti-
dsDNA, and p/c-anti-cytoplasmic antibodies were negative. Ophthal-
mologic evaluation, echocardiography and abdominal USG were nor-
mal. No additional features were found in peripheral smear and bone
marrow examination.
Methods: Abdominal Doppler USG was performed upon ongoing
fever, abdominal pain and high levels of acute phase reactants. The
patient was diagnosed with Takayasu Arteritis due to the wall thick-
ening in the first 4-5 cm proximal segment of the anterior mesenteric
artery and severe thickening in the left carotid artery wall.
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 39 of 243Results: She was treated with steroids and azatioprin. Abdominal
pain regressed and acute phase reactants decreased to normal limits
at the end of the second week.
Conclusion: Although Takayasu arteritis is included in the etiology of
FUO, diagnosing a patient may take time in the absence of common
findings including pulselessness or claudication. Takayasu Arteritis
should be kept in mind in patients with FUO and further investiga-
tion should be considered. Written consent for publication was ob-
tained from the parents.
Disclosure of Interest
None Declared
P049
GENDER DIFFERENCES IN RISK FACTORS (OF IVIG-RESISTANT) IN
PATIENTS WITH KAWASAKI DISEASE
Young Dae Kim1, Jong Gyun Ahn2, Kwang Nam Kim3
1Department of Pediatrics, Inje University Ilsan Paik Hospital, Goyang;
2Department of Pediatrics, Severance Children’s Hospital, Yonsei
University College of Medicine, Seoul; 3Department of Pediatrics, Sacred
Heart Hospital, Hallym University College of Medicine, Anyang, Korea,
Republic Of
Correspondence: Young Dae Kim
Pediatric Rheumatology 2018, 16(Suppl 2):P049
Introduction: Kawasaki disease (KD) is one of the most common vas-
culitis that may cause coronary artery complications. KD is more
common in boys than in girls with a male-to-female ratio of 1.36:1 to
1.62:1. Thus, it has been suggested that the susceptibility is closely
associated with sex differences.
Objectives: This study investigated the gender differences in clinical
and laboratory findings in patients with KD.
Methods: We reviewed the medical records of 148 patients (78 boys
and 70 girls) with KD who had been treated at our hospital between
September 2012 and March 2017.
Results: The incidence of coronary artery aneurysm and intravenous
immunoglobulin (IVIG) -resistant KD was significantly higher in the
boys as compared with the girls (P=0.02). But there were no signifi-
cant differences in WBC, Hb, CRP, ESR and urine abnormalities, such
as proteinuria, pyuria and microscopic hematuria, between the two
groups (P>0.05). There were significant differences in % neutrophil
counts (>80), CRP (>8mg/dL), AST (>100IU/L), ALT (>80IU/L), hypona-
tremia (<134mmol/L), total bilirubin (<0.9mg/dL) and illness at initial
treatment (≤4 days) between IVIG-responsive and IVIG-resistant
groups (P<0.05).
Conclusion: Coronary artery aneurysm and intravenous immuno-
globulin (IVIG) -resistant KD was more common in boys and there
were several risk factors, such as % neutrophil counts, CRP, illness at
initial treatment to progress IVIG resistant KD.
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Introduction: Immünglobulin A vasculitis (IgAV) is a systemic, inflam-
matory, leucocytoclastic vasculitis which is caused by IgA deposit to
small blood vessels. It is a self-limiting disease and etiopathogenesis
of IgAV is still unclear and cytokines such as TNF-α, IL-6 have been
implicated in the active phase of the disease. Signal peptide-CUB(complement C1r/C1s, Uegf, and Bmp1)-EGF (epidermal growth fac-
tor)-like domain-containing protein (SCUBE)1 is a new described, can
be secreted cell surface protein. It has been proven that SCUBE1 and
SCUBE 2 has a role in various pathophysiologic processes like vascu-
lar endothelial cells, inflammation, cancer metastasis and vascular
diseases.
Objectives: We aimed to research whether there is a relationship be-
tween SCUBE1 and SCUBE2 proteins and IgAV.
Methods: Between January 2016 and May 2017, the patient admit-
ting to outpatient clinics in pediatric department of Farabi Hospital
in Karadeniz Technical University and diagnosed with IgAV according
to Ankara 2008 diagnostic criteria were included. Patients who used
steroid or non-steroidal inflammatuary drug in last three months
were excluded. Blood samples collected from patients who were in
active and recovery phases of their diseases and healhty control
group. IL-1, IL-6, TNF-α, SCUBE1 and SCUBE2 levels studied by ELISA
method.
Results: A total of 26 patients, 13 (50%) male and 13 (50%) female,
aged between 3 and 17 years, who were diagnosed with IgAV, were
included in the study. The average age in healthy control group was
7.15±3.34 years. There was skin involvement in all of the patients
who were diagnosed with IgAV. Twenty three (88.4%) patients had joint
involvement, seven (26.9%) patients GI involvement, five (19.2%) pa-
tients kidney involment and three (11.5%) patients testicular involve-
ment. IL-1 levels are significantly higher in active phase of disease than
in healthy control group and recovery phase of disease (p=0.03). IL1, IL-
6 levels were statistically significant higher then in healthy control
group (p=0.006 and p=0.01, respectively). SCUBE1 and SCUBE2 levels
were not different in active and VIII recovery phases of the disease.
SCUBE2 levels have found significantly higher in recovery phases of the
disease when compared to healthy control group (p=0,008).
Conclusion: Increase of SCUBE2 levels in the recovery phase of disease
suggests that SCUBE proteins has a different role from inflammation in
tissues and various cell types. We believe that this situation can be elu-
cidated by studies on more patients in this regard.
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Introduction: Takayasu arteritis represents idiopathic large vessels
vasculitis of aorta and its main branches, rarely affecting children.
Objectives: Diagnostic and treatment delay can lead to potentially
life treating complications if neurological and cardiovascular injuries
occur. Reducing inflammation and achieving sustained remission is
important therapeutically goal, but not yet standardized.
Methods: We report a case of sixteen year old girl with refractory
Takayasu arteritis to standard treatment who entered remission and
could stopped steroids after inducing tocilizumab
Results: Sixteen year old girl was treated with antibiotics as having
pneumonia due to fever and cough. After two weeks she was ad-
mitted to the pulmology department of our hospital due to pro-
longed fever, dizziness and weakness, but without reporting other
symptoms. After excluding respiratory tract infection and tubercu-
losis she was transferred to the department of pediatric rheuma-
tology and immunology. Possible infection causes were ruled out
as procalcitonin, all cultures, virusology and atypical infections
testing were negative. Bone marrow biopsy, detailed immuno-
logical and endocrinological laboratory testing were not proved
hematological, immunodeficiency or autoimmune disease back-
ground. Due to persistently elevated inflammatory markers we
suspected on autoinflammatory disease, but feritin was mildly
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 40 of 243elevated. Slit lamp examination and angiotenzin converting enzym
have excluded possibile diagnosis of sarcoidosis. Abdominal ultra-
sound and echocardiography were normal. After the treatment
with non-steroid anti-inflammatory drugs (NSAIDs) fever has gone,
but elevated inflammatory markers persisted with profound feel-
ing of fatigue, weakness, and dizziness. Physical examination has
revealed less palpabile right radial pulse and higher blood pres-
sure on the same side. F-fluorodeoxyglucose positron emission
tomography (PET-CT) have confirmed diagnosis of Takayasu arteritis
of thoracic and abdominal aorta. Magnetic resonance angiography
(MRA) of the brain was normal. Methyl-prednisolon pulses were in-
duced with gradually steroid tappering and metotrexate treatment, but
unfortunately this could not stopped inflammation. Six months later
she was steroid dependent with chronic fatigue and persistently ele-
vated inflammatory parameters. MRA of the heart and large blood ves-
sels have revealed evidence of still active inflammation in the thoracic
aorta. Decision was made and tocilizumab was added on regular basis
treatment. Four months after inducing tocilizumab she was without
any symptoms with normalized inflammatory markers and steroids
could be tapered and stopped.
Conclusion: In the cases of the fever of unknown origin we should
consider Takayasu arteritis, even though it is rarely seen in childhood.
Early diagnosis and treatment could prevent serious systemic compli-
cations. Although we lack treatment algorithm recommendations in
children, this is the evidence that early and aggressive inducing of
tocilizumab could lead to sustained remission in Takayasu artertitis in
children. Informed consent to publish had been obtained.
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Introduction: Kawasaki disease is a systemic vasculitis affecting
mainly children; the most serious complications are coronary artery
lesions (CAL). Nonetheless, the spectrum of complications involves all
the vascular districts, such as the eyes, skin, kidneys, gallbladder,
liver, central nervous system. Sensorineural hearing loss is a low diag-
nosed complication of KD, however, it may be permanent.
Objectives: Auditory evoked potentials (ABR) and visual evoked po-
tentials (VEPs) are useful in evaluating children without auditory and/
or visual symptoms but with diseases that could sub clinically involve
these functions.
Methods: We enrolled 52 children (31 M, 21 F; age: 3 months-10 years)
with KD and evaluated ABR and VEPs in the acute phase of the disease
and during the follow up. We correlated the neurophysiological study
with clinical, biochemical parameters, the type of KD (typical, atypical,
incomplete) with cardiac involvement and time of IVIG and/or other
non-conventional treatment in the acute phase of KD.
Results: VEPs were pathological in 6 children (4 M; 2 F) (1 patient
with CAL had monoliteral alterations; 2 patients had ABR patho-
logical as well). ABR were pathological in 36/52 patients (69%) (2 pa-
tients without CAL had monoliteral alterations). Furthermore, in
those patients (31M; 21 F) there were no significant differences in
age, time of the diagnosis, time of the first dose of IVIG, biochemical
parameters (leukocytes, neutrophils percentage, AST, ALT, gamma-
GT, albumin, Na, fibrinogen, D-Dimer) vs KD patients without alter-
ations of ABR and VEPs.One patient showed a persistent sensorineural auditory loss.
During the follow up, ABR and/or VEPs alterations persisted in the
80% of the patients.
Most of the patients showed alterations of the wave V and the I-V,
expression of mesencephalic involvement.
Conclusion: We suggest evaluating ABR and VEPs in patients with
KD, both in patients with precocious diagnosis and treatment either
in children treated later than 10 days with IVIG.
We suggest studying also patients without CAL, in whom neuro-
physiological study may contribute to the complete follow up of
these patients.
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Introduction: Cutaneous sun exposure is an important determinant
of circulating vitamin D. Both sun exposure and vitamin D have been
inversely associated with risk of autoimmune disease, including mul-
tiple sclerosis and rheumatoid arthritis. In children with juvenile idio-
pathic arthritis (JIA), low circulating vitamin D is reportedly common,
but disease-related behavioural changes may have influenced sun
exposure behaviours (reverse causation).
Objectives: We aimed to determine whether sun exposure across the
life-course prior to diagnosis is associated with JIA.
Methods: Using validated questionnaires, we retrospectively measured
sun exposure for 202 Caucasian JIA case-control pairs born and living in
Victoria Australia and recruited to the CLARITY JIA Biobank. Cases and
controls were matched for year of birth and time of recruitment. All sub-
types of JIA were included in the analysis. Measures included maternal
sun exposure at 12 weeks of pregnancy, and child sun exposure across
the life-course pre-diagnosis. We converted sun exposure to UVR dose
using location-specific (Melbourne Australia, latitude 37.5°S) UVR data.
We looked for case-control sun/UVR exposure differences at various ages
pre-diagnosis, and cumulatively across the pre-diagnosis life-course,
using logistic regression, adjusting for potential confounders.
Results: Higher cumulative child pre-diagnosis UVR exposure was as-
sociated with reduced risk of JIA (e.g. total UVR dose quartile 1 vs 4,
adjusted odds ratio (AOR) 0.19, 95% CI 0.04 – 0.85, p = 0.030), with a
clear dose response relationship (test for trend p=0.025). UVR expos-
ure at 12 weeks of pregnancy was similarly inversely associated with
JIA (e.g. UVR quartile 1 vs 4, AOR 0.32, 95% CI 0.13 – 0.80, p = 0.014)
with evidence of a dose response (test for trend p=0.031). Associa-
tions were robust to sensitivity analyses for disease duration, and for
pre-diagnosis behavioural changes and knowledge of the hypothesis
as collected by parent questionnaire.
Conclusion: Increased UVR exposure across the pre-diagnosis life-
course is associated with reduced risk of JIA in our setting. This sug-
gests lower circulating vitamin D in JIA may be causative, but prospect-
ive studies that directly measure pre-disease vitamin D in JIA are
required. If confirmed, the associations point to an environmental factor
amenable to intervention that may reduce risk of JIA in the population.
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Introduction: In addition to its well-known neurotrophic activity,
the nerve growth factor (NGF) is involved in the immune regula-
tion. Our previous studies showed that the immature NGF,
proNGF, is the prevalent form in synovial fluids of patients with
juvenile idiopathic arthritis (JIA) and rheumatoid arthritis (RA).
The distinct roles of NGF, pro-NGF and their different receptors
(TrkA and p75NTR) in the regulation of the inflammatory re-
sponse are still unclear.
Objectives: To investigate if p75NTR and its specific ligand proNGF
modulate the activity of synovial fibroblasts and mononuclear cells
playing a role in the inflammatory response in the synovia of arthritis
patients.
Methods: Mononuclear cells (MNC) were purified from blood and
synovial fluids of JIA patients. Fibroblasts-like synoviocytes (FLS),
obtained from synovial tissue of RA patients (RA FLS), were used
to evaluate pro-inflammatory activity of proNGF. Skin fibroblasts
(SF) from healthy donors (HD) were used as controls. TrkA,
p75NTR, Sortilin, NGF, and cytokines expression were evaluated
by quantitative PCR (qPCR). Specific ELISA were used to analyze
NGF, proNGF and cytokine concentrations. p75NTR was inhibited
using a synthetic inhibitors (LM11A-31) or by small interference
RNA in order to evaluate how its inhibition can modify pro-
inflammatory pathways.
Results: Our data showed that p75NTR expression was signifi-
cantly up-regulated in MNC purified from blood and synovial
fluid of JIA patients and in FLS of RA patients. TrkA expression
was highest in HD cells and down-regulated in patient cells. Pa-
tient FLS but not MNC expressed high levels of NGF mRNA and
high amounts of proNGF. On the contrary, low levels of mature
NGF were detected in their conditioned media. Inflammatory
stimuli, such as IL-1β, IL-6, LPS, TNFα, further up-regulated both
p75NTR expression and proNGF production in synovial FLS. The
inhibition of the binding of proNGF to its specific receptor
p75NTR using synthetic inhibitor LM11A-31 in synovial FLS re-
sulted in a marked reduction of IL-6 release induced by either IL-
1β or other inflammatory stimuli.
Conclusion: The abnormal p75NTR expression levels and the modi-
fied p75NTR/TrkA ratio observed in JIA and RA patients might have a
crucial role in the chronicity of the inflammatory response. In
addition to inducing p75NTR up-regulation, inflammatory stimuli in-
creased the release of proNGF in synovial FLS. ProNGF further en-
hances pro-inflammatory cytokine production, creating a vicious
circle that amplify the inflammatory response. Blocking the binding
of endogenous proNGF to its receptor p75NTR, using a specific
p75NTR inhibitor, strongly reduces the production of inflammatory
mediators and suggests the use of p75NTR inhibitors as a new thera-
peutic approach to chronic arthritis.
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Introduction: Down syndrome (DS) is a common chromosomal dis-
order associated with the development of a range of medical and
immune abnormalities such as haematologic malignancies, increased
susceptibility to infections, and a high incidence of autoimmune dis-
eases, including Down’s Arthritis (DA). Previous work by our group
suggests that the prevalence of DA is 18-21 fold greater than JIA,
much higher than the previously reported DA prevalence of 8.7/
1000. Children with DA most often follow a polyarticular course of
disease, with erosive joint damage observed more frequently in this
cohort when compared to a cohort of children with JIA. Small joint
involvement is frequently observed, again in a significantly greater
proportion (p<0.01) of children with DA than expected in a typical
JIA cohort. These characteristics suggest that DA may be distinct
from JIA, however little is known about the differences in synovial
pathology or immunological regulation. Indeed no studies to date
have examined synovial pathology in DA
Objectives:
- To examine B-cell and T-cell subsets, and cytokine profiles in chil-
dren with DA and JIA
- To characterise & compare the synovial membrane immunohisto-
chemistry in DA & JIA.
Methods: Multicolour flow cytometry was used to analyse the
phenotype of B and T cells in peripheral blood mononuclear cells
(PBMCs) from 40 children (n=10 per group; Healthy Control (HC), JIA,
DS, DA). Cells were stained with the following panels; Panel 1 B cells
(CD38, CD24, CD20, CD80, CD27, IgM, CD138, CD45, CD19, MHCclas-
sII, BCMA, CD40, CD86, IgD); Panel 2 T cell cytokines analysed after
5hours PMA/Ionomycin stimulation (CD3, CD8, CD161, IFN-γ, TNF-α,
IL-17a, GM-CSF). Flow cytometry data was assessed by Flowjo soft-
ware analysis.
Synovial tissue obtained through ultrasound guided biopsy and analysed
by immunohistochemistry for CD3, CD20, CD68, Factor VIII (DA n=3; JIA
n=6). Synovial Inflammation and lining layer thickness were also scored.
Analysis was performed using semiquantification scoring method.
Flow cytometry was performed on PBMC samples from 4 distinct
gps; HC (50%F, age 9.2y (2.5-15.6)), JIA (91%F, age 13.2y (8.2-16.1)),
DS (45%F, age 6.5y (1-11.9)) & DA (60%F, age 11.4y (3.8-17.8)). All of
the children in the DA & JIA cohorts had a polyarticular RF negative
pattern of disease. Synovial tissue was obtained from 3 children with
DA & 6 JIA cases.
Results: Flow cytometry analysis revealed that children with DA have
a significantly lower number of circulating CD19+CD20+ B cells when
compared to children with JIA (p<0.05) & HC (p<0.001). However,
children with DA have a greater proportion of memory B cells
(CD27+) when compared to children with DS & no arthritis (p<0.05).
Analysis of cytokine production by CD8+/CD8- T cells showed that
IFN-γ & TNF-α production was greater in DA compared to both JIA
(CD8+IFNγ+ p<0.001; CD8+TNFα+ p<0.01; CD8-IFNγ+ p<0.05; CD8-
TNFα p<0.05) and HC (CD8+IFNγ+ p<0.05; CD8+TNFα+ p<0.05; CD8-
IFNγ+ p<0.05; CD8-TNFα p<0.01).
Examination of synovial tissue demonstrated higher levels of CD3+
cells (p<0.05), Macrophages (p<0.05), CD20+ cells & FVIII in the joints
of children with DA.
Conclusion: There are significant differences in B cell populations,
cytokine production and immunohistochemical features of synovial
tissue in children with DA & JIA. More work is required to verify these
results. Preliminary findings may begin to help explain the differ-
ences observed in the clinical picture of children with DA & JIA.
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Introduction: We have previously published and identified two di-
chotomous dysregulated populations within the Teff (CPLs) and
Treg (iaTreg) compartments that are inflammatory, antigen experi-
enced, correlating with disease activity and exhibiting similar TCR
oligoclonality with synovial T cells. Their commonality in pheno-
type despite being in two functionally distinct compartments, sig-
nal the possibility of a common pathogenic origin during active
disease manifestation.
Objectives: To determine the common transcriptomic drivers influen-
cing dysregulation in both Teff and Treg compartments during active
disease in JIA patients.
Methods: Next generation RNA sequencing was performed on sorted
CPLs (CD3+ CD4+ CD14- HLADR+ CD25/CD127 Teff gate) and iaTregs
(CD3+ CD4+ CD14- HLADR+ CD25hi CD127lo Treg gate) from 16 active
disease JIA PBMCs, 8 age-matched healthy PBMCs, and 8 paired
SFMCS. The corresponding total pool of Teff (Non-CPLs) or Treg
(Non-iaTreg) was also sorted as a comparative control. Sorted cells
were lysed and extracted for RNA, and cDNA conversion/amplifica-
tion were then carried out using SMART-seq v4. Libraries are pre-
pared and multiplexed using Nextera XT DNA library preparation kit,
and ran on the Illumina HiSeq High output platform. RNA-Seq raw
reads were mapped to human genome using STAR aligner with de-
fault options and reads were counted/summarised at gene level by
feature Count programme. Differential expression analysis were per-
formed using edgeR package, and pathway enrichments were done
under R statistical environment and Reactome.
Results: Comparative differential gene expression (DEG) reveal
strong transcriptomic convergence between CPLs and iaTregs as
compared with the common pool of Teff and Treg. Phylogenetic
analysis indicate the convergence has uncoupled the CPLs or the
iaTregs away from their respective original compartments (Teff or
Treg) into a common branch point. Restriction in TCR sequence
oligoclonality in CPLs/iaTregs versus that of the common Teff/
Treg pool reinforce the possibility of a common selection pres-
sure. Pathway enrichment analysis reveal similar dysregulated
pathways (IFN-g, PD1, CD28 costimulation) within T cell signalling
for both CPLs and iaTregs. Furthermore, Weighted gene correl-
ation network analysis (WGCNA) identified strongly coordinated
HLA-DR gene network module and suggests its potential role as
the driver of pathogenic T cell subsets away from conventional
subsets. Gene set enrichment analysis (GESA) suggest that HLA-DR
module genes are involved in TNFA signalling, inflammatory response,
complement, and apoptosis. Global transcription factors gene regula-
tory network (TF-GRN) analysis identified several key regulatory mole-
cules (FOXP3, CEBP, SPI and E2F1) driving the convergence of
pathogenic CPLs and iaTreg populations. Taken together , we have
shown that reveal several layers of mechanism operate to drive the
convergence of CPLs and iaTregs, suggesting the possibility of common
disease drivers in active JIA patients.
Conclusion: Overall the transcriptomic data indicate strong similarity
in both pathogenic populations and underscore a potential mechan-
istic role of the inflammatory microenvironment in shaping two func-
tionally dichotomic populations.
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Introduction: Juvenile idiopathic arthritis (JIA) is the most common
chronic rheumatic disease in pediatrics and is characterized by
marked clinical heterogeneity, including the age-related features of
the disease onset [1, 2].
Objectives: The aim of the study was to analyze the relationship between
the IL2-IL21 rs6822844 locus polymorphic variants and age at JIA onset.
Methods: The study included 328 patients with JIA from the Republic
of Bashkortostan, Russia. Genotyping was performed by real-time
PCR method and statistical processing of the results – with the
Mann-Whitney U test.
Results: The study of the IL2-IL21 rs6822844 single-nucleotide poly-
morphism showed, that in the carriers of the GG genotype (n=271),
JIA developed statistically significantly earlier than in the carriers of
the T allele (4.16 (2.14;8.09) vs 6.00 (3.03;8.78) years respectively,
p=0.045). In contrast, patients with the GT genotype (n=54) tended
to have a later onset of the disease than the other patients had (6.00
(3.01;8.78) vs 4.19 (2.19;8.09) years respectively, p=0.072). In a sex-
stratified analysis, similar patterns for the GG and GT genotypes were
found only for girls with JIA, being even more pronounced and in
both cases reaching a statistical significance level (GG (n=174) vs GT
+TT (n=42): 3.19 (1.90;6.79) vs 4.97 (3.01;9.65) years, p=0.008 and GT
(n=41) vs GG+TT: 4.64 (3.01;8.25) vs 3.21 (1.90;6.99) years, p=0.013 re-
spectively). It should be noted, however, that there was only one girl
with the TT genotype in the studied JIA patients’ sample, and age at
the disease onset of this girl was 9.65 years.
Conclusion: In this study, the association between the IL2-IL21
rs6822844 locus polymorphic variants and age at JIA onset in girls
was established.
References
1. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007 Mar 3; 369
(9563): 767-78.
2. Donn R, De Leonibus C, Meyer S, Stevens A. Network analysis and
juvenile idiopathic arthritis (JIA): a new horizon for the understanding of
disease pathogenesis and therapeutic target identification. Pediatr
Rheumatol Online J. 2016 Jul 2;14(1):40.
Disclosure of Interest
None Declared
P058
MOLECULAR AND CELLULAR BIOMARKERS THAT DISCRIMINATE
JUVENILE IDIOPATHIC ARTHRITIS FROM SEPTIC ARTHRITIS
Nadege Nziza1,2,3, Mailys Cren1,3, Aurelia Carbasse4, Perrine Mahe4,
Marion Delpont5, Djamel Louahem5, Hugues Chevassus6, Mirna Khalil6,
Thibault Mura7, Christian Jorgensen1,3,8, Isabelle Duroux-Richard1,3,
Eric Jeziorski4, Florence Apparailly1,3,8, Pascale Louis-Plence1,3
1National Institute of Health and Medical Research, Montpellier; 2Arthritis
R&D, Neuilly sur Seine; 3University of Montpellier; 4Paediatric Department;
5Pediatric Orthopedic Surgery Unit; 6Centre d'Investigation Clinique,
University Hospital of Montpellier; 7Department of Medical Information,
La Colombière Hospital; 8Clinical department of Osteoarticular diseases and
Biotherapy, University Hospital Lapeyronie, Montpellier, France
Correspondence: Nadege Nziza
Pediatric Rheumatology 2018, 16(Suppl 2):P058
Introduction: Juvenile idiopathic arthritis (JIA) and septic arthritis
(SA) are the most frequent cause of arthritis among children under
the age of 16 years. JIA is an auto-immune disorder involving
Table 1 (abstract P059). The mean plasma miRNA 2-ΔCT level of
patients in aJIA, iJIA and HC groups and comparison of it (include JIA
patients that treated with only methotrexate)
Mean 2-ΔCT Fold change/p value
aJIA iJIA HC aJIA-iJIA aJIA-HC iJIA-HC
miRNA-16 2.09 2.27 1.55 -1.08/0.68 1.35/0.55 1.46/0.33
miRNA-155 1.75 3.32 1.78 -1.89/0.006 -1.02/0.51 1.86/0.02
miRNA-204 0.13 0.04 0.15 3.25/0.07 -1.15/0.52 -3.75/0.02
miRNA-451 2.05 2.94 2.29 -1.43/0.16 -1.12/0.65 1.28/0.26
aJIA: active period of juvenile idiopathic arthritis, iJIA: inactive period of
juvenile idiopathic arthritis, HC: Healthy control
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is caused by bacterial infection in children joints. Although these dis-
eases have different physiopathological basis and involve different
treatments and prognoses, they share clinical similarities.
Objectives: To date, there are no markers sufficiently reliable to dis-
criminate between these two forms of arthritis at the onset of the
disease. Our goal is to respond to this clinical need by identifying diag-
nostic biomarkers capable of discriminating between JIA and SA. To
that end, we focused on microRNAs (miRNAs) and myeloid cell subsets,
both playing a major role in inflammation and autoimmune disorders.
Methods: We analyzed serum and synovial fluid (SF) samples from
patients with inflammatory or septic arthritis using a miRNAs Whole
Transcriptome Assay associated with a next-generation sequencing
detection technology to measure the expression level of 2083 miR-
NAs in a pilot study (oligoarticular JIA (oJIA): n=5; SA: n=3) and vali-
dated using RT-qPCR in a replicative study (oJIA: n=9; SA: n=9). In
parallel, we performed a phenotypic characterization of peripheral
blood (PB) and SF myeloid subpopulations using a flow cytometer in
order to identify cellular biomarkers (oJIA: n=9; SA: n=8).
Results: Principal component analysis and hierarchical clustering
characterizations did not show significant differences between serum
miRNAs of oJIA and SA patients. However, we observed a distinct
miRNA profile signature in SF between the two diseases with 16 up-
regulated miRNAs and 5 down-regulated that perfectly discriminates
oJIA and SA (p<0.01). In addition, phenotypic characterization re-
vealed the existence of 5 myeloid cell subsets with distinct accumu-
lation profile between the SF of oJIA and SA (p<0.05). A study of
their activation profile indicated differences in the expression of cel-
lular markers between the two groups.
Conclusion: In this study, we propose for the first time a synovial
fluid-based miRNA signature as well as 5 myeloid cell subsets that
discriminate between oJIA and SA and might be used as potential
diagnosis markers in juvenile arthritis.
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Introduction: Juvenile idiopathic arthritis (JIA) is the most common
chronic rheumatic disease of childhood and its etiology is unknown.
Microribonucleic acids (miRNAs) are small (16–24 nucleotides), non-
coding RNA molecules that have roles on the regulation of gene ex-
pression at the post-transcriptional stage. It is also known that micro-
ribonucleic acid (miRNA)s play a role in immunoregulation.
Objectives: We aimed to evaluate plasma expression of some candi-
date miRNAs that associated with pathogenesis of autoimmunity.
Methods: Thirty-one patients diagnosed with JIA and age-sex
matched 31 healthy children were enrolled for the study. Plasma levels
of four candidate miRNAs (miRNA-16, miRNA-155, miRNA-204 and
miRNA-451), which is known to be associated with autoimmunity were
examined in all subjects. Plasma levels of miRNAs were measured with
Real Time PCR in patients in active and inactive period and in healthy
controls. Groups were compared with each other.
Results:
Plasma miRNA-155 levels were found to be increased in JIA patients
compared to the healthy controls and it was statistically more signifi-
cant in inactive period. We found that JİA patients had higher levels
of miRNA-16 and lower levels of miRNA-204/miRNA-451 expressions
compare with the control group, but there was no statistically signifi-
cant difference. A statistically significant decrease in plasma levels of
miRNA-204 was found in patients that were in inactive disease withonly methotrexate therapy. Plasma miRNA expressions were com-
pared in JIA subtypes and it was observed that miRNA-204 levels
were higher in polyarticular JIA and miRNA-451 levels were higher in
entesitis related arthritis without statistical significance.
Conclusion: Significant alterations in the plasma expression of miRNA-
155 and miRNA-204 suggest to us that these molecules may be related
to pathogenesis of JIA. More comprehensive and functional researches
about the role of this molecules are needed in this regard.
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Introduction: Immune dysregulation, polyendocrinopathy, enterop-
athy, X-linked (IPEX) syndrome is a rare monogenic primary im-
munodeficiency affecting T regulatory lymphocytes caused by
FOXP3 mutation and is associated with multiple autoimmune dis-
orders including enteropathy, diabetes and atopic dermatitis. Kid-
ney involvement is uncommon but has been already reported.
Little is known regarding the impact of Tregs deficiency on renal
tolerance.
Objectives: This study is intended to describe the renal phenotype
of IPEX patients and to determine the self reactivity of patient’s sera
using a protoarray assay enabling the detection of the autoimmune
repertoire across 8000 peptides.
Methods: We retrospectively collected clinical, histopathological and
immunological data from IPEX patients seen in French pediatric im-
munology, rheumatology or nephrology centres. We retrieved pa-
tients sera and analyse the autoimmune repertoire targeting the
kidney with a combined strategy of immunofluorescence crossreac-
tivity on rats cell lines and direct crossreactivity on 8000 peptides
(Protoarray, Thermofisher).
Results: In the index case, immunofluorescence staining showed
linear deposits along the tubular basal membrane suggesting a
B-cell mediated immunopathogeny. The patient serum was tested
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 44 of 243on regular renal cells from rats and indirect immunofluorescence
showed crossreaction over species suggesting the presence of
autoantibodies targeting the basal membrane in the serum of
the patient.
Four other pediatric patients were included in this study in order
to better characterize nephropathy in IPEX syndrome. A total of
three patients had tubulonephritis, and this feature was the first
manifestation of the disease for two of them. One of the patients
had membranous nephritis and the other one presented microan-
giopathy secondary to calcineurin inhibitors toxicity. All patients
were treated with immunosuppressive drugs, two underwent
hematopoetic stem cell transplantation and one had kidney trans-
plantation. The results of the protoarray in the first patient elic-
ited more than 100 antibodies with high titers. Among them,
about 15 were kidney specific. Additional samples may help to
detect a common tubulointerstitial autoantibody.
Conclusion: This study highlights genetic and clinical heterogen-
eity of renal lesions in IPEX patients. Autoimmune nephropathy is
rare but does exist in IPEX syndrome and may appear as glomer-
ulopathy or tubulopathy. It is noteworthy to define specific auto-
antibodies that may help clinician to screen IPEX patients for
renal lesions.
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Introduction: Juvenile idiopathic arthritis (JIA) – is a chronic immune-
mediated inflammatory joint disease in children under the 16 years.
The peculiarities of JIA pathogenesis depend on JIA category and re-
lated to autoimmune or autoinflammatory mechanisms. Currently
there are no unique approaches to evaluate JIA activity. The classical
clinical and laboratory test, such as ESR and CRP no always correlate with
local inflammation, joint erosions and so on. The finding of new bio-
markers is actual, because can help more precise evaluate JIA activity,
choose the appropriate treatment and better prognosis of outcomes.
Objectives: The aim of our study was to demonstrate possibility
using of calprotectin, 14-3-3η and butirylcholinesterase (BUCHE) as a
potential JIA biomarkers.
Methods: in pilot study were included 13 patients with JIA (4 boys
and 9 girls) with enthesitis-related (n=3) and oligoarticular (n=9) JIA
categories in whom calprotectin and 14-3-3η levels and activity
of BUCHE in blood plasma - BP (n=12) and synovial fluid -SF (n=7)
were measured. The onset age of patients was 3.9 (3.1; 8.9) years, dis-
ease duration – 3.7 (1.3; 6.6) years. Plasma and synovial fluid super-
natant were used to determine the content of interleukin-6,
calprotektin, protein 14-3-3η by the ELISA. Statistical analysis of data
was carried out with the program Statistica 10.0. We utilized descrip-
tive statistics (Me; IQR), Mann-Whitny and Wilcoxon tests, Pirson’s
and Spearmen’s correlation analysis.
Results: Obtained data showed that the content of calprotectin in JIA in
SF - 57.3 (47.3; 102.8) ng/ml was higher than in blood plasma – 5.8 (3.6;
15.0) ng/ml (р=0.02). It was shown that the content of 14-3-3η protein in
JIA SF – 66.7 (56.4; 98.6) ng/ml is also higher than in BP- 46.4 (37.1; 53.1)
ng\ml (р=0.02) that is also coincides with literature data obtained for
blood plasma 14-3-3η levels in adult persons with rheumatoid arthritis
(Walter P. et al., 2014). Activity of typical fraction of BUCHE was higher in
BP -47.3 (39.8; 60.6) U/l than in SF - 30.2 (22.8; 39.1) U/l (р=0.027). Activityof atypical fraction of BUCHE was 14.2 (11.6; 16.7) U/l and 6.2 (5.0; 9.1) U/
l in BP and SF, relatively (р=0.046), and activitiy of minor fraction of
BUCHE was 0.46 (0.1; 1.1) U/l and 14.7 (12.2; 15.5) U/l in BP and SF, rela-
tively (р=0.027). There weren’t found correlation between studied bio-
markers and JIA measures, such as onset age, JIA duration, active joints
count, ESR, CRP, JIA category, beside positive correlation between minor
fraction of BUCHE in BP and active joints count (r=0,998; r<0,05) and
negative correlation between CRP and 14-3-3η (r=-0.999; p<0.05) in SF. It
was found that levels of calprotectin, 14-3-3η and minor fraction of
BUCHE more effective reflect local inflammation than routine markers.
We have found positive correlation between BP and SF for calprotectin
(r=0.997; r<0.05) and 14-3-3η (r=0.958; r<0.05), but not for minor fraction
of BUCHE.
Conclusion: We suppose that calprotectin and 14-3-3η in BP can be
used as possible non-invasive biomarkers of JIA activity. Further in-
vestigations required.
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Introduction: One of the key elements of immune pathogenesis
of human autoimmune arthritis is the resilience of pathogenic T
cells. We have previously described that CD4+ T cells in pa-
tients with arthritis have an increased level of autophagy than
their healthy equivalents. Here, we sought to explore at epigen-
etic and transcriptional levels the concept of persisting
increased autophagy as the consequence of “autophagic mem-
ory”, as one of the mechanisms conferring resilience to patho-
genic T cells, in particular to a subset of CD4+ T cells (CPL:
Circulating Pathogenic-like Lymphocytes), which are significantly
more represented in patients with active arthritis and resistant
to therapy with biologics
Objectives: T-cell resilience is critical to the immune pathogenesis of
human autoimmune arthritis Autophagy is essential for memory T
cell generation and associated with pathogenesis in rheumatoid arth-
ritis (RA). Our aim was to delineate the role and molecular mechan-
ism of autophagy in resilience and persistence of pathogenic T cells
from autoimmune arthritis
Methods: Autophagy was assessed in CD4+ T cell subsets from auto-
immune arthritis pateints and healthy subjects using flow cytometry.
RNA sequencing and methylation array analysis was performed to
understand the molecular mechanism of autophagic memory.
Transcription-factor gene regulatory network analysis was build to
identify key regulators. qPCR was used to confirm the gene expres-
sion level of key regulator
Results: We demonstrate “Autophagic memory” as elevated au-
tophagy levels in CD4+ memory T cells compared to CD4+
naive T cells and in Jurkat Human T cell line trained with star-
vation stress. We then showed increased levels of autophagy in
pathogenic CD4+ T cells subsets from autoimmune arthritis pa-
tients. Using RNA-sequencing, transcription factor gene regula-
tory network and methylation analyses we identified MYC as a
key regulator of autophagic memory. We validated MYC levels
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 45 of 243using qPCR and further demonstrated that inhibiting MYC
increased
Conclusion: The present study proposes the novel concept of au-
tophagic memory and suggests that autophagic memory confers
metabolic advantage to pathogenic T cells from arthritis and sup-
ports its resilience and long term survival. Particularly, suppression of
MYC imparted the heightened autophagy levels in pathogenic T
cells. These studies have a direct translational valency as they identify
autophagy and its metabolic controllers as a novel therapeutic
target.
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Introduction: Our group has recently described that the majority of
polyarticular juvenile idiopathic arthritis (pJIA) and a large fraction of
extended oligoarticular JIA (oJIA) patients fulfil classification criteria
for rheumatoid arthritis (RA) in adulthood. B cells play several import-
ant roles in RA pathogenesis, but it is still unclear if the pattern of B
cell involvement in pJIA and extended oJIA follows what has been
described for adults with RA.
Objectives: The main goal of this study was to characterize periph-
eral blood B cell phenotype and cellular activation in pJIA and ex-
tended oJIA patients when compared to established RA.
Methods: Blood samples were collected from JIA patients (N=10;
mean age 10 ± 4 years), established RA patients treated with syn-
thetic DMARDs (N=10; mean age 72 ± 7 years) and two correspond-
ing groups of age- and sex-matched healthy donors. B cell
phenotype was characterized by flow cytometry and B cell apoptosis
was assessed after 48H of in vitro cell culture.
Results: JIA patients recruited in this study were either classified as
extended oJIA (N=6) or pJIA (N=4). Seven JIA patients (4 extended
oJIA and 3 pJIA) were treated with methotrexate and three patients
(2 extended oJIA and 1 pJIA) were untreated. We found that JIA pa-
tients had similar CD19+ B cell levels in circulation when compared
to controls, but significantly higher CD19+ B cell frequencies in com-
parison to established RA. In addition, increased frequencies of tran-
sitional (IgD+CD38++) and naïve (IgD+CD27+) B cell subpopulations
were observed in JIA patients when compared to RA. However,
established RA patients had significantly higher levels of CD21lowC-
D38low, post-switch (IgD-CD27+) and IgD-CD27- memory B cell sub-
sets when compared not only to controls, but also to JIA patients. No
significant differences were detected in pre-switch (IgD+CD27+)
memory and plasmablasts (IgD-CD38++) levels in JIA patients when
compared to both controls and RA. Furthermore, the frequency of
CD5+ B cells, CD5 median fluorescence intensity (MFI), CD40 MFI and
CXCR5 MFI B cell expression levels were significantly increased in JIA
patients when compared to established RA, but not to controls. No
significant differences were observed between JIA and established
RA patients in BAFF-R, FcgRIIB, CD21, CD23, CD38, CD86, CD95, HLA-
DR, TLR9 and RANKL expression on B cells. After 48H of in vitro cell
culture a significantly higher B cell death was found in JIA in com-
parison to RA patients.
Conclusion: The increased frequencies of transitional, naïve and CD5
+ B cells in circulation and reduced levels of memory B cellsubpopulations in JIA patients when compared to established RA are
probably related to an immature immune system present in children
when compared to adults. Nevertheless, the similarity in B cell
phenotype found between extended oJIA, pJIA and established RA
patients suggests an early B cell involvement in the pathogenesis of
these two categories of JIA.
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Introduction: The australian arthritis and autoimmune biobank col-
laborative = a3bc a national paediatric and adult rheumatology clin-
ical research network
Objectives: The A3BC seeks safer, more effective and evidence-based
prevention, diagnosis, treatment and prognosis strategy in arthritis
and autoimmune disease. Key A3BC aims are to
Develop a higher level of capability by collaborating across multiple
disciplines and sector
Progress precision medicine by growing capacity in open-access,
data-linked biobanking
Innovate preventive medicine by forming unique partnerships with
population health research
Demonstrate a new era of data linkage and use to inform policy and
practice decision-making
-
Methods: The A3BC protocol was developed in consultation with
leading researchers, clinicians, industry and best practices. A3BC pro-
cesses will initially run parallel to the Australian Rheumatology Asso-
ciation Database (ARAD), but will merge in the future. The initial
A3BC disease focus is Rheumatoid Arthritis, Juvenile Arthritis, Psori-
atic Arthritis and Ankylosing Spondylitis.
Recruited through over 40 sites nationally, participants donate
blood (20-53mls) and synovial tissue/fluid, stored across 10 bio-
bank nodes as plasma, serum, PBMCs, DNA and RNA. On a pro-
ject basis, newborn screening cards, urine and/or faeces are
accessed.
These samples are accompanied by standardised pre-analytical vari-
ables and clinical data, and linked datasets including the ARAD, elec-
tronic medical records, Commonwealth health (e.g. Pharmaceutical
Benefits Scheme, Medicare)), registries (e.g. cancer, death), longitu-
dinal/lifecourse data (e.g. Juvenile Arthritis national CLARITY project),
and consumer entry (My Health Record).
Using cutting-edge capture, real-time analytics and dashboarding
processes and systems, all data is integrated and mined for patterns
and associations, then effectively communicated to practitioners and
policy-makers.
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 46 of 243Results: The A3BC protocol will result in new dataset integration sys-
tems, new multidisciplinary collaborations, and identification of new
risk factors, biomarkers and cross-dataset associations. It will improve
research by enabling innovative research questions and faster trans-
lation. And facilitate health policy/practice decision-making in preci-
sion and preventive medicine.
Conclusion: The A3BC protocol provides best-practice, quality as-
sured and validated methods to realise its aims. Current experience
from recruiting and processing participants demonstrates that the
protocol’s methods and technologies are fit-for-purpose.
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Introduction: Neither genetic, epigenetic nor environmental factors alone
have been able to unravel the pathogenesis of autoimmune and autoin-
flammatory diseases in children and adolescents. The specific aspects
which determine the individual susceptibility to the development of a
rheumatic disease are still to be elucidated. As of now, these conditions are
seen as multifactorial in respect of pathogenesis. The microbiome has been
under discussion as a contributing factor. Microbial communities who play
an important role in the physiological development of the immune system
may turn into "false friends" leading to the state of dysbiosis.
Objectives: We aimed to gain new data in this context via examing
the oral microbiome in patients with different rheumatic diseases in
children and adolescents.
Methods: We examined the oral microbiome by obtaining oral swabs
of 11 patients with juvenile idiopathic arthritis and 20 patients with
chronic non-bacterial osteomyelitis (CNO).
The hypervariable region V6–V7 of the 16S rRNA gene was amplified
and subsequently sequenced. The following bioinformatic analysis was
performed with QUIIME (Quantitative Insights Into Microbial Ecology).
Results: In accordance to previous studies we were able to identify Acti-
nobacteria and Fusobacteria on the phylum level as microbiota only
present in our JIA cohort. In the CNO cohort so far no distinct microbio-
tic players could be detected. For this entity the only data so far describe
an advantage in mice who were fed with a high-fat diet resulting in a
shift in the microbial environment leading to a better course of the dis-
ease. These mice data could - as of now - not be shown in our patients.
Conclusion: The microbiome may open a new door to a better un-
derstanding of multifactorial autoimmune and autoinflammatory dis-
ease. In accordance to previous studies we were able to identify
specific microbiota present only in JIA patients. However, the clinical
consequence and the exact immunological effects of dysbiosis are
still to be unravelled. As of now, studies of the microbiome may en-
hance the pathophysiologic understanding of these diseases.
Disclosure of Interest
None Declared
P066
EVALUATION OF THE ROLE OF SIGNAL PEPTIDE-CUB-EGF DOMAIN-
CONTAINING PROTEIN (SCUBE)1 AND SCUBE2 IN JUVENILE
IDIOPATHIC ARTHRITIS
Duygu Selimoğlu1, Ferhat Demir2, Süleyman C. Karahan3, Mukaddes Kalyoncu2
1Department of Pediatrics; 2Department of Pediatric Rheumatology;
3Department of Biochemistry, Karadeniz Technical University Faculty of
Medicine, Trabzon, Turkey
Correspondence: Duygu Selimoğlu
Pediatric Rheumatology 2018, 16(Suppl 2):P066Introduction: Juvenile idiopathic arthritis (JIA) is a disease that be-
gins in patients under sixteen years of age, continues longer than six
weeks, and diagnosed with arthritis in at least one joint. Other causes
of arthritis should be excluded for diagnosis of JIA. The etiopatho-
genesis is still unclear and it is thought that it is the result of the
immunological response due to environmental and genetic fac-
tors. Signal peptide-CUB (complement C1r/C1s, Uegf, and Bmp1)-EGF
(epidermal growth factor)-like domain-containing protein (SCUBE) is a
newly defined, secreted cell surface protein. SCUBE1 and SCUBE2
have been shown to play a role in various pathophysiological pro-
cesses such as vascular endothelial cells, inflammation, cancer metas-
tasis, and vascular diseases.
Objectives: We aimed to research whether there is a relationship be-
tween SCUBE1 and SCUBE2 proteins, and JIA.
Methods: Between January 2016 and May 2017, the patients admit-
ting to outpatient clinics in Pediatric Department of Farabi Hospital
in Karadeniz Technical University and diagnosed with JIA according
to ILAR criteria were included. Patients who used steroid or non-
steroidal anti-inflammatory drugs in last three months were ex-
cluded. Blood samples collected from patients who were in active
and recovery phases of their diseases and healhty control group. IL
(interleukin)-1, IL-6, TNF (tumor necrosis factor)-α, SCUBE1 and
SCUBE2 levels were studied by ELISA method. Patients with oligoarti-
cular JIA were classified as Group 1, patients without oligoarticular
JIA as Group 2 and these two groups were compared according to
the blood results of cytokines and SCUBE’s mentioned above.
Results: A total of 24 patients, 11 (45.8%) were male and 13 (54.2%)
female, aged between 2 and 17 years old, who were diagnosed with
JİA, were included in the study. Fifteen (62.5%) patients were diag-
nosed as oligoarticular JIA, eight (33.3%) patients polyarticular JIA
and one (4.2%) patient systemic JIA. İn the active phase of disease,
IL-1 and IL-6 levels found significantly higher in Group 2 than in
Group 1 (p=0.01 and p=0.004, respectively). TNF-α and SCUBE1 levels
were higher in healing phase of the disease than in active phase
(p=0.03 and p=0.01, respectively). TNF-α levels were higher in the ac-
tive period of the disease than in the control group (p=0.02). SCUBE1
levels in the healthy control group were found to be significantly
higher than the active period of the disease (p=0.009). TNF-α levels
were higher in the recovery period of the disease than in the control
group (p=0.004). SCUBE1 and TNF-α levels were found to be higher
in the healing period of disease than in the active period (p=0.02
and p=0.03, respectively). SCUBE2 levels were found to be higher in
patients with thrombocytosis in acute period (p= 0.01).
Conclusion: These results concluded that SCUBE can not be used as
early biomarker in JIA, but SCUBE may has a role of JIA pathogenesis.
We believe that this situation can be elucidated by studies on more
patients in this regard.
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Introduction: Timely diagnosis of various diseases of their nature, man-
ifested by inflammatory changes in the joint apparatus of the child, is
one of the priority tasks of modern children's rheumatology. Juvenile
idiopathic arthritis (JIA) remains one of the most serious and potentially
disabling diseases. At the same time, one of the most complicated tasks
is the timely differential diagnosis of various variants of the articular
form of juvenile arthritis and reactive arthropathy (ReA).
Objectives: To determine the concentration of individual Th1- (IL-1β,
IL-6, INF-γ), Th2- (IL-4) and Th17-associated interleukins (IL-17) in
serum in children with JIA and ReA.
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 47 of 243Methods: The study involved 78 children, aged 1.1 years to 16.11
years. A group of children with a verified diagnosis of JIA consisted
of 56 patients - 30 patients with an oligoarticular variant of the
course of the disease and 26 with a polyatricular variant, an average
age of 10.2 ± 3.8 years, a group of ReA - 22 children an average age
of 7.49 ± 3.95 years. To compare the revealed relationships, a similar
analysis was carried out in the group (n = 20) of relatively healthy
children, the average age was 9.2 ± 3.99 years.
The concentration of interleukins in the blood serum was determined by
ELISA using ready-made commercial kits for the detection of IL-1β IL-4 IL-
6 INF-γ from Vector-Best Europe (Novosibirsk, Russia) and IL-17 firm
"eBioscience" (Vienna, Austria).The work was carried on the automated
enzyme immunoassay analyzer "Lazurite" (Dynex Technologies Inc., USA).
Results: In children with JIA, a higher concentration of Th1-associated
cytokines was observed with respect to similar parameters in children
with ReA and from the comparison group, so the concentration of IL-
1β was 1.5-2 times higher than in patients with ReA and in relatively
healthy children , INF-ɣ was 1.9 times higher than in patients with ReA
and 3.5 times higher than the values in the comparison group. At the
same time, the concentration of Th2-associated cytokine (IL-4) in the
blood serum of children with JIA was practically the same as for the
comparison group and children with ReA.
In patients with ReA, in the absence of significant differences in the
concentration of IL-1β, IL-6, IL-4 in the blood serum from similar pa-
rameters in relatively healthy children, 1.8-fold increase in the INF-
отмеча level and a 1.5-fold decrease concentration of IL-17.
In children with articular form of JIA and ReA, there was a mixture of
immune responses toward the activation of Th1-associated cytokines
relative to the parameters of the comparison group, but with JIA this
imbalance was greater than in patients with ReA. A key role in mixing
immune responses towards the activation of Th1 cells in patients with
ReA was played by a change in the ratio INF-ɣ / IL-4. A change in the
balance in the Th1 / Th17 cell system was due to a change in the INF-ɣ
/ IL-17 ratio.
When performing the correlation analysis in patients with different
variants of articular pathology, the following significant correlation
pairs were obtained: for the oligoarticular version of JIA-INF-ɣ and IL-
4; polyarticular JIA-IL-1β and IL-4, IL-1β and IL-17, IL-6 and IL-17; ReA-
INF-ɣ and IL-17, 1β and IL-17.
Conclusion: The course of JIA and ReA is characterized by a definite uni-
directional disorder in the Th1- and Th2-associated cytokines, which fits
into the overall picture of the deployment of the cascade of immuno-
inflammatory reactions, which is relatively universal, but both by the
severity of the established imbalance and by the nature of the revealed
relationships immunological parameters has its own characteristics. The
most informative at the stage of the differential diagnostic process of the
joint form of JIA and ReA can be considered an interrelated analysis of
the immunological activity of the inflammatory reaction.
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Introduction: Autoantibodies targeting cytosolic 5′-nucleotidase 1A
(cN1a) were first identified in adults with inclusion body myositis buthave subsequently been reported in a variety of other autoimmune dis-
eases. They have recently been described in patients with Juvenile Idio-
pathic Arthritis (JIA) but to date clinical associations are unknown [1].
Objectives: We aimed to determine the prevalence and clinical asso-
ciations of anti-cN1a in a UK cohort of patients with JIA.
Methods: We screened sera from 227 patients with JIA enrolled in
the Childhood Arthritis Prospective cohort study for anti-cN1a by
ELISA (16 systemic, 98 oligoarthritis, 52 rheumatoid factor negative
polyarthritis, 12 rheumatoid factor positive polyarthritis, 9 enthesitis
related arthritis, 16 psoriatic, 12 undifferentiated). In addition, sera
from 45 healthy juvenile controls, 52 patients with Juvenile-onset
myositis (JDM) and 20 patients with Juvenile onset Systemic Lupus
Erythematosus (JSLE) were also screened. The negative cut-off was
defined as more than 5 standard deviations above the mean of 34
normal healthy (adult) serum controls.
Results: Anti-cN1a were not identified in any healthy controls nor
children with JDM but were present in 3 (15%) of patients with JSLE.
Anti-cN1a were present in 19 (8%) of children with JIA. They were
present in all ILAR defined subgroups with the exception of
systemic-onset JIA and were most common in those with enthesitis
related JIA (22% anti-cN1a positive).
JIA patients with anti-cN1a were typically older at disease onset,
although the age range was wide, median 8.8 years (IQR 2.7-12.1)
versus 5.5 (IQR (2.0-11.0). The proportion of females was similar
in both groups (74% anti-cN1a positive and 66% anti-cN1a nega-
tive). Patients with anti-cN1a were more likely to be ANA positive
84% versus 53% (p=0.02) a dense fine speckle or homogenous
immunofluorescence pattern was most common but different im-
munofluorescence patterns and ANA negative individuals were
found in both groups.
Data on uveitis was limited to 139 JIA patients (10 patients with anti-
cN1a). Three patients with anti-cN1a had a history of uveitis (one
each of rheumatoid factor negative polyarthritis, enthesitis related
arthritis and psoriatic arthritis) compared to 56 of 129 patients with
available data who were anti-cN1a negative. Of the 68 patients with
oligoarthritis with uveitis data, 10 were anti-cN1a positive and this
group were less likely to develop uveitis than oligoarthritis patients
who were anti-cN1a negative (p=0.03).
Conclusion: cN1a is a common target of circulating autoanti-
bodies in UK children with JIA and are seen in all subtypes ex-
cept systemic JIA. In patients with oligoartiuclar JIA, who are at a
higher risk of uveitis, the presence of anti-cN1a was negatively
associated with a history of uveitis. Further work is needed but
patients with oligoarticular JIA and anti-cN1a may be at a lower
risk of uveitis and may therefore not require as frequent ophthal-
mological screening.
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Table 1 (abstract P070). See text for description
FMF +
Definite
JSPA
FMF +
Probable
JSPA
FMF patients
without JIA
and JSpA
FMF + JIA
(except ERA
or JSpA)
Patients, n 32 5 268 15
Female, n (%) 10 (31.25%) 1 (20%) 148 (55.22%) 10 (66.66%)
Age of disease onset,
mean ±SD years
7.19 ± 3.68 5.60 ± 4.93 4.91 ± 3.40 4.93 ± 3.32
Age at study, mean ±SD
years
14.84 ± 3.70 13.40 ±
1.67
12.51 ± 4.43 10.73 ± 3.57
M694V mutation n(%) 19 / 30
(63.33%)
3 (60%) 148 / 245
(60.40%)
11 (73.33%)
Disease onset >6 yrs 26 (81.25%) 5 (100%) 6 (40%)
Oligorthritis 21 (65.62%) 1 (20%) 14 (93.33%)
Inflammatory back pain 17 / 32 (53.1%) 3 / 5(60%) 0 (0%)
Enthesopathy 3 / 5(60%) 0 (0%)
Sacroiliitis 22 /32(68.7%) 0 / 1 (0%) 0 /5 (0%)
Coxofemoral Arthritis 14 /21(66.7%)
19/32(59.37%)
2 / 5(40%) 0 / 15 (0%)
Tarsometatarsal
sensivity
1 / 5(20%) 1 / 7(14.3%)
HLA-B 27 Positivity 12 / 32 (37.5%) 0 / 1(0%) 0 / 3(0%)
Male Gender 4 / 5(80%) 5
/15(33.3%)
Response to NSAID 9 / 22(40.9%) 4 / 5(80%) 2 / 7(28.6%)
Limitation in Schober
test (< 4 cm)
22 /32(68.7%) 2 / 5(40%) 0 / 7(0)
21 / 26(80.7%)
Family history of SpA
group of disease, dactylitis,
psoriasis or presence
of IBD
7 / 32(21.87%) 1 / 5(20%) 1 /8(12.5%)
10 / 32(31.3%)
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 48 of 243Introduction: Literature showed the importance of classifying pa-
tients into the right Juvenile Idiopathic Arthritis (JIA) category to pro-
vide them with optimal treatment1. However, a substantial amount
of patients were classified as ‘undifferentiated JIA’ (UJIA) due to the
strict exclusion criteria, harbouring the risk of losing the indication of
the preferred treatment.
Objectives: The aim of this study was therefore to investigate the in-
fluence of ‘a first-degree relative with psoriasis’, which is an inclusion
criterion for psoriatic arthritis and an exclusion criterion for the
‘remaining five JIA categories’. This results in more insight in the ac-
curacy of the classification system for JIA from the International
League of Associations for Rheumatology (ILAR).
Methods: Analyses were made in a retrospective and prospective co-
hort of 8,309 patients with JIA. 606 patients were classified as UJIA,
303 patients as ‘psoriatic arthritis’ (PSA) and 7,400 patients as one of
the ‘remaining five categories’.
Results: 225 (37.1%) patients with UJIA had ‘a first-degree relative
with psoriasis’. No significant difference was found between the PSA
and UJIA category in the number of patients with ‘a first-degree rela-
tive with psoriasis’. None of the abovementioned 225 patients devel-
oped psoriasis during the observation period. Only 60 (20.8%)
patients were classified as PSA because of the inclusion criterion of
having ‘a first-degree relative with psoriasis’ in the PSA category.
Conclusion: The exclusion criterion ‘a first-degree relative with psor-
iasis’ increases the number of patients classified as UJIA. No signifi-
cant difference was found between the PSA and UJIA category in the
number of patients with ‘a first-degree relative with psoriasis’, sug-
gesting this criterion is not of added value for the ILAR classification
system for JIA. We conclude that ‘a first-degree relative with psoriasis’
is not a necessary inclusion criterion for psoriatic arthritis. For these
reasons, we suggest removing the inclusion and exclusion criterion ‘a
first-degree relative with psoriasis’ for all the JIA categories.
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Introduction: Familial Mediterranean fever (FMF) is the most common
monogenic autoinflammatory disease characterized with fever, recur-
rent episodes of self-limiting polyserositis and arthritis. FMF arthritis is
generally acute monoarthritis especially in the larger joints of the lower
extremities, healing without a sequelae. However some of the patients
develop different type of chronic arthritis, predominantly oligoarticular
juvenile idiopathic arthritis (JIA) and juvenile spondyloarthropathies
(JSpA). Studies on JSpA among childhood FMF patients are scarce.
Objectives: To evaluate the frequency of JSpA in a large childhood
FMF cohort. Furthermore, we aimed to define main characteristics of
JSpA among childhood FMF patients.
Methods: A total of 320 juvenile FMF patients were blindly ques-
tioned according to recently proposed criteria for JSpA by 3 re-
searchers (EO, DS, ET). A standardized case report form including
demographic data, clinical features, MEFV mutation and treatment
was prepared and completed for each patient. Patients fulfilled the
JSpA criteria were previously classified as probable JSpA. Afterwards,an expert in pediatric rheumatology (OK) reevaluated the classified
patients and some of them were confirmed to be a definite while
some of them were accepted as potential JSpA patients.
Results: 37 patients (11.5%) were initially classified as potential JSpA:
32 (10%) were accepted as definite and 5 (1.5%) as probable JSpA.
Demographic, clinical and treatment data of definitive JSPA patients
are shown in Table 1.
Conclusion: Articular involvement compatible with JSpA could be
seen in childhood FMF patients. Spondyloarthropathies were detected
in 10% of childhood FMF cases. The M694V mutation is the most
common MEFV mutation among JSpA patients with FMF. JSpA
should be considered in childhood FMF patients, especially in those
chronic arthritis, axial involvement and enthesopathy.
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Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 49 of 243Introduction: The OMERACT JIA Core Set Working Group formed in
2015 as an international initiative to revise the existing Core Set with
relevant patient/caregiver input. In efforts to develop an updated,
patient-centered Core Outcome, virtual focus groups (VFGs) to iden-
tify main patient/caregivers-valued themes regarding the physical,
mental, and social impact of JIA disease activity states were
conducted.
Objectives: To identify and prioritize key features defining patient-
perceived inactive disease state and to examine possible cross-
cultural differences in the main domains
Methods: Two sets of paired VFGs were conducted with JIA patients
(adolescents and young adults) and parents (split by ages of their
children) in two clinics, in the US and in Italy respectively. Eligibility
included prior or current experience of JIA disease inactivity (>3
months). A 3-day facilitated online board was held per group, focusing
on the impact of JIA on physical, mental and social health, and the per-
ceived differences between active and inactive JIA. Participants were
asked to identify and rank their five top priority features defining in-
active disease. Content analysis of transcripts was conducted independ-
ently in the two centers and compared. Coded transcripts were further
analyzed using network analysis, an approach that allows to study the
structure of the connections between domains and the impact of spe-
cific items, measured by centrality indexes.
Results: 86 subjects were included. Caregiver were split by ages of
their children (under and over 15 years old in the US sample; under
and over 10 years old in the Italian sample). Patients were split in ad-
olescents (15-17 years old in the US sample, 15-18 years old in the
Italian sample) and young adults (18-24 years old in the US sample,
19-25 years old in the Italian sample). Qualitative analysis revealed
psychosocial impact and limitations in daily activities emerged as
main domains in both samples; fear of relapses and burden of medi-
cations were indicated as concerns mostly by Italian patients and
caregivers, while the impact on children’s activities and family life ap-
peared relevant in US groups. Network models of ranked “top five”
remission-defining items identified absence of pain as the single item
with the highest degree, closeness and between centrality, indicating
high relevance; others central themes in both samples were absence
of functional limitations, improved engagement and autonomy.
When comparing network models by the two populations, reduction
of anxiety and absence of uveitis showed the greatest differences in
centrality across the samples, respectively showing higher centrality
in the Italian and in the US groups.
Conclusion: Data analysis revealed several domains that need to be
evaluated for the development of patient/parent-centered outcomes
assessment instruments. Network models revealed the central role of
pain, functional limitation and restricted participation in patient-
perceived remission in both populations. Main differences in the two
populations include the role of relapses, treatments and secondary
demands in the impact of disease. Further analysis and cross-cultural
validation of the results is planned to inform the development of pa-
tient/parent-centered outcomes measures.
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Introduction: Rheumatoid factor (RF) positive polyarticular juvenile
idiopathic arthritis (JIA) with is a rare subtype of JIA (2-5%) of pa-
tients. No series have been published on this topic.Objectives: Our objective was to describe the demographics charac-
teristics and the course of RF positive polyarticular JIA.
Methods: We performed a monocentric retrospective study of pa-
tients with RF positive polyarticular JIA included between 2008 and
February 2018 in the database CEMARA of the French reference cen-
ter for juvenile arthritis and rare pediatric systemic autoimmune
diseases (RAISE). This data base has been approved by the French
Commission Nationale Informatique et Libertés. We recorded pa-
tients age at onset, gender, familiy history, comorbities, growth-height
charts, acute phase reactants, positivity of antinuclear antibodies (ANA)
and anti-citrullinated protein antibodies (ACPA), treatments, side effects
and course. Clinical remission was defined according to Wallace
criteria1.
Results: Fourty-six patients (40 girls, 6 boys) were included. The me-
dian age at onset was 13 years (5-23) and the median follow-up 3
years (1-15). Sixteen patients (35%) had a familial history of auto-
immunity or juvenile inflammatory rheumatism. Two patients were
siblings from the same non-consanguineous parents. Fourteen pa-
tients (30%, 4/6 boys, 10/40 girls) had associated conditions: 4 pa-
tients had auto-immune diseases (thyroiditis, vitiligo, Raynaud
syndrome, insulin dependent diabetes), 3 (6,5%) had bronchiectasis,
5 (10,8%) a growth retardation. Finally two patients had a Mendelian
diseases: Marfan syndrome and hereditary multiple osteochondromas
resulting from heterozygote mutation of EXT1. ACPA and ANA were
positive in 27/33 (82%) and 19/24 (79%) patients respectively.
Twenty-one patients (45,6%) had an elevation of acute phase reac-
tants at disease onset. Eight patients (17%) had erosive arthritis
within the first year of evolution. The first line treatment was METHO-
TREXATE for 34 patients (74%) alone in 11 patients (32%)) or in asso-
ciation with anti-TNF in 23 patients (67%)). Twenty-four/27 patients
(88%) were treated by anti-TNF: ETANERCEPT (74%), ADALIMUMAB
(11%), and INFLIXIMAB (3.7%). Other biologic agents were RITUXIMAB
(n=2), TOCILIZUMAB (n=4). ABATACEPT (n=6). Sixteen patients (35%)
received short or sustained treatment with corticosteroids. Primary or
secondary resistance for the first biological agent occurred in 3
(6.5%) and 4 patients (8.6%) respectively. Seventeen out of 35 pa-
tients (48%) were on remission on treatment or off treatment (mean
follow-up without relapse: 7 and 8 years respectively). Four patients
(15%) who were treated by at least one biological agent presented
side effects, which required to stop the treatment.
Conclusion: Our study confirms the severity of RF positive polyarticu-
lar JIA and emphasizes its demographic and immunological heterogen-
eity. This first report of bronchiectasis in this population emphasizes
the need for a careful pulmonary evaluation. The frequency of family
auto-immunity history and the occurrence in two siblings suggest that
some FR positive polyarticular JIA might be monogenic diseases.
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Introduction: Juvenile idiopathic arthritis (JIA), is the most common
chronic rheumatic disease among the world and the diagnosis is
based on the exclusion of other causes in the presence of arthritis,
lasting at least 6 weeks in children under 16 years of age.
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 50 of 243Objectives: We aim to assess the frequency of thoracolumbar spine
(TLS) involvement and Magnetic Resonance Imaging (MRI) findings in
the patients with JIA.
Methods: Patients who underwent for thoracolumbar MRI, known
or suspected JIA between January 2015–2017, were retrospect-
ively re-examined by a musculoskeletal radiologist for the pres-
ence of inflammatory (central/corner lesion, costovertebral
inflammation, supraspinous or interspinous enthesitis) and erosive
(wedging, central erosion) lesions. At the time of spinal MRI we
also investigated the presence of sacroiliac joint (SIJ) involvement,
peripheral joint (PJ) involvement and symptoms for spine
involvement.
Results: Totally 108 patients were re-examined. Finally, 52 patients
(mean age: 14.5±3.4) with a definitive diagnosis of JIA were en-
rolled in the study. Among them 41 had enthesitis related arth-
ritis (ERA), 4 had oligoarticular (OA), 5 had polyarticular (PA) JIA,
one had psoriatic arthritis (PsA) and one had systemic JIA (sJIA).
Among ERA patients there were at least one inflammatory lesion
in 23 (56%), one erosive lesion in 3 (%7), and both inflammatory
and erosive lesions in 3 (7%) patients. In ERA patients with posi-
tive findings at TLS MRI, 19 (82%) had sacroiliitis and 14 (60%)
had peripheral arthritis concurrently. 15 (65 %) were clinically
asymptomatic in terms of TLS involvement (none of them had in-
flammatory back pain or morning stiffness, the Schober’s test [>6
cm] and chest expansion [>10 cm] were normal). Among the pa-
tients with other subtypes of JIA, there were at least one inflam-
matory lesion in 5 (45%) and at least 1 erosive lesion in 1 (9%).
In non-ERA patients with positive findings at TLS MRI, 6 (83%)
were clinically asymptomatic for TLS involvement. Of note, one
patient had sacroiliitis and 5 patients had peripheral arthritis in
addition to TLS involvement.
Conclusion: Although current literature indicates that spinal
MRI shows insufficient evidence for detecting early JIA; with this
study we demonstrated that, Inflammatory and/or erosive lesions of
thoracolumbar spine can be seen in asymptomatic patients of ERA
and even in non-ERA JIA patients and the majority of spinal lesions
detected in asymptomatic ERA and non-ERA JIA patients were
inflammatory.
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Introduction: Around 30% of children with juvenile idiopathic
arthritis (JIA) suffer from daily pain regardless of medication. Pain
in JIA causes disturbances in the circadian rhythm compared to
healthy children.
Objectives: To study if pain is related to disturbed sleep, physical ac-
tivity, and higher JIA disease activity compared to healthy age-
matched controls.
Methods: A prospective observational study was conducted between
2016 and 2018. We wanted to include 100 JIA patients and 200
healthy age-matched controls between 6-16 years old. JIA patients
were consecutively asked during their routinely visits to our out-
patient clinic. Controls were invited by notice on the parents IT-
based communication platform in schools. They were asked to
complete a sleeping schedule and a pain app daily for one week.
One time they answered retrospective surveys about pain, sleep, and
activity.
Results: 93 with JIA and 188 controls were included. 76% of JIA pa-
tients and 43% of controls reported pain in retrospectivequestionnaires. In one week's observation, 84% with JIA and 70% of
controls had pain minimum once. 32% with JIA and 6 % of controls
reported daily pain. Pain intensity (VAS score 0-10) reported as me-
dian [min;max] was: 1.00 [0;8.25] for JIA patients and 0.29 [0;6.29] for
controls. Pain prevalence and pain intensity were significantly higher
in JIA patients compared to controls (p<0.05). 55% with JIA and 90%
of controls always participated in physical education, thus JIA pa-
tients were significantly less active than controls. Pain did not reduce
physical activity in JIA, but pain significantly lowered the level of ac-
tivity in controls (p<0.001). No significantly relation between neither
sleep disturbances and study groups nor sleep disturbances and pain
was found. Disease activity (JADAS-27) in JIA was significantly posi-
tively correlated to pain intensity, and significantly related to reduced
physical activity (p<0.05).
Conclusion: Pain is common in JIA patients and controls. JIA patients
are significantly less active compared to controls. Low physical activ-
ity in JIA is not related to pain, but to increased disease activity.
Higher pain intensity is related to higher disease activity in JIA. In
controls, pain is related to reduced activity.
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Introduction: Perinatally HIV-infected adolescents (PHIVA) have
been shown to have a higher risk of developing musculoskeletal
diseases. Increasing access to antiretroviral therapy (ART) has dra-
matically improved life expectancy but little is known about mus-
culoskeletal disease in PHIVA who are on ART in Africa.
Objectives: To study the prevalence and spectrum of musculoskel-
etal abnormalities in PHIVA on ART using the pediatric Gait, Arms,
Legs, Spine (pGALS) screening tool.
Methods: HIV-infected and matched HIV-uninfected adolescents
(HIV-) enrolled in the Cape Town adolescent antiretroviral cohort
(CTAAC) had pGALS examination and screening musculoskeletal
questionnaires completed by trained study clinicians. Childhood
Health Assessment Questionnaires (CHAQ) were used to assess
participants’ musculoskeletal health status; participants with ab-
normal pGALS examinations were referred to rheumatology.
Results: pGALS was performed on 473 PHIVA (median age: 13.1
years; 49% female; median age at ART initiation: 4.3 years) and
101 HIV negative adolescents (median age: 12.8 years; 54% fe-
male). Median duration on ART was 8.8 years (IQR 5.8-10.5) with
38% initiating ART at ≤2 years of age. Twenty-three percent of
PHIVA were WHO HIV stage 4 at time of HIV diagnosis. At the
time of pGALS screening, 60% were on two nucleoside reverse
transcriptase inhibitors and a non-nucleoside reverse transcriptase
inhibitor and 36% were on two nucleoside reverse transcriptase
inhibitors and a protease inhibitor. Eighty percent of the PHIVA
had viral load ≤100 copies/ml and the median CD4 count was
711cells/uL.
Of the 23 (4%) participants with abnormal pGALS screening, 21
(4.4%) were PHIVA and 2 (2%) were HIV negative adolescents,
p=0.25. 45% of those with abnormal pGALS had abnormal
CHAQ, or a positive musculoskeletal screening question. Ten
(44%) of participants with abnormal pGALS screening reported
physical symptoms (4 had joint pain, 3 had difficulty in getting
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stairs, 1 had joint pain along with difficulty in getting dressed
and taking stairs).
Fifty percent of the PHIVA with abnormal pGALS were WHO HIV
stage 4 while 22% of those with a normal pGALS were WHO
stage 4, p=0.02. An abnormal pGALS was associated with longer
duration of ART (median duration: 9.9 years vs 8.7 years with nor-
mal pGALS, p=0.01).
Amongst the 23 participants with abnormal pGALS, 2 PHIVA were
diagnosed with Osgood-Schlatter Disease, 6 (4 PHIVA and 2 con-
trols) with orthopedic conditions including scoliosis or osteochon-
droma, 9 PHIVA had underlying neurological conditions including
cerebral palsy or a prior stroke and 6 PHIVA had mechanical joint
conditions.
Conclusion: There was a low prevalence of musculoskeletal abnor-
malities in this group of PHIVA established on ART. Advanced HIV
stage and longer exposure to ART were associated with musculoskel-
etal abnormalities. Screening for musculoskeletal abnormalities may
target these subgroups of PHIVA.
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Introduction: Patients with autoimmune diseases are susceptible
to infections due to their defective immune system and the re-
ceiving immunosuppressive treatment. Juvenile spondylarthritis
(jSpA) often requires life-long treatment with biologics, which
manage to fully control the disease. However, data regarding re-
sponse and long-term immunological memory to specific vaccines
are lacking.
Objectives: We aimed at a comprehensive assessment of how
anti-TNfα therapy interferes with vaccine-specific-IgG titers in chil-
dren with jSpA.
Methods: Prospective controlled study including 41 patients with
jSpA and 149 matched-healthy controls. All patients had received
two doses of MMR vaccine in early childhood. Demographic, clin-
ical and laboratory data were collected. Type and duration of
treatment was recorded. Samples were collected at diagnosis and
at one and two years’ follow-up. Seroprotection rates as well as
measles and rubella-IgG titers were measured and expressed as
GMC's. The Hospital’s Research and Ethics’ Committee approved
the study; written informed consent was obtained. Statistical sig-
nificance was set at p<0.05 and analyses were conducted using
STATA (version 13.0).
Results: The two groups had similar demographic characteristics,
vaccination history and immunization status. No significant differ-
ences were detected in terms of vaccine type, time interval between
the two vaccines as well as mean elapsed time from last vaccination
to blood sampling. All patients in the ERA group were HLA-B27 posi-
tive. Seroprotection rates were adequate for both groups at all times.
Both rubella and measles GMC’s were significantly lower in the jSpA
compared to the control group (p<0.01) at one and three years’ fol-
low up but not at diagnosis. During the follow-up period, the jSpA
group had greater decrease in antibody levels as indicated from the
significant interaction effect of analysis. Subgroup analysis showed
that longer disease duration was directly correlated to lower antibodyconcentrations (p<0.01). Subgroup analysis on other parameters tested
such as uveitis, sacroileitis, enthesitis, JADAS scores and type of
anti-TNFa treatment did not specifically correlate with antibody
loss. The same was true for comcommitant use of synthetic
DMARD's.
Conclusion: Ant-TNFα treatment seems to reduce measles and ru-
bella GMC’s. Further studies are required to assess long-term im-
munity conveyed by immunizations given at an early stage in
children with rheumatic diseases, especially the ones receiving bi-
ologics. However, evaluation of immunization status against all
vaccine preventable diseases in such patients may be beneficiary.
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Introduction: The parent global assessment of disease activity (PDA)
has been suggested to replace the parent global assessment of over-
all well-being (PWB) as the main patient-reported outcome incorpo-
rated in the Juvenile Arthritis Disease Activity Score (JADAS). JADAS
is an important tool in a treat-to target-strategy in children with ju-
venile idiopathic arthritis (JIA).
Objectives: To investigate any discordance between PDA and PWB
among children with JIA.
Methods: The EPidemiology, treatment and Outcome of Child-
hood Arthritis (EPOCA) study collected information on the health
status of children with JIA currently followed worldwide. More
than 9137 children with JIA from 118 pediatric rheumatology
centers in 49 countries were included, and we analyzed the PDA
and PWB reported by the parents. The differences between the
visual analogue 10-cm scale (VAS) (range 0-10) of PDA and PWB
were assessed. Discordance was defined moderate for a VAS dif-
ference >1 and ≤3, high for a VAS difference >3, and agreement
if VAS difference was ≤1.
Results: PDA and PWB were available in 8615/9137 (94.3%) of the
EPOCA participants. Mean (SD) PDA was 2.1 (2.7), while mean
(SD) PWD was 2.0 (2.6). Among the one-fourth of patients with a
VAS difference >1, the number of active joints, percentage of
children with morning stiffness, and pain scores were significantly
higher in the group assessing PDA higher than PWB. In contrast,
there was a higher score indicating impaired quality of life when
PWB was higher than PDA (Table 1). Also, in parents assessing
PWB higher than PDA, the number of girls and the age at visit
were significantly higher.
Conclusion: Overall,there is a high rate of agreement between PDA
and PWB. In parents rating PDA higher than PWB, patients have
higher number of active joints and pain scores, and more morning
stiffness, while parents rating PWB highest had lower quality of life
scores.
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Table 1 (abstract P077). Clinical characteristics of the cohort according
to level of discrepancy between the parent assessment of overall disease
activity (PDA) and the parent assessment of overall well-being (PWB).
PDA vs PWB Total Agreement Low discordance High discordance
Median
(ICR)
≤+/-1 PDA >1-3
worse
PWB >1-3
worse
PDA >3
worse
PWB >3
worse
Female gender,
n (%)
5956
(66.2)
4452
(65.4)
515
(70.3)
477
(69.1)
274
(64.9)
238
(69.8)
Age at visit
(years)
11.6
(7.7; 14.8)
11.5
(7.6; 14.8)
11.3
(7.6; 14.8)
12.7
(8.7; 15.6)
10.8
(7.1; 14.9)
12.6
(9.3; 15.4)
Disease
duration
4.0
(1.8; 7.0)
4.0
(1.9; 7.0)
3.5
(1.3; 6.7)
4.0
(1.8; 7.4)
3.5
(1.3; 6.6)
3.9
(1.8; 7.2)
Active Joints 0
(0; 2)
0
(0; 1)
1
(0; 3)
0
(0; 2)
1
(0; 2)
0
(0; 2)
Morning
stiffness, n (%)
2923
(33.7)
1875
(28.6)
400
(56.2)
301
(45.2)
222
(54.4)
125
(38.1)
Stiffness
duration
(min)
15-30 15-30 15-30 15-30 15-30 <15
Pain score 1.0
(0; 3.5)
0.5
(0; 2.5)
3.5
(1.5; 5.5)
2.0
(0.5; 5.0)
2.5
(0.0; 5.0)
2.0
(0.0; 5.0)
Quality of Life 3
(1; 7)
2
(0; 6)
5
(3; 9)
7
(4; 11)
4
(2; 8)
8
(4; 11)
Values are the median
(1st, 3rd quartile), unless indicated n
(%). PWB, parent global assessment of overall well-being
(range 0-10); PDA, parent global assessment of disease activity (range 0-10)
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Introduction: Up to now, few studies have been addressed to the
natural history of uveitis associated to Juvenile Idiopathic-Arthritis
(JIA-U) in order to properly select the treatment approach since the
early disease manifestations.
Objectives: Aim of the present study was to identify the clinical char-
acteristics of patients with benign course JIA-U in order to early se-
lect the appropriate treatment and predict the final outcome.
Methods: Patients with JIA-U with at least 3 year follow, classified ac-
cording with the SUN criteria for uveitis and followed at our Pediatric
Rheumatology/Ophthalmology unit entered the study. Information
gathered for each patient included: sex, age at onset of arthritis and
uveitis, interval time between arthritis and uveitis onset; uveitis lat-
erality, intraocular inflammation grading, number and yearly distribu-
tion of flares, structural complications. Uveitis flare was defined as an
increase of cells in the anterior chamber of 2+ or more as compared
to the baseline. JIA-U patients in which DMARDs or biological agents
have been started at first for arthritis have been excluded. Collected
data were analyzed using descriptive statistics
Results: A cohort of 75 patients with JIA-U, with a median follow-up of
12.2 years (range 3-23.6), entered the study. In 21 (28%) uveitis has
treated with just topical drugs (Group A), the remaining 54 (72%) with
systemic treatments (DMARDs or biological agents etc.) (Group B). No
relevant differences were found between the two groups as far as sex
distribution, JIA subtype, ANA frequency or uveitis laterality. Age at uve-
itis onset was significantly higher in Group A (5.4 years) than in Group
B (4.3 years). The interval time between arthritis and uveitis onset was
also greater in Group A (1.56 years) as compared to Group B (0.85
years). No patient in Group A reported ocular complications while inGroup B they were 0.61/patient. The mean number of uveitis flares dur-
ing the observation period was significantly less frequent in Group A
than in Group B (1.57 versus 6.96, p < 0.001). The same was observed
considering the mean number of relapses/year. Interestingly, patients
in Group A had no relapses during the second year of follow-up and
achieved a complete uveitis remission, on just topical treatment, after
mean 2.6 years from onset, significantly earlier than in severe forms
(Group B) (7.37 years, p < 0.001).
Conclusion: Benign course JIA-U can be identified as self-limiting
condition, with low number of relapses and lack of structural compli-
cations. Patients with uveitis onset after five years of age, interval
time between arthritis and uveitis onset greater than one year and
no relapses during the second year of follow-up are likely to have a
mild uveitis course.
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Introduction: Juvenile idiopathic arthritis (JIA) is the most common
rheumatic disease in childhood. In the last two decades, advances in
the knowledge of pathogenesis has allowed the development of spe-
cific biological therapies for the treatment of JIA with an improve-
ment ACR 50 of 70% on average with anti TNF and Tocilizumab a
year of treatment.
Objectives: To evaluate the improvement and adverse events in pa-
tients with juvenile idiopathic arthritis treated with biological therapy
(Etanercept, Adalimumab and Tocilizumab.).
Methods: Were included patients with JIA, <16 years who received
biological therapy (Adalimumab, Tocilizumab, Etanercept), for a mini-
mum of 6 months, from 2012-2017, all had signed informed consent.
Demographic variables were obtained at diagnosis, clinical character-
istics, laboratory and improvement variables at the beginning of the
biological, 6 months, a year and when entering the study (current).
Descriptive statistics were used, averages, frequencies and percent-
ages for, Wilcoxon and McNemar test to measure differences be-
tween two related samples.
Statistical significance was considered p <0.05.
Results: Forty-three patients were included, 20 male and 23 fe-
male. Average age 12 years, average age at diagnosis 8 years,
average evolution time before the biological 24 months. Sub-
types: Polyarticular FR+ 16 (37%), Polyarticular FR– 14 (32%),
enthesitis related arthritis 6 (14%), systemic 5 (12%), oligoarticular
2 (5%). Extra-articular symptoms: fever 6 (14%) uveitis 5 (12%).
Average improvement ACR at 6 months, a year and current with
adalimumab 66%, 76%, 74%; Tocilizumab 81%, 80%, 80% and
Etarnecept 88%, 67%, 67%, respectively.
The adverse events reported were pain in the puncture site 40%,
transaminasemia 9% and seroconversion of PPD 12%.
Conclusion: The ACR pedi improvement was greater than 70%
with the 3 biological therapies used in this study during the first
6 months of treatment, which is maintained during 28 months of
follow-up (ACR average of 66%). There is an adequate safety pro-
file with the biological treatment, without having a tuberculosis
case so far.
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Table 1 (abstract P080). See text for description.
Indicators Class 1 Class 2 Wald P-value R2
Fluid -0.96 0.96 8.91 0.002 0.05
Contrast enanchment -2.52 2.52 8.44 0.003 0.48
Condylar erosion -1.42 1.42 50.57 <000.1 0.36
Bone marrow edema -3.27 3.27 2.02 0.150 0.10
Reducted translation -1.27 1.27 46.28 <0.001 0.28
Disc displacement -0.91 0.91 4.28 0.038 0.03
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Introduction: Temporomandibular (TMJ) synovitis is a common but
rarely symptomatic involvement that can lead to severe functional
disabilities in children with Juvenile Idiopathic Arthritis (JIA). Individ-
ual clinical signs lack sensitivity and specificity to distinguish acute
synovitis from chronic damage or functional alterations, while the
current gold standard test to detect acute and chronic changes in
TMJ - contrast-enhanced MRI- is demanding and not available
everywhere.
Objectives: To identify potential patterns of clinical predictors of MRI
findings useful to stratify risk of synovitis in patients with suspected
TMJ involvement and select which patients mostly require MRI test-
ing and which can be treated directly.
Methods: Reports from 166 JIA patients (332 TMJ) followed in
our clinic who underwent contrast-enhanced MRI for suspected
TMJ involvement between 2007 and 2017 were retrospectively
collected and analyzed. Data included TMJ symptoms and their
timing, clinical signs of rheumatological and orthodontic exami-
nations preceding MR execution and MRI abnormalities. Using
MR findings (synovial fluid, bone marrow edema, synovial en-
hancement, condylar head erosions, disc displacement) we esti-
mated a latent class model that identified subgroups of patients
with different synovitis probability. The ability of clinical findings
to predict class membership was then assessed through a Tree
Augmented Naive (TAN) Bayes model. Finally, decision analysis
network and tree were estimated to identify the most advantage
clinical strategy for different combinations of signs and
symptoms.
Results: Latent class analysis of MR findings classified patients
into low (class 1, n = 176) and high (class 2, n = 156) likelihood
of TMJ synovitis. Condition probabilities of items in the two
groups are showed in the table. The classes showed association
with specific profiles of TMJ signs and symptoms. A TAN Bayes
model predicted low (class 1), high (class 2), and intermediate
(class 3) synovitis probability based on signs and symptoms with
an AUC of 0,87 for class 2, 0,89 for class 1 and 0,97 for class 3. 9
variables (limitation since less than 3 months, previous TMJ syno-
vitis, retrognathia, TMJ palpation pain, temporalis palpation pain,
laterodeviation at visit, limitation for 3-6 months, reduced con-
dylar translation, laterodeviation since < 3 months) showed direct
association with class membership. Based on these variables a
Bayesian decision analysis (DAN) was conducted, assigning higher
rewards respectively to immediate treatment for patients in class
2, non-treatment for class 1 and testing with MR in subjects with
intermediate probability (class 3). The DAN resulted in a decision
tree that revealed 4 clinical scenarios where immediate treatment
was most favorable, 3 where non-treatment was suggested, and
7 where testing with MR was indicated.
Conclusion: Our analysis has the potential to inform clinical prac-
tice as it can be used to stratify patients according to TMJ syno-
vitis risk. Particularly in limited-resource settings, the model could
provide a diffusible and potentially extendable tool to guide the
clinical work-up selecting patients who are most likely to benefit
from MR testing.
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Introduction: Juvenile idiopathic arthritis (JIA) is a chronic inflamma-
tory disease of unknown origin which can be considered as an auto-
immune disease.
Objectives: The aim of this study was to evaluate the frequency of
symptomatic autoimmune thyroid disease (AITD) in children with JIA
and to investigate if there are any factors contributing to a higher
risk of developing AITD.
Methods: 8,309 patients, with a total observation time of 51,324
patient-years, were studied. PharmaChild, the largest JIA-registry was
used for this, containing clinical and laboratory data. Patients who
were members of the Paediatric Rheumatology INternational Trials
Organisation (PRINTO) were enrolled for the registry. Numerous pa-
tient characteristics and the family history were calculated separately
for the JIA patients with AITD and the patients without AITD.
Results: 96 of the 8,309 patients had AITD, which provided a preva-
lence of 1,2%. The median age of onset was significantly higher in
the children with AITD (9,1 versus 7,1). Furthermore, significantly
more females (84,4% versus 67,3%), ANA positivity (51,7% versus
40,8%), rheumatoid factor (RF) positive JIA (9,4% versus 3,8%) and
psoriatic JIA (7,3% versus 3,4%) were seen in the AITD group. Add-
itionally, the AITD group had significantly more first degree relative
with any autoimmune disease (26,4% versus 13,4%), or more specific
Table 1 (abstract P082). Baseline clinical and biomarker levels
Parameter Responders (n=20) Non-responders (n=14) p value*
Age at onset (months),
median (IQR)
72(36,132) 87(30,108) 0.84
Mean delay in diagnosis
(months), median (IQR)
21(4,59) 30(18,54) 0.326
JIA Subcategory, n
SJIA 3 0 0.179
Oligoarticular 3 6
Polyarticular (RF+) 0 1
Polyarticular (RF-) 6 2
Entesitis related arthritis 7 5
Serum MRP 8/14 (pg/ml),
median (IQR)
117.7(87.4,155.8) 78.8(59,118) 0.027
Serum IL-6 (pg/ml),
median (IQR)
20.3(16.5,23.7) 14(12.2,18.2) 0.019
Serum IL-2 (pg/ml),
median (IQR)
126.5(45.9,134.5) 43(31.9,81.9) 0.21
Serum TNFa (pg/ml),
median (IQR)
30.7(27.4,32.9) 32.4(37,28.3) 0.43
Serum IL-12 (pg/ml),
median (IQR)
48.4(38.3,57.2) 45.5(34,82) 0.83
* The p values are based on Wilcoxon signed-rank test for comparison of
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significantly less prevalent in the AITD group (3,1% versus 11,1%).
Conclusion: This study showed that there is a higher prevalence of
AITD among children with JIA than in the general population. Older
at diagnosis of JIA, not having systemic JIA, ANA positivity, RF posi-
tive JIA and psoriatic JIA seemed to be risk factors, as well as as hav-
ing a family history of autoimmune diseases, especially first degree
relatives or more specific having a family history of Hashimoto’s
thyroiditis.
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Introduction: Introduction
Approximately 40% of the subjects fail to respond to 1st line therapy
including methotrexate and DMARDs, thereby requiring additional
therapy. This additional therapy is offered only after a failed trial of
methotrexate owing to non-availability of a reliable predictive bio-
marker. This approach exposes children to ineffective drugs in
addition to accrual of ongoing inflammation and joint deformities.
Pretreatment estimation of inflammatory biomarkers like myeloid re-
lated protein (MRP) 8/14 may predict the response to methotrex-
ate. We are presenting interim analysis of our ongoing study on role
of biomarkers in predicting the response to methotrexate in children
with JIA.
Objectives: To correlate baseline serum biomarkers; IL2, IL6, IL12,
TNF a and MRP 8/14 levels in children with JIA before starting
methotrexate with response to methotrexate as assessed by
American college of Rheumatology (ACR) criteria at 3 months
follow-up.
Methods: Baseline clinical characteristics of consecutive children
with JIA were recorded and blood samples for estimation of bio-
markers were collected prior to starting methotrexate. Clinical
response at 3 months follow up was assessed as per ACR. Pa-
tients achieving ACR ≥50 were classified as responders, whereas
those with ACR ≤ 30 were classified as Non-responders to
methotrexate. The predictive ability of baseline levels of bio-
markers for the response to methotrexate was studied using bin-
ary logistic regression models.
Results: 44 children (21 girls) with JIA who completed 3 months
follow up after starting methotrexate were included for this in-
terim analysis. 20 children were classified as responders while 14
were Non-responders. 10 subjects having an ACR between 30
and 50; have been excluded for this analysis. The median base-
line values of MRP 8/14 and IL-6 were significantly higher in re-
sponders as compared to non-responders (Table 1). Children with
higher baseline values of MRP8/14 and IL-6 were more likely to
achieve ACR 50 or more; unadjusted OR (95%CI) 1.02 (1,1.04),
p=0.047 and 1.28 (0.99,1.63), p=0.05 for MRP 8/14 and IL-6
respectively.
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The interim analyses showed that higher levels of baseline serum MRP8/14
and IL-6 have prognostic value in predicting response to methotrexate.
Estimating these biomarkers at baseline may help in predicting the
therapeutic response and guiding initial therapy.
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Introduction: The role of the gastrointestinal tract in pathogenesis of
JIA has raised attention since some of the risk factors for JIA relate to
an altered gastrointestinal immunological situation. Early introduction
of cow’s milk is one such risk factor. Cow’s milk includes more than 25
different proteins. In bovine milk β-lactoglobulin is the main whey pro-
tein, but antibodies against α-lactalbumin are more common in cow´s
milk allergy in children. IgG antibodies against cow’s milk antigens are
produced in plasma cells in the intestinal canal. The role of these anti-
bodies is unclear, they have been elevated in cow´s milk allergy but
not in cow´s milk intolerance. IgG4 antibodies against a specific food
antigen mainly relates to the degree of exposition. Antibodies against
nutritional antigens in children with JIA are only scarcely studied.
median between responders and non-responders
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cow’s milk antigens in children with JIA, at high compared with low
disease activity, and compare the results with antibody levels in
healthy controls. We also wanted to evaluate whether a history of
milk intolerance affected the results.
Methods: We investigated levels of IgG and IgG4 antibodies against
β-lactoglobulin, α-lactalbumin and casein in serum of 65 children
with different categories of JIA, at high and low disease activity, and
in 30 healthy controls. The analyses were performed with an auto-
mated FEIA method, ImmunoCAP ThermoFisher. At low disease activ-
ity the majority of children were treated with metotrexat and/or
biological agents. Disease activity was assessed by analysis of calpro-
tectin by ImmunoCAP in plasma and E-SR. In the group of children
reporting milk intolerance, IgE antibodies against milk antigens were
analysed with ImmunoCAP.
Results: Analyses revealed a significantly higher concentration of IgG
antibodies against all three milk antigens in high compared with low
disease activity, Md 4.7 mgA/L compared to 3.4 (p=0.001) for IgG β-
lactoglobulin, Md 2.2 mgA/L compared to 0.0 (p=0.032) for IgG α-
lactalbumin, and Md 7.3 mgA/L compared to 6.9 (p=0.003) for IgG
casein. There was no difference between high and low disease activ-
ity in concentration of IgG4 β-lactoglobulin. When comparing chil-
dren in high disease activity with children in the control group, there
was no difference regarding levels of β-lactoglobulin (p=0.29), α-
lactalbumin (p=0.14) or casein (p=1.0). The levels of β-lactoglobulin
in serum correlated with the levels of calprotectin in plasma in all
samples at high and low disease activity, rs= 0.26 (p=0,004), as well
as with E-SR, rs= 0.24 (p=0,007). There was a high correlation be-
tween E-SR and calprotectin, rs= 0.82 (p<0.001). None of the eight
children with current or earlier milk intolerance had positive IgE anti-
bodies against milk antigens and the milk intolerance did not influ-
ence levels of IgG antibodies against milk antigens.
Conclusion: In this study children with high disease activity in JIA
had the same degree of antibody-production against milk antigens
in serum as healthy children, but the levels were significantly de-
creased in lower disease activity. The stable concentration of IgG4 β-
lactoglobulin was considered a sign of unchanged exposition of cow´
s milk at high compared with low disease activity. Our results sup-
port influence on the gastrointestinal immune system by disease ac-
tivity and treatment in JIA.
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Introduction: The ILAR consensus establishes classification criteria,
dividing the JIA into 7 subcategories, with juvenile psoriatic arthritis
(APsJ) being one of them. In the adult population, the CASPAR classi-
fication criteria are usually used to classify a patient with psoriatic
arthritis. However, the two classifications have some differences that
sometimes produce confusion
Objectives: To assess the applicability of the CASPAR classification
criteria in a series of patients previously diagnosed in pediatric age
of JPAs or undifferentiated arthritis by exclusion criteria to be male>
6 years old and HLA B27 positive, comparing these with the ILAR
classification criteria, through the study of clinical features
Methods: Retrospective cross-sectional observational study. Clinical,
epidemiological, sociodemographic and analytical variables were col-
lected from 30 patients previously diagnosed with JPAs (6 years in
HLA B27-carrying male. It was assessed whether the patients met the
ILAR classification criteria as well as the CASPAR classification criteria,
which, unlike the previous ones, did not exclude HLA B27 positivepatients, considered the family history of the 2nd degree and added
a test radiographic
Results: The mean age at diagnosis was 11.23 ± 4.6 years; 15 of them
being women and 15 men. 15 (15/30) patients presented cutaneous
psoriasis at some point during the follow-up, in 5/15 patients psoria-
sis began before arthritis while 7/15 patients were previously diag-
nosed with arthritis than cutaneous psoriasis; in 3/15 patients the
diagnosis was simultaneous during the medical visit. 9 (9/30) patients
presented a family history of 1st degree cutaneous psoriasis and 7/
30 of them had a family history of 2nd grade psoriasis. Of the total
number of patients, 10 of them would not meet the ILAR classifica-
tion criteria, 8 because they presented as exclusion criteria being
male, HLA-B27 positive and> 6 years of age, among which, 7/8 would
fulfill CASPAR criteria, and 2 other patients who were not classified
according to ILAR criteria, did meet the CASPAR classification criteria,
given the presence in these criteria of negative RF, family history of
the 2nd degree and typical radiological alterations, which are not
present in the ILAR criteria. 1 (1/30) patient did not meet CASPAR cri-
teria, and belonged to the group of patients excluded from the ILAR
criteria for being male> 6 years HLA-B27 +. If we did not take into ac-
count the negative FR of the CASPAR criteria, 14 patients would not
meet these criteria and if we eliminated the 2nd grade AF, 5 patients
would not be classified (among them 2 who meet CASPAR and do
not ILAR)
Conclusion: In our series of patients despite the fact that the pres-
ence of current skin psoriasis contributes 2 points in the CASPAR cri-
teria, only 1 patient would not meet the CASPAR criteria, since the
majority of patients present other clinical or analytical manifestations,
such as the presence of negative rheumatoid factor or 2nd degree
family history. Patients who do not meet criteria for PsA by exclusion
criteria, practically all of them would be diagnosed with psoriasic
arthritis by CASPAR criteria.
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Introduction: Methotrexate (MTX) is a second line drug in the treat-
ment of juvenile idiopathic arthritis (JIA), either alone or in combin-
ation with biologic agents. However, there is variation in the clinical
response to MTX.
Objectives: The aim of this study was to investigate the role of fac-
tors such as age, gender, ANA status, number of active joints, and
JADAS-10 in predicting MTX response.
Methods: Clinical and laboratory data of oligoarticular and polyarti-
cular JIA patients diagnosed according to the International League of
Association for Rheumatology (ILAR) criteria, who had received MTX
treatment between January 2012 and March 2017, and continued
MTX treatment for at least 12 months were evaluated retrospect-
ively. The age at diagnosis, gender and ANA status were recorded.
The number of active and tender joint and levels of acute phase re-
actants were assessed at baseline, and 3, 6, and 12 months. Disease
activity score (JADAS-10) was calculated at onset of MTX
and at months 3, 6 and 12. Patients' responses to MTX treatment
were assessed according to the American College of Rheumatology
Paediatric (PedACR) improvement criteria. At each time the patients
were divided into responders and non-responders according to Ped-
ACR 30 and 70
Results: This study included 55 JIA patients (40 female). Thirt-four were
oligoarticular (2 extended oligoarticular) and 21 were polyarticular (5
rheumatoid factor positive) JIA. The mean age at onset of the disease
was 7.71± 4.83 years.(mean age was 6.75 ± x4.99 years in patients with
Table 1 (abstract P086). See text for description
Patient / Sex 1 / F 2 / F 3 / M 4 / F
Lung disease Bronchiolitis
Obliterans with
Organizing
Pneumonia
Surfactant
Protein C-
associated
ILD
Non-specific
interstitial
pneumonia
Chronic
bronchiectasis
Age at ILD
onset (y)
16,9 2 14,4 10,9
Chest X-ray
and scanner
abnormalities
Yes Yes Yes Yes
Diffusion
trouble
Yes Yes Yes No
Restrictive
syndrome
No No No No
Obctructive
syndrome
No Yes No No
Inflammatory
alveolar liquid
No Yes No
Biologics Ritux Eta Eta, Toci,
Aba, Inflix
No
IV steroids Yes Yes No No
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 56 of 243oligoarthritis, 9.27 ± 4.21 years in polyarticular patients). The median
JADAS 10 at beginning for all 55 children was 19 (10–40), and 16 (10-
27) for oligoarticular, and 28 (19-40) for polyarticular JIA. At month 3,
45% of all patients, %41 of oligoarticular, and 52% of polyarticular
JIA patients had a minimum PedACR 30 response. 13 patients (2 at
4th and, 11 at 7th months) received biologic agents along with MTX.
These patients were not included in the evaluation of treatment re-
sponses at 12th month. The remaining 42 patients had PedACR 30 re-
sponse at month 12. Moreover 81% of these patients (% oligoarticular,
% polyarticular JIA) reached pedACR 70 response at month 12. Patients
who had PedACR 30 response at 3 months had a higher rate of reach-
ing the Ped ACR 70 response at 12 months (p=0.009). In patients with
oligoarticular JIA, the 12th month Ped ACR response was negatively cor-
related with the number of involved joints (OR). The initial JADAS 10
did not effect the PedACR response at 3 months (OR), but it was found
that the 6th month of JADAS 10, had a significant effect on PedACR 70
response at 12th month (p<0.05). Age, gender and ANA status had no
effect on PedACR responses.
Conclusion: PedACR 30 response at the 3rd month, JADAS-10 at 6th
month and number of active joints in oligoarticular JIA were found
to be predictors of the ACR response at 12th month.
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Introduction: There is an association between juvenile idiopathic
arthritis (JIA) and chronic lung disease. These pulmonary disorders
are multiple - interstitial (ILD) or non-inflammatory - depending on
the type of underlying JIA - mainly polyarticular or systemic. In chil-
dren, because of absence of accurate and multi-center data, the
management of these chronic lung diseases remain difficult.
Objectives: This work aimed to constitute a national cohort of JIA pa-
tients presenting chronic lung disease.
Methods: A retrospective multicenter study was conducted. The
cases between 2007 and 2018 were obtained from appeal of French
Medical societies (SOFREMIP, RespiRare, SFR, CRI, database of
pediatric pulmonary arterial hypertension). JIA was defined according
to ILAR criteria; all had to have chronic pulmonary disease. Exclusion
criteria were: age at onset> 18 years old, systemic JIA, other docu-
mented auto-immune or auto-inflammatory disease, asthma, cystic fi-
brosis, bronchopulmonary dysplasia, chronic lung infection,
pulmonary primitive malformation. Data regarding clinical, paraclin-
ical, therapeutic and evolution items were collected.
Results: 8 files were selected; 4 met the study criteria. All patients
had positive rheumatoid factor polyarticular JIA, with female predom-
inance (3/4), mean age at rheumatism onset of 11.5 years (7.5-16).
They all had disabling polyarthritis, involving small/big articulations,
mostly symmetrical, involving neck in 3/4 and hips in 1/4 patients, X-
ray erosions in 2/4 patients. All had markedly erythrocyte sedimenta-
tion rate (32-107 mm, mean=65), hypergammaglobulinemia (14.8-
30.8 g/l, mean=22.5), high titers of CCP antibodies, elevated antinu-
clear antibodies (>1/320) - with specificities in patient 4 (SSA/SSB/
RNP without criteria for any connective tissue disease); patient 2 had
positive TRAK antibodies without functional consequences. Each pa-
tients had different subtypes of ILD (Table 1). Pulmonary symptoms
at diagnosis were: cough (2/4), exercise dyspnea (2/4), dyspnea at
rest (1/4), hemoptysis (1/4 – patient 4), digital clubbing (1/4 – patient
2), auscultation abnormalities (2/4). In patient 2, ILD/fibrosis wasrelated to SFTPC mutation. She had familial history of dominant in-
heritance of lung fibrosis and 2 ascendants with inflammatory
rheumatic disease (rheumatoid arthritis, unclassified). Treatment was
based on oral steroids, that could be associated with variable immu-
nomodulation. In contrast to methotrexate - used in all patients, Eta-
nercept was associated in patient 2 with ILD worsening, that
improved at treatment discontinuation. Among all patients at last
visit, patient 2 was the only who needed nutritive and respiratory
support, and died at age of 15 years old, 13 years after lung disease
beginning, on a graft waiting list.
Conclusion: The chronic pulmonary diseases related to JIA are ex-
tremely scarce. In this cohort only ILD form was observed in positive
rheumatoid factor polyarticular JIA patients. Treatment strategies of
both combined diseases were heterogeneous: oral corticosteroid was
used in all, methotrexate did not seem to aggravate ILD, conversely
to etanercept. The long-term interest will be to propose consensual
recommendations for management of these patients. Informed con-
sent had been obtained from the parents.
Disclosure of Interest
None DeclaredP087
“ONCE A DAY, ‘CAUSE YOU’RE GETTING LOTS OF INFORMATION”:
HOW CHILDREN AND YOUNG PEOPLE WITH JUVENILE IDIOPATHIC
ARTHRITIS WANT TO REPORT PAIN
Rebecca R. Lee1, Amir Rashid1, Wendy Thomson2, Lis Cordingley3
1NIHR Manchester Musculoskeletal Biomedical Research Centre, Arthritis
Research UK Centre for Epidemiology, Division of Musculoskeletal and
Dermatological Sciences; 2NIHR Manchester Musculoskeletal Biomedical
Research Centre, Arthritis Research UK Centre for Genetics and
Genomics, Division of Musculoskeletal and Dermatological Sciences;
3Centre for Musculoskeletal Research, Division of Musculoskeletal and
Dermatological Sciences, University of Manchester, Manchester, UK
Correspondence: Lis Cordingley
Pediatric Rheumatology 2018, 16(Suppl 2):P087
Introduction: Digital, remote, mobile health (mHealth) pain assess-
ments are increasingly used in the research and care of children and
young people (CYP) with long-term conditions, such as Juvenile
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 57 of 243Idiopathic Arthritis (JIA). However, little is currently known about the in-
fluence, impact or patient preference for particular ecological moment-
ary assessment (EMA) techniques in pain reporting.
Objectives: To explore patient preferences of different pain assessment
timing and frequencies in CYP with JIA remotely monitoring pain at home.
Methods: The study was a randomised n-of-1 crossover trial. Partici-
pants aged between 5 and 16 years of age were recruited from The
Childhood Arthritis Prospective Study, UK. Participants were loaned
an iPad for the duration of the study. The iPads were uploaded with
My Pain Tracker (MPT), a valid and acceptable multi-dimensional pain
assessment application for CYP with JIA. MPT collects information
about pain intensity, severity, location, qualities and interference and
can be used by CYP to track their pain independently. Participants
were randomised into one of four groups. Each group followed dif-
ferent administrative patterns of pain assessment reporting. Four differ-
ent timing schedules (once-a-week, once-a-day, twice-a-day and as-
and-when pain occurred) were randomised within the groups to occur
twice within an eight-week data collection period. Semi-structured in-
terviews were conducted over the telephone at the end of the study to
explore which timing schedules participants and their parents preferred
and why. Questions about subjective measurement reactivity (whether
participants or parents noticed a change in pain or emotion in
response to particular pain reporting schedules) were also included.
Results: Fourteen CYP took part in the study (M=11.93, SD=2.65). An
equal number of CYP reported that they preferred once-a-day and
as-and-when reporting schedules (42.9%). As-and-when reporting fa-
cilitated flexibility in pain tracking. Some participants considered this
an advantage and others, a burden. Flexibility was problematic be-
cause participants did not know what level of pain was sufficient to
report or how to report when they were in school. Furthermore, CYP
were not able to record and review ‘good’ or pain free days with this
schedule, which CYP found valuable for evaluating the contrast with
‘bad’ pain days. Creating habits or routines was one of the most im-
portant factors for successfully remembering to report pain. A priority
for CYP was capturing comprehensive information about recent pain
which they could still remember. The once-a-day schedule accommo-
dated these advantages. Higher frequency of pain reporting (more
than once-a-day) was perceived to affect mood and fatigue by some
participants and their parents. One parent reported a perceived
physical change in their child’s pain as a response to more intense
pain reporting schedules. The majority of participants and their par-
ents did not report any subjective measurement reactivity, with some
suggesting frequent assessment served as a distraction from pain.
Conclusion: To our knowledge, this is the first study to investigate the
impact of different EMA schedules with CYP with JIA and persistent pain.
Findings suggest that daily reporting of pain using multi-dimensional
mHealth assessment tools is feasible, sustainable and a reporting prefer-
ence for CYP with JIA. Findings are important for the development of
administrative guidelines for new mHealth pain assessment tools.
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Introduction: Juvenile Idiopathic Arthritis (JIA), is the most frequent
rheumatic disease in Pediatrics. Within the JIA, there are different
subtypes, better prognosis in oligoarticular JIA, but not in JIA polyar-
ticular rheumatoid factor (FR) positive, recent treatments allow pa-
tients to be diagnosed and treated as soon as possible to preventjoint damage. It would be useful to have biomarkers for both diagno-
sis and prognosis. Citrulline vimentin was recognized as a target
within the family of citrullinated proteins. The presence of mutated
citrullinated vimentin antibodies in JIA has been little studied.
Objectives: To determine levels of anti-citrullinated cyclic peptide,
citrullinated anti-vimentin and mutated citrullinated vimentin in pa-
tients with JIA. Describe clinical and epidemiological characteristics.
Methods: Cross-sectional study, patients with JIA from Pediatric
Rheumatology of the HIMFG, June 2017. Informed consent, 1ml of
blood serum. ELISA technique in INCMNSZ.
Results: Total of 62 patients (n = 62), female n = 46. Anti-CCP cut-off
value of 9.1U / ml, sensitivity of 71% and specificity of 97.8%. Anti-
VMCc value cut 18 U / ml, sensitivity 62.9% and specificity of 88.4%,
Anti-VMC value cut 18.7 U / ml, sensitivity 56.5% and specificity of
86.96%, U of Mann-Whitney anti-CMVc patients vs healthy controls
p0.5976, anti-CCP patients vs healthy controls p0.5220, anti-VCM pa-
tients vs healthy controls p0.003. 12 patients were reported with
anti-CCP negative and positive for anti-VMC.
Conclusion: A significant difference was observed in anti-MCV levels
compared to healthy controls. The anti-VMC could be supportive in
the diagnosis of Juvenile Idiopathic Arthritis.
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Introduction: Juvenile idiopathic arthritis is a common systemic
autoimmune inflammatory disease. Anti-CCP is important bio-
marker to differentiate those patients with aggressive JIA. hs CRP
could identify patients in clinical remission and their risk of dis-
ease relapse. Ultrasound on the joints is more sensitive in the de-
tection of disease activity than clinical examination alone. The
aim: evaluate the role of anti-CCP 2and hs CRP, MSUS in early
detection of activity of JIA.
Objectives: Evaluate the role of anti-CCP 2 and hs CRP, MSUS, and
Doppler study in early detection of activity of JIA children
Methods: Assessment of the disease activity of JIA was done
using the Juvenile Arthritis Disease Activity Score (JADAS27). Con-
ventional radiography, musculoskeletal US examination in a mini-
mum of two planes (longitudinal and transverse) and Global
ultrasound score were done for all 60 patients. Blood tests in-
cluded (IgM RF was assayed using quantitative immunonephelo-
metry test, hs CRP and Anti-CCP 2 (IgG) was measured by
commercially available second-generation ELISA kits DiastatTM
Axis, Shield Diagnostics, Dundee, Scotland) were done for all pa-
tients and 20 healthy control.
Results: 60 JIA patients; (41.66%) males and (58.33%) females. Their
mean age was 7.9. Their mean disease duration 3.5. They were di-
vided according to disease activity into 2 groups: group 1: 30 pa-
tients with JADAS27 score <3.8, group 2: 30 JIA patients of high
disease activity according to JADAS27 score ≥3.8 There was a highly
significant positive correlation between ESR, CRP, hs CRP and
JADAS27. On the other hand, there was a non-significant positive
correlation between anti-CCP levels and JADAS27. Global ultrasound
score had a highly significant positive correlation with JADAS27 P <
0.001. Global ultrasound score had a significant positive correlation
with hs CRP. Diagnostic performance of different parameters in dis-
crimination of disease activity of group I and group II ROC curve, hs
CRP was more sensitive in early detection of disease activity followed
Table 1 (abstract P091). ROC-Analysis of the questionnaire in different
groups
Sum Score Weighted Sum Score
AUC 95% CI AUC 95% CI
JIA vs. musculoskeletal pain 0.59 0.49; 0.70 0.63 0.53; 0.74
JIA with at least one active
joint vs. musculoskeletal pain
0.64 0.53; 0.75 0.68 0.57; 0.79
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 58 of 243by ultrasound score while anti-CCP and routine CRP showed lower
global sensitivity
Conclusion: hs CRP, MSUS Doppler are important tools in detection
of activity of JIA children.
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Introduction: Temporomandibular joint (TMJ) involvement occurs
around 30 to 80 % in children with Juvenile idiopathic Arthritis (JIA). The
correlation with certain subtypes with hypothesized. There are several
studies looeked at predictors of TMJ involvement. We reviewed in a
monocentric study a large patient population to asses the prevalence in
the different subtypes and prognostic markers for the TMJ involvement.
Objectives: To study the prevalence of TMJ involvement, as well as
associated clinical signs, symptoms and factors in children with JIA.
Methods: We performed a retrospective chart review on 3,999
consecutive patients who were followed in the Hamburg Centre
for Paediatric and Adolescent Rheumatology Eilbek between
January 2010 and July 2012. Demographic, clinical, laboratory and
radiographic data were collected. TMJ involvement was diag-
nosed clinically by the attending rheumatologist, or radiologically
by MRI.
Results: 35 % of 2,413 included patients had TMJ involvement. In a
multivariable analysis we found female sex (p = 0.021), increasing
number of joints with active arthritis (p < 0.001) and antinuclear anti-
body (ANA) positivity (p = 0.023) were significantly associated with
TMJ involvement. In the oligoarticular group (persistent and ex-
tended) was a positive association of TMJ involvement and age (OR
= 1.07, p < 0.001), while this association was negative in the enthesi-
tis related arthritis group (OR = 0.94, p = 0.015). A significant correl-
ation revealed between pathological MRI results and laterotrusion of
the chin (p = 0.012) and pain on palpation (p = 0.020).
Conclusion: Based upon our data we cannot recommend one unique
clinical parameter to diagnose TMJ involvement, and MRI is still the
gold standard to assure the diagnosis. Female sex, ANA positivity
and disease activity were correlated significantly with an increased
OR for TMJ involvement, and a significant interaction between age
and JIA categories (oligoarticular and enthesistis related arthritis) was
found. Further prospective controlled studies are still needed.
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Pediatric Rheumatology 2018, 16(Suppl 2):P091Introduction: Juvenile idiopathic arthritis (JIA) is the most common
chronic inflammatory rheumatologic disease in children and adoles-
cents with a prevalence of 1 in 1000 children in Germany. An early
referral of children suspected to have JIA to a pediatric rheumatolo-
gist is essential for an early diagnosis and starting treatment in the
therapeutic window to reach a better outcome. An easy-to-use and
time efficient questionnaire originally developed by a Brazilian study
group led by Claudio Len may detect children and adolescent under
risk for JIA.
Objectives: To determine, whether the German version of the
screening tool is reliable for the early diagnose of JIA and secondly,
whether a weighting scheme of individual questions improves its
diagnostic performance.
Methods: The original questionnaire was translated into German
by Dr. med Ivan Foeldvari. The questionnaires were distributed
among patients at the first clinical visit at the Hamburger Centre
für Kinder- und Jugendrheumatologie. The questionnaire includes
12 disease-orientated questions each with three possible re-
sponses, either: “Yes”, “No” or “I don’t know”. A retrospective
evaluation of patients diagnosed with JIA or with a non-
inflammatory joint pain (NJP) was performed later on. The sample
consisted of patients seen between August 2015 and July 2017.
All patients were at least older than 2 years and younger than 17
years at the time of evaluation. Only questionnaires, which were
fully answered, were evaluated. Subsequently, a weighting
scheme (based on the factor loadings from a confirmatory factor
analysis) of individual questions was applied in order to increase
the sensitivity of the tool. Standard statistical techniques were
used to find associations between the sum scores and clinical
characteristics and to compare the weighted and non-weighted
sum scores.
Results: In total 165 of 800 questionnaires could be evaluated for the
study. 133 (81%) were diagnosed with JIA and 32 (19%) with NJP.
The group of JIA patients consisted of 79 (59%) girls, whereas the
control group consisted of 21 (66%) girls. The analysis of the individ-
ual questions was performed by comparing the rate of a positive re-
sponse to the questions (“Yes”) between the two groups. Four
questions showed a highly significant difference by comparing an-
swers of the control group with a subgroup of JIA patients having at
least one active inflammatory joint. In particular, questions regarding
physical constraints (p= 0.20; AUC= 0.62), joint pain (p= 0.040; AUC =
0.61), swelling in the joints (p= 0.040; AUC =0.60) and stamina (p=
0.047; AUC = 0.60) seem to be relevant in the diagnostic approach. A
weight of 3 was assigned to the first and seventh, 2.5 to the fourth
and sixth, and 1.5 to the third and fifth item. The diagnostic accuracy
of the respective weighted sum score increased from 64% to 68% to
discriminate between patients with JIA with at least one active joint
and the control group in comparison to the ordinary sum score. An
optimal cutoff of 6.0 for referral to a pediatric specialist was
calculated.
Conclusion: The validation of the questionnaire showed a discrimina-
tive difference in patients with clinical diagnosed JIA and a control
group diagnosed with NJP. Furthermore, the weighted sum score
performed better to differentiate between JIA and NJP patients. The
modified questionnaire can be useful to screen for JIA and speed up
the referral to a pediatric rheumatologist.
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Introduction: One of the aim of the international child arthritis asso-
ciations is to provide proper treatment regimens in children with ju-
venile idiopathic arthritis (JIA) with proving effectiveness and safety.
Methylenetetrahydrofolate reductase (MTHFR) mutations, according
to Genome-Wide Association Studies (GWAS) are being involved in
most toxicities. The effective response to methotrexate (MTX) treat-
ment in JIA is remaining contradictory.
Objectives: To assess the MTHFR gene mutations in children with
JIA, treated with MTX for more than 6 months, and correlate them
with the Juvenile Arthritis Disease Activity Score (JADAS71) and
Pediatric ACR 20,50,70,90 Index.
Methods: There has been initiated a PhD observational case-control
study, involving at least 24 patients using MTX for JIA treatment. All
data is processed through IBM SPSS Statistics 22 programe.
Results: There has been examined 18 children yet, including 7
(38,9%) cases of no mutation, 2 (11,1%) cases of T/T homozygotes
and 9 (50%) cases of C/T heterozygotes in the 677 nucleotide of the
MTHFR gene. The JADAS71 score was higher in the heterozygote
cases with the mean value 18,1(p=0,0013), compared to the non-
mutation sample - 2,4 (p=0,0022). The Pediatric ACR index in hetero-
zygote sample had a mean value of 22% (p=0,0011) improvement
compared to the control group - 37% (p=0,001).
Conclusion: There has been determined a significant correlation be-
tween the MTHFR gene heterozygote mutation status and the MTX
non-responsiveness. The MTHFR mutation screening is an available
tool in assessing immunosuppressive therapy failure.
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Introduction: Many patients with JIA who reach clinical remission on
treatment harbour residual inflammation that is not detectable by
standard measures. MTX remains the first line DMARD for JIA, but is
frequently poorly tolerated due to gastrointestinal side effects. After
stopping MTX there is a significant risk of disease flare. Myeloid re-
lated protein (MRP) 8/14 has been shown as a marker of subclinical
disease activity and a predictor of patients with risk of disease flare
after stopping MTX.
Objectives: This study reviewed the impact of measuring serum
MRP8/14 concentration in clinical practice, to identify patients who
have reduced risk of disease flare if they stop MTX therapy.
Methods: MRP8/14 tests performed at a single paediatric centre using
a commercially available assay (Bühlmann) were analysed. Patients in-
cluded all subtypes of JIA, treated by MTX monotherapy at time of test
and had not previously been on a biologic or other disease-modifyingdrug. All were considering stopping MTX. Clinically inactive disease
(CID) was defined by Wallace criteria. JIA subtype, gender, age at diag-
nosis, disease duration, age at sample and disease activity variables
were recorded at time of test and over time. Disease flare in those off
MTX was defined as a patient that no longer met Wallace criteria and
required new intervention. Patients who met the inclusion criteria were
divided into those who did or did not meet Wallace criteria, and
whether they stopped, weaned or did not stop MTX. Statistical analyses
were performed using Prism Graphpad, Version 7.
Results: A total of 72 serum MRP8/14 concentrations from 72 pa-
tients were analysed. In patients who met Wallace criteria, compari-
son of serum MRP8/14 concentration values in those who stopped
versus those who didn’t stop MTX, demonstrated statistically signifi-
cant difference (Mann-Whitney test). In the group who stopped MTX
(n=18), sensitivity (high MRP8/14 indicating flare) was 86%, specificity
(low MRP8/14 indicating no flare) was 18% and the positive predict-
ive value (percentage of patients with a high MRP8/14 result who
went on to flare) was 40%. Flares in patients who met Wallace cri-
teria and stopped MTX treatment were plotted over time, split by
the MRP8/14 result; low (<4000ng/ml), n=6 and high (>4000ng/ml),
n=1. Statistical analysis showed no significant difference between
groups, likely due to small numbers in the analysis, however the
trend matched previous data.
Conclusion: Measurement of serum MRP8/14 can be used in clinical
practice to assist therapy decisions and as a predictor of flare post
stopping MTX therapy in JIA patients who have achieved CID. How-
ever, biomarkers providing greater predictive power are needed to
enable more accurate tailoring of treatment.
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Introduction: Juvenile idiopathic arthritis is a chronic inflammatory
childhood disease with symptoms such as joint inflammation, pain,
loss of quality of life. The number of joints and presence of pain
cause the child to be affected psychosocially as well as affecting
functional activity.
Objectives: The aim of this study is to examine the results of func-
tional and psychosocial status according to the type of joint involve-
ment and the presence of pain symptoms in children with JIA.
Methods: The study included 71 children diagnosed with JIA who
applied to Hacettepe University İhsan Doğramacı Children's Hospital
Rheumatology Department. After demographic information of chil-
dren was collected, functional and psychosocial status was assessed
with the scale which was developed in Hacettepe University for chil-
dren with rheumatism and functional status assessed with Child
Health Assessment Questionnaire (CHAQ). Children were divided into
groups according to joint involvement as oligoarthritis or polyarthritis
and presence or absence of pain. Mann-Whitney U test was used to
compare the data.
Results: Mean age and numbers of children were shown in Table 1.
There were no difference between groups, according to disease type
(p>0,05). On the other hand, comparing the scores according to pain
presence, CHAQ total, CHAQ general VAS assessment, functional and
psychosocial status were significantly different (p<0,05).
Conclusion: It is concluded that pain is an important determina-
tive on functional, psychosocial and overall disease assessment
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 60 of 243comparing to number of joints involved. It can be implicated that
affected joint number may be compansatible by muscle activa-
tion but pain may require a central organisation to be alleviated.
Thus, it must be taken into consideration that he child’s ability to
cope with pain should be improved.
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Type p Pain p
Oligoarthritis
(n=51)
Polyarthritis
(n=20)
Present
(n=21)
Absent
(n=50)
Age (years) 10,88±3,81 13,50±3,92 0,016 11,71
±3,77
11,58
±4,12
0,885
CHAQ Total 0,28±0,29 0,46±0,41 0,127 0,51±0,4 0,26±0,27 0,012
CHAQ
(General VAS)
2,49±2,43 3,93±3 0,068 4,46±2,86 2,24±2,3 0,002
Function 4,72±4,85 5,05±6,32 0,766 7,85±6,6 3,54±4,02 0,004
Psychosocial 23±5,67 14,5±5,82 0,363 16±5,74 12,34±5,4 0,012P095
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Introduction: Children with JIA are affected in participation and ac-
cording to Unicef every child is entitled to daily life participation.
Through participating in activities children develop abilities that form
upbringing and adult life. Children with JIA have effects on participa-
tion that is caused by the disease.
Objectives: The aim of the study was to describe experiences of par-
ticipation in activities among children with JIA.
Methods: A qualitative design with an interview method where eight
girls in ages 12-15 have been interviewed with semi-structured inter-
views. Data handling has been executed according to a content
analysis.
Results: Based on collected data the theme Participation influences
through interaction between the individual and the surroundings
with corresponding categories symptoms’ immediate effect, phys-
ical environment, strategies, personal treatment, relations and the
individual’s inner life were formed. Outcome shows that children
with JIA experience participation in every day life is influenced
by the disease symptoms, physical environment, social environ-
ment and the individual herself. Experiences of increased partici-
pation were affected by the individual’s choice of strategies, and
social environment.
Conclusion: Children with JIA experienced that participation in activ-
ities was influenced by disease symptoms, which resulted in absence,
and excluding participation. The social environment could increase
participation through good treatment and understanding, but the so-
cial environment could also decrease participation through misun-
derstanding and misinterpretation about the disease. The individual’s
attitude using strategies and adjustments during activities led to in-
creased participation, and those that chose not to, experienced a de-
creased participation.
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Introduction: Juvenile idiopathic arthritis (JIA) is the childhood dis-
ability from a musculoskeletal disorder. It generally affects large
joints such as the knee and the ankle. Muscle weakness, poor flexibil-
ity, atrophy, pain, and decreased proprioception of the affected
joints, abnormal biomechanics, articular cartilage damage are the
most common problems in patients with JIA. A greater Q angle has
been suggested as a risk factor for musculoskeletal problems in vari-
ous disease.
Objectives: We aimed to investigate the factors affecting Q angle
in patients with JIA having pes planovalgus and healthy
children.
Methods: Thirty-six participants as age range 4-16 years (25 female,
11 male) were enrolled this study. Children divided 2 groups (Group
I: patients with JIA have pesplanovalgus, Group II; Healthy children).
Hand held dynamometry was used to assess the strength of the
lower extremity muscles. Also, Range of Motion (ROM) of lower ex-
tremity was evaluated with a universal goniometer. While static bal-
ance evaluated with Flamingo Balance Test (FBT), dynamic balance
evaluated with Prokin balance system. Prokin balance system as-
sesses perimeter length, Medium equilibrium center (A-P, M-L). Q
angle was calculated by universal desktop ruler. Universal Desktop
Ruler allows you to measure not only a straight-line distance but any
curved distance on the screen. For statistical analysis SPSS Version
19.0 program was used.
Results: The means of age were 11.33±4.51 (Group I) and 11.28
±1.87 (Group II) years. When the groups were compared with
each other, Q angle was significantly higher in Group I (p=0.001).
Correlations were found between strength of knee extension (r=-
0.560, p=0.016) and ROM of knee flexion (r=0.528, p=0.024 with
Q angle for group I. Also, Correlations were found between
strength of hip abduction (r=-0.504, p=0.033), strength of hip ad-
duction (r=-0.564, p=0.015), strength of knee extension (r=-0.470,
p=0.049) and strength of ankle dorsiflexion (r=-0.713, p=0.001)
with Q angle for group I. But, there was no correlation between
Q angle and any parameters in Group II (p>0.05). According to
linear regression analysis, Q angle was affected by only strength
of knee extension for Group I (β=-0.13, p=0.000). However, it
was not found relationships between FBT, A-P and M-L with Q
angle for both of the groups (p>0.05).
Conclusion: Q angle as excessive dynamic knee valgus is an ab-
normality of neuromuscular control over the lower limb. This
study shows that Q angle was significantly increased and af-
fected by strength of knee extension negatively in patients with
JIA having pes planovalgus. So, this clear result suggests that
the lower extremity should be evaluated holistically and
strengthening of the knee extension should be considered in
the treatment of patients with JIA even if the problem is only
on the ankle. Besides, in future studies should assess educational
status and quality of life.
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Introduction: Juvenile arthritis (JA, JIA) is an umbrella-term describ-
ing a heterogeneous group of musculoskeletal diseases characterized
by chronic synovitis of unknown etiology. Typical classic forms of JIA
(oligo, poly, psoria, entheso) are well known. Genetic disorders with
musculoskeletal involvement that mimic chronic arthritis should be
considered in the differential diagnostics of JIA. The topically of the
problem in children is determined by frequent cases of treatment of
skeletal dysplasia by the DMARDs.
Objectives: The goal of this study was to improve the diagnosis of
skeletal dysplasia manifested as JIA.
Methods: We carried out a retrospective review of more than fifty
children with past-onset chronic undifferentiated arthropathy (low la-
boratory activity; progressive idiopathic contracture with entheso/
synovitis) which were hospitalized at Children Orthopedics Institute,
Saint-Petersburg between 2006 and 2016. The data of clinical of joint
involvement, laboratory, x-ray, ultrasound, MRI were analyzed.
Results: All children were divided into two groups based on their dis-
ease. The first group (large) consisted of children with recessive mul-
tiple epiphyseal dysplasia (rMED/MED4, gene SLC26A2 Mut, OMIM
226900) characterized by abnormal development of the bone and car-
tilage of the epiphyses. A second group (small) was children with JIA.
Children with congenital or early-onset forms of skeletal dysplasia and
other monogenic arthritis-like diseases were excluded from study.
1. Less of morning stiffness, bilateral painless joint contractures and
axial deformation of the lower limbs were the main finding of chil-
dren with pseudo-rheumatoid pathology. Most children with rMED in
the early childhood were characterized by a lack of signs of physio-
logical hypermobility, reduced daily motor activity and treated of bi-
laterally delayed ossification of femoral heads. Morning stiffness and
painful joint contractures were actually for children with JIA.
2. Radiology of JIA was characterized by inflammatory dynamic pic-
ture: overgrowth of metaepiphysis and joint osteoporosis at onset of
disease, development dystrophic and erosive changes of osteochon-
dral tissue at progressive durated and arthros-arthritis deformation
like outcome. Symmetric flattening of epiphyses of hands, hips,
knees and feet, double-layered patella were x-ray hallmarks of rMED.
Avascular necrosis may be superimposed on rMED. Dystrophic spon-
dylolisthesis at the L5-S1 vertebrae to 10-12 years of life was a fre-
quent sign of epiphyseal dysplasia.
3. Instrumental sign of synovitis (ultrasound, MRI) was detected
in most children. Synovitis in cases of skeletal dysplasia was
secondary nature due to chronic damage and degeneration of
the genetic defective articular hyaline cartilage (erosive-like
chondrolysis).
4. Sensitivity to anti-inflammatory therapy was not always verified of
the genesis of arthropathy and in most cases was dictated by the
presence of synovitis.
Conclusion: This comparative study was revealed some clinical and
instrumental characteristics of the skeletal dysplasia which mimic JIA.
Early orthopedic-related "hip problems" at anamnesis, symmetric de-
formity of epiphyses, double-layered of patella indicate a possible of
pseudo-rheumatoid genesis of arthropathy. Sequence of SLC26A2
gene should be recommended for use in cases with the not typical
clinical and x-ray findings for JIA.
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Introduction: Juvenile idiopathic arthritis (JIA) is the most common
chronic rheumatic disorder of childhood and encompasses a complex
group of disorders comprising several clinical entities with the common
feature of arthritis. Calprotectin is a calcium- and zinc-binding protein
that belongs to the S100 protein family and is released during the inter-
action of leucocytes with inflammatory activated endothelium at the
sites of inflammation as occurs in JIA. We undertook this study to
assess the usefulness of Calprotectin as a marker of disease activ-
ity in Indian children with JIA.
Objectives: To assess the effetiveness of serum Calprotectin levels as
a marker of disease activity in children with JIA.
Methods: Children who fulfilled the International League of Associa-
tions For Rheumatology (ILAR) criteria for JIA were recruited into the
study. Baseline demographic details were collected and Blood counts,
ESR, CRP and Calprotectin levels were analyzed in all children after
obtaining consent. Children were then divided into 2 groups based on
disease activity as per Wallace criteria. Calprotectin levels were also ana-
lysed in 10 normal healthy children. Calprotectin levels were measured
by using a “Human Calprotectin Kit” which works on the basis of
sandwich-enzyme linked immune sorbent assay technology (ELISA).
Results: 121 children with JIA were recruited into the study, 63 had
active disease and 58 had inactive disease. Systemic onset JIA consti-
tuted 42% of the study population and was the predominant disease
subtype. Calprotectin levels were elevated in children with active dis-
ease compared to those with inactive disease. Mean Calprotectin
value in active disease (3954ng/ml) was 2 fold higher than those with
inactive disease (1899ng/ml) (p value ˂0.001) and 16 times higher
than children who were normal healthy controls (mean of 233ng/ml).
Area under curve for Calprotectin was 0.744. For a cut off value of
1760 ng/ml, Calprotectin had a sensitivity of 77% and specificity of
61% for assessment of disease activity in JIA.
Conclusion: Serum Calprotectin levels was found to be a good marker
of disease activity in children with JIA. However, further studies which
involve serial monitoring of Calprotectin levels in a study population
will provide additional information about accuracy of these markers.
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Introduction: in the past few years, various indicators of disease activ-
ity in juvenile idiopathic arthritis (JIA) patients have been investigated,
allowing for the interpretation of different aspects of underlying inflam-
matory process (e.g. clinical, immunological, radiological etc.). Neverthe-
less, there is still evident lack of satisfactory support in diagnostic and
prognostic evaluations in everyday clinical practice, focusing research
activities on discovery of adequate biomarker that would support initial
diagnosis and allow feasible disease monitoring. While growing num-
ber of evidence indicates phagocytic S100 proteins, like MRP8/14 com-
plex (i.e. calprotectin), can be used to detect subclinical inflammatory
activity in systemic JIA, their performance in other forms of JIA is still
debatable, while in acute infectious diseases it is almost unknown.
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 62 of 243Objectives: compare serum calprotectin (sCAL), CRP and PCT levels
in patients with various forms of non-systemic JIA and previously
healthy children with acute febrile illness lasting <3 days, as well as
with juvenile arthritis disease activity score (JADAS).
Methods: out of 37 patients included in study, 17 were diag-
nosed with polyarticular form of JIA (pJIA), 8 with oligoarticular
form (oJIA), 2 with juvenile spondyloarthritis (jSpA) and 10 with
acute febrile respiratory illness of possible viral etiology (AFI).
sCAL, PCT and CRP were measured in all of the patients, while
JADAS70CRP was measured in all of the JIA patients. Inactive
disease was defined as JADAS ≤1. The average duration of JIA
was 64,2 (7-132) month, and all of the JIA patients were treated
with standard therapy, including biological (n=16) and conven-
tional (n=20) DMARDs. sCAL was measured by a commercial
ELISA assay (Buhlmann MRP8/14, Switzerland).
Results: among JIA patients, 8 pJIA, 4 oJIA and 1 jSPA had inactive dis-
ease, while 9 pJIA, 4 oJIA and 1 jSpA had active disease. Average con-
centration of sCAL among patients with inactive disease was 1,86 (0,5-
4,2) μg/mL, while in patients with active disease it was 2,37 (0,93-5,2)
μg/mL (p=0,37). Statistically significant correlation was observed be-
tween sCAL and JADAS (Spearman r=0,523; p=0,005) in JIA patients
and between sCAL and CRP (Spearman r=0,745; p=0,017) in children
with AFI. Average concentration of sCAL in children with AFI was 4,67
(1,67-8,32) μg/mL, significantly higher than in patients with inactive
(p=0,0024) or active JIA (p=0,0084) or in all JIA patients (p=0,0012).Disease N sCAL μg/mL
(range)
CRP mg/L
(range)
PCT ng/mL
(range)
JADAS
(range)
Inactive pJIA 8 1,67 (0,65-2,66) 3,475 (0,4-
17,5)
0,03 (0,01-0,10) 0,5 (0-1)
oJIA 4 2,575 (0,8-4,2) 1,225 (0,5-2,2) 0,02 (0,01-0,03) 0,75 (0-1)
Total 13 1,86 (0,5-4,2) 2,53 (0,02-
17,5)
0,02 (0,01-0,10) 0,5 (0-1)
Active pJIA 9 2,55 (0,93-4,1) 6,59 (0,2-40,4) 0,01 (0,01-0,02) 9,9 (2-22)
oJIA 4 2,26 (1,3-4,2) 10,3 (0,7-37,7) 0,01 (0,01-0,02) 7,4 (3-17,7)
Total 14 2,37 (0,93-5,2) 7,31 (0,2-40,4) 0,01 (0,01-0,02) 8,7 (2-22)
All JIA
patients
27 2,11 (0,65-5,2) 4,92 (0,2-40,4) 0,02 (0,01-0,10) 4,6 (0-22)
All AFI
patients
10 4,67 (1,67-8,32) 5,93 (0,4-26,7) 0,19 (0,09-0,16) /
Table 1 (abstract P100). Number of patients with abnormal serology
results at initial presentation (% treated with antibiotics). Reference
ranges from local laboratory. Titres given in international units (IU)
Anti-DNase B (% treated with antibiotics)
Normal (< 400) Abnormal (≥ 400)
ASOT
Normal (< 200) 19 0% 0 0%
Borderline (200) 2 0% 4 75%
Abnormal (≥ 400) 7 43% 4 100%Conclusion: preliminary results of our cross-sectional study showed
sCAL correlates with JADAS in non-systemic JIA patients, although there
was no significant difference between those with active and inactive dis-
ease. Interestingly, sCAL concentrations in long lasting JIA patients were
significantly lower than in children with short lasting viral illness. This is a
novel observation that emphasizes the need for vigilance in interpreting
sCAL levels in patients with concomitant acute communicable disease
and gives a possible explanation for some of the high(er) values noted
in patients with clinically inactive non-systemic JIA.
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Pediatric Rheumatology 2018, 16(Suppl 2):P100Introduction: For a child presenting to the paediatric rheumatology
clinic with a swollen, painful joint it can be difficult to differentiate
between a post-infective reactive arthritis and JIA. Antistreptolysin O
titre (ASOT) and anti-DNase B can be used, but the literature sug-
gests taking two samples 10-14 days apart for interpretation. (1) This
can be difficult in the clinical setting.
Objectives: · To analyse the use and interpretation of streptococcal
serology in new onset JIA patients at a tertiary hospital in the UK
· To compare this to evidence in the literature to recommend prac-
tical clinical guidance
Methods: The cohort consisted of patients with a new diagnosis of
JIA made in 2016-2017. Data was collected from patient records on
the following: recent illness, serology results and action taken. P
values were calculated using Fisher’s exact test.
Results: 36 of the 54 patients identified had streptococcal serology
(ASOT and anti-DNase B) at presentation. 16 (84%) of the 19 patients
who reported a recent illness received streptococcal serology, com-
pared to 20 (57%) of the 35 patients without recent illness. This dif-
ference was not statistically significant (p = 0.06).
There was no difference between the proportion of patients with
abnormal titres in those who reported recent illness (7 of 16, 44%)
compared to those without (8 of 20, 40%; p = 1). Furthermore,
reporting recent illness was not associated with antibiotic use (6 of
16 (38%) compared with 4 of 20 (20%) without; p = 0.29).
In total 10 patients received antibiotics after initial serology re-
sults. 10-14 days of penicillin was always given when both ASOT
and anti-DNase B titres were raised, but the decision to treat
when only one titre was raised was variable. 6 of 11 (54%) pa-
tients with one abnormal titre were given antibiotics. Antibiotics
were not given to patients with normal serology, or borderline
ASOT alone.
No patients had repeat serology within 10-14 days. 5 patients had
serology repeated, varying from 5 weeks to 14 months later.
Conclusion: This cohort consisted of patients with JIA and did not
include those diagnosed with reactive arthritis, which would be
valuable. ASOT typically rises 1 week after a streptococcal infec-
tion, falling between 2-8 months to baseline. Anti-DNase rises 2
weeks after infection and returns to baseline from 3-12 months.
(2) A fourfold rise in titres taken 10-14 days apart provides evi-
dence of recent streptococcal infection. However, taking repeat
blood tests in young children can be both traumatic and practic-
ally difficult, with limited access to age-appropriate phlebotomy.
A history of recent illness is not predictive of a raised titre in the
context of JIA. A pragmatic approach, therefore, is to treat a sin-
gle abnormal titre.
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Introduction: Little is known about the experiences of young adults
living with Juvenile Idiopathic Arthritis (JIA) preparing for employ-
ment and career development.
Objectives: The purpose of this study was to understand the impact
JIA has on career planning and early employment experiences of
young adults (16-30 years).
Methods: Using existing literature (including grey literature), an on-
line survey (consisted of 152 questions, 29 items related to young
adults two of which were free text questions) was developed and
sent to National Rheumatoid Arthritis Society (NRAS) members and
distributed to non-members via social media tools including Face-
book, Twitter and HealthUnlocked. Data collected included views
and experiences in career planning and employment. The data per-
taining to young adults are presented here.
Results: Of 1241 respondents 19 were young adults with JIA
(range 16-30 years), 89% were female and 84% had university or
equivalent qualifications. Due to incomplete responses there is
missing data on all 19 young adults. 4/13 young adults were
studying at university, 9/13 were in paid employment. 9/17 re-
spondents reported their school did not offer additional work-
related activities to students with disabilities and/or additional
needs. 10/14 young adults felt their school did not provide ad-
vice about coping with possible limitations on placements/train-
eeships due to their arthritis. 11/14 respondents thought about
their condition when thinking about future career plans e.g. “I
wanted to work as a ranger or similar for the National Trust but
it’s a fairly physically demanding job and I knew my joints would
suffer so I changed track slightly”. However, 8/14 felt their career
advisors did not take their arthritis into account e.g. “I had to
cease my physiotherapy master’s degree as my arthritis got too
bad to continue and change career choice. I wish there would
have been more discussion about it not being a reasonable
choice for me at the time as we just didn't have the information
then”. 8/14 young adults changed their career plans because of
their arthritis. Managing JIA symptoms and a physically demand-
ing role, as well as wanting to stay healthy, were the main rea-
son for changing career. Important aspects of employment
included: good relationships with your line manager, work you
like doing and a job you can use your initiative.
Conclusion: Despite small numbers these results highlight poten-
tial current unmet vocational needs of young adults with JIA in
the UK and the need for further research with this age group.
There appears to be a lack of structured support within schools
and universities offered to students with disabilities and/or add-
itional needs, about work-related activities and careers. Young
adults with JIA actively consider their condition whilst thinking
about career opportunities and value a productive and challen-
ging job with a good working environment, including relation-
ships with colleagues and supervisors.
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Introduction: There is evidence that obesity could be a risk of factor
for the development of RA due both to the mechanical effect of
overweight and to the potential pro-inflammatory effects of cyto-
kines produced by adipose tissue.
Objectives: To evaluate the role of overweight and obesity in a co-
hort of JIA patients, in terms of incidence, disease activity, outcome
and response to treatments.
Methods: This single-center retrospective cohort study evaluated 125
children affected by JIA under treatment with anti-rheumatic agents
(NSAIDs/IAS, DMARDs, biologic agents). Change from baseline in ERS,
CRP, number of active joints (with distinction between upper and
lower limb joints), and BMI was analysed under each treatment until
last visit. BMI categories of 5-84th (normal weight), 85-94th (over-
weight), and ≥ 95th (obese) percentile were used. Patients with sys-
temic JIA or chronic comorbidity under potentially confounding
systemic treatments were excluded. Informed consent was obtained
by the patients and their family.
Results: One hundred twenty-five JIA patients (36% oligoarticular JIA,
42,4% RF-negative polyarticular JIA, 0,8% RF-positive polyarticular JIA,
8% enthesitis related arthritis, l’11,2% psoriatic JIA, and 1,6% undiffer-
entiated unclassified arthritis) were enrolled in the study, 76,8% girls,
23,3 boys. The mean age was 5,9 years (± 3,8). Baseline BMI was ≤
84th percentile in 73,22% of patients, 85-94th in 19,64%, and ≥ 95th
in 7,14%.
We did not observe a significative association between BMI and ERS
(p=0,29), CRP (p=0,24), or number of active joints (p=0,45) at base-
line, while the involvement of the joints of lower limb was signifi-
cantly greater (p=0,025) in overweight/obese patients.
We also demonstrated a substantial equality in remission and relapse
rates in subjects with different BMI.
Conclusion: This study focuses on the complex relationship between
overweight/obesity and JIA. A significant correlation between obesity
and a greater involvement of the joints of the lower limbs was ob-
served at baseline. Furthermore, we observed that obesity does not
influence the course of the disease nor treatment response. These
data seem to suggest a prevalent mechanical effect of ponderal ex-
cess on JIA, rather than a biochemical influence due to pro-
inflammatory cytokines released by adipocytes.
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Introduction: Patients with Juvenile Idiopathic Arthritis (JIA) have lim-
ited fitness and reduced aerobic and anaerobic exercise capacity vs.
healthy peers. Furthermore, low intensity exercise programs are safe
in children with JIA and may improve fitness, joint excursion and
quality of life, reduce pain, fatigue and the employ to anti-
inflammatory drugs.
Table 1 (abstract P104). Clinical, laboratory and ultrasound data at
baseline between active and inactive patients. Data represent means ±
SD or median (interquartile range)
Active
n. 28
Inactive
n. 42
p-value
Age at enrollment (years) 7.28±3.79 12.45±4.95 <0.001
JADAS-27 score 10.6±5.5 0.4±0.5 <0.001
Disease duration (years) 1.67±3.25 7.56±4.54 <0.001
MRP8/MRP14 (μg/ml) 3.920 (2.417-5.078) 1.990 (0.85-2.86) <0.001
ESR (mm/h) 10.0 (6.0-32.0) 7.0 (5.0-9.2) <0.001
CRP (mg/dl) 0.610 (0.29-1.720) 0.29 (0.29) <0.001
Synovitis (Yes/no) 20/8 2/40 <0.001
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balance deficits and fitness with specific test battery in children and
adolescents affected by JIA.
Methods: We enrolled 30 patients with JIA (13 M; 17 F; age: 8-18
years); among those, 7 were evaluated longitudinally in the period
2016-2018, comparing the tests in different periods of the illness.
The posturography test was administered with the FreeMed posturo-
graphy system (the FreeMed baropodometric platform and FreeStep
v.1.0.3 software). A specific fitness test battery was used to evaluate
the physical fitness level of the patients (Abalakov test, backsaver sit
and reach, the toe touch test, sit-up test and hand grip test).
Results: 2 M and 5 F was in an acute phase of the disease (1 sJIA; 5
polyarticular JIA; 1 psoriatic JIA).
At the posturography test, the distribution of the weight between
left and right was pathological in 15 (4 sJIA; 9 polyarticular JIA; 2 oli-
goarticular JIA).
The load distribution between forefoot and hindfoot was patho-
logical in all the patients, with a more severe overload in polyarticu-
lar JIA patients.
Hand-grip test in 8 patients was <3°Centile; in 11 was < 20°Centile.
The patients who performed a regular physical activity program
showed fitness test in the normal range, and these parameters were
not correlated with the type of JIA and/or the treatment for the
arthritis.
Among the patients evaluated in follow up, 2 (1 with sJIA and 1 with
polyarticular JIA) maintained an asymmetry in the weight distribution
between left and right and a reduced fitness. 5 patients (2 M with
sJIA and 3 F with polyarticular JIA) normalized their parameters.
Conclusion: The persistent asymmetry of the load distribution be-
tween left and right foot and the persistent pathological distribution
between forefoot and hindfoot was more frequent in patients with
polyarticular JIA.
A regular physical activity program is the best strategy to maintain
an adequate fitness and the best control of the disease.
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Introduction: The identification of new biomarkers, the development
of more effective outcome measures and the refinement of imaging
techniques may foster the implementation of targeted and personal-
ized therapeutic interventions in patients with juvenile idiopathic
arthritis (JIA). Among new biomarkers, serum calprotectin (MRP8/
MRP14), a complex of calcium- and zinc-binding proteins, seems to
be promising. Besides, musculoskeletal ultrasonography (MSUS) is a
useful imaging tool for evaluating JIA patient disease activity. Many
studies have demonstrated that MSUS can improve the sensitivity
and the accuracy in the detection of the exact sites of inflammation
in the joint compared to the clinical examination only.
Objectives: To evaluate MRP8/MRP14 and MSUS in a group of JIA pa-
tients and to verify which of these tools best identifies disease activity.
Methods: 70 children with JIA referred to the Rheumatology Unit of
the Department of Pediatrics of Chieti, were enrolled. Serum MRP8/
MRP14 of each patient was detected by PhiCal Calprotectin ELISA.
MRP8/MRP14 was defined normal for values < 3 μg/ml. JADAS-27
was used to define disease activity. At study enrollment, all patientsunderwent an ultrasound assessment of all joints clinically affected.
A total of 452 joints were scanned for the presence of synovial effu-
sion (SE), synovial hyperplasia (SH) and power Doppler (PD) signal.
The ultrasound examinations technique as well as definitions and
scoring features were based on guidelines provided by the OMERACT
study group. In each joint, SE, SH and PD signal were graded on a 0–
3 scale. The threshold used for synovial abnormalities was 1.
Results: MRP8/MRP14 serum levels were increased in active vs in-
active disease patients (p-value <0.001). Significant differences be-
tween active and inactive patients were found in CRP, ESR, JADAS
score and the prevalence of synovitis (Table 1). According to the
score evaluating SE or SH and PD, 20 out of 28 (71.4%) JIA patients
with active disease had a score equal to 2 vs 2 out 40 (4.7%) patients
achieving remission (p-value 0.001). ESR, CRP, MRP8/MRP14 and
synovitis with its specifics components were all positively related to
JADAS-27. MRP8/MRP14 was positively correlated with presence of
synovitis and its specific characteristics.
Conclusion: To our knowledge, this is the first study comparing MRP8/
MRP14 and MSUS in a group of JIA patients. We found a significant as-
sociation between MRP8/MRP14 levels, clinical and laboratory markers
of disease activity. Moreover, we demonstrated an association between
MRP8/MRP14 serum levels and ultrasonography-determined syno-
vitis. Our study confirmed that both MSUS and MRP8/MRP14 may
be considered valid and reliable tools in the assessment of synovial
inflammation in JIA. Larger longitudinal studies are needed to es-
tablish the role of MRP8/MRP14 and MSUS in the diagnosis and
follow-up of childhood arthritis.
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Introduction: We present the development of an evidence based on-
line learning resource for rheumatologists who manage adolescents
and adults with JIA as part of their routine practice, including transla-
tion of a learning needs analysis into learning activity design and the
creation of three interactive learning modules.
Objectives: Many children and young people with JIA will continue
to have active disease as adults and will need treatment delivered by
adult rheumatology services. A learning needs analysis of the UK
adult rheumatology community identified key areas where further
training in the management of JIA is required:
- Knowledge about JIA, including understanding JIA subtypes, how
JIA manifests in adults, and how JIA differs from adult onset arthritis.
- Knowledge, skills and guidance for the management of adolescents
and young adults with JIA.
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The JIA in Adults e-learning series was developed with the British
Society for Rheumatology (BSR) to target these educational needs.
Methods: The content and format were informed through our re-
search to gather opinion from adult and paediatric rheumatologists
in the UK (Smith et al, 2017). A PACT analysis (People, Activities,
Context, Technology) informed the design process. Learning activities
were based on constructivist learning theory with cognitive consider-
ations for online learning activity design: activation of prior know-
ledge, construction of new knowledge and knowledge transfer.
Results: The ‘People’ element of the PACT analysis was an essential
consideration – experienced clinicians with a varied prior exposure
to adolescent and young adult (AYA) rheumatology, both through
formal training and clinical practice. Therefore, learning activities de-
signed to activate prior knowledge and therefore optimise the foun-
dation for further leaning were key.
Social considerations and the wider, National and Global view were
used to define purpose, motivate and prepare for learning. New
knowledge was presented around clinical cases so that key concepts
could be explored in depth and related back to prior experience. A
series of interactive cases with questioning focusing on evidence, ex-
planation, hypothetical reasoning, cause and effect and synthesis of un-
derstanding were used to develop clinical reasoning skills and to
facilitate knowledge transfer to new clinical scenarios. The inclusion
of the ‘more knowledgeable other’ in the form of feedback from an
expert in the field of AYA rheumatology further enhanced the devel-
opment of advanced clinical reasoning.
The learning needs analysis demonstrated that many find managing
the complex psychosocial needs of AYA to be particularly challenging,
therefore the cases explored these particular elements in more depth.
Further cognitive considerations in the module design included en-
hancing learning through the use of video media, data interpretation,
interviews, pictures and quizzes, and through the reduction and seg-
mentation of text.
Conclusion: An e-learning series for adult rheumatologists who manage
JIA in adults as part of their routine clinical practice was successfully cre-
ated through the application of an evidence-based learning needs ana-
lysis to inform learning activity design, appropriate to the prior
experience of the learners through interactive case-based learning.
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Introduction: Children with one or more subtypes of juvenile idio-
pathic arthritis, such as enthesitis-related arthritis (ERA), often exhibit
growth impairments.
Objectives: To explore the impact of adalimumab (ADA) on growth
in pediatric patients (pts) with ERA.Methods: Pts aged 6-<18 with ERA were enrolled in a phase 3,
multicenter, randomized, double-blind, study. Following 12 weeks
of treatment with ADA (24 mg/m2 BSA up to 40 mg every other
week [eow]) or placebo, pts were eligible to enroll in an open-
label extension and receive ADA eow for up to an additional 192
weeks. For this analysis, all pts who received ≥1 dose of ADA
were included, and pts were grouped by baseline height percen-
tiles into 2 categories: ≤25th and >25th percentiles based on the
World Health Organization (WHO) growth charts. Mean WHO per-
centile changes in height, weight, and body mass index (BMI)
percentiles were calculated through 204 weeks. Per protocol,
bone age and familial height were not collected. Growth and effi-
cacy data were analyzed as observed.
Results: Among the 46 pts who received ≥1 dose of ADA in this study,
67% were male with a mean age of 12.9 years; no pts had associated
IBD. Eleven pts (24%) were in the ≤25th height percentile, and these pts
had a numerically lower baseline height (147.7 cm) and weight (42.5 kg)
compared with those pts who were in the >25th height percentile (156.0
cm and 51.5 kg, respectively). Additionally, numerically higher propor-
tions of pts in the ≤25th percentile received concomitant corticosteroids
than did the >25th percentile group (54.5% vs 28.6%). Pts in the ≤25th
percentile group experienced a larger change in mean height percentile
through 204 weeks of ADA treatment (70.3 vs 20.5 for the >25th
percentile), a finding that was evident within the first 6 months
of treatment. Juvenile males in the ≤25th baseline height percent-
ile demonstrated the numerically highest rates of growth, al-
though similar levels of growth improvement were observed for
the lowest quartile of females as well. None of the 11 pts in the ≤25th
baseline height percentile remained in this category at their final
study visit (Table 1). Similar percentile increases were observed
for BMI percentiles between groups. ACR Pedi90 response rates
improved over time in both ≤25th and >25th percentile groups,
reaching approximately 80% at the end of 3 years treatment with
ADA.
Conclusion: Long-term ADA treatment was associated with growth
improvement and maintenance in children with ERA. These improve-
ments among children in the lowest WHO quartiles at baseline may
improve their quality of life and psychosocial environment. ADA
treatment improved ERA signs and symptoms, regardless of baseline
growth status.
Reference
1. Burgos-Vargas R, et al. Arthritis Rheumatol 2016;68(Suppl 10).
Disclosure of Interest
R. Burgos-Vargas Grant / Research Support from: AbbVie, Consultant for:
AbbVie, BMS, Janssen, Pfizer, and Roche. , S. Tse Grant / Research Support
from: AbbVie, Consultant for: AbbVie and Pfizer, K. Minden Grant / Research
Support from: AbbVie and Pfizer, Consultant for: AbbVie, Pfizer, Pharm-
Allergan, and Roche/Chugai, P. Quartier Grant / Research Support from:
AbbVie, Novartis, Pfizer, and Roche/Chugai, Consultant for: AbbVie, BMS,
MedImmune, Novartis, Pfizer, Roche/Chugai, Servier, and Sobi, J. Anderson
Employee of: AbbVie, K. Unnebrink Employee of: AbbVie, I. Lagunes
Employee of: AbbVie, G. Horneff Grant / Research Support from: AbbVie,
Pfizer, and Roche, Consultant for: AbbVie, Novartis, Pfizer, and Roche
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 66 of 243P107
CLINICAL AND THERAPEUTICAL FACTORS LINKED TO THE
JOINT INVOLVEMENT IN PEDIATRIC INFLAMMATORY BOWEL
DISEASE
Emanuela Del Giudice1, Ilaria Battagliere1, Anna Dilillo1, Franca Viola1,
Giuseppe La Torre2, Salvatore Cucchiara1, Fabrizio De Benedetti3, Marzia
Duse1
1Department of Pediatrics; 2Department of Public Health and Infectious
Diseases, Sapienza University of Rome; 3Division of Rheumatology, IRCCS
Ospedale Pediatrico Bambino Gesù, Rome, Italy
Correspondence: Emanuela Del Giudice
Pediatric Rheumatology 2018, 16(Suppl 2):P107
Introduction: The association between inflammatory bowel disease
(IBD) and joint involvement are well known, but the clinical and ther-
apeutical features linked to them has been poorly investigated
mostly in pediatrics.
Objectives: To identify factors associated with the joint involvement
in pediatric IBD
Methods: A retrospective cohort of 83 pediatric IBD with joint
complain(56 Crohn’ s disease [CD]/27 Ulcerative colitis[UC] were
enrolled in two medical centers in Rome, evaluated at the time
of the first rheumatologic manifestation and after 6,12 and 24
months.
The diagnosis of IBD was based on agreed endoscopic and histo-
logical criteria, CD and UC disease activity was measured respectively
by PCDAI and PUCAI.
Demographic data and disease related IBD variables at first joint
complain were recorded for each patient.
Laboratory tests and clinical examination including the type of active,
limited joints were assessed. Moreover the gastrointestinal tract af-
fected, the step up or top down therapy approach, the disease joint
remission were collected.
Joint complaints were categorized on the basis of clinical documen-
tation as sacroileitis, peripheral arthritis, and arthralgia.
Results: Regarding the different types of rheumatic manifestations
compared to the IBD diagnosis, arthritis begins earlier than arthral-
gia(p=0.031). Of the 83 patients,44(53%) had arthralgia and 39(47%)
arthritis, and in this last subgroup 23 had peripheral arthritis and 16
sacroileitis. The prevalence of arthritis or arthralgia was not significantly
different in both groups: CD(48% 44%) and UC(52%>56%)(p=0.930).16/
83 patients enrolled had a sacroileitis,11(69%) had a CD and 5(31%) UC.
In IBD group the frequency of small, coxo-femoral and sacroiliac
joints complain was higher in the arthritis than arthralgia
patients(p=0.006;p=0.001;p=0.001,respectively).
CD patients in both arthritis and arthralgia groups, showed a higher
prevalence of the Ileum-colon involvement (L3)(63%vs52%) than
ileum (L1)(15%vs27.7%) and colon disease (L2)(22%vs20.7%). Also in
the subgroup of sacroileitis in CD the L3 involvement was
higher(73%) than L1(18%) and L2(9%).
The joint remission was higher in arthritis patients on top down
treatment than those on step up and the difference was already sta-
tistically significant at follow up at times 6 and 12 month-
s(p=0.043,p=0.036,respectively).The peripheral arthritis group showed
a higher frequency of remission at the follow up at 6,12 and 24
months compared with the sacroileitis.
Conclusion: Arthritis is an earlier extraintestinal manifestation in
pediatric IBD compared to arthralgia, and sacroileitis is more frequent
in CD. Otherwise UC and CD have the same frequency to develop
arthritis or arthralgia.
The L3 localization in CD may be related itself to the development of
joint involvement.
The top down therapy in case of joint manifestation showed a higher
frequency of remission.
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Introduction: Enthesitis-related arthritis (ERA) is a category of juvenile
idiopathic arthritis considered to be a form of Juvenile Spondyloarthro-
pathy (SpA). Spondyloarthritis Research Consortium of Canada sacro-
iliac joint score (SPARCC SIS) measures inflammation in sacroiliac joints.
It has been used in adults but limited experience exists in children.
Objectives: To assess SPARCC SIS in children with ERA. To investigate
the association between SPARCC SIS score and clinical–biochemical
features
Methods: Patients with ERA (according to ILAR criteria) who had sacro-
iliac (SI) joints MRI were included in a cross sectional study. Demo-
graphic features and time of follow up were recorded. ASAS
classification criteria were applied to patients. SI joints were examined
using T1-weighted images, T2 fast –suppressed and short-tau inversion
recovery. The SPARCC was scored independently by 2 radiologists.
Readers were blinded to clinical features. SPARCC SIS assessed the pres-
ence, depth and intensity of bone marrow edema on consecutive
six slices as an increased signal in the iliac and sacrum bones. Scoring is
composed by 3 components: bone marrow (BM) edema (0-48), BM in-
tensity (0-12), BM depth (0-12). Maximum:72. Clinical variables were col-
lected in random visits: active joint (AJ), sacroiliac pain (SIP) , lumbar
pain (LP),lumbar limitation (LL) by Schöber´s test, wellbeing according
to the patient using a visual analogue scale (VASp), disease activity ac-
cording to the physician (VASphy), VAS pain ,JADAS-10(juvenile arthritis
disease activity score), JSpADA(juvenile spondyloarthritis disease activ-
ity index), ESR and functional capacity by CHAQ. Treatment with TNF in-
hibitors (TNFi) were recorded. Descriptive, summary statistics, Intraclass
Correlation Coefficient (ICC) for concordance between readers, Kruskal
wallis one way AOV -test and post-hoc comparisons were done. Chi2 for
categoric variables were used.
Results:
Thirty patients (83% M) fulfilled inclusion criteria. Median age was
12 (5-17) years and disease duration 5.6 (1-8) years. HLA-
B27 positive in 12 (40%). TNFi in 17 (57%). Twenty-five patients
(83%) had abnormal SI MRI. SPARCC SIS score was (medians±SD)
24±14.71. ICC for concordance between readers =0.73(p=0.02) IC
95% 0.43-0.88. MRIs were divided into 3 groups according to
score. Clinical and demographic variables were compared among
groups (Table 1).
There were no significant differences in activity measures (VASp,
VASphy, VAS pain, JADAS-10, JSpADA) neither ESR, nor CHAQ
among groups. MRI showed inflammation in 7 patients with
normal X-rays(p=0.005). All patients fulfilled ASAS criteria for
SpA. All patients who fulfilled ASAS-axial (14 patients) showed
MRI abnormalities (SPARCC SIS 24 ±13.6). 10/16 patients who
were classified as peripheral according to ASAS showed sacroilii-
tis (24 ±15.09). Eight patients met criteria for Ankylosing Spon-
dylitis (AS) according modified New York Criteria:their SPARCC
score was 24±12.0.
Conclusion: SPARCC SIS score was associated with age and dis-
ease duration. Patients classified as peripheral according to ASAS
had similar SPARCC scores to those of patients classified as axial,
which probably indicates this classification is not relevant for ERA
patients.
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Table 1 (abstract P108). See text for description
Group 1
n=5
Normal
MRI
Group 2
n=16
Score >1 to 24
(median±SD 21±5.7)
Group 3
n=9
Score >24 to 72 (median
±SD 36±9.78)
p
Age at
study*
10(5-17) 12 (9-16) 14 (7-17) 0.001
Duration
of disease*
2 (0-5) 4(1-8) 4(2-6) 0.02
AJ* 1 (0-5) 1(0-16) 2(0-8) ns
SIP ** 3 (60) 8 (50) 5(56) ns
LP** 1(20) 12(75) 4 (44) ns
LL ** 5 (4.5-5.5) 4.5 (3-7) 5 (3.5-6) ns
*median (range) **Nº(%)
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Introduction: juvenile idiopathic arthritis (JIA) is not uncommon dis-
ease among aboriginals in Sakha Republic (Yakutia) - SR(Y), which
can be related to high spreading of HLA B27 antigen. Aboriginals in
SR(Y) have higher prevalence of enthesitis-related category of JIA
and juvenile ankylosing spondylitis, increased family history of
rheumatic diseases, especially arthritis and have higher requirement
in biologic medicine (anti-cytokine antibodies) for arthritis control
compare to Caucasians.
Objectives: The aim of our study was to evaluate cytokine profile in
aboriginals in SR(Y) and compare to Caucasians have been living in
the same area.
Methods: In continuous study were included 108 JIA patients before
age 18 consisted of 96 SR(Y) aboriginals and 12 Caucasians with JIA
whom have been living in SR(Y). All patients have an active disease
course. In children HLA B 27 and interleukin-1β, interleukin-6,
interleukin-10, interleukin-4, tumor necrosis factor-α, γ-interferon
levels were detected.
Results: The prevalence of HLA B27 antigen was 50% in RS(Y) aborig-
inals. We have found differences in cytokines levels between aborigi-
nals and Caucasians: inerleukin-10: 3.75±1.7 and 3.24±0.9 pg/ml
(р=0.038), inerleukin-1β: 2.9±8.4 and 2.0±0.9 pg/ml (р=0.0000001),
tumor necrosis factor-α: 6.3±9.1 and 4.9±2.2 pg/ml (р=0.00001), γ-
interferon: 22.7±11.4 and 20.1±3.5 pg/ml (р=0.007). No differences
were observed in inerleukin-4 and inerleukin-6 levels between
groups. Inerleukin-6 positively correlated with ESR (r=0.72, p<0.05).
There was not found correlation between cytokines level and pres-
ence of HLA B27 antigen.
Conclusion: the prevalence of pro-inflammatory cytokines were ob-
served in aboriginals in SR(Y) compare to Caucasians. Further investi-
gations required to validate these data in clinical practice.
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Introduction: Although predictors for the development of uve-
itis in patients with juvenile idiopathic arthritis (JIA) are well
known, uveitis regarded as a separate, parallel disease has its
own models of disease course, and accordingly, its own trends
for remission. Adalimumab (ADA) is a highly effective anti-TNF
drug having a strong therapeutic effect on both JIA and
uveitis.
Objectives: This study aimed to assess the parameters associated
with achieving remission of uveitis as a comorbid disease in JIA dur-
ing ADA therapy.
Methods: The study involved 112 patients with uveitis who had
initiated ADA therapy at the National Medical Research Center
of Children's Health (Moscow). The median duration of JIA was
4 years (IQR 2:8.1); the median duration of uveitis was 1 year
(IQR 0:5). Twenty-nine patients (25.9%) had only one eye af-
fected. At ADA treatment initiation, 10 (8.9%) of patients had
remission of uveitis. Almost half (49.1%) of the patients had a
history of uveitis complication and 17.9% of patients had
already undergone eye surgery. Treatment efficacy was evalu-
ated according to the dynamics of clinical and laboratory
signs, as well as according to achieving stable remission of
uveitis.
Results: ADA therapy showed high efficacy in children with uve-
itis. After the first year of therapy, 89 patients (79.5%) achieved
stable remission of uveitis; none of them had uveitis flares dur-
ing the subsequent follow-up (the maximum follow-up period
was 5 years). At the last visit, 92 patients (82.1%) achieved re-
mission of uveitis. Among the remaining 20 patients (Flare
group, 17.9%), only one patient demonstrated no positive dy-
namics of the uveitis course; the other 19 patients developed
uveitis flare after 2-17 months of remission. Having compared
the Flare group with the Remission group, we found the factors
potentially associated with treatment response. The factors asso-
ciated with recurrent uveitis included the greater number of
uveitis flares in the past; complications affecting the vitreous
body or the cornea; two eyes affected; and longer JIA duration
before uveitis presentation.
Conclusion: ADA proved to be highly efficacious when used to
treat children with uveitis. However, the severe uveitis affect-
ing eyes with a large number of flares in the past and compli-
cations affecting the vitreous body and the cornea reduced
the likelihood of achieving stable remission in children with
JIA.
Disclosure of Interest
None Declared
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 68 of 243P111
THE ETIOLOGIC SPECTRUM OF PEDIATRIC NON-INFECTIOUS
UVEITIS
Mustafa Çakan1, Şerife Gül Karadağ1, Dilbade Yıldız Ekinci2, Nuray Aktay
Ayaz1
1Pediatric Rheumatology; 2Ophthalmology, Kanuni Sultan Süleyman
Research And Training Hospital, İstanbul, Turkey
Correspondence: Mustafa Çakan
Pediatric Rheumatology 2018, 16(Suppl 2):P111
Introduction: The most common causes of non-infectious uveitis in
pediatric age group are rheumatologic diseases [juvenile idiopathic
arthritis (JIA), Behçet disease (BD), sarcoidosis, and vasculitides], tubu-
lointerstitial nephritis and uveitis (TINU) and idiopathic uveitis.
Objectives: The aim of this study was to demonstrate the etiologic
spectrum and long term follow-up results of pediatric non-infectious
uveitis cases.
Methods: The files of patients with the diagnosis of non-infectious
uveitis were reviewed between May 2010 and September 2017.
Results: The cohort consisted of 54 juvenile uveitis cases. Mean dur-
ation of follow-up for uveitis was 18.6 months (6-60 months). Twenty
seven (50%) patients had JIA, 17 (31%) patients had idiopathic uve-
itis, 6 patients (11%) had BD, and 4 patients (7%) had TINU. The fre-
quency of uveitis in all JIA patients was 6.6% (27/405), and in BD it
was 22.2% (6/27).
Juvenile idiopathic arthritis cases consisted of 18 (67%) persistent oli-
goJIA, 3 extended oligoJIA, 2 enthesitis-related arthritis (ERA), 2 RF-
negative polyarticular JIA, 1 psoriatic arthritis, and 1 systemic JIA. Five
JIA cases had uveitis at the time of diagnosis of arthritis (4 persistent
oligoJIA, 1 RF-negative polyarticular JIA). Only one case had initial
diagnosis of uveitis and later diagnosed as ERA. Mean duration be-
tween diagnosis of JIA and uveitis was 21.2 months (0-77 months).
Male and female ratio was close to each other in the whole cohort
(26 males, 28 females) and in JIA cases (12 males, 15 females). While
idiopathic uveitis cases (6 males, 11 females) had female predomin-
ance, BD (5 males, 1 female) and TINU (3 males, 1 female) cases had
male predominance.
Mean age at the time of diagnosis of uveitis was 9.1 years (1-17.5
years) in the whole cases and this number was 5.0 years in persistent
oligoJIA cases, 11.8 years in idiopathic uveitis, and 13.7 years in BD.
Bilateral anterior uveitis was observed in 20 (74%) of JIA cases. Six
JIA patients had unilateral anterior uveitis and one case had inter-
mediate uveitis. Anti-nuclear antibody was positive in 90.4% of oli-
goarticular JIA-uveitis cases and 95.2% of oligoJIA associated uveitis
cases were asymptomatic.
Idiopathic uveitis cases had unilateral anterior uveitis (6 cases),
bilateral anterior uveitis (5 cases), bilateral intermediate uveitis
(5 cases), and bilateral panuveitis (1 case). All of the idiopathic
uveitis cases were symptomatic as red eyes being the most
common symptom. Three BD patients had bilateral panuveitis, 2
cases had unilateral anterior and 1 case had bilateral anterior
uveitis. Only one BD case was asymptomatic. TINU cases had bi-
lateral anterior uveitis (3 cases) and unilateral anterior uveitis (1
case) and all of them had red eyes.
At the time of enrollment 45 uveitis cases (83.3%) were under remis-
sion while 9 cases (5 idiopathic uveitis, 2 JIA, 1 BD, and 1 TINU) had
active uveitis. Biologics were used in 14 cases of methotrexate-
resistant JIA-related uveitis (adalimumab in 11 and tocilizumab in 3
cases). Half of BD uveitis patients were treated with biologics (2 cases
with interferon-alpha, 1 case with adalimumab).
Complications of uveitis were observed in 10 cases (18.5%) such as
intraocular hypertension (5 cases), adhesions (2 cases), band keratop-
athy (2 cases) and decreased visual acuity (1 case).
Conclusion: Patients with JIA and BD should be regularly checked for
uveitis. It is hard to find an etiology in uveitis cases that were sent
from ophthalmologist if initial examination and questioning do not
reveal an overt rheumatologic disease but simple urine test may help
in diagnosis of TINU.
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Introduction: Juvenile idiopathic arthritis (JIA) is the most common
rheumatic disease of childhood and uveitis is one of the major extra-
articular manifestations. Uveitis occurs more frequently in children
with antinuclear antibodies (ANA) positive disease and is often
asymptomatic and may lead to permanent visual impairment, if not
treated properly. ANA is the only biomarker that currently guides
uveitis screening in JIA but it remains not conclusive. Among various
ANA patterns, anti-DFS70 antibodies has been proposed as a novel
biomarker for uveitis screening, being positive in children likely to
develop uveitis. By contrast, in adults these antibodies seem to iden-
tify healthy individuals among asymptomatic ANA positive subjects.
Objectives: Aim of this observational study was to evaluate the cor-
relation between uveitis and anti-DFS70 antibodies in children af-
fected by JIA.
Methods: A total of 34 children (22 females, 12 males; median age
13.3 years) admitted to Rheumatology Unit of Verona and affected
by JIA were enrolled. Following data were recorded retrospectively:
JIA subtype, ANA positivity, anti-DFS70 positivity, presence of uveitis,
diagnosed by a well-trained ophthalmologist.
Results: In our series oligoarticular ANA+ JIA was the predominant sub-
type (23 cases, 67.6 % of total), followed by oligoarticular ANA- subtype
(6 cases, 17.6 % fo total), polyarticular ANA- JIA (3 cases, 8.8% of total),
and lastly polyarticular ANA+ JIA (2 cases, 5.9% of total).
23 (67.8% of total) patients presented a DFS/homogeneous ANA pat-
tern. 6 out of 34 patients (17.6%) developed mono- or bialteral uve-
itis and all of them were ANA positive, confirming that DFS/
homogeneous ANA pattern is the most common pattern associated
to uveitis. None of patients presented antibodies anti-DFS70, regard-
less of clinical history of uveitis.
Conclusion: DFS/homogeneous ANA pattern remains the most com-
mon pattern seen in JIA patients and seems to be an hallmark of
uveitis. In our series, we found that neither JIA nor uveitis risk in JIA
patients correlate with anti-DFS70 positivity. The role of these anti-
bodies in children remains thus unclear. Further studies are needed
to identify a reliable biomarker to guide ophthalmologic screening in
JIA patients and to identify children likely to develop uveitis.
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Introduction: Chronic anterior uveitis (CAU) is the most common
extra-articular sign of juvenile idiopathic arthritis (JIA) that can result
in a serious impairment and/or loss of vision in children. Standard an-
tirheumatic drugs in combination with local therapy are effective in
60%. When these drugs are ineffective, biological agents are used in
JIA with CAU. The issue of optimal and personalized biologic therap-
ies prescription and problem of switching between drugs are rele-
vant questions of modern pediatric rheumatology.
Table 1 (abstract P114). See text for description
Parameters Uveitis, yes n=32 Uveitis, no n=143 Р
Onset age, years 3.9 (2.1; 6.2) 5.5 (2.5; 10.5) 0.033
ANA positivity, n (%) 15/26 (57.7) 26/72 (36.1) 0.056
Ongoing methotrexate, n (%) 26 (81.3) 103 (72.0) 0.284
Time before 1st biologics, months 2.9 (1.5; 5.3) 2.2 (1.0; 5.2) 0.343
Remission duration, months 6.5 (2.4; 6.9) 13.1 (6.5; 28.0) 0.078
First significant flare, n (%) 14 (43.8) 24/142 (16.9) 0.0009
Time before first significant
flare, months
33.0 (16.7; 61.5) 48.6 (26.4; 65.7) 0.023
Switching of the first biologic, n (%) 7 (21.9) 18/142 (12.7) 0.180
Time before switching of the
first biologics, months
49.0 (24.5; 62.1) 52.3 (35.0; 66.2) 0.186
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 69 of 243Objectives: The aim of this retrospective observation was to de-
scribe trends in the biologic DMARDs prescription in first and sub-
sequent lines of biologic therapies for the treatment of JIA
associated with CAU.
Methods: We recruited 53 patients with JIA and eye involvement,
who received medical treatment at the Department of Pediatric
Rheumatology of Sechenov University since January 2015 to Decem-
ber 2017. Study group included 39 girls and 14 boys (2,8/1). Mean
age was 11,19 ± 3,87 years, age of disease onset was 4,80 ± 3,06
years; mean disease duration was 6,39 ± 3,45 years. Among included
patients 28 children (53%) had oligoarticular JIA, 25 children (47%) –
polyarticular RF- JIA. ANF was positive in 36 patients (68%). Disease
onset with initial joint damage was observed in 35 children (66%),
with eye involvement – in 7 children (13%), with both joint damage
and eye involvement – in 11 children (21%). Thirty-eight (72%) pa-
tients had bilateral ocular involvement, 15 patients (28%) – unilateral.
At baseline, 51 patients (96%) received concomitant therapy with
non-biological immunosuppressive drugs: 49 children (96%) received
Methotrexate, 2 children (4%) Cyclosporine A. Two children (4%) re-
ceived biologic DMARD as monotherapy. All patients received local
therapy due to the ophthalmologist recommendations.
Results: As a first biologic abatacept was used in 10 patients, etaner-
cept in 8 patients, infliximab in 1 patient. Adalimumab was used in
34 patients (64,15%±8,23), which was significantly more frequently
than abatacept, etanercept and infliximab as a whole – 19
(35,85%±11,01) (t=2,06; P>95,5%).
Later 13 children (24,53%) were switched from a first to a second
biologic agent. 11 patients were switched from the other biologics to
adalimumab. The main reasons for switching was the appearance of
CAU in 4 patients (36%), who were initially treated with etanercept,
and aggravation of CAU in 3 patients (27%), 2 of them received eta-
nercept as a first biologic and 1abatacept. The second reason for
switching was lack of therapeutic response or inefficacy (in 4 – 36%):
3 patients were initially treated with abatacept and 1 with infliximab.
Adalimumab was discontinued due to inefficiency only by 1 patient.
One patient discontinued adalimumab due to remission. At the end
of our observation alimumab was chosen as treatment for 43
(81,13%) patients with JIA and CAU.
Conclusion: Thus, adalimumab was preferred as a first- and second-
line biologic agent in treatment of JIA with CAU.
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Introduction: Treatment of moderate-severe form of juvenile idiopathic
arthritis (JIA) required using biologics in the cases of methotrexate inef-
ficacy or intolerance. The presence of extra-articular features, especially
uveitis usually required more intensive treatment approaches. The find-
ing of predictors of biologics efficacy is still actual problem.
Objectives: to evaluate the role of uveitis as a risk factor of flare and
survival of first biologic medication in non-systemic JIA.
Methods: Inclusion criteria: patient whom first biologic was adminis-
trated with or without MTX or MTX was discontinued after start of bi-
ologics due to different reasons (remission, intolerance, adverse
events). Exclusion criteria: treatment with current systemic corticoste-
roids, infliximab, rituximab. After selection 175 patients were eligible
to analysis. We evaluate clinically significant flare with jointinvolvement (required change of biologic or non-biologic DMARD),
time to flare. We compare two groups: i) patients with uveitis (n=32)
and ii) patients without uveitis. For statistical analysis we Cox’s re-
gression models, Log-Rank test, x2 test and Mann-Whitny test.
Results: the data of comparison between groups depending on the
uveitis in the Table 1. There was no difference in the gender distribu-
tion, and achievement of remission. The main biologic in non-uveitis
group was etanercept (64.3%), in uveitis group – adalimumab
(71.9%). Presence of uveitis increases the risk of JIA flare: OR= 3.8
(95%CI: 1.7; 8.7), and cumulative probability of flare: RR=4.5 (95%CI:
1.7; 12.1), р=0.003; Log Rank test, p=0,001; after adjustment on
methotrexate RR=3.1 (1.6; 6.0), p=0.0008. In subgroup of patients
treated with adalimumab absence of methotrexate increases the cu-
mulative probability of flare RR=6.5 (95%CI: 1.4; 31.1), р=0.02.
Conclusion: presence of uveitis was assumed as risk factor of JIA
flare, methotrexate can decrease the cumulative flare probability. Fur-
ther trials are required.
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Table 1 (abstract P116). TNF inhibitor treatment
Uveitis Group Infliximab N=7
(Remission)
Adalimumab N= 6
(Remission)
Idiopathic 4 (3) 5 (3)
JIA-U 3 (1) 1 (1)
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 70 of 243Introduction: Uveitis is the most common extra-articular manifest-
ation in children with juvenile idiopathic arthritis (JIA). Early identifi-
cation and treatment is important in order to prevent sight-
threatening complications and ongoing disease activity in to adult-
hood. Long-term population-based data on uveitis course, outcome
and complications are sought for.
Objectives: The aim was to assess long-term course, outcome and
complications of uveitis in the Nordic JIA cohort 18 years after dis-
ease onset.
Methods: A multicenter longitudinal prospective Nordic JIA cohort
study in which 510 patients from defined geographical areas of
Denmark, Finland, Sweden and Norway with disease onset in 1997-
2000 were included. The study aimed to be as population-based as
possible. At the 18-year follow-up 434 patients were included. Uveitis
information was available for 431 participants, and 272 were examined
by an ophthalmologist at the study visit. Otherwise information about
uveitis and medication was collected by the pediatric rheumatologist.
Results: Uveitis developed in 94/431 (22%) patients during the obser-
vation period of 18 years. Non-symptomatic uveitis was found in
73% of the patients, and 84% had an insidious onset of their uveitis.
Anterior uveitis was described in 70%. Among the uveitis patients
83% had received treatment with methotrexate and 58 % treatment
with biologics at some point during the disease course. At the final
study visit 36% had ongoing local treatment with eye drops, while
32% used systemic medication due to, or partly due to, uveitis. 7/94
(8%) had a best corrected visual acuity ≤0.5 in at least one eye. Cata-
ract developed as a complication in 25/94 (27%) and glaucoma in
22/94 (23%). Surgery was performed for cataract in 20/25 (80%) and
for glaucoma in 18/22 (82%) of the patients.
Conclusion: We found a high incidence of uveitis among nordic young
adults with JIA. Cataract and glaucoma were the most common struc-
tural complications. For the majority of the young adults with these
complications surgery was needed within 18 years after onset of JIA,
pointing to severe implications of uveitis in a life-long perspective.
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Introduction: Non-infectious uveitis is a leading cause of blindness in
the developed world. Juvenile idiopathic arthritis associated uveitis
(JIA-U) is one of the most commonly reported immune mediated
cause of uveitis in children. However, as in other developing coun-
tries, infectious uveitis is more common in Africa and there is a pau-
city of data on the epidemiology of non-infectious uveitis in children
in this setting. To our knowledge, this is the first description of non-
infectious uveitis managed at a tertiary paediatric rheumatology ser-
vice from sub-Saharan Africa.
Objectives: To describe the disease characteristics and treatment of
children with non-infectious uveitis at a tertiary paediatric rheumatol-
ogy service in Cape Town
Methods: A retrospective analysis of children managed by the paedi-
atric rheumatology and ophthalmology service for uveitis from 1
January 2010 to 31 December 2017, was conducted. Ethics approval
was obtained, and relevant data extracted from patient medical
rheumatology and ophthalmology case files. Descriptive statistics
were employed and comparisons between JIA-U and idiopathic uve-
itis groups were made, with p-values < 0.05 considered significant.
Results: Thirty-four children (60 eyes) were reviewed - 18 boys and
16 girls with a median age at first visit of 76 months (age range 25
to 156 months).Chronic anterior uveitis predominated in 23 (68%), acute anterior
uveitis occurred in 3 (9%), panuveitis in 4 (14%), followed by 3 (9%)
posterior, and 1 (3%) intermediate uveitis.
Fourteen (41.1%) were associated with juvenile idiopathic arthritis (JIA),
12 (35.3%) were considered idiopathic, while 2 (5.8%) were due to sar-
coidosis, 1 (3%) to Behcet’s, 2 (5.8%) to human immune deficiency virus
(HIV), 2 (5.8%) post streptococcal and 1 (2.9%) to toxocara.
The JIA-U group were characterised by a female preponderance, me-
dian age of onset of 56 months and chronic anterior uveitis. Further re-
view according to the International League of Association for
Rheumatology (ILAR) classification showed 10 (71,4%) to be oligo-
persistent antinuclear antibody (ANA) positive while 3 (21,4%) were
poly-articular rheumatoid factor negative and 1 (7,1%) had psoriatic-JIA.
9 (64.2%) of the JIA-U group and 8 (73%) of the idiopathic group pre-
sented with complications, predominantly cataracts, followed by
band keratopathy and posterior synechiae. There was no significant
difference in age and complications at presentation, between the
two groups, p-values 0.4 and 0.62 respectively, though a male pre-
ponderance was evident in the idiopathic group.
All children were treated with standard initial therapy which included
steroids (topical, oral and/ or intravenous) and methotrexate, of
which 21 (61.7%) achieved remission. Thirteen children required the
addition of a tumour necrosis factor (TNF) inhibitor, due to failure of
Mycophenolate Mofetil in 2 and Azathioprine in 7. Eight (61.5%)
achieved remission (Table 1).
Conclusion: Here, JIA-U appears to have similar disease characteris-
tics as previously described. However, the high rate of complications
at presentation, requires further review of overall visual outcomes
and the effectiveness of current screening and treatment strategies.
Optimum management of non-infectious uveitis therefore necessi-
tates a close relationship between paediatric rheumatologists and
ophthalmologists.
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Introduction: Biosimilar infliximab (Remsima®) has been introduced
in our country, together with other European countries in 2014. Infor-
mation regarding the use in child age group is limited but it is re-
ported that its therapeutic efficiency and safety is similar to the
reference molecule regarding the pediatric Chron disease
Objectives: In this study, our aim was to reporte the efficiency and
safety of BI used for children with non-infectious uveitis.
Methods: In this study, there were 13 subjects (9 boys, and 4 girls)
diagnosed with non-infectious uveitis.
BI (Remsima9 treatment had been given in 5 mg/kg in 0.,2.,4 th week
and then every 8th week. Ophthalmic assessment of disease activity
and ocular complications were measured throughout the trial with
the use of slit-lamp biomicroscopy for uveitis activity, according to
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lated of patient year (HY), adverse event (AE) was assessed using the
CTCAE criteria. The median values due to the small number of pa-
tients are considered.
Results: The patients who were include the study, 5 had diagnosed
extended oligo JIA, 2 with enthesitis-related arthritis (ERA) ,2 with
persistent oligo JIA, 2 with pars planitis and one of them Behcet’s dis-
ease. At the time of evaluation, the median age was 10 years (3-13),
age at diagnosis of their disease 8 years (1-13), respectively. The me-
dian age of uveitis diagnosis was 8 years. The median disease dur-
ation before BI was 10 months. All of the patients had methotrexate
therapy with BI and BI before.
Only one patient used a different biological agent prior to BI, and re-
vealed they were determined that considered unresponsive.
Other patients (n=12) had biosimilar infliximab as first biologic drug
due to the activation of disease after using the drug methotrexate.
After therapy of BI, in all of the patients, joint and eye symptoms
were improvement.
The systemic steroid therapy was cut down in the first month in all
patients, 2 of them continue prophylactic topical steroids.
The median duration of BI therapy was 10 months. There was one
case of anaphylaxis in all the patients, whereas five of them frequent
upper respiratory tract infection have been observed as side effect.
Conclusion: In this preliminary report, This biosimilar infliximab treat-
ment appears to be safe and effective in pediatric age group on the
pediatric patients with non-infectious uveitis. These results must be
supported by multicenter studies and registries.
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Introduction: There are no established treatment guidelines for pa-
tients with juvenile idiopathic arthritis-associated uveitis (JIA-U).
Objectives: Therefore, multi-center survey was conducted to examine
the present treatment status for JIA-U in Japan to establish treatment
guideline in the future.
Methods: Questionnaires were sent to medical centers with pediatric
rheumatologists at April in 2016 to investigate the patients’ profile
and how JIA-U was treated in each center.
Results: Of 726 patients involved in this study, 44(6.1%) had JIA-U
and 36/44 (81.8%) was oligoarticular onset. Of 40 JIA-U patients re-
cruited by the 2nd detailed survey, 23 (57.5%) had been treated with
NSAIDs in 13 (32.5%), MTX in 16 (40.0%), glucocorticoids (GCs) in
1(2.5%), and etanercept (ETN) in 1 (2.5%) by the time when JIA-Uwas diagnosed. After JIA-U was diagnosed, topical GC was started in
all cases in combination with MTX in 3(7.5%) and/or systemic GC in
2(5.0%). Some biologic agents (infliximab (IFX) and adalimumab
(ADA)) were used more frequently in JIA-U patients than non-uveitis
patients (P <0.0001, P = 0.0029). Of 40 JIA-U patients, 22 patients
(55.0%) were treated with biologic agents such as IFX in 9(22.5%),
and ADA in 11 (27.5%). Surgical treatments for JIA-U such as intraoc-
ular lens implantation underwent in 15 cases (37.5%). Symptoms and
findings related to uveitis improved with treatment in all 40 JIA-U pa-
tients, and no blindness was observed in this survey.
Conclusion: Treatment for JIA-U in real clinical settings in Japan was
similar to that of previous reports from other countries. Higher inci-
dence of JIA-U onset in MTX treated patients in Japan may be ex-
plained by the differences in administration dose or method. Further
investigation with larger scale is essential to establish the evidence-
based treatment recommendation for JIA-U.
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Introduction: In 2014 the Region of Southern Denmark created the
application (app), “Mit forløb” (“My Pathway”) giving the different de-
partments at the hospitals, the option to create their own specific
section of the app. The app is available for everybody but using the
communication and registration tools requires access granted by the
relevant department.
“My Pathway” is patient empowerment put into practice because the
patients can be more involved in their own treatment and gain
knowledge about different aspects of their disease and management
thereof.
Objectives: To provide the young patients with JIA an easy and ac-
cessible way to find information on their disease, treatment and
rights before and during transition to adult medicine a smart phone
app was created.
Methods: The information in the app was written in collaboration be-
tween health professionals from the pediatric department and the
department of Rheumatology, securing a uniform structure and lan-
guage. It covers JIA, pain management, treatments and their side ef-
fects. Also included is general information on the department, its
structure and staff.
A chat function was developed which enables communication with
the hospital in a flexible way; the patient can write whenever the
question occurs and the hospital staff can answer when they have
the time and have looked into the patient journal.
“My Pathway” meets the young patient where they are; online any-
time and anywhere via the smartphone in their pocket. Regarding
transitioning focus was put on patients’ rights and the app was cre-
ated to it could be accessed both as a patient at the pediatric de-
partment and the department of Rheumatology.
Results: The app is still a very new initiative and has not yet been
widely spread to the young patients. Around 30 young patients have
been granted access to the app, and the feedback has been positive.
Feedback from the patients has been a wish for more personalized
information, regarding treatment and consultations, and to be able
to see future appointments.
As of yet the chat feature has not been in much use probably due to
reduced awareness among families and staff.
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towards informing the young patients about JIA, medication, pain-
management, transfer to the department of Rheumatology etc.
As the app is a new implementation there must be expected a
period of time for adjusting, both for patients and health
professionals.
There is need for further development for the app to achieve full
potential. Adapting the feedback from the young patients and
the health professionals working with the app is an ongoing
process.
The app is planned to include all rheumatic diagnoses and also ac-
cess for younger children and their parents in the future.
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Introduction: Juvenile idiopathic arthritis (JIA) is the most common
chronic rheumatic disease of childhood requiring long-term treat-
ment. JIA has an fluctuating and unpredictable course. The fluctu-
ation of disease activity, asks for continuous monitoring by a
pediatric rheumatologist to achieve good health outcomes. Children
with JIA live with chronic or recurrent pain and disability, which can
severely limit their ability to complete daily physical tasks and partici-
pate in school and social activities.
An app was developed with input of patients, parents and caregivers
to help close the gap between hospital care and the normal daily life
activities of children with JIA in between hospital visits.
Objectives: To create an ehealth platform (Reuma2GO) that aims to
significantly improve the care for children with JIA and the dialogue be-
tween children with JIA, their parents and team of caregivers and
hence, to advance true patient participation both in care and research.
Methods: We performed a two-day workshop which was attended
by patients, parents, app developers and caregivers about the
added value of eHealth for the JIA patient and their parents. The
participants were asked what they wanted from an app in their
therapy that they are not currently finding. The workshop partici-
pants then worked together to come up with design and concept
features that their ideal app should have and identify the critical
success factors giving app developers a clear, clinically-approved
model to work to.
The Reuma2GO app tracks joint pain, fatigue, morning stiffness, daily
activities and manages appointments and medication. Patients can
communicate with health professionals in the app for advice or ques-
tions. Weekly feedback is sent on the self-reports by the care team
to support patients and parents. The patient-generated data in the
app will be integrated into the EMR in the near future.
Results: The Reuma2GO app is developed and tested among pa-
tients and care professionals according to the agile scrum method.
180 JIA patients and 7 rheumatologists/immunologists are using the
Reuma2GO app. The app was evaluated as helpful in self-
management and recommended by patients. The app generates a
dynamic reflection of the daily life of a JIA patient. This allows pa-
tients to efficiently monitor the impact and actual status of their
disease.
Conclusion: Reuma2GO is an eHealth platform that enables JIA pa-
tients to better understand and monitor the burden of the disease
and thereby providing patients a way to become more actively in-
volved in their disease management. By sharing their data inbetween hospital visits both patients and care professionals should
benefit by offering more personalized care and using monitored data
for research. Planning is to scale up the app to other hospitals in Eur-
ope that participate in the PRES network in the coming period.
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Introduction: From the patients perspective, the big promise of
health apps (mHealth) is to increase self-awareness and self-care. For
chronic conditions such as juvenile idiopathic arthritis (JIA), mHealth
may provide a way for patients to become more actively involved in
their disease management. With input of patients, parents and care-
givers the Reuma2GO app was developed in 2017. It was intended
to close the gap between hospital care and the normal daily life ac-
tivities of children with JIA. The Reuma2GO app creates insights for
patient, parents and caregivers into all aspects of JIA that influence
the burden of disease (e.g. joint pain, fatigue, morning stiffness, daily
activities, medication use, side effects). By offering the possibility of
instant reporting about health issues one does not have to rely on
their memory for conditions that were present weeks before the rou-
tine visit. Moreover the app allows for built-in thresholds with auto-
matic alerts to physicians. A closed communication system allows
the patient to open discussions with their physician.
We feel that some routine visits of JIA patients, when in a stable in-
active episode (either on or off medication), can be skipped as long
as the patients agree that they are still doing fine.
Objectives: To evaluate if patients/parents are capable of self-
monitoring with the Reuma2GO app when they feel the disease is
quiet in order to skip future hospital visits.
Methods: Data from the Reuma2GO-app, the JAMAR at the hospital
visit (question 6: “Considering all the symptoms…. evaluate the level
of activity of your child’s illness at the moment”) and the physician’s
global assessment of disease activity (PGA) were compared.
The data used from the Reuma2Go app were the following (total
score 0-40)
1: How much pain did you have in the past week (0-10)?
2: Do you have pain and/or swelling in your joints today (max 10
joints)?
3: Did you suffer from morning stiffness in the last week (5 step-
scale; 2 points per step)?
4: How active is your illness at this moment (0-10)?
We only included those patients that had completed the abovemen-
tioned questions in the Reuma2Go-app 0-3 weeks before the routine
visit and scored a maximum of 1 point in total and only allowed for
question 1 and 4 (=Wallace’s criteria for inactive disease according to
parent/patient).
Results: 186 (128 Female) patients aged 12.07±4.27 years use the
Reuma2GO app.
The distribution of JIA categories was: 19.4% polyarticular RF-
negative, 6.9% enthesitis-related arthritis, 3.5% polyarticular RF posi-
tive, 11.8% extended oligoarticular, 40.3% persistent oligoarticular,
5.6% systemic JIA, 4.9% artritis psoriatica and 7.6% had undifferenti-
ated arthritis.
Preliminary data show that 17 patients completed the questions and
considered the JIA to be inactive. In 16 (94%) of the cases the phys-
ician confirmed that the JIA was inactive and the JAMAR question on
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the JAMAR during the visit, while the app scored a 0 before. This pa-
tient was suspected to have still a bit of unilateral TMJ arthritis and
received a PGA of 1/10 as well, although no change in medication
was performed
Conclusion: The Reuma2Go-app creates a continuum of care by
which the physician does not need to make treatment plans depend-
ing on one-point in time conditions at prescheduled visits. Moreover
94% of the patients that felt their disease was quiet were right about
it. The only one that changed his/her mind at the visit was backed
up by the physician, although no treatment change was needed. Fu-
ture studies will look into the safety of giving autonomy to patients
when they feel a visit can be skipped.
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Introduction: Identifcation of a need to replace a paper based activ-
ity diary used as part of pain management intervention with a more
accessible and user friendly smart technology resource. Researchers
within the field of E-technology have demonstrated the use of smart
phones for self-monitoring pain and symptoms preferable to paper
based forms noting that the information recorded was more accurate
and time efficient. Pain diary apps exist however they tend to focus
on reporting and recording pain rather than activity levels. At the
time of development there were no activity diary apps specifically
aimed at children and young people.
Objectives: To develop an interactive user-friendly e-diary app that is
accessible on android and iOS smart mobile phone.
Methods: At concept a business plan was submitted to secure financial
funding and obtained authorisation clinical design group within NHS
trust. Consultation with multi-disciplinary team and user groups on the
style, content, usability. This led to consultations with the nominated
app developer to bring the concept to wireframe draft format. Educa-
tional content was then researched and drafted. Further consultation
with user-groups to sign off the final draft of the app.
Results: The development process was initially estimated to be
completed within 12 months. In fact the entire process was 3
years in duration, underestimating the volumes of work and time
that would be involved. A particularly steep learning process for
the therapist who was a novice to app development. Despite this
editing drafts and trailing the app was required to ensure that all
glitches were identifeid and rectified the app is now a the point
of final sign off. The app is at point of release on app store(s).
The next phase is to research the efficacy of the app in the fol-
lowing 12 months.
Conclusion: Many challenges emerged during the app development
process, with important lessons learnt. Technology is ever-evolving at a
fast pace. Ensuring the app was relevant was a key driver in the devel-
opment process, the additional time taken to complete this project in-
creased the risk that the app would be out of date or other activtiy diary
apps may become available before the completion date was reached.
Having to use an external organisation to develop the app had
limitations in being able to communicate quickly and easily to
ensure alterations to the drafts were completed in a timely man-
ner. Future updates that may be required to the app will be lim-
ited as this will have to go through the app developer and will
have a cost implication.
Improvements emerged during the development phase that were
beyond the scope of the app and were not included in the original
costings therefore could not be included. It is hoped once theefficacy of the app is researched that further funding can be secured
to include the additional functions to the app to build of the scope.
Engagement with user groups was a vital part of the development
process providing opinions on the look, and userability of the app
interface. The focus group contributed significant modifications to
the final app and included setting reminders and a notification facil-
ity as well as assisting with naming the app.
The next phase is to research the efficacy of the app in the following
12 months. An essential part of the process is making links with other
researchers in this field to continue to the build on the access to
evidence-based e-technology tailored specifically for young people.
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Introduction: Genia is an app created as a patient support system
for improved communication and collaboration with patients, fam-
ilies and the health care team. Its designed for IOS so far and is avail-
able in app store in both Swedish and English.
Objectives: Through the app, patients can take notes and track self-
assessed observations in daily living, which could include Visual Analog
Scale trackers on various symptoms, activities and other areas reflecting
quality of life. Automatic data collection, such as Steps from Apple
eHealth, is also included. In addition users can send Pre-Visit report to
health care to help both patients/families and care team to prepare for
meetings as well as to help understand patients needs and preferences.
Methods: A pilot project using the app has been driven by a physio-
therapist, occupational therapist and the head physician of the Chil-
drens rheumatology department in Karolinska University Hospital in
Stockholm. Currently 56 patients at the clinic have Genia.
Results: The feedback on experience from both patient/families and
the clinic include that the app:
1. helps patients/families remember, reflect and prepare
2. support clinic visits
3. support patient activation and communication
Conclusion: As health professionals we see great potential in the app
to get the patient more active, understanding their disease and aware
that their behavior and selfcare can make a different in how they feel.
Genia is co-designed with JIA patients, families and members of the care
team and continues to be iterated with feedback and ideas provided by
stakeholders. There are further opportunities to co-develop the app to
be helpful to patients and clinics, for example the creation of different
types of reports, new or improved trackers that could support patients
or/and assist care teams to support patients in self-care, etc.
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Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 74 of 243Introduction: The Juvenile Idiopathic Arthritis (JIA) chronicity, com-
bined with the psychosocial effects of the entire therapeutic process
on children and parents, often leads to non-compliance and a signifi-
cant financial burden. These parameters, in the era of the economic
crisis, are an incentive to seek new approaches to physiotherapy.
Objectives: To investigate the applicability of a physiotherapy tele-
rehabilitation program on children with JIA and to explore the pro-
gram’s impact on children and their families.
Methods: Thirty JIA patients, with Medical Doctor’s global assessment
(MDVAS) <2, who applied a home-exercise program, were selected
and randomly divided in the tele-rehabilitation (TRG, n=15) and the
control group (CG, n=15). Each child from the TRG participated, add-
itionally at home-exercise program, in a 30-minute tele-session (using
personal computers, at home) with a qualified pediatric physiother-
apist, twice a week, for 12 weeks, performing their exercises under
the supervision and guidance of the specialist. Before and after the
tele-rehabilitation program (T1 and T2, respectively), TRG and CG pa-
tients and a parent/guardian completed the Juvenile Arthritis Multi-
demensional Assessment Report questionnaire (JAMAR) and a rele-
vant one for the implementation and compliance on the home-
exercise program. Residual disease was estimated at T1 and T2 from
a physiotherapist, different from the one performing the tele-
rehabilitation program. At T2, TRG patients and their parents com-
pleted a questionnaire, evaluating the tele-rehabilitation program.
One month after T2, a reassessment of compliance with the home-
exercise program was performed.
Results: The children’s median (range) age was 12.8 (8-16) years. Nine-
teen children (63%) had JIA with poly-articular course and 11 (37%)
with oligo-articular. All TRG children completed the tele-rehabilitation
program. At T2, the TRG children performed the home-exercise pro-
gram more frequently (p=0.023), for a longer time (p=0.034) and with
less promoting (p=0.004), compared to T1. Moreover, there was in-
creased compliance with the home-exercise program (p=0.001), func-
tionality (p=0.008) and quality of life (p=0.007) and less pain due to JIA
(p=0.017). In the CG children, there was no statistical significant change
in the abovementioned parameters. The residual disease was improved
in both groups (TRG: p=0.002, CG: p=0.018), but the improvement in
TRG children was greater (p=0.043). The applicability of the tele-
rehabilitation program was rated in a 0-10 VAS scale with a median
(range) of 10 (7-10) by children and 10 (9-10) by their parents. The tele-
rehabilitation program’s total benefit was rated with a median of 10 (8-
10) by TRG children and 10 (9-10) by their parents. Finally, one month
after T2, the compliance with the home-exercise program was still
greater, compared to T1 (p=0.001).
Conclusion: The implementation of an interactive physiotherapy
tele-rehabilitation program, is applicable and effective in children
with JIA, providing an additional tool in their rehabilitation.
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Introduction: Ongoing proteinuria causes long term damage to the
kidney. This is reflected by a change in estimated glomerular filtration
rate(eGFR) over a period of time. A fall in eGFR is a poor marker and
heralds damage. There is paucity of data about eGFR in children with
lupus nephritis. We undertook this study to add to the existing data
Objectives: To estimate the eGFR by using the bedside Schwartz for-
mula at the onset of nephritis,at one year after treatment and at last
follow upMethods: Charts were reviewed retrospectively of 82 children with
lupus nephritis. Height records at disease onset were available for 69
and these were included for analysis. eGFR was calculated using the
bedside Schwartz formula: 0.413*(Height/Creatinine).
Results: 69 children with lupus nephritis were included for the ana-
lysis of eGFR. Two children did not complete one year of treatment
and were thus not included for analysis of eGFR at one year and at
last follow up.
Median age at onset of nephritis was 12 years. Median duration of
follow up of the cohort was 55 months(9-164months).
Median eGFR at onset of nephritis prior to treatment was 82ml/min./
1.73m2(IQR 63-115). Median eGFR at one year after treatment was
127ml/min/1.73m2(IQR 89-150).eGFR at last follow up was 128ml/
min/m2(IQR 101-145)
The change in eGFR from baseline to one year was statistically sig-
nificant (p =<0.001) and the change at last follow up visit from base-
line was also better and was statistically significant (p=<0.001).
However there was no statistically significant change in eGFR from
one year to last follow up value (p=0.72).
39 children had eGFR less than 90ml/min/m2 at onset of neph-
ritis and of these 14 had eGFR <60ml/min/m2.After one year of
therapy one child had eGFR< 60ml/min./m2 and 18 had eGFR
<90ml/min/m2.
39 children had eGFR less than 90ml/min/m2 at onset of neph-
ritis and of these 14 had eGFR <60ml/min/m2.After one year of
therapy one child had eGFR< 60ml/min./m2 and 18 had eGFR
<90ml/min/m2.
This could imply that aggressive treatment early on led to a signifi-
cant improvement and there was not much deterioration
subsequently.
Conclusion: Stringent follow up is practiced at our unit and a tight
treat to a target approach is employed. Early aggressive therapy is
the norm. This is probably a reason for better outcomes.
Another possibility is that many children have not spent a long time
in the disease course and a longer follow up is needed to actually
determine the renal damage.
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Introduction: Juvenile systemic lupus erythematosus (jSLE) is a multi-
systemic disease that has its onset in childhood. It is accompanied
by an important morbidity related to the disease and its therapy.
Ped-SDI index is used to measure the organ damage in these pa-
tients. Morbidities and comorbidities can impact this index in a posi-
tive or negative way.
Objectives: To evaluate the relationship between morbidities and co-
morbidities with the ped-SDI damage index in patients with juvenile
systemic lupus erythematosus being followed up in 2 paediatric
rheumatology clinics in Bogotá, Colombia.
Methods: A descriptive, cross-sectional study of a retrospective co-
hort of patients evaluated between 1997 and 2016. Morbidities, co-
morbidities and treatment were identified and the ped-SDI damage
index was measured in the last visit. The statistical analysis was done
using Stata V12.
Results: 112 participants with juvenile systemic lupus erythematosus
were included, the female: male ratio was 5,2:1. Sixty-two percent
were 12 years or older at the diagnosis. The mean time of follow up
was 49,3 months (6-161). Seven patients (6,25%) died during follow
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 75 of 243up with variable causes of death. The most frequently involved or-
gans were musculoskeletal, mucocutaneous and hematologic. Pa-
tients who have taken 3 o more different immunosuppressive drugs
(excluding antimalarial and steroids) during their disease, had a sta-
tistically higher damage index at last visit. Medication non-adherence
was found in 40% of patients, being this related with a higher dam-
age index at last visit. The morbidities associated with a higher organ
damage index were acute kidney injury (p=0,0277), chronic kidney
disease (p=0,0275), dialysis requirement (p=0,0072), neuropsychiatric
(p=0,0020), cardiovascular (p=0,0000), pulmonary (p=0,0000), gastro-
intestinal (p=0,0082) and ocular involvement (p=0,0001). The pres-
ence of polyautoimmunity was also associated with a higher index
(p=0,003). In contrast, the presence autoimmune thrombocytopenia
was associated with a lower damage index (p=0,0378).
Conclusion: These findings showed that morbidities and comorbidi-
ties can impact the prognosis of juvenile lupus patients in a positive
or negative way. These findings help to understand some different
factors that can contribute to organ damage in these pediatric pa-
tients. Searching for these conditions and starting an early and di-
rected therapy would impact the prognosis in a positive way.
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Introduction: Although hepatic disease is not a significant cause of
morbidity/mortality in jSLE,it is now considered to have greater clin-
ical significance.
Objectives: To report two cases of SLE who presented with abnormal
liver function tests several months before the onset of the rest clin-
ical manifestations.
Methods: The first case is a 12,5 years old girl who presented with a
one month history of malar rash and joint pain (ankles and knees).
One and a half year before, elevated transaminases (2fold above the
upper normal limit) were noticed during a routine exam. An exten-
sive laboratory work up for viral hepatitis A,B and C,Wilson disease,
celiac disease, hepatotropic viruses (EBV),a1 antithrypsin level and
autoimmune hepatitis (ASMA,AMA.anti LC-1) had failed to reveal any
kind of hepatic disease. Antinuclear antibodies were positive (1/320).
Liver elastography was normal.
The second case is a 15,5 years old girl who came to our department
with the diagnosis of autoimmune hepatitis (AIH).8 months earlier, la-
boratory exams done due to a persistent maculopapular rash of
hands and feets had revealed a significant increase of transaminase
levels (4fold above the upper normal limit). Based on positive sero-
logical markers (positive antinuclear, smooth muscles and anti liver
cytosol type 1 antibodies) the diagnosis of AIH had been considered
as most probable although liver biopsy was normal.
Results: On physical examination the first girl had malar rash and
arthritis of both knees and ankles. Blood examinations showed leuco-
penia (3370/μL),low C3 (32,3mg/dl),ANA positive (1/640),anti DNA
positive (254units) and mild proteinuria (120mg/24h).The diagnosis
of jSLE was set and treatment with hydroxychloroquine and steroids
was started. Transaminases level returned to normal quickly after the
initiation of treatment.
The second girl had on physical examination reticular peliosis, arth-
ritis of metatarsophalangeal joints and a papular rash of hands andfeet. Supplemental laboratory exams revealed low C3 and positive
anti Ro antibodies and Coombs test. JSLE was diagnosed while the
diagnosis of autoimmune hepatitis was considered as less probable
based on normal liver histology. She started hydroxychloquine and
prednisone leading to a complete resolution of hepatitis. Nine
months later, while receiving a low dose of steroids, she developed a
typical malar rash and nephritis with significant proteinuria and hy-
poalbuminemia. A renal biopsy showed early membranous nephritis.
Treatment with pulses of methylprednisolone followed by per os ste-
roids and azathioprine leaded to a complete resolution of symptoms.
Conclusion: A wide spectrum of liver disorders is associated with SLE
classified as liver parenchymal injury associated with SLE (“lupus hepati-
tis”),overlap syndromes with autoimmune liver disease and non-
autoimmune hepatopathy (drug induced, viral hepatitis, fatty liver,
thrombosis). Although abnormalities of liver function are not included
in the diagnostic criteria, hepatitis is frequently noticed at disease on-
set. The diagnosis of SLE should be kept on mind in every child who
presents with asymptomatic biochemical liver abnormalities (even if it
doesnot fulfill the diagnostic criteria) and proper clinical and laboratory
examination should be done towards this direction.
Informed consent to publish these case reports has been obtained
from the patients and their parents.
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Introduction: The association between systemic lupus erythematous
(SLE) and early onset atherosclerosis has been widely accepted. In
2006, childhood-onset SLE (cSLE) was included by the American
Heart Association and the American Academy of Pediatrics in the list
of pediatric diseases with an increased risk of cardiovascular diseases
(CVD). Carotid intima-media thickness (IMT) is frequently used as a
precocious marker to detect early subclinical atherosclerosis and to
identify higher risk patients.
Objectives: To assess early subclinical atherosclerosis in patients af-
fected by cSLE, and to investigate its possible correlation with dis-
ease related parameters and traditional cardiovascular risk factors
Methods: Patients with diagnosis of cSLE by ACR classification cri-
teria, followed at our center were included in the study. Demo-
graphic, clinical and laboratory features and therapeutic
interventions were retrospectively collected from clinical charts. In all
patients IMT of the distal 10mm of the far wall of common carotid ar-
tery was determined by ultrasonography with an highly automated
method (qIMT). Concurrently with carotid IMT measurement,
atherosclerosis-related biomarkers, such as plasma lipid levels and
blood pressure were measured, and an accurate evaluation of trad-
itional clinical CVD risk factors (smoke, exercise, familiar history of
CVD, renal disease and hypertension) was performed. The SLEDAI
was used to measure the disease activity. Correlation between ca-
rotid IMT and disease related parameters and traditional CVD risk fac-
tors was calculated by means of Spearman's test or Mann-Whitney U
test as appropriate.
Results: We present the preliminary data on 15 cSLE patients (12 fe-
males, 3 males) enrolled so far. The median age at time of IMT evalu-
ation was 15 years. The median SLEDAI was 7 at cSLE onset and 4 at
time of IMT evaluation. Median lipid and apolipoprotein plasma levels,
uric acid, and renal functional index were in range with age related ref-
erences. Measured carotid IMT values observed in our 12 patients were
in range with age and sex matched published values. In three patients
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onset and a short disease course (< 3 years). IMT values according to
ENA profile and treatment are shown in Table 1.
No traditional blood marker of dyslipidemia nor other disease re-
lated features nor therapeutic intervention were associated with
IMT in our cohort.
Conclusion: Carotid IMT is a non-invasive marker for subclinical athero-
sclerosis that should be considered in the follow up of cSLE patients.
Our data suggest that patients with short disease duration could be at
higher risk of having higher IMT values. The correlation with short dis-
ease duration may be due to the burden of the induction steroidal
therapy or to the effect of new onset uncontrolled disease. Our results
are preliminary from a small cohort and needed a further confirmation
in a larger prospective sample with a control group.
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negative/untreated positive/treated p-value
median (μ) IQR median (μ) IQR
Anti-SM 398 18 359 17 0,97
Anti-SSA/Ro 359 57 389 44 0,73
Anti-SSB/La 396 63 359 45,5 0,12
U1-RNP 398 18 342 20 0,0232
azathioprine 392,5 70,5 366 59 0,9
ciclophospamide 392,5 49,25 359 88,5 ns
idroxicloroquine 359 65 400,5 56,25 0,13P129
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Introduction: Drug induced-lupus erythematosus (DILE) is an auto-
immune disorder characterized by typical lupus-like symptoms in the
setting of drug exposure. Genetic factors, including differences in
drug metabolism and immunologic features, affect the risk of devel-
oping the disease. Recently, it was found that DILE might also be as-
sociated with epigenetics, since some drugs known to induce a
lupus-like phenotype inhibit DNA methylation.
Lamotrigine is used as an anticonvulsant and mood stabilizer drug.
Between 5 to 10% of the patients develop a skin reaction to the
drug, which, infrequently, can be life threatening, namely Stevens-
Johnson syndrome, DRESS syndrome and toxic epidermal necrolysis.
DILE associated with lamotrigine has been, very rarely, described.
Objectives: Describe a patient with lamotrigine-induced systemic
lupus erythematosus in order to improve our knowledge of the drugs
and phenotypes associated with DILE.
Methods: Clinical description of a patient with more than two years
of follow up.
Results: CASE DESCRIPTION: 17-year-old female, with panic and gen-
eralized anxiety disorders, treated with quetiapine, propranolol and
lamotrigine. The latter was started four days before the beginning of
the symptoms. The patient presented to the emergency room with a
three week history of daily fever, fatigue, odynofagia, arthralgias and
myalgias. On physical exam it was identified a non-pruritic diffuseerythematous maculopapular rash, vasculitic lesions on the fingers and
lips and vulvar edema. There were no manifestations of serositis or
neurological involvement. Alopecia, oral and nasal ulcers, organo-
megalies and arthritis were not detected. It was identified
leukopenia (3920/μL), lymphopenia (880/μL) and a slightly ele-
vated C-reactive protein (2.9mg/dL), with normal hemoglobine
and platelets count; serologies were negative for cytomegalovirus,
epstein barr, parvovirus, coxsakie, echovirus, herpes virus, Myco-
plasma pneumoniaeand Chlamydia. The patient was admitted to
the hospital and treatment with lamotrigine was immediately
stopped. There was a significant clinical improvement including
apirexia and regression of the maculopapular rash in less than 24
hours after withdrawal of the drug. Positive antinuclear antibodies
(1/80), positive anti-double stranded DNA (anti-dsDNA) antibodies
(50.5 UI/mL), positive anti-Ro (SSA) antibodies (163.2 UQ) and low
serum C3 (59 mg/dL) and C4 complement level (9 mg/dL) were
found; antibodies anti-histones were negative (<1.1 U/mL).
The patient remained asymptomatic for two years under therapy with
hydroxychloroquine (6.5mg/kg/day). C3 and C4 remained below nor-
mal ranges and anti-dsDNA antibodies persisted elevated. Recently, the
patient developed photosensitivity and had a new vasculitic rash on
the fingers, which improved with a short course of steroids.
Conclusion: We describe a rare case of lamotrigine DILE, who pre-
sented with a diffuse erythematous rash, leukopenia, lymphopenia,
low serum C3 and C4 and antinuclear and anti-dsDNA antibodies,
thereby fulfilling the SLICC criteria. The withdrawal of the drug was
essential for clinical improvement. In conclusion, DILE should always
be included in the differential diagnosis of a patient with systemic
lupus erythematosus and the medical community should be aware
of the drugs that might cause it. Drug withdrawal is a fundamental
step for a favourable outcome.
For this case submission written informed consent was obtained
from the patient and family.
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Introduction: The association of thrombotic thrombocytopenic pur-
pura (TTP) and systemic lupus erythematosus (SLE) is a rare entity and
usually occurs in advanced stages of SLE, here we present a case of a
female patient 5 years old with simultaneous diagnosis of systemic
lupus erythematosus and thrombotic thrombocytopenic purpura.
Objectives: Present the clinical case with diagnosis and treatment of
systemic lupus erythematosus and thrombotic thrombocytopenic
purpura in a pediatric patient.
Methods: Description of diagnosis and management of a case of
newly diagnosed SLE and PPT in pediátric patient.
Results: Women's 5 years previously healthy age with symptoms of
fever and arthritis 5 months of evolution, admitted to the institute by
the presence of generalized edema and decrese output urine, ele-
vated serum creatinine, proteinuria, metabolic acidosis and hyperten-
sion, presenting a rapidly progressive glomerulonephritis requiring
renal replacement therapy with hemodialysis, renal biopsy was per-
formed finding diffuse proliferative glomerulonephritis endocapillary,
class IV lupus nephritis and thrombotic microangiopathy and hyper-
tensive; The antibody profile denote ANA, antiDNA, anti B2-IgM
glycoprotein and anticoagulante lupic positiv. For a history of sei-
zures (7 days prior to admission) craneal MRI showed consistent data
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of arterial and venous flow in both kidneys was performed and re-
quired anticoagulation heparin infusion for 21 days.
She was presented persistent thrombocytopenia, elevated DHL, 1%
schistocytes peripheral smear and Ac IgG Anti ADAMS 13 positive
(activity normal limit) in addition to histological finding of renal bi-
opsy thrombotic microangiopathy integrated diagnostic thrombotic
thrombocytopenic purpura, was administered treatment with methyl-
prednisolone, gamma globulin, monthly cyclophosphamide, and
plasmapheresis every 48 hours (first sessions entirely with albumin
later albumin and plasma 1: 1), requiring 17 sessions, after which pre-
sented remission, with platelet count in 150,000, improvement of
renal function and neurological status.
Conclusion: The incidence of SLE and PTT is unclear, lower incidence
of 0.5% reported being more common in adult patients with pro-
longed evolution of SLE, it is difficult to establish the diagnosis be-
cause the two entities have laboratory findings in common, being
key finding schistocytes in peripheral blood smears, and antibodies
ADAMS 13.
There are no clear for the number of sessions of plasmapheresis pa-
tients requiring these guidelines, however The British Committee for
Standards in Hematology (BCHS) guidelines recommend continuing
the sessions at least two days after having a platelet count above
150.000, normal neurological status, hemoglobin levels and lactic de-
hydrogenase normal.
The diagnosis of thrombotic thrombocytopenic purpura in patients
with SLE is underdiagnosed, it´s essential to consider no matter the
time of diagnosis of SLE if there is presence of persistent
thrombocytopenia, neurological and kidney disease or histological
findings compatible with thrombotic microangiopathy. Informed con-
sent for publication has been obtained from the parent.
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Introduction: In the mechanisms of atherosclerotic arterial damage
and the formation of comorbid conditions in rheumatic diseases, in-
cluding systemic lupus erythematosus (SLE), many factors are involved,
both traditional and those that are induced by inflammation and dam-
age to the vessels by thrombosis and various kinds of antibodies.
Objectives: The aim was to study the relationship between the activ-
ity indices of the process (C-reactive protein (CRP), complement titer,
circulating immune complexes (CIC)) with lipid profile (total choles-
terol, triglycerides (TG), high-density lipoprotein cholesterol), the clot-
ting system (prothrombin index, fibrinogen) and the functional state
of the kidneys and liver (serum creatinine, glomerular filtration rate).
Methods: 35 children with SLE at the age of 7-18 years were examined,
of which 4 (11.4%) were boys and 31 (88.6%) were girls. The majority
(in 74.29%) patients was diagnosed with comorbid pathology. In the
structure of comorbid conditions, violations of the functional state of
the liver (in 40%) and kidneys (in 80%), pulmonary lesions (in 20%) and
hip joint prevailed (in 20.0%), as well as cardiovascular disorders (in 11
%). Changes in the lipid spectrum of atherogenic orientation and signs
of osteoporosis were recorded in half of patients (in 51.43% and in
50.0%, respectively), and changes in the coagulogram with signs of hy-
percoagulability occurred in 35.7% of the examined patients.
Results: In patients with SLE and comorbid conditions, an inverse
correlation was established between the values of CRP and the levelof complement (r = -0.477, p <0.05), the complement level was in-
versely correlated with the level of triglycerides (r = -0.744, p <0.05),
and triglyceride levels correlated closely with the level of circulating im-
mune complexes (r = 0.896, p <0.01), which confirms the interdepend-
ence of atherogenesis and immunocomplex inflammation.
The level of triglycerides of blood also had an inverse correlation
with the parameters of the glomerular filtration rate (r = -0.892, p
<0.05) and the straight line with serum creatinine (r = 0.834, p <0.05,
and transaminases, in particular with ALT (r = 0.848, p <0.05).
With the help of multiple regression analysis it was found that an in-
crease in the activity of the disease with an increase in the level of
circulating immune complexes in children suffering from SLE and co-
morbid conditions is accompanied by an increase in the level of total
cholesterol and triglycerides, a decrease in the complement titer,
which is represented by the equation:
CEC ¼ 1:44278þ 0:188976 OKS‐1:51503  complementþ 0:35388  TG
R ¼ 94:25%;R2 ¼ 90:02%; p < 0:01 :
Conclusion: Thus, changes in the lipid spectrum of atherogenic
orientation in patients with SLE of childhood not only take place
against the background of the disease, but also contribute to the de-
velopment of comorbid pathology
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Introduction: One of the important aspects in estimating the prog-
nosis of patients with systemic lupus erythematosus and creating op-
timal differentiated therapies for them is to identify potentially
irreversible lesions of various organs and systems.
Objectives: The purpose of the study was to determine the damage
index in children with systemic lupus erythematosus.
Methods: A total of 39 children with systemic lupus erythematosus
(SCL) aged 7-18 years were examined. The average duration of the
disease at the time of the survey was 45.8 ± 2.9 months. The diagno-
sis of SLE was based on the SLICC classification criteria (2012), an
adult rating scale (SLICC / ASR Damage Index) was used to assess the
damage index.
Results: In 46.2% of patients (18 people), PI was zero. The duration
of the disease at the time of examination of patients in this subgroup
was 45 ± 3.3 months. The remaining 21 patients (53.8%) had an IE of
1 to 4 points, i.e. there were signs of irreversible damage to certain
organs and systems, namely, the nervous, cardiovascular systems,
the lungs, the kidneys, the bone and muscle system, and the eyes.
The duration of the disease in these patients varied from 3 to 113
months, on average 47 ± 6.9 months.
In 15 cases the IP was equal to 1 point. These patients had an irre-
versible damage to the nervous (9 persons) and cardiovascular sys-
tems (1 person), as well as the kidneys (1 person) and lungs (4
people). In 5 patients, PI was 2 points due to irreversible damage to
the organ of vision (4 persons) and musculoskeletal system (1 child).
In one patient, the injury index was 4 points due to persistent dam-
age to the organ of vision as a cataract of both eyes and the nervous
system in the form of convulsive seizures requiring prolonged use of
anticonvulsants.
The most commonly damaged CKD was the damage to the nervous
system, which was observed in 25.6% of patients and in all cases was
represented by cognitive impairment, and only one patient had con-
vulsive seizures. In the second place, the frequency of occurrence
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 78 of 243was damage to the organ of vision (in 12.8% of patients). This kind
of damage was due to the presence of cataracts of both eyes. Some-
what less frequently, lung damage was detected (10.3% of the sub-
jects) in the form of pleural fibrosis according to the X-ray
examination. Irreversible damage to the kidneys, cardiovascular and
musculoskeletal systems was noted at the same frequency (2.6%).
Damage to the kidneys was represented by the development of
massive proteinuria, cardiovascular system - cardiomyopathy, and
damage to the musculoskeletal system is due to avascular necrosis
of the femoral head.
Conclusion: Thus, the obtained results testify to the expediency of
the use of PI in systemic lupus erythematosus in childhood in order
to clarify the nature and degree of damage to organs and systems,
which will allow timely correction of treatment.
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Introduction: The antiphospholipid syndrome (APS) is a multisystem
and autoimmune disease, which is mainly characterized by the pres-
ence of thrombotic events, gestational morbidity, in the presence of
high titers of antiphospholipid antibodies. It can present as a primary
entity, or secondary to another autoimmune disease. The under-
standing of this pathology is still evolving and even more in its pres-
entation in the pediatric patients. The presence of antiphospholipid
antibodies has been widely reported in pediatric patients with
thrombosis. APS is considered the most common acquired cause of a
prothrombotic state. At the moment, there are no reliable data of its
presentarion in pediatrics. The long-term morbidity and mortality as-
sociated with thrombosis events in pediatric population may be
minored by determining prognosis and select patients for prophylac-
tic treatment and more rigorous follow-up.
Objectives: To describe the clinical presentation and evolution, in
addition to laboratory findings, in Mexican pediatric population with
diagnosis of APS. Identified patients with arterial or venous throm-
bosis and its relation with laboratory findings. Describe epidemiology
of Mexican pediatric population with APS.
Methods: Retrospective cohort study of the Children’s Hospital of
Mexico Federico Gomez, last 10 years. We reviewed the data form
the clinical archives of the patients with diagnosis of APS according
to the Miyakis criteria, from 2007 to 2017. The variables analyzed in-
clude age at diagnosis, sex, subtype of APS, clinical finding of throm-
bosis, laboratory finding of antiphospholipid antibodies and
outcome.
Results: A total of 29 patients fulfil the diagnosis criteria of APS. The
mean age of patients at diagnostic was 9.8 years, with a minor age
at diagnosis of 2.2 years and a maximum of 16.4 years of age. Of the
total population 52% were females and 48% males. Primary APS was
diagnosed in 48%, of which 71% were males. Secondary APS was
present in 52% of the population, all diagnosed with Systemic Lupus
Erythematosus. Of the patients with secondary APS, 85% were fe-
male. Arterial thrombosis was present in 48% of the cases, primarily
in the group of secondary APS. Of the total cases 20% presents with
a second thrombosis event despite anticoagulant therapy, of this
66% were diagnosed with secondary APS. Lupus anticoagulant (LA)
was present in high titers in 93% of the patients, while anti-B2
glycoprotein-1 antibody IgG was present in 27% and IgM in 31%.Anticardiolipin antibody IgG was positive in 17% of the population,
while isotype IgM in 24%. All patients receive long term anticoagu-
lant therapy. One male patients, with secondary APS developed cata-
strophic APS. One patient required of amputation for deep venous
thrombosis, and another patient died as a complication of gastro-
intestinal thrombosis, both males with primary APS.
Conclusion: During a 10 year follow up, we diagnosed 29 patients
with APS. As reported in literature, a greater percentage of patients
are female and present with a secondary APS. Most patients with
primary APS are males. In our population, in contrast with what lit-
erature report, secondary APS presents with a greater percentage
of arterial thrombosis. The mayor site of venous thrombosis was
low extremities and of arterial thrombosis was cerebrovascular
events. The presence of positive LA implicates a higher risk of
thrombosis. Our pediatric population diagnosed with APS requires
of a close follow up in order to monitor anticoagulant therapy and
to prevent the patients from developing a second thrombotic event
that may lead to death.
Disclosure of Interest
None Declared
P134
SEVERE PULMONARY ARTERIAL HYPERTENSION AS THE INITIAL
MANIFESTATION OF SYSTEMIC LUPUS ERYTHEMATOSUS IN A 7-
YEAR-OLD MALE PATIENT: A CASE REPORT.
Maria T. Brana1, Luis A. Aparicio2, Sofía Osorio3, Enrique Faugier4, Andres
Rodriguez4, Rocio Maldonado4
1Pediatric Rheumatology; 2Hospital Infantil de Mexico, Federico Gomez,
Hospital Infantil de Mexico Federico Gomez; 3Hospital Infantil de Mexico,
Federico Gomez, Hospital Infantil de Mexico, Federico Gomez; 4Hospital
Infantil de Mexico, Federico Gomez, Hospital Infantil de México, Mexico,
Mexico
Correspondence: Maria T. Brana
Pediatric Rheumatology 2018, 16(Suppl 2):P134
Introduction: Pleural pulmonary manifestations in patients with sys-
temic lupus erythematosus are reported in approximately 5% of
cases. Presenting as pleural effusion, alveolar hemorrhage, diffuse
interstitial lung disease, pulmonary infections and pulmonary arterial
hypertension, among others, they are a manifestation difficult to
diagnosis. Pulmonary arterial hypertension is defined as a pressure
greater than or equal to 25mmHg. The world health organization has
classified pulmonary arterial hypertension into five categories, the
first group being associated with connective tissue disease such as
systemic lupus erythematosus. Pulmonary arterial hypertension is a
rare condition, usually occurring 3 to 5 years after the diagnosis of
systemic lupus erythematosus and conditioning a high risk of mor-
bidity and mortality. Initially, the majority of patients with SLE and
PAH are asymptomatic and as the disease progresses, they present
with progressive dyspnea, fatigue, intolerance, exercise, chest pain
and non-productive cough.
Objectives: We report the case of a 7-year-old male patient who pre-
sented with pulmonary arterial hypertension as the initial manifest-
ation of systemic lupus erythematosus.
Methods: Case report.
Results: Clinical case
A 7-year-old male patient who was admitted to the Pneumology De-
partment at Children's Hospital of Mexico Federico Gómez due to re-
spiratory distress. In emergency assessment, pulmonary arterial
hypertension of 66mmHg was identified, of unknown cause. The pa-
tient did not have significant medical background, having enjoyed of
good health up to 6 months prior to his admission. He presented
with a history of non-quantified fever, as well as episodes of fatigue
and dyspnea. Two months before admission, chest pain was added,
exacerbated with inspiration. On admission, transthoracic echocardi-
ography revealed severe dilatation of right cavities, moderate tricus-
pid insufficiency, with left ventricular ejection fraction of 56% and
arterial pulmonary pressure of 66mmHg. The diagnostic approach is
initiated. Due to a history of pulmonary tuberculosis in the patient
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node biopsy, ruling out the diagnosis. Infectious process causing the
manifestations was also ruled out. The patient was discharged with
medical treatment, requiring readmission in for 7 days, with facial
edema and in lower extremities, generalized pallor, asthenia, adyna-
mia and 4 days before a decrease in urinary volumes and frequency.
On admission, right heart failure, secondary to increase of pulmonary
hypertension for discontinuation of diuretic administration. A renal
biopsy was performed, which was reported as class IV lupus ne-
phropathy, with an index of activity and chronicity of 0. The diagno-
sis of systemic lupus erythematosus is integrated based on the ACR
criteria. Induction of remission of lupus nephropathy based on the
CARRA protocol. As treatment was administered the patient showed
important clinical improvement.
Conclusion: Pulmonary arterial hypertension is a rare condition, usu-
ally occurring 3 to 5 years after the diagnosis of systemic lupus ery-
thematosus. In pediatric population, it is reported as a lupus
complication in 5 to 14% of patients, and less than 1% as an initial
manifestation. It is a clinical complication that gives the patient a
high risk of morbidity and mortality. It is important to acknowledge
that pulmonary arterial hypertension can be the initial manifestation
of lupus in pediatric population. A prompt identification assures a
prompt treatment and a better prognosis. Informed consent to pub-
lish had been obtained from the parents.
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Introduction: Childhood-onset systemic lupus erythematosus (cSLE)
is a multisystemic, chronic autoimmune disease occurring in children
and adolescents under 18, presenting heterogeneously, with the
course of the disease often more severe than in adults, and the activ-
ity of the disease widely being evaluated by Systemic Lupus Erythe-
matosus Disease Activity Index (SLEDAI 2K) and damage by the
SLICC/ACR damage index (SDI).
Objectives: To compare and explore the correlation between the
SLEDAI-2K disease activity index at the time of diagnosis and the
SLICC/ACR damage index (SDI) of patients at their last follow up, to
examine the quantity of organ damage in regard to patients’ charac-
teristics and disease duration and to predict the risk of organ dam-
age occurrence in time.
Methods: The retrospective study included children treated for
cSLE in the period from January 1991 to September 2017 at De-
partment of Pediatrics, University Hospital Center Zagreb. The fol-
low up data of patients after the age of majority at 18 and who
were under care of the Department of Internal Medicine, Univer-
sity Hospital Center Zagreb was also included. All children were
diagnosed according to the ACR 1997 and SLICC 2012 criteria.
Data analysis was done using R environment for statistical
computing.Results: The disease development of 93 children (74 females and 19
males) with cSLE was examined in this study. The median (range) fol-
low up time was 7 (0.5-24) years and the median (range) age at diagno-
sis was 13 (5-19) years. Two patients have died during the examined
period. Mean (SD) SLEDAI-2K was 18.3 (9.0) at the disease onset. 35 chil-
dren (38 %) had organ damage at the last follow up with the median
(range) SDI 0 (0-7). The first organ systems damaged in affected pa-
tients were renal (28%), musculoskeletal (22%), ocular (19%), neuro-
psychiatric (17%), cardiovascular (11%) and peripheral vascular (2.8%),
but with no significant statistical difference regarding the type of organ
damage. Kendall rank correlation coefficient was used to evaluate the
relationship between SLEDAI-2K at the disease onset and SDI, deter-
mining a positive correlation which was statistically significant (τb =
0.252, p = 0.003). However, no significant correlation was determined
between the duration of the disease and SDI (τb = 0.042, p = 0.628) or
follow up period and SDI (τb = 0.111, p = 0.191) nor was there signifi-
cant difference of SDI in regard to gender (Asymptotic Wilcoxon-Mann-
Whitney Test, p= 0.574). Using Kaplan-Meier method we estimated the
decrease in ratio of patients without organ damage since diagnosis or
the occurrence of the first symptoms. Since the estimated ratio of pa-
tients with organ damage at the endpoint was less than 50%, we could
not estimate the time required for damage development in 50% of pa-
tients. However, we are 95% sure that the damage is not happening in
the first 9 or 10 years after diagnosis or the occurrence of the first
symptoms, respectively.
Conclusion: The high correlation detected between SLEDAI-2K and
SDI indicated that the presentation of the cSLE at onset can be prog-
nostic of the course and long-term prognosis of lupus. Our findings
suggest that it is unlikely that organ damage will occur in 50% of pa-
tients in the first nine years of the disease course.
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Introduction: A seventeen-year-old boy was admitted to our Hospital
after an episode of lipothimia, followed by dyspnea and tachycardia
with prolabial cyanosis.
The patient was in a follow-up program for an anti-DNAse2 defi-
ciency syndrome (Rodero et al., Nat Commun, 2017): a newly de-
scribed, auto-inflammatory genetic disorder with significant overlap
with systemic lupus erythematous.
His past medical history was characterized by the presence of neo-
natal hepatopathy, cytopenia, recurrent fever, polyarticular arthritis,
chronic glomerulonephritis, lipodystrophy, lupus pernio and growth
retardation. The diagnosis of anti-DNAse2 deficiency was made at
the age of 14 by whole exome sequencing and was suggested by
the high value of the interferon signature that highlighted the piv-
otal pathogenetic role of type 1 interferon.
This clinical picture progressively worsened despite several thera-
peutic trials with glucocorticoids, immunosuppressant and biological
agents. Therefore, a trial treatment with two antimalarials (hydrossi-
chloroquine and mepacrine) and ruxolitinib was started, together
with abatacept: this treatment had led in the previous months to an
overall improvement of his symptoms and a reduction of the gluco-
corticoids dosage.
Objectives: At admission, clinical and instrumental evaluation
showed a severe pulmonary hypertension (PAH) with a mean pul-
monary pressure of 77 mmHg and a severe dysfunction of his right
cardiac chambers. A drug adverse effect was considered and all the
treatments were discontinued. Considering the possibility that PAH
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SLE, steroid boluses were administered. Moreover, a vasodilatant
therapy with iloprost, ambrisentan, sildenafil and diuretics was
started. During the hospital course he developed a severe pancyto-
penia (Hb 10 g/dl, WBC 1020/mmc, PLT 20.000/mmc). Hemophagocy-
tic Limphohistiocytosis (HLH) and malignancy were ruled after
performing a bone marrow aspiration, showing an hypocellular bone
marrow. A viral infection was also excluded.
Methods: Given the poor response to corticosteroids, ruxolitinib was
then reintroduced at higher doses than previously administered (10
mg twice daily), based on the previous benefits and on the anecdotal
evidence of efficacy in PAH.
Results: A dramatic improvement of his pulmonary pressures was
noted, more successful than expected with only vasodilatant ther-
apy, with an estimated pulmonary pressure at discharge of 35
mmHg.
His cardiologic follow-up showed a slow but progressive im-
provement of PAH so far; the symptoms related to his basal
condition also improved. Ruxolitinib was maintained at the dose
of 7.5mg BID. No other adverse event was noticed a part from a
moderate title elevation of BK virus in the urine and a transient
herpes zoster infection that rapidly healed with acyclovir
therapy.
Conclusion: We therefore concluded that specific therapies for gen-
etically determined conditions are double-edged with the need of
carefully balancing efficacy with potential adverse events. Great cau-
tion should be taken in particular with JAK inhibitors as an abrupt
stop of treatment may associate with severe inflammatory rebound.
Informed consent to publish had been obtained.
Trial registration identifying number: This work was funded by
IRCCS Burlo Garofolo grant RC24/17 anf Telethon Foundation grant
GGP15241.
Disclosure of Interest
None Declared
P137
EVALUATION OF CHOROIDAL THICKNESS AND PERIPAPILLARY
RETINAL NERVE FIBER LAYER IN PATIENTS WITH JUVENILE
SYSTEMIC LUPUS ERYTHEMATOSUS
Selcan Demir1, Abdullah Ağın2, Ata Baytaroğlu2, Hafize E. Sönmez1, Erdal
Sağ1, Yelda Bilginer1, Sibel Kadayıfçılar2, Bora Eldem2, Seza Özen1
1Department of Peditarics, Division of Rheumatology; 2Opthalmology
Departmant, Hacettepe University Faculty of Medicine, Ankara, Turkey
Correspondence: Selcan Demir
Pediatric Rheumatology 2018, 16(Suppl 2):P137
Introduction: Systemic lupus erythematosus (SLE) is an autoimmune
disease that involves multiple organs, including ocular involvement.
Objectives: This study aims to evaluate choroidal thickness and
peripapillary retinal nerve fiber layer in patients with juvenile SLE
(jSLE).
Methods: We have included all jSLE patients (n=21) diagnosed accord-
ing to Systemic Lupus International Collaborating Clinics classification
criteria between January 2017 and April 2017 and age sex-matched
control group (n=21). The SLE disease activity index (SLEDAI) was used
to assess disease activity. After routine eye examinations, choroidal
thickness (ChT) in five points (750 and 1500 microns from the center of
the fovea both in the temporal, nasal quadrant and under the fovea),
presence of subretinal and/or intraretinal fluid, retinal nerve fiber layer
thickness of optic disc (RNFL) were evaluated.
Results: In ophthalmologic evaluation, only one patient was active
[SLEDAI 2 (1-4)]. One patient had episcleritis, one patient had
corticosteroid-induced cataract and glaucoma. Median age was 3,5
years (1-8,5 years), despite the use of hydroxychloroquine retinal pig-
mentation or visual field defects were absent in patients. There was a
significant increase in ChT at 5 points, but RNFL thicknesses were
similar compared to healthy controls in jSLE patients. When therelationship between OCT findings and other variables were evalu-
ated, a significant negative correlation was found between the initial
creatinine values and the ChT. Intraretinal or subretinal fluid were
not present in any of the patients.
Conclusion: The results of our study suggest that increased ChT is re-
lated to mononuclear cell infiltration, immune complex accumulation,
autoantibodies against retinal pigmentation or some vascular mech-
anism in jSLE patients.
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Introduction: Systemic Lupus Erythematosus (SLE) is a rare, chronic,
systemic disease with juvenile onset occurring in 10 to 20% of cases.
Its variety of clinical presentations with an unpredictable relapsing-
remitting course can make it a challenging illness to diagnose and
deal with throughout childhood.
Objectives: The aim of this study was to evaluate educational, pro-
fessional and family outcome along with quality of life appreciation
in a cohort of pediatric SLE (SLEp) patients, fields for which data is
still scarce.
Methods: This multi-center study included all 65 SLEp patients from
the PedOLup unit (JIR cohort) of two french centers, Lyon (Hôpital
Femme Mère Enfant, Centre Hospitalier Lyon Sud) and Lille (Hôpital
Claude Huriez). Data regarding clinical presentation, education, em-
ployment, personal family outcome and quality of life were obtained
from the PedOLup database and completed with medical records
and oral interview.
Results: 75,4% of our patients had visceral involvement with a
mean disease duration of 13,6 years. Disease activity and damage
scores (SLEDAI and SDI) were low at the time of the study (me-
dian of 0). The proportion of graduates in those over 25 years of
age was similar to national references and 87,3% of patients were
presently either employed of following a study course. Half of
those over 20 lived as a couple and 34% of them had children
with a mean number of person per household comparable to
French references. There seemed to be little difference when
comparing quality of life in our patients to a healthy French ref-
erence population.
Conclusion: Despite the severity of juvenile forms of SLE on diag-
nosis, long term social and professional outcome of patients
followed in this cohort seems satisfying. However, this study
points out elements of precarity in the field of employment
opening the way for thinking about work support and
accommodation.
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Table 1 (abstract P141). Demographic information and cardiovascular
manifestations in a paediatric SLE cohort from South Africa
Demographic/Disease
Manifestation
% All patients
(N=93)
% Patients with
cardiovascular
involvement (N=44)
% Patients who had
echocardiography
(N=23)
Female (%, N) 83 (77) 84 (37)
Median age of
diagnosis (SD)
12 (3.4) 11 (3.5)
African ancestry (%, N) 91 (85) 91 (40)
Any cardiovascular
manifestation (%, N)
47 (44) 100 (44)
Pericardial
effusion (%, N)
26 (24) 55 (24)
Stroke (%, N) 8 (7) 16 (7)
Cardiac failure (%, N) 9 (8) 18 (8)
Left ventricular
hypertrophy (%, N)
– 20 (9) 39 (9)
Mortality (%, N) 10 (9) 20 (9)
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Introduction: The presence of immunologic markers (autoantibodies,
hypocomplementemia or a positive direct Coombs test) are key features
in the Systemic Lupus International Collaborating Clinics (SLICC) criteria
for the classification of Juvenile Systemic Lupus Erythematosus (jSLE).
Objectives: The authors present a case of a female adolescent with
sickle cell disease and lupus nephritis with a severe presentation and
without any serologic markers to corroborate the diagnosis.
Methods: A 14-year-old female with Sickle Cell Disease (SCD), born
and living in Angola until 3 days before admission, was hospitalized
in the past 3 months due to a nephrotic syndrome, complicated with
pneumonia with empyema, arterial hypertension, seizures and exac-
erbations of the SCD requiring frequent red blood cell transfusions
and long term corticosteroids.
Results: The patient arrived to Portugal for further investigation and was
admitted in the Paediatric Intensive Care Unit with respiratory deterior-
ation due to a pyopneumothorax, requiring thoracentesis and intravenous
antibiotics. At D13 of hospitalization she presented seizures and neuro-
logical deterioration. The magnetic resonance imaging performed was
suggestive of a posterior reversible encephalopathy syndrome. The renal
biopsy revealed a proliferative glomerulonephritis with mesangial and ca-
pillary deposition of several types of immune complexes, mainly IgG, also
known as “full-house” immunofluorescence pattern, highly suggestive of a
class III lupus nephritis. The laboratory results were inconsistent with the
diagnosis of jSLE – negative autoantibodies, mild elevation of complement
and a negative direct Coombs test. Treatment with mycophenolate mofetil
and prednisolone was started in order to induce remission of lupus neph-
ritis, having attained a clinical remission (without proteinuria, normal renal
function and normal blood pressure) in one week.
Conclusion: In jSLE, renal involvement compromises the prognosis with
significant morbidity and mortality. Few cases of lupus nephritis without
serologic markers have been described to date. The literature reports
two main presentations of seronegative lupus nephritis: one with a life-
long seronegativity, either with renal-limited or extra-renal manifesta-
tions; other with a serologic conversion, latter in the course of the
disease. The authors hypothesized if the diagnosis of sickle cell disease
and previous corticotherapy are related with this atypical presentation.
Regardless of the clinical picture, a prompt and accurate treatment
should not be delayed. This is an example of how an association of two
complex diseases can present an hard treatment challenge. Informed
consent to publish had been obtained from the parent.
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associated with a high rate of major organ involvement, and patients
of African ancestry tend to develop more aggressive SLE than those of
Caucasian descent. A particularly severe disease phenotype has been
described in this multi-ethnic South African cohort of children with SLE.
Although cardiovascular involvement appears to be common in paedi-
atric SLE, there are few published reports on the subject and none have
been conducted in an African paediatric SLE population.
Objectives: This study aims to describe the frequency and character-
istics of cardiovascular manifestations of paediatric SLE in a multi-
ethnic South African cohort.
Methods: Demographic, clinical, and echocardiographic data were
collected from paediatric SLE patients at 2 centres in Cape Town,
South Africa. At the time of investigation, this cohort consisted of 93
participants diagnosed with SLE according to the Systemic Lupus
International Collaborating Clinics (SLICC) or 1997 American College
of Rheumatology (ACR) SLE criteria, prior to the age of 19 years. Indi-
viduals with cardiovascular involvement were identified by retrospect-
ive chart review. Cardiovascular involvement was defined as presence
of: pericardial effusion, myocarditis, cardiomyopathy, cardiac failure,
Libman-Sacks endocarditis, myocardial infarction, deep vein throm-
bosis, pulmonary embolism, sinus thrombosis, stroke, arrhythmia, cen-
tral nervous system vasculitis, or other vasculitis. Echocardiographic
data were included in the analysis, when available. Statistical analysis
was performed with R software package version 3.4.1.
Results: Cardiovascular involvement was present in a total of 44 par-
ticipants, or 47% of the PULSE cohort (Table 1.) This is much higher
than previously published reports of 3-32%. Those with cardiovascu-
lar involvement did not differ significantly in gender, age at diagno-
sis, or race/ethnicity from the overall cohort. Echocardiographic data
were available for 23 of these participants. The most common cardio-
vascular manifestation observed in this cohort was pericardial effu-
sion (n=24), followed by cardiac failure (n=8) and stroke (n=7).
Cardiovascular manifestations were frequently severe, with one third
of cases of pericardial effusion requiring intervention, and 3 patients
presenting with cardiac tamponade. Mortality was high in patients
with cardiovascular involvement, at a rate of 20.5%.
Conclusion: Cardiovascular involvement was found to be common in
this multi-ethnic cohort of South African children with SLE, with pericar-
dial effusion being the commonest cardiovascular manifestation. The
mortality rate was high, and severe cardiovascular manifestations includ-
ing stroke and cardiac tamponade were frequent. Prospective research
is required to identify risk factors for cardiovascular involvement, in order
to inform practice and improve outcomes for this high-risk population.
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Introduction: Treatment patterns of non-renal and non-neuropsychiatric
systemic lupus erythematosus (non-renal, non-NP SLE) in Germany are
not well understood and formal treatment recommendations do not
exist, unlike for patients with severe lupus nephritis or neuropsychiatric
SLE.
Objectives: To assess treatment preferences for patients with non-
renal, non-NP SLE among German pediatric rheumatologists.
Methods: We designed an online survey including a generic case
scenario of a patient with moderate juvenile non-renal, non-NP SLE
and one main disease manifestation based on the premise that treat-
ment of SLE is typically dictated by the most severe organ involve-
ment. One question targeted general management of patients with
non-renal, non-NP SLE. Then, overall, 21 manifestations of SLE were
queried, ranging from constitutional symptoms to various organ-
related, and laboratory manifestations and from mild to severe. Re-
sponses were given via multiple choice, including various pharmaco-
logic treatment options: non-steroidal anti-inflammatory drugs,
various disease-modifying antirheumatic drugs, biologics, i.v. immune
globulins and anticoagulants. Descriptive statistics are used to report
the findings.
Results: Forty-seven pediatric rheumatologists experienced in the
management of SLE responded. There is consensus that all pa-
tients with non-renal, non-NP SLE should receive hydroxychloro-
quin (97% or respondents), should be counseled about important
preventive measures, including sun protection, contraception,
avoiding smoking (100%), that vaccinations should be kept up-to-
date (91%) and that vitamin D should be considered (25% in all
patients, 25% only in case of glucocorticoid therapy and 47% ac-
cording to blood levels). Regarding pharmacologic management
of the different manifestations, there was overall marked variabil-
ity. For some life-threatening manifestations (myo-/pericarditis
with tamponade, pulmonary hemorrhage and mesenteric vascu-
litis), the majority of respondents opted for high-dose glucocorticoid
therapy and intensive immunosuppression with mycophenolate mofetil
or cyclophosphamide, similar to what is often used in severe
lupus nephritis. The preferences for different glucocorticoid regi-
mens were especially variable, for example, ranging from none to
high-dose for constitutional symptoms or fatigue. Methotrexate
was preferred for various musculoskeletal manifestations whereas
azathioprin was preferred for cutaneous and hematologic
manifestations.
Conclusion: Treatment preferences for non-renal, non-NP SLE in
Germany among pediatric rheumatologists are markedly variable.
There is consensus that all patients with non-renal, non-NP SLE
should receive hydroxychloroquin, be counseled regarding prevent-
ive measures, that vaccinations should be up-to-date and vitamin D
substitution be considered. Data obtained with this survey may be
helpful in developing consensus-based strategies for the manage-
ment of non-renal, non-NP SLE.
Disclosure of Interest
None DeclaredP143
TREATMENT OUTCOME IN CHILDHOOD LUPUS NEPHRITIS
PATIENTS TREATED WITH MYCOPHENOLATE MOFETIL: REAL-
WORLD DATA IN COMPARISON WITH ADULT LUPUS NEPHRITIS
Seung Min Jung1, Hye Won Kim2, Hyun-Sook Kim3, Yong-Beom Park1
1Yonsei University College of Medicine, Seoul; 2Seoul National University
Bundang Hospital, Seongnam; 3Soonchunhyang University Seoul
Hospital, Seoul, Korea, Republic Of
Correspondence: Seung Min Jung
Pediatric Rheumatology 2018, 16(Suppl 2):P143
Introduction: Childhood-onset systemic lupus erythematosus is a
rare and severe autoimmune disease with a high prevalence of lupus
nephritis (LN). Although there is a growing interest on treatment
with mycophenolate mofetil (MMF) in LN, data on treatment out-
come in childhood LN is limited.
Objectives: This study aimed to evaluate the therapeutic outcome of
MMF in childhood LN from a real-world clinical practice, and com-
pare the clinical characteristics with adult LN.
Methods: Korean pediatric and adult patients with pathologically
proven LN class III, IV, and V were recruited from rheumatology clinic
in Severance Hospital, Yonsei University College of Medicine between
Nov 2011 and Aug 2017. Patients who treated with MMF for at least
3 months were included in the analysis. The probability of remission
after MMF therapy, and the difference between pediatric patients
and adult patients were analyzed using the survival analysis and the
descriptive statistics.
Results: Of 153 patients with pathologically proven LN class III, IV,
and V, 16 pediatric patients and 100 adult patients were included in
this study. Pediatric patients showed a more preserved renal func-
tion, and adult patients had a higher prevalence of LN class IV. Mean
protein/creatinine ratio in spot urine was 3.7 and 4.8 in childhood LN
and adult LN, respectively. However, the baseline characteristics
showed no statistically significant difference between childhood and
adult. During median follow-up period of 5 years (childhood 7.5 years
vs. adult 4.7 years), 75 % of pediatric patients and 77% adult patients
achieved clinical remission of LN after MMF treatment. Median time
to remission after initiation of MMF was shorter in pediatric patients
(4.3 months vs 7 months), although statistically insignificant. Risk fac-
tors for failure of remission in pediatric patients were nephrotic-
range proteinuria and seronegativity of anti-dsDNA antibodies,
whereas impaired renal function was also important for predicting
remission failure in adult LN.
Conclusion: This study shows the real-world data on MMF treatment
in childhood LN and adult LN. In childhood LN, MMF has a good
therapeutic effect, similar to adult LN.
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Introduction: Blau syndrome (BS) is a rare auto inflammatory
granulomatous disorder, characterized by a clinical triad of recur-
rent uveitis, arthritis and dermatitis. It is a dominantly inherited
condition due to mutation in the pattern recognition receptor of
NOD gene. No therapeutic trials have been conducted in Blau
syndrome and only limited case reports regarding treatment are
available
Objectives: The aim of this study is to report the first Arab patient
with BS who was refractory was conventional therapy but had rapid
quiescence after using Tocilizumab. We also conducted a systematic
literature review about biologic treatments in BS.
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 83 of 243Methods: A 3.5 year old boy was referred at the age of 8 month for
evaluation of intermittent fever, rash and polyarthritis that started at
the age of 2 months. He also had a granulomatous panuveitis with pos-
terior synchia and lens cataract. Skin biopsy revealed non-caseating
epitheloid granuloma. DNA analysis identified a heterogenous missense
mutation in exon 4 of the NOD2 gene. Over the course of years, patient
had a difficulty stormy course with severe polyarthritis that was refrac-
tory to conventional treatment including pulses of methlypredni-
slone, oral prednisolone, methotrexate, adalimumab and infliximab.
Tocilizumab 12mg/kg every 2 week was introduced 8 months ago with
rapid improvement of arthritis with ability to taper oral prednisolone to
2mg/day. Serum Amyloid levels dropped from 246 mg/L to >6.4 within
3 months. Further attempts to decrease the dose or interval of Toci-
lizumab infusions were unsuccessful.
Results: On literature review, we identified 32 cases of Blau syn-
drome that were treated with biologic agents; Etanercept (13), Inflixi-
mab (14), Adalimumab (10), Anakinra (3), Canakiumab (2),
Tocilizumab (3), Abatacept (1). The clinical characteristics and treat-
ment outcome are shown in Table 1 (table could not be inserted due
to limitations in number of rows)
Conclusion: There is wide diversity in the clinical phenotype of Blau
syndrome in terms of age of onset, clinical presentation, disease se-
verity and response to treatment which may be related to functional
difference in NOD 2 mutation. Informed consent to publish had been
obtained.
Trial registration identifying number: not applicable
Disclosure of Interest
None Declared
P145
CHRONIC RECURRENT MULTIFOCAL OSTEOMYELITIS: SINGLE
CENTER EXPERIENCE
Ceyhun Acari1, Hatice Adiguzel Dundar1, Serkan Türkuçar1, Balahan
Makay2, Erbil Ünsal1
1Department of Pediatrics, Pediatric Rheumatology Unit, Dokuz Eylul
University, Faculty of Medicine; 2Pediatric Rheumatology Unit, Dr. Behcet
Uz Children's Hospital, Izmir, Turkey
Correspondence: Ceyhun Acari
Pediatric Rheumatology 2018, 16(Suppl 2):P145
Introduction: Chronic recurrent multifocal osteomyelitis (CRMO) is an
autoinflammatory bone disease that is characterized by sterile bone
lesions. 500 CRMO cases are reported as individual cases or case
series in the literature.
Objectives: In this study, we aim to share our clinical experience of
10 pediatric patients with CRMO.
Methods: The files of patients were retrospectively reviewed by
pediatric rheumatologist. The cases were analyzed to define symptoms
at onset, clinical findings, laboratory parameters and imaging results.
Patients were re-evaluated according to CRMO diagnostic criteria.
Results: The mean age of cases was 8.7 years (min:3, max: 13) at
diagnosis and 7 patients were male and the others were female. The
mean lack time for diagnosis was 8.8 months (min:2, max:24). The
mean follow-up of cases was 45.1 months. Magnetic resonance im-
aging (MRI) in all patients and bone scintigraphy in 9 patients were
performed. The diagnosis of 9 cases were confirmed by histopatho-
logical examination. Two of the cases were brothers. Other diagnoses
were Familial Mediterranean fever in two cases, nephrolithiasis in
one case and keratite-bound corneal ulcer in one case. At the time
of admission, all patients were suffering from pain of bone and/or
joint and showed multifocal involvement such as femur (7 cases),
pelvic bones (5), tibia (4), clavicle (2), vertebra (2), ankle (2) and man-
dible (1). In laboratory results, C-reactive protein level was found as
elevated (18.7 mg/L [1.8-78]; mean erythrocyte sedimentation rate
was found as elevated (51 mm/h [15-119]. Sulfasalazine and nonste-
roid antiinflammatory drugs were used in all cases and methotrexate
was added in 6 cases. Three cases required steroid treatment. Resist-
ant cases needed anti-TNF (etanercept or adalimumab) in two pa-
tients and IV pamidronate in one patient. The mean time ofremission was 19.25 months (min: 6, max:48). Currently, three pa-
tients are in remission without medication, and five patients are in
remission with medication.
Conclusion: Chronic recurrent multifocal osteomyelitis (CRMO) is a rare
idiopathic inflammatory disease that affects usually children and young
adults. Clinical signs and symptoms are nonspecific and usually the
diagnosis is delayed. Diagnosis is based on excluding infections espe-
cially osteomyelitis and malignant diseases. Mostly, metaphyseal-
diaphyseal region of long bones such as the femur and tibia are in-
volved, Laboratory tests show a mild to moderate acute phase eleva-
tion. Nonsteroids are used as the first step in the treatment, but usually
sulfasalazine or methotrexate is added, particularly with vertebral in-
volvement. Anti-TNF agents may be effective in patients those unre-
sponsive to conventional treatments and frequent relapses. In recent
years, bisphosphonate (pamidronate) is used as an effective and safe
agent for the treatment of bone lesions, as well as pain control.
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Introduction: Familial Mediterranean fever (FMF) is the most com-
mon autoinflammatory disease with autosomal recessive inheritance.
There is MEFV gene mutation encoding the pyrine protein in the
short arm of chromosome 16 that leads to overexpression of IL-1.
The basic treatment in FMF has been colchicine since 1972. Colchi-
cine is effective both in the prevention and treatment of attacks, and
in reducing the frequency of amyloidosis. However, there is resist-
ance to colchicine in 5-10% of FMF cases, and anti interleukin-1 (anti
IL-1) is effective in these cases.
Objectives: In this study, we aimed to find out possible risk factors for
colchicine resistance in FMF by comparing the clinical and demo-
graphic data of patients with and without colchicine resistance, and to
examine anti IL-1 effectiveness in patients with colchicine resistance
Methods: Data charts of children with FMF from Dokuz Eylul Univer-
sity childrens’ hospital and Dr.B.Uz childrens’ hospital (n=950) were
reviewed. Despite the use of adequate doses of colchicine, the pa-
tients with over 3 attacks in last 6 months were considered to be col-
chicine resistant. Then, colchicine resistant patients were compared
with colchicine responsive group.
Results: Thirty four (3.6%) of 951 patients had colchicine resistance and
all of them used anti IL-1 (canakinumab). 67.7% of these patients were
male and 47.1% had positive family history. Median age of symptoms
onset was 40 (24-75) months, median age of diagnosis and colchicine
onset were 72 (43-115) months. Median diagnosis delay time was 12
(9-47) months and median time of follow-up was 52 (33-99) months.
There was not statistically difference between the 2 groups. Most com-
mon symptoms were fever, abdominal pain and musculoskeletal symp-
toms in both groups, while fever (85.3%), arthralgia (53%), arthritis
(41.2%) were significantly higher in group with colchicine resistance
when compared with other group (p:0.032, p:0.048 and p:0.001 respect-
ively) Other frequent symptoms were myalgia, chest pain and erysip-
elas like rash in both of groups. The number of attacks in last 6 months
after colchicine treatment was statistically higher in group of colchicine
resistance than in other group (median numbers of attack: 6(3-10)
(p:0,000). Colchicine resistant group response to canakinumab was
good; the median number of attacks was 1(0-2) in the last year
When the groups were compared in terms of FMF gene mutation,
exon 10 mutation was 88.2% positive in-group of colchicine
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 84 of 243resistance, while 67.7% in other group. M694V mutation was also sig-
nificantly higher when compared with other group (85.3% and 50.2%
respectively) (p:0.000).
All patients with colchicine resistance responded the canakinumab
treatment except one who had enthesitis related arthritis. There was
pneumonia in one patient, urinary tract infection in 2 patients, recur-
rent upper respiratory tract infection in 2 patients after canakinumab
treatment. No serious side effects were reported in the patients that
use canakinumab.
Conclusion: Colchicine is still best treatment in FMF. 96.4% of our
cases responded to colchicine. In cases with colchicine resistance, IL-
1 inhibition was successful. Resistant cases had specific features. Male
dominance, exon 10 with M694V mutation and arthritis constituted
the major properties of this group.
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Introduction: Familial cold auto-inflammatory syndrome-2 (FCAS-2) is
an autosomal dominant disorder due to the NLRP12 mutation which
plays a role in the regulation of proinflammatory cytokines. It is char-
acterized by fever, headache, joint symptoms, urticarial rash that is
triggered by cold; usually starting in early infancy. Episodes are gen-
erally last for 5-10 days. It can also be accompanied by conjunctivitis,
hearing loss and myalgia.
Objectives: Presenting a familial cold auto-inflammatory syndrome
case with atypical presentation.
Methods: Case presentation.
Results: A 17-year-old girl presented to outpatient clinic with re-
current arthritis, urticarial rash for 6 years. She had no accom-
panying fever in any of the episodes. The frequency of attacks
increased in last 2 years, often lasting for 10 days, which were
unresponsive to NSAIDs. Attacks were triggered irrelevant from
cold exposure. She also had clinical diagnosis of mature onset
diabetes in young (MODY), and autoimmune thyroiditis. On phys-
ical examination, she had arthritis and urticarial rash on left
ankle. Acute phase reactants were increased. FMF was the initial
diagnosis, however no mutation was found in MEFV gene se-
quencing. Auto-inflammatory next generation sequencing (NGS)
panel demonstrated NLRP-12 gene mutation (p.Arg352Cys) com-
patible with FCAS-2. Colchicine treatment (1.5 mg/day) was able
to provide disease control.
Conclusion: Familial cold auto-inflammatory syndrome (FCAS) is
characterized by recurrent attacks of cold-triggered fever, arthritis
and urticarial rash mostly starting in infancy. This case differs from
the classical pattern by old age, and it seems fever is not always one
of the presenting symptoms. Informed consent to publish had been
obtained from the parent.
Trial registration identifying number: Note: Followings case report
contains a method which in our thought is not appropriate in a case
report abstract. Hence, the method was depicted as “case presenta-
tion”. If committee have any suggestion in following days it could be
changed accordingly.
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Introduction: Abscesses Aseptic (AA) syndrome is an autoinflamma-
tory disorder mostly reported in adult, of unknown etiology charac-
terized by occurrence of fever, AA and elevated acute phase
reactants. It responds to steroid treatment. It is either associated with
inflammatory diseases, such as Crohn's disease or relapsing poly-
chondritis, or as « idiopathic ». Pediatric-onset AA has been reported
in only 8 patients and never in association with JIA.
Objectives: To report the association of JIA and muscle AA.
Methods: we retrospectively analyzed the medical notes from pa-
tients followed in two pediatric departments from the French FAI2R
network for rare autoimmune and autoinflammatory diseases who
presented both Juvenile Idiopathic Arthritis and multiple aseptic
muscle abscesses. Patients had been included in the CEMARA plat-
form for rare diseases, which benefits from an agreement from the
French Commission Nationale Informatique et Liberté. According to
the French legislation, no ethics committee agreement was re-
quested for such a retrospective, observational survey.
Results: We identified 3 male patients diagnosed with JIA between
the age of 4 and 5 years. Patient 1 had systemic-onset with spiking
fever, polyarthritis, myalgia, pericarditis; patient 2 had a seronegative
polyarticular JIA; patient 3 had Rhumatoid Factor and ANA positive
polyarticular JIA. There was no familial anamnesis of interest and the
3 patients were born from unrelated parents. Biological inflammation
was present at in all cases with CRP > 70mg/L at diagnosis. Muscle
abscesses developed 4, 30 and 48 months respectively after the diag-
nosis of JIA. At this time, patient 1 was on oral steroids, patient 2 on
remission off treatment and patient 3 on oral steroids and subcuta-
neous etarnercept. Abscesses were revealed by painful tumefactions,
associated with fever, flare of polyarthritis and an elevation of CRP.
Ultrasound and MRI revealed a collection consistent with abscess in
the biceps (patients 1 and 2) or the mesogluteus muscles (Patient 3).
Corticosteroids and biologics were stopped and surgical drainage
was performed in patient 1 and 2, showing an exudate of poly-
morphonuclear neutrophils. An extensive microbiological screen for
bacteria, fungi and mycobacteria was negative in both cases. We also
ruled out in the 3 patients chronic granulomatous disease as well
as XIAP and PSTPIP1 mutations. In the 3 patients after 7 to 10 days
on large spectrum of antibiotic treatment with no effect on lesions
nor on the CRP level, steroid 1 to 2mg/kg/day were re-introduced or
initiated, which was associated with quick improvement and a
complete resolution of symptoms within 5 to 10 days. After tapering
the dose of steroid, patient 1 developed a relapsing-remitting course,
with recurrent biceps muscle abscesses that responded each time to
increase of the steroid dosage. After 4 to 5 years from the onset of
abscesses and the failure of several treatments including, in 2 cases
the interleukin (IL)-1 receptor antagonist anakinra, all 3 patients were
put on the anti-IL-6 receptor antibody tocilizumab and achieved re-
mission that persisted, off steroid at the latest follow-up, 10 to 12
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 85 of 243years later. However, severe bilateral erosive hips arthritis had devel-
oped in two patients before the onset of tocilizumab.
Conclusion: The diagnosis of muscle AA should be considered in a
patient with abscesses associated with polyarthritis, particularly in
the absence of documented infection or response to antibiotics. The
association of early-onset polyarthritis, systemic inflammation and
aseptic muscle abscess is likely a peculiar autoinflammatory disorder
that may respond to anti IL-6 blockade.
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Introduction: Familial Mediterranean fever (FMF) is an inherited auto-
inflammatory disease characterized by recurrent episodes of fever
and acute inflammation of the membranes lining the abdomen,
joints. FMF usually begins during childhood. Most affected individ-
uals experience their initial episode before the age of 20.
Objectives: We aimed to compare the demographic, clinical and
genetic data of the patients whose symptoms started before the age
five and after the age five to see the effect of age to the severity and
outcome of disease, to evaluate the presence of mutations according
the the age of symproms onset.
Methods: Children who are diagnosed as FMF at Sağlık Bilimleri
University KSSEAH Pediatric Rheumatology outpatient-clinic ac-
cording to Tel-Hashomer Criteria were involved to the study. Pa-
tients were grouped based to the age of onset of the symptoms
related to FMF. In the first group consisted 100 children with the
clinical features that began before age of 5 and the second
group consisted 100 children with the clinical features starting
after age of 5. All the patients were carrying either heterozygous
or homozygous MEFV mutations. Retrospective analysis of the
files of the patients were done. Demographic data, genetic ana-
lysis, consanguinity, family history, age that first symptom ensue,
duration passed until the diagnosis was made, frequency of at-
tacks, duration of attacks and the involved sites during attacks,
reports of MEFV analysis, laboratory data including CRP, ESR, SAA,
blood counts, urinary protein levels were recorded. Severity of
the disease were evaluated according to the Pras score.
S
Results: Mean age of the patients was 11.7±4.04. Mean age of
the children whose symptoms began before age of 5 (Group 1)
was 9.65±3.83 years, mean age of the children whose symptoms
began after age of 5 (Group 2) was 13.7±3.09 years. Group 1
consisted 57 girls, group 2 consisted 46 girls. Consanguinity was
35% for group 1and 21% for group 2 (p<0.05). Clinical features
started at the mean age of 2.37±1.19 years in group 1 and 8
±2.39 years in group 2. The duration that passed till diagnosis
was 2.19±1.99 years and was not different between groups. Al-
though group 1 had more frequent attacks than group 2, the
duration af attacks were similar in both groups. Colchicine dose
was more than the dose needed for age in group 1, 14% of chil-
dren needed increased doses, while in group 2 only 2% needed
higher doses appropriate for their age (p<0.05). Fever and ab-
dominal pain was present in 64% of all patients as the first
symptom. Fever only was the presenting symptom in 19 children
under age 5, while non of the patienst in group 2 had just fever
as the presenting symptom (p<0.05). Artrhitis and chest pain
were the presenting symptoms in group 2, but not the firstsymptom in group 1 (p<0.05). Mean Pras score of patients in
group 1 was significantly higher (7.35±1.24) than the mean score
of group 2 (6.14±1.55). Homozygous M694V mutations were statis-
tically more frequent in group 1 (p<0.05). Leukocyte counts and
CRP levels were higher, hemoglobin concentrations were
lower during attacks in group 1 than group 2 (p<0.05).
Conclusion: Age of onset of FMF is an important factor while eavlu-
ating clinical features and severity of the disease. Increased doses of
colchicine may be needed in children with early onset of disease. Se-
vere disease causing mutations are also frequently seen when the
disease starts early. Presence of recurrent fevers even without accom-
panying symptoms must warn the physician about the presence of
FMF that will prevent the delay in diagnosis. So, both the complica-
tions like amyloidosis and the severe burden of disease will be
avoided
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Introduction: Misdiagnosis in patients with such autoinflammatory
syndromes as juvenile idiopathic arthritis (JIA) occurs rather fre-
quently in routine practice. Because of the heterogeneity of JIA and
the lack of widespread genetic testing, children with autoinflamma-
tory syndromes can be treated for many years using the standard
protocols before they turn out to be ineffective.
Objectives: The objective of this study was to estimate the incidence
of autoinflammatory syndromes among biologic-naïve patients with
JIA and those with a long-term disease, as well as the ineffectiveness
of therapy with one or more biologics.
Methods: The prospective study conducted at the National Med-
ical Research Center of Children's Health (Moscow) involved 300
patients having a diagnosis of systemic JIA at enrollment. All the
patients underwent automated direct sequencing on an ABI 3500
XL automated DNA sequencer (Applied Biosystems) using a Big-
Dye Terminator Cycle Sequencing Ready Reaction kit (Applied
Biosystems, Foster City, CA, USA). If no mutations were detected
in the hot spots of the MEFV, MVK, NLRP3, and TNFRSF1A genes,
all the coding and the adjacent intronic regions of the MVK,
MEFV, TNFRSF1A, NLRP3, NLRP12, CECR1, IL1RN, TMEM173, NLRC4,
LACC1, NOD2, PSTPIP, LPIN2, PSMB8, and TRNT1 genes in patients
with suspected autoinflammatory syndromes were examined by
next-generation sequencing, which allows one to simultaneously
analyze extensive areas of the human genome. After genetic veri-
fication of the diagnosis, the patients were assigned to the
groups receiving either TNFα inhibitors, or anti-IL6 receptor
monoclonal antibodies, anti-IL1 monoclonal antibodies. At the
final visit (within 1 year), the efficacy and safety of targeted per-
sonalized biologic therapy was evaluated.
Results: Among the 300 patients enrolled, 180 were biologic-naïve
(60%, the naïve group). Among the remaining cohort (40%, the
switched group), 27% of patients were previously treated with 2 or
more biologics. Prior to molecular genetic examination, only 16% of
patients had inactive disease. An ACR70 response (compared with
the disease onset) was achieved in 16.3% of patients (27 (15%) naïve
and 22 (18.3%) switched patients). Only 8% of patients (13 (7.2%)
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 86 of 243naïve and 11 (3.6%) switched patients) reached the inactive disease
phase/remission.
The conducted molecular genetic study showed that biologic ther-
apy was personalized in 53/180 (29%) naïve patients and 46/120
(38%) switched patients according to the revealed pathogenic vari-
ants of the genome. Personalized treatment reduced the JADAS71
index down to < 3 in 71% of patients and allowed 70% of children
achieve the inactive disease phase and remission after one-year
follow-up
Conclusion: The frequency of pathogenic variants of the genome
and autoinflammatory syndromes in patients with juvenile idiopathic
arthritis is high. The revealed genomic abnormalities make it possible
to personalize biologic therapy, which allows achieving the remission
rate of > 70%.
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Introduction: Familial Mediterranean Fever (FMF) is an inflammatory
disease related to MEFV gene mutations which is characterized recur-
rent fever and abdominal pain. Colchicine is used for preventing at-
tacks as the routine treatment. However, the effect of anti-
interleukin-1 (IL-1) was shown in colchicine resistant patients.
Objectives: It is aimed to present the characteristics of pediatric FMF
patients who followed with an anti-IL-1 agent, canakinumab.
Methods: The medical files of 29 pediatric FMF patients who are
followed in Izmir Dr. Behcet Uz Children’s Hospital were investigated
retrospectively.
Results: Seventeen male and 12 female cases with colchicine re-
sistant FMF were included in the study. The cases with three or
more attacks in the last six months and high AFR while using ad-
equate dose colchicine were defined as the colchicine resistant.
The median age was 16 years (min-max: 4.5-19 years), median
symptom onset age was 4 years (min-max: 1-15 years), median
diagnosis age was 6 years (min-max: 2-15 years), and median
follow-up time was 7 years (min-max: 2-14 years). Twenty-two
cases were (75.9%) M694V homozygote. Recurrent fever (100%),
abdominal pain (86.2%), and arthritis (48.3%) were the most com-
mon symptoms. The cases used colchicine for median 7 months
(min-max: 2-14 months) prior to canakinumab. Four of the cases
(13.8%) have tried anakinra treatment prior to canakinumab.
Canakinumab was started with 3-5 mg/kg (max: 150 mg). The
cases in the present study were used canakinumab for 11
months (min-max: 2-76 months). Two cases had a urinary tract in-
fection (6.9%), and pneumonia was developed in one case (3.4%)
following the canakinumab. Total remission was achieved in 26
cases (89.7%) following canakinumab treatment.
Conclusion: Although the colchicine is still the first line therapy
in the FMF, anti-IL-1 agents provide effective treatment in colchi-
cine resistant cases. Canakinumab is a promising agent which
controls FMF attacks effectively. According to our experience, the
colchicine resistant FMF patients might achieve high rates of total
remission without severe adverse effects following canakinumab
treatment.
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Introduction: Chronic recurrent multifocal osteomyelitis (CRMO) is a
rare autoinflammatory polygenic bone disease characterized by asep-
tic bone inflammation that affects more frequently pediatric popula-
tion. Its management, clinical, radiological findings and treatment
have not yet been standardized.
Objectives: The clinical, radiological characteristics were analyzed as
well as response to treatment options.
Methods: We performed a retrospective, descriptive multicentric
study of patients diagnosed of CRMO in four tertiary level hospi-
tals’ pediatric rheumatology section. There were 16 patients
included.
Results: The median age at diagnosis was 10,5 years, female:-
male ratio 62,5:37,5%. The delay in the diagnosis had a median
of 4.5 months, being less than one year in 11 patients,taking up
to 24 months in a patient with unifocal pelvic involvement.
Bone pain was the first symptom in 100% of the patients ac-
companied by fever in 25% of them. A single patient presented
perilesional arthritis. A slight-moderate increase on acute fase
reactants was observed at the debut of the disease: median ESR
47.5mm/h.
The median number of locations at disease onset was 2.5 (range 1-
14), with multifocal involvement in 75%. The most frequent location
was tibia (56%), followed by pelvis (44%) and vertebrae (31,25%).
Other locations less frequent were: carpus (12.5%), femur (12.5%)
mandible (6%) and sternum (6%).
Biopsy was performed in 14/16 patients and bone scintigraphy
with Tc99 in 12/16 patients, with pathological uptake observed in
91.6% of cases. MRI was the radiological test of suspected diag-
nosis in 15/16 patients.
NSAIDs were the initial treatment being Ibuprofen and Naproxen the
most frequently used. 5 patients received different antibiotic therapy
regimens, without clinical or radiological improvement. 56.25% of pa-
tients required other treatments. Systemic corticosteroids were used
in 12.5% of patients and bisphosphonates in 43.75%(100% of pa-
tients with axial involvement). After 6 months of treatment with
biphosphonates, 57.14% had complete remission, 28.57% partial re-
mission and 14.28% worsening. 12.5% of the patients had a torpid
evolution, receiving sequential therapies with multiple synthetic or
biological DMARDs (Anakinra, Canakinumab, Etanercept), and an-
other 12.5% required surgery.
Conclusion: The diagnosis of CRMO represents a big challenge in
the absence of pathognomonic features which frequently leads
to delay in diagnosis and the initiation of treatment. In our cen-
ters the biphosphonates were the treatment strategy used in pa-
tients with spinal involvement with 85.67% response at 6
months.
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Introduction: Blau syndrome is an autoinflammatory syndrome
caused by a mutation in NOD2. The syndrome is often a challenge to
treat. A variety of anti-inflammatory agents have been used but none
has so far being universally effective.
We describe an 18 year-old boy previously treated with several
non-biologic DMARDS in combination with TNF-blockade, Il-1
blockade and IL-6 blockade. He has never been free of inflamma-
tion and always needed oral corticosteroids (0.15-0.20 mg/kg). His
main clinical problems have been arthritis and uveitis. During the
last 5 years he had intermittent headache that seems to correlate
with flares of the disease. In December 2017 his headache be-
came worse.
Objectives: Investigate CNS symptoms in a child with Blau syndrome
Methods: Repeated lumbar punctures and serial measurements of
CSF biomarkers were performed. Extensive infectious work-up was
done.
Results: Repeated MRI of the brain between 2011 and 2017 did not
show any progress but only a discrete periventricular signaling of
unclear significance around both anterior horns. Brain MRI 2018 was
unchanged compared to earlier MRIs. The infectious work-up was
normal.CSF findings
181228 180131 180321 180503
opening 27 27 47 33
pressure cm H2O
WBC count (/μl) 188 45 6 7
Lymphocytes (/μl) 180 44 6 6
Neutrophils (/μl ) 8 1 0 1
Protein (g/L) 0,71 normal normal
NFL(<380ng/L) 4350 4740 50700 pending
GFA(<175ng/L) 390 670 330 pending
Tau (<250 ng/L) 759 526 500 pending
Glucose(mmol/L) 3.0 3.1
Lactate (mmol/L) 2.3 1.8
Serum findings
181228; CRP 4 mg/L, WBC 17.1 x 109/L, ANC 13.2 x 109/L, ALC 2.4 x 109/LHis symptoms and CSF leukocytes have decreased after increasing
the corticosteroids and after changing from prednisolone to dexa-
methasone with better penetrance of the blood-brain barrier.
Conclusion: CNS inflammation in Blau syndrome was not described
earlier. The results of the investigations clearly points to CNS inflam-
mation in this teenager and that this is possibly a part of Blau syn-
drome. The late increase of NFL is reflecting the dynamics of thisbiomarker and not an evidence of worsening of the CNS involve-
ment. Our conclusion is that CNF involvement should be part of the
work-up of children with Blau syndrome.
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Introduction: Cryopirin associated periodic syndromes (CAPS) are auto-
inflammatory diseases associated to NLRP3 gene mutations, leading to
inflammasome hyperactivity and IL-1βhypersecretion. Three pheno-
types (FCAS, MWS and CINCA) represent a continuum of the same dis-
ease characterized by different severity degrees. Chronic infantile
neurologic, cutaneous, articular (CINCA) patients, affected by the most
severe form, presented recurrent fever, systemic inflammation and cen-
tral nervous system disabilities.
Objectives:
– increase the knowledge on pathologic consequences of NLRP3
mutations;
– understand central nervous system involvement;
– identify new drugs and molecular targets for the treatment of
CAPS diseases.
Methods: Cytokines secretion from bone marrow derived dendritic
cells (BMDCs) was evaluated by ELISA.
Hystological analysis was evaluated with hematoxylin and eosin staining.
Results: We engineered N475K mutation (corresponding to mutation
N477K in human) in mouse NLRP3 gene and generated a novel
knock-in (KI) model that presents two different phenotypes: hetero-
zygous and homozygous form. Although both KI mimic CAPS human
disease, homozygous (homo)-KI mice presented a much more severe
phenotype and exhibited typical clinical manifestation of CINCA pa-
tients. Homo-KI mice showed severe skin rush and growth delay re-
spect to Wild Type (WT) controls. Survival and body weight were
severely decreased. Interestingly, IL-1β, IL-18 and IL-1α secretion was
strongly increased respect to WT and heterozygous mice of the same
littermate mice, while IL-1RA antagonist secretion was extremely re-
duced when compared to the same littermate mice.
Hystological analysis showed a generalized inflammatory phenotype char-
acterized by alteration of spleen, lungs, liver and kidneys. More interest-
ingly, homo-KI mice presented serious cerebral complication that prevent
walking. Hematoxylin and eosin staining reveal a delay in cerebellum de-
velopment and an alteration of the lamination of cerebral cortex.
Conclusion: Homo-KI mice recapitulate clinical and immunological
features of CINCA patients. In the future this mouse model could be
used to gain insights into the mechanisms associated to neurological
defects and their consequent treatment.
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Introduction: Chronic non-infectious osteitis (CNO) or Chronic recur-
rent multifocal osteomyelitis (CRMO) is a rare auto inflammatory dis-
order characterised by the presence of sterile bone lesions. The disease
affects the metaphyses of long bones, pelvis, vertebra and clavicle.
Objectives: To understand the demographics, clinical features and
treatment outcomes of Chronic Non-Infectious Osteitis (CNO) from
three tertiary paediatric rheumatology services in the United Kingdom.
Methods: Children less than 18 years of age diagnosed with CNO be-
tween 2001 to 2016 from one tertiary service and between 2001 to
2017 from two tertiary services were included. Clinical notes were
reviewed and all pertinent data were collected on a pre-defined pro-
forma. One hundred and thirty one patients were included in the study.
The Bristol diagnostic criteria was applied retrospectively.
Results: Retrospective analysis of the data showed that the disease
was more common in girls than boys (2.5:1), the mean ± SD age at
diagnosis was 10.64 ± 2.93 years and the mean ± SD time to diagnosis
was 16.48 ± SD 16.18 months. Bone pain was the predominant symp-
tom in 118/129 (91.4%) followed by swelling in 50/102 (49.01%). Associ-
ated auto inflammatory conditions included IBD (n=1) and psoriasis
(n=5). Raised inflammatory markers were present in 39.68% of the pa-
tients. Whole body Magnetic Resonance Imaging (MRI) was a useful
diagnostic tool. Metaphyses of long bones were most often involved
and the distal tibial metaphyses 65/131 (49.6%) was the most common
site. With the use of Bristol Diagnostic Criteria 31.50% of the bone biop-
sies could have been avoided. Non-steroidal anti-inflammatory drugs
were used as first line (81.67%) followed by bisphosphonates (61.79%).
The disease was in remission in 80.91% of the patients during the last
follow up and 17.55% had recurrent disease.CHARACTERISTICS NUMBER(%)
Age at diagnosis (mean±SD years) 10.64± 2.93
Gender F/M;ratio 94/37;2.54
Fever (n=79) 6(7.59%)
Raised inflammatory markers(n=126) 50(39.68%)
HLA B27 positive(n=15) 1(6.66%)
Number of clinical sites 1.29 (range 0-3)
Number of radiological sites 3.27 (range 1-13)Conclusion: Our multicentre study describes features and outcomes
of CNO in a large number of patients in the United Kingdom. It also
highlights the ability to avoid biopsies in some children and the
need to develop standardised pathways for management of CNO.
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inflammatory diseases. Little is known about efficacy and safety of vac-
cinations in these patients, which might affect decision to vaccinate.
Objectives: The aim of this study was to determine vaccination
coverage in children with PFAPA syndrome and other autoinflamma-
tory diseases, to find out the reasons for potential vaccination drop-
out and to assess the frequency and nature of potential side effects
after vaccination in these patients.
Methods: All children with PFAPA syndrome and other autoinflam-
matory diseases who visited rheumatology outpatient clinic at the
University Children's Hospital (UCH) Ljubljana since 2008 were invited
to participate in the study. They were asked to provide a written vac-
cination record and they were sent a questionnaire about the rea-
sons for potential vaccination dropout and potential side effects after
vaccination. The study was approved by the national ethics commit-
tee. Hereby we report the preliminary results of the study.
Results: Since 2008, 191 children with autoinflammatory diseases (in-
cluding 147 children with PFAPA syndrome) were seen in rheumatol-
ogy outpatient clinic at UCH Ljubljana. By the end of April 2018 we
sent the questionnaires to 78 patients, 26 (33 %) returned the data.
Among them, 23 had PFAPA, 2 FMF and 1 CAPS. 17 (65 %) were
boys. Median age was 7 (3.5 – 19.2) years, median age at diagnosis,
disease onset and end of fever episodes in children with PFAPA was
3.5 (1.6 – 7) years, 1.9 (0.08 – 3.8) years and 6 (3 – 10) years, respect-
ively. Six of the patients with PFAPA still have fever episodes at this
point. Five of the patients with PFAPA received methylprednisolone
at least once and 9 had a tonsillectomy. Twenty-two (84.6 %) pa-
tients had a complete vaccination status according to the Slovenian
immunization programme. Reasons for vaccination dropout included
recommendation of the primary physician, fear of side effects of vac-
cination and recurring febrile illness. 6 patients had fever 0-7 days
after vaccination that lasted 2-14 days, one of them also had a rash
and another one had diarrhoea and vomiting. None experienced ser-
ious side effects or disease flares.
Conclusion: Vaccination coverage in children with autoinflammatory
diseases seems to be lower than in general population in Slovenia.
Vaccination didn’t cause serious side effects or worsening of the
autoinflammatory disease in our cohort.
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Introduction: Type I interferonopathies are a clinically heterogeneous
group of Mendelian disorders characterized by constitutive upregula-
tion of type I interferon activity. Aicardi-Goutières syndrome (AGS) man-
ifests as an early-onset encephalopathy and mimics a congenital viral
infection. Cohesinopathies such as Cornelia De Lange syndrome, are
characterized by both physical and mental abnormalities. Mutations in
cohesin complex genes (NIPBL, SMC1, SMC3, RAD21, HDAC8) result in in-
creased sensitivity to DNA damage and exhibit global gene expression
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 89 of 243deregulation. However, the true extent of the phenotype associated
with pathogenic variants in CdL-related genes is not yet known.
Objectives: To report on a patient with combined Cornelia de Lange
syndrome and AGS.
Methods: A twenty years old male presented since early infancy with
violaceous, scaling lesions of the fingers and toes, resorption of distal
phalanges, dystrophic nail changes and, violaceous lesions on the nose
that worsened during the cold season. He was diagnosed at the age of
7 years with Cornelia de Lange syndrome (CdLS) based on the pheno-
type associating severe somatic and psychomotor retardation, micro-
cephaly, hypertrichosis, synophrys, arched palate, strabismus, hearing
loss, cryptorchidism and unilateral vesicoureteral reflux with kidney
scarring. Laboratory investigations showed mild thrombocytopenia and
positive anti-thyroid antibodies. A cerebral MRI showed an important
intracerebral large vessel involvement with cerebral vascular accidents.
The patient was found to be homozygous for a novel
NM_015474.3:c.66del:p.(Ser23Glnfs*43) variant in SAMHD1 gene. Whole
Exome Sequencing (WES) of the patient was performed. PBMCs were
isolated from peripheral blood and cell subsets were monitored for ab-
errations compared to healthy donors. DNA damage was assayed in cell
subsets through phospho-γ-H2AX staining. Finally, RNA-seq (in pro-
gress) for CD14+ monocytes and total PBMCs of patient will provide a
list of differentially expressed genes as well as explain immune abnor-
malities correlating to the patient phenotype.
Results: Using WES, we confirmed the presence of the homozygous
mutation in SAMHD1 gene. Moreover, a novel mutation of SMC1A gene
associated with Cornelia de Lange syndrome was identified (SMC1A,
NM_006306.3:c.3306C>A :p.(Asn1102Lys)). The population of classical
monocytes (CD14+CD16-) in the patient was enhanced compared to
healthy individuals, while intermediate and non-classical monocytes
were not significantly altered. Total T cell abundance was different (re-
duced at 50%) and much lower for dendritic cells. Levels of DNA dam-
age in PBMCs of patient seem rather similar to healhty ones. RNA-seq
analysis is in progress for CD14+ monocytes and total PBMCs of patient.
Conclusion: We describe a novel mutation in SMC1A gene, diagnos-
ing genetically Cornelia de Lange syndrome in a patient diagnosed
already with AGS. Immune cell abundance abnormalities are ex-
pected to reflect gene expression alterations. Informed consent to
publish has been obtained from the parents.
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Introduction: Behçet's disease (BD) usually appears in young adults
between 25 and 40 years of age, although in a smaller percentage of
patients the disease can begin in the pediatric age. Classically, the
criteria published by the International Study Group of EB (ISGBD-
1990) have been used for the diagnosis, but recently new cri-
teria have been proposed of the Study Group on Childhood EB
(PEDBD2016) in order to impove the sensitive and specific
Objectives: Assess the applicability of the new criteria for the child-
hood BD in a cohort of patients previously diagnosed with BD, com-
paring these with the classification criteria previously used (ISGB1990
and ITR-ICBD 2014) and compare with an adult cohort.
Methods: This is a retrospective cross-sectional observational study.
Clinical and analytical variables were collected from 9 juvenile pa-
tients previously diagnosed with childhood BD, according to criteria
of ISGB 1990 and / or of ITR-ICBD 2014, followed in a Pediatric Rheu-
matoloy Unit in at a tertiary hospital and also from 43 adult patients.
It was assessed whether the juvenile patients met the new criteriafor provisional classification of childhood EB 2016, analyzing and
comparing the spectrum of clinical manifestation of the 2. The mean
age at diagnosis was 11.4 ± 5.1 years; 8 of them being women and 1
male. Five patients (5/8) fulfilled the criteria of the ISGB-1990 and eight
(8/8) had a score greater than or equal to 4 points that defined the BD
according to the criteria of the ITRICBD - 2014. Only 3 of our patients
(3/8) fulfilled the new criteria for pediatric BD of the PEDBD-2016. In
the group of patients who fullfiell the new criteria: 100% had oral
aphthae and genital ulcers as well as joint involvement and skin lesions
(3/8). Ocular involvement was detected in two patients and neuro-
logical manifestations was seen in two patients; being 2 of them HLA-
B51 (+). The 5 patients (5/8) who did not meet these criteria were those
who presented mild clinical manifestations as oral ulcers, genitals and/
or positive paternity test, with only one of them ocular involvement.
One of the patients had incomplete Behcet follow-up
Conclusion: In our series, patients classified as pediatric BD by the
2016 criteria presented cutaneous, ocular and neurological manifes-
tations. A greater number of patients met the previous classification
criteria, since it was enough to have mucocutaneous manifestations.
Additional studies are required to improve the diagnostic perform-
ance and characterization of patients with childhood BD
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Introduction: Interferon gamma (IFNγ) plays a pathogenic role in pri-
mary and secondary HLH. An ongoing phase 2/3 trial with emapalu-
mab in primary HLH provides encouraging preliminary data and a
pilot trial in MAS in the context of sJIA has just been initiated. Gain-
of-function mutations in NLRC4 are associated with a distinct autoin-
flammatory syndrome, with recurrent HLH.
Objectives: To report safety and efficacy of emapalumab treatment
in two patients carrying de novo missense mutations in NLRC4, with
severe early onset HLH.
Methods: Cytokine levels were measured by multiplex assay and by
specific ELISAs and expression of IFNγ in freshly isolated PBMCs by
cytometry.
Results: Pt 1. Caucasian male, presented, at age 20 days, fever and
rash and progressively developed clinical and laboratory features of
HLH leading to multi-organ failure. A de novo missense mutation
in NLRC4 (T337N) was found. High-dose glucocorticoids and
cyclosporine-A (CyA) led only to partial improvement. A sepsis trig-
gered HLH reactivation. Emapalumab was started (compassionate
use) on background of dexamethasone (13.6 mg/m2) and CyA. After
3 months, the child was discharged in excellent conditions (prednis-
one 0.3 mg/kg). Infections resolved during treatment with emapalu-
mab. After 7 months of emapalumab treatment, all therapies,
including emapalumab, were discontinued, without clinical or labora-
tory signs of HLH reactivation.
Pt 2. This is 16 months old Caucasian boy with recurrent HLH and
vasculitic skin lesions, since 1 month of life, secondary to a de
novo missense mutation in NLRC4 (I343N). His disease was not con-
trolled despite treatment with repeated methylprednisolone pulses
and chronic daily glucocorticoid therapy, CyA (5 mg/kg) and
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 90 of 243anakinra (ranging from 5 to 25 mg/kg/day). When anakinra was with-
drawn prior to start emapalumab he immediately developed high-
grade fever, skin rash with vasculitic lesions and diarrhoea with la-
boratory features of HLH. Emapalumab was started (compassionate
use) on background of methylprednisolone and CyA with rapid reso-
lution of fever and improvement in biochemical parameters. During
emapalumab treatment the patient resolved his initial HLH flare and
presented two HLH episodes of mild intensity controlled with moder-
ate intensification of glucocorticoid therapy. These episodes were
triggered by systemic infections caused by pathogens translocated
from the gut. His diarrhoea persisted with low grade inflammation;
emapalumab was eventually withdrawn after 3 months. His subse-
quent course was characterized by additional mild episodes of MAS.
In both patients increased production of IFNγ was demonstrated by
high levels of CXCL9 (pt.1: 5670 pg/ml, pt.2: 3310 pg/ml), a chemo-
kine induced specifically by IFNγ, by increased IFNγ expression in NK
cells and CD8T cells, and by presence of high levels of total IFNγ
bound to circulating emapalumab.
Conclusion: In both patients with HLH secondary to NLRC4-related
disease, treatment with emapalumab was well tolerated, no safety
concerned emerged, normalization of all HLH clinical and laboratory
abnormalities was achieved. Pt. 1 showed no disease reactivation
even in the absence of treatments In pt. 2 IFNγ neutralization has
provided control of HLH, while his underlying disease and, in particu-
lar, gut inflammation and gut colonization by MDR pathogens
remained unchanged. Informed consent to publish had been ob-
tained from the parents.
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Introduction: NLRP1-associated autoinflammation with arthritis and
dyskeratosis (NAIAD syndrome) is a monogenic autoinflammatory syn-
drome caused by mutations in NLRP1 gene. It was first reported in
2016 and described as a complex syndrome of inflammasome hyperac-
tivation with release of pro-inflammatory cytokines, dyskeratotic and
papilloma-like skin lesions, arthritis and features of antibody-mediated
autoimmunity with impairment of B-lymphocyte maturation.
Objectives: To report a case history of an 8-year-old Russian girl with
some clinical features of NAIAD syndrome who was referred to our
Center.
Methods: genetic defect was confirmed via exome next generation
sequencing; lymphocyte immunophenotyping was done according
to the standard flow cytometry protocols.
Results: We identified a heterozygous mutation in NLRP1 c.160 G>A,
p.Ala54Thr in the patient, presenting with severe anemia (hemolytic
and chronic inflammation anemia), thrombocytopenia, hyperkeratotic
skin rash, dyskeratotic nail changes, additional auricular appendages,
alopecia, arthritis and short episodes of alveolitis. The clinical feature
that had not been previously described in NAIAD patients was cor-
neal opacity with severe vision impairment. Until 8 years of age the
patient suffered mostly from skin and eye sympthoms and cytopenia,
that was treated by regular blood transfusions but otherwise hadstable clinical condition. While in the process of clinical evaluation in
our Center the patient deteriorated rapidly and developed a life-
threatening condition with respiratory and acute kidney failure and
secondary HLH, requiring artificial lung ventilation. Features of re-
spiratory distress was found on CT-scans. The blood tests showed
highly elevated inflammatory serum markers (CRP up to 220 mg/l),
hypergammaglobulinemia. Peripheral blood B-cells predominantly
consisted of transitory forms with decrease of the post-switch B-cells.
Urine tests showed proteinuria and hematuria. After the evaluation
of potential clinical significance of the discovered mutation, the pa-
tient was started on IL-1R inhibitor (anakinra) and rituximab (N=4)
with dramatic improvement in a matter of days. We further en-
hanced her therapy with ruxolitinib addition, hoping to curb IL-18
hyperproduction. Currently the patient is at home and well, on ruxo-
litinib and anakinra therapy.
Conclusion: Since its first description in 2016 by S. Grandemange
et al. there are only 3 patients reported worldwide so far. We con-
ducted a literature search and found that NLRP1 c.160 G>A, p.Ala54Thr
mutation was reported in a patient diagnosed with another NLRP1-
associated entity – Multiple Self-Healing Palmoplantar Cracinoma
(MSPC). Except for skin and corneal lesions the disorder is characterized
by the elevated serum IL-1a, IL-1b and IL-18 levels (C.-H. Yu et al, 2017).
One more disease associated with mutations in NLRP1 is Corneal Intrae-
pithelial Dyskeratosis (CID) (V.Soler et al, 2013). Informed consent to
publish had been obtained from the parent.
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Introduction: ADA2 gene (previously named CECR1 gene), located on
chromosome 22q11.1, encodes for adenosine deaminase 2, an enzym-
atic protein also involved in the homeostasis of endothelial and
hematopoietic cells. Loss of function mutations in ADA2 gene are re-
sponsible of a rare autosomal recessive condition, named DADA2, char-
acterized by a broad clinical spectrum ranging from a systemic
inflammatory disease with vascular and multiorgan involvement, re-
sembling Panarteritis Nodosa, to clinical conditions associated to a vari-
able range of immunodeficiency and immune-deregulation. A certain
percentage of patients, despite a consistent phenotype and lack of the
ADA2 enzymatic activity, have an incomplete or negative genotype.
Objectives: to define the genetics underlying a patient with a clinical
phenotype consistent with DADA2 and a deficient enzymatic activity
but without any mutation in the coding region of the CECR1 gene.
Methods: Whole exome sequencing (WES) was performed in a 9 year
old patient with a clinical phenotype consistent with DADA2 (fever,
livedo reticularis, hypertension, hypogammaglobulinemia and two epi-
sodes of ischemic stroke) and a complete lack of ADA2 activity in circu-
lating monocytes. In particular, we analyzed the proband and the
asymptomatic parents by using Illumina’s Nextera Rapid Capture Ex-
panded Exome libraries and Illumina Hiseq2000 Instrument with 75bp
paired-end reads. Since no coding mutation was identified as poten-
tially candidate to account for the clinical phenotype, whole Genome
Sequencing (WGS) was performed in the proband by TruSeq Nano
DNA Library Prep kit and HiSeq 3000 Instrument with 150bp paired-
end reads. Structural variants were identified with Manta.
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encompassing exons 3 and 4 (involving 12895 bases), generated by
two breakpoints in intron 2 and intron 4 respectively, was assessed
by the WGS data. This has led to a gene transcript postulated to con-
tain 1967 instead of 1536 nucleotides, due to an in tandem duplica-
tion of the sequences corresponding to exons 3 and 4, thus leading
to a frameshift starting from codon V252 followed by a premature
stop codon after 11 aminoacid residues (p.V252Gfs11*).
Conclusion: The structural variation identified in the patient represents
the first evidence of a genetic defect, different from the presence of bi-
allelic loss-of-function point mutations, involving the ADA2 gene. A timely
identification of ADA2 enzymatic impairment in the presence of a pheno-
type clearly consistent with DADA2 should lead to a careful and extensive
molecular approach in all patients presenting a monoallelic variant or
even in the absence of any mutation at standard DNA sequencing.
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Introduction: Autoinflammatory diseases are a group of immuno-
logical disorders characterized by ‘seemingly unprovoked’ episodes
of fever and inflammation without evidence of autoantibodies or
antigen-specific T cells, implying the importance of dysregulation in
the innate immune system.
Objectives: To report a case of severe rheumatic carditis that, in a
significant host predisposition, could trigger an underlying autoin-
flammatory syndrome (associated with a mutation in MVK gene)
Methods: M, a caucasian previously healthy 11-years old boy, diagnosed
with a rheumatic fever with carditis at the age of 10 (years old) based on
the following criteria: fever, polyarthralgia, erythrocyte sedimentation rate
> 60 mm/h, C-reactive protein (RCP) > 3.0 mg/dl, increased anti-
streptolysin O titer (1700), prolonged PR interval on ECG and echocardiog-
raphy/Doppler evidence of mitral and aortic valve regurgitation. He was
treated with steroid therapy and secondary prophylaxis with Benzathine
penicillin (every 21 days). After two months of the steroid withdrawal, he
presented recurrent fever attacks (every 2-3 weeks). Each attack was her-
alded by chills, followed by a sharp rise in body temperature and lasted
4-5 days with gradual defervescence. Abdominal pain with vomiting or
diarrhea and increased acute phase markers almost always accompanied
the fever attack. Laboratory exams such as immunologic tests for auto-
immunity as well as serology for CMV, parvovirus B19, EBV, adenovirus,
coxsackie virus, and antistreptolysin O titer resulted negative or within
normal limits. Common causes of infections were ruled out. Intravenous
antibiotics were administered at any episode of fever and induced a par-
tial remission of the disease activity and inflammatory markers, but his
heart disease dramatically worsened such he needed to undergo to car-
diac surgery (mitral valve repair and aortic valve replacement using mech-
anical prosthesis). Three days after the surgery, because of hyperpyrexia
despite antibiotic therapy, he started corticosteroid therapy again achiev-
ing a partial remission in the following three months. When off steroid
therapy, he developed four fever attacks lasting 4-7 days in 3-5 weekly in-
tervals accompanied by abdominal pain and recurrent serositis (e.g.,
pleuritis, pericarditis) with acute phase markers increased and infectious
disease tests, immunological and autoimmune exams always negative.
SAA (serum amyloid A) levels were reported to be high in the inter-
episode periods while acute phase markers were negative.
Results: Because of the recurrence of pericarditis and steroid de-
pendence, we decided to start the treatment with dailysubcutaneous injections of IL-1 receptor antagonist IL-1Ra (Anakinra)
at a dosage of 1 mg/kg.
He performed the extended genetic analysis for autoinflammatory
syndromes that detected the presence of the genomic variant C.1129G
> A in heterozygosity in the MVK gene (mevalonate kinase) due to
maternal segregation. After a follow-up of 2months, we noticed a
decreased duration and severity of flare on therapy with Anakinra.
Conclusion: Although the identified variant has been described as associ-
ated with MVK deficiency (MKD) if present in homozygosity or compound
heterozygosity, some patients with classical disease and only a single iden-
tified mutation have reported too (Ref. Barron KS Arthritis Rheum. 2013).
In our case, because of maternal segregation, we must suppose whether a
hypomorfic expression of gene in the mother or the additional influence
of other unknown genes as modifiers of the residual mevalonate kinaseac-
tivity. Otherwise the SBEGA infection might have unmasked the underlied
MKV. Informed consent to publish had been obtained.
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Introduction: Neonatal onset multisystem inflammatory disease
(NOMID) is a rare autoinflammatory disease with onset in infancy. To-
gether with familial cold autoinflammatory syndrome (FCAS) and
Muckle-Wells syndrome (MWS), they form the spectrum of cryopyrin-
associated periodic syndrome (CAPS) with NOMID at the most severe
end of the spectrum. CAPS is caused by single heterozygous germ-
line or somatic gain of function mutations in the NLRP3 gene encod-
ing the protein cryopyrin. To date, 209 different sequence variants of
the NLRP3 gene and more than 90 heterozygous mutations are iden-
tified in patients with CAPS, and the list is expanding [1]. The case re-
port here demonstrates a new sequence variant of NLRP3 gene in a
patient with NOMID phenotype of Asian ancestry.
Objectives: To report the finding of a new sequence variant
c.1568T>A of NLRP3 gene in an Asian infant with NOMID
Methods: Case report
Results: A 10-month old girl developed a generalized skin rash
within hours of birth. The rash was described as “migratory” and
“waxes and wanes” every day. A skin biopsy at 7 months of age
showed periadnexal and perivascular neutrophilic infiltrates. At 8
months of age she developed a prolonged fever of 2 weeks. Physical
examination showed frontal bossing, a mild delay of gross motion
function and mild central hypontonia. A generalised macular rash
was found and some of them were of urticarial morphology. There
was persistent elevation of inflammatory markers with highest C-
reactive protein (CRP) of 180mg/L (0.1-1.0mg/L), erythrocyte sedi-
mentation rate (ESR) 77mm/h (2-34mm/h), and serum amyloid A
greater than 16,000 ng/ml (1000-5000ng/ml). MRI brain showed
macrocephaly with prominent supratentorial ventricular and extra-
axial cerebral spinal fluid (CSF) spaces with bilateral papilloedema.
Lumbar puncture (LP) showed elevation of white cell count (WCC)
38x10^6/L and protein 0.41g/L (0.15-0.4g/L) in CSF. There was no
skeletal deformity found on radiographic bone survey. Next gener-
ation sequence genetic testing revealed a rare sequence variant of
the NLRP3 gene (c.1568 T>A). Genetic testing of the parents were
negative for this variant. Thus, it appears to have arisen de novo and
is likely pathogenic. Anakinra (4mg/kg/day) was started and the fever
and rash resolved within a day. A repeated LP after one year of
treatment showed normalization of WCC and protein in CSF. The fol-
low up MRI brain also showed interval improvement of supratentorial
Table 1 (abstract P165). See text for description.
Pt n. Age
(years)
Sex IFN
score
Disease
activity
ESR Bone
localization
Other clinical
features
1 20.6 M 18.2 Clinical
Remission
15 Clavicula Low neutrophils,
lymphocytes and
platelets count.
Previous
spondyloarthritis.
2 13.6 M 10.9 Clinical
remission
24 Multifocal —
3 17.0 F 9.3 Moderate 13 Multifocal Ankle arthritis
4 18.2 F 5.7 Moderate 5 Multifocal Psoriasis
5 13.8 F 0.7 Low 26 Multifocal —
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development is appropriate to age.
Conclusion: NOMID is a severe disease with onset within hours of
life. Different systems can be affected and permanent organ damage
can occur if treatment is delayed. However, not every feature presents
in early infancy and they may appear later in the disease course. The
skin biopsy finding of neutrophil infiltrates in our case provides a crucial
clue of an autoinflammatory condition. CNS involvement is a unique
feature of NOMID in the CAPS spectrum. Treatment with IL-1 blocking
agents results in significant clinical and laboratory improvements in
NOMID and has become the standard of care [2,3]. The IL-1 receptor
antagonist anakinra can penetrate into the CNS and treatment im-
proves CNS inflammation. The list of sequence variants of NOMID or
other diseases in the CAPS spectrum is expanding, with emerging new
variants among Asian populations. This case report documents a patho-
genic sequence variant recently discovered in a newly diagnosed
NOMID patient of Asian background. Written onsent for publication
was obtained from the parent.
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Introduction: The use of bisphosphonates has increased in recent
decades in patients of pediatric with osteoporosis (OP) and bone
pain. The effectiveness and safety data of Pamidronate (PA) in OP
secondary schools are limited.
Objectives: To describe the effectiveness and safety of PA in
pediatric patients with bone diseases.
Methods: A retrospective study of patients below 18 years of age who
had received PA in a third level hospital between 2012 and 2017 was
performed. The demographic, analytical variables and densitometry
data have been collected by DXA (L1-L4) prior to PA infusion and 2
years after its onset, the existence of pathological fractures and the ad-
verse events of the treatment. Descriptive and analytical statistics have
been used through the IMB SPSS Statistics20 program.
Results: Twenty-eight patients (46.4% males) with an average age of
12.6 years received an average total dose of 32 mg (0.8 mg/kg/infusion)
of PA. The indication was in 53.6% of the cases OP secondary to cortico-
steroids, in 39.3% due to bone pain and in 7.1% OP secondary to immo-
bility. In 39.3% of the patients a previous fracture was detected,
decreasing to a 32% at 2 years after the treatment has begun. 78.6% of
the patients reported an improvement on the pain. Only 2 mild adverse
events were reported. A statistically significant increase in BMD was ob-
served in gr/cm² after two years of treatment (0.631 to 0.729, p = 0.001).
Conclusion: Treatment with PA increases bone mass 2 years after its
onset and provides an improvement on bone pain. Adverse effects
were very infrequent.
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Pediatric Rheumatology 2018, 16(Suppl 2):P165Introduction: Chronic non-bacterial osteomyelitis (CNO) is an inflammatory
disorder of uncertain pathogenesis. On one hand, the occurrence of inflam-
matory osteomyelitis with similar characteristics in Majeed syndrome and
DIRA syndrome supports the classification of CNO among autoinflammatory
diseases. On the other hand, the existence of subgroups of CNO with asso-
ciated autoimmune disorders, such as arthritis and psoriasis, suggest that
more complex pathogenic mechanisms may be implied in the disease.
Objectives: Since autoinflammatory and autoimmune manifestations
are common in interferonopathies, we hypothesized that interferon
mediated inflammation could be involved as well in CNO.
Methods: To determine the role of interferon in the pathogenesis of
the disease we started to quantify the interferon signature (IS) in our
CNO patients.
All patients with CNO currently followed at our clinics were enrolled
in the study. Blood specimens were withdrawn after obtaining a
signed informed consent and collected in RNA preserving tubes.
Interferon signature was assessed by analyzing the six genes (IFI27,
IFI44L, IFIT1, ISG15, RSAD2, SIGLEC1) and the interferon score was cal-
culated as described by Crow et al (J Clin Immunol, 2017). We consid-
ered as positive values above 10 (as almost all SLE display IS>10),
and negative score below 5 (as almost all JIA in our experience have
IS<5). Values between 5 and 10 were considered border-line.
Results: Five patients were enrolled (3 females, 2 males, mean age
16.6 years, range 13.6-20.6). Positive/border-line interferon score was
recorded in four out of five patients (Table 1). There was no apparent
correlation with disease activity and ESR.
Conclusion: Apart from a single patient with concomitant hematologic
cytopenia, we detected only mild or border-line elevation of IS scores.
It is uncertain whether these low scores can reflect or not an involve-
ment of type 1 interferon in the inflammatory pathogenesis of CNO.
However, it is worth noting that these results could be influenced by
low disease activity in most of the investigated patients.
Further investigations are needed to evaluate the real role of inter-
feron 1 in the pathogenesis of CNO and the potential utility of this
assay in stratification of patients for therapeutic choices.
Trial registration identifying number: This work was funded by
IRCCS Burlo Garofolo grant RC24/17 and Telethon foundation grant
GGP15241
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Table 1 (abstract P167). The mean plasma miRNA 2-ΔCT level of
patients in aFMF, rFMF and HC groups and comparison of it
Mean 2-ΔCT Fold change/p value
aFMF rFMF HC aFMF-rFMF aFMF-HC rFMF-HC
miRNA-16 0.97 1.05 0.90 -1.09/0.40 1.08/0.96 1.17/0.52
miRNA-155 0.55 0.44 0.69 -1.25/0.15 -1.25/0.18 -1.56/0.03
miRNA-204 0.019 0.002 0.017 9.50/0.001 1.10/0.34 -8.50/0.001
miRNA-451 1.85 2.10 1.59 -1.13/0.50 1.16/0.67 1.32/0.85
aFMF: attack period of Familial Mediterranean fever, rFMF: remission period of
Familial Mediterranean fever, HC:Healthy control
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 93 of 243Introduction: Autoinflammatory diseases (AIDs) are a group of heteroge-
neous disorders characterized by recurrent fever and systemic inflammation
(aseptic and non-autoimmune) , and the NLRC4- associated autoinflamma-
tory diseases have been only recently described.
Objectives: To describe two pediatric cases with two variants of
NLRC4 gene with a different spectrum of clinical manifestations
Methods: We describe two pediatric patients presented with recur-
rent fever and nonspecific symptoms.
Patient 1 F., caucasian, 8 years old boy presented with recurrent fever
(maximum of 39°C), lasting 3-10 days with intervals of 3 days in apyr-
exia, not always responsive to oral corticosteroids, associated with rhin-
itis, cough, not-itchy rash on trunk and face, sometimes periorbital
edema and conjunctivitis. In the last two years he developed arthralgia
involving the small joints of the hands and bilateral knee pain, in some
cases associated with joint swelling. He reported headache, vomiting
and recurrent abdominal pain, often diarrhea without blood or mucus.
Laboratory tests revealed a persistent increase of inflammatory markers
and serum amyloid A (SAA) . The abdominal ultrasound showed a thick-
ening of ileum wall tract of about 30 mm with an intestinal distension
and fluid-corpusculated material upstream, without hepatosplenome-
galy and the fecal calprotectin was negative. Screening for infectious
diseases and malignancies was negative.
Patient 2 A., caucasian, 17 years old girl. At 11 years she was hospital-
ized due to persistent fever associated with pharyngodynia, rash lo-
cated on the upper eyelids, edema of the face and disabling joint
pain and she was diagnosed a macrophage activation syndrome
(MAS). At the age of 15 years she had the second episode of MAS,
likely to be triggered by an EBV infection. At 16, the appearance of
polyarthritis evolved in MAS in the absence of febrile episodes / pre-
vious infectious and a diagnosis of juvenile idiopathic arthritis in a
patient with recurrent MAS was made.
Results: In the patient 1 the genetic molecular analysis revealed the
presence of a heterozygosis mutation of the genomic variant
c.2785G> T of NLRC4 gene. This child is currently on therapy with
colchicine with clinical and laboratory remission. Otherwise the pa-
tient 2 is currently on therapy with methotrexate and anti-TNF Eta-
nercept with good clinical response. The extended analysis for
autoinflammatory syndromes has detected the presence of the gen-
omic variant c.2357G> T in heterozygosis of the NLRC4 gene. The re-
lated family genetic studies are going in both cases.
Conclusion: Mutations in heterozygosis of the NLRC4 gene, although
defined as not-causative, appear to be associated with various clinical
pictures in the context of auto-inflammatory syndromes, as well as a
high susceptibility to developing MAS. In first our cases it could be asso-
ciated to the autoinflammatory syndrome with enterocolitis (SCAN4),
also called as autoinflammation with infantile enterocolitis (AIFEC),
while in the second one, according to the reported literature, corre-
sponds to a variant with uncertain meaning. In these cases, genetics
can help us in the management of infective episodes, which must be
treated promptly and appropriately to prevent the occurrence of com-
plications and focus attention at follow up on onset of gastrointestinal
symptoms. Informed consent to publish had been obtained.
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Introduction: Familial Mediterranean fever (FMF) is one of the most
common cause of autosomal recessive inherited autoinflammatory
disease in childhood. The MEFV mutations cause the impaired func-
tion of a protein called pyrine by incorrect coding and that process
results with uncontrolled inflammation. Microribonucleic acids(miRNAs) are small (16–24 nucleotides), non-coding RNA molecules
that have roles on the regulation of gene expression at the post-
transcriptional stage. The plasma expressions of miRNAs are altered
in various autoimmune and autoinflammatory diseases. Therefore,
miRNAs may have a role in the pathogenesis of autoinflammation
and may be used in diagnosis and follow-up of these diseases.
Objectives: We aimed to evaluate plasma expression of some can-
didate miRNAs that associated with pathogenesis of autoimmun-
ity and autoinflammation in patients with FMF.
Methods: Thirty patients diagnosed with FMF and age-sex matched
30 healthy children were enrolled for the study. Plasma levels of four
candidate miRNA (miRNA-16, miRNA-155, miRNA-204 and miRNA-
451), which is known to be related to autoimmunity and inflamma-
tion, were examined in all subjects. Plasma levels of miRNAs were
measured with Real Time PCR in attack and remission period of pa-
tients and healthy controls. Groups were compared with each other.
Results: Plasma miRNA-204 levels were decreased 6.5-fold in remis-
sion period of FMF patients, compared to the healthy controls (p
<0.001). This decrease was more prominent in M694V mutation car-
riers. It was also found that plasma miRNA-155 levels were lower in
remission period of FMF patients (p <0.03).
Conclusion: Our data suggest that, miRNA-155 and miRNA-204 may
play a role in the pathogenesis of FMF. Further investigations about
the role of miRNAs in FMF may help to elucidate the pathogenesis of
the disease.
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Introduction: New classification criteria for the inherited periodic fever
syndromes (TRAPS, FMF, MKD and CAPS) have recently been developed
during a Consensus Conference held in Genoa in March 2017.
Objectives: The aim of our study was to compare these new classifi-
cation criteria for monogenic recurrent fever syndromes with the
diagnoses of clinicians in a real-life setting. For this purpose we used
the JIRcohort database, an international platform gathering data of
patients with pediatric inflammatory disease.
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current fever syndrome were enrolled to the study. Criteria were applied
to all the patients and then compared to the clinical diagnosis of the
treating physician. An analytical study, describing concordance between
clinician diagnosis and Genoa criteria classification was performed.
Results: Cryopyrin Associated Periodic Syndrom: 14 patients of the JIRco-
horte matched Genoa criteria for CAPS. 8 had also been diagnosed CAPS
by clinicians. The remaining 6 patients fulfilling the classification criteria for
CAPS had various diagnoses made by the clinicians: SURF in 2 cases,
PFAPA in 3 cases, FMF in 1 case. Clinicians considered CAPS in 19 further
patients but none of them fulfilled the Genoa classification criteria for
CAPS. None of these patients displayed a confirmatory genotype for CAPS.
Familial Mediterranean Fever: 153 patients matched Genoa criteria
for FMF of whom 77 patients had also been diagnosed as FMF by
the treating physician. The remaining 76 patients had various clinical
diagnoses made by the treating physician: 14 SURF patients, 12
PFAPA patients, 12 TRAPS patients, 2 MKD patients and 2 CAPS pa-
tients. Interestingly 3 out of these 76 patients displayed genetic vari-
ants in another gene than MEFV while the others matched clinical
Genoa criteria for FMF. The new classification criteria for FMF needs
to be restricted to patients with genetic variants in MEFV. Clinicians
diagnosed FMF in 23 further patients not classified as FMF according
to the Genoa criteria for FMF: 6 with a heterozygous pathogenic
MEFV mutation, 1 with a heterozygous VOUS, 3 with homozygous
undetermined mutations, 12 without any genetic mutation.
Tumour Necrosis Factor Receptor Associated Periodic Syndrom: 18 pa-
tients matched Genoa criteria for TRAPS of whom all had been diag-
nosed TRAPS by the treating physician. All these patients had
pathogenic or likely pathogenic mutations. Clinicians diagnosed TRAPS
in 4 further patients, but none of them had a confirmatory genotype.
Mevalonate Kinase Deficiency: 217 patients matched Genoa criteria
for MKD, of whom only 5 were diagnosed as having MKD by their
treating physician. The remaining 212 patients fulfilling the Genoa
criteria for MKD had various diagnoses: 119 PFAPA, 3 CAPS, 31 SURF,
5 TRAPS and 41 FMF with half matching Genoa criteria for FMF. 5 pa-
tients had been diagnosed MKD without matching Genoa criteria for
MKD: 2 did not have genetical screening, 3 had heterozygous muta-
tion with incomplete data.
Conclusion: This study is the first evaluation of the Genoa criteria
in a real-life setting. The classification concordance with physician
diagnosis is high for patients with confirmatory genotype and
helps classifying patients with non confirmatory genotype. The
classification concordance with physician diagnosis is low when
patients did not display at least one gene mutation.
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Introduction: Lipoid pneumonia (LP) is a rare entity with two clinical
forms. Endogenous LP, putting aside cases associated with an ob-
structive cause, has been reported to be associated with metabolic,
infectious or systemic inflammatory diseases. Diagnosis may be chal-
lenging as clinical presentation is insidious and non-specific. Radio-
logical findings are well described with an unusually low density on
chest CT scan suggesting the presence of fat. Histopathology, when
available, describes lipid laden alveolar macrophages.Objectives: Lipoid pneumonia is scarcely described in pediatric
rheumatology and treatment strategy remains unclear.
Methods: We report the cases of two patients sharing a similar pres-
entation of auto-inflammatory disease of early onset with the associ-
ation of arthritis, urticarial eruption and hyper eosinophilia. For both,
progression was marked by lung involvement (lipoid pneumonia)
with major clubbing in the absence of hypoxia.
Results: The auto inflammatory presentation resembles systemic
Juvenile Idiopathic Arthritis (JIA) with a form particularly resistant
to biotherapies and hypersensitivity reactions to drugs. Biologic-
ally, we did not detect any marker of auto immunity and genetic
analysis with whole exome sequencing did not enable us to iden-
tify mutations in the genes associated with auto inflammatory dis-
eases nor new variants in a common gene to the two patients.
However, it is interesting to point out that under high doses of
anti interleukine 1(IL1) therapy (10mg/kg), these patients maintain
positive circulating levels of IL1 suggesting a central role of the
inflammasome in the presentation of these patients. The early on-
set of clubbing associated with lipoid pneumonia and in the ab-
sence of hypoxia seems characteristic and syndromic of this entity.
Conclusion: The combination of systemic autoinflammation with lip-
oid pneumonia (AILP) illustrates a new clinical entity with IL1
hypersecretion.
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Introduction: In 2008 the Paediatric Rheumatology European Society
(PReS) promoted an International Project for the study of Autoinflamma-
tory Diseases (AIDs) named Eurofever, whose main purpose is to create
a web-based registry for the collection of information in AIDs patients.
Objectives: To implement the Registry with the new recently de-
scribed AIDs and to increase the collection of longitudinal data.
Methods: The data analyzed in the study were extracted from the
Eurofever registry, which is hosted in the PRINTO website (http://
www. printo.it). From February 2015 we started the longitudinal col-
lection of follow-up data with particular focus on treatment, modifi-
cation of the clinical picture, onset of complication/adverse events.
Results: Up to date 4046 patients have been enrolled in the Registry
from 62 different countries (3773 of them with complete baseline
demographic information, represented in Table 1). Most of patients
(2618; 69%) reside in western Europe, 489 (13%) in central-eastern
Europe, 452 (12%) in southern-eastern Mediterranean countries
(Turkey, Israel, North Africa), 127 in Asia, 76 in South America and 11
in Australia. Compared to the first Eurofever report (Toplak et al,
2012) we have observed an increase of enrollment in central-eastern
Europe (from 6 to 13% of the total). 3444 (91%) patients have a
pediatric onset of disease (< 16 years); 400 (12%) of them received
diagnosis in adult age. 329 (9%) patients had an adult onset (81 FMF
patients, 52 TRAPS patients, 40 CNO patients, 12 Schnitzler syn-
drome). The median onset age is 4 years (range 1 month – 75 years),
the median diagnosis age is 8 years (range 1 month - 78 years). The
median diagnosis delay is 2 years (range 0-76 years); the diseases
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 95 of 243with the longer diagnostic delay were NLRP-12 mediated FCAS2
(mean 25 years, range 5-71), CAPS (mean 14 years, range 0-65), PAPA
(mean 13 years, range 0-50) and TRAPS (mean 12 years, range 0-76).
In 3292 pts (81%) complete clinical information from disease onset
to diagnosis are also available. At the moment of enrollment 3062
patients were in the pediatric age, 230 were adults. Longitudinal data
on treatment are available for 448 pts (11%).
Conclusion: The enrolment in Eurofever Registry is still ongoing. The
analysis of data will improve our knowledge both on the natural his-
tory of the single disease and on the efficacy/safety of treatment
commonly used in the clinical practice.
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Disease Pts
number
M/F Mean onset
age (years,
range)
Mean
diagnosis
age (years,
range)
Western
Europe
Eastern
Europe
Eastern-
Southern
Mediterranean
Others
Countries
Monogenic Disease
FMF 1078 561/517 6 (0-66) 10 (0-72) 540 120 290 128
CAPS 296 145/151 5 (0-57) 19 (0-77) 239 27 13 17
TRAPS 271 138/133 9 (0-63) 21 (0-77) 238 25 4 4
MKD 204 92/112 2 (0-45) 12 (0-51) 175 17 5 7
Blau disease 49 25/24 3 (0-29) 8 (0-45) 24 1 3 21
PAPA 40 20/20 6 (0-18) 19 (2-57) 31 5 2 2
DADA2 13 10/3 4 (0-10) 12 (6-18) 10 - 3 -
NLRP-12 12 6/6 12(0-29) 37 (4-76) 11 - - 1
SAVI 3 1/2 1 (0-4) 10 (1-17) 2 - - 1
DIRA 3 0/3 1mth 2 (0-7) 2 - 1 -
Majeed 3 3/0 18 (0-55) 23 (1-68) 3 - - -
CANDLE 1 0/1 10 12 1 - - -
Multifactorial autoinflammatory disease
PFAPA 664 376/288 2 (0-29) 5 (0-37) 333 224 94 13
CNO 564 210/354 11 (0-62) 12 (1-68) 513 16 24 11
Undefined
fever
346 170/176 12 (0-73) 17 (0-75) 295 40 4 7
Behcet 214 108/106 9 (0-56) 12 (2-57) 189 14 9 2
Schnitzler 12 5/7 53 (36-75) 57 (41-78) 12 - - -
Total 3773 1870/1903 - - 2618 489 452 214P171
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Introduction: Efficacy of TNF inhibitors in sideroblastic anaemia with
immunodeficiency, fevers, and developmental delay (SIFD) has been
recently reported1. The authors also demonstrated high levels of IL-6,
IL-12p40, IL-18, and interferon (IFN)-γ in two patients.
Objectives: To describe activation of the type I IFN pathway in two
patients with SIFD.
Methods: We assessed type I IFN status by IFN-α digital-ELISA quanti-
fication in serum, STAT1 phosphorylation and RNA expression of IFN-
stimulated genes (ISGs) in whole blood.
Results: Patient 1 (P1) was a 12-month-old girl referred because of re-
current attacks of fever with high levels of CRP from the age of two
months, with or without documented infections, chronic microcytic an-
aemia and failure to thrive. Aseptic febrile manifestations included vulv-
itis, parotiditis, adenitis, and neutrophilic panniculitis. She developed
progressive lymphopenia, with undetectable levels of B cells by age 15
months, so that IVIG was initiated at this time. At last follow-up, aged
six years, her height and development were normal and she was no
longer subject to recurrent infections. However, she continued to ex-
perience three to four febrile attacks each month, associated with ele-
vated CRP levels. Whole exome sequencing identified compound
heterozygous mutations in the TRNT1 gene (c.1213G>A, p.G405R /
c.1057-7C>G). Patient 2 (P2), a girl born at term to first-cousin parents
presented with intrauterine growth retardation (IUGR) and severe neo-
natal anaemia necessitating blood transfusion on the first day of life.
During infancy she required regular blood transfusions because of side-
roblastic anaemia, which resolved spontaneously at the age of four
years. She also demonstrated developmental delay and severe auto-
inflammatory flares associated with fever and high levels of CRP, diar-
rhoea and dehydration. Mild T and NK lymphopenia together with a
profound B cell defect were evident at four years of age. Sanger se-
quencing of TRNT1 identified a homozygous mutation in exon 7
(c.977T>C, p.I326T). Using an ultra-sensitive digital ELISA combined with
a high specificity pan-IFN-α antibody pair, we observed an increased
concentration of IFN-α protein in the serum from P1 (246.44 fg/mL,
healthy controls <10 fg/mL) and P2 (108.18 and 38.05 fg/mL, healthy
controls < 10 fg/mL), comparable to the levels measured in the context
of certain monogenic type I interferonopathies. We also recorded an in-
creased expression of ISGs in the whole blood of P1 and P2 on 3 occa-
sions. In an ex vivo flow cytometry assay, STAT1 and STAT3 were
constitutively phosphorylated in T lymphocytes and monocytes from
P2. Both patients also displayed a negative IFN score on one occasion,
suggesting a fluctuating biological process.
Conclusion: These data indicate a constitutive activation of the type I
IFN pathway in patients with biallelic mutations in TRNT1, and thus
suggest a possible role for type I IFN in the pathogenesis of SIFD. An
increase in serum IFN-α protein and an enhanced expression of ISGs
have been previously reported in one patient2. How aberrant tRNA
processing secondary to TRNT1 dysfunction might mediate enhanced
type I IFN production and signalling remains to be determined.
Informed consent to publish had been obtained from the parents
of the two patients.
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Introduction: So far several mutations of three prime repair exo-
nuclease 1 (TREX1) were identified as cause of Aicardi-Goutières syn-
drome (AGS). This rare autoimflammatory disease has been recently
in focus of research due to its pathogenetic and phenotypic similar-
ities with systemic lupus erythematosus (SLE).
Objectives: Autors present case of a child with AGS caused by newly
discovered mutation of TREX1 gene.
Methods: Retrospective analysis of AGS patient medical data includ-
ing results of whole exome sequencing.
Results: A seven days old female newborn was referred to our de-
partment of Pediatrics due to diffuse petechiae, hypotonia with inter-
mittent tremor and high-pitched crying. The child was born from the
third, normal pregnancy, at term, BW 3520 g, BL 50 cm, Apgar scores
10/10. Family history is unremarkable.
Diagnostic evaluation revealed mild trombocytopenia combined with
cerebrospinal fluid lymphocytosis. Results of serological tests and
PCR for intrauterine and perintal infections were negative. MR brain
scans showed simplified gray matter gyration, cerebelar hypoplasia
and multiple periventricular and basal ganglia calcifications.
Due to suspicion of AGS, whole exome sequencing was performed
and two heterozygous mutations in TREX 1 gene have been identi-
fied. The mother and dauther are carryers of c.506G>A mutation pre-
viously linked to AGS. The father and dauther have novel, to our best
knowledge, undescribed mutation c.197T>G.
Beside experimental attempts, there is no specific therapy for this
condition so far. Two-year follow-up of our patient was marked by
classical signs of AGS: severe developmental delay, occasional occur-
rence of chilblain like nail folds dyscolorations and mild progression
of periventricular calcifications verified by repeated MR brain scans.
Conclusion: Our discovery of new TREX1 mutation represent a small step
toward the definitive understanding of AGS. Reveling the mysteries of this
rare interferonopathy will eventually improve our comprehension of SLE.
Written consent for participation in this presentation was obtained
from both parents of the child.
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Introduction: We report the case of an 18-year-old girl with clinical
symptoms supportive of CANDLE syndrome. Her medical history in-
cluded: lupus pernio, ulcerative lesions distributed to extremities andface, alopecia areata, periorbital edema, diffuse arthralgias, poliarticu-
lar arthritis and growth hormone deficiency. Another remarkable
clinical feature was multiple painful pannicular nodules, which re-
sulted in a severe diffuse lipodystrophy, particularly on the face, with
subsequent need to undergo a course of lipofilling. She displayed a
highly positive interferon signature, but her genetic evaluation, in-
cluding whole exome sequencing, performed taking into account the
family history of connective tissue disease, was inconclusive.
Objectives: Her disease had always showed a moderate response to
corticosteroids, while several therapeutic attempts with immunosup-
pressant drugs (cyclosporine, azathioprine, ciclophosfamide, hydroxy-
chloroquine), intravenous immunoglobulins and biological agents
(anakinra, infliximab and abatacept), together with hyperbaric ther-
apy did not lead to significant improvement of her symptoms.
Methods: Given the severity of the cutaneous involvement with its
related emotional burden and acknowledging the role of interferon
in the pathogenesis of the disease, a therapy with 10 mg BID tofaciti-
nib (JAk1-JAK3 inhibitor) was started.
Results: She displayed a prompt improvement of her lipodystrophy
and chilblains along with a slow but progressive hair re-growth. An
almost complete healing of the panniculitic lesions was observed,
along with the halving of her interferon signature score.
Conclusion: However, during therapy she developed raised levels of
CK and LDL cholesterol. While the latter is an adverse event fre-
quently reported in subjects treated with tofacitinib and easily man-
ageable, increased CK are rarely observed and more difficult to be
interpreted. For this reason, the dosage of the drug was reduced to
7,5mg BID. No other adverse event was noticed. Informed consent to
publish had been obtained from the patient.
Trial registration identifying number: This work was funded by
IRCCS Burlo Garofolo grant RC24/17 and Telethon Foundation grant
GGP15241.
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Introduction: Type I interferon (IFN) gene expression signatures have
been found to be strongly up-regulated in patients with various
monogenetic diseases, i.e. in type I interferonopathies. These ex-
tremely rare diseases share manifestations with autoimmune con-
nective tissue diseases. Others have used so-called IFN scores to
assess the degree of type I IFN expression in peripheral blood.
Objectives: To report patterns of IFN gene expression in patients
with monogenetic interferonopathies, pediatric rheumatic diseases
and healthy controls.
Methods: PAXgene blood samples were obtained from children with
rheumatic diseases and healthy controls (children with non-
inflammatory conditions). We measured the expression of several
IFN-stimulated genes (ISGs), namely ISG15, RSAD2, IFIT1, IFI44L, IFI27,
SIGLEC1 (preferentially activated by type I interferons) and CXCL9
(preferentially activated by IFN-gamma) compared to the housekeep-
ing genes GAPDH and RPL by SYBR Green PCR. Expression values
were normalized to the same batch of healthy control RNA. The me-
dian normalized expression value of ISG15, RSAD2, IFIT1, IFI44L, IFI27
and SIGLEC1 (the IFN score) was assessed. Descriptive statistics were
performed to analyze the findings.
Results: Among 24 children with non-inflammatory disease in
PAXgene-derived RNA, there was strong correlation among the indi-
vidual probe sets within the IFN score (Pearson’s r ranging from 0.57-
Table 1 (abstract 175). Demographical data and evolution of different
disease groups
CAPS TRAPS MKD FMF BEHCET CRMO SAPHO All patients
Number of
patients
(families)
21
(19)
5
(5)
16
(15)
38
(34)
20
(20)
61
(61)
5
(5)
166
(159)
Gender (M;F) 8;13 1;4 5;11 16;22 12;8 18;43 2;3 62;104
Age at disease
onset* (years)
0†
(0†-
11)
5,5
(0-11)
1
(0†-
11)
3
(0-9)
6
(0-12)
9.5
(3-14)
8
(4-15)
8
(0-15)
Duration of
follow-up*
(years)
7
(0,5-
26)
3,75
(0-9)
4,25
(0-
18)
3,5
(1-
18)
2,75
(0-16)
12.5
(0-17)
2
(0-2,5)
8
(0-26)
Complications
or side effects
(%)
15
(71)
3
(60)
9
(56)
9
(23)
15
(75)
15
(24)
1
(20)
67
(40)
Number of
biologic
DMRADs*
2
(1-3)
1
(1-1)
2
(0-4)
0
(0-2)
0
(0-2)
0
(0-1)
0
(0-0)
0
(0-4)
Clinical
remission on
treatment (%)
18
(85)
0
(0)
9
(56)
24
(63)
7
(35)
15
(24)
0
(0)
73
(44)
Clinical
remission off
treatment (%)
0
(0)
1
(20)
0
(0)
2
(5)
0
(0)
13
(21)
3
(60)
19
(11.5)
Relapse after
remissions (%)
2
(9)
1
(20)
3
(18)
1
(2)
0
(0)
7
(11)
0
(0)
14
(8)
*median (range); † day 1 of life
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 97 of 2431,00) but no relevant correlation of those probe sets with CXCL9; the
correlation was even stronger among patients with varying degrees
of type IFN activation. The 5th and 95th centile for the IFN score
among healthy children were 1 and 4.8 and for CXCL9 2.4 and 13.7,
respectively. We could demonstrate a robust and persistent up-
regulation of the IFN-score in patients with known monogenetic type
I interferonopathies, including C1q deficiency, SAVI or Aicardi-
Goutières syndrome. The highest IFN-score was demonstrated in a
patient with new-onset anti-NXP2 antibody-positive juvenile derm-
atomyositis, and this was responsive to change, normalizing with
therapy and clinical remission. In contrast, some patients with Still’s
disease demonstrated a marked up-regulation of CXCL9 with normal
IFN-score.
Conclusion: We have established normal values for a type I IFN gene
and CXCL9 gene expression signature. Assessment of the expression
of ISGs may be useful in clinical practice, e.g. in order to screen for
potential monogenetic type I interferonopathies, autoimmune con-
nective tissue diseases and to assess changes in disease activity upon
treatment. The use of an extended gene expression panel to also in-
clude CXCL9 which is up-regulated by IFN-gamma may assist in the
understanding of the disease process in individual patients.
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Introduction: The autoinflammatory diseases (AID) include mono-
genic and polygenic disorders characterized by primary dysfunction
of the innate immune system1.
Objectives: Our objective was to analyze the clinical spectrum, gen-
etic background, therapeutic strategy and outcome in a cohort of
AID patients followed in a reference Pediatric Rheumatology center.
Methods: We performed a retrospective analysis of the medical records
of monogenic AID patients followed in the French reference center for
juvenile arthritis and rare pediatric systemic autoimmune diseases
(RAISE) between May 2007 and February 2018. Patients had been in-
cluded in the French data base system for rare diseases (CEMARA) with
an agreement of the Commission Nationale Informatique et Liberte. Ac-
cording to the French legislation, no ethics committee approval was re-
quested for such a retrospective survey.
Results: One hundred sixty-six patients were included: 21 Cryopyrin-
Associated Periodic Syndromes (CAPS), 5 TNF-Receptor-Associated
Periodic Fever Syndrome (TRAPS), 16 Mevalonate Kinase Deficiency
(MKD), 38 Familial Mediterranean Fever (FMF), 20 Behçet’s Disease
(BD), 61 Chronic Recurrent Multifocal Osteomyelitis (CRMO) and 5
Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis Syndrome (SAPHO).
Demographics features (Table 1), show a median follow-up of 8 years
(0-26), a sex-ratio of 62/104 and a median age of 8 years at disease
onset. Eighty-two patients (49%) have relevant familial history. Clin-
ical manifestations included musculoskeletal (83%), fever (50%),
gastrointestinal (47%), mucocutaneous (35%), neurological (21%),
ocular (16%), cardiorespiratory (10%) and genitourinary (0,6%) find-
ings, lymphadenopathy with/or hepatosplenomegaly (12%) and
growth impairment (12%). Complications/sequelae appeared in 40%
of cases. One mutant allele was found in 18/21 CAPS, 4/5 TRAPS and
11/38 FMF. Two mutant alleles were present in 14/16 MKD and 20/38
FMF. The most used treatment were NSAID (62%), biological DMARDs
(37%), colchicine (35%) and corticosteroids (31%). Sixty-six patientsreceived one or more biological DMARDs: Anakinra (56%), Canakinu-
mab (50%), Etanercept (30%), Adalimumab (4.5%), Infliximab (4.5%)
and Tocilizumab (3%). Anti-interleukin-1 therapy and colchicine
proved efficacy in CAPS and FMF, respectively. In addition, favorable
responses have been demonstrated anti-interleukin-1 therapy in
MKD, TRAPS, and colchicine-resistant FMF patients, as well as Etaner-
cept in TRAPS, MKD and CRMO patients non-responsive to NSAIDs.
Fifty-seven% and 41% of patients were in complete and partial re-
mission, respectively, at last visit.
Conclusion: AID in children are associated with a broad spectrum of
manifestations. Early diagnosis and referral are essential, as efficient ther-
apy can be proposed in most cases and early complications avoided.
Reference
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Introduction: Although histiocytic necrotizing lymphadenitis (HNL) or
Kikuchi-Fujimoto disease, which is characterized by self-limiting re-
gional lymphadenopathy with prolonged fever, has a low recurrence
rate, this rate appears to be higher and the disease progresses to se-
vere forms associated with autoimmune diseases such as systemic
lupus erythematosus (SLE) in some previous reports.
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 98 of 243Objectives: We analyzed the clinical characteristics of patients with
HNL focusing on cases with recurrence to define the predictive fac-
tors of recurrent HNL.
Methods: This was a retrospective study of patients diagnosed with
Kikuchi-Fujimoto disease from April 1995 to May 2017 in South
Korea. Electronic medical records were searched for clinical and la-
boratory manifestations. Patients with pathologically confirmed HNL
through biopsy of an enlarged lymph node were enrolled and recur-
rence was defined as having additional episodes of febrile lymph-
adenopathy before or after the pathological diagnosis.
Results: A total of 151 pediatric patients under 18 years of age (31.5%)
and 480 patients of all ages was analyzed. In the case of children under
18 years of age, the proportion of boys (43%; n = 65) and girls (57%; n =
86) was similar, but in adults, the ratio of women increased with 95 men
(28.9%) and 234 women (71.1%). At the pathologic diagnosis, 455
(94.8%) had lymphadenopathy and were mainly involved in the cervical
lymph nodes. Fever was present in 381 of the patients (79.4%). Cutane-
ous lesions (skin rash or maculopapular erythema) (5%) were the most
common extranodal symptoms, and complained of myalgia, fatigue,
cough, or rhinorrhea. Laboratory wise included leucopenia (22.5%; n =
108), neutropenia (9.8%; n = 47), and lymphopenia (33.3%; n = 160). Anti-
nuclear antibodies (ANAs) were present in 14.4% of the patients (n = 69),
of whom 32 (46.4%) were children under 18 years of age. Fifty-four pa-
tients (11.3 %) experienced recurrent HNL, and 1 patient recurred up to
4 times. In comparison between patients with recurrent HNL and non-
recurrent HNL groups, more extranodal symptoms including cutaneous
lesions, myalgia, or fatigue (p=0.013) and a prolonged duration of lym-
phopenia were significantly associated with recurrent HNL. The number
of patients with lymphopenia was higher in the recurrent HNL groups.
Conclusion: Our results suggest that recurrent HNL is more frequent
than reported, and recurrent HNL should be considered in patients
with extranodal symptoms or prolonged lymphopenia.
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Introduction: Chronic recurrent multifocal osteomyelitis (CRMO); is a rare
autoinflammatory bone disease characterized by recurrent, sterile inflam-
matory lesions occurring primarily in children and adolescents. Symp-
toms of presentation may range from mild unspecific bone pain, local
swelling and warmth to severe pain, malaise, fevers and even fractures.
Objectives: In this study, we aimed to evaluate our patients who had
a diagnosis of CRMO , retrospectively.
Methods: Six patients who were diagnosed with CRMO between 2010-
2017 years were included in the study. The CRMO diagnosis was based
on characteristic clinical features and magnetic resonance imaging find-
ings. The clinical data were obtained from the records of electronic files.
Results: The female to male ratio of the cases was 4/2 and the me-
dian age was 11.15 years (6-12). The age of diagnosis was 10.35 years
(4-12.5), the median period for diagnosis delay was 3 years (0.75-8).
The most common complaint was localized pain (n = 6, 100%). Ac-
companying diseases were detected in 3 patients; 1 case had inflam-
matory myositis, 1 case had PFAPA syndrome and 1 case had
selective IgA deficiency. Multifocal bone involvement was present in
4 (66%) cases and unifocal bone involvement in 2
(33%) cases. The most common site of disease was femur. Acute
phase reactants were high most of the cases; elevated erythrocyte
sedimentation rate (ESR) in 5 cases (83.3, n=6), elevated c-reactive
protein level in 4 cases (66.6%, n = 6), elevated serum amyloid a level
in 3 cases (60%, n=5), and elevated fibrinogen in 2 cases (50%, n=4)
were present. ANA was found positive at low titer in only 1 case,whereas rheumatoid factor was negative in all cases. Non-steroidal
anti-inflammatory drugs were prescribed in all cases and anti TNF
drugs in 3 (Etanercept in 2 cases and adalimumab in 1 case).
The diagnosis of CRMO is difficult and no consensus exist on diagno-
sis and treatment. Multifocal bone lesions with characteristic radio-
logical findings are very suggestive of CNO. The first line treatment is
usually NSAIDs, however, anti TNF treatment are needed in some pa-
tients to achieve for remission. Our case is the second one who had
inflammatory myositis and CRMO according the literature.
Conclusion: The diagnosis of CRMO is difficult and no consensus
exist on diagnosis and treatment. Multifocal bone lesions with char-
acteristic radiological findings are very suggestive of CNO. The first
line treatment is usually NSAIDs, however, anti TNF treatment are
needed in some patients to achieve for remission. Our case is the
second one who had inflammatory myositis and CRMO according
the literature.
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Introduction: Behςet’s disease (BD) is a chronic, relapsing, multisystem
inflammatory disorder classified as vasculitis and characterized by re-
current oral and genital ulcerations, uveitis, and protean clinical signs of
skin, central nervous system, musculoskeletal, and gastrointestinal in-
volvements. Oral ulceration is more common in younger patients. How-
ever, there are few reports about chronic hypopharyngeal ulceration,
are rare involvements in child in early phase. We report the case of a 4-
year-old Japanese girl with refractory laryngeal edema who was suc-
cessfully treated with multidrug therapy including infliximab (IFN).
Objectives: This report aimed to scrutinize of BD-related laryngeal and
hypopharyngeal manifestations in a Japanese young girl. We show that
rare clinical phenotype in early phase of pediatric-onset BD.
Methods: A young girl with multiple ulceration and stenosis of the
hypopharynx and laryngopharyngeal involvement at onset.Clinical
features, especially laryngeal findings by laryngoscopy in our patient
were described in detail about the findings symptoms at onset and
during the course. By using the paediatric Behςet’s disease (PEDBD)
classification criteria, the case was diagnosed.
Results: In a 4-year-old Japanese girl with a 2-year history of recur-
rent fever, recurrent ulcerative gingivostomatitis, snoring or respira-
tory disorder during sleeping, was referred to our hospital with the
suspicion of rheumatic diseases after tracheotomy was enforced due
to the breathing disorder and dysphagia. Before tracheotomy, phys-
ical examination revealed that her voice was hoarse and dysphasia.
Soft tissue lateral neck film revealed straightening of the cervical
spine with edema of the epiglottis and upper airway. Laryngeal en-
doscopy findings showed that laryngeal and hypopharyngeal in-
volvements were edematous severely. After tracheotomy, the patient
received oxygen supplementation, methylprednisolone. Involvement
in ulcerative colitis was estimated by using colon fiverscopy. By using
the PEDBD classification criteria, the case was diagnosed.Her symp-
toms except for intestinal involvement did not change with these
maneuvers. On admission, the patient showed body temperature of
37 °C, heart rate of 107/min, respiratory rate of 28/min, and blood
pressure of 108/66 mmHg. Genital ulcers were absent, and repeat
ophthalmologic examinations showed no symptoms. Laboratory ex-
aminations revealed the presence of nonspecific inflammation: white
blood count, 11,100/μL; C-reactive protein (CRP) level, 2.0 mg/dL;
electron spin resonance (ESR) level, 20 mm/h. Hypocomplementemia
was absent. The results of immunological examinations were nega-
tive for specific autoantibodies, including antinuclear antibody, anti-
Table 1 (abstract P180). See text for description.
Group N Age mean (SD) ADA2 U/L median (IQR)
Stroke 14 9.6 (5.0) 10.0 (9;11)
HIDS 8 15.7 (3.0) 8.0 (7; 12.5)
VAS 5 16.6 (1.1) 6.0 (6;9)
SLE 6 16.1 (0.9) 16.0 (15;17)
PFAPA 21 4.7 (2.8) 12.0 (11;13)
JDM 14 12.5 (4.4) 8.5 (8;10)
NONINFLAMMATORY 20 9.2 (4.0) 10.0 (9;12)
ADULTS 21 40 (12.8) 10.0 (9;11)
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test for HLA- B51 was positive. Bone marrow examination showed no
evidence of malignancy. Then, colchicine and 1mg/kg/day of pred-
nisolone (PSL) therapy was started. When the dose of PSL was de-
creased, her snoring and respiratory disorder relapsed. Therefore,
infliximab (IFX) therapy was started and the dose of PSL was grad-
ually decreased. For approximately 1 years, she showed a good gen-
eral condition with laryngeal swelling improved.
Conclusion: There is a case of BD in a child, who has multiple ulcer-
ation and stenosis of the laryngeal and hypopharyngeal involve-
mentsThe Upper airway manifestations could be critical to identify
potentially life-threatening laryngeal involvement at onset by direct
laryngoscopy. In our case might deal with the successful treatment of a
laryngopharyngeal involvements with IFX as anti-TNF-alpha agents. In-
formed consent to publish had been obtained from the parent.
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Introduction: Adenosin deaminase type 2 (ADA2), encoded by CECR1
gene, is an important enzyme in purine metobolism and a growth
factor for endothelial and myeloid cells. Loss-of-function mutation in
CECR1 gene causes deficiency of ADA2 (DADA2) leading to an auto-
inflammatory disease with vasculitic features. While DADA2 patients
have decreased ADA2 enzyme activity, its increase has been shown
in other inflammatory diseases like systemic lupus erythematosus
(SLE). Less is known about ADA2 in other conditions.
Objectives: To assess ADA2 activity in a spectrum of inflammatory
diseases and in controls in order to optimize its use as a screening
test for DADA2 in the Czech Republic.
Methods: Serum ADA2 enzyme activity was measured using Adenosin
Deaminase Assay Kit (Diazyme Laboratories) with using specific ADA1 in-
hibitor in patients recruited from our clinics and from controls after ap-
propriate consent. Enzyme activity was expressed in U/L and values were
compared among disease groups and controls using Mann-Whitney test.
Results: Total of 109 individuals were examined: 88 children (mean age
10.2, SD 5.4yrs) and 21 healthy adult volunteers. Disease groups were
as follows: children with stroke of unknown aetiology (Stroke), hyper-
IgD syndrome (HIDS), systemic vasculitis (VAS), systemic lupus erythe-
matosus (SLE), juvenile dermatomyositis (JDM), PFAPA syndrome (Peri-
odic Fever, Aphtae, Pharyngitis, Adenitis), children with non-
inflammatory conditions. ADA2 activity in Stroke, HIDS and JDM pa-
tients was comparable to controls while patients with vasculitis had
lower and patients with SLE and PFAPA higher ADA2 activity than con-
trols (p=0.012;0.001;0.025 respectively. (Table 1). The lowest absolute
ADA2 activity was detected in a 18 years old patient with HIDS (3 U/L)
while 17 years old SLE patient had the highest activity (23 U/L).
Conclusion: We have demonstrated wide range of ADA2 enzyme ac-
tivity in a spectrum of rheumatic diseases in children. As age influ-
ences ADA2 activity inversely highest levels in the youngest PFAPA
subgroup is not surprising. Mechanisms that lead to increased ADA2
in SLE noticed also by others are not fully understood. Nevertheless,
in respect to DADA2 low enzyme activity is of importance, though its
exact cut-off value has not yet been established. All our patients hadADA2 activity above levels reported in DADA2. It appears that ADA2
activity assessment is a feasible method that may serve as a useful
screening test in patients with clinical picture suggestive of DADA2.
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Introduction: Mevalonate kinase deficiency (MKD) is a rare autosomal
recessive autoinflammatory disease caused by mutations in MVK gene.
Objectives: MKD patients typically have an early onset of symptoms
including recurrent episodes of high fever, abdominal pain, diarrhea
and vomiting, arthralgia and lymphadenopathy (AIDAI criteria for
HIDS). However not all patients have typical symptoms at the time of
onset. MKD treatment remains an unsolved problem, since none of
the modalities previously used for MKD treatment are fully effective
in the disease control.
Methods: We conducted a retrospective analysis of clinical features
of fifteen patients (7 females, 8 males) with genetically confirmed
MKD. Ten patients received therapy with inhibitors of IL-1 (Anakinra
and\or Canakinumab). One of the patients died from amyloidosis
and macrophage activation syndrome (MAS) prior to treatment initi-
ation, her diagnosis was verified post mortem.
Results: Thirteen patients had manifested within the first 6 months
of life, one – at the age of 1.5 years, one – at three years of age. Dur-
ing the course of the disease all patients had periodic fever and per-
ipheral lymphadenopathy ( mainly cervical group), as well as
abdominal pain, nausea\vomiting. Six patients had diarrhea, some-
times with blood, one patient suffered from severe constipation.
Rash was seen in eight patients, myalgia, artralgia were observed
only in nine. Oral ulcers were noted in eight children. Three patients
had neurological involvement, one patient had it as the main symp-
tom. One patient had periorbital edema and hyperemia during at-
tacks, which to our knowledge, have not been reported previously in
MKD. Thrombocytopenia, neutropenia were only one. One patient de-
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 100 of 243veloped amyloidosis and MAS before IL1 inhibitor treatment initi-
ation, which led to her death. In patients receiving anti-IL-1 ther-
apy AIDAI index decreased from 58.3±11,2 before to 1,5±1,4 after 6
month of therapy (p =0.003).
Conclusion: MKD symptoms can be variable and sometimes atypical,
which requires physician’s awareness. In our cohort of MKD patients
anti IL-1 therapy was highly effective.
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Introduction: In 2011, Etanercept (ETA) was approved for clinical appli-
cation in patients with juvenile idiopathic arthritis (JIA) older than 2
years of age; adalimumab (ADA) was approved in 2013. However, the
available data for these patients are not sufficient even in large-scale
registers. Uveitis in older children is a factor taken into consideration
when choosing anti-TNF therapy, so we believe that its onset at early
age may affect efficacy of treatment with different anti-TNF drugs.
Objectives: This study aimed at evaluating comparative efficacy of ADA
and ETA in children of young age depending on their uveitis status.
Methods: Comparative analysis involved patients who had initiated
ETA (n=49) or ADA (n=25) therapy at the National Medical Research
Center of Children's Health (Moscow) at an age of ≤4 years. None of
ETA patients had previous history of uveitis. ADA patients were allo-
cated into 2 subgroups depending on their uveitis status. Patients in
group 1 had active uveitis (n=13), while group 2 patients had no ac-
tive uveitis (n=12). Treatment efficacy was evaluated according to
the dynamics of clinical and laboratory signs using the ACRPedi cri-
teria. The Wallace criteria were used to evaluate whether or not re-
mission had been achieved.
Results: Therapy with ETA and ADA in children under 4 years of age
was found very efficacious as soon as after the first month. The CHAQ
and JADAS disease activity scores, CRP and ESR laboratory values, morn-
ing stiffness duration, and the VAS score (assessed by both patient and
physician) significantly decreased after 4-week therapy in all three
groups (p<0.01). After 3 months of therapy, the number of affected joints
(swollen or painful joints, joints with the limited range of motion and
with active arthritis) reduced substantially in all three groups (p<0.01).
The percentage of ETA patients who achieved ACR50/70/90 by the
end of follow-up period, with allowance for patients who discontin-
ued treatment because of AEs or poor efficacy, was 85.7/83.7/77.6%,
respectively. The percentage of ADA patients who achieved ACR50/
70/90 by the end of follow-up period was 76.9/76.9/69.2% (ADA pa-
tients with uveitis) and 75/58.3/41.7 (ADA patients without uveitis).
The groups were characterized by different dynamics of achieving
ACR (Figs. 1-2). Treatment efficacy was comparable in ADA patients
with uveitis and ETA patients without uveitis, while significantly
fewer ADA patients without uveitis reached ACR70/90.
Comparable percentages of ETA patients and ADA patients with uve-
itis achieved remission (53.1% and 53.8%, respectively), while only 3
(25%) of ADA patients without uveitis achieved long-term clinical re-
mission (p-values are insignificant)Conclusion: In patients younger than 4 years of age, efficacy of ADA
and ETA treatment differs in different patient groups according to
baseline clinical parameters. ADA shows higher efficacy in achieving
ACR70/90 and inactive stage of the disease according to the Wallace
criteria in patients with uveitis as compared to patients with the
negative uveitis status. Children without uveitis show better response
to ETA, although there is a 6-10% risk of de novo uveitis. Therefore,
ADA is the drug of choice for children with uveitis under 4 years of
age, while ETA is preferable in children without uveitis.
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Introduction: Approximately 10–22% of biologic naive juvenile idio-
pathic arthritis (JIA) patients discontinue etanercept (ETN) within 12
months because of primary inefficacy or loss of response. In adult pa-
tients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS),
the results of studies that investigated the relationship between
serum ETN levels and clinical response are conflicting. In children, no
study has investigated the possible relationship between ETN circu-
lating level or immunogenicity and disease activity in a population of
JIA patients
Objectives: To investigate the relationship between etanercept (ETN)
levels, the presence of anti-drug antibodies to ETN (ADAb) and clinical
response to ETN in patients with Juvenile Idiopathic Arthritis (JIA).
Methods: Prospective study of JIA patients under 18. Clinical and
pharmacological data were collected at two visits. Clinical remission
and JIA activity on ETN were assessed according to the Wallace criteria
and the Juvenile Arthritis Disease Activity Score (JADAS) respectively.
ETN and ADAb serum levels assessments were determined using ELISA-
based assays. The relationship between ETN concentration and the re-
mission status or disease activity was assessed by an univariate logistic
analysis and a multiple regression analyses adjusted on age, size de-
scriptors, co-treatments and JIA classification.
Results: One hundred and twenty-six patients were enrolled. The me-
dian duration of ETN treatment at inclusion was 569 days (range 63-
2,330). ADAb were undetectable (< 10 ng/ml) in 171/224 (76%) sam-
ples, and were > 25 ng/mL in 2. No significant relationship between
ETN concentration and the remission status or disease activity was
found using either univariate or multiple logistic regression analyses.
No correlation was found between the remission status and the detec-
tion of ADAb.
Conclusion: This study did not demonstrate any correlation between
circulating ETN levels and JIA activity in a large population of pa-
tients with JIA previously treated with ETN for at least 2 months. As
described for adults, it confirms that ETN is marginally immunogenic
in pediatric patients. These results do not support monitoring ETN
concentrations or ADAb for the management of such JIA patients.
Trial registration identifying number: The study is registered at
Clinical Trials.gov under number NCT02030613. All patients (or their
parents) gave written informed consent
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Introduction: Although nowadays intraarticular corticosteroid injec-
tions may be considered a somewhat obsolete method of treatment
of juvenile idiopathic arthritis, they still might serve as an alternative
to stronger but more expensive DMARDs/biologic drugs.
Objectives: To assess the outcome of joint injections (JI) with appli-
cation of corticosteroid in children with juvenile idiopathic arthritis
(JIA) and factors affecting the time to flare of arthritis.
Methods: Clinical documentation of patients with JIA under the care of
the Paediatric Rheumatology Department in Leeds General Infirmary,
UK, who received joint injections with triamcinolone hexacetonide (or
in some cases methylprednisolone acetate if small joints were injected)
between January 2015 and December 2016 was analysed. The time to
flare of arthritis was recorded based on follow-up visits. We evaluated
predictors such as gender, age of disease onset, oligo- or polyarticular
course of disease, disease duration, general anaesthesia, concurrent
medication, CRP and ESR at the time of JI application.
Results: 117 patients (41 boys and 76 girls in age 1-17 years) with JIA
received in total 460 intraarticular injections (75 patients in general
anaesthesia). 75 children had history of arthritis in 5 or more joints.
Flare of arthritis was observed in 64.1% of children after a median of
115 days. The cumulative probability of survival without flare of syno-
vitis was 63.2% after 6 months and 49.6% after 12 months. In our co-
hort of patients, the outcome of joint injections was not influenced
by any of named predictors.
Conclusion: Even in the age of DMARDs and biologic drugs, joint in-
jections with application of corticosteroid can be considered an ef-
fective therapy in the treatment of JIA.
Disclosure of Interest
None Declared
P185
BIOLOGICS IN PEDIATRIC RHEUMATOLOGY
Mustafa Çakan, Şerife Gül Karadağ, Nuray Aktay Ayaz
Pediatric Rheumatology, Kanuni Sultan Süleyman Research And Training
Hospital, İstanbul, Turkey
Correspondence: Mustafa Çakan
Pediatric Rheumatology 2018, 16(Suppl 2):P185
Introduction: Biologics are medications that target specific molecules
expressed on cells or secreted into the extracellular space. Use of bi-
ologics has increased in pediatric rheumatology since 2000s and pa-
tients with sequels have decreased sequentially.
Objectives: The aim of this study was to demonstrate indications of
biologic usage in pediatric rheumatology.
Methods: Between May 2010 and September 2017, the files of all pa-
tients that biologics were used were reviewed. The patient had to be
using a biologic agent for at least three months and had to be com-
ing regularly to follow-up visits.
Results: In this study, 236 biologic agents were used in 172 patients.
Mean duration of biologic use was 18.7 ± 14.0 months. In 69% of pa-
tients only one biologic was used while 31% of the patients needed
2 or more biologics. Six patients needed 3rd biologic, one patient 4th
and one patient needed 5th biologic agent.
Indications for biologic use were; JIA (123 cases), FMF (29 cases),
CAPS (5 cases), HIDS (4 cases), Behçet disease (3 cases), CRMO (2
cases) and one case for each of the following diseases; Takayasu dis-
ease, SLE, DADA2, idiopathic recurrent pericarditis, idiopathic uveitis
and pyoderma gangrenosum.
Juvenile idiopathic arthritis was the most common indication for bio-
logics. Biologics were needed in 30.3% of all JIA cases (123/405). Themost common subtypes that biologics were used in JIA were extended
oligoarticular JIA (64.7%) and rheumatoid factor positive polyarticular
JIA (57.1%). With biologic treatment, remission was achieved in 79% of
cases while 21% of cases were active despite use of biological treat-
ment. In 14 JIA cases biologics were used for refractory uveitis.
Familial Mediterranean fever was the second most common indica-
tion for biologic use with 29 cases. Total number of FMF patients that
were followed during the same period was 1097, so the frequency of
colchicine-resistant FMF was 2.6%. M694V homozygous mutation
was present in 76% of colchicine-resistant FMF patients. With bio-
logics complete remission was achieved in all FMF patients.
In 236 biologic agents, etanercept (34%) was the most commonly
used agent followed by anakinra (19%), adalimumab (17%), and
canakinumab (14%).
In 29% of patients isoniazid prophylaxis were used due to tuberculin
skin test positivity. None of the patients develop tuberculosis infec-
tion during follow-up.
Conclusion: Biologics are being used more frequently in pediatric
rheumatology. With the report of good outcomes biologics are used
at the earlier stages of the diseases to prevent sequel formation. Our
cohort also supports this opinion that biologics seem to be effective
and safe in children with rheumatic diseases.
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Introduction: The usefulness of intra-articular steroids (IAC) are
well described, including rapid resolution of synovitis, relief of pain,
support for normal functioning, and reduction of arthritis complica-
tions. IACs may have side effects, but they may be relatively mild
compared to those associated with disease modifying antirheumatic
drugs (DMARDs) or biologics.
Objectives: To investigate the efficacy and safety of IAC treatment in
single and multiple joints in children with juvenile idiopathic arthritis
(JIA) and to investigate the factors staying in remission of synovitis.
Methods: The clinical records of 41 patients who received IAC injec-
tion between January 2012 and December 2017 were reviewed. A
total of 65 procedures were evaluated for efficacy, length of time be-
tween repeat injections, safety, and post-procedural complications.
The corticosteroid used was triamcinolon hexacetonide for large
joints and methylprednisolone for small or difficult to access joints.
The effect of JIA subgroups, disease duration until performing IAC,
ANA status, acute phase reactants and concurrent methotrexate
(MTX) and biological drug treatment on the duration of remission in
joints treated with IAC was investigated.
Results: A total of 65 IACs were performed in 41(27 female) patients.
Among 41 patients, 32 had persistent oligoarthritis, 4 extended oli-
goarthritis, 3 polyarthritis and 2 enthesitis related arthritis. The me-
dian age at diagnosis was 7 (1.5-16) years, median follow-up time
was 38 (5-69) months and the median time of the first IAC injection
was 2 (0-49) months after diagnosis. Anti-nuclear antibodies were
positive in 28(68%) patients. The median ESR was 33( 1-120) mm/h,
and CRP was 9( 4-110) mg/L at the time of injection.
First IAC injection was done in 47 knees, 4 ankles, and 1 each wrist,
elbow and proximal interphalangeal joint. In 13 patients two
joints were injected at the same time. Repeat injection was done in
11 joints, all were knee.
Twenty-one of 41 patients received IAC, 17 received concurrent or
ongoing MTX with IAC, 4 received MTX and anti-TNF therapy. The
duration of remission without exacerbation of synovitis in joints
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 102 of 243treated with injection was found to be median 11,5 (range 1-66 )
months. The median interval between repeat injections was 27.5 (6-
57) months. Three joints did not respond to IAC injection.
Subgroups of the disease and disease duration had no effect on the dur-
ation of remission. The duration of remission was longer in boys (11.5 vs
8 months), in ANA positives (13,5 vs 10 months), and in patients with
concurrent MTX treatments (12 vs 9 months) . However, the differences
were not statistically significant. The level of acute phase reactants had
not been shown to correlate with the duration of remission.
No early or late adverse events were observed after the IAC procedure.
Conclusion: In single or multiple joints, IAC treatment induced remis-
sion in a significant proportion of patients without major side effects.
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Introduction: Tocilizumab is a monoclonal antibody against
interleukin-6 that has recently emerged as an alternative treatment
modality for juvenile idiopathic arthritis (JIA).
Objectives: We aimed to discuss the clinical and laboratory findings
and treatment response of JIA cases to tocilizumab therapy.
Methods: The study group consists of JIA patients who were treated
with tocilizumab and followed up between the years of 2014-2016 in
the Department of Pediatric Rheumatology of Hacettepe University
Faculty of Medicine. Clinical characteristics, laboratory findings, treat-
ment responses and disease activity were reviewed from medical
charts and electronic files of the patients, retrospectively.
Results: There were 20 JIA patients aged between 0-18 years,
were followed up from 2014 to 2016 and received tocilizumab
treatment in our clinic. Treatment response could be not evalu-
ated in two patients since they developed anaphylactic reactions
due to tocilizumab. Of the remaining 18 patients, seven of them
(38.9%) had polyarticular JIA, and eleven (61.1%) had systemic
JIA. Platelet counts, erythrocyte sedimentation rate(ESR) and C-
Reactive Protein(CRP) levels, active joint counts, and JADAS71
were significantly decreased at the third month in both polyarti-
cular and systemic JIA, while there were not any significant dif-
ferences between the third and sixth months. All of the patients
with polyarticular JIA had low disease activity at six months. Eight
patients with systemic JIA had an inactive disease at six months,
whereas the remaining three patients had high levels of CRP
without presence of any clinical symptoms. Steroid treatment was
terminated at the sixth month in all patients except for three pa-
tients who continued to receive 0.05-0.25 mg/kg steroid treat-
ment. Two patients developed thrombocytopenia, one patient
developed macrophage activation syndrome, and one patient had
elevated transaminases due to tocilizumab treatment.
Conclusion: Previous studies have shown that tocilizumab treatment
is well-tolerated, effective, and safe for use in JIA patients. In the
present study, we also demonstrated the efficacy of tocilizumab
treatment in JIA patients from our clinic.
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Introduction: The introduction of biologic drugs (BD) (such as mono-
clonal antibodies, cytokines, and fusion proteins) has represented a
major breakthrough for the treatment of rheumatic diseases during
the last two decades. However due to their high molecular weight,
long half-life and parenteral use, hypersensitivity reactions may be
seen frequently and may limit their use.
Objectives: In cases where the use of the drug is absolutely necessary,
the drug may be given by desensitization if there is no contraindication.
Methods: In this report, we presented four cases with rheumatic dis-
eases who were successfully treated by desensitization following ana-
phylaxis due to that biological drug.
Results: Four patients (1 systemic lupus erythematosus, 1 granuloma-
tous polyangiitis, 1 polyarteritis nodosa, and 1 systemic juvenile idio-
pathic arthritis) participated [duration of follow-up: 5.5 (0.5-9) years].
Two patients had anaphylaxis during rituximab infusion and two pa-
tients had anaphylaxis during tocilizumab infusion [number of infusion
dosage: 3 (2-5)]. All patients had active disease at time of reaction. Two
patients had received another biologic drug previously. All patients
were administered premedication before desensitization [methylprednis-
olone 2 mg / kg (maximum 60 mg) before 4 hours and 1 mg / kg
hydroxyzine (25 mg maximum), ranitidine 2 mg / kg, paracetamol
before 1 hour]. In the presence of respiratory distress, montelukast was
also added. Desensitization protocol consisted of 12 step, drug dosage
was increased by every 15 minutes. After the desensitization protocol,
all patients received a median of 12 (8-15) drug infusions without any
reaction.
Conclusion: In some cases, biologic drugs may be the only treatment
alternative, however allergic reactions restrict the usage of them. In
referral centers, desensitization protocols may help to control disease
activity in these resistant patients.
Disclosure of Interest
None Declared
P189
LONG-TERM SAFETY AND EFFICACY OF ETANERCEPT IN GREEK JIA
ADULTS AT THE TRANSITION PERIOD
Despoina Dimopoulou1, Maria Trachana2, Dimitrios Deligeorgakis1,
Artemis Koutsonikoli2, Polyxeni Pratsidou-Gertsi2, Alexandros Garyfallos1
1Rheumatology Unit, 4th Department of Internal Medicine; 2Pediatric
Immunology and Rheumatology Referral Center, 1st Department of
Pediatrics, Aristotle University, Hippokration Hospital, Thessaloniki, Greece
Correspondence: Despoina Dimopoulou
Pediatric Rheumatology 2018, 16(Suppl 2):P189
Introduction: Our published follow-up assessment on adults with Ju-
venile Idiopathic Arthritis (JIA) until 2011, revealed that half of the
patients had flares in adulthood, despite previous administration of
several anti-TNFs.
Objectives: a) To describe the long-term outcome of JIA adults after
transition, who had received Etanercept (ETN) (from 8/2001 to 12/
2017), as the only or the last anti-TNF. B) To evaluate our model of tran-
sition in a subgroup of refractory to conventional DMARDs JIA patients,
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Methods: Retrospective cohort analysis of Greek adults with estab-
lished diagnosis of JIA. The disease activity state was assessed by 2
contemporary quantitative tools: the Juvenile Arthritis Disease Activ-
ity Score-10 (JADAS 10) (Clinical Remission, CR, Low, Moderate and
High Disease Activity, LDA, MDA, HDA, respectively) and Wallace cri-
teria (CR on/off ETN). Baseline was defined as the 1st ETN dose.
Results: 35 patients (female 25), aged (mean±SD) 23.5±4.6 years, were
followed for a median (IQR) of 9 (3.6, 12.7) years. The median (IQR) pa-
tients’ age at the 1st ETN dose was 16.4 (12.1, 17.8) years and the lag
time from JIA onset to baseline was 6.5 (2.8, 12.5) years. The majority of
the patients had a polyarticular course (27/35, 77.1%), regardless of the
JIA subtype. ANA positivity was recorded in 16/35 (45.7%) and previous
uveitis in 4/35 (11.4%). Nine patients (25.7%) had previously received
other anti-TNFs (Adalimumab n=6, Infliximab n=3). The baseline median
(IQR) patients’ JADAS-10 was 14/40 (9.5, 20.5) and the ETN yr-
administration was 3.5 (2, 5.5). 33/35 (94.3%) patients were compliant
to ETN and the study drug was well-tolerated. Regarding safety, only 3
patients (8.6%) experienced 6 adverse events (0.04/patient-years),
namely injection site reaction (n=1), uterine hemorrhage (n=1), transi-
ent ANA positivity (n=1) and uveitis (n=3, 2/3 as flares). Uveitis under
ETN led to the drug discontinuation in 2 patients (1 with new, 1 with
pre-existing). Four patients discontinued ETN due to efficacy loss and
one due to latent TB infection. 7/35 (20%) achieved CR and discontin-
ued ETN after 3.3 (2, 4.5) years (median, IQR). The remaining 21 patients
were still on ETN at the last evaluation. The median (IQR) percent dur-
ation of CR remission on ETN, according to the Wallace criteria, was
86%. CR off ETN lasted 1.17 (0.8, 4.3) years (median, IQR). In respect to
the disease activity state at the last assessment: A) among the ETN on-
going receivers, 66.7% were in a CR state, 19% in LDA, 14.3% in MDA
(median JADAS: 1). B) CR achievers still remaining off ETN, sustained this
state in 85.7% (median JADAS: 0).
Conclusion: ETN in the critical transition period proved to be safe as
adverse events were rare. ETN had a long-term and sustained effi-
cacy, allowing CR off anti-TNF in 20% of the patients. Our transition
policy supported the patients’ meticulous follow-up and compliance
to ETN in adulthood.
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Introduction: Over the last fifteen years, the development of biological
agents improved dramatically the outcome of children suffering from
Juvenile Idiopathic Arthritis (JIA). Adult studies indicate that treatment
with biological agents lead to an increased risk of serious infections,
but very little is known about this risk in children.
Objectives: The main objective of our study is to assess the infectious ad-
verse events (IAEs) occurring in JIA children treated with biological agents.
Methods: Patients were selected from the retrospective module of the
JIRcohorte, a multicenter registry for children with inflammatory and
rheumatological diseases. Data concerned the period between January,
10th 2001 and August 2015. Besides demography, diagnosis and treat-
ment options of the patients, infectious adverse event (IAE) were re-
trieved. For every infectious side effect, the date, the severity, the need
for an hospitalization, the accountability of the treatment on the occur-
rence, and the consequence of the event on the biologic course were
noted. The type of microorgansim and the affected organ were also an-
alyzed. Incidence rates were expressed in number of events per 100
person-years (100p-y), and OR were calculated; for their comparison,
we used the Fischer test with a significance threshold at 0.05.Results: Six hundred eighty-six patients with JIA from thirteen French-
speaking rheumatologic reference centers were included in the study.
A total of 1095 treatments with biological agent, for 3075.4 person-
years of exposure were analyzed. One hundred eighty-four IAE occur-
ring under a treatment with biologics were described, that is to say an
incidence rate of 6.0 events/100 p-y, 15.5/100 p-y with Tocilizumab,
9.6/100 p-y with Canakinumab, 7.4/100 p-y with Abatacept, 6.9/100 p-y
with Golimumab, 6.7/100 p-y with Aankinra, 6.3/100 p-y with Infliximab,
4.8/100 p-y with Etanercept, and 3.7/100 p-y with Adalimumab. Risk of
developing an infection was significantly higher with IL6 antagonists
than with TNF-inhibitor (TNFi) (OR 3.67 IC95% [2.41 ; 5.49] p<0.001), or
with IL1 antagonists (OR 2.34 IC95% [1.7 ; 4.4] p=0.004). Forty point
eight percent of the IAE affected the upper respiratory tract or the ENT
sytstem. A total of 12 IAE were described as severe or very severe,
which represented an incidence rate of 0.4/100p-y, 43% occurring with
TNFi. The risk of developing a severe or very severe infection was
higher with IL6 antagonist or IL1 antagonist than with TNFi. Twenty-
two herpes zoster infections, including twenty under biologics were re-
ported (0.7/100 p-y), and there were more virus due to immunosup-
pression with IL6 antagonist than with TNFi. No case of tuberculosis,
opportunistic infection, or death was reported.
Conclusion: Infectious complications with biologics occurring in children
treated for JIA are rare, and in most of the cases have a mild or moder-
ate severity, affecting mainly the upper respiratory tract or the ENT.
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Introduction: ABIRISK is a project funded by Innovative Medicine Initiative,
with the aim to investigate anti-drug antibody (ADA) formation in the
treatment of JIA with biologics (BPs). A major limitation to the use of bio-
logics is the development of ADA that may decrease the efficacy of BPs.
Objectives: The aim of this project is to improve the capability to
predict biologic immunogenicity in JIA patients.
Methods: JIA Patients (by ILAR criteria) followed by 24 PRINTO centres in
12 countries were prospectively enrolled and treated with Etanercept,
Adalimumab or Tocilizumab. Patient’s data were obtained from Pharma-
child, a pharmacovigilance data registry of JIA patients. For each patient
detailed demographic and clinical information were reported; biologic
samples were collected for PK and ADA detection before therapy start
as well as at periodic visits up to month 18 of follow-up. Disease activity
was assessed with Juvenile Arthritis Disease Activity Score-10 (JADAS10)
and JIA American College of Rheumatology (JIA ACR) criteria.
Results: 148 patients were included in the analysis. Five patients
were considered twice because treated with 2 different sequential bi-
ologics. Demographic and clinical data by therapy are represented in
the table. 54% of the patients were treated with Adalimumab. Dis-
ease duration was higher in the group receiving Tocilizumab. Disease
activity showed a pattern of improvement over time both globally
and for each treatment group (Table 1). Anti-adalimumab and anti-
tocilizumab antibodies were detected respectively in 14 and 3 pa-
tients, while no patient developed antibodies anti-etanercept.
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 104 of 243Conclusion: Preliminary data show a global improvement of disease
activity during follow-up period. Analysis of the correlation between
drug concentration/ADA development and clinical information will help
to determine which patients will respond best to which biologic.
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Adalimumab
n=80 (54%)
Etanercept
n=36 (24%)
Tocilizumab
n=32 (22%)
Total n=148
Age at onset, years 6.1 (3.1-10.4) 4.9 (1.9-9.7) 6.1 (3.8-9.1) 5.8 (2.7-10.1)
Age at JIA diagnosis, years 6.8 (3.3-11.9) 5.5 (2.1-10.6) 6.4 (4.1-9.2) 6.4 (3.2-11.0)
Disease duration, years 2.4 (0.9-4.8) `2.2 (1.1-5.5) 4.1 (1.4-6.5) 2.6 (1.1-5.8)
Female 60 (75.0) 26 (72.2) 23 (71.9) 109 (73.6)
ILAR JIA category
Systemic 2 (2.5) 0 7 (21.9) 9 (6.1)
Oligoarthritis 30 (37.5) 7 (19.4) 9 (28.1) 46 (31.1)
Polyarthritis 27 (33.8) 23 (63.9) 13 (40.6) 63 (42.6)
Psoriatic arthritis 1 (1.2) 0 0 1 (0.7)
Enthesitis related arthritis 16 (20.0) 3 (8.3) 0 19 (12.8)
Undifferentiated arthritis 4 (5.0) 3 (8.3) 3 (9.4) 10 (6.7)
Anti-Drug Antibodies* 14 (18%) - 3 (9%) 17 (11%)
Anti-Drug Antibodies** 5 (6%) - 2 (6%) 7 (5%)
JADAS 10
M0 12.6 (7–17) 15.6 (10–18.5) 15.6 (11.6–23.2) 13.5 (8.5–18.3)
M1 4 (1.5–6.5) 5.7 (3.4–12.7) 5.5 (3–11.4) 4.5 (2–8)
M3 2.7 (1–5.9) 2.2 (0–7.7) 2.5 (0.7–6) 2.5 (0.5–5.9)
M6 1.5 (0–5) 1 (0–8) 2 (0.5–7.5) 1.7 (0–5.8)
M12 0.5 (0–5) 0.5 (0–4.2) 2 (0.5–4.5) 0.5 (0–4.7)
ACR 70
M1 30 (46.2) 8 (33.3) 5 (31.3) 43 (41.0)
M3 40 (62.5) 17 (63.0) 10 (62.5) 67 (62.6)
M6 41 (67.2) 18 (62.1) 13 (76.5) 72 (67.3)
M12 42 (71.2) 19 (76.0) 13 (76.5) 74 (73.3)
*in at least 1 determination ** in at least 2 determinationP192
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Introduction: We are presenting 2 patients after liver transplantation
who developed juvenile idiopathic arthtiris. Patients received com-
bined therapy of tacrolimus and methotrexat.
Objectives: Case 1: Boy, born 18.08.2013, underwent liver transplant-
ation in 2014, from mother, due to cirrhosis in the course of atresia
of the bile ducts, on the chronic tacrolimus, heviran treatment.
In 08.2015 patient developed symptoms: pains and swelling of knees,
wrists, elbows. In laboratory tests:ESR-95mm/h, Rheumatoid factor
(RF) negative, antinuclear antibodies (ANA) negative; the number of
EBV virus copies 3870, after correction of dose of tacrolimus 2050,
other infections were excluded: CMV ( DNA CMV negative), Borelia
brg, Yersinia sp, Tuberculosis, Campylobacter, Mycoplasma pn , Clos-
tridium dif.. In USG active inflammation was found with effusion ,
swelling of synowial membrane. The Juvenile idiopathic arthritis poly-
articular onset was diagnosed. Patient received encorton , metotrexat
, tacrolimus. The remission was achieved.
Methods: Case 2 : Boy with autism, born 2003, in the neonatal period
surgery due to obstruction of the duodenum secondary to the annu-
lar pancreas and imperfect turn of the intestine ( bowel restitution );
in the first year of life operational correction of ASD, VSD.
In 2012 patient underwent liver transplantation due to congenital ex-
trahepatic portosystemic shunts with hyperamonaemia and hepato-
pulmonary syndrome and focal changes in the liver, tacrolimus treat-
ment was conducted. Since 11.2015 there have been: pain, big edema
and limitation of joint mobility in right wrist , rigth foot ( MTP joins).
CRP-24 mg/l, ESR-54mm/h, WBC- 13 G/L, present HLA B27 antigen
, negative RF, ANA, infection were excluded: Borelia brg, Yersinia sp, Tu-
berculosis HCV . In Xray of hand (04.2016)- generalized osteoporosis
and periarticular osteoporosis bones of wrist and bones of IV ,V MCP
joints of right hand. In feet Xray-hypetrophy of further physis of meta-
tarsal bones of right foot. In USG thickened synovium with intensive in-
creased vascularity in the joints of right wrist and MCP; also in right
MTP 3-4, PIP 3-4 joints, thickened synovium in the MTP 1-2 joints and
the toe IP. USG of liver – no abnormalities. Enthesitis related arthritis
was diagnosed. Methotrexat was used to treat 15mg/ week , then
20mg/week ( 15mg.m2 bs), a gradual resolution of inflammatory
changes in the joints was achieved. In 2017 in USG of right foot was in
norm, in right wrist was thickening, moderately increased vascularity of
synovium , intrarticular glikokortykosteroid was injected to the wrist.
Within 2 years of treatment liver enzymes were correct. In January
2018, was noticed temporarily increase of GGTP-154 U/L , ALAT-34 n 26
U / L, AST-23 U / L, CMV DNA - not detected, EBV DNA - not detected.
Ultrasound showed transplanted liver unimpaired, non-biliary oblong
vein, portal vein width 6mm, PV vmax 48cm / sec, HAV max 69cm /
sec, hepatic flow three-phase normal. In Liver biopsy 01.2018: The
organ structure preserved, without features of acute cell rejection. The
stipend of fibrous connective tissue with the creation of port-port brid-
ges within the port space (S3 according to Ishak). Discrete inflammatory
infiltrates of a chronic nature in the area of the gantry-biliary and
focaly intralobulary, no cholestasis, no steatosis, no ductopenia.
The hepatologist decided to add to treatment encorton, continue ta-
crolimus and methotrexat.
Results: The use of methotrexate due to JIA in patients after liver
transplantation on tacrolimus treatment allowed for rapid improve-
ment in joints.
Conclusion: During 2 years of obserwation frequent laboratory control
and liver assessment in USG and liver biopsy showed a stable function of
the transplanted organ. Informed consent to publish had been obtained.
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Introduction: Juvenile Idiopathic Arthritis (JIA) represents the most
common chronic rheumatic disease in childhood and an important
cause of short and long term disability. Non steroidal antinflamma-
tory drugs (NSAIDs) and intra-articular steroids represents the first
line treatment for JIA. Systemic steroids, Disease modifying anti-
rheumatic drugs (DMARDs) and biologic drugs are used in children
with severe disease. It is not possible at onset of disease to predict
when a child can suspend pharmacological treatment, so children af-
fected from JIA have to continue pharmacological treatment for sev-
eral months, or in some case for several years.
Objectives: We aimed to investigate if a long exposure to pharmaco-
logical treatment can be responsible of renal injury, evaluating pa-
tients affected from JIA without primary kidney disease.
Methods: We retrospectively evaluated 110 patients suffering from
JIA. JIA diagnosis was made according to ILAR criteria and treatment
was assigned with recommendations of the American College of
Rheumatology. For each patient we recorded the type and the dur-
ation of pharmacological treatment and the presence of renal injury.
Renal injury was defined by the presence of hypertension, protein-
uria or reduced eGFR. Hypertension was defined by the persistence
of systolic and/or diastolic blood pressure greater than the 95th per-
centile corrected for age, gender and height. Proteinuria was defined
on a first morning void as persistent (confirmation within 3 months)
UPr/Cr greater than 0.5 mg/mg for children lessthan 2 years old and
greater than 0.2 mg/mg for those more than 2 years old. Reduced
eGFR was defined as eGFR less than 90 ml/minute/1.73 m2 for chil-
dren older than 2 years and according to specific reference values
for age for children less than 2 years old.
Results: The mean age at the last follow-up visit was 13.3±5.61 years.
Nine out of 110 patients (8.1%) showed kidney injury (8 with hyper-
tension and 1 with proteinuria). Considering the whole population,
the cumulative proportion of patients free from renal injury at 216
months from the JIA onset was 56.8%. The patients with renal injury
were significantly older (18.4±3.1 vs 12.9±5.6; p=0.004), with a longer
JIA duration (152.1±58.3 vs 75.2±56.7; p= 0.0003) and with higher
number of months of treatment with NSAIDs (70.0±50.1 vs 39.9
±38.4; p=0.02). There was a linear relation between duration of JIA
and duration of NSAIDs administration (R-squared 46.2%; p<0.0001)
Conclusion: The longer duration of the JIA and longer duration of treat-
ment with NSAIDs are associated to the development of renal injury.
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Pediatric Rheumatology 2018, 16(Suppl 2):P194Introduction: Rheumatic diseases are one of the most common
chronic diseases in childhood. Although novel therapies are emer-
ging, there is still a significant number of patients not reaching re-
mission easily. That is why many parents/legal guardians turn to
complementary and alternative medicine (CAM), usually not reveal-
ing it to their physicians. Even though valid tools for assessing CAM
use exist, such as questionnaires, they are not routinely used prob-
ably due to their relative complexity.
Objectives: To assess the prevalence and patterns of CAM use and
variables associated with it in children with chronic rheumatic dis-
eases in a single center pediatric rheumatology clinic.
Methods: We conducted the cross-sectional study from April to May
2017 at the Department of Clinical Immunology and Rheumatology,
Sestre Milosrdnice University Hospital Center, Zagreb, Croatia, on the
consecutive sample of parents/legal guardians of the children diag-
nosed with chronic rheumatic diseases. The outcome was the self-
reported frequency of CAM use. For the purposes of our study, we
developed an anonymous questionnaire to answer our study ques-
tions and written informed consent was obtained from all the par-
ents/legal guardians prior to enrollment in the study.
Results: Out of the 100 children whose parents/legal guardians were
interviewed, 67 (67%) had juvenile idiopathic arthritis (JIA) while
other diagnosis included systemic lupus erythematosus, juvenile
scleroderma, juvenile dermatomyositis, etc. 63 (63%; CI 95%
54%−73%) of parents/legal guardians have used CAM in the treat-
ment of their child. Out of those, 43/63 parents/legal guardians
(68,25%) did not inform any medical staff about it. The majority of
them, 55/63 (87%; CI 95% 77%−94%) used it concomitantly to their
standard therapy and 40/63 (64%; CI 95% 50%−75%) declared their
intent to use it in the future as well. Only 6/63 (10%; CI 95%
4%−20%) were sure they would no longer use it. Out of the listed
CAM groups, the most commonly used were herbal remedies
(30.49%) along with orthomolecular therapy (25%) such as vitamins,
minerals, immune boosting products and probiotics. Statistical ana-
lyses of collected data showed that a significantly higher frequency
of CAM use was associated with parents/legal guardians with lower
monthly income (OR 9.66; p<0.05), acquaintances who use CAM (OR
4.58; p<0.05) and certain types of disease (JIA-polyarticular type; OR
5.40; p<0.05; JIA-oligoarticular type; OR 4.30; p<0.05). Parents/legal
guardians from medical professions have used CAM less often than
those from non-medical professions (OR 0.27; p<0.05).
Conclusion: Our study showed that the frequency of CAM use is asso-
ciated with the nature of the parent/legal guardian’s profession, their
monthly income, acquaintances who use CAM and their child’s diagno-
sis. CAM was concomitantly used to the standard therapy and medical
staff was not informed about it (87%; 68.25%, respectively). Due to
rarely documented CAM side-effects and the possible interferences be-
tween CAM and standard therapy, it is essential for pediatric rheuma-
tologists and other medical personnel to improve the communication
with families in order to achieve optimum disease management out-
comes. Therefore, more data on population characteristics and com-
monly used types of CAM, would allow medical staff to raise awareness
of the benefits and consequences that such therapies offer.
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Introduction: Patients with juvenile idiopathic arthritis (JIA) and their
use of biologic medication were registered in our hospital-based
registry at Oslo University Hospital, Rikshospitalet in the period 2008-
2015.
Objectives: To evaluate patient and disease characteristics, according
to use of biologic medication, from the registry.
Methods: JIA patients were classified using the ILAR criteria and data
was registered several times for each patient. The registrations are di-
vided into “start up”, “controls” and “discontinuation”. Gender, date
of registration, self-reported Childhood Health Assessment Question-
naire (CHAQ) and physicians’ assessment of disease activity (VAS 0-
10cm) were recorded, in addition to number of active joints, number
of joints with limited range of motion, ESR and CRP. For patients
under the age of 16 years CHAQ were reported by one of the par-
ents. CHAQ disability index (range 0-3) was calculated.
Results: In the period 2008-2015 a total of 1047 registrations con-
cerning biologic treatment were made on 264 patients with JIA. 178
(66%) were females. Mean age time at start up registration was 10.7
years (SD 4.7), at registrations from control visits 12.1 years (SD 4.0)
and at registrations from discontinuation 12.4 years (SD 4.2).
The numbers of registrations were distributed as follows; start up 92
(9%), controls 901 (86%) and discontinuation of biologics 54 (5%) (18
due to remission, 25 due to insufficient response and 13 due to ad-
verse events). Physicians’ assessment of disease activity, number of
active joints, number of joints with limited range of motion, CRP, ESR
and CHAQ were significantly higher in the “start up medication
group” than in the registrations from control visits; all p`s <0.01 (data
not shown). When comparing registrations from control visits with
those in the discontinuation group, disease variables were signifi-
cantly better in the 18 registrations from patients discontinuing bio-
logics due to remission”; all p`s<0.05, and significantly worse in
registrations from patients discontinuing due to insufficient response;
all p`s <0.05 (data not shown).
Severe disability (CHAQ score >= 1.5), was found in 146 (14%) of the total
registrations; 24 (26%) in the “start up group”, 113 (13%) in the "control
group", and 9 (17%) of the registrations in the "discontinuation group";
however, no significant differences between the groups were found
Conclusion: Registrations on biologic medications consist mainly of
patients with polyarticular and extended oligoarticular JIA (55% of
registrations), but also a relatively large proportion of systemic JIA
(21% of registrations). The most frequently used biologics were eta-
nercept, followed by adalimumab, tocilizumab and infliximab.
Disease activity measures, inflammatory parameters and physical sta-
tus improved from start up registrations to control visits.
Severe disability was found in a relatively large proportion of
registrations.
Disclosure of Interest
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Type
of
medication
Registrations* Systemic
JIA*
Poly
(RF neg)
JIA*
Poly
(RF pos)
JIA*
Oligo
(persistent)
JIA*
Oligo
(extending)
JIA*
Enthesitis
related
JIA*
Psoriatic
JIA*
Undifferentiated
JIA*
Registrations,
total
1047 (100) 231 (21) 363 (35) 98 (9) 113 (11) 138 (13) 66 (6) 31 (3) 7 (1)
Etanercept 490 (47) 34 (7) 177 (36) 63 (13) 45 (9) 94 (19) 54 (11) 21 (4) 2 (0.4)
Infliximab 91 (9) 10 (11) 34 (37) 12 (13) 24 (26) 4 (4) - 4 (4) 3 (3)
Adalimumab 219 (21) 15 (7) 104 (48) 15 (7) 41 (19) 24 (11) 12 (6) 6 (3) 2 (1)
Anakinra 45 (4) 42 (93) 3 (7) - - - - - -
Tocilizumab 155 (15) 109 (70) 34 (22) 6 (4) 1 (0.6) 5 (3) - - -
Abatacept 24 (2) 6 (25) 7 (29) 2 (8) 2 (8) 7 (29) - - -
Other 26 (2) 18 (69) 4 (15) - - 4 (15) - - -
*Numbers of registrations (%)P196
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Introduction: Low-dose methotrexate (MTX) is a cornerstone in the
treatment of juvenile idiopathic arthritis (JIA) with a polyarticular
course and an essential component of the maintenance treatment of
acute lymphoblastic leukaemia (ALL). MTX intolerance associated to
low-dose MTX treatment is a known phenomenon within JIA and a
tool quantifying MTX intolerance has been developed(1).
Objectives: To compare MTX intolerance to low-dose MTX treatment
in children with JIA and children with ALL.
Methods: Enrolled were children diagnosed with JIA[1]or ALL[2],
treated with low-dose MTX and aged ≥ 9years. Children were ex-
cluded if not fluent in Danish or if cognitively impaired. Children with
JIA were enrolled from December 2013 - July 2016 and children with
ALL from April 2015 - August 2017. MTX intolerance was determined
using the MTX intolerance severity score (MISS)(1) completed by the
patient’s parents. The MISS total score ranges from 0 to 36. A child is
categorized MTX intolerant if MISS total score ≥6 and min. 1 point for
an anticipatory and/or associative and/or behavioural symptom. A
blood sample was drawn for an erythrocyte-MTX-polyglutamate con-
centration measurement (E-MTX-PG).The local research ethics com-
mittee approved this cross-sectional study.
[1] According to ILAR criteria
[2] Treated on the Nordic Society of Pediatric Hematology and
Oncology (NOPHO) ALL-2008 protocol
Results: The MISS and the Ery-MTX-PG analysis were completed
for 119 children with JIA and 22 children with ALL. The JIA group
was treated with a lower MTX dose than the ALL group and had a
lower E-MTX-PG level than the ALL group (Table 1). Within the JIA
group there was no difference in the median MTX dose between the
subgroup treated with low-dose MTX orally (MTXO) and the subgroup
treated subcutaneously (MTXsc) (Median MTX dose: MTXO=9.6 mg/
m2/week (IQR: 9.0-10.7) and for MTXsc =9.8 (IQR: 8.7-11.0), p=0.87).
But the mean E-MTX-PG level was lower in the MTXOsubgroup com-
pared to the MTXscsubgroup (mean E-MTX-PG: MTXO=4.6 (95% CI: 4.1
– 5.1) and for MTXSC=5.6 (95% CI: 5.2-6.1), p=0.0033).
The JIA group had a higher MISS than the ALL group (for JIA median
MISS =8 (IQR: 3-14) and for ALL =1 (IQR: 0-3), p<0.0001). In addition,
the JIA group had a larger proportion of MTX intolerant children
compared to the ALL group (JIA: 73/119 (61%) versus ALL: 4/22
(18%); p<0.001). We found no differences between boys or girls be-
ing MTX intolerant neither in the JIA group, nor in the ALL group.
Conclusion: The level of MTX intolerance was higher and more attrib-
uted to anticipatory, associative and behavioural symptoms in the JIA
group compared to the ALL group. This finding contrasted the fact that
the JIA group was treated with a lower MTX dose and had a lower E-
MTX-PG level than the ALL group. However, the MTX treatment duration
was longer in the JIA group compared to the ALL group. Furthermore,
within the ALL group the MTX intolerant children had longer duration
of low-dose MTX treatment compared to the MTX tolerant children.
Trial registration identifying number:
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(1) Bulatovic M, Heijstek MW, Verkaaik M, van Dijkhuizen EH, Armbrust W,
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methotrexate intolerance severity score. Arthritis Rheum 2011
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Patient Group JIA (N=119) ALL (N=22) p
Age, median (IQR) years 13.3 (11.3-15.1) 11.9 (10.2-14.6) 0.18
Gender, girls: boys 81 : 38 9 : 13 -
MTXO: MTXSC, n 45 : 74 22 : 0 -
MTX dose, median (IQR)
mg/m2/week
9.7 (9.0-10.9) 14.7 (10.4-20.0) 0.0002
MTXintol : MTXtol 9.6 (8.6-11.0) : 10.1
(9.4-10.9)a
16.3 (14.7-18.4): 13.3
(9.0-21.0)b
a0.22 ;
b0.55
E-MTX-PG, mean (95% CI)
nmol/ mmol Hb
5.3 (4.9-5.6) 6.5 (5.5-7.6) 0.028
MTXintol: MTXtol 5.4 (5.0-5.9) : 5.0
(4.5-5.5)a
7.6 (4.5-10.8) : 6.3
(5.0-7.5)b
a0.21;
b0.31
MTX treatment duration,
median (IQR) days
336 (141-766) 114 (71-254) 0.0003
MTXintol: MTXtol 370 (143-766) : 262
(141-629)a
300 (191-354) : 97
(64-197)b
a0.38 ;
b0.033
Table 1 (abstract P197). See text for description
JIA (N=121) p
MTXO: MTXSC, n 45 : 76
MTX dose, median (IQR) mg/m2/week 9.7 (9.0 – 10.9) -
MTXo : MTXSC 9.6 (9.0-10.7) : 9.8 (8.8-11.1) 0.86
MTX treatment duration, median
(IQR) days
340 (142-766) -
MTXo : MTXSC 261 (143-543) : 417 (134-853) 0.39
BAI-Y raw score (total 0 – 60), mean
(95%CI)
27.4 (26.2 – 28.6) -
MTXintol : MTXtol(MISS) 27.8 (26.1-29.4) :26.9 (25.3-28.6) 0.48
MTX-induced nausea: All others
(Diary)
28.0 (26.3-29.6) : 24.4 (22.8-26.0) 0.0024
Unfavourable Coping Strategies[1],
mean (95% CI)
16.5 (15.5-17.5) -
MTXintol : MTXtol (MISS) 17.3 (15.9-18.7) :15.2 (13.8-16.5) 0.0287
MTX-induced nausea: All others
(Diary)
17.7 (16.2-19.3) :13.0 (11.6-14.4) <0.0001P197
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Introduction: Gastrointestinal adverse effects to low-dose MTX treat-
ment are a clinical challenge in juvenile idiopathic arthritis (JIA) and
include MTX-induced nausea and MTX intolerance. The latter is a
compound concept of stomachache, nausea, vomiting and behav-
ioural symptoms associated with low-dose MTX. Inter-individual vari-
ation exists in the level of MTX-induced nausea and MTX intolerance.
For high-dose chemotherapy anxiety and coping strategies have
been associated to chemotherapy-induced nausea and vomiting(1).
Objectives: To investigate if MTX-induced nausea or MTX intolerance
is associated with anxiety or coping strategies in children with JIA
treated with low-dose MTX.
Methods: Children were eligible if diagnosed with JIA (ILAR criteria),
aged ≥9 years and treated with low-dose MTX. If children were cogni-
tively impaired or not fluent in Danish they were excluded. Enrol-
ment was from December 2013 - July 2016. The anxiety level was
determined using Beck’s Youth Inventory – Anxiety (BAI-Y)(2). Coping
strategies were evaluated by a nausea coping questionnaire
(NCQ)[1]. MTX-induced nausea was registered by the children’s com-
pletion of a nausea diary. MTX intolerance was assessed by the MTX
intolerance severity score(MISS)(3) completed by the parents. The
local research ethics committee approved this cross-sectional study.
[1] Subscales: Information seeking/problem solving, seeking social
support, positive self-statements, behavioural distraction,cognitive distraction, externalizing and internalizing/catastro-
phizing. Frequency of use: 1=never, 2=hardly ever, 3= some-
times, 4 = often, 5 = very often.
Results: Enrolled were 121 JIA patients (82 girls: 39 boys), the median
age (IQR) was 13.3 (11.3-15.1) years.The MISS was completed for 120
children, 77 children completed the nausea diary (min. 7 days) and 119
completed the BAI-Y and the NCQ. MTX was given orally to 45 patients
(MTXO) and subcutaneously to 75 patients (MTXSC). Seventy-three chil-
dren (61%) were MTX intolerant (MISS≥6)(3) (MTXO: 23/45 (51%); MTXSC:
50/75 (67%); p=0.07) and the median MISS score (IQR) was 8 (3-13.5)
(MTX
O
: 6 (1-12); MTXSC: 9 (4-14); p=0.044). Fifty-six children (73%) had
MTX-induced nausea deduced from the diaries (MTXO: 16/27; MTXSC:
40/50; p=0.051). The BAI-Y raw score was higher in the MTX-induced
nausea (diary) subgroup compared to all others, but there was no dif-
ference in BAI-Y raw scores between the MTX intolerant and MTX toler-
ant subgroups (Table 1). Unfavourable coping strategies were used
more often in the MTX intolerant subgroup and the MTX-induced nau-
sea (diary) subgroup compared to all others.
[1] The scores of the subscales externalising and internalising/
catastrophizing are summed up, ranging from 10 to 50.
Conclusion: MTX-induced nausea was associated with unfavourable
coping strategies (externalizing and catastrophizing) and anxiety in
children with JIA, MTX intolerance was associated with unfavour-
able coping strategies. These psychological factors need attention
when children with JIA commence low-dose MTX treatment, in order
to intervene when appropriate.
Trial registration identifying number: (1) Tyc VL, Mulhern RK, Jaya-
wardene D, Fairclough D. Chemotherapy-induced nausea and emesis
in pediatric cancer patients: an analysis of coping strategies. J Pain
Symptom Manage 1995 Jul;10(5):338-347.
(2) Thastum M, Ravn K, Sommer S, Trillingsgaard A. Reliability, validity
and normative data for the Danish Beck Youth Inventories. Scand J
Psychol 2009 Feb;50(1):47-54.
(3) Bulatovic M, Heijstek MW, Verkaaik M, van Dijkhuizen EH, Armbrust
W, Hoppenreijs EP, et al. High prevalence of methotrexate intolerance in
juvenile idiopathic arthritis: development and validation of a methotrex-
ate intolerance severity score. Arthritis Rheum 2011 Jul;63(7):2007-2013.
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Introduction: Autoimmune rheumatic diseases (AIRDs) need treat-
ment that includes disease-modifying antirheumatic drugs, immu-
nosuppressants and biological agents. However these medications
can result in several adverse events (AEs) that vary in severity, re-
quiring the use of other medications, dose reduction or even the
suspension of the medication that caused the AE. AEs contribute to
disease morbidity or even mortality in some cases. The severity of
AEs depends on the medication doses, route of administration, use
duration, drug association, or presence of other risk factors.
Objectives: To describe the AEs of all drugs used to treat AIRDs and
to assess their severity, associated factors, medical procedures given
and outcome of these events in pediatric patients with juvenile idio-
pathic arthritis (JIA), juvenile systemic lupus erythematosus (JSLE)
and juvenile dermatomyositis (JDM).
Methods: retrospective descriptive and analytical study of a cohort
of children and adolescents treated at a specialized center in
pediatric rheumatology. The study evaluated all the AEs of the drugs
reported in the patient's charts. The data were compiled through a
specific questionnaire for each disease and then stored in excel
spreadsheets. The associations between the aggravating factors for
the AEs, such as patient age, dose, route of administration, and dur-
ation of medication use, were evaluated in patients treated with
methotrexate (MTX) and glucocorticoids.
Results: Of 662 patients (391 JIA, 162 JSLE e 69 JDM) from our center,
547 patients were included and 951 AEs were recorded. MTX was the
most common cause of AEs occurring in 63.3% of patients, followed by
glucocorticoids. Other medications such as cyclophosphamide, cyclo-
sporine, azathioprine, mycophenolate, leflunomide, chloroquine, eta-
nercept, infliximab, adalimumab, tocilizumab, rituximab and human
immunoglobulin also caused AEs. Abatacept did not cause any EA.
Most patients with MTX-associated AEs had gastrointestinal intolerance
and increased liver enzyme levels. When the AEs were stratified by dis-
ease, they were associated to MTX doses ≥ 0.6 mg / kg/week. Doses ≥
0.5 mg/kg/day of glucocorticoids were associated with increased AEs.
On the other hand, treatment with pulse therapy with corticosteroid
did not induce AEs. Two patients (0.2%) had life-threatening AEs and
35 (3.7%) had severe AEs. No death related to medication was re-
corded. The most frequent medical procedures for the AEs were with-
drawal or reduction of medication or change in route of administration,
or use of other medications, apart from advice to the patients.
Conclusion: This study is unique because it is the largest retrospect-
ive study in the literature that focused on the AEs of the medications
used during the treatment of AIRDs in real-life of children and ado-
lescents at a specialized center. We concIuded that the AEs associ-
ated with the treatment of AIRDs are frequent and need constant
monitoring and the associated factors to the occurrence of AEs such
as age, dose, time of treatment, route of administration should be
evaluated. This study showed that the occurrence of AEs may be re-
lated to the disease itself or other associated treatments.
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Introduction: Hepatitis B infection remains a significant public health
challenge, particularly for patients on chronic immunosuppressive
therapy, due to a considerable mortality risk associated with hepatitis
B reactivation.
Objectives: Our primary aim was to determine the burden of
non-immunity against hepatitis B, provide insight into factors
leading to lack of immunity against hepatitis B and establish the
basis for the need for universal screening of these patients. Sec-
ondarily, we determined serologic response to a single hepatitis
B vaccination booster.
Methods: Subjects are patients seen at the rheumatology and inflam-
matory bowel disease (IBD) clinics who are immunocompromised.
We use a clinical algorithm as part of standard practice to check
hepatitis B serology in immunocompromised patients, offer a booster
vaccination if needed, and then repeat serology to determine the re-
sponse. The results of anti-HBsAb are reported as positive, negative
or indeterminate. Immunity is defined as a positive result for anti-
HBsAb. An indeterminate or negative result for anti-HBsAb is non-
immune. A retrospective chart review was performed to collect
demographic and clinical factors as well as serology results. Descrip-
tive statistics were calculated for all variables. R software was used to
perform all analyses. For continuous variables, mean and standard devi-
ation are reported, and comparisons were calculated using two-sample
t-tests. For categorical variables, frequency and percentage are
reported, and comparisons were calculated using chi-square tests.
Results: A total of 592 patient charts between the ages of 7 and 30
years old were reviewed. Non-immunity was defined as a negative or
indeterminate hepatitis B surface antibody level. Out of the 592 pa-
tients, 70% were non-immune. The highest portion of non-immune
patients were those between the ages of 16-20 years (p=0.005)
(Table 1). There was no statistically significant difference between im-
mune and non-immune patients with regards to diagnosis (p=0.32),
age at the start of treatment (p=0.62), duration of treatment
(p=0.054) or type of medications (except for anti B-cell). Seventy one
percent of non-immune patients received a booster dose of hepatitis
B vaccine and 68% of those re-screened responded appropriately to
the vaccine. Of note, one patient was identified with a previously un-
known hepatitis B infection.
Conclusion: A majority of patients were non-immune to hepatitis B.
Lack of immunity is highest at 16-20 years. No association was found
between age at the start of treatment or diagnosis and non-
immunity. Being on anti B-cell was associated with non-immunity. A
majority of patients responded appropriately to the booster vaccin-
ation. Results support screening of immunocompromised patients
and further analysis may better delineate other factors and guide the
screening protocol.
Disclosure of Interest
None Declared
Table 1 (abstract P199). Demographics and clinical characteristics by
immune status
Non-immune
(n=414)
Immune
(n=178)
P-value
Age (y)
7-10 years 30 (7%) 20 (11%) 0.00
11-15 years 129 (31%) 39 (22%)
16-20 years 188 (46%) 73 (41%)
> 20 years 67 (16%) 46 (26%)
Biologic*
Anti TNF 310 (75%) 139 (78%) 0.95
Anti IL-6 42 (10%) 12 (7%) 0.44
Anti IL-1 16 (4%) 3 (2%) 0.29
Anti T-cell 35 (8%) 11 (6%) 0.60
Anti B-cell 14 (3%) 14 (8%) 0.00
Others 9 (2%) 1 (1%) 0.20
Continuous variables reported as mean (standard deviation). Categorical
variables reported as frequency (percentage). P-values in bold are
statistically significant
* This reflects the number of patients with history of medication use (% is
reported out of total patients)
Table 1 (abstract P200). Classification, anatomopathology and
treatment of JIA patients
JIA category and histological
findings
Number of
patients
Synoviorthesis
(n)
PDN
(n)
MTX
(n)
ETN
(n)
Oligoarticular 10 10 1 2 0
ANA - 6 6 0 0 0
Chronic synovitis 3 3 0 0 0
Mild inflammatory infiltrate 3 3 0 0 0
ANA+ 4 4 1 2 0
Chronic synovitis 4 4 1 2 0
ERA 4 4 3 3 3
Chronic synovitis 3 3 3 3 3
Mild inflammatory infiltrate 1 1 0 0 0
Psoriatic arthritis 1 1 0 1 0
Inflammatory infiltrate
suggestive of septic arthritis
1 1 0 1 0
ANA: antinuclear antibodies, ERA: enthesitis-related arthritis, PDN:
prednisolone, MTX: methotrexate, ETN: etanercept
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Introduction: Synovial tissue biopsy is a safe and well tolerated way
of studying multiple articular diseases. Many forms of juvenile idio-
pathic arthritis (JIA) present as a monoarthritis and synovial biopsy
results might be useful to exclude other causes of arthritis namely in-
fection or conditions with typical histological features such as syn-
ovial benign tumors or crystal-induced arthritis.
Objectives: To report our experience with synovial biopsies in
pediatric age.
Methods: Descriptive study with a retrospective analysis of patients
under 18 years-old performing a synovial biopsy in Hospital de Santa
Maria since 2006. Demographic, clinical and anatomopathological
data were collected.
Results: Since 2006, 35 children had 36 synovial biopsies (25 knees,
five wrists, three hips, and three ankles). Twenty-one were male
(60%), with a mean age of 11.1± 6.0 years. Indication for biopsy was
monoarthritis in 27 patients (23 knee, two hip and two ankle arth-
ritis), synovial cyst in six, knee oligoarthritis in one and a trochanteric
lesion in one patient. Symptoms were present for a mean time of 8.2
± 14.1 months. Procedures were performed by our Pediatric Rheuma-
tology Unit in 19 cases (16 ultrasound-guided needle biopsies and 3
mini-arthroscopies), Orthopedic department in 10 cases (7 open bi-
opsies and 3 arthroscopies), and Pediatric Surgery in seven cases.
From the 27 patients with monoarthritis, 15 were classified as JIA
(Table 1). In the remaining cases, histological aspects and culture
confirmed septic arthritis in 5 patients, one patient had a pigmented
villonodular synovitis and another one a moderate inflammatory infil-
trate with important vessel congestion and hemosiderin depositssuggestive of hemarthrosis (consistent with the history of
hemophilia). After magnetic resonance imaging, four patients with
normal biopsies or with a mild to moderate inflammatory infiltrate
had the diagnosis of a mechanical lesion. The patient with knee oli-
goarthritis had a chronic synovitis with extensive fat tissue that
might correspond to a lipoma arborescens, which was also the diag-
nosis of the trochanteric lesion. Synovial cyst was confirmed in 5/6
cases, the other corresponding to a giant cell tumor of the tendon
sheath. No major complications were reported for the procedures.
Conclusion: Synovial biopsy has been performed in children in our cen-
ter over the last 12 years with good results. There is an increasing number
of biopsies in the last few years, namely by less invasive US-guided and
arthroscopic procedures, which are reliable for synovial tissue sampling
and are replacing open biopsies. In children, synovial biopsy can give an
important clue in the differential diagnosis of an initial monoarthritis.
Trial registration identifying number:
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Introduction: Complex regional pain syndrome (CRPS) is a rare, but
chronic and invalidating pain syndrome that affects both children
and adults. Hans Christian Andersen Children’s Hospital (HCA) in the
Region of Southern Denmark has a multidisciplinary inpatient
programme for children affected by this disease.
Objectives: To describe the incidence of the disease, the demog-
raphy, symptoms and psychosocial characteristics of the patients and
to evaluate our treatment results.
Methods: Medical records of children referred to HCA for CRPS in an
eleven-year period from 2004 to 2014 were investigated.
Results: Twenty-nine children were identified, equalling a mean inci-
dence of 2,4 per 100.000 children annually. The patients were mainly
ethnic Danish (97%) girls (90%) with a median age of 11 years [8
-14]. Their body mass index (BMI) was normal and most had been
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 110 of 243active athletes prior to disease development with normal social con-
tacts but at admittance they were experiencing social isolation and
had ceased all physical activities. Ad admittance the children were in
severe pain, most frequently the condition involved a lower extremity
(86 %) and 59% were depending on a wheelchair or crouches. The time
from symptom appearance to diagnosis was 174 days [1-1280].
At discharge, after a median hospitalization of 14 days, all had re-
markably pain reduction or were completely free of pain, and every-
one was reintroduced to their social life. Using the affected extremity
was achieved by 97% at discharge and by the end of the outpatient
training program (1 month later) almost half could run and the rest
improving. Setbacks were seen in 6 patients (21%), but all, except
one, were managed solely at our outpatient clinic.
Conclusion: CRPS in children was a rare but invalidating disease. In our
material it was most often seen in girls around the age of 11 years affect-
ing a lower extremity. The children were prior to the disease physical ac-
tive with a normal BMI. Despite the long diagnostic and referral delay
great improvement was achieved with our in-patient treatment approach.
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Introduction: Castleman disease (CD) is a rare and heterogeneous dis-
ease. The pathophysiology and factors contributing to disease outcome
are poorly understood. CD is considered a lymphoproliferative disorder
and classified into two anatomically-defined categories: multicentric
(MCD) and unicentric (UCD). Patients with MCD usually present with
florid systemic symptoms. The most promising and currently approved
standard treatments for MCD patients are interleukin 6 (IL-6) receptor
antibodies (tocilizumab and siltuximab) [1-3]. In contrast, patients with
UCD seldom have systemic symptoms and can usually be treated by
surgical resection of the affected lymph nodes (LNs). Current under-
standing of CD in paediatric patients is very limited [4-9] and our case
series is the largest case series reported to date.
Objectives:
1. To describe the clinical presentation, diagnosis, treatment, and
outcomes of paediatric patients with CD
2. To identify possible prognostic factors associated with
outcome
Methods: This is a retrospective chart review study, including paedi-
atric patients with a histologically-confirmed diagnosis of CD diag-
nosed over the last 20 years at The Hospital for Sick Children
(SickKids), a tertiary care referral centre in Ontario, Canada.
Results: There were a total of 16 patients diagnosed with CD at SickKids
in the past 20 years. Five had MCD and eleven had UCD. Of the MCD pa-
tients, 3 (60%) were male. The age at diagnosis ranged from 2 to 17 years
old with the mean/median of 13.2/17 years old. Two showed plasma cell
subtype histologically and two belonged to the mixed type; one had an
undefined subtype. All of the MCD patients tested negative for HIV and
four patients tested for HHV8 were also negative. Two MCD patients di-
agnosed in 1999 died (one committed suicide and the other died of irre-
versible pulmonary fibrosis complicated by pulmonary haemorrhage and
multiorgan failure). The three surviving MCD patients, including one with
TAFRO (Thrombocytopenia, Ascities (anasarca), microcytic Anaemia,myeloFibrosis, Renal dysfunction and Organomegaly) syndrome, were di-
agnosed in recent years. All of them were diagnosed at the age of 17
years old with a duration of follow up of 0.6 to 10 months before their
transition to adult care. They were treated with rituximab, tocilizumab
and siltuximab respectively. The patient treated with Rituximab (4 weekly
doses) responded very well clinically. However, she still has persistently
high serum inflammatory markers. In contrast, both patients treated with
anti-IL6 receptor antibodies achieved clinical and biochemical remis-
sion. There were 11 patients with UCD (54% female). The mean/median
age at diagnosis was 11.27/11 years old. Only one had systemic symp-
toms; a 17 year-old girl who was also diagnosed with systemic lupus ery-
thematosus. Among all patients with UCD, the cervical lymph nodes
were the most commonly involved site (63%). The other lymph nodes af-
fected included the axillary, mediastinal/thoracic, inguinal and intra-
abdominal lymph nodes. The SickKids record showed one case of recur-
rence of UCD at the inguinal lymph node with successful clearance after
repeated surgeries.
Conclusion: Patients with UCD generally had good outcome and sel-
dom recurred after surgical removal of involved lymph nodes. They
are usually systemically well apart from those associated with other
autoimmune conditions [10]. The outcome of patients with MCD ap-
peared to be favorable with the treatment of biologics like monoclo-
nal anti-CD20 antibody and IL-6 receptor antibodies. Extension of
data collection after patients being transferred to adult care is under-
way for studying protracted outcome.
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Introduction: Idiopathic musculoskeletal pain syndrome (IMPS) is de-
fined as the presence of intermittent pain in three or more body re-
gions for at least three months, excluding organic diseases that
could explain the symptoms. Its etiopathogenesis is multifactorial
and includes physical factors such as lower central pain threshold, in-
creased nociceptive receptor sensitivity and autonomic nervous sys-
tem disorders, and emotional factors and social. In some patients,
there may be other clinical findings related to pain, such as joint hy-
permobility and obesity, among others. Some points of the etio-
pathogenesis of IMPS are still unknown, among them, gait disorders.
Objectives: To study the gait of children and adolescents with IMPS
by means of dynamic baropodometry.
Methods: 32 patients with IMPS and 32 healthy controls without
pain, matched by age, sex, social class, and Body Mass Index (BMI)
were enrolled. All were evaluated for pain intensity through the Vis-
ual Analogue Scale (VAS) and gait evaluation using dynamic baropo-
dometry (FootWork Pro, AM cube, Gargas, France).
Results: The mean age of the IMSP group was 13.6 years (SD = 2.1,
range 9.8 - 16.9) and the mean age of the control group was 13.5
years (SD = 2.0, range 9.6 - 16.5). The mean pain scale was 5.4 cm in
the IMPS group. In gait, the mean right foot velocity of the IMPS
group was significantly lower than that of the control group (p =
0.034), the time of the IMPS group step was significantly higher than
that of the control group (p = 0.003) and the pace of the IMPS group
was significantly lower than that of the control group (p = 0.001).
Conclusion: Children and adolescents with IMPS present gait alter-
ations when evaluated by dynamic baropodometry.
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Table 1 (abstract P205). See text for description
Age at visit
(years)
PATIENTS GROUP
(n=28)
CONTROL GROUP
(n=18)
PATIENTS VS
CONTROL GROUP
CHILDREN VS PARENTS
Median (1st - 3rd
quartile)
Median (1st - 3rd
quartile)
(Mann Whitney U test) (Mann Whitney U test)
9.8 (9.0-14.0) 9.4 (7.6-10.0) 0,1
QUESTIONARY CHILDREN PARENTS CHILDREN PARENTS CHILDREN PARENTS PATIENTS
GROUP
CONTROL
GROUP
Physical scale 93.8 (78.2-
93.8)
87.5
(65.7-
96.9)
93.8 (90.7-
96.9)
93.8
(87.5-
98.5)
0.20 0.21 0,84 0.96
Emotional
scale
77.5 (60.0-
91.3)
67.5
(50.0-
92.5)
85.0 (80.0-
95.0)
80.0
(70.0-
95.0)
0.30 0.24 0,55 0.56
Social scale 97.5 (86.3-
100.0)
97.5
(80.0-
100.0)
100.0
(92.5-
100.0)
95.0
(72.5-
100.0)
0.40 0.76 0,84 0.22
School scale 75.0 (57.5-
85.0)
70.0
(60.0-
86.3)
95.0 (80.0-
97.5)
90.0
(80.0-
100.0)
0.0085 0.021 0,98 0.93
Psychosocial
heath
summary
score
83.4 (67.1-
92.1)
76.7
(68.4-
89.6)
93.3 (85.0-
97.5)
86.7
(75.0-
96.7)
0.050 0.17 0,84 0.51
TOTAL SCORE 87.0 (66.0-
92.7)
78.8
(66.9-
90.5)
94.6 (88.1-
96.8)
90.2
(77.2-
96.2)
0.047 0.11 0,7 0.57
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Introduction: Rheumatic fever (RF) is an acute immune-mediated
consequence of group A beta-hemolytic streptococcus (GABHS) in-
fection. Rheumatic heart disease is the most threatening feature and
the main cause of morbidity and mortality. Due to the high risk of re-
currence in case of another streptococcal infection, RF patients need
a long term secondary antibiotic prophylaxis in order to prevent a re-
lapse. The use of intramuscular benzylpenicillin is still recommended
worldwide as the most effective drug for secondary prophylaxis
against GABHS. However its effect on health-related quality of life
(HRQL) has never been investigated so far.
Objectives: To evaluate the impact of long term prophylaxis with
intramuscular benzylpenicillin on the quality of life of patients with
rheumatic fever
Methods: RF patients in secondary antibiotic prophylaxis for more
than 1 year, referring to our pediatric rheumatologic center, and their
parents were asked to fulfil a HRQL questionnaire: due to its high
face validity the Pediatric Quality of Life (PedsQL 4.0) was chosen.
An age-matched group of healthy children and their parents were
used as control samples considering the absence of a control group
of patients with previous RF off secondary prophylaxis, due to eth-
ical reasons.
The Global Score (GB) was calculated as the sum of all the items in
the four domains evaluated (physical, emotional, social and school
functioning); the Psychosocial Health Score (PHS) was the sum of all
items related to emotional, social and school functioning domains.
Comparisons between groups were analysed by means of Mann-
Whitney U test.
Results: PedsQL questionnaire was sent to 28 families of RF patients
and 18 controls respectively. The median age of RF patients was 9,8
years with a median duration of secondary prophylaxis of 20 months,
and 9,4 years for controls . All the RF patients had a complete adher-
ence to prophylaxis. No relapses were observed. The main results are
shown in Table 1.
Patients with RF and their parents scored lower than controls in school
scale domain. Patient with RF had a trend to lower levels of GB and also
PHS compared to aged matches controls.
No differences were detected between parents and children in con-
trol groups
Conclusion: Although RF families have a good compliance to long
term secondary prophylaxis with intramuscular benzylpenicillin, this
prolonged treatment affect the quality of life of both children and
parents.
The results of this study are preliminary, but if confirmed on a bigger
sample, might stimulate a collaborative effort in reviewing the evi-
dence on secondary prophylaxis in RF patients.
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Introduction: Chronic red eye is a common cause of paediatric
rheumatology consultation to exclude a rheumatic disease. Paediatric
ocular rosacea (POR) is a underdiagnosed disease, even by ophthal-
mologists. Since 1999 twelve cases of POR were diagnosed in our
Paediatric Rheumatology Unit and Pediatric Ophthalmology Unit, the
majority of which with significant diagnostic delay.
Objectives: To alert to clinical features, diagnosis and therapeutic ap-
proaches of POR.
Methods: Retrospective study. Patients were include based in POR
Coimbra criteria: (> 3 criteria): a) Chronic or recurrent keratoconjunc-
tivitis and/or red eye and/or photophobia; b) Chronic or recurrent
blepharitis and/or hordela and/or chalazia; c) Eyelid telangiectasia; d)
Features of cutaneous rosacea and/or periorifical dermatitis; e) Posi-
tive family history of cutaneous and/or ocular rosacea.
Results: Twelve children: seven boys and five girls. Mean age at diag-
nosis was 10,5 years (±4,0); with a median diagnostic delay of 2,5 years
(IQR 3,9). Bilateral hyperaemia, ocular irritation and eyelid inflammation
were found in all patients. Significant improvement occurred with a
minimum of three months treatment with oral macrolides (erythro-
mycin or clarithromycin) or topical azithromycin. Leukoma occurred in
6 children and spontaneous corneal perforation in 1.
Conclusion: POR is a disease with high morbidity. POR Coimbra cri-
teria can improve its prompt recognition avoiding treatment delay. A
high level of suspicion is needed in patients with red eye when
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 112 of 243chronic blepharoconjunctivitis and ocular irritation are reported, even
in the absence of skin signs. Oral or topical treatment with macro-
lides or topical tetracyclin for at least 3 months has shown good re-
sults, avoiding significant sequelae such as blindness.
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Introduction: Carnitine palmitoyltransferase II (CPTII) deficiency is a
long-chain fatty-acid oxidation disorder. Carnitine palmitoyl transferase
II is localized in the inner mitochondrial membrane and catalyzes the
formation of acyl-coenzyme A. Three phenotypes of CPT II deficiency
are known: a lethal neonatal form, a severe infantile hepatocardiomus-
cular form and a mild myopathic form. The disease follows an auto-
somal recessive mode of inheritance. Clinical features are attacks of
muscle weakness, myalgia, pain and rhabdomyolysis with or without
renal failure. Trigger factors are fever, prolonged exercise and exposure
to cold.The severity of attacks is highly variable and some of these at-
tacks may be complicated by acute renal failure . The CPTII deficiency is
the most common cause of hereditary myoglobinuria and the most fre-
quent disorder of lipid metabolism affecting skeletal muscle.
Objectives: To emphasize considering CPT II deficiency in a patient
with recurrent episodes of rhabdomyolysis triggered by fever.
Methods: A six years old child came to our department because
of fever, myalgia and generalized muscular weakness. She had a per-
sonal history of diffuse muscular pain and generalized weakness trig-
gered by fever . Before coming to our observation both Duchenne
Muscular Dystrophy and Becker Muscular Dystrophy were ex-
cluded. When she was admitted to our department she was unable
to walk and presented generalized weakness, muscular pain, and
fever. Laboratory text showed an increase of serum creatine kinase
levels (15,400 U/L, normal value < 190U/L), aspartate aminotransfer-
ase (586 U/L, normal value <30U/L), alanine aminotransferase (382 U/
L, normal value< 30U/L). Complete blood count and renal function
tests were in normal range. Her urine was brown-colored, while urin-
alysis was negative for red blood cells. She was managed with intra-
venous hydration with immediate clinical and laboratory
improvements. The recurrence of severe episodes of rhabdomyolysis
and normal creatine kinase value between attacks suggested Carni-
tine palmioyltransferase II (CPTII) deficiency .
Results: The genetic analysis of the CPT II gene revealed homozygosity
for the p.Ser1133Leu mutation, so CPTII deficiency was diagnosed. A
low- fat and rich in complex carbohydrates diet was prescribed. She
was advised to avoid physical exertion and exposure to cold and to
receive additional carbohydrates before exercise and during illness.
Conclusion: CPT II deficiency should be suspected in children with
recurrent rhabdomyolysis triggered by fever, exercise and exposureto cold . Molecular genetic analysis of the related gene should be
performed to confirm the diagnosis. A prompt diagnosis and a care-
ful management are essential to prevent further episodes of rhabdo-
myolysis. Consent to publish had been obtained.
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Introduction: Septic arthritis is one of the most deadly diseases that
the absence of rapid diagnosis and initiation of treatment can cause
irreparable effects. There are several diagnostic features of the dis-
ease, which in some cases takes time and also don’t have a high de-
gree of confidence. So finding new rapid and affordable methods to
diagnose septic arthritis is very important.
Objectives: This study aimed to determine the diagnostic value of
leukocyte esterase (urine dipstick bar) is designed for the diagnosis
of septic arthritis.
Methods: Diagnostic study was carried out on 47 children with sus-
pected septic arthritis admitted to Mofid children’s hospital on 2014-
15. After obtaining the consent of the parents and child, joints in-
volved aspirated. Aspirated liquid analyzed for bacterial infection cul-
ture, smear, white blood cell count and biochemical. The joint fluid
aspiration was evaluated for leukocyte esterase by using the urinary
Dipstick bar immediately. Demographic data, clinical and laboratory
findings were recorded in questionnaire form. The data were entered
in SPSS software version 21.
Results: In the present study joint fluid cultures were positive in 45%
that female to male ratio was 1:4.3. Using positive cultures, the urine
leukocyte esterase strips had a sensitivity of 95.2%, specificity of
100%, PPV of 100%, and NPV of 96.3%. When using a synovial fluid
white blood cell greater than 50000 WBC/mL, these values were 92.3,
76.5%, 60.0%, and 96.3%, respectively. ROC curve analysis showed
the area under the curve for urine leukocyte esterase strip was more
than white blood cells.
Conclusion: This study showed that the use of leukocyte esterase
strip is rapid, reliable and effective method for diagnosis of septic
arthritis in children.
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Introduction: Episodic monoarthritis is not a common presentation
in rheumatology clinics. It may be a manifestation of mechanical,
hematological, or metabolic disease, or numerous inflammatory
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 113 of 243disorders. Eight case reports and case series have placed different
vascular malformations as an optional diagnosis for episodic or
chronic knee swelling. Intra-articular venous malformations are very
rare. Some of these lesions may expand abruptly following trauma or
hormonal changes, presenting as an episodic joint swelling, and be
misdiagnosed as an infection or juvenile idiopathic arthritis (JIA).
Objectives: To characterize patients with venous malformations of
the knee and offer key clinical features leading to diagnosis.
Methods: Patients' medical and imaging files were reviewed and
analyzed.
Results: Within a period of 1 year, four patients were diagnosed with
venous malformations of the left knee in the Pediatric Rheumatology
Unit of Meir Medical Center in Israel. Patients' ages at diagnosis were
3 to 8.5-years-old, the youngest was the only female. Time to diagno-
sis since first visit in the rheumatology clinic was 7 months to 6.5
years. Symptoms began during the first or second year of life, and
consisted primarily of episodic swelling of the knee, along with ten-
derness and limping, but without fever or any extra-articular mani-
festation (including uveitis). Some episodes began after minor local
trauma and lasted days to months. Physical examination revealed
swollen and mildly tender left knee, and mild limitation of the range
of motion. Two patients had vascular skin lesions on their left lower
limb. Laboratory workup was unrevealing, in general, with the excep-
tion of highly elevated C-reactive protein in the female patient, dur-
ing a single episode (she was later found as heterozygote for the
V726A mutation in the MEFV gene). Anti-inflammatory drugs (includ-
ing colchicine in the girl) and intra-articular corticosteroid injections
in 3 patients had no measurable effect on the course of the disease.
Bloody fluid was aspirated from the knees of two patients. Differen-
tial diagnosis included JIA, familial Mediterranean fever, anatomic dis-
orders of the knee and pigmented villo-nodular synovitis. As
radiographs, bone scintigraphy and ultrasonography revealed incon-
sistent findings, MRI scans were performed, and diagnosis was finally
made. At the time of writing this report, two patients were already
successfully treated with sclerotherapy.
Conclusion: Intra-articular vascular malformation should be sus-
pected in patients with dermal vascular malformations, episodic
monoarthritis, without extra-articular involvement, with normal in-
flammatory markers, history of aspiration of bloody synovial fluid, or
when anti-inflammatory treatment fails. MRI is the diagnostic modal-
ity of choice, revealing high T2 and low T1 signal intensity and
patchy enhancement after intravenous contrast medium injection.
Treatment of the vascular lesion depends on the type of malforma-
tion and the flow within it and can include excisional surgery,
embolization, sclerotherapy and irradiation.
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Introduction: Wiskott-Aldrich Syndrome (WAS, OMIM#301000) is a X-
linked primary immunodeficiency syndrome. Classical triad includes
eczema, micro-thrombocytopenia and recurrent infections. Making
the diagnosis may be challenging since patients may not always
present with the classical symptoms. Presented here is a young boy
with known thrombocytopenia since neonatal period. The diagnosis
of WAS was only established after the development of recurrent
symptoms suggestive of autoinflammation. The presentation of auto-
inflammation instead of the more commonly reported autoimmun-
ity1 may be related to his novel mutation of the WAS protein gene.Objectives: not applicable
Methods: not applicable
Results: CF first presented at 3 weeks old with PR bleeding. He was re-
ferred to the paediatric haematologist due to refractory thrombocytopenia
despite IVIg and platelet transfusion. The first Mean Platelet Volume (MPV)
was 7.4 fl (7-10) before any treatment. Despite extensive investigation, the
cause for thrombocytopenia remained uncertain. At 5 months he had
mild ear discharge with good response to topical antibiotics. The bleeding
episodes continued.
At 7 months old CF started to have pyrexia of unknown origin, recur-
rent rashes and polyarthritis. The rashes were in various forms, includ-
ing erythematous maculopapular, urticarial and extensive livedo
reticularis(fig). He also had marked inflammatory response (elevated
ESR and CRP, leukocytosis, hypoalbuminaemia). All sepsis screen was
negative. Bone marrow examination were repeated for total 3 times
and were negative for malignancy. Skin biopsy showed neutrophilic
dermatoses without vasculitis (perivascular and interstitial neutrophil in-
filtration, focal extravasated red cells but not much nuclear dust, no vas-
culitis). He had positive ANA only. His clinical picture was suggestive of
an autoinflammation though he did not fit into a single entity. Systemic
corticosteroid was started. However he only responded to very high
dose (2mg/kg/day). Fever recurred whenever tapering was attempted.
Taking together the known thrombocytopenia, WAS was suspected.
Genetic test confirmed a novel insertion mutation causing a frame-
shift mutation (T insertion at nucleotide position 431-2 in exon 4,
causing a frameshift start at Lysine 144 and a stop codon (TGA) cre-
ated at position 168(K144fsX168)). 2 months later he underwent hae-
matopoeitic stem cell transplant.
Conclusion: In this case the diagnosis of WAS was only suspected
after the onset of autoinflammation as the platelet size was nor-
mal. Neutrophilic dermatoses (ND) may be considered a continuum
with other autoinflammatory conditions2, especially in patients with
mark systemic symptoms like in our case. Having said that ND is also
reported in autoimmune diseases like SLE. Our patient’s presentation
may relate to his particular WAS protein mutation.
Early recognition of this possible association could help making the
diagnosis earlier and hence definitive treatment. Informed consent to
publish had been obtained from the parents.
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Introduction: A large body of evidence demonstrates the pivotal role
of interferon gamma (IFNγ) in the pathogenesis of secondary hemo-
phagocytic lymphohistiocytosis (sHLH) and macrophage activation syn-
drome (MAS). IFNγ is a key endogenous activator of macrophages and
exerts its biological activities by phosphorylation of the transcription
factor Signal transducer and activator of transcription 1 (STAT1).
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 114 of 243Objectives: In this study, we aimed to investigate whether the phos-
phorylation status of STAT1 in whole blood cells represents a good bio-
marker for the identification of patients at early stages of MAS/ sHLH.
Methods: Whole blood samples from patients with suspected un-
treated MAS/sHLH (n=7) and suspected treated (glucocorticoids)
MAS/sHLH (n=9) were collected prospectively. As controls, whole
blood samples from patients with active systemic Juvenile Idiopathic
Arthritis (sJIA) without MAS at sampling (n=6) and healthy subjects
(HS, n=7) were used. Fresh whole blood cells were left unstimulated
or stimulated with different concentrations of IFNγ (0.01, 0.1, 1, 10
ng/ml) for 10 minutes. The intracellular phosphorylation levels of
Tyrosine (701) STAT1 (pSTAT1) were evaluated by flow cytometry. Re-
sults have been expressed as Delta mean fluorescence intensity
(MFI), calculated by subtracting the MFI of cells stained with isotype
control antibody (Ab) from that stained with anti-pSTAT1 Ab. Anti
CD3, CD14 and CD16 staining was performed to discriminate the
monocyte, neutrophil, natural killer- and T- cell subpopulations. In
addition, western blot (WB) analyses were carried out on unstimu-
lated whole blood cell lysates, in order to further evaluate the basal
levels of pSTAT1 and total STAT1.
Results: In both treated and untreated MAS/sHLH patients, flow cyto-
metric analyses showed no significant differences in pSTAT1 levels in
unstimulated monocyte, neutrophil, natural killer and T cell subpopu-
lations, compared to sJIA and healthy subjects. Interestingly, we
found that, compared to sJIA and healthy subjects, in patients with
untreated MAS/sHLH, pSTAT1 levels were significantly higher in
monocytes (p<0,01 Vs HS, p<0,05 Vs sJIA and p<0,01 Vs HS, p<0,05
Vs sJIA, for stimulation with 1 and 10 ng/ml of IFNg respectively) and
neutrophils (p<0,05 Vs HS, p<0,05 Vs sJIA and p<0,01 Vs HS, p<0,01
Vs sJIA) stimulated with the higher concentrations of IFNγ (1 and 10
ng/ml). In contrast, we did not find differences in the levels of
pSTAT1 observed in stimulated monocytes and neutrophils from
treated MAS/sHLH patients or those observed in cells from active sJIA
and healthy subjects. In order to further evaluate the phosphoryl-
ation status of STAT1, we also performed WB analyses on patient
whole blood cell lysates. We found that pSTAT1 levels were markedly
higher in untreated MAS/sHLH patients and also in treated MAS/
sHLH patients, compared to active sJIA patients without MAS.
Conclusion: Our results demonstrate that the combined evaluation
of pSTAT1 levels by flow cytometry in monocytes and neutrophils
stimulated with high doses of IFNγ and by WB in fresh whole blood
cell lysates show high levels of pSTAT1 and might contribute to the
identification of patients at early stages of MAS/sHLH. WB might be
more sensitive and technically simpler approach, although it takes at
least 2 days. In addition, our results further support the involvement
of IFNγ in the development of the diseases, as suggested by the in-
creased phosphorylated STAT1 levels exclusively in patients with ac-
tive MAS/sHLH and not in patients with active sJIA.
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Introduction: Systemic onset juvenile idiopathic arthritis (sJIA) is an
autoinflammatory disease, characterized by typical fever andsystemic features such as arthritis, rash, lymphadenopathy, hepatos-
plenomegaly and serositis.
Objectives: In this study, we aimed to figure out the clinical and la-
boratory features, treatment responses and prognosis of sJIA patients
from a tertiary rheumatology center.
Methods: Patients whom were classified as sJIA due to ILAR criteria
and being followed at Hacettepe University Department of Pediatric
Rheumatology between 2010-2017 were included in this study. Patient
files were analyzed retrospectively for clinical and laboratory features.
Results: 75 sJIA (%56 male) patients were included. The mean age at
diagnosis was 6,45±4,80 yrs. At the time of diagnosis all of the pa-
tients had typical fever while 78,7% of them had arthritis, 66,2% of
them had rash, 37,3% of them had arthralgia, 28,4% of them had
hepatosplenomegaly (HSM), 20,3% of them had lymphadenopathy,
and 17,6% of them had serositis. 24% of the patients had MAS
(macrophage activation syndrome) features at the time of diagnosis
while in total 36% of the patients had at least one MAS attack any-
time on disease course. Patients who had MAS at the time of diagno-
sis were older than other sJIA patients (8,9 vs 5,3 yrs; p=0,004), they
had less WBC (7166 vs 17864/mm3 p<0,001) and platelet (179000 vs
689000/mm3 p<0,001) count, and had a lower Erythrocyte Sedimen-
tation Rate (ESR: 12 vs 63/hr, p<0,001) as expected.
These group of patients had more serositis (%44,4 vs %7,5; p<0,001)
and hepatosplenomegaly (%55,6 vs %18,9; p= 0.004) however there
was no significant difference in terms of arthritis, arthralgia, rash and
lymphadenopathy.
All of the patients were treated with NSAID or corticosteroids at the
beginning of the disease. 20% of the patients reached remission with
NSAID, corticosteroid or DMARDs however rest of the patients
needed at least one biologic drug.
Anakinra was the most common first-line biologic treatment choice
(n=45). Among the patients whom remission was achieved, 44% of
them were treated with anakinra, 12% with canakinumab, 10,7% with
tocilizumab. 46% of the patients had recurrent attacks however 54%
had one attack (26% monophasic, 28% persistant). 18,7% of the pa-
tients had polyarticular joint involvement during the disease course.
There was no significant difference between the patients with poly-
phasic and monophasic course in terms of laboratory and clinical fea-
tures other than HSM (%42,4 vs %17,1; p=0,016 respectively).
40% of the patients are being followed without any treatment after
remission was achieved. Five out of 8 patients who had remission
with tocilizumab had polyarticular joint involvement, thus it can be
speculated that anti IL-6 treatment is very beneficial in this specific
group of patients.
Conclusion: sJIA is an important disease with high risk of morbidity
and mortality. As our center is one of the most important tertiary re-
ferral rheumatology center, we expect to see higher MAS incidence
than the previous reported sJIA series. Although 1/5 of the patients
achieved remission without any biological agent, they are still the
most beneficial treatment in most of the sJIA patients. Anti-IL1 drugs
are the mostly preferred treatment choice and they have the highest
success rate. Anti-IL-6 agents are very efficient in patients with sys-
temic onset polyarticular course.
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Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 115 of 243Introduction: Serum soluble CD163 (sCD163) level is a valuable diag-
nostic marker in hemophagocytic lymphohistiocytosis (HLH) and sys-
temic juvenile idiopathic arthritis (s-JIA) associated macrophage
activation syndrome (MAS). However, it is still unclear whether serum
sCD163 level is useful for the assessment of disease activity of s-JIA.
Furthermore, it is unknown whether sCD163 expression is modified
by interleukin (IL)-6 blocking.
Objectives: This study aims to investigate the clinical significance of
serum sCD163 levels as a predictor of the disease activity of s-JIA.
Methods: In this study, we examined 63 patients with s-JIA, four with
Epstein–Barr virus-induced HLH (EBV-HLH), and seven with Kawasaki
disease (KD), along with 14 healthy controls. We quantified serum
cytokine levels (sCD163, neopterin, IL-18, IL-6) by enzyme-linked im-
munosorbent assay and compared the results with the clinical fea-
tures of s-JIA.
Results: Serum sCD163 levels were significantly elevated in patients
with s-JIA associated MAS and EBV-HLH compared to those in pa-
tients with acute-phase s-JIA and KD. In addition, serum sCD163
levels profoundly increased with the progress of MAS and correlated
positively with the disease activity of s-JIA, even in patients receiving
tocilizumab. Furthermore, serum sCD163 levels significantly de-
creased in the inactive phase compared to those in the active phase
and normalized in remission.
Conclusion: The correlation between macrophage activation and
serum sCD163 levels might be a unique indicator of the disease ac-
tivity and a potential diagnostic laboratory criterion for clinical remis-
sion in patients with s-JIA, including those receiving tocilizumab.
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Introduction: Severe lung disease including pulmonary alveolar pro-
teinosis (PAP) and interstitial lung disease is an increasingly recog-
nized complication of Systemic Juvenile Idiopathic Arthritis (SJIA).
The inflammatory features and patterns of this lung disease are
poorly described.
Objectives: To describe the experience of SJIA-associated lung dis-
ease in a large US referral center as well as novel immunological and
pathophysiological findings.
Methods: Informed consent was obtained from all patients and/or
their legal guardians through protocols approved by the CCHMC IRB.
Clinical data was abstracted from medical records, and cellular, bio-
marker, and genomic analysis performed as indicated.
Results: Since 2010, we have evaluated 12 patients with SJIA-
associated lung disease. The number of new patients evaluated has
markedly increased during this timeframe, with 5 newly diagnosed
patients evaluated in 2017 alone. Considering only local patients,
the incidence of severe lung disease in SJIA patients may be as
high as 5-10%.
Most patients with SJIA-associated lung disease had refractory dis-
ease despite treatment with multiple biologics, predominantly sys-
temic features, and history of overt or subclinical macrophage
activation syndrome (MAS). Patients with active SJIA and lung dis-
ease also had markedly higher serum IL-18 levels than patientswithout lung disease (median 45,854ng/ml vs 7,194, p<0.01), levels
comparable to that seen in MAS.
Chest imaging (CT and MRI) findings included diffuse ground-glass
opacities, subpleural reticulation, interlobular septal thickening, and
lymphadenopathy. F-18-FDG positron tomography was also per-
formed in one patient, showing multifocal uptake consistent with an
inflammatory process.
Five patients had open lung biopsy. While there was substantial vari-
ability in findings, typical findings included patchy but often exten-
sive lesions histologically comprised of lymphoplasmacytic (CD4+
and CD8+) infiltrates and mixed features of PAP and endogenous lip-
oid pneumonia. Air spaces were filled with granular lipoproteineous
material typical for PAP, foamy macrophages and cholesterol clefts.
Pleural and interlobular septal collagenous fibrosisas well as vascu-
lopathy was prominent is some cases.
PAP results from disordered surfactant homeostasis, often secondary
to defective alveolar macrophage GM-CSF signaling. However, SJIA-
associated lung disease patients had several features atypical for GM-
CSF signaling related PAP. Bronchoalveolar lavage (BAL) fluid often
did not reflect biopsy findings and typically did not contain the
abundant proteinaceous material seen in PAP with only a minority of
macrophages being lipid-laden (3-25%). BAL fluid did contain high
levels of IFNg-induced chemokines CXCL9-11, observed in serum and
tissue during MAS. Whole exome sequencing was performed on
seven patients, which failed to reveal any variants associated with fa-
milial PAP. Finally, isolated alveolar macrophages showed normal
STAT5 phosphorylation in response to GM-CSF, suggesting that this
signaling axis is functional.
Conclusion: Severe lung disease is increasingly detected in children
with SJIA, particularly in association with MAS. Pathologic hallmarks
of disease are often absent from BAL fluid, supporting utility of lung
biopsy. This entity has distinct clinical and immunologic features
from other disorders including PAP, and represents an uncharacter-
ized inflammatory lung disease.
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Introduction: Previous reports showed serum IL-18 level is signifi-
cantly elevated in active phase of systemic juvenile idiopathic arth-
ritis (s-JIA). However, it is still unknown whether serum IL-18 level is a
useful biomarker for the diagnosis of s-JIA and the differentiation
from other inflammatory diseases. Furthermore, there are few long-
term follow-up studies to examine whether serum IL-18 level is use-
ful for the assessment of the disease activity and remission in s-JIA.
Objectives: To investigate clinical significance of serum interleukin
(IL)-18 level for the diagnosis of systemic juvenile idiopathic arthritis
(s-JIA) and clinical usefulness of serum IL-18 level for the assessment
of the disease activity and remission in s-JIA.
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 116 of 243Methods: One hundred sixteen patients with s-JIA, 128 other inflam-
matory diseases and 20 healthy controls were analyzed. Longitudin-
ally measurement of serum IL-18 levels from active phase through
remission or relapse were performed in forty one patients with s-JIA.
Serum IL-18 levels were quantified by enzyme-linked immunosorbent
assay. Results were compared with clinical features and disease
course of s-JIA.
Results: Serum IL-18 levels in s-JIA were significantly elevated com-
pared to other inflammatory diseases. The cutoff value of serum IL-18
levels for the differentiation s-JIA from other diseases was 4560 pg/ml,
with sensitivity of 99.14 %, and specificity of 96.15 %. Serum IL-18 levels
were correlated positively with the following measures of disease activ-
ity: ferritin, asparartate transaminase and lactate dehydrogenase. The
longitudinal kinetics of serum IL-18 levels from active phase to remis-
sion or relapse were closely correlated with disease activity of s-JIA.
Conclusion: Serum IL-18 levels >4560 pg/ml might be useful for the
diagnosis of s-JIA. Furthermore, serum interleukin-18 level reflects
the disease activity of s-JIA. Thus, serum IL-18 level might be a prom-
ising biomarker for the diagnosis and the assessment of disease ac-
tivity of s-JIA.
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Introduction: Early diagnosis and treatment of systemic-onset juven-
ile idiopathic arthritis (SJIA) are crucial in order to avoid long-term
complications. However, the existing International League of Associa-
tions for Rheumatology (ILAR) classification criteria for SJIA have
been criticized. A substantial percentage of SJIA patients fail to fulfill
them, mostly because of the absence of arthritis, or due to the exclu-
sion criteria requiring regular testing of HLAB27, which is often not
performed in real-life clinical practice.
Objectives: To evaluate and compare the existing Yamaguchi and ILAR
classification criteria as well as a new set of ILAR ‘modified’ criteria with-
out HLAB27 testing, in an international cohort of SJIA patients.
Methods: This is a multicentre, retrospective and inception cohort study,
through the international platform JIRcohorte. The existing ILAR classifi-
cation criteria, a new set of ‘modified’ ILAR classification not including
HLAB27 testing and the Yamaguchi criteria were applied in SJIA patients
followed in one of the participating centres in Switzerland, France,
Belgium and Morocco. 50 SJIA patients with no more than one missing
criteria in the database were enrolled (sex ratio 1:1) and compared to
a control group of 46 patients with other autoinflammatory and auto-
immune diseases presenting with systemic and articular manifestations.
Results: Of 50 SJIA patients enrolled, only 56% (28/50) fulfilled the
ILAR classification criteria for SJIA, 14% (7/50) were classified in an-
other JIA category and the remaining 30% (15/50) were unclassified.
Among the 22 patients who failed to fulfill the ILAR criteria, 4 (18%)
had no arthritis, 9 (41%) had no other systemic manifestations thanfever at diagnosis, 1 (5%) had family history of psoriasis, and in 8 pa-
tients (36%) HLAB27 testing has not been performed. ILAR ‘modified’
criteria identified 74% (37/50) of SJIA patients (kappa value 0.73).
Their sensitivity and specificity in the discrimination of SJIA patients
from the control group were of 74% and 100% respectively, their
positive predictive value (PPV) of 100% and their negative predictive
value (NPV) of 78%. Yamaguchi criteria were accomplished in 46%
(23/50) of SJIA patients (kappa value 0.41), with a sensitivity of 44%,
a specificity of 98%, a PPV of 96% and a NPV of 62% respectively.
Conclusion: A substantial percentage of SJIA patients (44%) followed
through the international, real-life JIRcohorte platform, failed to fulfill
the existing ILAR classification criteria. The application of Yamaguchi cri-
teria in our SJIA population was no more advantageous. However, ILAR
‘modified’ criteria had a better diagnostic value raising questions about
the usefulness of HLAB27 testing in SJIA. The frequent absence at diag-
nosis of arthritis or systemic manifestations other than fever, may sug-
gest the need of development of international consensus based
strategies for diagnosis and treatment of probable and definitive SJIA.
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Introduction: Anti-IL-1 treatment has improved outcomes in sJIA. Re-
mission and treatment discontinuation in severe longstanding sJIA is
a desirable goal.
Objectives: To indicate that IL1β inhibition leads into off medication re-
mission longstanding active SJIA with predominately systemic features
Methods: Case-series
Results: Patient details are presented in Table 1. Patient 1 initially
treated with steroids (CS) developed 2 MAS events on the 1stmonth ne-
cessitating IVCS pulses (IVMP). MTX was added; a 3rdMAS event devel-
oped during CS tapering. Anakinra (ANA) was added 4 months after
onset and changed to CAN for adverse event-AE. A4thMAS event devel-
oped on CAN-1 year-and MTX-5 months after CS withdrawal. It sub-
sided by IVMP, and cyclosporine. MTX was discontinued after 18
months and CAN after 2,7years remission. Patient 2 initially manifested
MAS treated by CS. Disease relapsed 4 months after CS withdrawal;CS
were reinitiated along with MTX. 11 months after onset a relapse remit-
ted by CS; ANA permitted CS taper. MTX was discontinued after 3 years
for AE; ANA sustained remission for 7 months. Due to poor compliance
ANA was changed to CAN. After 1 year CAN was withdrawn. After
21month remission a flare with fever and monoarthritis remitted by
CAN reinitiation. Patient 3 suffered 2 relapses during CS tapering in the
1st month; MTX was added and discontinued in 3 months for relapse
during CS tapering; 6 months after onset ANA allowed CS discontinu-
ation. After 3 months ANA was changed to CAN due to AE. ANA wash-
out led to reactivation. Remission was achieved in 8 months. CAN was
discontinued after 2 years. Patient 4 suffered 5 years of active disease
presenting by CNS insulting MAS. MTX was added and discontinued in
6 months due to flare after CS withdrawal. ANA&CS were added 10
months after onset maintaining minimal activity for 10 months until a
2nd MAS. HLH treatment protocol led to remission for 2 months; for 1
year minimal activity under NSAID persisted. 4 years after onset fever,
rash and arthritis remitted by CAN administration 2 mg/kg/month and
Intraarticular CS. A flare after 4 months remitted by dose increase. For 1
year transient spontaneously remitting rash and arthritis occurred. The
disease remained in remission on CAN for 19 months; it was discontin-
ued due to thrombocytopenia after initiation of Growth Hormone initially
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 117 of 243considered AE of CAN/ GH, still persisting after 2,8years. Patient 5 mani-
fested fever, rash, polyarthritis and carditis attributed to C.burnettii unre-
sponsive to antibiotics abating by CS. Disease flared 2 months after CS
withdrawal necessitating reinitiation. MTX was added 6 months after on-
set. A flare 10 months after onset off CS remitted by ANA-withdrawn after
2 months for AE; disease flared and was treated by CS& CAN; MTX was
discontinued after 6 months. CAN was discontinued by interval-increase
after sustaining remission on medication for2,6years and 1year off medi-
cation. A flare with systemic manifestations remitted by CAN reinitiation
Conclusion: Canakinumab leads into off medication remission highly
active SJIA. Informed consent to publish had been obtained.
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Gender/current age/
age at SJIAonset-
years{y}
1 2 3 4 5
M/12/4,0 F/15/
7,6
M/12/
6,6
M/16/5,5 M/17/
12,3
MAS before/on CAN 3/1 1/0 0/0 2/0 0/0
Drugs before /CS on
CAN initiation
MTX, ANA,
CYC,CS/ yes
MTX,
ANA,
CS/ -
MTX,
ANA,
CS/ -
MTX, ANA,
CS,HLH-
protocol/ -
MTX,
ANA,
CS/ yes
IVMP before/on CAN/
relapses during CS
withdrwal
2/1/2 -/-/2 -/-/3 5/0/5 /–/2
activity on CAN
initiation/flares under
CAN treatment
-/1 -/- yes/- yes/2 -/-
Time(t) from onset to
CAN initiation y
0,5 4,1 0,7 4,1 1,2
t of CAN
administration y
3,6 1,0 2,7 3,0 2,6
remission t on/off
CAN y
2,6/2,5 1,0/1,8 1,6/2,5 1,6/3,4 2,6/1
t from CAN initiation
to remission y
- - 0,8 1,2 -
AE URIs,
pneumonia
- - Herpes
zoster, URIs
URIs
Table 1 (abstract P218). AE Rates
TCZ 12 mg/kg IV Every 2 Wk
MEP
n = 11
OEP
n = 7
Entire Study Period
n = 11
Total pt-y at risk 2.3 5.1 7.4
No. of AEs (rate per 100 pt-y at risk)
Any AE 32 (1396.4) 47 (926.5) 79 (1072.7)
Serious AE 5 (218.2) 2 (39.4) 7 (95.1)
AE with fatal outcome 0 0 0
AE leading to withdrawal 4 (174.6) 1 (19.7) 5 (67.9)
AE leading to dose interruption 1 (43.6) 12 (236.5) 13 (176.5)P218
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Introduction: The US Food and Drug Administration approved intra-
venous (IV) administration of tocilizumab (TCZ) for the treatment of pa-
tients (pts) ≥2 years (y) of age with systemic juvenile idiopathic arthritis
(sJIA) in 2011 based on results of the phase 3 TENDER study.1 This ap-
proval was associated with a postmarketing requirement to investigatethe use of TCZ in pts with sJIA <2 y (study NP25737). Results from the
12-week (wk) main evaluation period (MEP) have been reported.2
Objectives: Safety results following completion of the optional exten-
sion period (OEP) of NP25737 (until 52 wk from baseline or 2 y of
age, whichever was longer, was reached) are now reported.
Methods: NP25737 was a multicenter, open-label, single-arm study
to evaluate the pharmacokinetics and safety of IV TCZ 12 mg/kg
every 2 wk for 12 wk in pts <2 y with active sJIA for ≥1 month
whose treatment with corticosteroids and nonsteroidal anti-
inflammatory drugs failed and who were receiving stable back-
ground therapy. After the 12-wk MEP, pts could participate in the
OEP and continue TCZ treatment (without requirement for stable
background therapy) to evaluate long-term safety. Cumulative ad-
verse events (AEs) over the entire study period are reported.
Results: Seven of 11 pts enrolled in the MEP continued to the OEP
and received ≥1 dose of TCZ. Across the entire study period (n =
11), the median number of TCZ doses was 11.0 (range, 2-26) and
the median duration of exposure to TCZ was 22.1 wk (range, 4.1-
58.1). Most pts (10/11; 90.9%) had ≥1 AE; most AEs were mild or
moderate and unrelated to study drug. The most common AEs
were upper respiratory tract infection (6/11 pts; 54.5%), hypersensi-
tivity, neutropenia, rash, viral upper respiratory tract infection, and
vomiting (3/11 pts each; 27.3%). Seven serious AEs occurred in 5 of
11 pts (45.5%); 2 occurred during the OEP (transaminases increased,
histiocytosis hematophagic), 3 occurred during the MEP (hypersen-
sitivity), and 2 occurred during the safety follow-up of the MEP (sJIA
flare, hand-foot-and-mouth disease). AEs leading to dose modifica-
tion occurred in 5 of 11 pts (1 in MEP, 4 in OEP) mostly because of
infections, neutropenia, and elevated liver enzymes; all were mild
or moderate. AEs leading to withdrawal occurred in 5 of 11 pts
(45.5%): during the OEP, 1 pt was withdrawn because of a serious
AE of increased transaminases; during the MEP, 3 pts were with-
drawn because of serious hypersensitivity reactions to TCZ, and 1
pt was withdrawn because of thrombocytopenia. No deaths were
reported during the study. AE rates per 100 pt-y of exposure are
?A3B2 show $132#?>reported (Table 1).
Conclusion: During the OEP, long-term treatment with TCZ was well
tolerated in sJIA pts <2 y, and no additional safety signals were re-
ported in the OEP beyond those reported in the MEP or observed
previously for pts with sJIA ≥2 y.
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PATIENT WITH REFRACTORY DISEASE
Shima Yasin1, Rachel Brown1, Maggie Henderlight1, Ndate Fall1, Krista
Solomon1, Scott Canna2, Charlotte Girard3, Cem Gabay3, Edwardo
Schiffrin4, Andrew Slight4, Alexei Grom1, Grant Schulert 1
1Rheumatology, Cincinnati Children’s Hospital Medical Center and
Department of Pediatrics, University of Cincinnati College of Medicine,
Cincinnati; 2Pediatric Rheumatology & Immunology, Children’s Hospital
of Pittsburgh/UPMC, Pittsburgh, USA; 3Rheumatology, Geneva University
Hospitals and University of Geneva, Geneva; 4AB2Bio, Lausanne, Switzerland
Correspondence: Shima Yasin
Pediatric Rheumatology 2018, 16(Suppl 2):P219
Introduction: Systemic juvenile idiopathic arthritis is an autoinflam-
matory disorder with prominent innate immune activity. Macrophage
activation syndrome is a severe, potentially fatal complication of sJIA.
IL-18 is felt to play a key role in pathogenesis of sJIA and in particular
MAS; possibly through IFN-g activation.IL-18 binding protein (IL-
18BP) is an endogenous inhibitor that binds IL-18. However, clinical
effects of blocking IL-18 in sJIA are still unknown.
Objectives: To examine total serum IL-18 levels in sJIA patients with
regards to disease activity, MAS features, and other SJIA and MAS
biomarkers. Additionally, we report the use of recombinant IL-18 BP
(rIL-18BP) in a patient with severe, refractory sJIA.
Methods: Serum samples obtained from 40 established sJIA patients.
Total IL-18, CXCL9 and S100 protein were measured. In addition, in
one patient serial total serum and free IL-18 levels were determined.
We compared IL-18 levels in patients with active vs inactive disease
and with history of MAS vs no MAS.
Results: Total serum IL-18 levels (in pg/ml) were higher in patients with
active sJIA (Median:16499, Interquartile Range(IQR):4816-240986, N=21),
but were still persistently elevated (Median: 1163, IQR (587-38539),
N=19, upper limit of normal 540) in majority of patients with inactive
disease (p=0.0004). Patients with history of MAS had significantly higher
IL-18 levels (Median: 13880, IQR (4212-62628), N=20) as compared to
those without MAS history (Median: 956, IQR (276-5425), p=0.0001). Pa-
tients with active fever and arthritis at the time of sampling had signifi-
cantly higher IL-18 levels compared to those without (P=0.0173 and
0.0170 respectively). Also, those with systemic features and elevated
ESR/CRP showed significant difference from their counterparts
(p=0.0225 and 0.002 respectively). We observed moderate significant
correlation between total IL-18 and CXCL9 (correlation coefficient of
0.558 (p=0.0002), as well as S100A8/A9 and A12 (r=0.474 and 0.456).
Given these findings by us and others, we utilized Tadekinig alfa
(rhIL-18BP) in a 5 year old male with sJIA and persistently elevated
free IL-18 levels. His course was complicated by recurrent MAS, fail-
ure of all prior biologic treatments, chronic high dose steroids with
flare of sJIA and MAS upon attempts to wean steroids. He was
started on rhIL-18BP 2mg/kg/dose subcutaneous every 48h in
addition to continuous IL-1 inhibition. His initial total and free serum
IL-18 levels were high at 117356 pg/ml and 46.8 pg/ml respectively.
Although his total IL-18 remained elevated after start of rhIL-18BP,
free IL-18 was undetectable.
In addition, since initiation of rIL-18BP, steroid dose was decreased
by more than 50% with increase in linear growth. While on rIL-18BP,
he developed two MAS episodes (triggered by parainfluenza and
acute gastroenteritis), both were mild and easily controlled.
Recently, he had worsening lung disease and rIL-18BP was tapered.
Immediately after, he developed MAS flare. This time MAS flare was
very severe and difficult to control.
Conclusion: Total serum IL-18 levels were elevated in the majority of
sJIA patients regardless of disease activity, with higher levels in patients
with active disease and those with history of MAS. This indicates that IL-18 might be an important driver of sJIA and MAS. Use of rIL-18 BP im-
proved patient disease course with less frequent and easily controlled
MAS episodes. This response raises optimism about use of rIL-18 BP in
patients with IL-18 driven disease preventing life-threatening MAS.
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Introduction: Macrophage activation syndrome is a rare and poten-
tially fatal disorder, caused by excessive activation and proliferation
of T lymphocytes and macrophages. It can be triggered by drugs,
malignancies, infections, and rheumatic diseases.
Objectives: This study was established as a retrospective review of the
patients diagnosed and followed-up in Sağlık Bilimleri University KSSEAH
Pediatric Rheumatology clinic as MAS between the years 2010 and
2018. Our purpose was to report our single-center experience with MAS.
Methods: The medical charts of patients diagnosed and followed-up
as MAS between the years 2010–2018 retrospectively. Totally 25 pa-
tients were enrolled to the study. Data recorded included age, sex,
age at-diagnosis, delay to the diagnosis, laboratory data, treatment
modalities and outcomes.
Results: In our study, a total of 25 patients with macrophage activation
syndrome were reviewed. 20 patients were diagnosed with macro-
phage activation syndrome secondary to systemic juvenile idiopathic
arthritis (soJIA). Two patients were diagnosed with MAS secondary to
Kawasaki disease (n=1) and periodic fever syndrome (n=1). Virus-related
MAS (1 parvovirus B19, 1 leishmania and CMV, 1 streptococcus) was
progressed in three patients. Thirteen (52%) of these patients were fe-
male and twelve (48%) were male. The mean age at the time of diagno-
sis was found to be 6.9 ± 0.4 years. The mean time between soJIA
diagnosis and MAS diagnosis was 4.7days. The most common clinical
finding at presentation (100%) was increased body temperature. Bone
marrow aspiration was performed at all patients except one. While
hemophagocytosis was not observed in 7 (29.1%) of MAS patients,
hemophagocytosis was observed in 3 (12.5%) patients without MAS
finding. Systemic steroid treatment was administered to all patients ex-
cept one patient. Cyclosporine A was given to fourteen patients (56%),
biological agents were given to ten patients (40%). Plasmapheresis was
performed in three patients. Six patients (24%) received intensive care
support. Mortality was not observed. In patients with systemic JIA
who were diagnosed with MAS, monocyclic course was observed in
9 (45%) patients, polycyclic in 7 (35%) patients and chronic polyarti-
cular in 4 (20%) patients. In the last control, 13 (52%)patients were
in remission without medication, while 12 (48%) patients were in
remission with medication.
Conclusion: Macrophage activation syndrome (MAS) is the term used
to describe a potentially life-threatening complication of systemic
inflammatory disorders, which occurs most commonly in systemic
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 119 of 243juvenile idiopathic arthritis (JIA), although its occurrence in patients
with other autoimmune or autoinflammatory conditions, i.e., adult-
and childhood onset systemic lupus erythematosus, Kawasaki dis-
ease, and periodic fever syndromes, is being reported with increased
frequency. Virus-associated MAS is a well-recognized entity. Most
cases are related to Epstein–Barr virus (EBV), cytomegalovirus (CMV),
and herpesvirus, while streptococcus and parvovirus B19-induced
MAS is very rare. Complete recovery can be provided with early and
efficient treatment in macrophage activation syndrome.
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Introduction: Kawasaki disease (KD) is rarely described in siblings in
the same time. In these cases, an infectious trigger must be
excluded.
Objectives: We describe the clinical course of two brothers who
showed severe KD all at once, secondary to Parvovirus infection.
Methods: A 9-month-old female showed fever, pallor, vomiting, bilat-
eral non-secreting conjunctivitis, rash. Anamnesis revealed that 12 days
before, she had fever, spontaneously resolved. At admission, 9 days
after fever onset, she showed fever, conjunctivitis, pharyngitis, rash, and
cervical adenopathy. Haematological parameters showed: leukocytosis,
neutrophilia; anaemia; CRP: 2.31; ESR: 120. ECG and echocardiography
were normal, including coronary Z-scores. She showed positive Parvo-
virus IgM. Spontaneous defervescence occurred. Further cardiological
evaluation was performed to exclude a pericarditis secondary to Parvo-
virus, and at day 26 after fever onset, coronary artery lesions (CAL) were
documented: proximal right coronary artery Z-score of 6.02; left main
coronary Z-score: 5.72; left anterior descending Z-score: 5.78. The child
was promptly treated with IVIG plus ASA.
A further echocardiographic evaluation showed worsening of CAL,
with a sacciform aneurysm in the left anterior descending artery (Z-
score:5.08). Laboratory test did not show inflammation; however, the
girl was treated with 3 bolus doses of intravenous methylpredniso-
lone (30 mg/kg/dose). The Z-score of CAL did not change and the
patient was treated with anakinra (4 mg/kg/day), with a progressive
improvement of CAL, and after 2 months, Z-scores normalized.
The 7-year-old brother presented fever, vomiting at the same time of
the sister, with spontaneous resolution after 4 days. Four days later,
he presented again fever with abdominal pain, tachypnoea and
tachycardia, secondary anuria. He had: leukocytosis, neutrophilia,
anemia; CRP: 0.24; CPK: 773; creatinine: 0.77; BUN: 111; elevated myo-
cardial necrotic enzymes (c-Troponin T: 91.4; Pro-BNP: > 70.000).
Echocardiogram showed generalized hypokinesia, a severe reduction
of the ejection fraction (EF) (20-25%); increased left atrium (Z-score:
3.3) and mitral valve with moderate insufficiency. He received dopa-
mine, dobutamine, furosemide plus steroids. He showed a constant
improvement of echocardiographic parameters, plasmatic enzymes
and clinical signs. In 16th day he was discharged with an EF of 45%
and persistent septal hypokinesia. However, specific serology anti-
Parvovirus was tested and showed increased IgM, with negative IgG.The cardiological outcome revealed a progressive improvement of
EF, which reached the 50%.
Results: CAL significantly improved after anakinra, at the contrary,
the clinical evolution in the brother was different.
Conclusion: We describe familial KD in two siblings which had the
same infectious trigger (Parvovirus). The brother was diagnosed as a
post-viral myocarditis. However, considering the two parallel and dif-
ferent evolution, the girl showed late CAL with aneurisms, and the
brother a Kawasaki shock syndrome picture with myocardial dysfunc-
tion. Viral illnesses are recognised trigger of KD, and in these cases
the rareness is the coincident KD in two siblings, with different and
severe clinical course. Noteworthy, the girl had aneurisms which re-
solved with anakinra, a therapy which has been recently shown to
be promising for this disease. Informed consent to publish had been
obtained from the parents.
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Introduction: Henoch-Schönlein purpura (HSP) is the most frequent
vasculitis in children. Typically, it is characterized by palpable purpura,
joints swelling, arthralgia, abdominal pain with possible intestinal bleed-
ing. In more severe cases, the patients show acute abdomen.
Acute pancreatitis is a rare dramatically evolutive, life-treating mani-
festation of SHS and it can be associated with a fulminant course.
Persistent abdominal pain, need to be investigated by the dosage of
serum pancreatic amylase, lipase and by abdominal MRI. In these pa-
tients, corticosteroid treatment is recommended and must be associ-
ated with parenteral feeding.
Objectives: We analysed the full series of children with HSP admitted
to our paediatric unit in the period 2011-2018.
Methods: We retrospectively collected data of 50 children (age: 4-14
years), with HSP who needed hospitalization.
4/45 patients (9%) developed an acute pancreatitis.
All the patients were males, age:3-10 years. All the patients did not
show other risk factors of pancreatitis.
Results: The treatment was parenteral feeding in 100% of the patients.
One patient with pancreatitis and nephrotic syndrome received 3 bolus
doses of methylprednisolone (30 mg/kg/dose) followed by prednisol-
one (2 mg/kg/day) and mycophenolate; one patient with pancreatitis
and acute renal failure, received 3 bolus doses of methylprednisolone
(30 mg/kg/dose) followed by a single-dose of cyclophosphamide (750
mg/m2), followed by azathioprine (50 mg/day). One patient showed a
mild pancreatitis and healed with prednisolone (2 mg/kg/day) and par-
enteral feeding. One patient showed acute pancreatitis, associated with
acute intestinal bleeding, orchitis, was treated with 3 bolus doses of
methylprednisolone (30 mg/kg/dose) followed by prednisolone (2 mg/
kg/day). Steroids treatment was progressively tapered until the
complete resolution of the pancreatic involvement.
Conclusion: Acute pancreatitis is a rare and life-treating manifestation of
HSP. High-doses steroids are a recognised and useful treatment, associ-
ated with parenteral feeding. In non-responders to steroids, immune
suppression treatment is the second-line treatment to induce remission.
The choice depends on associated manifestations of HSP and on as-
sociated failure of other organs.
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Introduction: Kawasaki disease (KD) is a systemic vasculitis that af-
fects the medium-and small-size arteries.Some children do not re-
spond to the first line of therapy.The treatment for IVIG non-responsive
patients is controversial,but adding steroids to the second IVIG dose can
be effective at reducing the incidence of CAA. For those non-responders
to this second step of therapy,other approaches have been described.In
recent years,some reports have suggested the role that Anakinra can play
in the treatment of severe or resistant cases of KD.
Objectives: We present a case of an IVIG and steroids-resistant KD
treated with Anakinra.
Methods: We present the case of a one-year-old with persistent fever
for six days,a generalized rash,lymphadenopathy,conjunctivitis,cheili-
tis,swollen hands and feet,diarrhoea and irritability.Blood tests revealed
increased C-reactive protein (100.80 mg/L),D-Dimer (532.00 ng/mL) and
Fibrinogen (810.00 mg/dL).There was increased platelet count (532,000/
mm3) and hyperneutrophilia (neutrophils 79.80 %);He showed low
levels of serum albumin (2.9 g/dl),serum sodium (130 mEq/L) and
serum chloride (90 mEq/L).Blood cultures and serological tests for infec-
tion were negative.He underwent an echocardiography that showed an
enlarged coronary diameter,(right 3.9 mm, left 3.6 mm; circumflex 3.1
mm, proximal anterior inter-ventricular 3.1 mm; worse Z score +5).
Results: From the presence of fever that had lasted for more than five
days,the lymphadenopathy,conjunctivitis,the cutaneous rash and the
oedema of the hands and feet with cardiac involvement,we diagnosed
complete Kawasaki disease and started IVIG (2 g/Kg) and Aspirin (80
mg/Kg).Despite the initial IVIG treatment, the fever,rash,conjunctivi-
tis,cheilitis and mild oedema of hands and feet remained,and additional
IVIG doses and three metilprednisolone (30 mg/kg) pulses were adminis-
tered in the following days.The patient underwent another echocardiog-
raphy that did not show any changes.Maintenance treatment with oral
prednisone (0.5 mg/kg/day) was initiated.The patient became afebrile,
and the rash, cheilitis and conjunctivitis gradually disappeared.Serologi-
cal markers of inflammation returned to the normal range.After ten days,
the patient’s fever recurred with irritability, exanthema,conjunctivitis, and
hand and feet desquamation.Blood tests showed a significant increase
of CRP (65.30 mg/L),ESR (50 mm/h);anaemia (Hb 10.4 g/dL) and more
platelets (566,000) were also registered.Echocardiography did not show
changes.Further Metilprednisolone pulses were administered over three
days.After one day the patient repeated the Echocardiography, which
showed a worsening of the enlargement of the coronary diameter,(right
6 mm (Z score 13),left 6 mm (Z score 9.9),proximal anterior inter-
ventricular 5.7 mm (Z score 15).There was an aneurism in the diagonal
branch of left anterior descending coronary (7.2 mm; Z Score >10) with
a thrombus inside.After three days, the patient’s fever continued.Due to
the persistence of the fever,the worsening of the echocardiography fea-
tures and blood tests,with the agreement of his parents,other intraven-
ous treatments with IL-1RA were initiated (Anakinra 2 mg/kg
subcutaneously once a day for two weeks).One day later, the fever dis-
appeared and CRP, ESR, platelet and haemoglobin levels returned to
normal in the subsequent blood tests.The Aspirin dose was reduced to
the antiplatelet dose and Clopidogrel (5 mg) was added.
Conclusion: Treatment with Anakinra was maintained for two
weeks, and Prednisone (0.5 mg/kg/dy), Aspirin and Clopido-
grel.There were no flares of the disease after discontinuing the
Anakinra and blood tests were within the normal range. Echocardi-
ography tests showed an improvement in his coronary enlarge-
ment. Written informed consent was obtained from the patients
for publication of Case Report.
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Introduction: Henoch-Schonlein purpura(HSP) is the most common
childhood systemic vasculitis.The disease affects the skin,the gastro-
intestinal tract,the joints and kidneys.In rare cases the skin can
present as haemorrhagic,bullous or necrotic lesions.
Objectives: We describe a case of HSP presenting with severe skin le-
sions that did not respond to standard therapy with corticosteroid-
s,and was therefore treated with intravenous immunoglobulins(IVIG).
Methods: An 11-year-old girl was admitted to our department with
fever,abdominal pain,arthralgia,severe purpuric palpable rash and
haemorrhagic bullae distributed on the buttocks and lowerextremi-
ties.Physical examination showed a purpuric palpable rash,multiple
haemorrhagic bullae and vesicles ranging in size from five to 30mm
on the buttocks and lower limbs.The abdomen was painful but soft.-
Blood tests revealed a white blood cell (WBC) count of 20.730/ml
with normal differential, platelets (PLT) 336.000/ml,haemoglobin (Hb)
13.3 g/dl,erythrocyte sedimentation rate (ESR) 30 mm/1h (nv 20 mm/
1h), C-reactive protein (CRP) 13 mg/L.She tested negative for strepto-
coccal tests showed Antistreptolisine (ASLO) 778 IU/mL (nv 0-200)
and anti-DNAse 1170 IU/mL (nv 0-200).Microscopic analysis of the pa-
tient’s urine showed mild proteinuria (30mg/dl) and an occult blood
test on a stool sample was negative.Abdominal ultrasound was unre-
markable.A skin biopsy revealed peri-nuclear infiltration of poly-
morphs,nuclear leukocyte and mononuclear cells with IgA deposition
in immunofluorescence studies,typical of leukocytoclastic vasculitis.
Results: Clinical findings were consistent with HSP and she was
started on oral prednisone (1mg/kg/daily),as well as antibiotics with
teicoplanin for the super-infection of skin lesions (Staphylococcous
Aureus).After ten days she was discharged,with an improvement in
skin appearance.She was given a schedule to progressively taper and
stop steroid therapy within a month.At the 15-day follow-up,she pre-
sented new onset of purpuric rash on her lower extremities and scars
of previous bullae.We decided to increase the dosage of corticoster-
oid therapy from 0.5mg/Kg to 1mg/kg/die.At the one-month follow-
up she presented a new purpuric rash and haemorrhagic bullae on
her lower extremities,associated with abdominal pain.She was there-
fore readmitted to our department.Blood tests revealed WBC 10.730/
ml with normal differential count,PLT 300.000/ml,Hb13.2 g/dl,ESR 40
mm/1h,CRP 15 mg/L;creatinine,were within range.The results of uri-
nalysis,an occult blood test of a stool sample and an abdomen ultra-
sound were all negative.She started an IVIG infusion (2g/kg),while
still on oral prednisone (1mg/kg/daily),progressively tapered.After
treatment she showed good improvement in respect of her skin le-
sions and was discharged.At the 15-30-60 day follow-up visits the pa-
tient was in good general condition;she did not have any new
lesions but only scars on her lower limbs.
Conclusion: There is no consensus about the management for cuta-
neous manifestations in HPS.In the case of rare skin complications,-
such as haemorrhagic bullae lesions,immunosuppression with
corticosteroid therapy is often necessary in order to control the in-
flammation and limit the expanse of necrosis.Unfortunately,our pa-
tient gained only partial benefit from corticosteroid therapy.As a
consequence,we decided to treat her with an IVIG (2g/kg as a single
infusion) associated with oral prednisone (1mg/kg/daily),progres-
sively tapered,which induced rapid and persistent resolution of
symptomatology.Written informed consent was obtained from the
patients for publication of Case Report.
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Introduction: Behçet ´s disease is a systemic inflammatory disease
characterized by recurrent oral aphthae affecting the oral and
genital mucosa, and several systemic manifestations such as
ocular, neurologic or vascular disease, skin lesions, gastrointestinal
involvement or arthritis. Even though its peak age of onset is
in young adults 20 to 40 years of age, it ocasionally occurs in
children.
Objectives: To report a pediatric-onset HLA-B51 positive case of Beh-
çet ´s disease.
Methods: Review of the medical records.
Results: An 11-year-old boy with recurrent oral aphthae was re-
ferred from the pediatric emergency department to the pediatric
rheumatology consultation after two episodes of great saphenous
vein superficial thrombophlebitis. He had been experiencing daily
oral aphthae with spontaneous resolution after 10 days for the past
three years (>3 episodes in a year). Besides, his mother described
various episodes of folliculitis with formation of pustules over the
previous months. He denied fever, rash, weight changes, sleep dis-
turbance, headaches, abdominal pain, change in bowel habits or di-
uresis, respiratory symptoms, visual disturbances or fatigue. His
physical exam and pediatric gait arms legs spine exam was normal
except for two oral aphthae and some acneiform lesions. Laboratory
data including complete blood count with renal function, ionogram,
reactive c protein, coagulation studies, viral markers for hepatitis B
and C and HIV, herpes simplex and varicella-zoster virus serology
and calprotectin were negative. Immunglobulin levels were normal
and autoimmunity studies with beta 2 glycoprotein antibodies,
lupus anticoagulant, anti-HLA-B27, anti-nuclear, anti-SSA and SSB,
anti-RNP, anti-SM, anti-Scl-70, anti-JO-1, anti-cardiolipin and anti-ds-
DNA antibodies and markers for celiac disease were negative. Urine
testing showed discrete proteinuria. A pathergy test was performed,
which was negative. His echocardiogram was normal and his ophtal-
mologic evaluation did not show any signs of uveitis. Thus, a diag-
nosis of Behçet ´s disease was established according to the
International Classification Criteria for Behçet ´s disease. HLA- B51
testing was later requested, which was positive. According to the
EULAR 2008 guidelines, he initiated colchicine without further epi-
sodes of oral aphthae. He currently maintains a regular follow-up in
the pediatric rheumatology and vascular surgery consultation, with-
out any further occurences except for an episode of self-limited
epididymitis.
Conclusion: Although the diagnostic criteria for Behçet ´s disease
are well-established in adults, diagnosis and treatment is still a chal-
lenge in the pediatric population, as there are no pathognomonic
laboratory tests and diagnostic criteria are not adapted to children.
The consensus classification criteria have been recently developed
for pediatric Behçet ´s disease in an attempt to increase the sensitiv-
ity of the prior criteria. We described a case illustrating that a de-
tailed clinical history and a thorough physical exam associated with
a high level of suspicion remains the most suitable approach. These
patients require a periodic ophtalmologic evaluation and a close
vigilance of prothrombotic states.
Written informed consent has been obtained from the legal repre-
sentative of the subject involved.
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Introduction: Last year, a subcutaneous injection of tocilizumab
(scTCZ) was approved for Takayasu arteritis (TA) over 12 years of age
in Japan. Based on our experience in pediatric patients, we describe
the effects and the issues.
Objectives: To consider the positioning of scTCZ for chilhood TA, the
appropriate dosage form and the evaluation means.
Methods: We examined medical information that was extracted from
patients’ charts, such as vital signs, the Indian Takayasu Arteritis Clin-
ical Activity Score (ITAS2010), results of blood examination, echocar-
diography, vascular ultrasonography and other imaging inspection,
and evaluated the change before and after the initiation of scTCZ by
the dosage of 125mg once a week.
Results: There are two children with TA treated with scTCZ. Case 1 is a
12-year-old girl who developed reversible cerebral vasoconstriction syn-
drome combined with cerebral infarction. Because of the upper extrem-
ity blood pressure differential and cervical murmurs, contrast CT and
vascular ultrasonography were performed that revealed the wall thick-
ening and stenosis of cervical and subclavian arteries. HLA-B52 was
positive, but other blood examination shows no abnormality, including
erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and inter-
leukin (IL)-6. Oral prednisolone (PSL) was started that resulted in no im-
provement of artery wall thickening, then intravenous TCZ (8mg/kg,
every other week) was initiated 4 months after the onset. The thicken-
ing of arteries, blood flow acceleration and ITAS2010 improved, and
prednisolone was decreased to 5mg/day. 11 months after the onset,
the dosage of TCZ was switched to 125mg subcutaneously once a
week and the effect continues. Case 2 is an 11-year-old girl whom com-
plicated with ulcerative colitis and had been treated with azathioprine,
prednisolone and infliximab. She complained fever, fatigue, leg pain
after exercise, and was accompanied with high CRP level. Positron emis-
sion tomography revealed integration at cervical, subclavian, brachial
and femoral arteries. The upper extremity blood pressure differential
and cervical murmurs were confirmed. The symptoms, the inflamma-
tory response on blood examination and the findings of vascular ultra-
sonography improved by the administration of systemic PSL, however,
serum ferritin level remained high and the thickening of arteries exacer-
bated as the PSL was tapered. Infliximab was switched to scTCZ
24weeks after the diagnosis and there has been no deterioration of dis-
ease activity with the lowest level of serum ferritin. In both cases, vascu-
lar ultrasonography and ITAS2010 enabled us to detect disease activity,
even if CRP was negative and was not useful as an evaluation means.
Conclusion: The scTCZ was effective for childhood TA, however, there
are many issues that should be discussed; timing of indication, pres-
ence or absence of immunosuppressants, dosage form for patients
under 12 years of age, safety for complications such as UC, evaluation
index instead of CRP, the minimum ?A3B2 show $132#?>maintenance
dose of PSL, and so on. Consent to publish had been obtained.
Reference
Nakaoka Y, Isobe M, Takei S, Tanaka Y, Ishii T, Yokota S, et al. Efficacy and
safety of tocilizumab in patients with refractory Takayasu arteritis: results
from a randomized, double-blind, placebo-controlled, phase 3 trial in
Japan (the TAKT study). Ann Rheum Dis 2018;77:348–354.
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Table 1 (abstract P227). The Evaluation index before and after scTCZ
administration
CRP at
diagnose
(mg/dl)
CRP
after
scTCZ
(mg/
dl)
ESR at
diagnose
(mm/1h)
ESR
after
scTCZ
(mm/
h)
Serum IL-
6 at diag-
nose (pg/
ml)
Serum
IL-6
after
scTCZ
(pg/
ml)
ITAS2010
at
diagnose
ITAS2010
after
scTCZ
Case1 0.14 <0.01 4 2 <1.5 8.2 15 3
Case2 10.25 <0.01 68 4 Not
studied
(0.07 with
0.5mg/kg
of PSL)
85 5 3
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Introduction: Middle aortic syndrome (MAS) is a clinical condition
generated by segmental narrowing of the abdominal or distal de-
scending thoracic aorta. The syndrome may have a different etiology:
acquired, caused for example by Takayasu disease or congenital, at-
tributed to developmental aortic anomalies. The Williams-Beuren syn-
drome is a congenital, genetically conditioned disorder, caused by
deletion on the long arm of chromosome 7, in the region 7q11.23. It
is characterized by a group of congenital malformations with dys-
morphic features, abnormal psychomotorical development, intellec-
tual disability, cardiovascular defects, most often in the form of
supravalvular aortic stenosis or peripheral pulmonary artery stenosis,
muscular tension disorders and a changed behavioral profile.
Objectives: The aim of our study is to present the diagnosis the Williams-
Beuren syndrome in patient with suspected systemic vasculitis.
Methods: Retrospective analysis of patient's history.
Results: The first symptoms: palpitations and chest pains after physical ex-
ertion were first noticed at the age of 15. Subsequently, the patient was
evaluated by a cardiologist and a nephrologist – they diagnosed hyper-
tension, aortic valve regurgitation and mitral valve insufficiency. Directed
to the Department of Rheumatology with suspected systemic vasculitis.
During observation, the patient was seen to be capable of tolerating
moderate physical exertion, and variable blood pressure was observed
with the difference between L and P of the upper limb. Subsequent
stages of diagnosis revealed thoracic, abdominal and aortic stenosis, as
well as stenosis in the renal and internal carotid arteries. The patient met
the criteria of Takayasu arteritis: angiographic abnormality, pulse deficit
blood pressure discrepancy and hypertension but PET / CT scans showed
no irregularities. The results of laboratory tests (including morphology,
hemostasis, inflammation, pANCA, cANCA) were also normal. The patient
was referred to the genetic counselling. Numerous dysmorphic features
were noticed in the physical examination. An MLPA study was performed
using a set of probes for region 7q11.23, confirming the presence of dele-
tions. The results of the molecular tests let to the diagnosis of Williams-
Beuren syndrome. Correct MLPA results from both parents confirmed that
the deletion in the patient's 7q11.23 region is de novo.
Conclusion: In the diagnosis of patients with vasculitis symptoms,
congenital diseases, including rare genetic syndromes, should be
considered. Multidisciplinary cooperation is a prerequisite for making
the correct diagnosis. Informed consent to publish had been ob-
tained from the parent.
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Introduction: Takayasu arteritis is an idiopathic large-vessel vascu-
litis that primarily affects the aorta and its major branches.
Chronic granulomatous inflammation leads to stenosis and occa-
sionally aneurysms of the involved portions of the arteries, produ-
cing a wide variety of symptoms. High-dose corticosteroids are
the mainstay of therapy but adjunct immunosuppression is fre-
quently required. TNF-a blocking agents have shown to be effect-
ive in refractory cases.
Objectives: Characterization of patient demographics, clinical fea-
tures, disease extent, treatment and outcomes in children with
Takayasu arteritis
Methods: Retrospective data analysis of a case series of children
fulfilling the EULAR/PRINTO/PRES criteria for childhood Takayasu
arteritis in a tertiary hospital setting during a 10-year period.
Results: A total of 4 children (3 female), with a median age at diagnosis
of 7 years (5 -10 years) were identified during this period. The most
common clinical features at presentation were systemic symptoms and
cardiovascular involvement (4/4). Weak peripheral pulses, discrepant
systolic blood pressure between limbs and arterial bruits were present
in all cases. Arterial hypertension was detected in half of the patients.
Neurological manifestations were also very common (3/4), with seizures
at the initial presentation in 2 patients and ischemic stroke in 1 case. A
minority of patients complained of gastrointestinal (1/4) and respiratory
(1/4) symptoms. Acute phase reactants (ESR and CRP) were elevated in
all patients. Thrombocytosis (3/4) and chronic disease anaemia (2/4)
were also commonly found.
The distribution of the involved arteries according to the angiographic
classification of Takayasu arteritis showed a pattern type V in 3 cases,
one of which was VP+. The remaining case displayed a pattern IIa.
First-line treatment in all cases included high-dose corticosteroids and
methotrexate. Cyclophosphamide was added in 2 cases. Due to a se-
vere and refractory disease course, TNF-a blocking agents were admin-
istered in all patients (Infliximab, 2 cases; Adalimumab, 2 cases).
Endovascular procedures were required in 2 patients with irreversible
stenosis: renal artery percutaneous transluminal angioplasty (2 cases)
and pulmonary artery stenting (1 case).
There were no relevant infections or mortality during the follow-
up period. Repeated magnetic resonance angiography to assess
disease activity showed improvement in vascular lesions in 3
patients, with remission in 1 case. None of the patients presented
disease progression with involvement of new vessels.
Conclusion: The diagnosis of childhood Takayasu arteritis remains
challenging, mainly due to the insidious clinical course and the
lack of specificity of the presenting symptoms. The abnormal per-
ipheral pulses in the setting of elevated inflammatory markers
should raise suspicion for this condition.
Previous studies found that constitutional features like low-grade
fever, weight loss and arthralgia are more frequently found in
childhood Takayasu arteritis compared with adult patients. In our
series these symptoms were present in all patients.
We report a higher frequency of neurological involvement com-
pared with other paediatric reports, perhaps reflecting the sever-
ity of the angiographic pattern and the delay in diagnosis.
None of our patients achieved stable remission with high-dose corti-
costeroids and methotrexate only. Anti-TNFa showed to be beneficial
in refractory patients with clinical improvement in the majority of the
cases, as previously reported in other studies.
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Introduction: Childhood Takayasu (c-TA) as a rare large vessel vascu-
litis remains challenging from the initial diagnostics to the manag-
ment of the disease, accordingly morbidity and mortality remains
high. In literature, there exist some promising reports of treating
otherwise treatment-resistant systemic vasculitis with autologous
peripheral blood stem cell transplantation.
Objectives: To demonstrate the difficulty of managing c-TA after allo-
geneic stem cell transplantation due to Hyper-IgE Syndrome
Methods: Case report
Results: Here, we report on the case of a 10 year old boy who devel-
oped c-TA several months after allogeneic hematopoietic stem cell
transplantation having received for the correction of a severe Hyper-
IgE-Sydrome. At the time of diagnosis of c-TA the patient was off sys-
temic immunosuppressive treatment, with stable donor chimerism
and without any clinical evidence of graft versus host disease.
The management of the immunosuppressive therapy was challen-
ging, but the introduction of infliximab resulted in stabilisation of the
disease course.
Conclusion: The difficulty of monitoring disease activity due to lack
of specific biomarkers, the importance of radiological follow-up, the
common complications and the non-steroidal treatment options will
be discussed here. Informed consent to published had been ob-
tained from the parents.
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Introduction: Kawasaki disease (KD) epidemiology and its etiology
are the subject of vivid debates after more than 50 years of its initial
characterization by T. Kawasaki. Among the many causes invoked,
environmental as well as genetic studies pointed to incomplete
views on what is still today, a medical mystery.
Objectives: The identification of regular variability cycles modulating
population epidemiology of KD in Japan at temporal scales ranging
from seasonality to interanual cycles and their close association to
variability in wind dynamics, raised new questions and altered our
former understanding of KD. At seasonal timescales,wind intensity and
wind direction closely mimick variability in KD. At longer scales, regional
climate features, like interhemispheric winds in the north andmidlatitude Pacific Ocean and the El Niño-Southern Oscillation (ENSO)
phenomena seem to play a dominating role. However, despite daily
dynamics were also proved to be related between local winds and
hospital case admissions, variability at these fast time scales has never
been studied in relation to local air physics and air quality
Methods: Machine learning data clustering and a suite of classifica-
tion techniques were applied to both KD incidence and environmen-
tal datasets in Kumamoto (Japan), during two intervals covered with
intensive daily surveillance. KD incidence, physical air determinants
and air chemistry factors are pooled together in these analyses.
Results: Interestingly, new associations emerge that strongly link the
nature of air masses to very high frequency cycles in KD. Results are
supported by analyses reproduced during different synoptic weather
conditions and among typologies of KD epidemiological events, sug-
gesting a clear role of air determinants in the population epidemi-
ology of this vasculitis.
Conclusion: Air quality and its dynamics should be considered as a
determinant factor of enhanced KD incidence in Japan. These results
may be the basis for widening our long-standing views on this para-
digmatic disease, and be useful in the case of other similar diseases.
Specific surveys aimed at precisely characterizing these air determi-
nants are urgently needed to unravel what constellation of environ-
mental factors seem to be modulating KD incidence.
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Introduction: ADA2 Deficiency is a new autoinflammatory disease
characterized by systemic vasculopathy and episodes of strokes, but
some patients can present mild immunodeficiency. The defect is due
to a loss of function mutation of CECR1 gene, coding for Adenosine
Deaminase 2 protein. This protein regulates the catabolism of extra-
cellular adenosine, which we have shown is an important regulator
of Class Switch Recombination in B lymphocytes.
Objectives: ADA2 Deficiency is a new autoinflammatory disease char-
acterized by systemic vasculopathy and episodes of strokes, but
some patients can present mild immunodeficiency. The defect is due
to a loss of function mutation of CECR1 gene, coding for Adenosine
Deaminase 2 protein. This protein regulates the catabolism of extra-
cellular adenosine, which we have shown is an important regulator
of Class Switch Recombination in B lymphocytes.
Methods: 14 patients carrying mutations in CECR1 were examined.
They showed clinical history with livedo reticularis, fever, vasculitis
and neurological symptoms. 6 patients presented hypogammaglobu-
linemia or recurrent infections. We analyzed peripheral B and T cell
phenotype by flow cytometry. B cells isolated from healthy donors
and DADA2 patients have been cultured alone or in co-culture with
CD4+ T cells and in vitro B cell proliferation has been evaluated by
CFSE dilution. In vitro B cell differentiation to Immunoglobulin secret-
ing cells in response to TLR9 agonist and T cell help has been evalu-
ated by ELISA/ELISPOT assay. Moreover cytokines production and
CD40L expression from patients T cells have been evaluated.
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 124 of 243Results: Flow cytometric analysis showed a significant reduction of
memory B cell compartment (CD19+CD27+) in DADA2 patients, in
particular in Swich memory B cell subset.
We also observed a reduced absolute number of CD4+ and CD8+ T
cells, whereas the subpopulations of T cells resulted normal, with the
exception of TEMRA CD8+ T cells, significantly expanded in DADA2
patients. Moreover we identified an expansion of circulating Tfh cells
in DADA2. Then we investigated a role of ADA2 in B cells: we found
that ADA2 is expressed, secreted by B cells, but the enzymatic activ-
ity is impaired in patients’ B cells that show functional impairment in
proliferation and differentiation.
We addressed in vitro the interaction of B and T cells, essential for
generation of memory.
Analysis of proliferation and differentiation showed that proliferation
of patients’ B cells is not sustained from patient’s T cells and IgG se-
cretion is significantly reduced in the presence of CD4+ T cells ob-
tained from DADA2 patients with respect to normal CD4+ T cells.
Moreover T cells from DADA2 show an impairment in the production
of IL21, key cytokine for B cell help and a significantly downregula-
tion of CD40L.
Conclusion: Our findings suggest that CECR1 mutation could affects
directly B cell function and leads also to an impairment of T cell help
functions.
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Introduction: ADA2 deficiency (DADA2) is an immunological disease
caused by autosomal recessive mutations in the CERC1 gene coding
for ADA2 enzyme. DADA2 is causing various and heterogeneous
manifestations, including systemic inflammation, vascularitis, throm-
botic events, cytopenias, immune deficiency, and autoimmunity.
Timely diagnosis and treatment are crucial to prevent cerebral
strokes as well as other multisystemic serious complications of the
disease.
Objectives: We describe here the case of a 4-year old Caucasian child
diagnosed with DADA2 in the context of positive family history.
Methods: Case report.
Results: This 4-year-old boy, originating from Portugal, presented
with persistent fever in the last 3 months, lower limbs pain, systemic
inflammation, anaemia, livedo reticularis, and hypogammaglobuline-
mia M and A. The personal history showed failure to thrive since the
age of 2 years. Family history revealed consanguinity and a fourth
degree relative with the diagnosis of DADA2 due to a homozygous
R169Q mutation. After exclusion of infectious and oncologic causes,
targeted genetic analysis was performed and showed the presence
of the same R169Q mutation with enzymatic tests confirming the ab-
sence of ADA2 activity. After diagnosis, oral steroids were introduced
with remission of symptoms and normalization of inflammatory
markers within 3 weeks and was followed by anti-TNF alpha therapy.
Genetic testing of the parents is ongoing.
Conclusion: DADA2 diagnosis may be challenging with no specific
symptoms at presentation; the presence of livedo, hypogammaglo-
bulinemia and thrombotic events should raise the awareness of phy-
sicians. We describe here a case of DADA2 promptly diagnosed due
to the positive family history. Early diagnosis of DADA2 is essential to
prevent serious complications of the disease, highlighting the im-
portance of genetic testing in all family members. However, the man-
agement of presymptomatic patients remains a matter of
controversy. In the absence of biomarkers predicting the onset ofthe disease, a close and regular follow-up is recommended in case of
the mutation. Written informed consent was obtained from the pa-
tients for publication.
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Introduction: Antineutrophil cytoplasmic antibody-associated vascu-
litides (AAV) are very rare in childhood vasculitides with an increased
risk of morbidity and mortality. Five factor score (FFS) is a tool de-
signed to assess prognosis at diagnosis of the patient with systemic
necrotizing vasculitides and is found to be a good predictor for sur-
vival rate in adult studies.
Objectives: This study was aimed to evaluate renal prognostic factors
in childhood AAV with the perspective of ANCA serotype, histopatho-
logical classification and FFS.
Methods: Pediatric AAV patients from 11 referral centers in Turkey,
who were followed up between January 2006 and March 2018, were in-
cluded to study. The demographics, clinical findings, AAV subtypes, out-
comes, and FFS were evaluated retrospectively. Kidney biopsies were
classified histopathologically according to the Berden classification.
Results: Totally 39 patients, including 68.4% GPA, 21.1% MPA and
10.5% EGPA were enrolled in the study. Among all patients, 74.4%
had renal involvement, 56.4% ear-nose- throat (ENT) involvement,
51.3% had musculoskeletal involvement. PR3 ANCA was positive in
48.7% and MPO ANCA was positive in 30.8%. During the follow-up,
impaired renal function and end-stage-renal-disease (ESRD) were
assessed in 69.2% and 28.2%, respectively. At the diagnosis, FFS
was ≥ 2 in 53.8%. The most common histopathologic classifications
were as follows; crescentic type in 40.7%, sclerotic type in 25.9%.
ETN and renal involvement statistical significance among the AAV
subgroups (p <0.001, p = 0.001, respectively). Presence of PR3-
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 125 of 243ANCA antibody was higher in the GPA group. Gastrointestinal and
renal involvement, MPO-ANCA positivity, serum creatinine levels
and impaired renal function during the follow-up were significantly
higher in patients with FFS ≥ 2, compared to patients with FFS <2.
Patients with FFS ≥ 2 had more common crescentic, mixed and
sclerotic histopathologic findings in biopsies. By logistic regression
analysis forward method, the strongest single-risk factor among all
the parameters was the initial level of creatinine in patients with
ESRD, compared to the other patients (p = 0,007)
Conclusion: We have presented the association between poor histo-
pathologic findings and MPO-ANCA positivity, impaired renal func-
tion and FFS ≥ 2 at the diagnosis. The most important predictor
factor for renal prognosis was initial serum creatinine level. In con-
clusion, evaluation of the FFS, ANCA serology and the creatinine
levels may help to predict renal prognosis.
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Introduction: Kawasaki Disease (KD) is a self-limited childhood vascu-
litis of unknown origin and coronary artery aneurisms are its most
significant complication. Timely treatment with Intravenous Immuno-
globulin (IVIG) represents the standard care, but more than 10% of
children are unresponsive. Many treatment options have been re-
ported, but the most effective therapy for refractory cases is still
not defined. Although mice models have suggested a significant role
of Il-1 in the pathogenesis of KD and coronary artery aneurisms,
treatment with Interleukin - 1 Receptor Antagonist (Il - 1 RA) has
been seldom used.
Objectives: We report two patients with refractory KD who achieved re-
mission with Anakinra following IVIG and systemic corticosteroid failure.
Methods: Describing case series.
Results: Case #1 is a previously healthy four-month-old male, pre-
senting for high fever not responsive to empiric antimicrobial ther-
apy, marked irritability and poor feeding, bilateral conjunctivitis,
micropapular rash involving face and extremities, keilitis, perianal
hyperemia and mild hand and feet edema. KD was diagnosed and
the patient was started on aspirin and IVIG on day 5th from the onset
of fever; a second dose of IVIG was administered two days later be-
cause of persistent fever. Despite this treatment, his general condi-
tions deteriorated and cutaneous rash worsened significantly,
evolving into necrotic-hemorragic vasculitic lesions. Pulse methyl-
prednisolone was started on day 8th, followed by high dose oral
prednisone. Ten days later the patient relapsed and a third IVIG infu-
sion was administered. Seriated echocardiographies showed from
the 23rdday of illness a marked dilation of both right and left coron-
ary arteries.
Case #2 is a previously healthy 4-year-old male who was admitted to
General Pediatric Unit because of 4 days high-grade fever, feeding
difficulties, conjunctival injection, cervical adenopathy, mucositis, ab-
dominal rash and palm and sole erythema. KD was diagnosed, as-
pirin was started and 2 IVIG infusions were administered without
improvement. Seriated echocardiographies showed coronary involve-
ment with mild dilation of left coronary artery. From the 8thday of
fever, 3 pulses of methylprednisolone were administered, followed
by oral prednisone, with initial improvement. Four days later he was
febrile again and in poor general conditions with severe irritability.Given the resistance to IVIG and corticosteroids, IL1 - RA (anakinra)
was started in both patients at the dose of 2 mg/kg once a day, sub-
cutaneously. They both showed a rapid improvement; particularly,
patient #1 showed a gradual resolution of the severe cutaneous vas-
culitic lesions. Two weeks after starting biological therapy, both pa-
tients could be discharged from hospital on anakinra, tapering oral
corticosteroid. Treatment with anakinra was maintained for 1 month
in both children and no relapses occurred after its discontinuation;
patients did not experience any side effect during therapy. Echocar-
diographic controls showed progressive reduction of coronary dila-
tion with complete resolution after 5 months in patient #1 and after
6 weeks from the onset of KD symptoms in patient #2.
Conclusion: Our case series suggests that treatment with IL-RA
may be considered as an effective and safe therapeutic option
for refractory KD. Informed consent to publish was obtained from
the parents.
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Introduction: Henoch-Schönlein purpura (HSP) is the first cause of
systemic vasculitis in childhood, characterized by immunoglobulin A
(IgA) deposits in small vessels. Two-thirds of children have abdominal
involvement with at least abdominal pain due to sub-mucosal
hemorrhage and edema of the intestinal walls.
Objectives: We report data on microbial translocation, as well as
serum and in stool IgA levels in pediatric Henoch-Schönlein purpura.
Methods: Three groups of children, 3 to 15.6 years old, were included:
group A, acute HSP (n=30); group B, remitting HSP (n=30); group C,
healthy controls matched for age (n=38). Bacterial translocation was
evaluated by measuring plasma bacterial 16S rDNA levels using quanti-
tative PCR. Serum IgA levels were quantified by immunonephelometry.
Secretory IgA (sIgA) concentrations in stools were measured by ELISA.
Results: 63% and 73% of children in group A and B, respectively, pre-
sented with gastrointestinal manifestations. Mean 16S rDNA levels
tended to be lower in A (7.90 [SD, 3.72] cp/μl) and B (9.84 [SD, 5.11]
cp/μl) than in C (12.45 [SD, 8.1630] cp/μl). Mean serum IgA levels
were significantly higher in A (1.95 [SD, 0.84] mg/mL) than in B (1.20
[SD, 0.53] mg/mL, p=0.02) and C (0.94 [SD, 0.77] mg/mL, p=0.0001).
By contrast, sIgA levels were significantly lower in A (3.81 [Sd 8.40]
mg/mL) than in C (6.25 [Sd 10.84] mg/mL, p=0.045).
Conclusion: Bacterial translocation was lower in HSP children than in
healthy subjects. Serum IgA were higher during acute HSP, while
secretory IgA levels were paradoxically reduced in stools. These data
provoke the hypothesis that IgA overproduction in HSP might pre-
vent microbial translocation. The low stool sIgA levels observed in
acute HSP might be the consequence of IgA consumption during this
process. Further studies are necessary to test this hypothesis. In-
formed consent to publish had been obtained.
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Introduction: Takayasu Arteritis (TA) is a large vessel vasculitis which
primarily affects the aorta and its primary branches. Renal arterial in-
volvement is common in TA. In severe cases, it can cause total occlu-
sion of renal arteries.
Objectives: We hereby present a case of Takayasu arteritis causing
bilateral renal artery stenosis, leading renal failure and treated with
renal auto-transplantation (RAT).
Methods: A case with Takayasu Arteritis and bilateral renal artery
stenosis were presented.
Results: A 17-year old male patient applied to our hospital with
swelling in the periorbital area and legs. On physical examination,
he had periorbital and pretibial edema and periumblical bruit. His
blood pressure was 185/115 mmHg on both upper and 240/160
mmHg on lower extremities. Initial creatinine level was 1.19 mg/dL;
ESR and CRP levels were 63 mm/h and 52.4 mg/L, respectively.
Renal doppler ultrasonography demonstrated total occlusion of the
left renal artery, severe stenosis of right renal artery (nearly oc-
cluded) and vascular wall thickening of the abdominal aorta and
superior mesenteric artery (SMA). Magnetic resonance (MR) angiog-
raphy showed wall thickening and perivascular inflammation of
aorta and its major branches which is consistent with Takayasu ar-
teritis. Significant narrowing in SMA and right renal artery, total oc-
clusion of left renal artery and T2 signal decrease in left kidney
suggested diffuse ischemia and infarct. Accordingly, he was diag-
nosed as Takayasu arteritis, and given pulse methylprednisolone
(PMP) treatment immediately at his first day of admission. However
within 12 hours, he became anuric, his edema increased, and cre-
atinine level elevated to 4 mg/dL. Urgent hemodialysis (HD) was
performed and due to the rapid progression of the disease intra-
venous pulse cyclophosphamide (CYC) was added. Despite daily HD
and intense immunosuppressive therapy with CYC and 5 day
course PMP, creatinine levels continued rising (7 mg/dL). On the
sixth day of admission, thoracoabdominal aortography was per-
formed but the attempt for revascularization of renal arteries by
balloon angioplasty was unsuccessful. Considering his severe renal
failure and inadequate response to the medical and endovascular
interventions, RAT was performed. His relatively preserved right kid-
ney was dissected and directly anastomosed to right external iliac
artery. Postoperatively, diuresis started immediately, creatinine
levels decreased slightly right after surgery, and returned to normal
levels (0.99 mg/dL) on post-operative day 10. Immunosuppressive
therapy was continued with 60 mg/day oral corticosteroid (CS) and
second dose of CYC was given 3 weeks after RAT.
Conclusion: This case shows that early diagnosis and immediate ap-
propriate interventions are life-saving in TA. In experienced trans-
plant centers, RAT performed in selected cases is a kidney-saving
method and provides dialysis-free-survival. Informed consent to pub-
lish had been obtained from the parents.
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Introduction: Juvenile idiopathic arthritis (JIA) is known as an auto-
immune disease and the severity of inflammation in arthritic joints is
thought to be due to the imbalance of pro-inflammatory and anti-
inflammatory cytokines. Pro-inflammatory type 1 helper (Th1) and
anti-inflammatory type 2 helper (Th2) T cell activity are shown as
serum levels of soluble CD26 (sCD26) and sCD30.
Objectives: The aim of this study is to assess serum levels and clinical
significance of sCD26, sCD30 and sCD30/sCD26 ratio in patients with JIA.
Methods: Forty eight JIA patients (19 patients with RF+ poly-articular
JIA (p-JIA), 8 with RF- p-JIA, and 21 with oligo-articular JIA (o-JIA))
and 9 healthy controls (HCs) were enrolled. Serum levels of sCD26
and sCD30 were measured using enzyme linked immunosorbent
assay. Furthermore, we investigated the correlation between these
levels and clinical manifestations.
Results: In JIA patients, serum CD26 levels were lower and serum
CD30 levels were higher compared to HCs, although not statistically
significant. In RF+ and RF- p-JIA patients, serum sCD30/ sCD26 ratio
was significantly elevated compared to HCs in active phase. Serum
sCD30/ sCD26 ratio was significantly decreased in inactive phase
compared to active phase. Furthermore, in RF+ p-JIA patients, serum
sCD30/sCD26 ratio was correlated with arthritic disease activity in-
cluding tender joint counts, swollen joint counts and serum levels of
matrix metalloprotease-3. On the other hand, In RF- p-JIA and o-JIA
patients, those correlation were not observed.
Conclusion: The serum sCD30/sCD26 ratio might be a useful bio-
marker for disease activity and joint inflammation in patients with RF
+ p-JIA. Increasing Th2 cell activity might have an important role in
the pathogenesis of RF+ p-JIA.
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Introduction: The benefits of physical activity are multiple and are en-
hanced when it is done routinely1. Pediatric patients with rheumato-
logical diseases develop chronic proinflammatory conditions, which
causes an increase in the burden of disease and the appearance of co-
morbidities such as overweight, obesity and cardiovascular disease that,
associated with sedentary lifestyle, increases morbidity and mortality in
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 127 of 243the medium and long term2. Studies in the population with juvenile
idiopathic arthritis (JIA) and juvenile systemic lupus erythematosus
(SLEj) show that these children are less active than their healthy coun-
terparts, causing an increase in the rates of disease and damage3
Objectives: Quantify the physical activity performed by patients with
JIA and SLEj treated in the pediatric rheumatology consult of a
pediatric service in the city of Bogotá and in a population without
rheumatological diseases in the first half of 2017
Methods: Analytical cross-sectional study of patients with JIA, SLEj and
without rheumatological pathologies. Physical activity was evaluated
with the validated physical activity questionnaire for children (PAQ - C,
for children under 13 years old) or adolescents (PAQ - A, age 14-16
years), scoring tool from 0 (without physical activity) to 5 (intense phys-
ical activity). The patients completed the child health questionnaire
(CHAQ) and assessed activity and damage associated with the disease.
Results: The study included 95 patients with rheumatologic disease
(JIA: 52 patients and SLEj: 43 patients) and 100 healthy individuals.
Average age of presentation of the disease 13.5 years (SD 3.1 years
range 4 - 18 years). Regular physical activity was performed by 28.8%
of patients with JIA, 19% without pathology and 13.9% of patients
with SLEj. The median physical activity (PAQ) in individuals with JIA
was 1.8 (SD: 1.0, range: 1 to 5), 1.6 (SD: 0.79, range: 1 to 4) for pa-
tients with SLEj and 1.59 (SD: 0.911, range: 1 to 4) for the population
without rheumatological pathology, the 3 groups of patients had a
very low intensity in physical activity. Patients with JIA in this series
had activity indexes measured by JADAS10 with a median of 7 (SD:
7.7, range: 0 -33) and patients with SLEj, with an activity index mea-
sured by SLEDAI with a median of 1.8 (SD 1.9). , range: 0-6). The dam-
age index in patients with SLEj was reported with a median of 0.37
(SD: 1.15, range: 0 - 7) and in patients with JIA the index of joint
damage was reported with a median of 0.94 (SD: 2.3, range: 0-11)
and the average extra-articular damage index was 0.32 (SD: 1.09,
range: 0-5). There was a low inverse correlation between the PAQ ac-
tivity score and the activity and damage indexes for JIA and SLEj, re-
spectively. The average of sedentary hours was 3.3 both for patients
with pathology and for individuals without any disease. The most fre-
quent cause of physical inactivity in all patients was lack of time.
Overweight was documented in 25% of patients with SLEj, 19% in
JIA and 11% of the population without rheumatic disease. 6% of pa-
tients without rheumatic disease were classified in the obesity range
in contrast to 2% of patients with JIA and SLEj.
Conclusion: Both the population with rheumatological diseases and
individuals without documented disease have low rates of regular
physical activity. In this group of patients with JIA and SLEj the high
rates of physical activity are related to lower rates of both disease ac-
tivity and damage.
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Introduction: Juvenile Idiopathic Arthritis (JIA) patients from Eastern
Denmark, a well-defined geographic area comprising of the Copenhagen
municipality and adjacent rural districts including smaller cities, villages
and islands located in the eastern part of the country where about 45%(2.5 mill.) of the Danish population live, are at the time of diagnosis rou-
tinely referred to regular temporomandibular joint (TMJ) evaluation at
the Special Clinic for Congenital and Acquired Craniofacial Anomalies at
Department of Odontology, Faculty of Health and Medical Sciences, Uni-
versity of Copenhagen.
Objectives: The objectives for the current analysis were to character-
ise the referral patterns during a 21 year observation period from
1996 to 2016.
Methods: Data collection was based on dental and medical records
including demographics and JIA related variables. In order to look for
trends, the 21 year period was divided into three consecutive 5 year
periods and a 6 year period (2011-2016).
Results: In total 1472 JIA patients (female/male = 959/513 (65%/
35%)) with a median age at diagnosis of 7.7 years; age range: 0-18
years (1st quartile 3.5, 3rd quartile 11.3) were referred to regular TMJ
screening. A steady increase in the number of referred new JIA cases
was observed during the observation period: 1996-2000: N=203;
2001 – 2005: N=221; 2006 – 2010: N=330; and 2011 – 2016: N=715.
Throughout the observation period the gender ratio, age at onset
and ILAR subtype distribution were significantly altered. The propor-
tion of males increased (p=0.006), age at onset decreased (p=0.003)
and ILAR subtype was altered (p<0.001). In addition, the fraction of
patients with TMJ involvement fell dramatically from 28 to 9%
(p<0.001). A similar decline was observed in the fraction of patients
with uveitis (p=0.002).
The analysis suggests more than doubling incidence of JIA in Eastern
Denmark over a 21 year period. This could be attributed to increased
awareness and centralisation of JIA treatment during the period, but
possibly also other factors as gradual introduction of musculoskeletal
ultrasound (MSK US) over the observation period possibly resulting
in JIA diagnoses in “borderline” mild cases that previously would not
have fulfilled the criteria for a JIA diagnosis. An increase in the frac-
tion of very mild cases is consistent with unchanged absolute num-
bers of patients with TMJ involvement and patients with uveitis.
Availability of improved JIA treatment options could potentially also
have contributed to an increased fraction of milder cases.
Conclusion: Although the current study suggests dramatically in-
creasing incidence of JIA in Eastern Denmark, the results must be
interpreted with great caution due to potential confounding fac-
tors including increased JIA awareness and new technological de-
velopments in diagnostic tools e.g. MSK US. The data suggests
that due to increasing use of MSK US we may be diagnosing
many more mild JIA cases that previously would not have been di-
agnosed with JIA.
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Introduction: Physician global assessment (PGA) is considered an im-
portant responsive measure of disease activity in juvenile idiopathic
arthritis (JIA) and is included in the composite juvenile arthritis dis-
ease activity score. However, studies of inter-observer agreement of
PGA are scarce and guidelines for rating PGA in JIA are lacking.
Objectives: To evaluate the consistency of PGA scoring across physi-
cians treating children with JIA in Sweden.
Table 1 (abstract P243). General characteristics of the study group
No. of patients 1st time point
(n=80)
2nd time point
(n=53)
Female (%) 54 (67.5%) 36 (67.9%)
Oligoarticular JIA (%) 54 (67.5%) 35 (66.0%)
Enthesitis-related JIA (%) 14 (17.5%) 8 (15.1%)
Polyarticular RF-negative JIA (%) 11 (13.8%) 9 (17.0%)
Polyarticular RF-positive JIA (%) 1 (1.2%) 1 (1.9%)
High disease activity (%) 49 (61.3%) 19 (35.8%)
Parent acceptable symptom state
(%)
5 (6.3%) 6 (11.3%)
Minimal disease activity (%) 7 (8.7%) 12 (22.7%)
Remission (%) 19 (23.7%) 16 (30.2%)
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 128 of 243Methods: Twenty fictive JIA cases were introduced orally and in written
to 26 physicians attending an annual national Swedish meeting of
pediatric rheumatology. A mentimeter was used to collect information
about the physicians and the PGA rating score for the cases presented. In
order to mimic ratings on a 10-cm visual analoug scale, participants were
allowed to chose a score between 0 and 100, where 0=no activity and
100=maximum activity.
Results: Most physicians were specialists, women, aged > 55 years and
worked at county hospitals. Eighteen (69%) had more than 8 years ex-
perience of pediatric rheumatology. The PGA scores for some cases
presented varied considerably, the median of differences in PGA scores
across physicians was 70 (range 5-86). The distribution of the medians
of the physicians' individual PGA scores also differed, the mean was
42.5 (range 20-86). Only in a few cases, PGA score was significantly af-
fected by physicians' age (1 case), place of work (4 cases), profession (1
case) or pediatric rheumatology experience (1 case). Physicians' charac-
teristics did not affect distribution of the individual scores significantly.
Conclusion: PGA scores of cases with JIA were not consistent across
physicians treating JIA patients in Sweden. Establishment of guide-
lines for PGA rating in JIA would be valuable in order to create more
congruent disease activity evaluation across physicians.
Disclosure of Interest
None Declared
P242
THE VACCINATION STATUS OF PATIENTS WITH JUVENILE
IDIOPATHIC ARTHRITIS
Paulina Frańczak-Chmura, Maria B. Tomaszek, Aleksandra Sobiesiak,
Violetta Opoka-Winiarska
Department of Pediatric Pulmonology and Rheumatology, Medical
University of Lublin, Poland, Lublin, Poland
Correspondence: Violetta Opoka-Winiarska
Pediatric Rheumatology 2018, 16(Suppl 2):P242
Introduction: Disorders of immune system as well as immunosuppres-
sive treatment of patients with rheumatic diseases increase risk and se-
vere course of infections. Safe and effective vaccinations are key to
preventing many infections. Vaccinations are often postponed or over-
looked in patients with rheumatic diseases, both children and adults.
Objectives: The aim of this study was to check vaccination status of
children with JIA from one rheumatology centre in Poland.
Methods: Status of vaccination in children with JIA treated at the Rheuma-
tology Clinic in Lublin was tested based on child vaccination books. It was
recorded using a questionnaire together with date of the disease.
Results: Study included 53 patients with JIA diagnosed. Their mean age
was 9,94 years (range 2 – 16) and the mean age of diagnosis 5,72 years.
All children in the time of the survey were on DMARDs, 28 % (15/53) on
biologic DMARDs (9 – ETA, 4-TCZ, 2-ADA). Until the disease was diagnosed,
all patients were vaccinated according to the Polish immunization program
(mandatory vaccination), while in the time of the survey only 49% (26/53)
of children have completed all mandatory vaccinations on schedule. The
most often postponed vaccination was MMR (9/27). Other vaccinations rec-
ommended by EULAR and national program (paid by parents) were rarely
used. Only 26,4% of patients received pneumococcal vaccination, 9,4%
meningococcal and 1,7% - influenza vaccine. Disease exacerbation and dis-
seminated infection were physician and parents' main concern.
Conclusion: Vaccination status of children with JIA is low despite
EULAR [1] and Polish recommendation [2]. The educational programs
are still needed for parents and physicians on the safety and efficacy
of vaccinations of children with rheumatic diseases.
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Introduction: Achieving the optimal balance between the benefits of
early aggressive therapy and the possible risk of overtreatment is the
crucial objective of the future management of children freshly diag-
nosed with juvenile idiopathic arthritis (JIA). Serological biomarkers
have become a promising perspective for appropriate assignment of
patients into separate therapeutic approaches in accordance with the
treat-to-target concept. Studies involving rheumatoid arthritis (RA)
patients suggest the potential predictive value of the marker of endo-
thelial permeability called vascular endothelial cadherin (VE‑cadherin).
Objectives: The aim of the study was to evaluate the potential use-
fulness of measuring serum levels of VE‑cadherin in diagnosing and
monitoring disease activity in JIA patients.
Methods: Serum concentrations of VE-cadherin were measured in 80
patients (mean age 10.4±4.4 years) diagnosed with JIA (excluding sys-
temic subtype) and 29 age- and sex-matched healthy controls. Blood
samples were obtained twice in 53 JIA patients (with average interval
of 102.4±26.0 days) in order to assess dynamics of VE‑cadherin levels.
Database included patients’ history and laboratory tests results.
Results: Serum levels of VE-cadherin were higher in the study group than
in healthy controls (6.69±2.13 ng/ml vs 5.13±2.86 ng/ml, p<0.001). How-
ever, the difference was not statistically significant (p=0.11) for the results
obtained at second time point (5.57±2.10 ng/ml). As a diagnostic bio-
marker of JIA, VE‑cadherin had 87.5% sensitivity and 69.0% specificity for
the cutoff level 4.36 ng/ml (Youden index 0.56). VE-cadherin concentra-
tions were independent of JIA subtype. In 40 patients (75.5%) VE‑cadherin
level was decreased at second time point (mean difference 1.27±1.06 ng/
ml). In 29 of them (72.5%) the reduction of JADAS27 was observed as well.
VE-cadherin concentrations at baseline were significantly decreased
in patients using glucocorticosteroids (p=0.00296). Lower VE-
cadherin levels at second time point were observed in patients with
positive history of both systemic and intraarticular administration of
glucocorticosteroids during the first hospitalization (p=0.00485 and
p=0.0131, respectively).
Conclusion: VE-cadherin can be utilized as a screening test in diag-
nostic process of JIA. Moreover, it may become a reliable marker of
response to treatment. Nevertheless, usage of glucocorticosteroids
may reduce its predictive value. Further investigation in more con-
sistent group of patients is necessary to validate the potential clinical
use of this biomarker.
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Introduction: Articular involvement is reported as the most common
extraintestinal manifestation of IBD in childhood (5-20%).
Objectives: To evaluate epidemiologic data, clinical features and labora-
tory data of patient affected by IBD presenting articular manifestations.
Methods: This is a retrospective cohort study involving 104 pa-
tients (age 4-18) affected by IBD (according to the revised Porto
Criteria 2014) followed by our Gastroenterology Unit. We evalu-
ated sex, age at diagnoses, growth chart, inflammatory index
(ESR, CRP, calprotectin), Disease Activity Index (PCDAI o PUCAI),
endoscopic localization and histology of lesions (Paris Criteria),
abdomen ultrasound with study of the last ileal loop, presence of
extraintestinal manifestations (EIMs) and therapy. Patients with ar-
ticular involvement were divided in 2 groups: peripheral arthropa-
thy type 1 (pauciarticular, duration <10 weeks) and peripheral
arthropathy type 2 (polyarticular, duration> 10 weeks).
Results: We evaluated 104 patients, 51 females (49%) and 53 males
(51%), with average age 14.3 aa, 40 with MC diagnoses, 61 with RCU
diagnoses and 3 indeterminate colitis. The median age at diagnosis
was 11.2 y for MC and 9.5 y for RCU. Among patients with MC, 52.5%
had ileocolonic involvement, 20% cecal, 12.5% colonic, 15% of the
upper digestive tract. Among patients with RCU, 32.7% had extensive
colitis, 37.7% pancolitis, 14.7% ulcerative proctitis, 13% left colitis,
1.6% ileal lymphoid hyperplasia. Presence of one of the EIMs was re-
ported in 15.3% of patients: erythema nodosum 0.96%, sclerosing
cholangitis 2.84% (exclusively in patients with RCU) and articular
symptoms/signs 11.5%. In the group of patient with articular involve-
ment, 67% were female and 33% male; 50% had diagnosis of MC
and 50% of RCU. The average age of onset of the underlying disease
is 12 y for the MC and 11.8 y for the RCU. In 17% of patients, articular
symptoms were observed at the onset of the disease while in 42% of
the patients they were associated to a clinical exacerbation. The
mean values of ESR, CRP and calprotectin were increased. Arthralgia
has been identified in 75% of patients with articular involvement.
The joints involved were knee in 25%, coxo-femoral in 42%, sacroiliac
in 16.5% and tibio-tarsia in 16.5%. Involvement was monolateral in
84% of cases, bilateral in 16%. Only 1 patient presented monolateral
knee and bilateral sacroiliac arthralgia. Disease activity index at the
onset of articular symptoms was pathological in 8 patients (67%): 4
patients with MC (PCDAI> 10) and 4 patients with RCU (PUCAI> 10).
Two patients (16.6%) reported a traumatic event preceding the onset
of articular manifestations. In 11 cases (91.6%) articular symptoms
were transient, in 1 case (8.4%) the manifestations led to a polyarti-
cular arthritis diagnosis. The articular manifestations were treated
with paracetamol (33.3%), ibuprofen (25%), naproxen (8.3%), rectal
steroid therapy (16.6%), physiokinesitherapy (8.3%). The patient af-
fected by polyarticular arthritis is currently in therapy with Metho-
trexate and Adalimumab.
Conclusion: In our cohort, the articular manifestations are more
frequently associated to MC (14% of patients) than to RCU (10%
of patients). The majority of patients (91.6%) have peripheral ar-
thropathy type 1 or pauciarticular (92% of patients, 100% of
whom affected by MC and 83.3% with RCU). Despite of the
current literature, our patients affected by MC with articular mani-
festations, had prevalently ileocecal localization of bowel disease.
All patients responded to a short-term treatment with anti-
inflammatory drugs, in 1 case physiokinesitherapy was necessary.
The patient with polyarticular arthritis diagnosis required Metho-
trexate and Adalimumab to control articular disease.
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Introduction: According to the recent National Statistics, the rate of
unemployment in Greek citizens >25yrs is about 25% (26% Females)
and the raising pool of pensioners <50yrs, 39%.
Objectives: To investigate the impact of Juvenile Idiopathic Arthritis
(JIA) on the work life of parents having off springs with the disease,
due to lack of relevant data.
Methods: This prospective case-control study analyzed the parental
responses through a developed for the study questionnaire. Between
6/2017 and 12/2017, 107 consecutive parents (107 JIA pts) escorting
their child in the Outpatient Pediatric Rheumatology Clinic consented
to participate in the survey. The majority were mothers (F: 85, mean
aged 42 yrs) and consisted the JIA-parental (JIA p) Group. 111 par-
ents (F:49, mean aged 38.7yrs, p>0.7) of healthy children during the
same period served as controls, after their given consent (Hp).
Results: The JIA subgroups did not differ from the expected distribu-
tion (p=). Among patients 86 (80.37%) were on medication. The 2
groups (JIAp and Hp) did not significantly differ in terms of: educa-
tional level (p=0.82), percent of the remaining family members re-
quiring assistance (p=0.97), self- or spouse unemployment (p=0.43,
p=0.16), reduced work performance manifested by fatigue, anxiety or
depression (p=0.77), or resign or work dismissal (p=0.8, p=0.8, re-
spectively). In contrast, less JIAp than Hp were working in the Private
Sector (p=0.01) or had a steady-fullterm work schedule (p=0.04),
while more JIAp had been retired (p=0.02). An increased but non-
significant trend for a prolonged work absence >60 hours /month)
attributed to JIA (17% vs 0%, p=0.07) in the JIAp was observed. The
parental observation or performance of drug administration or home
physio-exercise program was not associated with the parental time
spent with the affected child (p=0.48). Additionally, the presence of
JIA flares or worsening was not associated with an increased duration
of home care in respect to the Hp (p=0.68).
Conclusion: The contemporary and holistic JIA management did not ad-
versely affect the working state of these Greek parents or their spouses
in respect to work performance, the duration of home care of the af-
fected child, regardless of the drug administration or home physio-
exercise program. Noteworthy, an increased but non-significant chance
of retirement was recorded among the parents having a child with JIA.
Disclosure of Interest
None Declared
P246
DISTRIBUTION OF SERUM HOMOCYSTEINE LEVELS IN JUVENILE
IDIOPATHIC ARTHRITIS PATIENTS COMPARED WITH CONTROLS: A
STUDY FROM BANGLADESH.
Mohammad Imnul Islam, Shahana Rahman, Fakhrul Alam, Mohammed
Mahbubul Islam
Department of Paediatrics, Dhaka, Bangladesh, Bangabandhu Sheikh
Mujib Medical University (BSMMU), Dhaka, Bangladesh
Correspondence: Shahana Rahman
Pediatric Rheumatology 2018, 16(Suppl 2):P246
Introduction: Abnormal levels of serum homocysteine may be found
in JIA patients. There are some studies about the level of homocysteine
(Hey) in children with JIA and the results are conflicting, but no study is
available in Bangladesh concerning JIA and homocysteine level.
Objectives: This study was done with the objectives to assess homo-
cysteine levels in JIA patients and to compare the levels with control
CAT Non-CAT Total p-value
Number of medications tried (SD) 4.55
(± 0.243)
3.77
(± 0.170)
4.04
(± 0.142)
0.0094
Number of medication side-effects (SD) 2.49
(± 0.346)
1.15
(± 0.160)
1.60
(± 0.164)
0.0006
Medication adherence (SD) 96.6
(± 1.12)
91.6
(± 1.84)
93.3
(± 1.29)
0.0215
SD = standard deviation
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cysteine among JIA patients.
Methods: This was a cross sectional study conducted in the Depart-
ment of Paediatrics, Bangabandhu Sheikh Mujib Medical University
(BSMMU), Dhaka from January 2016 to March 2017. A total of 50 chil-
dren with JIA were included. Demographic characteristics, duration of
illness and type of JIA, were recorded in a predesigned questionnaire.
Controls were selected from the patients attending Paediatrics OPD.
Results: The majority of the patients belonged to the age group of 11-
15 years. Males were more than females. Almost two third (64%) pa-
tients had normal and 36% had high homocysteine levels among the
cases. On the other hand, 100% had normal homocysteine levels in
control group. The difference of mean homocysteine level was signifi-
cant (p<0.05) between the two groups. Hyperhomocysteinemia was
found in 69% of JIA patients having duration of illness more than one
year. Mean homocysteine levels of polyarticular RF positive JIA and SJIA
were found significantly higher in comparison to the controls.
Conclusion: Hyperhomocysteinemia were found in 36% of JIA cases
and it increased with the longer disease duration. Homocysteine
levels were higher among Polyarticular and systemic JIA cases.
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Introduction: Juvenile idiopathic arthritis (JIA), is the most prevalent
cause of chronic arthritis at pediatric age. It is associated with various
extra-articular manifestations. The renal involvement is not studied
frequently. Previously, the most common overt renal disease related
to JIA was renal amyloidosis. Actually, some studies have revealed
subtle tubular and glomerular abnormalities in children with JIA.
Renal lesions in patients with JIA are usually complications of the
underlying rheumatic disease or side-effects of antirheumatic drugs.
Objectives: Describe the renal involvement according to the subtype
of JIA, in a cohort of patients with JIA identified in 2 pediatric
rheumatology clinics in Colombia in 2018.
Methods: Multi-center, retrospective, descriptive study. The medical
records of the last 100 patients assessed were reviewed and the in-
formation was recollected using a data collection format.
Results: N=100. 56% of patients were female. Sex ratio F 1.3 - M 1. The
median age of admission to the study was 14 years (interquartile range
of 5 years). Mean time between the diagnosis and the onset of renal in-
volvement was 16.28 months (SD 25 months). The proportion of pa-
tients according to subtype of JIA was: oligoarticular 27%, polyarticular
RF negative 23%, arthritis related enthesitis (ERA) 19%, systemic 17%,
polyarticular RF positive 10%, psoriatic 3% and undifferentiated 1%.
Prevalence of renal involvement during follow-up was 36% and it
was evidenced by hematuria, proteinuria or an altered glomerular
filtration rate (GFR). 37% of the patients with oligoarticular JIA devel-
oped renal involvement, polyarticular RF negative 34.8%, polyarticu-
lar RF positive 30%, ERA 42%, systemic 35% and in the only one
patient with undifferentiated arthritis. 10% of patients had some ab-
normality in the uranalysis: 16% leukocyturia and 3% hematuria. 69
patients who collected a 24-hour urine sample, 54% presented pro-
teinuria (54% mild proteinuria, 43% moderate and 3% in the neph-
rotic range), 1 patient had resolution of proteinuria and the other
persisted with proteinuria mild. 18 patients a sample was recorded
for calciuria in 24 hours, 11% was positive.
Mean serum creatinine was 0.64 mg/dl (SD 0,27, range 0.3-1.0 mg/dl).
The average TFG was 113 ml/min/1.73 (SD 26,17, range 63.9-184
ml/min/1.73). 68% had normal GFR, 19.5% decreased GFR and
12.3% elevated GFR. 3 patients presented abnormal renalultrasonography (nephrolithiasis, grade III vesicoureteral reflux
and mild pyelectasis) with normal GFR. Nobody required renal bi-
opsy. There were no statistical differences in subtype of JIA, clin-
ical manifestation and renal involvement.
Treatment at renal involvement: 80.5% received steroids, 61%
NSAIDs, 94.5% methotrexate, 2.7% sulfasalazine, 2.7% leflunomide
and 29.7% biologics. A statistically significant difference was
found between treatment and renal involvement (p<0,001).
Conclusion: In this cohort, renal involvement was 36%. Proteinuria
and alteration in GFR were the most frequent. A greater proportion
of renal involvement was observed in patients who received steroids,
methotrexate and NSAIDs. In patients with JIA, uranalysis and renal
function should be routinely monitored for early diagnosis of renal
disease, which causes morbidity.
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Introduction: Complementary and alternative therapy (CAT) use is
common among children and young people with juvenile idiopathic
arthritis (JIA)(1)(2)(3)(4). There has been no previous research on this
topic in Australia. In addition, little is known about patterns of CAT
use and the impact on existing clinical care.
Objectives: To determine the prevalence of CAT use, define the
types of therapies being used, assess factors associated with CAT
use, evaluate perceived efficacy and to explore whether patients had
discussed CATs with their treating specialist.
Methods: A prospective, cross-sectional, questionnaire-based study of
patients attending the Royal Children’s Hospital, Melbourne, Australia
was conducted via convenience sampling between June and December
2017. Patients with JIA under the age of 20 were included. χ2 test and
two tailed unequal variances t-test were used for statistical analysis.
Results: 198 patients were included for analysis. 74.7% had previ-
ously had intra-articular steroid injections, 69.2% had used a disease
modifying anti-rheumatic drug (DMARD) and 31.3% had used a bio-
logic DMARD. 67 (33.8%) patients had ever used one or more CATs.
The most frequently used CATs were vitamins and minerals (17.6%),
probiotics (13.1%), dietary changes (11.6%) and non-vitamin/non-
mineral supplements (10.1%). Patients who had used CATs had previ-
ously tried more conventional medications, experienced more con-
ventional medication related side-effects and had better
conventional medication adherence compared to those who had
not. 173/198 (87.4%) respondents agreed or strongly agreed that
conventional medications were helpful in managing their arthritis.
Comparatively, 31/67 (46.3%) of CAT users agreed or strongly agreed
that CATs were helpful. Only 20.0% of patients had been asked about
previous CAT use by their treating doctor.
Table 1 (abstract P249). Muscle strength and bone health in patients
and controls
JIA total
(n=60)
Controls
(n=60)
p JIA oligo
(n=30)
JIA poly
(n=30)
p
Quadriceps strength
dominant side (PT) a
124 (38) 146 (34) 0.001 131 (33) 118 (42) 0.186
Hamstring strength
dominant side (PT) a
65 (26) 83 (22) <0.001 64 (25) 66 (28) 0.600
Quadriceps endurance
dominant side (TW) b
2470
(633)
2660
(466)
0.063 2516
(650)
2424
(624)
0.578
Hamstring endurance
dominant side (TW) b
1065
(461)
1376
(409)
<0.001 1109
(470)
1018
(455)
0.332
Hand grip strength
dominant side (kg)
23.2
(7.4)
27.9 (8.4) 0.002 22.9
(7.0)
23.5
(7.8)
0.776
BMDTB (g/cm
2) 0.971
(1.127)
1.033
(0.128)
0.009 0.970
(0.128)
0.972
(0.129)
0.939
BMDTB z-score (g/cm
2) 0.152
(0.810)
0.712
(0.910)
0.001 0.200
(0.909)
0.103
(0.709)
0.648
Numbers are mean (SD). a PT: Peak torque given in newton meter divided by
body weight x 100, b TW: Total work given in Joule divided by body weight x
100. BMDTB: total body bone mineral density
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 131 of 243Conclusion: Use of CATs is common among children with JIA and a
broad range of therapies are used. Despite recent therapeutic ad-
vances, medication related side-effects continue to be a problem for
many patients and may lead to patients trying unconventional ther-
apies. Treating specialists are often unaware that these therapies are
being used. Given the potential for harm (5) and possible interactions
with conventional medications, we would urge all clinicians to rou-
tinely enquire about CAT use.
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Introduction: Previous studies indicate that juvenile idiopathic arth-
ritis (JIA) patients compared to healthy controls have lower muscle
strength, poorer bone health and impaired body composition with
higher fat mass and low lean mass. However, knowledge about these
components of physical fitness is limited in JIA patients diagnosed in
the era of biologics.
Objectives: To compare muscle strength, total bone mineral density
(BMD) and body composition in JIA patients diagnosed in the era of bio-
logics with healthy controls; to compare muscle strength, total BMD and
body composition between patient subsets; to examine associations be-
tween disease variables and muscle strength and total BMD in patients.
Methods: Sixty patients (50 girls) with persistent oligo JIA and polyarti-
cular disease (extended oligoarthritis and polyarticular RF +/-), ages 10-
16 years, and 60 age- and sex-matched controls were included. Isokin-
etic quadriceps and hamstrings muscle strength (Cybex) and isometric
hand grip strength (Baseline dynamometer) were measured bilaterally.
Total BMD and body composition were measured by Dual-energy X-ray
Absorptiometry. Current pain, pain and fatigue during previous week,
pubertal status, blood values and physical activity (PA) levels (accelero-
metry) were assessed in all participants. In patients, disease activity and
functional disability were evaluated by validated tools.
Results: Biologic drugs were used by 42 % of the patients. Patients
had lower muscle strength bilaterally compared with controls in al-
most all variables tested. Results for the dominant side are shown in
Table 1. Total body BMD and total body BMD z-scores were lower in
patients compared to controls (Table 1). Total fat mass and fat mass
percentage were comparable between patients and controls, whilethere was a tendency for patients to have lower lean mass compared
to controls, p=0.06. Muscle strength, total BMD and body composition
were comparable between patient subsets. In patients, higher muscle
strength was associated with higher age, male sex, higher BMI and
higher vigorous PA levels. Higher BMD was associated with higher total
lean mass, higher age and female sex. No disease related variables were
identified as determinants for muscle strength or BMD.
Conclusion: Muscle strength and BMD are lower in JIA patients diag-
nosed in the biological era compared to controls. Body composition is
more favorable in JIA patients than previously reported, with compar-
able fat mass and fat mass percentage between patients and controls.
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Introduction: Randomised controlled trials (RCTs) are central to im-
proving the clinical care and outcomes of children and young people
(CYP) with juvenile idiopathic arthritis (JIA). RCTs have traditionally
been designed by research teams with outcomes selected by re-
searchers and healthcare professionals. However, it is children and
their families who live with the effects of the illness and its treat-
ments. It is increasingly clear that they can and must be involved in
prioritising different outcomes to research teams. Accessing chil-
dren’s and parents’ unique perspectives and experiences of JIA can
help to inform the selection of outcomes. As part of a wider process,
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 132 of 243qualitative interviews with children with JIA and their parents may
help to identify which outcomes are most important to children
treated with corticosteroids for JIA and their families.
Objectives: In the context of a feasibility study for a planned trial
comparing corticosteroid delivery routes, we explored children’s and
parents’ experiences of corticosteroid treatments and the outcomes
they considered important in the assessment of the impact of the
disease and its treatments on their everyday life.
Methods: Semi-structured qualitative interviews were conducted with
children who had recently received corticosteroids to treat JIA, as well
as with their parents. Participants were recruited from four UK paediat-
ric rheumatology centres. Audio recorded interviews were transcribed
and analysed thematically, drawing on the Framework Method.
Results: Twenty eight children and parents (9 children [aged 8-16
years], and 19 parents) from 15 families were interviewed. Children’s
and parents’ experiences of steroids often varied depending on individ-
ual characteristics like needle phobia, or fear of anaesthetics (required
for intra-articular injections). They evaluated corticosteroid treatments in
terms of whether these relieved pain, fatigue, stiffness and swelling, im-
proved mobility, lead to changes in weight and appetite and the impact
on children’s social life and education. Children prioritised outcomes re-
lated to quality of life and social and school life. Typically, parents’ prior-
ities concerned “controlling” the JIA and short term treatment effects.
Conclusion: Previous research has focused on children’s and parent’s
experiences of JIA but not their perspectives on steroid treatments in
JIA. There was considerable overlap in the outcomes that children
and parents regarded as important in evaluating such treatments.
However, children prioritised quality of life, while parents empha-
sised managing and controlling disease flares. These insights may be
useful in everyday clinical practice and could enrich the development
of a core outcome set as part of a wider consensus process.
Children’s and family perspectives on outcomes may inform the devel-
opment of research studies that are more meaningful and important to
patients. Using outcomes that are more relevant to stakeholders could
ultimately improve recruitment to JIA clinical trials and achievement of
outcomes that are important to patients and their families.
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Introduction: Vitamin D deficiency is widespread and re-emerging
major health problem globally. 13.0% of European individuals have
serum 25(OH)D concentrations <30 ng/mL on average in the year
[Cashman et al., 2016]. Although vitamin D is known to have an immu-
nomodulatory effect [Myszka et al., 2014], it is still unclear whether defi-
ciency is associated with higher disease activity. Some studies show no
associations of serum 25(OH)D levels with musculoskeletal disease ac-
tivity or functional status [Pakchotanon et al., 2013], while others sug-
gest that vitamin D deficiency may be linked to disease severity in
rheumatoid arthritis [Kostoglou-Athanassiou et al., 2012].
Objectives: The study was carried out in order to determinate the
prevalence of hypovitaminosis D in pediatric population with rheum-
atic disorders and to find out whether there is significant association
between serum concentration of vitamin D and disease activity.
Methods: A retrospective analysis of 98 subjects with rheumatic dis-
orders, aged 1-18 years, was performed. Patients were divided into
two groups: patients with juvenile idiopathic arthritis (JIA) (n=58) and
patients with postviral reactive arthritis (n=40).
Serum concentration of 25-hydroxyvitamin D vitamin was deter-
mined by electrochemiluminescence method.During the study data of patients’ age, sex, height, weight, serum 25-
hydroxyvitamin D, rheumatoid factor, titers of antinuclear antibodies,
anti-dsDNA antibodies and anti-TNF alpha were gathered.
The relationships between serum concentration of vitamin D and dis-
ease activity markers were found using Pearson’s correlation coefficient;
differences of values were analyzed using Mann-Whitney-Wilcoxon test.
Results: Vitamin D level of analysed patients ranged from 8,17
to 52,71 ng/mL. 69,39% (n=68) were diagnosed with vitamin D defi-
ciency (serum 25-hydroxyvitamin D (25[OH]D) below 30 ng/mL). Serum
level of vitamin D in group of patients with JIA is significantly lower
than in group of patients with reactive arthritis (p = 0.036). Weak nega-
tive correlations between vitamin D level and patients age (r = - 0.443;
p = 0.000) and body mass index (r = - 0.372; p = 0.002) were found.
Positive correlation between vitamin D and ESR was found in JIA pa-
tients (r =0.446; p = 0.002). There were found no statistically significant
relationships between vitamin D level and any other paramether.
Conclusion: Vitamin D deficiency is commonly seen in children with
rheumatic disorders. The results of the study indicate that patients with
JIA have significantly lower serum level of vitamin D than patients with
reactive arthritis. Adolescents have lower vitamin D concentration, com-
paring to younger children, which is also consistent with previous stud-
ies [Mithal et al., 2009; Rockell et al., 2005; Looker et al., 2002].
Further investigation that include such information as eating habits,
the use vitamin D supplements and sun exposure are required in
order to expand this study.
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Introduction: Due to a higher susceptibility to infections than adults,
paediatric patients with polyarticular‐course juvenile idiopathic arth-
ritis (pJIA) receiving abatacept or other biologic DMARDs with im-
munosuppressive effects may be at increased risk of vaccine-
preventable infections such as diphtheria and tetanus.
Objectives: To evaluate antibody responses to diphtheria/tetanus
vaccine in paediatric patients with pJIA receiving SC abatacept.
Methods: This sub-study enrolled 2 to 5-year-old patients with pJIA from
the Phase III, open-label, single-arm trial (NCT01844518)1 of weekly
weight-tiered SC abatacept: 10–<25 kg (50 mg), 25–<50 kg (87.5 mg)
and ≥50 kg (125 mg). Patients who participated in this sub-study re-
ceived diphtheria/tetanus vaccine prior to enrolment; the vaccine was
not administered during the study period. Blood samples to assess pro-
tective antibodies to diphtheria and tetanus were measured in patients
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 133 of 243with at least 2 months of abatacept treatment. Assessment for protective
antibody levels was performed by a central laboratory2 using quantitative
multiplex bead assays with protective levels defined as >0.1 IU/mL based
on central laboratory and World Health Organization criteria.2–4
Results: A total of 29 patients were enrolled in this sub-study. All pa-
tients were white, from either Europe or South America, aged 2–5
years and weighed 12–26 kg. Abatacept exposure durations were:
19/29 (66%) >12 months, 1/29 (3%) 6–12 months and 9/29 (31%) 2–
<6 months. At the end of the sub-study, all 29/29 (100%) patients
had protective antibody levels to tetanus (range: 0.2–23.2 IU/mL).
Protective antibody levels to diphtheria were observed in 26/29
(90%) patients (range: 0.2–8.0 IU/mL). The remaining three patients
each had a protective antibody level of 0.1 IU/mL, which bordered
the lower threshold of protection. No cases of diphtheria or tetanus
were observed. There was no evidence of recognizable association
between infection risk and abatacept treatment.
Conclusion: In this sub-study, paediatric patients with pJIA aged 2–5
years who received ≥2 months of SC abatacept were able to main-
tain effective diphtheria/tetanus vaccination protection.
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Introduction: Juvenile idiopathic arthritis (JIA) is the most prevalent
chronic rheumatic disease in childhood and a major cause of pain
and disability. The majority of children and their families live in less
resourced countries (LRC) and face significant socioeconomic and
healthcare challenges impacting their ability to access high-quality
pediatric rheumatology care. These include, but are not limited to:
poverty, political unrest, high burdens of endemic disease, low
healthcare spending and limited access to medications. Current rec-
ommendations for standards of care and treatment for JIA do not
consider children living in LRC.
Objectives: To develop recommendations for the care of children
with JIA in less resourced countries.
Methods: A group of experienced paediatric rheumatologists from
less resourced countries was convened with additional inputs from a
steering group of international paediatric rheumatologists with ex-
perience developing recommendations and standards of care for JIA.
Following a needs assessment survey of 502 healthcare workers car-
ing for children with JIA in LRC’s, a literature review was carried out
and recommendations formulated using Delphi technique and a final
consensus conference. The degree of consensus, level of agreement
and level of evidence for these recommendations are reported.
Results: The general amount of available evidence for critical ap-
praisal was low, reflecting a shortage of research specifically focused
on less resourced countries. Recommendations cover 5 themes: 1)
Diagnosis 2) Referral and Monitoring 3) Education and Training 4)
Advocacy and Networks and 5) Research. Thirty-five final statements
highlight endemic diseases relevant to the diagnosis and treatment
of JIA in less resourced nations. They endorse existing guidelines for
the treatment of JIA,vaccinations in the context of rheumatic disease
and, uveitis screening. They also advocate for standards of care to
pediatric rheumatology services and strategies to raise awareness of
JIA through education of stakeholders as well as make arguments for
the support and development of research and researchers in JIA in
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 134 of 243developing nations. All but one statement achieved 100% consensus
and levels of agreement were high.
Conclusion: Our recommendations offer novel insight and present
consensus-based strategies for the care of children with JIA in less
resourced countries. The emphasis on communicable and endemic
diseases influencing the diagnosis and treatment of JIA serves as a
valuable addition to existing recommendations on the management
of JIA. Statements presenting standards of care aim to guide best
practices in the development of pediatric rheumatology in LRCs. With
increasing globalization, these recommendations – as a whole – provide
educational and clinical utility for clinicians worldwide. The low evidence
base for our recommendations is an impetus for further inquiry towards
optimizing care for children with JIA in LRC’s and around the world.
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Introduction: Although symptomatic lung involvement is uncommon
in children with JIA there have been reports of significant restrictive
pattern manifest at lung function test reports.
Objectives: To evaluate lung function in children with JIA.
Methods: Lung function testing including diffusion capacity for carbon
monoxide (DLCO) was performed in 58 children diagnosed with different
subtypes of juvenile idiopathic arthritis according to ILAR criteria. Forced
vital capacity (FVC), forced expiratory volume in 1 second (FEV1), FEV1/
FVC ratio, forced expiratory flow between 25-75% of vital capacity
(FEF25-75%), peak expiratory flow rate (PEFR) and DLCO were measured.
Data regarding current and previous treatment modalities (NSAR,
DMARD, biologic therapy) was extracted using medical charts and CRP
level, sedimentation rate and disease activity were determined at the
time of lung function testing. None of the included patients had any
symptoms of pulmonary disease.
Results: Out of 58 children with JIA, 72.4% were female and 27.6% male,
with median age of 14.1 (8.3-20.7) years. Patients were diagnosed with
oligo JIA (31%), poli JIA (31%), ERA (19%), systemic JIA (10.3%), psoriatic
JIA (5.2%) and reactive arthritis (3.5%). In 9 patients results of DLCO were
inadequate for interpretation, as well as data of lung function tests in 2
patients. At the time of lung function testing 74.1 % (43 patients) were
being treated with NSAR, 24.1% (14 patients) with low dose oral cortico-
steroids, 36.2% (21 patient) with DMARD and 17.2% (10 patients) with
biologic therapy. During the previous treatment course 44.8% were
treated with methotrexate and 19.0% with biologic therapy.
Lung function tests did not reveal any obstructive or restrictive alter-
ation of ventilation in patients. Mean values were FVC 95.7%, FEV1
97.5%, FEV1/FVC 89.2%, FEF 25-75 99.3%, MEF25 110.9%. Although
mean value of DLCO among patients was 80.2%, there were 10 patients
with DLCO lower than 70%, and 7 of them were previously treated with
methotrexate. Analysis revealed that DLCO<70% is associated only with
previous MTX treatment (Chi square=3.78, p=0.051) and not with other
treatment modalities or current disease activity.Conclusion: In our group of patients with different JIA subtypes testing
revealed normal lung function. However, a marginal decrease of DLCO
in small number of patients was associated with previous MTX treat-
ment. Although MTX may cause severe adverse pulmonary side-effects
in adult population, those are rare in children, and marginally de-
creased DLCO in our and previous studies support relative safety of
MTX treatment in JIA.
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Introduction: Juvenile idiopathic arthritis (JIA) is a systemic inflam-
matory disease which affects mainly joints. The search for factors that
regulate the development and the course of the JIA remains relevant
for the future. One of them is the provision of vitamin D in children
with JIA, which role is not fully understood.
Objectives: The aim of this study was to study of the relationship of
individual characteristics of the disease course (duration of the dis-
ease, disease activity, number of injured and active joints) with the
level of the vitamin D metabolite in children with JIA.
Methods: Thirty three patients with JIA were examined. The median
age of patients was 10,5 ±1,7 years, from 1,8 to 17,6 years (23 female, 10
male) .The total duration of the disease was 3 years 4 months ± 1.3 years,
from 2 months to 13 years 2 months.The serum level of vitamin D was
measured through blood test by chemiluminescence method. The rela-
tionship between the level of vitamin D and disease activity was analyzed
based on juvenile arthritis disease activity score (JADAS 27).
Results: The average level of vitamin D in serum was 23,05±6,4 ng/
ml. It was found that the level of vitamin D was correlated with age
of patients (r = -
- 0,43; p < 0,05). Using the regression method, a relationship was
established between the level of vitamin D in serum and the age of
the child, the number of affected joints and the number of active
joints (33,48 – 0,065*age of the patient - 0,55* number of injured
joints + 0,37 * number of active joints ).The results of the present
study indicated that there was no significant relationship between
the level of vitamin D in serum and disease duration and activity.
Conclusion: JIA patients are presented with low vitamin D levels. It
was found the relationship between the vitamin D deficiency, age of
the patient and the number of affected and active joints.
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Table 1 (abstract P256). Characteristics of Participating Pts with JIA
Approaching Transition
Pt number Pt 1 Pt 2 Pt 3 Pt 4 Pt 5
Age at registry entry, years 15 13 13 14 13
Current age, years 19 18 18 16 17
Distance from paediatric rheumatology centre,
km (miles)
90
(56)
39
(24)
126
(78)
248
(154)
48
(30)
Duration in registry, years 4.1 5.0 4.9 2.4 4.8
Duration of abatacept treatment, years 4.1 2.1 5.2 3.0 3.2
Current pt pain score* 4 3 5 0 8.5
Recent well-being score† 4 1.5 4.5 0 8.5
Physician-perceived ability to successfully
transfer JIA care‡
10 7 8 10 7
Physician Global Assessment of current disease
activity§
0 0.5 1.5 1 2
*Self-rated: 0=none, 10=extreme; †Self-rated: 0=well, 10=poor; ‡Physician-rated:
0=unqualified; 10=fully qualified; §Physician-rated: 0=no activity, 10=maximum
activity (all 0.5 increments)
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aimed at studying the long-term safety of ABA in juvenile idiopathic
arthritis (JIA). Transfer of care is a vulnerable period when young
adults with JIA (YAs) are often lost to follow-up for unclear reasons.
Participants entering the ABA Registry are on average 13 years
old1,2; hence 10 years of follow-up includes transferring care from
paediatric to adult rheumatology.
Objectives: To understand the motivations and beliefs surrounding
transition from paediatric to adult care in YAs in the ABA JIA
Registry.
Methods: An ethnographic qualitative study to understand YA/care-
giver beliefs/behavioural drivers related to the realities of transition-
ing from a paediatric to an adult care environment was conducted.
A healthcare ethnographer performed interviews and used a formal
interview guide with YAs/caregivers to better understand their lived
and clinical environment experiences. Corresponding clinicians were
also interviewed. Interviews were audio and video recorded. Tran-
scripts were analysed and coded to identify common themes re-
lated to the objective.
Results: Completed interviews consisted of five YA/caregiver in-
person at-home interviews and four corresponding paediatric
rheumatologist interviews. All participants were identified and
consented by study coordinators at Cincinnati Children's Hospital
Medical Center through the ABA JIA Registry. See Table 1 for YA de-
scriptive data. Preliminary overall emerging themes for a successful
transition are as follows. Process begins when patients (pts) are
children and includes active and ongoing efforts to teach, encour-
age and practice behaviours necessary to instil a sense of independ-
ence, confidence and responsibility as pts enter adulthood. For
parents, knowledge of symptoms and treatment are prioritized. For
YAs, measures are taken so YAs feel supported, comfortable and
confident in their ability to live with JIA and manage care. For treat-
ing physicians, the goal is to facilitate the learnings, behaviours and
practices in children and parents to have positive outcomes in tran-
sition. In-depth coding is ongoing and will be available at the time
of presentation.
Conclusion: YAs, caregivers and physicians agree that an early start
may be key for a successful transition; however, each has a unique
perspective that needs to be considered.
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Introduction: Juvenile idiopathic arthritis (JIA) is one of a number of
autoimmune (AI) diseases. After cancer and heart disease, AI diseases
are the most common type of disease in the US, with an overall esti-
mated prevalence of 3.2 and 5.9% in the US1 and Europe,2 respect-
ively, depending on the source, with a corresponding increase in
mortality.3 Many AI diseases share a common pathogenic mechan-
ism, but there are few to no published studies quantifying the occur-
rence of other AI diseases in patients with JIA.4
Objectives: To estimate the prevalence of coexisting AI diseases in
patients diagnosed with JIA, stratified into two cohorts (<18 and ≥18
years of age).
Methods: Using a US medical claims database, two cohorts of patients
with a diagnosis of JIA (ICD-9 code 714.3x) between 1 January 2006 and
30 September 2015 were identified in the MarketScan Commercial and
Supplemental Medicare database. Patients were required to have ≥180
days of continuous health plan enrolment before the qualifying JIA diagno-
sis. For each of the JIA cohorts, member age at diagnosis was determined.
Thirty-seven different AI diseases were assessed by ICD-9 code. Coexisting
AI diagnosis codes were identified 12 months prior to and post JIA diagno-
sis. A minimum of two of the same diagnosis codes for an AI disease was
considered co-existing and contributed to the overall prevalence estimate.
A similar study of co-existing AI diseases in an adult RA cohort is also pre-
sented to highlight differences in the frequency of AI diseases between pa-
tients diagnosed with JIA and those diagnosed with RA.
Results: The most frequently reported co-exiting AI diseases, defined as
being present in ≥1% of patients in the <18 and ≥18 year cohorts with a
JIA diagnosis, and in an RA population, are presented (Table 1). Mean age
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 136 of 243was 10 years for the <18 cohort, 36 years for the ≥18 cohort and 53 years
for the adult RA cohort. Most patients were female. Uveitis was the most
frequently occurring AI disease in patients with JIA <18 years of age and
SLE was the most common AI disease in patients with JIA ≥18 years of
age. Sjögren’s syndrome was most common in adult patients with RA.
Conclusion: These results show variability in AI prevalence by age
group among patients with JIA and separately for patients with RA.
Whether this variability is a consequence of the limitations of health-
care claims data requires further investigation. Understanding the co-
existence of AI diseases among patients with JIA may play an important
role in patient management, treatment decisions and outcomes.
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Outcome JIA
<18 years
n=7883
JIA
≥18 years
n=4867
RA
≥18 years
n=286,601
Uveitis 4.44 (3.99, 4.89) 1.50 (1.16, 1.84) 0.52 (0.49, 0.55)
SLE 1.13 (0.90, 1.36) 3.10 (2.62, 3.59) 3.78 (3.71, 3.85)
Type 1 diabetes mellitus 0.79 (0.59, 0.98) 1.87 (1.49, 2.25) 1.83 (1.78, 1.88)
Chronic urticaria 1.74 (1.45, 2.03) 1.71 (1.34, 2.07) 0.71 (0.67, 0.74)
Ankylosing spondylitis 1.67 (1.39, 1.96) 1.48 (1.14, 1.82) 1.16 (1.12, 1.20)
Crohn’s disease 1.18 (0.94, 1.42) 1.62 (1.27, 1.98) 1.12 (1.08, 1.16)
Ulcerative colitis 0.44 (0.30, 0.59) 1.36 (1.03, 1.68) 0.87 (0.83, 0.90)
Sjögren’s syndrome 0.15 (0.07, 0.24) 1.29 (0.98, 1.61) 2.42 (2.36, 2.48)
Raynaud’s syndrome 0.63 (0.46, 0.81) 1.23 (0.92, 1.54) 1.12 (1.09, 1.16)
Data are presented as prevalence rates, % (95% CI). SLE=systemic
lupus erythematosusP258
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Introduction: Patients with juvenile idiopathic arthritis (JIA) have an
increased risk of being infected. Approximately half of all serious in-
fections in children with JIA are associated with airway involvement.
Objectives: Our aim was to study the efficacy and safety of the
pneumococcal 13-valent conjugate vaccine (PCV) in children with JIA.Methods: In a prospective cohort study, 5 groups were formed: chil-
dren with JIA in the remission phase on methotrexate therapy (group
Ia) or etanercept (group Ib), with JIA in the active phase prior to the
appointment of methotrexate (group IIa) or etanercept (group IIb),
control group (conditionally healthy children). 0.5 ml of the 13-valent
PCV was administered once subcutaneously during therapy in pa-
tients in the remission phase or 3 weeks before the appointment of
methotrexate or etanercept in patients in the active phase. The main
study outcome was the proportion of patients with a protective (40
mg/L) level of specific anti-pneumococcal antibodies (anti-SPP) IgG
to Streptococcus pneumoniae 4 weeks after vaccination. In addition,
we assessed the incidence of infectious events before and after vac-
cination as well as changes in the content of a high-sensitivity C-
reactive protein, S100 protein, and post-vaccination period.
Results: The study included 125 children. Four weeks after vaccin-
ation, the protective level of anti-SPP IgG was established in 21
(84%) patients in the 1st, 23 (92%) in the 2nd, 22 (88%) in the 3rd,
24 (96%) in the 4th and 5th groups (p =1.0). Increase in the concen-
tration of S100 protein and high-sensitivity C-reactive protein after
vaccination was not noted. JIA exacerbation episodes were not re-
corded in any patient.
Conclusion: Vaccination with the 13-valent PCV in children with JIA
is highly effective and is not accompanied by the flare of JIA.
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Introduction: Ultrasonography (US) studies carried out on joints of ju-
venile idiopathic arthritis (JIA) patients in clinical remission demonstrate
the presence of subclinical synovitis. The significance of subclinical
synovitis and the positive power Doppler (PD) signal on US in JIA.
Objectives: The objectives of this study were to assess whether the
changes detected by US induced by intra-articular corticosteroid in-
jection in JIA patients.
Methods: We evaluated 49 joints (47 knees, 1 tibiotalar and 1 elbow)
of 32 patients who diagnosed JIA. We used grey-scale US by high
frequency transducer (7.5-10) MHz at study entry and after a thera-
peutic intervention. Each joint was scored for grey-scale (GS) and
power Doppler (PD) abnormalities according to a 4-point semiquanti-
tative scale. Pre- and post-treatment US scores were compared and
the sensitivity to change of GSUS and PDUS was estimated. US as-
sessment was performed separately, immediately after the clinical
evaluation, by an experienced pediatric rheumatologist (BS) with cer-
tificated by EULAR. Medical records were reviewed for JIA subtype
and state of disease. Clinical examination, including routine joint
examination was carried. Clinical response was assessed using the
ACR paediatric (pedi ACR) response criteria
Results: Five patients had polyarthritis, 5 had enthesitis-related arthritis,
22 had oligoarthritis. Nine patients (28%) underwent intra-articular cor-
ticosteroid injection (IACI) only, 23 (71,9 %) were given IACI and systemic
medications. The medication used were methotrexate (22 patients),
Sulfasalazine (2 patients), and methotrexate and biologic (5 patient).
Synovial hyperplasia, joint effusion, PD signal and tenosynovitis in at
least one joint were detected in 77.4%, 100%, 33.3% and 15% of
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 137 of 243patients, respectively. Both GSUS and PDUS scores improved signifi-
cantly (p<0.0001) from baseline to follow-up. At the follow-up visit,
18/49 (36.7%) joints complete resolution among these patients 2 had
minimal synovial hyperplasia. Although, 31/49 (63.3%) joints residual
US abnormalities were judged in remission on clinical grounds.
Conclusion: US is a sensitive tool to assess therapeutic response in
patients with JIA. Subclinical disease on US is common in joints with
clinically-defined remission. Further studies are needed to establish
the impact of US on therapeutic decision-making in JIA.
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Introduction: Anti-Citrullin Protein Antibodies (ACPAs) are known to
precced onset of Reumatoid Arthritis in adults with years to decades
and differentiate between different clinical outcomes. Less is known
about clinical correlation with ACPA subtypes in Juvenlie Idiopathic
Arthritis (JIA) patients.
Objectives: We set out to study Cyclic Ctrullin Peptide (CCP) anti-
bodies and ACPA subtypes in patients with JIA in order to correlate
precense of antibodies with clinical characeristics.
Methods: 280 patients from the Juvenile Arthritis Bio Bank Astrid
Lindgrens Children Hospital (JABBA) was analysed with regard to
CCP antibodies with av CCP-2 ELISA. APCA sub specificities were ana-
lysed in a subset of 90 patients in a Immunocap- ISAC chip system
and results were compared to clinical parameters obtained from the
Swedich Pediatric Rheumatology registry and medical charts.
Results: Results show a precense of CCP antibodies of 6 % compared
to 3% in a healthy pediatric control group. All CCP positive patients
were female and most commonly poly arthritis patients. CCP titers were
significantly higher in CCP positive JIA patients as compared to CCP
positive healthy controls and JIA patients with CCP antibodies display a
greater number of ACPA subtypes. ACPA subtypes in the JIA patients
included antibodies to Enolase, Vimentin, Fibrogen and antibodies ,
CPP3, directed to Porphyrominas Gingivalis a known periodontal patho-
gen. Correlation to clinical outcomes are ongoing.
Conclusion: CCP precense in our JIA cohort correspond to findings
from other investigators. An increased numer of ACPA subtypes in
CCP positive JIA patients indicate epitope spreading in the patho-
genic process. Correlation of ACPA subtypes compared to clincal out-
comes are ongoing. Interestingly antibodies to CCP-3 were detected
strengthening the relation of pediatric periodontal helath and JIA.
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Introduction: In a context of strong development of Therapeutic
Patient Education (TPE) in Juvenile Idiopathic Arthritis, there is no
reference system to support the process of program construction or
educational actions.Objectives: The objective was to conduct a participatory plan to
build a referential of skills that could help young patients and
parents and be useful to healthcare professionnals. (HCP)
Methods: On the initiative of an association of patients and a
rheumatologist experienced in TPE, a steering committee (COPIL)
was constituted bringing together rheumatologists, pediatricians and
associative representatives. After a qualitative phase (review of litera-
ture and focus groups of children, adolescents and parents), the
COPIL identified skills of knowledge, know-how and know-how-to-be
in different areas of interest for people affected by JIA. The work by
topic allowed the balance between the biomedical and psychosocial.
For the quantitative phase, all the French competence centers as well
as the KOURIR association and the RESRIP Network were invited to
participate in a validation using different online questionnaires. Each
center had to involve HCP, children and parents. For each area, the
participants had to indicate the three skills that seemed to them to
be priorities and could, if they wanted, to propose a competence not
listed. The analysis consisted in classifying the answers by type of re-
sponder (Children, parents, HCP) to identify the priorities of each
group, then to weight the skills of each theme (3 points for skills
ranked first, 2 points for second place skills, 1 point for third place
skills). Finally an average was made for the overall ranking.
Results: 19 competence centers, Kourir and RESRIP contributed to
this approach. Thirteen themes were explored (disease, treatment,
pain, care, myself, information, relationship to others, relationship to
the health care team, schooling, home, living daily, fatigue and sleep,
physical activity-sport-rehabilitation). The "children" skills question-
naire brought together 78 respondents (19 children, 22 parents, 37
HCP), the "teenagers" questionnaire 50 respondents (10 teenagers,
17 parents, 23 HCP), the "parents of children" questionnaire 59 an-
swering machines (8 children, 28 parents, 23 HCP) and the question-
naire "parents of adolescents" 30 respondents (6 teens, 14 parents,
10 HCP). Priorities differ among groups. On the subject of treatment
in particular, we note a tendency of parents to privilege theoretical
knowledge whereas children focus their choices on coping and living
with JIA and the HCP put forward intermediate skills.
Conclusion: This collaborative and participatory work makes it possible
to identify the children's priorities, without neglecting the expected
skills by the parents and the HCP. The classification by theme will allow
teams wishing to develop educational approaches to rely on real no-
tions and not only on HCP projections. This repository wants to be
closer to problems and expectations of children and their families. It is
not, however, a list of ideal skills that all child, adolescent or parent
must master but a source of reflection to implement custom actions.
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Introduction: Juvenile Idiopathic Arthritis (JIA) is the most frequent
chronic rheumatic disease during childhood. It can result in disabil-
ities, loss of quality of life and mood changes. Furthermore, literature
reviewing the effects of arthritis on children and family is inconsist-
ent, with studies showing significant difference or not, compared to
healthy children.
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 138 of 243Objectives: The purpose of this study is to present results regarding
the functional status, psychosocial status and disease activity of chil-
dren with JIA, and their effects on the child's family. The second aim
is to present the correlations between these parameters.
Methods: The study included children diagnosed with JIA who ap-
plied to Hacettepe University İhsan Doğramacı Children's Hospital
Rheumatology Department. After demographic data was collected,
all children were assessed with Child Health Assessment Question-
naire (CHAQ) for daily living activities, with the Juvenile Arthritis Dis-
ease Activity Score (JADAS) for disease activity and with a newly
developed scale from Hacettepe University Faculty of Health Sciences
Department of Physiotherapy and Rehabilitation for children with
rheumatism by Edibe Ünal for functional and psychosocial status.
Cut-off point was accepted as ≤2.7 for disease activity. The Family
Impact Scale (FIS) was used to assess parents’ perspective.
Results: A hundred and ninety-six children were included in the study. The
Mean age of children was 12,44±3,97 and female/male ratio was 55,6/
44,4. Although the mean JADAS score was 3,33±4,21, it only detected ac-
tive disease in 81 children. There was a moderate correlation between
CHAQ (Pain) and functional scores of Ünal’s scale and JADAS score. CHAQ
total score was well correlated with function and psychosocial scores. The
correlation between FIS and other scales was very low (Table1).
Conclusion: This study concluded that pain and function were af-
fected by disease activity. It was also shown that the psychosocial
states that children expressed with their own knowledge are related
to their participation in daily living activities. It has been determined
that these changes do not reflect in the perspective of the family. It
was concluded that the functional and psychosocial aspects of JIA
children should also be taken into consideration.
Disclosure of Interest
None DeclaredTable 1 (abstract P262). Correlations
CHAQ Total CHAQ Pain CHAQ Overall Function Psychosocial FIS
JADAS
r 0,362 0,499 0,336 0,423 0,216 0,245
p 0,000 0,000 0,000 0,000 0,003 0,002
CHAQ (Total)
r 0,384 0,355 0,757 0,507 0,292
p 0,000 0,000 0,000 0,000 0,000
CHAQ (Pain VAS)
r 0,357 0,438 0,308 0,210
p 0,000 0,000 0,000 0,006
CHAQ (General VAS)
r 0,360 0,358 0,296
p 0,000 0,000 0,000
Function
r 0,474 0,273
p 0,000 0,000
Psychosocial
r 0,291
p 0,000
Table 1 (abstract P263). Frequency of injections in specific tendons in
the 182 JIA patients of the study
Type of tendons injected Nr. of injections (%)
Posterior tibialis tendon 172 (28.2%)
Flexors digiti proprii tendons (from I to V) 135 (22.1%)
Peroneals 113 (18.5%)
Wrist extensors (from I to VI compartment) 67 (11%)
Flexor digitorum of the foot tendon 56 (9.2%)
Flexor hallucis longus tendon 22 (3,6%)
Others 45 (7.4%)
Total 610 (100%)P263
TENDONS GLUCOCORTICOID INJECTIONS IN JUVENILE IDIOPATHIC
ARTHRITIS (JIA): FAKE OR RELIABLE TREATMENT OPTION?
Andrea Uva1, Rebecca Nicolai2, Fabrizio De Benedetti2, Silvia Magni-Manzoni2
1Department of Pediatrics, Sapienza-University of Rome; 2Rheumatology
Division, IRCCS Bambino Gesù Children’s Hospital, Rome, Italy
Correspondence: Andrea Uva
Pediatric Rheumatology 2018, 16(Suppl 2):P263Introduction: Due to the spread use of ultrasound (US)-guidance,
JIA patients undergoing glucocorticoid joint injections are more
frequently injected in periarticular sites, such as tendons. How-
ever, the frequency of tendon injections in JIA patients is un-
known and little is available about the frequency of remission at
the injected tendons.
Objectives: To identify the clinical features of JIA patients with ten-
don involvement treated with glucocorticoid injection, the tendon
sites most commonly injected, the frequency of and the time for
achieving remission in the injected tendons.
Methods: Records of patients with JIA from the database of gluco-
corticoid injection procedures performed at the study centre in a 5
years period which included tendon injections were reviewed. Demo-
graphic and clinical features, sites of injection, procedure setting,
glucocorticoid used, time to achieve local remission, disease activity
in the injected sites at the last follow-up, and eventual local side-
effects were recorded.
Results: 262 procedures with an amount of 610 tendon injections in
182 JIA patients (79% females) were identified, out of a total of 715
injection procedures (37%). Persistent oligoarthritis was represented
in the 54.4% of the patients, extended oligoarthritis in 19.8% (36),
polyarthritis in 24.7%, systemic JIA in 1.1%. The median age of the
patients at the time of the injection was of 8 years (IQ 4.6-11.3). All
procedures were US-guided; 97% were performed under general an-
aesthesia. Acetate methylprednisolone was the glucocorticoid used
in all the injections except 16 (2.6%), performed with triamcinolone
hexacetonide. Type and frequencies of the most injected sites are
shown in Table 1. In 226/262 procedures (86%), patients experienced
remission in the injected tendons after a median of 2.3 months (IQ,
1.9-3.2). Forty patients underwent repeated procedure in the same
tendon due to flare or persistent activity after at least 2 months from
the first injection. A total of 61 tendons (10%) were re-injected. At
the last follow up, after a median of 21.7 months (IQ 8.4-36), 165 chil-
dren out of 182 (90.6 %) were in remission in the injected site.
Thirty-five out of the 40 patients who underwent to repeated injec-
tion in the same site (87.5%) also showed remission at the last
follow-up. Twenty out of 182 patients (11%) showed local side effects
(subcutaneous atrophy, cutaneous hypopigmentation); no other side
effects were reported.
Conclusion: Tendons have been frequently injected at a tertiary care
Paediatric Rheumatology centre for the management of inflamma-
tory involvement outside the joint space in children with JIA, mostly
represented by the oligoarthritis subtype. The posterior tibialis ten-
don and the flexor digiti proprii tendons were the most frequently
injected. Local remission was observed in 86% of the procedures
after a median of 2.3 months and was found in the majority of the
patients at the last follow up, after a median of almost 2 years. Fur-
ther studies are planned to explore the impact of concomitant
medication in achieving and maintaining local remission and the
role of imaging in supporting the definition of remission in the
injected sites.
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Introduction: According to official statistic data in Ukraine there are
more than 3 thousand kids suffer from JIA and disease has strong
tendency to spreading. The most dangerous, that up to 50% of the
patients lose functional abilities within 3 – 5 years of life, up to 30%
of them has high activity of the inflammatory response on basic
treatment. Well known, that pathogenesis of the JIA is mediated by
molecular interactions between immune cells, inflammatory cyto-
kines, macrophages, that lead to hyper activation of the inflamma-
tion response, somehow connected with NF-kB. Previous in vitro
studies presented important role of NF-kB for generation of the ac-
tive response on the treatment of the process, caused by active in-
flammation reaction. Goals of the JIA treatment are suppression of
inflammation activity, dangerous clinical signs, limit iatrogenic effect
of concomitant treatment and support condition of the patient.
Ukrainian kids with JIA has limited access to biology treatment, that
is why very often we get complicated variants if the disease with sig-
nificant influence on patients quality of life.
Objectives: The aim of our study was to evaluate efficacy of the stand-
ard basic treatment, and in a combination with available biological
drugs, its influence on inflammation cytokines, NF-kB in kids with JIA.
Methods: For the achievement of the goals we checked up 78 kids
of our center with estimated diagnose of JIA, mid age of them – 12,7
years, mid duration of the disease – 19 months. Most of the kids had
polyJIA (52%) in seronegative subtype, seropostivite variant of poly-
JIA was met rarely – in 7,6%, all other cases – 40,4% were presented
by oligoJIA; we didn’t take into account sJIA. For characteristic of the
clinical features, we took into account amount of the active joints, re-
sults of CHAQ, VAS, ESR value. According to JADAS27-ESR score, most
of the patients had moderate disease activity (5,2±0,7) – 62,8%. For
estimation of the laboratory activity we checked absolute amount of
CRP, IL-1β, IL-6 and NF-kB in serum of the patients with JIA, by using
of the ELISA method.
Results: Laboratory activity of the inflammatory response was presented
by enlarged concentration of CRP (7,2±3,1g/l), ІL-1β (5,8±4,2 pg/ml; N
ranges <5 pg/ml), IL-6 (10,2±2,4pg/ml; N ranges <9 pg/ml), and as well
high concentration of NF-kB (70,5±3,1pg/ml; N ranges 20 – 48 pg/ml).
Concentration of CRP, IL-1β was slightly increased through all groups of
clinical variants JIA, IL-6 and NF-kB correlated with activity of the clinical
signs, were significantly higher in patients with polyJIA. To evaluate
efficacy and response on treatment, we checked="checked" the
same laboratory parameters in 6 months after the treatment: with
methotrexate in 51 (65,3±3,9%) patients, with methotrexate+adali-
mumab in 17 (21,8±1,9%) and methotrexate+tocilizumab in 10
(12,8±1,4%) patients. In a 6 months after the treatment 66,7% pa-
tients with MTX achieved ACR30 response, 76,4% of patients MTX
+ADA and 90,0% of patients MTX+TOC achieved ACR50. In a group
of MTX patients we didn’t observe significant decrease of IL-6 or
NF-kB concentration, it was at the equivalent level with primary re-
sults. Group of the patients with MTX+ADA showed significant low-
ering of CRP, IL-1β, and IL-6 on 28,7% to compare with baseline
level. In group of MTX-ADA decreasing of NF-kB wasn’t clinically
significant. Group of the patients that received MTX+TOC presented
the best results – with significant decreasing of CRP, IL-1β and IL-6.
As well was observed significant decreasing of NF-kB on 41,7 %,
that can be estimated as pathogenically linked therapeutic effect.
Conclusion: So, patients with JIA that meet high concentration of IL-
6 and NF-kB as laboratory predictors of high clinical activity, are more
lucky to get good treatment response in case of start therapy of
MTX-TOC to compare with MTX-ADA or isolated MTX treatment.
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Introduction: To date, monoarticular Juvenile Idiopathic Arthritis
(monoJIA) is included in the oligoarticular subgroup (oligoJIA) although
a few studies, in the past, have highlighted some distinctive features.
Objectives: We investigated whether patients with persistent isolated
monoJIA have peculiar clinical features and outcome as compared to
those with oligoarticular disease.
Methods: From a cohort of patients with oligJIA followed for at least 5
years since the disease onset, monoJIA were selected on the basis of
the exclusive involvement of one single joint during the overall disease
course. Each patient was followed with check visits, including ophthal-
mologic evaluation, every 3-4 months. The following parameters were
considered: sex, age at onset, presence and family history of joint hy-
permobility (JH), ANA, presence and site of active arthritis and uveitis,
treatment during the overall course of the disease and final outcome.
Treatment was grouped in four categories: intra-articular corticosteroid
injection (IACs), non-steroidal anti-inflammatory drugs and/or oral corti-
costeroids (AIDs), MTX and other disease-modifying anti-rheumatic
drugs (DMARDs), and biological agents (BAs). Outcome was defined ac-
cording to Wallace criteria3 as: clinical remission (CR), clinical remission
on medication (CRM) and active disease (A).
Results: 236 patients with oligoJIA, followed for mean 9.6 years (5-
22.6) entered the study. 172 (72.9%) presented oligoJIA and 64
(27.1%) monoJIA. Within the monoarticular forms, the knee was the
most affected site (79.9%) followed by ankle (10.9%). MonoJIA re-
sulted significantly different from oligoJIA for the lesser frequency of
ANA+ (75.0 vs 85.5%, p = 0.05) and uveitis (18.8 vs 37.2%, p = 0.007),
the higher frequency of JH (85,9 vs 70.3%, p = 0.015) and family his-
tory for JH (60.0% vs. 31.3%; p = 0.010).
As for treatment, a greater use of systemic drugs were recorded in
oligoJIA than in monoJIA (P = 0.000) while the frequency of subjects
undergoing IACS injection was comparable between the two groups
(93.0% vs 89.1%). At 5 year follow up, 79.9% monoJIA were in CR
and only 10.9% were still active. Conversely, only 24.4% oligoJIA were
in CR and 52.3% were still active (p 0.0001).
Conclusion: MonoJIA seems to be an entity in its own right with less
frequency of ANA and uveitis, less severity course and better long-
term outcome than oligoJIA. These preliminary findings may open
new insights on JIA classification and, maybe, on a different treat-
ment approach.
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Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 140 of 243Introduction: It was recently shown that the Human Epidermal
Growth Factor Receptor 2 (HER2) participates in the pathogenesis of
Lupus Nephritis (LN). HER2 expression is dramatically increased in
the kidneys of patients with LN and not in other proliferative glomer-
ulonephritides. Furthermore, HER2 is increased in the kidneys of
NZM2410 mice, a lupus nephritis mouse model, and correlates with
disease activity. Interferon alpha was identified as a driving force for
HER2 overexpression. Interestingly, a connection was found between
HER2 and epigenetics. HER2 overexpression is associated with a de-
crease on miR-26a and miR-30b, two microRNAs that control the ex-
pression of cell cycle related genes, including Cyclin E2, in human
mesangial cells. It is, therefore, hypothesized that HER2, miR-26a and
miR-30b control mesangial cell proliferation in LN.
Preliminary data showed that urinary (u) HER2 is increased in LN, but fur-
ther studies are necessary to address the real clinical value of uHER2 for
the diagnosis and monitoring of this disease and as a prognostic tool.
Objectives: To determine the clinical value of uHER2 as a biomarker
of LN activity.
Methods: A multicentre prospective study of children with LN was
performed. Clinical data and urine samples were collected in each
visit. Simultaneously, clinical data and urine samples from adult pa-
tients with systemic lupus erythematosus (SLE) were obtained from
the Johns Hopkins lupus cohort. Controls were age- and gender-
matched individuals without renal disease. Active lupus nephritis was
defined as renal SLEDAI ≥4. Urine supernatants were analyzed by
commercial enzyme-immunoassays for HER2, TWEAK and VCAM1.
T tests and Mann-Whitney U tests were used for comparisons between
samples. The relationship between HER2 and SLEDAI and HER2 and
other urinary biomarkers was defined by Spearman’s correlation.
Results: We analyzed 100 children with LN followed at five Pediatric
Rheumatology Academic Centers, median age 15 YO, female to male
ratio 3.4:1, 33% African-American, 31% Hispanic, 18% Asian and 18%
Caucasian. Mycophenolate mofetil was used in 89% and IV cyclo-
phosphamide in 34% of the patients.
Children with LN had significantly higher levels of uHER2 compared
with controls (p=0.008), particularly those with active LN at time of
urine collection (p=0.003). uHER2/Creatinine correlated with uTWEAK/
Creatinine (p=0.0001) and uVCAM1/Creatinine (p=0.018) levels.
Regarding the adult study, 142 SLE patients and 23 controls were an-
alyzed. uHER2/Creatinine levels were increased in SLE patients when
compared to controls (p=0.04), once again, this difference was higher
in patients with active LN at the time of urine collection
(p=0.004). Furthermore, uHER2/Creatinine levels correlated with SLE-
DAI at the time of urine collection (p=0.0039).
Conclusion: A new non-invasive biomarker is much needed to guide
clinical practice in LN. In two large prospective studies, one in children
and another in adults, it was shown that uHER2 is significantly in-
creased in LN patients, particularly when the disease is active, and that
it correlates with SLEDAI and other LN biomarkers. These are promising
results for the role of HER2 in clinical practice. Moreover, these results
establish a rationale for the development of other studies focusing on
the use of the already available HER2 drugs for the treatment of LN.
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Introduction: Linear Scleroderma (LS) is the most common subtype
of Juvenile Localized Scleroderma (JLS) and the one most frequently
associated with tissue damage and functional disability. During the
last decade, methotrexate (MTX) has been used as first choice agentfor LS but, to date, available data on long-term outcome are partial
and incomplete.
Objectives: To assess the disease course and the long-term outcome
of children with LS treated with MTX since diagnosis.
Methods: We conducted a retrospective and cross-sectional study in-
cluding children with LS followed at our Paediatric Rheumatology
Centre between 2000 and 2016. Patients treated with MTX for at
least one year and currently followed at our Centre with at least one
visit in the last 2 years were included. Disease course was evaluated
by retrospective analysis of clinical features, type of treatment and
recurrence. Outcome at the last visit was assessed by evaluation of
disease activity and severity of tissue damage and/or functional im-
pairment by Localized Scleroderma Cutaneous Assessment Tool (LoS-
CAT) and thermography.
Results: 50 patients, 24 with LS of the trunk/limbs and 26 with LS of
the face, entered the study. The mean follow-up was 7.8 years (me-
dian 6.8, range 2.1-16.3) and MTX treatment mean duration was 3.1
years (median 2.9, range 1.8-8.5 years). Only 16% patients did not re-
spond to first therapy with MTX, 16% had at least one flare of the
disease, on average 30 months after starting MTX, but 10% pre-
sented recurrent relapses. Within 5 years follow-up, 81.8% of patients
achieved partial remission (inactive disease on treatment) and 18.2%
complete remission (inactive disease, off treatment for >2 years), but
by 10 years follow-up 80.0% obtained complete remission. In the
group of 16 patients with >10 years of follow-up, complete remission
was reported in 87.5%. At last evaluation tissue damage was mild in
42% of cases, moderate in 32% and severe in 26%. Various degree of
functional limitation was reported in 41.7% of patients with LS of the
limbs. Severity of tissue damage was not related to LS subtype and
disease duration, while functional disability was more frequent in LS
of the limbs (p=0.039). Subtype of LS and severity of tissue damage
were not associated with disease recurrence and achievement of re-
mission, while length of therapy was related to disease relapses
(p=0.040) and severity of tissue damage (p=0.003).
Conclusion: Most patients with LS treated with MTX achieve complete
remission without flares and only a minority present repeated relapses
and active disease after more than 10 years. The long-term monitoring
of the patients even after therapy withdrawal is crucial to promptly
identify possible flares and treat them adequately, as they tend to recur.
Overall aesthetic and functional sequelae are moderate, probably be-
cause tissue damage establishes early in disease course as its severity
does not seem to be related to disease duration.
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Introduction: Juvenile Localised Scleroderma (jlSc) is believed a rare
autoimmune disease, which occurs 10 times more often then sys-
temic sclerosis in childhood and is believed to have a prevalence of
one per 100 000 children(1). There is no prevalence data published.
Objectives: We aimed to calculate the prevalence of jlSc in childhood
using administrative claims data.
Methods: We used Truven MarketScan® commercial insurance claims
data from the United States for the years 2010 through 2014, inclu-
sive. MarketScan contains billing records associated with physician
office visits, outpatient infusions, and pharmacy claims, among other
data, and is intended to be representative of all persons covered by
employer-sponsored health insurance in the United States. In each
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 141 of 243individual calendar year, we identified all persons in the claims data
who were less than 16 years old.
Results: The results for each calendar year are shown in Table 1.
There were approximately 1600-2200 children per year with diagno-
ses of localized scleroderma and <3% of them had concurrent diag-
noses of systemic sclerosis or mixed connective tissue disease. The
prevalence estimates in each year ranged from 3.2 to 3.6 per 10,000
children. The proportion of children with localized scleroderma who
received methotrexate in each year ranged from 3.2% to 4.4%.
Conclusion: This prevalence data showes a higher than expected
prevalence compared to the published incidence data with with 2.7
per 100 000 to 2.5 children per million per year. We need more
prevalence data from other resources to reassure our findings.
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None DeclaredTable 1 (abstract P268). The estimated prevalence of juvenile localised
Scleroderma in the United States
Year Total
Children
(N)
Diagnosis
Code for
Localized
Scleroderma
(N)
No Diagnosis Code
for Systemic
Sclerosis or Mixed
Connective Tissue
Disease (N)
Use of
Methotrexate
Estimated
Prevalence
per 10,000
Children
[95% CI]
2010 5,894,628 2064 2006 / 2064 75 / 2006 3.4 [3.3-3.6]
2011 6,231,475 2269 2222 / 2269 86 / 2222 3.6 [3.4-3.7]
2012 6,278,118 2198 2154 / 2198 68 / 2154 3.4 [3.3-3.6]
2013 4,950,018 1732 1692 / 1732 61 / 1692 3.4 [3.3-3.6]
2014 4,933,523 1620 1588 / 1620 71 / 1588 3.2 [3.1-3.4]P269
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Introduction: Juvenile systemic scleroderma (jSSc) is an orphan
disease with a prevalence 3 in a 1 000 000 children(1). There is
not much published data about the course of jSSc with standard-
ized assessment of the patients. We report our date form juvenile
scleroderma inception cohorte with a follow up of 12 months in
the cohort.
Objectives: to evaluate the development of the disease during the
first 12 months in the cohorte
Methods: The juvenile scleroderma inception cohorte is a prospect-
ive multicenter registry of patients with jSSc, who fullfill the adult
classification criteria, and have age of disease onset of less then 16
years of age and less then 18 years at the time of inclusion in the co-
hort. We evaluted the patients characteristics of the patients, who
were followed 12 months in the registry.
Results: 60 patients were followed 12 months in the registry. 77%
were female and 75% had diffuse subtype. 18% had overlap feu-
tures. Mean disease duration at time of inclusion was 3.2 years. Mean
age of onset of Raynauds was 8.8 years and the first non-Raynauds
9.5 years. 78% received DMARDs at the time of inclusion and 90%after 12 months. 87% of the patients were ANA positive, around 35%
anti-Scl70 positive and around 2% anticentrome positive. The mean
modified skin score decreased from 18 to 15.1. The frequency of Ray-
naud´s stayed around 75%. The frequency of the nailfold capillary
changes increased from 67% to 72%, but the frequency of active ul-
cerations decreased from 23% to 19%. The number of patients with
FVC <80 % decreased from 41% to 17% (p=0.027). The number of
patients with DLCO< 80% increased from 46 to 54% (p=0.651). The
number of patients wiht pulmonary hypertension assessed by ultra-
sound decreased from 12% to 8% ( p=0.543). No patient devel-
oped hypertension or renal crisis. Gastrointestinal involvement
stayed stable around 37%. Number of swollen joints decreased from
22% to 10% (p=0.08). Total muscle weakness decreased from 24 %
to 7% (p=0.031) amd elevated CK from 28% to 11% (p=0.045)
too. Several patient related outcomes improved significantly. Patient
global disease activity (VAS 0-100) from 51 to 36(p=0.021) and pa-
tient global disease damage (VAS 0-100) from 49 to 37 (p=0.049) as
physitian global disease activity (VAS 0-100) from 50 to 31 (p=0.001)
and physitian ulceration activity (VAS 0-100) from 17.5 to
8.5(p=0.038).
Conclusion: Over the 12 months observation period patient related
outcomes , number of patients with decreased FVC, number of swol-
len joints and number of patients with muscle weakness improved
significantly and fortunately the other clinical parameters stayed
stable. It seems, that the current treatment can reach improvement
on some areas and at least stabilisation of the patients.
1. Beukelman T, Xie F, Foeldvari I. Assessing the Prevalence of Juven-
ile Systemic Sclerosis in Childhood Using Administrative Claims Data
from the United States. Journal fo Scleroderma and Related Disor-
ders. 2018;3.
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Introduction: Juvenile systemic scleroderma(jSSc) is an orphan dis-
ease with a prevalence of 3 in 1 000 000 children(1). There is no
large date published regarding the clinical presentation of jSSc. The
juvenile systemic scleroderma inception cohort is a multinational co-
hort with a prospective standardized assessment of the patients. We
present the clinical characteristics of the patients at time of the inclu-
sion in the cohort.
Objectives: Evalution of the jSSc patients at the time of inclusion in
the juvenile scleroderma inception cohorte
Methods: The juvenile scleroderma inception cohorte is a prospect-
ive multicenter registry of patients with jSSc, who fullfill the adult
classification criteria, and have an age of disease onset of less then
16 years and less then 18 years of age at the time of inclusion in the
cohort. We evaluated the patients characteristics at time of inclusion
in the cohort.
Results: Till 15th of April 2018 hunderdnine patients were included.
80% of them had diffuse subtype. 90% of them were caucasian and
Table 1 (abstract P271). See text for description.
Condition Time Assay Number of
replicates
p-value for detected
significant changes
Control JSLE 0 h mRNA n=13 p=0.003 TLR2; p=0.01
S100A9 for Ctrl vs. JSLE
Stratified JSLE: CD16b
p=0.01 IFN high vs Ctrl;
p=0.02 IFN high vs IFN low
protein n=7 control p=0.02 TLR; p=0.03 S100A9
n=6 JSLE
phagocytosis n=7 control p=0.04 E.coli
n=6 JSLE
IFNa 2 h mRNA n=6 p=0.03 CD16b
7 h protein n=5 p=0.02 CD16b
TNFa 30min mRNA n=5 n=6 required for analysis
2 h protein n=6 p=0.03 TLR2
Apoptotic
supernatant
2h, 6h mRNA n=5 p=0.01 CD16b
6h protein n=5 p=0.02 CD16b
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 142 of 24379% female. 15% of them had overlap feutures. Mean age of onset
of Raynauds was 9.7 years in the diffuse subtype(djSSc) and 10.5
years in the limited subtype(ljSSc) ( p=0.62). The mean age of non-
Raynauds was 10.2 in the djSSc and 11.2 in the ljSSc (p=0.52). Mean
disease duration at time of inclusion was 3.4 in the djSSc and 2.5 in
the ljSSc group. Around 80% received DMARDs. ANA positivity was
around 86% in both groups. Anti-Scl70 was 32% in djSSc and 39% in
the ljSSc group. Anticentromere positivity was 4% in the djSSc and
11% in the ljSSc group(p=0.28). Mean Modified Rodnan skin score
was 18.2 in the djSSc and 7.7 in the ljSSc (p=0.001). Gottron papulae
were significantly more common the djSSc woth 27% compared to
7% in the ljSSc group. History of ulceration was significantly more
common in the djSSc with 57% comparedot 29% in the ljSSc group (
p=0.010). FVC<80% occured in 34% in hte djSSc and 21% in the ljSSc
group(p=0.295). DLCO <80% occured 44% in the djSSc and 43% in
the ljSSc group. Pulmonary hypertension assessed by ultrasound
occured 7% in both groups. No hypertension or renal crisis was re-
ported or observed. Gastointestinal involvement occured 35% in the
djSSc and 24% in the ljSSc (p=0.28). Number of swollen joints were
observed around 20% in both groups. Muscle weakness wtih joint
contractures were present in 12% in the djSSc and 28% in the ljSSc
group. Tendon friction rub was present in 4 % in djSSc and 7% in the
ljSSc group. djSSc patients had significantly worse scores for physitian
global disease activity (VAS 0-100) 41.6 compared to 30.7 ( p=0.041)
and for physitain global disease damage(VAS 0-100) 38.2 compared to
18.9 ( p=0.023).
Conclusion: In this large cohort of jSSc patients are surprisingly not
many significant differences between djSSc and ljSSc. According the
physitian global the djSSc paitents have a significantly more severe
disease.
1. Beukelman T, Xie F, Foeldvari I. Assessing the Prevalence of Juven-
ile Systemic Sclerosis in Childhood Using Administrative Claims Data
from the United States. Journal fo Scleroderma and Related Disor-
ders. 2018;3.
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Introduction: JSLE is a multisystem autoimmune disease with auto-
antibodies potentially caused by dysregulated phagocytosis and in-
creased apoptotic burden. Our metabolomics data from JSLE serum
and transcriptomic analysis of neutrophils (PMN) suggest dysregula-
tion of phagocytosis related genes (PRGs), many of which are
dependent on the interferon (IFN)-induced gene signature (IGS) of
the patient.
Objectives: Investigate the contribution of IFNa, TNFa and apoptotic
environment to the expression of PRGs.
Methods: PMNs from healthy controls and JSLE patients were tested
for expression of PRGs (CR3, FCGR3B(CD16b), TLR2, S100A9) and IGS
(IFI6, LY6E, OAS2, IFI44L) genes. CD16b, TLR2 and S100A9 protein
was measured with flow cytometry and ELISA. Phagocytic ability was
assessed by phagocytosis assays using different pHrodo coated bio-
particles. Apoptotic supernatant was collected from 1.5x106 PMNs in-
cubated for 24 h at 37°C. Healthy paediatric control PMNs were
stimulated with either IFNa (10ng/ml) or TNFa (1ng/ml). Healthy adult
control PMNs were stimulated with apoptotic supernatant (+/-5%PBMC) or media. PRG expression was measured with qPCR. Pro-
tein expression was measured with flow cytometry and ELISA.
Results: Significant increase in expression (see Table 1) was found for
CD16b, TLR2 and S100A9 mRNA and protein in JSLE patients com-
pared to controls; CD16b was only significant after patients were
stratified by their IGS. This profile suggests a strong phagocytic abil-
ity which we confirmed with phagocytosis assays. We found IFNa to
regulate CD16b expression, while apoptotic supernatant caused
CD16b shedding. TNFa increased TLR2. We did not find significant
differences in S100A9 protein expression for any stimulation.
Conclusion: Expression of PRGs and proteins is strongly up-regulated
in JSLE patients and can partly be explained by factors in the lupus
environment. A “ready to phagocytose” phenotype could make neu-
trophils oversensitive to phagocytic triggers or danger molecules.
This is further suggested by our metabolomics data indicating that
neutrophils are active in patients even in non-flaring patients. Over-
reactive cells can cause harm to the body once flares occur. The mol-
ecules investigated are therefore potential targets for preventive
treatment.
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Introduction: Pediatric systemic lupus erythematosus (pSLE) is an auto-
immune disease characterized by the production of autoantibodies
against self-antigens and immune dysregulation, resulting in tissue dam-
age. Standard treatments of pSLE are high-dose glucocorticoids and im-
munosuppressive agents; however, a sustained response is still not
achieved in a significant proportion of patients. In the last decade, several
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 143 of 243studies showed an up-regulation of genes induced by type I interferons
in peripheral blood and tissues of pSLE patients. The expression of this
group of genes, known as the interferon signature, correlates with disease
activity. More recently the type II interferon has been implicated in pSLE;
however, its precise role has not been extensively investigated yet.
Objectives: To investigate the role of type II IFN, IFNγ, in the pathogen-
esis of pSLE evaluating: 1) the expression levels of IFN-related genes
and serum levels of IFN-related chemokines in the peripheral blood of
pSLE patients; 2) the cross-talk between type II and type I IFNs.
Methods: Expression levels of type I IFN-induced genes (IFI27, IFI44L,
IFIT1, RSAD2, ISG15, SIGLEC1) and type II IFN-induced genes (CXCL9,
CXCL10, IDO1) in peripheral blood of pSLE patients was evaluated by
quantitative PCR (qPCR). Serum levels of IFNγ-related chemokines
were measured by ELISA. For each patient, SLEDAI score was calcu-
lated. Human peripheral blood mononuclear cells (PBMCs) from 6 HD
were stimulated in vitro with recombinant human IFNγ and IFNα2b
and gene expression was evaluated by qPCR.
Results: Expression levels of both IFNα-induced genes and IFNγ-
induced genes were increased in the peripheral blood of pSLE pa-
tients with active disease (n=12) compared to healthy donors (HD)
(n=10) and pSLE patients with inactive disease (n=13). We developed
a type II IFN score similarly to the type I IFN score described by Crow
et al. Type I and type II IFN scores were calculated for each pSLE pa-
tient. The type II IFN score significantly correlated with the SLEDAI
(r=0.64, p<0.01); as previously reported, also the type I IFN score sig-
nificantly correlated with SLEDAI (r=0.67, p<0.01). To confirm the
gene expression data, we evaluated the serum levels of two cyto-
kines induced by IFNγ, CXCL9 and CXCL10, and we found that both
were increased in pSLE patients compared to HD.
We, then, investigated a possible crass-talk between type I and type II
IFNs: we found that IFNγ induced the expression of type I IFN-related
genes in human PBMCs in a dose-dependent manner. Moreover, IFNγ
upregulated the expression of both TLR7 and TLR9, two potent inducer
of IFNα by pDC. Finally, human PBMCs stimulated with recombinant
IFNα2b strongly up-regulated the expression of IFNγ, thus, once acti-
vated, IFNα can potentiate the production of IFNγ.
Conclusion: Our data suggest a potential role of IFNγ in the
pathogenesis of pSLE. IFNγ-induced genes in whole blood and
serum levels of IFNγ-induced chemokines are increased in pa-
tients with pSLE patients; moreover, a type II IFN score correlates
with disease activity. We show that type I interferon and IFNγ es-
tablish a positive crosstalk that can potentiate their reciprocal
biological activity in SLE.
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Introduction: Rituximab (RTX) is increasingly used in rheumatologic
[1, 2], hematologic [3] and renal diseases [4]. The induced B cell de-
pletion can lead to hypogammaglobulinemia and thus an increased
risk of infection [5]. B cell depletion is not always achieved, and this
has a negative effect on therapeutic response [6]. Anaphylaxis is a
frequent side effect of RTX and has been associated with the occur-
rence of anti-drug antibodies (ADA) against RTX [7].
Objectives: To describe in different pediatric patient groups the
pharmacodynamics of RTX in children by outcome variables, i.e.success of B-cell depletion and time of B cell repopulation, as well as
the risk factors for severe infections and anaphylaxis.
Methods: Patient data of children who received RTX between 2008
and 2017 at our center were retrospectively collected. Three patient
subgroups were defined: autoimmune diseases (AID), immune dys-
regulation (ID) and renal diseases (RD). B cell repopulation was de-
fined as a number above the cut-off value of B cell depletion
(=0.050*10^6/l or <2% of the total amount of lymphocytes).
Results: B cell measurements were performed in 53/55 patients. B
cell depletion was not achieved in 9 patients. In the 35 patients with
B cell repopulation, median time until repopulation was 155 days
(IQR 105-222): in the AID group (n=12) 129 days (IQR 77.5-243,
p=0.363), in the ID group (n=5) 172 days (IQR 154-181, p=0.574) and
in the RD group (n=18) 163 days (IQR 121-229, p=0.847). After RTX
treatment, in 36 patients IgG levels were measured of which 14
(39%) had low IgG levels on at least one occasion (median 7 g/L
[range 0.6 - 38.1g/L]). Severe infections leading to hospitalization oc-
curred in 15 (27%) cases. An allergic reaction during or directly after
RTX infusion was observed in 27 patients (49%). Anaphylaxis, defined
as a systemic allergic reaction, characterized by impairment of air-
way, breathing, circulation or consciousness, occurred in 10 of these
patients (18% of total cohort). Seven patients were tested for anti-
RTX antibodies of whom 6 tested positive: 5 patients in the AID-
group and one patient with renal disease. Allergic reactions occurred
in all 6 while RTX failed to induce B cell depletion in 4 of these.
Conclusion: Time-to-B-cell-repopulation after RTX did not signifi-
cantly differ between different pediatric patients groups. Severe in-
fections were common (27%) in the cohorts studied. It is unclear
from our data whether this is merely related to RTX treatment. Pres-
ence of ADA against RTX seems to predict failure of B-cell depletion
and/or anaphylaxis after RTX treatment.
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Introduction: Raynaud’s phenomenon (RP) is characterised by abnormal
vascular responses manifesting clinically with bi/triphasic colour changes
of the digits. The vasospasm can be evoked by cold temperature, but
other precipitating events may have a role in its pathogenesis, mostly
when occurring in young patients. It can be a primary condition (PRP)
or the very first presenting symptom of various systemic inflammatory
conditions in which case it is referred to as secondary RP (SRP). Al-
though extensive special testing is not always necessary, every patient
with a diagnosis of Raynaud phenomenon (RP) should be carefully eval-
uated to distinguish the primary from the secondary disorder. Risk fac-
tors at diagnosis that predict evolution of presumed PRP into SRP
remain unclear.
Objectives: To describe the presenting clinical features and labora-
tory investigations , risk factors and treatment in children with pri-
mary and secondary RP seen in a large tertiary paediatric and
adolescent rheumatology centre Great Ormond Street Hospital,
London and to identify baseline predictors of likely SRP.
Methods: Retrospective single-centre study. Data collection of demo-
graphic, clinical, laboratory and treatment characteristics of children
and adolescents with RP was performed. Patients were classified as
having PRP if no associated systemic inflammatory symptoms were
Table 1 (abstract P275). Correlation of change of biomarker from
previous to current visit (d visitt-1 and visitt) with the clinical course
(SLEDAI-2k)
SIGLEC1 C3 C4 ds-DNA-ab
SLEDAI-2k n = 129 n = 110 n = 108 n = 107
betaST = 0,24 betaST = -0,11 betaST = -0,04 betaST = 0,13
p = 0,006 p = 0,31 p = 0,67 p = 0,20
betaST: standardized beta-coefficient; n: number of analyzed visits; ds-DNA ab:
double-stranded DNA antibodies
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ethnicity, sex, age at disease onset, anti-nuclear antibody, double
stranded DNA, complement factor 3 and 4, age and disease duration,
full blood count and acute-phase reactants, and concomitant sys-
temic medications. Continuous data were summarised as median
and range. Comparison between groups was performed using Chi-
square test for categorical data and Mann-Whitney U Test for con-
tinuous data.
Results: A total of 128 patients (103 females) with RP, median age 11
(range 7 – 14) years old, with a median age at disease onset 10
(range 7-13) years were included. Sixty were diagnosed with PRP and
68 with SRP. Children with SRP were more commonly of Caucasian
ancestry (p=0.008) and had constant symptoms (p=0.022), arthritis
(p=0.001), ulceration (p=0.029), dilated nailfold capillaries (p=0.002)
and positive ANA (p=0.0004) when compared to children with PRP.
Nifedipine was the commonest first line treatment (35%) followed by
glyceryl trinitate patch (26%). On logistic regression analysis, Cauca-
sian origin (p=0.002), arthritis (p=0.006), positive ANA (p=0.002), and
dilated nailfold capillaries (p=0.007) were the strongest predictors as-
sociated with secondary RP.
Conclusion: Differentiation between primary and secondary RP in
children remains challenging due to the lack of specific biomarkers.
In our cohort, 53% of referred children developed a systemic inflam-
matory disease over time highlighting the significance of close moni-
toring and re-visiting the possible diagnosis of PRP. Nailfold
capillaroscopy may be a useful non-invasive tool to allow in addition
to other laboratory tests and clinical signs the differentiation be-
tween the two forms of RP.
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Introduction: SIGLEC1 (sialic acid-binding Ig-like lectin 1, CD169) is a
monocytic adhesion molecule induced by interferon-α. In adult sys-
temic lupus erythematosus (SLE), SIGLEC1 correlates cross-sectionally
and longitudinally with disease activity1,2.
Objectives: The aim of this work was to examine whether SIGLEC1
also reflects the disease activity in pediatric SLE.
Methods: Over a period of 29 months, from October 2014 to March
2017, the disease activity was clinically evaluated using SLEDAI (SLE-
Disease Activity Index-2000). In 28 consecutive pediatric SLE patients
(mean age 16 years, range 3 - 38 years, 86% female, 14% male), the
number of SIGLEC1 molecules was measured quantified and stan-
dardized by the amount of SIGLEC1 molecules per CD14 + monocyte
in peripheral blood monocytes at 158 times using flow cytometry in
a routine laboratory. At the same time, the level of anti-ds DNA anti-
body titer (ELISA) and the concentration of complement factors C3
and C4 (nephelometry) were determined. The association between
SIGLEC1, C3, C4 and ds DNA-antibody with SLEDAI was estimated
using a mixed linear model to model the repeated measurement of
parameters within a patient. The cut-off for the change in SIGLEC1
between two consecutive visits to predict clinical improvement or
worsening in SLEDAI was chosen on the maximum Youden Index3.
Results:
The density of SIGLEC1 molecules on the surface of the monocytes
based on two visits, correlated with the SLEDAI (129 determinations,betaST 0.24, p <0.006), but not with the C3 (110 determinations,
betaST -0.11, p = 0,31), the C4 (108 determinations, betaST -0.04, p
<0.67) and the anti-dsDNA-antibodies (107 determinations, betaST
0.13, p = 0.19). SIGLEC1 is a more change-sensitive biomarker than
the conventional laboratory parameters C3, C4 and ds-DNA-AB (Tbl.
1). Patients with an increase in SIGLEC1 of > 1063 molecules / mono-
cyte between two visits show a higher probability (OR = 9.4, p
<0.001) of clinical worsening (SLEDAI-2k ≥ 2 points4). Patients who
show a decrease > 2902 SIGLEC1 molecules / monocyte have a
higher chance (OR = 6.8, p<0.001) to have a clinical improvement
(SLEDAI ≤ 2 points).
Conclusion:
1. SIGLEC1 is significantly increased in active pSLE
2. There is a significant relationship between the measured interferon
biomarker SIGLEC1 and the disease activity in pSLE patients
3. A cut off in SIGLEC1 can be defined which correlates with clinical
worsening
Thus, SIGLEC1 represents a potential marker for activity monitor-
ing in pSLE disease.
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Introduction: Subclinically passing endocrine pathology plays an
important role in the development and progression of the ath-
erosclerotic process and is often underestimated not only by
rheumatologists, but also by endocrinologists. The mechanism of
development of autoimmune thyroid pathology, as well as sys-
temic diseases of connective tissue, is closely related to the im-
balance of the immune system, mainly with the Th1 immune
response. Under the influence of pro-inflammatory cytokines, the
expression of receptors activating the apoptosis of follicular cells
of the thyroid gland occurs, which ultimately leads to the devel-
opment and progression of hypothyroidism. Deficiency of thyroid
hormones can promote the appearance of hypercholesterolemia,
cause disturbances in the state of the autonomic nervous system
and energy metabolism.
Objectives: The aim of the study was to evaluate the state of lipid me-
tabolism and thyroid function in children with juvenile scleroderma
Methods: 40 children with juvenile scleroderma at the age from 5 to
16 years were examined. The parameters of the immune system, lipid
spectrum of blood and thyroid hormone levels were studied.
Results: According to the results of immunological examination, a
significant increase in the relative amount of B-lymphocytes, a redis-
tribution of immunoregulatory subpopulations of T-lymphocytes by
decreasing the number of CD8 + cells against a background of
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 145 of 243increased number of CD4 + cells, hyperproduction of total IgG and
IgM, a significant increase in TNF-α and a decrease in serum IFN-γ
was established in children with juvenile scleroderma when com-
pared with the control group (P <0.01).
As a result of the thyroid function study, a significant (p <0.05) de-
crease in the levels of total and free T3 and T4 in the blood serum of
children with JS was compared with that in the children of the con-
trol group: the mean levels of total T3 in children with JS were 1,4
(0,8, 1,9) nmol / l, in children of the control group - 2.1 (1.5, 2.4) nmol
/ l; the average values of free T3 in children with JS 3.4 (3.1, 4.1) nmol
/ L, in children of the control group - 5.1 (2.7, 5.8) nmol / l; the mean
levels of total T4 in children with with JS were 84.4 (73.8, 99.2) nmol
/ l, in children of the control group - 102.1 (93.1, 108.6) nmol / l;
mean free T4 in children with JS were 11.8 (11.2, 12.8) nmol / l, in
children of the control group - 14.6 (12.6, 18.9) nmol / l. The level of
TSH in children with JS was significantly higher than in children of
the control group - 3.1 (2.6, 4.6) mIU / l in children with JS, 1.9 (1.5,
5.4) mIU / L in children of the control group.
The children with JS have violations in the lipid spectrum of athero-
genic orientation, characterized by hyperlipidemia> 7.0 g / l (62.5%),
hypertriglyceridemia> 1.1 mmol / l (22.5% of children), hypercholes-
terolemia (32.5% of children ) and dyslipoproteinemia in the form of
a decrease in HDL cholesterol and an increase in LDL, an increase in
the ApoV / ApoA ratio> 1 (17.5%) and a decrease in ApoE (p <0.001),
which together with hemostasis changes can be regarded as a risk
factor for atherothrombosis.
Conclusion: The atherogenic orientation of lipid metabolism caused
by the autoimmune process and hypothyroidism of the thyroid gland
is characteristic for children with juvenile scleroderma.
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Introduction: Juvenile scleroderma is a rarely seen chronic con-
nective tissue disorder.The hands are commonly affected in pa-
tients with JS, and Raynaud’s phenomenon, finger swelling and
joint pain are the primary manifestations of the disease. Skin
thickening is a manifest consequence of JS. The hands account
for only a small fraction of the total skin area of the body, but
are necessary for many important functions in daily life.
Objectives: The purpose of our study is to examine the effects of
sense and functionality changes in the hands on activity and par-
ticipation in patients with JS.
Methods: 30 patients (26 girls, 4 boys) with JS between the ages
of 6-18 and 30 healthy controls (20 girls, 10 boys) with similar
age and gender were included in our study. 14 of 30 JS patients
were JSS and the rest of them were JLS.The inclusion criterias
were to have been diagnosed with Juvenile Scleroderma 6
months prior to the ILAR classification and to be at the mental
level that could respond to the assessments to be used in the
study. The follow-up form was prepared considering the relevant
parameters such as gender, socio-demographic status, clinical
family story of JS disease. Children rated their pain severity on a
six-item Wong-Baker FACES® Pain Rating Scale (WBS) from none
to worst. Hot-cold, pain, and touch sense were evaluated in both
groups. Vibration sence is assessed with 256Hz diapozon, light
touch-deep pressure sensation is with Semmes Weinsteinmonofilament (SWMT) test, static-dynamic 2 point 2-point dis-
crimination test is with a discriminator, localization sensation test
is with a pencil. In addition moberg pickup test, stereognosis
evaluation, wrist joint position sense, sympathetic activation were
evaluated. The hand joint range of motion was measured by
goniometer , hand grip strength by "Jamar Plus + Hand Dynom-
ometer (JPHD)", the pinch gripping force by "Jamar® Pinch Gauge
- Hydraulic" pinchmeter, the hand mobility by modified Hand Mo-
bility in Scleroderma (mHAMIS). Children completed their activtiy
and participant performance status with “Childhood Health As-
sessment Questionnaire (CHAQ)”, “Duruoz Hand Index (DHI)”,
“Jebson Taylor Hand Function Test(JTHFT)”, “Community Integra-
tion Questionnaire (CIQ)” tests. The quality of life were evaluated
with “Scleroderma Health Assessment Questionnaire(SHAQ)”. Sta-
tistics were analyzed with the SPSS for Windows 21.0 program.
Results: The mean age of the JS group was 14.06±3.24, while the mean
age of the control group was 12.43±3.24 years. There were significantly
differences between the two groups in pain (WBS), light touch-deep
pressure sensation, sense of touch localization, range of motion, func-
tional assessment (JTHFT), activity and participation scores (CHAQ, DHI)
and quality of life scores (SHAQ)(p<0,05). Almost half of the JS group
describes the character of their pain as inflammable or whining.There
was a significant correlation between SWMF and CHAQ (r=0,52), SWMF
and DEI (r=0,62), SWMF and SHAQ-Total (r=0,57) scores. There was a
significant correlation between resting pain and CHAQ-Total (r=0,576)
and Resting Pain and DEI (r=0,674) scores.
Conclusion: Consequently, sense and functional changes after hand in-
volvement in JS patients cause limitations in daily living activity and
negatively affect the effective use of the hands.Assessments of sensa-
tion symptoms that affect the functionality, activity level and participa-
tion should be taken into consideration in patients with JS.In addition,
we think that the use of sensory therapies in JS treatment will be an im-
portant factor in increasing the effectiveness of rehabilitation.
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Introduction: Juvenile systemic scleroderma (jSSc) is an orphan dis-
ease with a prevalence 3 in a 1 000 000 children(1). There is not
much published data about the course of jSSc with standardized as-
sessment of the patients. We report our date form juvenile sclero-
derma inception cohorte with a follow up of 24 months in the
cohort.
Objectives: to evaluate the development of the disease during the
first 24 months in the cohorte
Methods: The juvenile scleroderma inception cohorte is a prospect-
ive multicenter registry of patients with jSSc, who fullfill the adult
classification criteria, and have age of disease onset of less then 16
years of age and less then 18 years at the time of inclusion in the co-
hort. We evaluted the patients characteristics of the patients, who
were followed 12 months in the registry.
Results: 40 patients were followed 24 months in the registry. 80%
were female and 77.5% had diffuse subtype. 20% had overlap feu-
tures. Mean disease duration at time of inclusion was 3.2 years. Mean
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8.7 years. 73% received DMARDs at the time of inclusion and 95%
after 24 months. 85% of the patients were ANA positive, around 25%
anti-Scl70 positive and around 3% anticentrome positive. The mean
modified skin score decreased from 14.4 to 12.9. The frequency of
Raynaud´s stayed around 87.5%. The frequency of the nailfold capil-
lary changes increased from 55% to 62%, but the frequency of active
ulcerations decreased from 23% to 20%. The number of patients with
FVC <80 % decreased from 42% to 39% (p=0.8). The number of pa-
tients with DLCO< 80% decreased from 54 to 44% (p=0.58). The
number of patients with pulmonary hypertension assessed by ultra-
sound increased from 5% to 10% ( p=0.396). No patient devel-
oped hypertension or renal crisis. Gastrointestinal involvement
decreased from 32.5% to 22.5% (p=0.317). Number of swollen joints
decreased from 23% to 17.5% (p=0.53). Total muscle weakness de-
creased from 5 % to 0% (p=0.224) amd elevated CK from 17% to
11% (p=0.54) too. Several patient related outcomes improved signifi-
cantly. Patient global disease activity (VAS 0-100) from 49.2 to
29.4(p=0.001) ,patient global disease damage (VAS 0-100) from 43.9
to 29.8 (p=0.013) and patient Raynaud activity VAS 0-100) from 26.7
to 14.2 (p=0.045)as physitian global disease activity (VAS 0-100) from
48.3 to 33.2 (p=0.021) .
Conclusion: Over the 24 months observation period patient related
outcomes improved significantly and fortunately the other clinical
parameteres did not revealed any significant deterioration. It seems,
that the current treatment can reach improvement judged by the pa-
tients and stablisation of the disease.
1. Beukelman T, Xie F, Foeldvari I. Assessing the Prevalence of Juven-
ile Systemic Sclerosis in Childhood Using Administrative Claims Data
from the United States. Journal fo Scleroderma and Related Disor-
ders. 2018;3.
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Introduction: Juvenile systemic scleroderma (jSSc) is an orphan dis-
ease, with an estimated prevalence of 3 per 1000 000 children. Most
jSSc patients primarily present with Raynaud phenomenon (RP).
Objectives: We investigated in our patient of the juvenile sclero-
derma inception cohort, how fare patients with (RP+) and without
(RP-) RP differed in their clinical presentation at enrolment.
Methods: The jSSc is a prospective cohort of jSSc patients. Patients
were enrolled who were diagnosed with jSSc, had a jSSc onset age
under 16 years and were younger as age of 18 years at the time of
inclusion. The patients are prospectively assessed every 6 months ac-
cording to a standardized protocol. We reviewed the organ involve-
ment pattern of our patients currently followed in the cohort.Results: 100 patients are currently followed in the cohort and 89
(89%) of them had RP. The female/male ratio was lower in the RP+
group, 3.7:1 compared to 4.5:1(p=0.808). Diffuse subtype was more
common in the RP+ group, 72% compared to 63%. Mean age of on-
set of first non- Raynaud symptomatic was 10.4 years in both groups.
Mean disease duration was slightly higher in the RP+ group, 3.4 com-
pared to 2.2 years. ANA positivity was higher in the RP+ group, 88%
compared to 70% (p=0.48). Anti-Scl70 was 34% in the RP+ and 20%
in the RP-group (p=0.34). Interestingly 7% of RP + but none of the
RP+ were anti-centromere positive. The mean modified skin score
was lower in RP + group (mean of 14.8 compared to 17.0). There
were significantly more nailfold capillary changes (70% compared to
18%, p=0.001) and a higher rate of history of ulceration in the RP+
group (49% compared to 20%, p=0.083). Decreased DLCO and
FVC<80% was higher in the RP-negative group with 45%/50% com-
pared to 37.5%/31% respectively. Pulmonary hypertension occurred
in 7% in the RP+ group and there was no case in the RP- group
(p=0.335). RP- group had a higher rate of urinary sediment changes
18% compared to 4.5% in the RP+ group (p=0.07). No renal crisis or
hypertension was reported in neither groups. Gastrointestinal in-
volvement was similar between the two groups with around 35%.
Occurrence of swollen joints was similar in both groups as the fre-
quency of muscle weakness with around 20%. The tendon friction
rub occurred around 10% in both groups. In the patient related out-
comes, there was only a difference in rating of Raynauds activity.
Conclusion: The RP– group differed from RP + group in the clinical
presentation at enrolment. The absence of Raynaud phenomenon
was associated with a decreased rate of history of ulceration, no oc-
currence of pulmonary hypertension. Interestingly higher rate of urin-
ary sedimentary changes and no anticentromere positivity was
observed in RP- patients.
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Introduction: Pulmonary vascular disease and interstitial lung fibrosis
are the leading causes of morbidity and mortality in Juvenile Sys-
temic Sclerosis (JSSc). Six-minute walk test (6MWT) is a self-paced
submaximal exercise test used for evaluating functional exercise cap-
acity, prognosis and response to therapy in patients with cardiopul-
monary diseases. While the results of studies on the availability of
the test in adults are contradictory, there are limited data concerning
the usefulness of 6MWT in children with JSSc.
Objectives: To evaluate the walking distance and oxygen desatur-
ation during the 6MWT in JSSc, and to establish correlations between
the 6MWT results and other clinical findings in children with JSSc.
Methods: 25 JSSc, 27 Juvenile Systemic Lupus Erythematosus (JSLE)
and 30 healthy controls were included. The test is conducted accord-
ing to the guidelines recommended by the American Thoracic Soci-
ety (ATS), standardized in 2002. The Borg Scale which is a well-
validated scoring system on a 0-10 point scale was used to deter-
mine the patient self reported fatigue and dyspnea levels.
Results: A total of 25 (22 female/3 male) JSSc , 27 (21 female/6 male)
Juvenile Systemic Lupus Erythematosus (JSLE) and 30 (16 female/14
male) healthy controls were included. The mean age of patients was
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 147 of 24316,44±3,19 years for JSSc, 16,74±3,59 years for JSLE and 15,57±1,50
years for healthy controls. There was no significant difference
between patients and healthy controls according to the age at the
study.
Mean walking distance was 480,18 ± 47,22 m in JSSc; 513,66 ± 51,70
m in JSLE and 553,21 ± 41,65 m in healthy controls. JSSc pa-
tients walked significantly less distance comparing to controls (p
<0.001). The mean oxygen saturation in JSSc was 98.0 ± 0.9% before
the test and 97.5 ± 1.6% after the test (p = 0,01). JSSc patients with
lung involvement walked less than those without lung involve-
ment (476.08 ± 47.13 m vs .483.96 ± 48.89 m). However, there was
no statistically significant difference (p = 0.68). JSSc patients with car-
bon monoxide diffusion capacity (DLco) ≤ 60% walked less than
those with DLco ≥ 60% (466.92 ± 45.74 m vs. 485,33 ± 48,05 m). How-
ever, no statistically significant correlation was detected. (p =
0.39). No significant difference was found when patients walking dis-
tances were compared to activity scores (Juvenile Systemic Sclerosis
Severity Score(J4S)) (p = 0.26). Lower extremity pain during and after
the test was more statistically significant in JSSc patients (p = 0.001).
Patients with myalgia were found to walk less than those without
myalgia (498.61 ± 46.94 m vs. 460.20 ± 40.29 m) (p = 0.038).
Conclusion: The findings of our study showed that patients with
JSSc have limited walking distances.The pulmonary involvement
and associatively high disease activity score are unable to deter-
mine the results of the 6MWT in JSSc patients. However, the
musculoskeletal involvement may influence the walk distance and
complicate interpretation of the 6MWT in JSSc patients. Since
there is a limited number of studies regarding the role of 6MWT
in the evaluation of JSSc, we believe that the results of our study
will enlighten the future studies.
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Introduction: Juvenile localized scleroderma (jLScle), a limited
autoimmune disease, theoretically renders patients susceptible to in-
fections due to their defective immune system and the immunosup-
pressive treatment. However we lack data regarding response and
long-term immunity conveyed by specific vaccines.At present, we are
experiencing major measles’ outbreaks throughout Europe.Measles
infection harbors potentially serious consequences. Rubella infection,
on the other hand, may harbor significant long-term sequences for
the mother and the fetus. Thus it is critical that we understand the
impact of jLScle on young patients’ immunity to measles and rubella.
Objectives: In this study we determined the immune status against
measles and rubella in previously vaccinated jScle patients, prior to
commencement of treatment and at one and three years, and com-
pared this to healthy controls.
Methods: This was a prospective controlled study including 28 newly
diagnosed jLScle patients and 56 healthy controls. All participants
had two doses of the live attenuated MMR vaccine in early child-
hood. Demographic, clinical and laboratory data were collected. Type
and duration of treatment was also recorded. Seroprotection rates
and rubella-measles-IgG titers were measured at enrolment (prior to
commencement of treatment) and at 1 and 3 years. Total IgG levels
were measured simultaneously. Measles and rubella specific IgG anti-
bodies were assessed by ELISA and were expressed as GMC’s. The
cut-off value for seroprotection was deemed at 10IU/ml and 120IU/
ml for measles and rubella respectively. The Hospital’s Research andEthics’ Committee approved the study; written informed consent was
obtained. Statistical significance was set at p<0.05 and analyses were
conducted using STATA 13.0.
Results: The two groups had similar demographic characteristics,
vaccination history and immunization status. No significant differ-
ences were detected in terms of vaccine type, time interval between
the two vaccines as well as mean elapsed time from last vaccination
to blood sampling. Seroprotection rates were adequate for both
groups. Nonetheless, the jLScle group had marginally lower seropro-
tection rates at one and three years (both measles and rubella).
Measles-specific-GMC’s were similar between the patient and control
group at all time points. Rubella-specific-GMC’s were significantly
lower in the jLScle compared to the control group (p<0.01) at one
and three years’ follow up but not at diagnosis. None of the partici-
pants had hypogammaglobulinaemia at the time of blood sampling
The use of methotrexate did not seem to exceed any significant effect
on seroprotection rates but had a negative impact on rubella-GMC’s.
The use and duration of systemic steroids as well as topical treatments
did not have any effect on rubella or measles-specific-GMC’s.
Conclusion: In conclusion, although seroprotection rates were similar
between the two groups, rubella GMC’s were significantly lower in
the jSLcle group. Further studies are required to address the question
of long-term immunity conveyed by immunizations given at an early
stage in children with rheumatic diseases.
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Introduction: Systemic sclerosis is an auto-immune disease charac-
terized by small-vessel vasculopathy, dysregulation of innate and
adaptive immunity, and extensive fibrosis of the skin and visceral
organs which can lead to loss of organ function. However its
pathogenesis is not completely understood. In the past few years
research in adult patients has focused on the role of type I inter-
feron in the pathogenesis of the disease, with variants in several
interferon related genes being identified as a genetic risk factor.
Objectives: The aim of this study was to characterize the type I
interferon response in paediatric patients with systemic sclerosis
as well as to assess the potential contribution of genetic variants
in IRF7 to this response.
Methods: DNA was extracted from saliva using Oragene saliva
collection pods and DNA extraction protocol. Exons 1 to 9 of the
IRF7 gene were sequenced by Sanger using an AB1 sequencer.
Peripheral blood was collected to PAXgene tubes for RNA
stabilization and extraction. RNA was transformed into c-DNA
using High Capacity c-DNA Reverse Transcriptase kit. Changes in
gene expression were assessed by real-time polymerase chain re-
action. The interferon score was calculated by assessing the rela-
tive expression of six interferon related genes (SIGLEC1, RSAD2,
ISG15, IFI44L, IFI27, IFIT1). Patients’ demographics were collected
from medical records.
Results: Two patients with paediatric-onset systemic sclerosis were re-
cruited into this study. Both patients were female and black British. Pa-
tient 1 is 16 years old and has long standing disease with multiple
organ involvement diagnosed at the age of 9 years. Patient 2 is 5 years
old and has early stage disease (less than 6 months since diagnosis).
A high interferon score was detected in Patient 1, with long standing
disease, but not in Patient 2. Patient 1 also had a modest increase in
expression of IRF7 (2.3 fold), but not in the other interferon related
genes tested.
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same variant, p.K192E, in both patients. Although frequent in the
general population, this variant has been linked in GWAS studies to
increased risk of Systemic Lupus Erythematosus (SLE) and Rheuma-
toid Arthritis.
Conclusion: Our results show an increased type I interferon response
in a patient with long standing disease. A high interferon score has
been shown both in long standing disease and early stage disease in
adult patients. However, our patient with early stage disease did not
have increased expression of any of the interferon related genes
tested. Interestingly, both patients presented the same variant in
IRF7, which has been linked with disease risk for SLE. Variants in
other interferon related genes could eventually have additional rele-
vance to the disease phenotype. Larger studies in paediatric patients
with systemic sclerosis are needed to determine the relative import-
ance of type I interferon response in the pathogenesis and progres-
sion of this disease. Informed consent to publish had been obtianed.
Disclosure of Interest
None Declared
P283
PROSPECTIVE VALIDATION OF CONE BEAM COMPUTED
TOMOGRAPHY FOR THE ASSESSMENT OF DISEASE PROGRESSION
IN LINEAR SCLERODERMA OF THE FACE IN COMPARISON WITH
THE CURRENTLY USED TECHNIQUES
Alessandra Meneghel1, Stefano Puggina2, Eleni Kamburi1, Giorgia
Martini1, Fabio Vittadello1, Francesco Zulian1
1Department of Woman and Child Healt, University Hospital of Padua,
PEDIATRIC RHEUMATOLOGY UNIT, Padova; 2Iniziativa Medica, Monselice
(PD), Italy
Correspondence: Alessandra Meneghel
Pediatric Rheumatology 2018, 16(Suppl 2):P283
Introduction: Currently, the techniques used for the monitoring of
Localized Scleroderma of the face (LSF) have significant limitations.
Objectives: We prospectively evaluated the reliability of the Cone
Beam Computed Tomography (CBCT), a non-invasive, reproducible
technique with a radiation dose lower than a conventional CT, to
quantify changes of facial asymmetry over time as compared with
the clinical and instrumental methods currently in use.
Methods: Consecutive patients with LSF, followed from January 2009
to December 2017 at our Pediatric Rheumatology Center, entered
the study. CBCT was carried out following the same method previ-
ously described1. Measurements of total thickness, soft tissue and
bone thickness were taken in both affected and unaffected sides of
the case. These data allowed us to calculate the Absolute Rate of
Change (ARC) of the lesion over time and the comparison with the
ARC obtained from the healthy side, allowed us to calculate the Rela-
tive Rate of Change (RRC). The judgment of stability or worsening of
the lesion was compared with the one derived from the physician
global assessment (PGA), infrared teletermography (IT) and sequen-
tial clinical photographs (SCP). The Sensitivity-to-change of CBCT was
assessed by Standardized Response Mean (SRM) and Effect Size (ES)
Results: 26 subjects with LSF, 15 females and 11 males, mean age
7.6 years (range 1.2-17.8) entered the study. 18 patients presented
Parry Romberg syndrome (PRS), 5 En coup de sabre (ECDS) and 3 fa-
cial hemiatrophy (FH). The disease duration at the first CBCT was 3.7
years (range 0-28). During the study period, 69 CBCTs have been per-
formed. On average, each patient underwent 2.7 CBCTs, 15 patients
underwent two CBCTs, 8 patients three, and one patient 4, 5 or 6
CBCTs each, respectively. In all, the total thickness of the affected
and unaffected side were evaluated. A worsening of CBCT with RRC
> 5%, was found in 10 out of 40 evaluations (25%). The agreement
between the CBCT and SCP was found in 20 out of 37 evaluations
(54%). The comparison of the four clinical-instrumental methods per-
formed in 40 evaluations, revealed an overall agreement of 66.7%.
CBCT results were consistent with the PGA in 67.6% evaluations, with
IT in 62.2%. The sensitivity to change of CBCT over time was very
good at the mandibular condyle level (SRM values ranging from 0.53to 0.77, ES 0.40-0.50) on the healthy side. The affected side reported
SMR and ES values <0.5.
Conclusion: CBCT is an innovative technique that allows to assess
the changes of the affected side, usually the non-growth, of LSF in
comparison with the healthy side, during the developmental phase
of pediatric patients. CBCT represents a reliable and objective tool for
monitoring LSF over time in association with the other clinical-
instrumental methods currently in use. Its practical benefit lies in its
potential of correctly addressing therapeutic changes including the
timing of start the reconstructive surgical process.
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Introduction: Raynaud's phenomenon (RP) is a condition characterized
by periodical vasospasm in response to cold temperatures or emotional
stress exposure, that in the vast majority of patients exists without
other disorders, but sometimes is associated with several autoimmune
rheumatic diseases and, to distinguish between these two types, clin-
ical examination, laboratory findings, nailfold capillaroscopy and com-
puterized color telethermography (CCTT) are necessary.
Objectives: The aim of this research was to analyze RP features in
children in correlation with the most frequently associated laboratory
tests, CCTT and nailfold capillaroscopy.
Methods: This retrospective study included children who were clinically
recognized as RP in the period from 2011 to 2017 at University Hospital
Centre Zagreb. Laboratory data included serum level of IgG, C3, C4,
CH50, RF, presence of ANA and ANCAs. Nailfold capillaroscopy and
CCTT were utilized to distinguish between primary and secondary RP.
McNemar's test was used to evaluate whether capillaroscopy or CCTT
was more effective in the diagnosis of secondary RP and to estimate
was there a difference between capillaroscopy and CCTT in matching
with the results of immunological laboratory findings.
Results: Out of 224 children with RP, 169 were females (75.4%) and 55
were males (24.6%) with female/male ratio 3:1. CCTT was performed in
188 patients (83.9%), nailfold capillaroscopy in 89 patients (39.7%) and
both investigations in 80 patients (35.7%). CCTT classificated 15 patients
as primary RP, 57 patients as secondary RP (among them, 33 had at
least one pathological laboratory finding), while in 47 patients no classi-
fication could be made. In 69 patients clinically recognized as RP, CCTT
findings were normal. Among patients classificated as secondary RP on
CCTT, the most of them, 14 (24.6%), were diagnosed with juvenile idio-
pathic arthritis (JIA). There were 5 patients (8.8%) with systemic sclerosis
(SSc), 2 (3.5%) with mixed connective tissue disease (MCTD), 1 (1.7%)
with systemic lupus erythematosus, 11 (19.3%) with undifferentiated
connective tissue disease (UCTD), whilst 24 patients (42.1%) had no evi-
dent other disease. The appearance of abnormal capillaroscopic pattern
was found in 17 patients (among them, 11 had at least one patho-
logical laboratory finding) and nonspecific capillaroscopic alterations
were noticed in 27 patients (among them, 16 had at least one patho-
logical laboratory finding), while 45 patients had normal capillaroscopic
findings. Among patients with the appearance of abnormal capillaro-
scopic pattern, 5 (29.4%) were diagnosed with SSc, 3 (17.6%) with JIA, 2
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 149 of 243(11.8%) with MCTD, 1 (5.9%) with dermatomyositis, 2 (11.8%) with
UCTD, whilst 4 patients (23.5%) had no evident rheumatic disease. All
patients with RP diagnosed with SSc and MCTD had both the appear-
ance of abnormal capillaroscopic pattern and CCTT findings consistent
with secondary RP. No statistically significant difference between capil-
laroscopy and CCTT in predicting the diagnosis of secondary RP was
determined (McNemar's test, χ2 = 0.042, p = 0.838) nor was there sig-
nificant difference between capillaroscopy and CCTT in regard to the
results of laboratory findings (χ2 = 1.042, p = 0.307).
Conclusion: Both nailfold capillaroscopy and CCTT have important
role in the diagnosis of RP in children. We found that both methods
were equally effective in the diagnosis of secondary RP and that
there was no difference between them in regard to the results of im-
munological laboratory findings distinctive with secondary RP.
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Introduction: Juvenile localized scleroderma (JLS) is a rare condition
in childhood. we studied the clinical features of JLS in children who
refered to Children's Medical Center of Tehran University of Medical
Sciences between 2005 and 2017.
Objectives: Juvenile localized scleroderma (JLS) is a rare condition in
childhood. we studied the clinical features of JLS in children who
refered to Children's Medical Center of Tehran University of Medical
Sciences between 2005 and 2017.
Methods: The study was conducted by collecting information on the
demographics, family history, clinical and laboratory features, and
treatment of patients with Juvenile localized scleroderma.
Results: A total of 41 patients , 28 (68.29%) were female and13
(31.70%) male. The female to male ratio was 2.15:1. The mean age of
onset was 9.5 years(range 2-16). The mean duration of disease from
diagnosis was 1.5 years . The most common of constitutional sign
were fatigue 36(87.80%)and weight loss 21(51.21%) .And other signs
were : articular 22(53.65%), raynaud ҆s phenomen 11(26.82%) , vascu-
lar 12(29.26%), gastrointestinal 3 (7.31%), Uveitis 2(4.87%).None of
patients have symptoms of involved cardiac,pulmonary and renal .
Six patients (14.63%) had a positive family history for rheumatic or
autoimmune diseases. ANA was positive in 56.09% of the patients.
Scl-70 was detected in 7.31% of the patients, anticentromere anti-
body in 2.43% ,anti-double-stranded DNA in 7.31%, anti-cardiolipin
antibody in 14.63% and rheumatoid factor in 19.51%.Oral prednisol-
one and Methotrexate were the drugs most frequently used.
Conclusion: Treatment with oral corticosteroid and methotrexate led
to disease improvement in the most patients and the prognosis of
these patients was good in our study.
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Pediatric Rheumatology 2018, 16(Suppl 2):P286Introduction: RASopathies are neurodevelopmental syndrome
caused by heterozygosity for germline mutations in genes that en-
code protein components of RAS/MAPK pathway. There are several
reports of RASopathies complicated with autoimmune disease, such
as Noonan syndrome with germline mutation of PTPN11 or SHOC2
associated with systemic lupus erythematosus (SLE) [1]. Recently, it is
revealed that somatic mutations of KRAS and NRAS cause auto-
immune lymphoproliferative syndrome (ALPS)-like disease, which
called RAS-associated-ALPS-like disease (RALD) [2]. Some patients with
RALD showed clinical and laboratory features of SLE.
Objectives: We aim to investigate the relationship between BRAF-as-
sociated RASopathy and development of SLE.
Methods: We present a Japanese case of cardio-facio-cutaneous syn-
drome with germline BRAF mutation complicated with SLE refractory
to conventional treatments.
Results: A 5-year-old girl with cardio-facio-cutaneous syndrome with
germline mutation of BRAF was referred to hospital due to recurrent
fever and erythema. Laboratory data showed pancytopenia, hypocom-
plementemia, high erythrocyte sedimentation rate, positive antinuclear
antibody, elevation of serum anti-dsDNA antibody, and proteinuria. She
was diagnosed as having SLE. The histological findings of renal biopsy
showed lupus nephritis ISN/RPS class III. She received three times of
methylprednisolone pulse therapy and combination of mycophenolate
mofetil and tacrolimus that showed poor response. Interestingly, per-
ipheral blood immunophenotyping by flow cytometry showed in-
creased TCRαβ+CD4-CD8-double negative T cell, which indicate
dysfunction of T cell apoptosis such as ALPS.
Conclusion: This is the first report of SLE with germline mutation of
BRAF. The prognosis and clinical features of SLE with RASopathies are
various depending on the related component of RAS/MAPK pathway.
This case would be more severe compared with previous reports. To
investigate the difference of each gene mutation of RASopaties asso-
ciated with SLE might lead to new insights of monogenic SLE.
References
[1] Bader-Meunier B, et al. Are RASopathies new monogenic predisposing
conditions to the development of systemic lupus erythematosus? Case
report and systematic review of the literature. Semin Arthritis Rheum.
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Introduction: Anti-C1q has been associated with systemic lupus ery-
thematosus (SLE) as well as in other connective tissue diseases. They
have been considered as a marker for disease activity and presence
of nephritis in previous studies
Objectives: To determine the prevalence of anti- C1q antibodies in
the pediatric SLE population
To determine clinical associations of elevated anti- C1q antibody
levels especially with lupus nephritis.
Methods: Sera of pediatric SLE patients who fulfilled ACR criteria for
SLE were recruited. After obtaining informed consent, blood samples
were tested for anti- C1q antibody by commercially available ELISA
kit. Prevalence of anti-C1q and its association with lupus nephritis
were determined.
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 150 of 243Results: Out of total 150 children with SLE, anti- C1q positivity was
present in 95 children (64%), at a cut off value of 20U/ml. Children
with proteinuria, low C3, low C4 and anti dsDNA positivity had were
significantly more likely to have anti- C1q antibody positivity. Chil-
dren with lupus nephritis were significantly more likely to have anti
C1q antibodies positive than children without renal involvement
(74% vs. 51% , p= 0.02). Among the children with lupus nephritis,
children with active renal disease were more likely to have anti- C1q
positivity than in children with quiescent disease (88% vs. 53% , p=
0.002). Anti-C1q antibodies had a sensitivity of 74% and specificity of
54% at a cut off value of 22U/L , for renal disease in pSLE
Conclusion: Out study confirms previous findings of the association
of anti-C1q antibodies with nephritis and disease activity in
pSLE. Anti-C1q antibody titers were found to have positive correl-
ation with renal disease in children with pediatric SLE, and could be
used as an adjunctive biomarker in monitoring disease activity in
children with lupus nephritis.
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Introduction: Natural killer (NK) cells are critical for modulating im-
mune response1. JSLE patients studies demonstrated depleted number
of NK cells and defective cytolysis that related with disease activity1,2.
Objectives: To evaluate whether apoptosis-related proteins expres-
sions in NK cells contribute to its defects in JSLE patients and relate
with disease activity parameters, neuropsychiatric involvement and
nephritis.
Methods: Thirty-five JSLE patients (30 girls, mean age 15.1±2.7 yrs,
ACR criteria), 7 sex- and age-matched healthy individuals (6 girls,
mean age 13.0±2.9), 4 JIA disease controls (3 girls, mean age 10.7
±4.8 yrs, ILAR criteria) and 13 JDM controls (8 girls, mean age 13.1
±3.5 yrs, Bohan and Peter criteria) had Fas, FasL, TRAIL, TNFR1, Bcl-2,
Bax, Bim and Caspase 3 expressions in NK (CD3-CD16+CD56+) cells
simultaneously determined by flow cytometry. Disease activity pa-
rameters included SLEDAI score, ERS, CRP, anti-dsDNA, C3 and C4
levels. Eleven patients had active disease (SLEDAI ≥4), 21 had positive
anti-dsDNA, 9 had neuropsychiatric involvement and 28 had neph-
ritis. Mann-Whitney test was used for two group comparisons and
Spearman’s rank for correlations. P values <0.05 were considered
significant.
Results: Reduced proportion of TRAIL-expressing NK cells was ob-
served in JSLE patients (median 11.4 vs. 51.9%, p=0.03), in those with
active disease (median 5.4%, p=0.02), in patients with positive anti-
dsDNA (median 6.6%, p=0.009), in those without neuropsychiatric in-
volvement (median 13.8%, p=0.03) and in patients with nephritis
(11.4%, p=0.02) compared with healthy controls. Reduced proportion
of Bcl-2-expressing NK cells was seen in JSLE patients (median 81.8
vs. 94.3%, p=0.04), in those with inactive disease (83.7%, p=0.04) and
in patients without neuropsychiatric involvement (median 80.0%,
p=0.03) compared with healthy controls. JSLE patients with nephritis
also had increased proportion of caspase 3-expressing NK cells(median 2.5 vs. 1.0%, p=0.03) compared with healthy controls. Sur-
prisingly, proportion of FasL-expressing NK cells positively correlated
with SLEDAI score (r=0.6, p=0.002) and with C3 levels (r=0.5,
p=0.005). No differences were observed comparing JSLE patients, JIA
and JDM disease controls.
Conclusion: JSLE patients present altered expressions of TRAIL, Bcl-2
and caspase 3 apoptosis-related proteins in NK cells, particularly in
those with active disease, with positive anti-dsDNA, with nephritis
and those without neuropsychiatric involvement, which may contrib-
ute to NK cells defects and consequently to disease pathogenesis.
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Introduction: SLE has been mainly associated with primary immuno-
deficiencies of early complement components and selective IgA defi-
ciency1,2. LRBA deficiency leads to immuno-deficiency of heterogenous
presentation, as respiratory infections, hypogammaglobulinemia, re-
duced number of specific B cell subsets, functional T cell defects and ab-
errant autophagy3. LRBA gene mutations have also been associated
with autoimmune diseases, including inflammatory bowel disease,
endocrinopathy, autoimmune hemolytic anemia and thrombocytopenia,
and occasionally arthritis but not SLE.
Objectives: To report clinical and laboratory features of a JSLE pa-
tient carrying a novel mutation in LRBA gene.
Methods: Whole exome sequencing was performed from -80ºC
stored genomic DNA (PIDBioRep)4.
Results: A 10-year-old girl born from healthy consanguineous parents
presented with wheezing and cough since 1-year-old, and respiratory
infections, arthralgia and chronic bloodless liquid diarrhea since 7 years
of age. A sister with bronchitis, few diarrhea episodes and hypertiroid-
ism had been diagnosed with Graves’ disease. Our patient initial tests
showed normal sodium and chloride sweat dosage, negative stool cul-
tures, non-specific colitis in colon biopsy, increased IgG, decreased IgM
that afterwards normalized (39 mg/dL and 130 mg/dL, respectively),
normal IgE and decreased IgA (1.0 mg/dL), normal C3, C4 and CH50
levels and immunophenotyping. After 6-month follow-up she had poly-
dipsia and polyuria, serum glucose was 724 mg/dL, anti-insulin anti-
body was positive while anti-GAD and anti-IA2 were negative.
Diagnosis of diabetes mellitus was established and NPH insulin initi-
ated. After 1-year follow-up she presented acute polyarthritis (cervical
spine, left elbow, wrists and knees), autoimmune hemolytic anemia
(hemoglobin of 7.3 g/dL and positive Coombs test), alopecia, malar rash
and pericarditis. Autoantibodies analyzes revealed homogeneous ANA
1/1,280, positive anti-dsDNA (119, normal up to 50 IU/mL), anti-
cardiolipin IgG (13 GPL, normal up to 10 U/mL), anti-TG and anti-TPO
with normal free T4 level, and negative anti-Sm, antiSSA/Ro and
antiSSB/La. As patient fulfilled criteria for JSLE, prednisone, hydroxy-
chloroquine and cyclosporine were initiated. During follow-up she pre-
sented respiratory infections, venous thrombosis, septic shock and died
at 20 years of age from pneumonia. The whole exome sequencing
identified a novel homozygous 1-bp deletion in exon 44 of the LBRA
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 151 of 243gene, resulting in a frameshift with introduction of a premature stop
codon (p.Trp2248Glyfs*26). This mutation is located in a highly con-
served region within the BEACH domain that interacts with CTLA4 and
prevents its degradation, and is predicted to result in nonsense-
mediated mRNA decay of the transcript, leading to absence of protein.
Conclusion: LRBA-deficient patients have been shown to present de-
creased intracellular and cell-surface CTLA4 and reduced Treg function,
which is likely to explain their multiple autoimmune syndromes, now
shown to include SLE. Therefore, abatacept might be a therapeutic op-
tion for JSLE cases in which LRBA deficiency may be suspected, such as
in patients presenting other autoimmune diseases. Informed consent
for publication had been obtained from the parents.
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Introduction: Systemic Lupus Erythematosus (SLE) is a complex auto-
immune disease. Genetic an environmental factors intervene in its
physiopathology. It is dercribed the involvement of estrogens in the
pathogenesis and course of the disease1. In pediatric patients the dif-
ferences in frequency of SLE are smaller between male and female
individuals. Variations in the clinical presentation and severity of both
adult and pediatric male patients are described in the literature2.
Objectives: To describe the clinical and paraclinical characteristics of a
cohort of male patients with Juvenile Systemic Lupus Erythematosus.
Methods: Multicenter, descriptive, retrospective study. A unique data
collection format was used. Analysis of the information was made
with SPSS20
Results: N = 57. Mean age at diagnosis 12 years (SD 2.8 and range 4-17
years), 60%> 12 years. Average follow-up time of 26 months (SD 23m).
The commitment by organs /systems at debut was: 1. Skin in 52.6% 2.
Oral / nasal ulcers 16% 3. Arthritis 56% (poly 49%) 4. Serositis 32% 5.
Renal 68%, kidney biopsy at onset 18/39, 61% class IV nephropathy,
15% required dialysis 6. Hematologic: 21% hemolytic anemia, 19%
thrombocytopenia , 33% leukopenia / lymphopenia 7. Neurological
5.3%. Autoantibody profile: 95% positive antinuclear antibodies, titers>
1: 640 63% and 54% mottled pattern. 77% had positive anti-DNA anti-
bodies, 51% positive anti-SM antibodies, C3 hypocomplementemia
95% and C4 hypocomplementemia 97%.Other clinical manifestations at
onset: Antiphospholipid syndrome 14%, 7% Hashimoto's thyroiditis,14% infection (88% pneumonia). All patients received steroid at debut
60% in IV pulses and 53% cyclophosphamide (CFM). During follow-up,
11 patients had renal involvement, 43% had Class IV nephropathy. Im-
munosuppressants frequency during the course was: 42% CFM, 53%
Azathioprine, 30% Mycophenolate mofetil, 10% Methotrexate. 28%
used more than one medication. 10% of patients required Rituximab.
Complications during follow-up: 23% short stature, 18% pubertal delay,
7% depression, cataract and chronic dialysis, 5% osteoporosis 3.5%
fibromyalgia and 2% kidney transplant. Mortality 10%. A statistically sig-
nificant difference was found between prepubertal disease onset
(under 12 years of age) and frequency of short stature (p 0.019). There
were no statistical differences in clinical manifestations at onset, auto-
antibody profile, treatment and other complications between pre- and
postpubertal patients.
Conclusion: In this cohort of male patients with juvenile SLE the
mean age of diagnosis was in early adolescence with a higher fre-
quency of cases in postpubertal patients. The skin, hematological
and renal manifestations were the most frequent at debut. The pa-
tients required an intensive treatment for the control of the disease
and had a high prevalence of complications especially in relation to
growth and a mortality of 10%. Lupus in this cohort of males be-
haves in a similar manner to that reported in the literature of pa-
tients with juvenile SLE.
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Introduction: In recent years, several mutations located in the TREX1
gene have been associated with different disease phenotypes.
Aicardi-Goutières syndrome, familiar chilblain lupus (FCL), systemic
lupus erythematosus (SLE) and retinal vasculopathy with cerebral leu-
kodystrophy are included among these conditions.
Objectives: To describe the clinical and analytical characteristics of a
patient with a homozygous mutation in the TREX1 gene.
Methods: Clinical chart review
Results: We present a boy, of gypsy ethnicity and son of non-
consanguineous parents, who consulted in our unit at 6 years of age
due to swelling, limitation and pain affecting knees, ankles and el-
bows. The child also reported recurrent severe episodes of pallor and
erythema involving fingers and toes during several years, which had
even led to amputation of the distal phalanx of the second finger of
the left hand due to necrosis. Initially he was diagnosed with Juvenile
Idiopathic Arthritis (JIA), antinuclear antibodies (ANA) negative, and
secondary Raynaud syndrome. Etanercept and methotrexate were
started with modest response. However, two years later, several in-
tense chilblain appeared, affecting both auricular pavilions, and all
fingers and toes. Given the suspicion of associated vasculopathy, im-
munological screening was performed, with no relevant findings; and
a genetic study of autoinflammatory/autoimmune diseases was car-
ried out by NGS panel, detecting a homozygous mutation in the
TREX1 (R97H). This mutation has been previously reported as associ-
ated with Aicardi-Goutières syndrome, and also described in one pa-
tient with early onset SLE who presented cerebral vasculitis one year
after disease onset1,2. Nevertheless, the clinical features and the la-
boratory results of our patient (Raynaud syndrome, chilblain and
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 152 of 243arthritis with no neurologic symptoms and absence of autoantibody)
permit to include him among familiar chilblain lupus phenotype2.
When the family tree data were collected, a history of chilblain, deaf-
ness, abortion due to malformations, neurological delay from the
neonatal period, arthritis and amputations were found through both
family branches. A genetic study of the patient relatives will be per-
formed in the near future, in order to confirm wether the various fa-
miliar antecedents are related to the mentioned mutation as this
option seems probable.
Conclusion: To our knowledge, this is the first time that a R97H mu-
tation in homozygosis is described in a patient with FCL phenotype.
However, the family history suggests that he same mutation may be
associated to different phenotypes too, as has been previously de-
scribed in the literature2,3.
Written informed consent has been obtained
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Introduction: Protein Losing Enteropathy (PLE) is a rare expression of
intestinal diseases characterized by loss of serum proteins into the
gut lumen. PLE has been seldom associated to Systemic Lupus Ery-
thematosus (SLE) and has been rarely described in infancy as clinical
presentation of SLE.
Objectives: To describe a case of pediatric Lupus Protein Losing En-
teropathy (LUPLE) and provide an update on the characteristics of
LUPLE in children.
Methods: Report of a patient with recurrent unexplained episodes of
hypoalbuminemia and review of literature concerning LUPLE, carried
out searching MEDLINE database via PubMed, with no limits on the
date of publications.
Results: A 10-year-old Vietnamese boy was referred to our Pediatric
Rheumatology Unit for the third episode of sudden anasarca. He previ-
ously presented two steroid-responsive episodes of hypoalbuminemia
with oedema, ascribed to nephropathy, even if no nephrotic protein-
uria was detected. At the admission, the serum albumin was undetect-
able and raised levels of acute phase reactants were detected
(Erythrocyte sedimentation rate: 75 mm/h; C-reactive protein: 3,85 mg/
dl). Liver and kidney function tests were normal and 24-h urinary pro-
tein quantification was negative for proteinuria. An increase of faecal
alpha-1 antitrypsin (αAT) was disclosed (7.21 mg/g with normal range
0.38-0.5) and 99mTc-labelled human serum albumin scintigraphy (99mTc-
HAS) confirmed severe PLE, mostly deriving from the duodenojejunal
area. Gastrointestinal biopsies revealed gastric and duodenal lymphan-
giectasias and a colonic mucosal chronic inflammation. Positivity of an-
tinuclear antibody (ANA) with speckled appearance and SSA/SSB
antibodies (146 U and 70 U with normal range <20) was detected.
Thereby, the diagnosis of LUPLE was suspected. Treatment with intra-
venous methylprednisolone was started, followed by daily oral prednis-
one combined to daily oral azathioprine, with a progressive
improvement in values of serum albumin and clinical response. Almost
two years later, the patient developed other clinical findings that ful-
filled the Systemic Lupus International Collaborating Clinics (SLICC)
diagnostic criteria for SLE.
The systematic literature searching revealed 7 cases of LUPLE in chil-
dren younger than 16 years. Considering reported cases and the
present case, this condition is prevalent in females (6/8) and in Asi-
atic patients (3/8). PLE could represent either the first presentation ofthe collagen disease (4/8) or a successive complication. All the 8 pa-
tients showed peripheral oedema but only one patient presented
gastrointestinal symptoms, such as diarrhoea and abdominal pain. To
identify gastrointestinal protein loss and protein leakage site, αAT
faecal clearance and 99mTc-HAS are respectively the most specific
diagnostic methods. As concerned gastrointestinal histology, non-
specific inflammation involving at least one of duodenum and colon
was observed in 5 patients and lymphangiectasias were detected in
our and in another patient. Concerning autoimmune profile, ANA
antibody is usually present; positivity of anti-DNA and anti-SSA/SSB is
described in the half of the reported children. All but one reported
pediatric cases were treated with both steroids and immunosuppres-
sive treatment in order to control gastrointestinal disease or the
other manifestations of the autoimmune disease.
Conclusion: The diagnosis of LUPLE has to be suspected in every
child with hypoalbuminemia without evidence of renal and hepatic
disease, even without gastrointestinal symptoms. It could represent a
manifestation of the disease either already diagnosticated or not de-
tected yet.
Written consent for publication was obtained from the parents of
patient.
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Introduction: Pertussis infections have increased worldwide and
knowledge on the immune response after adult Tdap vaccine is
scarce in patients with autoimmune diseases.
Objectives: This study evaluated the immune response through anti-
body profile after Tdap vaccine in juvenile systemic lupus erythema-
tosus (jSLE) and controls. The jSLE group was also monitored for
possible disease flares.
Methods: We included 21 jSLE and 19 healthy adolescents who had
already received three whole-cell DTP vaccine (DTwP) plus two
booster doses and had lymphocytes count > 500. Blood samples
were collected immediately before the Tdap vaccine and 14 and 28
days thereafter.Tetanus, diphtheria and pertussis antibodies were
tested by ELISA.
Results: jSLE group median age was 15y (9-18y) and control group,
15y (9-15.6y). The immune response was evaluated according to anti-
body levels as shown in Table 1. Both groups had a similar response
for antibody levels for tetanus and diphtheria. The opposite was seen
for pertussis, with similar antibody levels. In the control group 96.7%
on D14 and 100% on D28 seroconverted to pertussis (p=0.012). On
the other hand, in the jSLE group, many adolescents did not sero-
convert on D14 and D28 (54.5% vs 63.6%, p = 0.581). Protective
levels were noted for tetanus (p=0.031) and diphtheria (p<0.001) in
jSLE group. No difference was found between groups on the fre-
quency of adverse events (p=0.081), except for local tenderness,
which was more frequent in the control group (p=0.042). Disease
flares were not observed after the vaccine.
Conclusion: In this study, children and adolescents with jSLE and
healthy controls showed adequate humoral immune response to tet-
anus and diphtheria. The response to pertussis after Tdap vaccine
seemed to be less evident in jSLE patients.
Disclosure of Interest
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Table 1 (abstract P293). Tetanus, diphtheria and pertussis antibodies
for jSLE patients and control group on days 0, 14 and 28 (mean and SD)
D0 D14 D28 p1
Tetanus
Control 0.33 ± 0.45 B 41.46 ± 41.73A 47.50 ± 44.07 A <0.001b
Lupus 0.20 ± 0.18 B’ 39.08 ± 54.76 A’ 46.57 ± 59.77 A’ <0.001b
Diphtheria
Control 1.12 ± 1.40 B 40.43 ± 33.23 A 29.98 ± 21.17 A <0.001b
Lupus 0.21 ± 0.28 B’ 14.67 ± 21.99 A’ 11.65 ± 14.20 A’ <0.001b
Pertussis
Control 8.16 ± 8.26 B 90.68 ± 105,69 A 76.81 ± 90,59 A <0.001b
Lupus 15.55 ± 13.50 B’ 53.35 ± 50.69 A’ 52.70 ± 50.38 A’ <0.001b
p1 – Friedman test (b)
(A) and (B) mean differences in Dunn-Bonferroni multiple comparison test in
the control group
(A’) and (B’) mean differences in Dunn-Bonferroni multiple comparison test in
the jSLE group
Kolmogorov-Smirnov test for tetanus (p=0.007), diphtheria (p<0.001) and
pertussis (p<0.001)
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Introduction: Bullous systemic lupus erythematosus (BSLE) is an
autoantibody mediated vesicobullous disease characterized by pres-
ence of circulating anti- type VII collagen antibodies. BSLE manifests
commonly in second or third decade of life and is rarely seen in
children.
Objectives: We describe this rare variant in a girl who was difficult to
treat in the initial weeks but is now in remission.
Methods: A 11 year old female initially presented to another centre
in June 2017 with arthralgia, hair fall and oral ulcers. She was diag-
nosed as systemic lupus with no other organ involvement and
started on hydroxychloroquine.
She presented to us in November 2017 - 5 months later, with extensive
skin eruptions on face, neck, trunk, extremities and oral mucosa since 3
weeks. On examination, her weight was 54 kg with height of 155 cm,
she had tense vesico-bullous lesions filled with clear fluid on face, neck,
trunk, extremities and in the oral cavity. Systemic examination was nor-
mal. Her SLEDAI score was 4. There was no recent drug ingestion.
Her hemogram, erythrocyte sedimentation rate and urinalysis were
normal, Direct Coombs Test was 1+ with C3 - 53.3 mg/dl, C4- 11.5
mg/dl and negative dsDNA, APLA IgG/IgM and lupus anticoagulant.
Skin biopsy was performed and immunofluorescence examination
showed IgG and C3 positive linear deposits at the dermo-epidermal
junction with positive IgM, IgA, C1q and fibrinogen.
Results: She was pulsed with methylprednisolone (30mg/kg) for 3
consecutive days, followed by oral prednisolone (1mg/kg/day), dap-
sone (1mg/kg), hydroxychloroquine and supplements. As the new le-
sions continued to erupt, dose of dapsone was increased at the end
of Week 2 (1.5mg/kg) and methotrexate (10mg /sq m po once
weekly) was added. With no change in clinical status, Mycophenolate
Mofetil (MMF) (330mg/sq m/dose, twice a day po) was added at the
end of Week 4 and titrated upwards (500mg/sq m,twice a day po) in
Week 12. By Week 15 there were no new crops and she finally
achieved remission with no fresh lesions and normal hemogram and
complement levels with residual hyperpigmentation. Steroid tapering
has commenced successfully and currently she is on oral prednisol-
one (0.15mg/kg/day), dapsone (1.5mg/kg), MMF (500 mg/sq m/dose,twice a day po), methotrexate (10mg/sq m po once a week), hydro-
xychloroquine and supplements.
Conclusion: Vesicobullous lesions in lupus may morphologically re-
semble Stevens Johnson syndrome but are easily differentiated on
histology and immunofluorescence. Such cutaneous lesions are rare
in childhood and our case was rather severe in the initial weeks, re-
fractory to Dapsone which usually is effective in this form. In our case
the SLEDAI does not accurately reflect the true intensity or activity of
the skin domain. Informed consent had been obtained.
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Introduction: Spondyloenchondrodysplasia (SPENCD) is a very rare
genetic immuno-osseous dysplasia characterized by skeletal
anomalies (short stature, platyspondyly) and enchondromas in the
long bones or pelvis. SPENCD may have a heterogeneous clinical
spectrum with neurological involvement or autoimmune manifes-
tations, such as systemic lupus erythematosus (SLE).
Objectives: We describe an Indian child with SPENCD, who pre-
sented with features of SLE , skeletal dysplasia and enchondromas.
Methods: A 9 year old male born of second degree consanguin-
eous marriage presented with fever, oral ulcers, leg pain with
morning stiffness since 1 month. He was worked up by his pri-
mary paediatrician for pyrexia of unknown origin and a summary
of laboratory tests performed included, hemogram with
hemoglobin 8.7 gm/dl, white cell count 5900 /cu mm, platelet
1.85 x 103 cu mm, erythrocyte sedimentation rate 100 mm/hr, an-
tinuclear antibody 4+. Suspecting connective tissue disease child
was referred to us for further evaluation.
Results: On further enquiry, there was past history of multiple medical
visits for poor growth since infancy and a bony swelling of the right
forearm leading to incomplete supination for which he was operated at
age 5 years. No details were available. His milestones were appropriate
for age with normal scholastic performance. His weight (16.9 kg) and
height (113cm) were below the 3rd centile. On examination, he had
pallor, facial rash, mucositis of the palate, generalised lymphadenop-
athy, triangular facies, prominent anteverted ears, prominent conjunc-
tival blood vessels, supernumerary teeth, right elbow swelling, paucity
of body hair. On systemic examination abdomen was soft with hepa-
tosplenomegaly and other systems were normal.
On further investigation his dsDNA was 4+, Direct Coombs test was
positive, C3 - 19.1 mg/dl, C4 - 3.36 mg/dl, urinalysis was normal, Anti
Ro and lupus anticoagulant were negative and APLA IgG was positive
and APLA IgM negative. The diagnosis of SLE was confirmed.
Considering, consanguineous marriage, short stature and right elbow
swelling with other subtle dysmorphisms described above, a syn-
dromic form of lupus was suspected and a skeletal X ray analysis
showed extensive areas of metaphyseal abnormalities with epiphys-
eal remodelling changes and platyspondyly. Hence a clinical diagno-
sis of Spondyloenchrondrodysplasia (SPENCD) was considered.
Sanger sequencing of ACP5 encoding the protein TRAP revealed
homozygous non sense mutation (c.849T>A, p.(Tyr283stop) confirm-
ing the diagnosis of SPENCD. He was further investigated for diseases
associated with SPENCD, which revealed normal thyroid function, IGF
– 1, immunoglobulin levels and 2DECHO.
He was started on hydroxychloroquine (5mg/kg/day), oral prednisol-
one (0.6mg/kg/day), low dose aspirin, supplements and was advised
Serial
/ Sex
CSM Onset
(m)/time
to
diagnosis
(m)
Clinical Positive
Antibody
profile
C3/
C4/
CH50
Genetics Treatment Followup
(m)/Outcome
1/F N 10 / 7 Rash, mucositis;
neuroregression
ANA
Ds DNA
Anti Ro
175/
23/
42.1
Homozygous for
a
c.606delA /
p.Gly204Alafs*78
variant in C1QA
HCQ
Sx
AZT
21/Improved
2/ F Y 24 / 24 Rash; mucositis;,
arthritis; herpes
zoster
ANA
Anti Ro
203/
73/
54
Homozygous for
a
c.622C>T /
p.Q208* STOP
variant in C1QA
HCQ, Sx,
AZT MMF
96
/Improved
3/ M Y 21 / 12 Rash; mucositis;
delayed
development;
hyperreflexia
ANA
Ds DNA
Anti Ro
ACLA IgG
158/
47.7/
43
Homozygous for
a c.622C>T /
p.Q208* STOP
variant in C1QA
HCQ, Sx
AZT
9 / Improved
4/ M Y 12/ 24 Rash; mucositis;
hyperreflexia;
seizures
ANA
Anti Ro
117/
39/
18.6
Homozygous for
a
c.171delT /
p.Gly58Alafs*224
variant in C1QA
HCQ
Sx
AZT MMF
34
/Improved
5 / F Y 27/ 4 Rash, mucositis;
neuroregression;
hemiparesis;
cerebral atrophy;
hyperreflexia;
hypothyroidism
ANA
Anti Ro
ACLA
IgM
Anti TPO
179/
42.8
Homozygous for
a c.79C>T /
p.Arg27* variant
in C1QA
HCQ
Sx
Cyc
AZT
24/
Improved
6/ M Y 42/0.5 Rash; mucositis ANA
ACLA
IgM
114/
NA/
NA
Afflicted sibling
of Sr no 2
Not tested
HCQ
Sx
15/
Improved
7/ F Y 48/36 Rash; mucositis;
arthritis;
proteinuria;
infections
(varicella,scabies,
impetigo);
hypothyroidism
ANA 30/
NA/
35.7
Demise before
testing
HCQ,
Sx,
Cyc
MMF
Death
Abbreviations: F: Female, M: Male, CSM: Consanguinity, Y: Yes, N: No, m: months, Sx: Steroids, AZT:
Azathioprine, Cyc: Cyclophosphamide, MMF: Mycophenolate
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weight, was afebrile and there was no arthritis, mucositis or rash
Conclusion: SPENCD is an immunosseous dysplasia and a very rare
cause of monogenic lupus. This, is the second case of SPENCD re-
ported from India. The entity should be suspected in children with
SLE with a consanguineous background who have short stature and
bony abnormalities. We expand the phenotype here with additional
dysmorphic features comprising supernumerary teeth, triangular fa-
cies, prominent anteverted ears and prominent conjunctival blood
vessels not described before to the best of our knowledge. Informed
consent for publication had been obtained.
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Introduction: Systemic Lupus Erythematosus (SLE) is an autoimmune
disease with multisystem involvement. In pediatric patients, renal dis-
ease is higher in comparison with that observed in adults, and it is
reported that up to 99% of patients with SLE develop a certain de-
gree of affection throughout the disease. Lupus Nephropathy in His-
panic patients is more aggressive, with reports of failure to first-line
treatment in up to 43% of cases, which is why multitarget therapies
are currently being studied, the use of two or more immunosuppres-
sants, to achieve a complete remission in patients with lupus ne-
phropathy, specifically class IV.
Objectives: The objective of the study was to evaluate the response
to treatment using schemes with double immunosuppressant: intra-
venous cyclophosphamide associated with mycophenolate mofetil or
azathioprine.
Methods: In material and methods, 60 case files of patients
treated at this Institution were reviewed, of which only 40 com-
plied with the treatment schedule for at least 6 months and had
a written report of renal biopsy for Class IV Lupus Nephropathy
performed at the Hospital Infantil de México.
Results: From the results it was found that 82% corresponded to fe-
male patients and 18% to male patients, the average age during
follow-up was 12.4 years. The main pattern reported of ANA antibodies
was a homogeneous pattern and 92.5% presented anti-double-
stranded DNA by Elisa positive. The response to the treatment was
evaluated with 2 parameters, the first one based on renal function (cre-
atinine) and urinary sediment finding that 67.5% had complete remis-
sion, while based on the response to 12-hour proteinuria, a complete
remission was reported. 46% Improvement was observed in other indi-
ces such as hemoglobin, creatinine and complement levels. The ad-
verse effects of infectious type reported were 28% pneumonia and
22% upper respiratory infection, with a mean hospital stay of 5.1 days
(3.5). Only 20% of the patients presented vomiting associated with the
application of cyclophosphamide.
Conclusion: We conclude that our population presented a response
greater than 50% with the use of double immunosuppressive
scheme, a value that is comparable with that reported in other series
and also without presenting a higher rate of associated adverse ef-
fects. Although the study presented limitations due to the fact that
not all the indices were requested to assess remission according to
the current definitions, it is an initial descriptive study that shows
that the therapy used in our institution presents good results.
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Introduction: While systemic lupus erythematosus (SLE) is classic-
ally considered as a multifactorial polygenic disease, hereditary
monogenic forms are well recognized. Deficiencies in the early
components of the classical pathway strongly predispose to the
development of SLE, of which C1q deficiency is the commonest.
Children with C1 q deficiency are estimated to develop SLE in
93% of cases. We report our experience with this entity.
Objectives: To describe the clinical and laboratory profile and follow up
of a cohort of seven children with hereditary complement deficiency.
Methods: We reviewed our data on seven children with hereditary com-
plement deficiency and obtained a genetic diagnosis in 5 of these 7 pa-
tients using next-generation sequencing. Informed consent was taken
from the parents and the data was tabulated in the study proforma.
Results:Conclusion: Based on our study and others reported, hereditary com-
plement deficiency (notably C1Q deficiency) is the commonest form
of monogenic lupus in our part of the world. Afflicted children
present most commonly with rash and mucositis below 5 years of
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 155 of 243age and there is a significant delay in diagnosis due to lack of phys-
ician awareness. Neurologic features are frequently seen while renal
manifestations are not. Neuroregression responds to immunosup-
pressive therapy with children improving on their mental, motor and
speech milestones. Except in one patient major life-threatening infec-
tions have not been a challenge despite high infection rates in the
community coupled with immunosuppression.
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Introduction: Juvenile systemic lupus erythematosus (jSLE), develops kidney
involvement among up to 75% of patients and 10-50% of them progress
on to end-stage renal disease. Lupus nephritis (LN) is more frequent and se-
vere in young patients and causes significant morbidity and mortality.
Objectives: Describe the clinical, laboratory, histopathological features
and treatment in a cohort of LN patients.
Methods: Multi-center, retrospective and descriptive study. Medical
records were reviewed and the information was recollected using a
data collection format. The data analysis was performed with SPSS 20.
Results: N = 163. Sex ratio F4: M1, mean age was 12 years (4-
16). 37,4% developed jSLE before their 11th birthday. The most com-
mon clinical manifestations were: arterial hypertension 48.5%, mild to
moderate proteinuria 34.4%, nephritic-nephrotic syndrome 33.1%,
hematuria 24%, nephrotic syndrome 20.9% and nephritic syndrome
13,5%. 19% developed acute kidney injury (AKI) and 8.6% progresses
on to early chronic kidney failure. The mortality rate was 13.5%. 18% of
patients with class IV nephropathy died during follow-up.
137(84%) biopsies were analyzed. The distribution by nephropathy sub-
type was: 46.6% class IV, followed by 12,9%class II, 9.2% class V, 6.7%
class III and 5.8% presented mixed changes (class IV-V in 6 and III-V in 2
patients) and 3.7% histology was modified by treatment. Patients with
class IV nephropathy developed: nephrotic syndrome 46,7% (p=0.002),
nephritic-nephrotic syndrome 62% (p=0.032) and AKI 76,9% (p=0.057).
86,6% (p=0.002) of class V patients developed nephrotic syn-
drome. There were no differences between types of LN and the profile
of autoantibodies or levels of hypocomplementemia.
Induction treatment: 81,6% received pulses of methylprednisolone plus
76% intravenous cyclophosphamide and 5,5% mycophenolate mofetil
(MMF). Maintenance treatment: 32% received MMF and 54% azathio-
prine. 11.7% required Rituximab, 5.5% intravenous immunoglobulin
and 2.5% plasmapheresis. Early dialysis was used for patients with class
IV nephropathy and severe deterioration of renal function.
Conclusion: In this cohort, LN was severe and associated with signifi-
cant morbidity which is similar to previously reported studies in med-
ical literature. The most frequent subtype was class IV nephropathy;
64% of them developed nephritic-nephrotic syndrome or nephrotic
syndrome with a significant percentage to complications at onset
and course of the disease. Second most frequent was class II ne-
phropathy and this one subtype did not have an adequate patho-
logical clinical correlation. The biopsy is essential to classify LN and
guide the immunosuppressive treatment.
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Introduction: Compelling evidence from studies in systemic lupus
erythematosus (SLE) demonstrates that Interferonα (IFNα) and type I
IFN signaling are implicated in disease pathogenesis; moreover, up-
regulation occurring in IFNα production/signaling has been linked
to a group of autoinflammatory monogenic diseases named type I
interferonopathies.
Objectives: The aim of our study was to evaluate type I IFN signal-
ing by assessing two read-outs of IFN activation: STAT1 (both total
STAT1 and phosphorylated pSTAT1), and Interferon Score (IS)[1],
mirroring the expression of 6 IFN stimulated genes, in two different
populations. In a group of SLE patients we wanted to evaluate if the
assessment of type I IFN signaling correlates with clinical pheno-
type/laboratory inflammatory markers (anti dsDNA antibodies)/dis-
ease activity and then could be a useful tool for monitoring
treatment response. In a group of undiagnosed patients, strongly
suggestive for a systemic autoimmune/autoinflammatory disorder
(SAD), we aimed to evaluate if the assessment of type I IFN signaling
could help in clustering the kind of disorder.
Methods: In the last 3 years we have enrolled 21 patients. 9/21 were
diagnosed with SLE (ACR criteria). 12/21 patients were highly sug-
gestive for SAD. During periodical evaluations, disease activity index
was performed, blood samples were collected and type I IFN signal-
ing was evaluated as compared to healthy controls.
Results: In the 9 SLE patients we detected a strong upregulation of
type I IFN signaling. These data are in agreement with recent publi-
cations, in which type I IFN is described as a main contributor to SLE
pathogenesis. Comparison among controls, SLE and SAD groups at
time of first examination (T1), showed a significant increase in IS,
pSTAT1 and STAT1 in the SLE group as compared to controls (IS:
p<0,0001, pSTAT1 and STAT1: p<0,001). Moreover, in the SLE group,
a significant reduction of IS, pSTAT1 and STAT1 was evident by com-
paring samples collected at T1-T2 (ΔT: 6-8 months) and this mir-
rored both clinical improvement measured by SLEDAI and lowering
of anti-ds DNA antibody titres. Results from the SAD group are ap-
parently heterogeneous: only some patients showed an activation
of type I IFN axis, but this was quite expected given the criteria by
which the patients were recruited.
Conclusion: We noticed a good concordance between SLEDAI,
anti dsDNA antibodies and pSTAT1/IS, thus stating that the evalu-
ation of type I IFN signaling can be a useful tool for evaluating
therapeutic effectiveness in SLE patients. In the SAD group, the
evaluation of type I IFN signaling helped us to discriminate
among disorders: when the IFN pathway was inactivated, we
could more easily rule out previously hypothesized diagnosis of
an autoimmune disorder. In those patients where a strong type I
IFN activation was detected without a final diagnosis, a strict fol-
low up has been provided, as the upregulation of the IFN path-
way may be an early clue of SAD.
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Introduction: The sensitivity and specificity of the ACR-1997 and
SLICC-2012 classification criteria in juvenile-onset systemic lupus ery-
thematosus (SLE) are already studied. In previous reports, the main
limitations of the ACR-1997 and SLICC-2012 were low sensitivity and
low specificity, respectively. To avoid misclassifications, a new set of
classification criteria have been developed by the collaboration of
the European League Against Rheumatism (EULAR) and the American
College of Rheumatology (ACR) and the draft was presented at the
2017 ACR/ARHP Annual Meeting in San Diego, California. After appli-
cation on 500 SLE patients and 500 controls, the sensitivity and spe-
cificity were found as 98% and 97%, respectively.
Objectives: To compare the sensitivity and specificity of the new
EULAR/ACR criteria with those of the 1997 American College of
Rheumatology (ACR) criteria and 2012 Systemic Lupus International
Collaborating Clinics criteria in juvenile-onset SLE patients.
Methods: Juvenile SLE patients initially were evaluated by ACR-1997,
SLICC-2012 and EULAR/ACR classification criteria at baseline, when
the diagnosis for the first time had been established by an expert
pediatric rheumatologist (OK). All data were obtained from patient
records. The diagnostic sensitivity of the three sets of classification
criteria were further tested within 1 year of diagnosis and at last pa-
tient visit, longitudinally. Subjects with a clinical diagnosis other than
SLE for at least 1 year-period, consecutively enrolled as controls.
Since patients with autoinflammatory diseases, particularly with FMF
constitute the vast majority of our outpatient appointments, these
subjects were excluded.
Results: A total of 104 juvenile-onset SLE patients were enrolled for
the sensitivity performance of classification criteria at diagnosis and
104 controls (69 juvenile idiopathic arthritis, 9 juvenile systemic scler-
osis, 5 juvenile dermatomyositis, 1 mixed connective tissue disease,
15 vasculitis and 5 other diseases) for specificity at their last visit.
Since the follow-up period was less than 1 year, 12 SLE subjects ex-
cluded after baseline evaluation. Finally, 92 SLE subjects were eligible
for sensitivity evaluation within 1 year of diagnosis and at last visit.
The median age of the SLE patients at diagnosis of clinician was 13.0
years (range 3.1–17.9 years) with a median disease duration of 5.0
years (IQR 3.0-8.0 years). The female-to-male ratio was 4.7:1. The
newly developed EULAR/ACR classification criteria were more sensi-
tive than SLICC-2012 and ACR-1997 at diagnosis (93.3% versus 91.3%
and 85.6%, respectively), and at first year (95.7% versus 94.6% and
90.2%, respectively (p>0.05). At last visit the sensitivity of the new set
of criteria and SLICC-2012 were same (97.8 %), but higher compared
to ACR-1997 criteria (95.7%).
Specificity of the EULAR/ACR criteria (86.5%, n=90) were found to be
higher than SLICC-2012 (81.7%, n=85). Compared to SLICC-2012, an
additional 5 subjects among 104 controls without SLE succeeded to get
rid of misclassification as SLE by the newly developed criteria. However,
the performance of the new EULAR/ACR criteria in diagnostic specificity
(86.5%), could not reach the level of ACR-1997 criteria (89.4%).
Conclusion: Juvenile-onset systemic lupus erythematosus was classi-
fied by the newly proposed EULAR/ACR criteria with higher sensitiv-
ity compared with SLICC-2012 and ACR-1997 at disease onset and
within one year of diagnosis. Although the difference was not signifi-
cant, the new set of criteria seem to be capable of recruiting morechildren with juvenile SLE to clinical trials. The performance of the
newly developed criteria seems more successful in specificity com-
pared to the SLICC-2012.
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Introduction: Systemic lupus erythematosus (SLE) is an autoimmune
disease characterized by high-levels of autoantibodies mainly target-
ing nuclear antigens and loss of self-tolerance. Peroxisome-
proliferator activated receptor gamma (PPARγ) and nuclear factor-
kappa beta (NF-κB) are transcription factors, which, within normal
levels, have shown to be crucial in immunomodulation namely, acti-
vation and development of normal lymphocytes, negative and posi-
tive selection of T and B cells. High-levels of NF-κB has inflammatory
properties such as release of autoreactive T cells. On the contrary,
PPARγ has anti-inflammatory effects, which has been demonstrated
to be effective when used early in prevention of disease in murine
models of systemic lupus erythematosus.
Objectives: Herein, we investigated whether NF-κB and PPARγ could
exert opposite effects in the immune response and the possible implica-
tions in immunomodulation of juvenile systemic lupus erythematosus.
Methods: Serum NF-κB and PPARγ levels were measured in 42 juven-
ile systemic lupus erythematosus. In addition,19 juvenile systemic
sclerosis and 25 age-matched healthy children were selected for pa-
tient control and healthy control, respectively. We have also assessed
the relation of these transcription factors with organ involvement
patterns, disease activity, damage scores, autoantibody and acute
phase reactant levels.
Results: The control group did not differ from the juvenile SLE pa-
tients for age (p>0.05). According to our study, serum NF-κB levels
(ng/mL) of juvenile SLE and juvenile systemic sclerosis patients were
significantly higher (1.87 ±1.0 and 2.17 ±1.0 versus 1.25 ±0.7), while
serum PPARγ levels (ng/mL)were significantly lower than that of
healthy controls (1.58 ±0.6 and 1.52 ±0.5 versus 2.03 ±0.9) (p<0.05).
The difference in serum levels of both transcription factors was not
significant between juvenile systemic lupus erythematosus and ju-
venile systemic sclerosis. In patients with juvenile systemic sclerosis
serum NF-κB levels negatively correlated with serum PPARγ levels
(R= -0.49; p=0.032); however, this relationship was not observed in
juvenile SLE patients and healthy controls. There was a significant
correlation between rodnan skin score and NF-κB levels in juvenile
systemic sclerosis patients (R2=0.45, p<0.05).
Conclusion: Increased serum NF-κB levels represent upregulated sig-
naling cascades, so it is associated with increased levels of pro-
inflammatory cytokines. Since juvenile systemic sclerosis and juvenile
systemic lupus erythematosus are autoimmune diseases, patients
had high levels of NF-κB and low levels of PPAR than controls, as ex-
pected. Previous studies revealed that PPARγ activation inhibits NF-
κB transcriptional activity. Correlation results in juvenile systemic
sclerosis cohort were compatible with this finding, however not in ju-
venile systemic lupus erythematosus patients. This could be due to
the limited number of patients. Further studies with large number of
patients are needed to better elucidate the implication of these tran-
scription factors in therapeutic pathways.
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Table 1 (abstract P303). See text for description
Significant proteinuria at 1 year Yes (n=9) No (n=14) p-value
Median age at LN onset, yr 12.8 14.3 0.19
Class II LN, n (%) 0/9 (0) 4/14 (28.6) 0.13
Nephrotic proteinuria at LN onset, n (%) 4/9 (44.4) 2/14 (14.3) 0.16
Leukopenia at LN onset, n (%) 0/9 (0) 4/13 (30.8) 0.12
Hypertension at LN onset, n (%) 2/4 (50) 9/12 (75) 0.55
Median SLEDAI at LN onset 12 17 0.30
Anti-dsDNA, n (%) 8/9 (88.9) 12/13 (92.3) 1.0
Anti-Sm, n (%) 2/9 (22.2) 5/14 (35.7) 0.66
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Introduction: The majority of patients with juvenile systemic lupus
erythematosus (jSLE) develop lupus nephritis (LN), a major cause of
morbidity and mortality. Recent evidence in adult-onset SLE suggests
that prompt achievement of proteinuric remission is associated with
improved long term renal outcomes. Data on time to proteinuric re-
mission in jSLE are still limited.
Objectives: To describe the clinical course of LN in our cohort of jSLE
patients and to analyze potential clinical and laboratory features as-
sociated with proteinuric remission.
Methods: The clinical records of jSLE patients followed at our centre
in the last thirty years were retrospectively reviewed. To be included
in the study patients needed to satisfy ACR criteria for SLE, to have
an age at SLE diagnosis <18 years, a biopsy-proven LN, and at least 5
years of follow-up. Demographic, clinical, laboratory and histological
data at LN onset were collected. Significant proteinuria was defined
as proteinuria >0,5 g/day or urine protein creatinine ratio (UPCR)
>0,5. To be classified as in proteinuric remission patients needed to
achieve a proteinuria under the cut-off in two consecutive visits. Data
of patients with and without persistent significant proteinuria at 1
year were compared using Fisher's exact test or Mann-Whitney U test
as appropriate. Correlation between time to proteinuric remission
and variables at LN onset was calculated by means of Spearman's
Rho test or Mann-Whitney U test, as appropriate.
Results: Twenty-six patients were included in the study, 22 were fe-
males. Median age at jSLE onset was 12,9 years (range 5,1-16,2), and
at LN onset 13,6 (range 6,2-23,7). In 19/26 patients (73%) kidney in-
volvement was present at jSLE diagnosis. The majority of patients
were histologically classified with LN class III and IV (69,2%). All pa-
tients received high dose corticosteroids as induction treatment; in 7
patients cyclophosphamide i.v. pulses were added. Twelve patients
(46%) received ACE-inhibitors or angiotensin II receptor blockers
(ARB). Proteinuric remission was achieved in 73,9% and in 82,6% of
patients at 1 and 5 years from LN onset, respectively. Median time to
proteinuric remission was 5,4 months (range 0,2-68,8 months). In two
patients (7,6%) a severe renal damage occurred. The main features of
patients with and without significant proteinuria at 1 year from LN
onset are presented in Table 1. Although statistical significance was
not achieved, persistence of proteinuria seemed associated with a
younger age and nephrotic proteinuria at LN onset. No patient with
Class II LN developed persistent significant proteinuria. Correlation
analyses highlighted that patients treated with ACE-inhibitors/ARB
presented a faster remission of proteinuria (p=0,03).
Conclusion: Our cohort suggests that younger patients with neph-
rotic proteinuria at LN onset present a higher risk of prolonged pro-
teinuria and should be carefully monitored. Treatment with ACE-
inhibitors/ARB could be useful to achieve a faster proteinuric remis-
sion. Due to the small size of our population, these results need con-
firmation in larger studies. Furthermore, a longer follow-up will allow
to evaluate the role of time to proteinuric remission on long term
renal outcome in jSLE.
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Introduction: An acquired form of angioedema (AAE) with symptoms
of swelling in subcutaneous and mucosal tissues is clinically similar
to hereditary angioedema but it is rarer than the hereditary type.
Objectives: The AAE occurs rarely the existence of a systemic lupus
erythematosus (SLE). The antibodies in SLE may change the structure
of C1-INH or diminish its regulatory capacity.
In this study, we aim to present AAE as the initial presentation of SLE
and literature review.
Methods: We presented a case report and provided information
about AAE related to SLE. Hence, literature was researched using the
keywords “acquired angioedema,” “systemic lupus erythematous,”
and “C1 esterase inhibitor protein.”
Results: A 16 year old girl was admitted to our clinic with persistent an-
gioedema in the eyelids and lips, alongside polyarthralgia with fatigue.
Her family and she had no remarkable history for recurrent angio-
edema or rheumatological disease.
On examination, she had bilateral periorbital and lip swelling without
dyspnoea. There was a pain and limitation in the joints of both hands
and fingers. The other organ systems were normal on examination.
Laboratory investigations showed leukopenia with a white cell count
of 2.19 x 109/L, serum C-reactive protein 0.09 mg/dL (<0.5), erythro-
cyte sedimentation rate 90 mm/h (0-20), IgG 1811 mg/dL (600-1400).
Immunological tests showed a major classical pathway-mediated
complement depletion with low C3 of 28.1 mg/dl (90-180) and a low
C4 of 2 mg/dl (10-40). C1-INH level was normal of 21.70 mg/dL (18-40).
There was no hematuria or proteinuria. . In addition, ANA, anti-dsDNA,
anti-Smith antibody in high titer and the direct Coombs tests with com-
plements were positive. According to the SLICC criteria, she was diag-
nosed as SLE and AAE with the presence of polyarthralgia, leukopenia
and positivity of immunologic criteria. After pulse methylprednisolone
therapy (1 gr/day), the patient received oral prednisolone (2 mg/kg/day),
hydroxychloroquine (4 mg/kg/day) as maintenance treatment. After
seven days, the angioedema resolved. The patient has been under treat-
ment for 2 years with prednisolone (4 mg/day) and hydroxychloroquine
(4 mg/kg/day) and has experienced neither SLE flares nor angioedema.
Angioedema can occur as either hereditary or acquired types due to
vasodilation and increased vascular permeability resulting from in-
flammatory mediators, especially bradykinin. Bradykinin production is
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 158 of 243normally regulated by C1-INH. C1-INH has also inhibits the plasma
kallikrein-kinin system, which releases bradykinin.
The relationship between SLE and acquired C1-INH deficiency is not
fully understood yet. It may be associated with the existence of auto-
antibodies against C1-INH. In few reports it is suggested that chronic
consumption of C2 and C4, production of C2 kinin and other active
products resulting from SLE appeared to induce the development of
AAE. Why severe complement consumption develops in SLE and sets
off AAE is unknown. The complicated reactions during complement
consumption notably increase vascular permeability, resulting in a
subcutaneous and mucosal edema.
To date, 18 AAE cases were associated with SLE, two patients were
male, and the others were female. All patients had positive ANA re-
sults. Complement levels of 17 patients were low. Five patients were
presented with glomerulonephritis. Three patients developed neuro-
psychiatric manifestations. The angioedema in lids, face, extremities
or intestine had benign prognoses and responded to basic SLE treat-
ment. Patients’ treatments were variable according to their clinical
symptoms.
Conclusion: Although it is a rare condition, AAE might occur during
SLE with a functional or quantitative deficiency of C1-INH. New onset
AAE in adolescent girls should be investigated to look for auto-
immunity conditions and SLE. Informed consent had been obtained.
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Introduction: Mutations of CECR1 have been recently reported as
causative of an inflammatory condition characterized by an early on-
set vasculopathy resembling polyarteritis nodosa. The clinical mani-
festations of the disease are heterogeneous with a wide range of
severity. Patients with a more serve phenotype present early onset
cerebral stroke, which can be either ischemic or hemorrhagic.
Objectives: to describe the neuroradiologic features of patients affected
by ADA2 deficiency with central nervous system (CNS) involvement.
Methods: We reviewed the contrast-enhanced brain MR, MR angiog-
raphy (MRA), and digital subtraction angiography (DSA) examinations
of 5 patients with a confirmed molecular diagnosis of ADA2 defi-
ciency and CNS involvement. The patients were two brothers (R312X
and E328D mutations in compound heterozygosis) and three other
unrelated patients: a male homozygous for the T360A mutation, a
girl homozygous for the G47R mutation and a girl with a structural
variation in 22q11.1 leading to not functional enzyme.
Results: Four patients presented multiple acute and/or chronic small
ischemic infarcts involving the basal ganglia and the midbrain, in
keeping with small-vessel occlusions (lacunar strokes). One patient
additionally presented a large hemorrhagic infarct in the temporal
lobe. Areas of focal accumulation of hemosiderin due to intrapar-
enchymal bleeding were also noted. Interestingly, three patientspresented an abnormal contrast-enhancing soft tissue in the inter-
peduncular cistern, encasing the midbrain perforating arteries.
These neuroradiological findings regressed after the treatment with
anti-TNF agents. The fifth patients presented a large haemorrhagic
infarct in the frontal lobe and after few years a subarachnoid haem-
orrhage due to the rupture of aneurysm of anterior communicating
artery; an aneurysm of the left superior cerebellar artery was also
detected. Inflammatory alterations of the vessels were not demon-
strated. The brain MRA and DSA performed in all patients showed
no relevant vascular stenosis of the major arteries of the circle of
Willis.
Conclusion: Typical lacunar strokes in patients with ADA2 deficiency
are due to occlusion of small perforating arteries, which can be
missed on conventional arterial imaging focusing on the vessel
lumen of relatively large arteries. We hypothesize that the abnormal
soft tissue detected in the interpeduncular cistern in the present pa-
tients may represent an abnormal inflammatory perivascular re-
sponse, leading to small vessel stenosis. The presence of aneurysms
in one patient, without signs of inflammation, enlighten a different
pattern of vascular involvement of DADA2 mainly represented by
structural rather than inflammatory alterations. Wider use of contrast-
enhanced high-resolution MR examinations may better demonstrate
vascular manifestations in patients with ADA2 deficiency.
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Introduction: Recurrent pericarditis is a complication of acute peri-
carditis and affects 15-30% of patients after an initial attack. The eti-
ology is poorly understood and about 80% of recurrent pericarditis
are "idiopathic". The therapy seems to be very important to avoid
the recurrences. Conventional treatment includes NSAIDs, glucocorti-
coids, colchicine, and in the last years, treatment with Anakina (anti
IL-1) became common in the clinical practice
Objectives: To analyze clinical findings and treatment in a cohort of
pediatric patients presented with recurrent pericarditis.
Methods: patients with at least two episodes of idiopathic pericardi-
tis, followed at Necker Hospital (Paris) and at Bambino Gesù Child-
ern’s Hospital (Rome) between 2006 and 2016 were included in the
study. Patients with a known history of autoimmune or autoinflam-
matory disease were excluded.
Results: Thirty-two patients (19 F and 13 M) with recurrent pericarditis
were included. The median age at disease onset (first episode of pericar-
ditis) was 11.8 years (range 8-17). The first episode was treated differ-
ently: 15 (46%) patients received NSAIDs, 6 (18.8%) and colchicine,
and 11 (34.4%) glucocorticoids. Patients who had received glucocorti-
coids at the first episode showed relapsed before than the others ,re-
spectively 1.9 vs 6 months with a statistical difference (p<0.02). The first
treatment did not influence the number of relapses in our study. More-
over we can divided our study population in two groups: Group 1 (20
patients): recurrence of pericarditis was treated only with NSAIDs, colchi-
cine or glucocorticoid (alone or associated); Group 2 (12 patents) in
which the treatment with anakinra (IL 1 inhibitor) was necessary. The
group 2 showed a higher number of relapses than the group 1 (median
Table 1 (abstract P307). See text for description
PTS with consensus PTS with no consensus
Pts Genetic classific. Pts Genetic classific.
FMF 36 Conf/cons 27 (75%) 15 Conf/cons 3 (20%)
Unc. signif 1 (3%) Not class 2 (13%)
Not class 1 (3%) Not confirm 10 (67%) (9
heteroz for P variants)
Not confirm 7 (19%) (7 heteroz
for P variants)
MKD 56 Conf/cons 50 (96%) 3 Conf/cons 1 (33%)
Not confirm 2 (4%) (2 heteroz
for P variants)
Not confirm 2 (67%) (2/3
heteroz for P variants)
CAPS 32 Conf/cons 27 (84%) 19 Unc. signif 13 (68%)
(Q703K,V198M)
Unc. signif 1 (3%) (V198M) Not confirm 6 (32%) (genetic
NEGATIVE)
Not class 4 (13%)
TRAPS 39 Conf/cons 36 (93%) 1
1
Conf/cons 2 (18%)
Unc. signif 2 (5%) (R92Q,D12E) Unc. signif 7 (64%)
(R92Q,P46L)
Not class 1 (2%) Not confirm 1 (9%) (genetic
NEGATIVE)
Not class 1
UNDEF. 81 Conf/cons: 1 for MVK 14 Unc. signif: 2 for TNFRSF1A, 3
for NLRP3
Unc. signif 2 for MEFV Not confirm 1 for MEFV
Not confirm: 9 for MEFV, 7 for
NLRP3, 8 for TNFRSF1A
PFAPA 37 Unc. signif (1 for NLRP3, 3 for
TNFRSF1A)
17 Unc. signif: 1 for NLRP3, 1 for
TNFRSF1A
Not confirm: 3 for MEFV Not confirm: 2 for MEFV, 1 for
MVK
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patients in comparison to the group 1 (respectively 72.7% vs 21.1 ;
p<0.005). In the group 2, all patients treated with anakinra showed a
complete response within few days (in median after 2-3 days) and were
able to discontinue the glucocorticoid therapy. During daily treatment
with Anakinra no relapse was reported. In 7 out of 12 patients, the dose
of anakinra was tapered and of these patients relapsed. The tapering
strategy was to progressively reduce the days of administration during
the week. The mean time from the start of anakinra to tapering was 11
±3,4 months (range 6-15 months) in the 4 patients who experienced re-
lapse versus 17.6 ±4.6 months (range 15-23 months ; p<0.04) in those
who did not flare. All the patients who relapsed responded quickly to
the reintroduction of anakinra. In 5[IA2] out of 12 patients, anakinra
was discontinued after a mean duration on treatment of 32.2 months
(range 16-58) ; two patients of these 5 patients relapsed within 2
months, and anakinra was reintroduced with a good response.
Conclusion: Our study shows the high variability of treatments of recur-
rent pericarditis and underlines the importance of a standardized ther-
apy to avoid relapses. Glucocorticoid therapy is associated with a
shorter period to flares than the other treatment. Anakinra is an effect-
ive treatment; however, discontinuation of anakinra lead to relapses in
many cases, principally when it was tapered or stopped within a few
months. This study suggests that IL- 1 inibithion should be used rather
than steroids in patients with inadequate response to NSAIDs and col-
chicine . Moreover our data suggests also that a longer term therapy
with anakinra reduces the risk of relapses. Further experience on larger
population is needed to define treatment duration.
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Introduction: Recently a group of geneticists classified the variants
reported in Infevers at March 2017 for the MEFV, MVK, TNFRSF1A and
NLRP3 gene and propose a genotype interpretation according to the
combination of the single variants and mode of inheritance of the
diseases (J Med Genet 2018)
Objectives: To evaluate the concordance between the pathogenicity
classification proposed by geneticists and the classification in 360
real patients blinded evaluated by 33 experienced experts
Methods: 360 patients with recurrent fever were analyzed during the
process of patients’ validation performed for the identification of the
new Eurofever classification criteria (Gattorno, PRES 2017, in prepara-
tion).We compared the pathogenicity classification of the genotype
with the final classification reached by the experts. According the ge-
neticists classification each variant was classified in pathogenic (P), likely
pathogenic (LP), variant of unknown significance (VOUS), benign (B),
likely benign (LB) in a validated or provisional way. Variant for which a
consensus was not reached were classified as unsolved.The genotypewas considered i)confirmatory, if the patient carries 1 P or LP variant in
autosomal dominant (AD) diseases or 2 P/LP variants in autosomal re-
cessive (AR) disease; ii)consistent, in presence of 2 P or LP variants (not
phased) or 1 P/LP variant and 1 VOUS or unsolved variant in AR dis-
eases; iii)of uncertain significance, if composed by 1 VOUS variant in AD
diseases or 2 VOUS variants in AR diseases.We defined as not confirma-
tory the genotype of patients carrying 1 or more variants and not in-
cluded in the previous groups (i.e heterozygous patients for AR
diseases) or negative patients for genetic analysis
Results: A total of 281 patients reached a consensus during the evalu-
ation by the experts. The majority of patients with consensus obtained
the classification as confirmatory or consistent genotype. The most rele-
vant discrepancy observed was the lack of classifications of some het-
erozygous patients (7 FMF and 2 MKD) for AR diseases in the
consensus group. The 2 MKD patients were positive for mevalonic acid
in the urine. Only 1FMF, 1 CAPS and 2 TRAPS with uncertain pathogenic
variants reached a consensus among the experts (Table 1)
Conclusion: Generally a good correlation between the two methods of
classification was observed. Nonetheless a limitation of this method
might be the lack of classification of a subgroup of patients (heterozy-
gous patients in AR disease) that otherwise reached a consensus on the
diagnosis when considering both clinical and genetic data.
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Introduction: Canakinumab, an IgG1 human anti-IL-1 monoclonal anti-
body, has been shown efficacious and safe in the treatment of patients
with all cryopyrin associated periodic syndrome (CAPS) phenotypes1.
However, no data are available for real-life safety of different doses of
canakinumab in CAPS patients of different age groups. Here we analyse
the safety of different doses of canakinumab in CAPS and non-CAPS
patients from a real-life study (Beta-confident registry).
Objectives: To monitor the long-term safety of different CAN doses
(<2, 2−<4 and 4−<8mg/kg) across different age groups (<4 to 65
years) in pts with CAPS and other autoinflammatory syndromes.
Methods: The β-CONFIDENT Registry was a multicenter, long-term,
prospective, observational study conducted at 39 sites across 13 coun-
tries. Patients with different CAPS phenotypes and those with other
autoinflammatory diseases receiving canakinumab at physician’s discre-
tion were enrolled in the registry. Cumulative safety data were reported
as exposure-adjusted incidence rate per 100 pt–years (IR/pyr) from en-
rollment of the first pt (November 2009) until the end of study (Decem-
ber 2015). Patients were followed up for at least 1 yr. The protocol did
not mandate any visits or procedures. All observed and reported ad-
verse events (AEs) and serious AEs (SAEs) were recorded for the follow-
ing age groups: <4, 4−<12, 12−<18, 18−<65 and ≥65 yrs.
Results: Of the 285 pts enrolled, 21% (n=60) discontinued the study
mainly due to loss to follow-up (35%, n=21) followed by AEs (10%, n=6),
poor efficacy (8%, n=5) and pt preference (3%, n=2). In total, 1114 AEs
and 155 SAEs were reported in 223 pts (110.7 IR/100 pyr) and 83 pts
(15.4 IR/100 pyr), respectively. Exposure-adjusted incidence rate of AEs
(IR/100 pyr) among pts in the <4 and 4 –<12 yr age group, were lowest
in pts who received <2 mg/kg (130.3 and 59.7, respectively) compared
with pts who received 2–<4 mg/kg (450.8 and 169.6, respectively) and 4
–<8 mg/kg (121.5 and 90.0, respectively) CAN. In pts aged 12 –<18 yrs,
IR/100 pyr were lowest in pts who received 2–<4 mg/kg doses (118.2)
compared with pts who received <2 mg/kg (169.6) and 4 –<8 mg/kg
(139.4) CAN. Similarly, in the 18 –<65 yr age group, IR/100 pyr were low-
est in pts who received <2 mg/kg (93.1) compared to pts who received
2–<4 mg/kg (100.7) and 4 –<8 mg/kg (154.4) CAN. In the ≥65 yr age
group, IR/100 pyr decreased with increasing dose (<2 mg/kg: 26, 2−<4
mg/kg: 17). Overall, 5, 13, 19, 84 and 7 SAEs were reported in the <4, 4
−<12, 12−<8, 18−<65 and ≥65 yr age groups, respectively. One death
(metastatic rectal adenocarcinoma in a 76-yr-old Muckle-Wells syndrome
patient) was reported.
Conclusion: The incidence of adverse events in each dose group in-
creased with age (<4−<65 yrs). No meaningful pattern of AEs was
observed, however, with increasing doses. Canakinumab demon-
strated a safety profile consistent with previous reports2,3, and is well
tolerated in CAPS patients aged <4−65 years.
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Introduction: Secondary, AA amyloidosis and infertility are most
common and severe complications of Tumour necrosis factor
Receptor-Associated Periodic Syndrome (TRAPS) in adults.
Objectives: To define the best treatment approach in patients with
TRAPS and the effect on long-term outcomes.
Methods: We reviewed all data of 100 patients carrying a total of
40 TNFRSF1A gene variants who were referred to fever clinic at
the National Amyloidosis Centre in London up to January 2018.
The Auto Inflammatory Diseases Activity Index (AIDAI) was used
to estimate the long-life disease severity.
Results: 29 patients had intronic variants of the TNFRSF1A gene and
displayed milder disease than the 71 patients with mutations affect-
ing coding regions with an AIDAI score <5 (P<0.005), less abdominal
pain and skin rashes but more frequent headache or mouth ulcers
during fever attacks (P<0.001 and P<0.05, respectively), none devel-
oped AA amyloidosis. Amyloidosis affected 13 patients and the stron-
gest association was duration of untreated disease, independent of
the AIDAI score. Almost 70% of patients required maintenance ther-
apy. Anti-interleukin (IL) 1β drugs were the most frequently used, in
53 patients, with the highest efficacy rate (86% complete response),
while Etanercept was less effective and discontinued in 72% of 25
patients. No patients on anti-IL1β treatment developed amyloidosis
and 10 patients with amyloidosis have been successfully treated with
anti IL-1 agents with preservation of native renal function in 7 and
excellent long term transplant function in 2. Nine women had a his-
tory of failure to conceive and seven had successful pregnancies
without fertility treatment following complete disease control with
anti-IL1β drugs. Long term safety profiles for anti IL-1 agents were
excellent even in the presence of comorbidity.
Conclusion: Anti-IL1β drugs are the best maintenance treatment
in TRAPS with potential to reverse the most serious disease com-
plications of AA amyloidosis and infertility. The diagnosis of
TRAPS should be considered very carefully in patients carrying in-
tronic variants of the TNFRSF1A gene.
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Introduction: Blau syndrome (BS) is a rare monogenic form of sar-
coidosis with paediatric onset resulting from mutations in the pat-
tern recognition receptor NOD2. It is phenotypically characterized
by the triad of granulomatous polyarthritis, uveitis and skin involve-
ment. Although skin involvement occurs in about 2/3 of cases, only
very little is known about its initial clinical presentation and evolu-
tion during disease course.
Objectives: The aim of this study is to describe skin manifestations of BS.
Methods: We retrospectively studied a French national cohort of 20 pa-
tients with a genetically confirmed BS. Patients have been identified
through a call to SOFREMIP and Dermatology French Society. Epidemio-
logical clinical data have been collected and data about skin involvement
(medical record, photographies, biopsies) were analyzed by two inde-
pendent expert dermatologists. 5 skin biopsies were analyzed by one
anatomopathologist.
Results: The mean age at diagnosis was 14.3 (0.25–54) years. Skin in-
volvement, present in 15/20 (75%) patients, was early at a median
age of 1.5 (0.25-20) years and always inaugural of BS except in one
case. Skin lesions have been initially considered as nonspecific
dermatitis in 2/15 patients. Skin lesions were mainly (13/15 patients)
diffuse erythematous or flesh-colored micropapules, sometimes with
livedoid disposition, or nodules (2/15 patients) which coexisted in
one patient. All skin biopsies revealed dermic granuloma without
caseous necrosis. 9/15 (60%) of patients got a dermatological con-
sultation and 7/15 (47%) a skin biopsy. Average time before diagno-
sis was 6.3 (-0.8-41) years and 1 (0-3) in case of skin biopsy. Mean
age at diagnosis in patients with skin involvement was earlier (10.6
y vs 14.3y) and significantly lower 2.1 (0.25-4.2) years when a skin bi-
opsy has been realized.
Conclusion: Skin involvement in BS is often unrecognized or consid-
ered as a nonspecific dermatitis. The skin lesions occur in early child-
hood, are inaugural with stereotypical clinical manifestations and a
dermal granulomatous histology. These observations suggest that a
better recognition of evocative lesions and a skin biopsy could allow
earlier diagnosis and management of patients.
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Introduction: STING-associated vasculopathy with onset in infancy
(SAVI) is a recently described autoinflammatory disease caused by
gain-of-function mutations in the TMEM173 gene (1). Most cases are
due to de novo mutations; however, familial cases have been re-
ported (2). Manifestations include progressive interstitial lung disease
(ILD), polyarthritis and cutaneous changes including acral violaceous
plaques and digital ulceration.
Objectives: To describe a patient with ILD and a pathogenic
TMEM173 mutation without the typical features of cutaneous vascu-
lopathy and arthritis.
Methods: The index case presented at 4 months of age with fail-
ure to thrive, increasing oxygen requirement, tachypnoea and
intermittent fever. Past history was significant for prematurity (28
+5 weeks gestation) and chronic lung disease having been dis-
charged home at 3.5 months of age on low flow oxygen.
Progressive deterioration necessitated mechanical ventilation. No in-
fectious agent was identified and antimicrobial therapy failed to alter
the disease course. Lung biopsy was non-diagnostic, showing inter-
stitial fibrosis and pneumocyte hyperplasia.
The patient’s mother and maternal grandmother had been affected by
severe arthritis and ILD suggesting a familial syndrome. The patient’s
mother was diagnosed with rheumatoid factor (RF) positive juvenile
idiopathic arthritis (JIA) aged 2. She developed respiratory issues in
young childhood and lung biopsy had shown non-specific changes of
lymphoid interstitial pneumonia. Her symptoms had been stabilised
with regular rituximab having previously failed treatment with metho-
trexate, mycophenolate and adalimumab. The patient’s maternal grand-
mother died at the age of 38 having undergone a single lung transplant
aged 30. She too had been diagnosed with RF positive JIA and subse-
quently with rheumatoid arthritis associated pulmonary fibrosis.
The family history and clinical features of ILD, fever, acute phase re-
sponse, positive antinuclear antibodies and non-response to conven-
tional immunosuppressive therapy raised the possibility of SAVI.
Results: Bidirectional Sanger sequencing revealed a heterozygous
c.463G>A; p.(Val155Met) mutation in the TMEM173 gene in the child
and mother. Functional assay confirmed significant upregulation of
interferon stimulated genes in both patients. Posthumous genetic evalu-
ation of the patient’s grandmother is underway with results awaited.
Treatment with baricitinib led to clinical and laboratory improve-
ment. The patient is thriving six months after starting treatment but
remains dependent on home oxygen treatment.
Conclusion: SAVI has a varied phenotype and we present a case
without the typical cutaneous and articular manifestations. Prompt
recognition and treatment is important to prevent irreversible lung
disease. This diagnosis should be considered in children with ILD
where other more common causes are not apparent; even in the ab-
sence of typical cutaneous or joint findings. Accurate identification of
rare, inheritable diseases in children can allow for retrospective diag-
noses and more precise treatment for family members.
Written informed consent for publication of their clinical details was
obtained from the parent of the patient.
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Introduction: Recurrent Multifocal Osteomyelitis (CRMO) is an aseptic
inflammatory bone disease that typically affects the metaphases of
the long bones. It affects children, adolescents and young adults. The
main presenting feature is local bone pain and/or swelling. It has a
protracted course for years with exacerbations and improvement
with treatment. The diagnosis of CRMO can be made on clinical pres-
entation and confirmed by magnetic resonance imaging (MRI) and
bone biopsy. On MRI examination there are mostly multifocal, and
symmetrical lesions (especially in the metaphysics of tubular long
bones, flat bones and spine). CRMO can be associated with skin, gut
involvement and other rheumatological conditions.
Objectives: We report a single centre experience (GOSH) of the asso-
ciation of CRMO and IBD.
Methods: We reviewed reports of whole body MRI scans of 300
children, done in last 5 years between January 2012 and Decem-
ber 2016. Patients with MRI scan results consistent with CRMO
were included in the study. Retrospective analysis of electronic
clinical records of these patients was done and we recorded their
clinical symptoms at presentation, any associated illnesses and
Family history. Histopathological/ microbiological findings of bone
biopsies were reviewed to rule out haematological, infectious or
malignant causes.
Results: Twenty three patients were included in the study.Five were
male and eighteen female. These children were 8-18 years old with
median age of 15 years. The clinical feature of CRMO at first presen-
tation are as under.All patients presented with musculoskeletal symp-
toms like backache, clavicular involvement, or joint pain.Five patients
(21%) presented with abdominal pain and blood in stool. These pa-
tients were diagnosed as Inflammatory bowel disease(IBD) on the
endoscopic and histopathological findings. Three patients presented
with gut symptoms first and later on they developed joint pain and
swelling. However one patient presented with joint pain to start with
and diagnosed as CRMO. This patient later on developed gut symp-
toms. One patient presented with simultaneous onset of diarrhoea,
blood in stool, abdominal pain and joint pain with swelling.There is
significantly more raised inflammatory markers in the IBD/CRMO
group than in the CRMO alone groupHistory of trauma was present
in 13% of patients who presented with musculoskeletal symptom-
s.Hyper mobility was present in four patients. Juvenile idiopathic
arthritis was an associated diagnosis in three patients. One patient
was diagnosed as Enthesitis related arthritis (ERA) and CRMO overlap.
Psoriasis, palmoplantar pustulosis , acne, atopic dermatitis, dermatitis
artefacta were the skin conditions associated with CRMO but not in
IBD/CRMO overlap group.There was family history of connective tis-
sue disorders in six (26%) out of 23 patients, including systemic lupus
erythematosus, ankylosing spondylitis, Crohn’s disease, rheumatoidarthritis, antiphospholipid syndrome and psoriasis. Only one patient
(4%)out of 23 was HLAB27 positive.
Conclusion: CRMO has a varied presentation. We identified that
CRMO is associated with IBD in 21% of the patients. Further studies
are needed to identify whether the CRMO/IBD overlap group has a
separate phenotype.
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Introduction: Familial Mediterranean Fever (FMF) patients with a
poor compliance to follow-up (FU) appointments and treatment may
not only be mischaracterized as resistant to colchicine, but poten-
tially may have an unfavorable long-term disease outcome.
Objectives: Primary objective: To assess the level of compliance in
patients with FMF, in respect to the disease outcome and the devel-
opment of amyloidosis. Secondary objective: To detect the tolerant
patients, who need additional treatment for the disease control.
Methods: A retrospective study of all patients with an established diag-
nosis according to Tel-Hashomer criteria and a minimum FU of 6 months
was performed. After 2015, the auto-inflammatory diseases activity index
(AIDAI) was given to all patients attending the FU appointments, aiming
to the disease self-monitoring. For the purpose of the study, good com-
pliance to the scheduled FU was defined as consistent attendance to all
visits (twice yearly). Compliance to treatment was assessed according to
the family/patient information given in the FUs. In those with continuous
colchicine administration, the presence of clinical or subclinical inflam-
mation was recorded to estimate the disease gravity.
Results: Over a 31 year period (1986 – 2017), 71 patients (female: 42)
with a median age of 5.66 years at diagnosis, a median lag time to diag-
nosis 1.83 years, a median disease duration of 15.63 years and a median
age of 19.5 years at the final visit were recorded. Their cumulative FU dur-
ation was 917.87 years and 12.92 FU years per patient. All patients were
receiving colchicine. Totally, the overall compliance to the scheduled FU
was good 54.92 % (39/71). Regarding colchicine, 50/71 (70.42%) patients
had a good compliance. Among these compliant patients, good response
to colchicine was recorded in 47/71 patients (66.19%), partial response in
20/71 (28.16%) and no response in 4/71 (5.63%). Clinical remission was
achieved in these 4 recalcitrant patients, with step-up therapy, namely
canakinumab (2), methotrexate (1, for sacroiliitis) and infliximab (1, for co-
existence of Crohn disease). Regarding the non-compliant patients (21/
71, 29.58%), 7 were lost to FUs and 4/21 experienced period crises. The
remaining 10/21 patients, finally adhered to treatment and achieved re-
mission. No cases of amyloidosis were observed.
Conclusion: Findings of the study revealed an overall non-
compliance in less than half of the patients, nevertheless with a
declining rate, attributed to an improved patient/family experien-
tial disease education. Of note, clinical remission was accom-
plished in a high percentage of patients. The detection of the
low percentage of the actually non-responders, led to the intensi-
fication of the treatment with additional DMARDS, which finally
resulted to a favorable disease outcome.
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Table 1 (abstract P314). See text for description
Clinical preliminary criteria Presumed
IFN
mediated
AIDs
n=12
Heathy
controls
n=8
Autoimmune
diseases (SLE or
JDM)
n=8
1. Skin manifestations (nodular
erythema, violaceous plaques in cold-
sensitive acral areas)
12/12 0/8 0/8
2. Vasculopathy (chill-blain like rash,
microangiopathic vasculopathy,
gangrene/ulcers/infarcts in acral
areas)
6/12 0/8 1/8
3. Lipodystrophy 2/12 0/8 0/8
4. Joint manifestations (contractures,
non-erosive arthritis)
5/12 0/8 2/8
5. Myositis (patchy) 2/12 0/8 0/8
6. CNS manifestations (basal ganglia
calcifications, leukoencephalopathy,
white matter disease, L/P
lymphocytic findings)
8/12 0/8 0/8
7. Pulmonary involvement (interstitial
lung disease, pulmonary fibrosis,
pulmonary hypertension
2/12 0/8 1/8
8. Leukopenia/lymphopenia with
flares
4/12 0/8 4/8
Median 6-gene IFN score (minimum-
maximum)
137.87
(0.251-
380.09)
-2.54
(-3.57-
2.48
106.26 (-1.47-
381.69)
Median) 28-gene IFN score (mini-
mum-maximum)
324.01
(24.66-
949.98)
0.83
(-7.91-
16.79)
299.9 (2.75-
475.96)
CXCL10 z-score (STD) 186.07 46.91 57.59
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Introduction: Several rheumatic diseases are characterized by
overexpression of type I interferon(IFN)-inducible or viral response
genes, termed the IFN signature. Recently, this signature has
been reported in a novel group of monogenic autoinflammatory
interferonopathies.
Objectives: We aimed to study a previously suggested set of IFN
score in patients with suggestive clinical features and develop a
clinical score based on the features of patients with a high IFN
score and compare to patients with other autoimmune diseases
such as systemic lupus erythematous(SLE) and juvenile
dermatomyositis(JDM).
Methods: We identified 12 patients with a probable interferono-
pathy based on their clinical features. We compared the IFN sig-
nature with 22 controls(8 healthy children, 6 oJIA, 4 SLE, 4 with
JDM). The expression of 28 IFN-related genes was quantified
from RNA from whole blood using NanoString technology. Sum-
mary scores for IFN6/IFN28/ and a z-score for CXCL10(IP10)
were calculated(as described elsewhere) Four of the probable
interferonopathy patients had mutations related to the IFN
pathway genetic analysis on the other are ongoing. Depending
on the features of patients with a significantly high IFN signa-
ture, we created a preliminary clinical score to identify autoin-
flammatory interferonopathies based on literature review and
expert opinion (Table 1).
Results:
The median IFN6, and IFN28, scores were significantly higher in
the probable interferonopathy cases as compared to healthy con-
trols and oJIAs patients, but did not differ from SLE and JDM pa-
tients. Interestingly, CXCL10(IP10) scores were higher in the
probable interferonopathy group than the SLE and JDM groups.
The mean clinical score was 3(3-5) among these patients. Thus
patients with high IFN signature, lacking features of SLE and JDM
may be classified to have a autoinflammatory interferonopathy
and the suggested clinical score may be helpful to the clin-
ician. Further genetic analysis will enable defining the underlying
mutation in the pathway and treatment results on IFN blocking
treatments are needed to confirm the pathogenic role of type I
IFN in these diseases.
Conclusion: We suggest to use this new clinical score for screen-
ing patients with undifferentiated inflammatory diseases, and the
IFN signature quantified in the 6-gene or 28-gene(preferably) IFN
score to identify patients with potential autoinflammatory inter-
feronopathies. The mutation screening for specific mutations is
ongoing in these patients.
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Introduction: Chronic Non-bacterial Osteomyelitis (CNO) is a rare in-
flammatory disorder that is characterized by onset of pain, local bone
expansion and radiological findings suggestive of osteomyelitis,
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 164 of 243usually at multiple sites. Although CNO pathogenesis remains still un-
known, the hypothesis that CNO might be a genetic disease in the
spectrum of autoinflammatory disorders has acquired importance.
The strongest evidence comes from the syndromic forms of CNO
(Majeed syndrome and Cherubism) and from the presence of
chronic inflammatory osteomyelitis in two monogenic diseases
caused by mutations of genes involved in the activation of the
NLRP3 (pyogenic arthritis, pyoderma gangrenosum and acne:
PAPA) and IL-1 beta receptor (deficiency of IL-1 receptor antag-
onist: DIRA). Although it has been suggested the existence of
genes contributing to sporadic CNO, the identification of a gene
related to its aetiology has not been identified so far; however it
has been recently demonstrated that FBLIM1, a protein involved
in the regulation of bone remodeling, could be involved in the
pathogenesis of sterile bone inflammation [1]
Objectives: To sequence FBLIM1 in a cohort of 83 Italian patients
with CNO and correlate the possible results with clinical
manifestations.
Methods: The coding regions of FBLIM1 were sequenced in a co-
hort of 83 CNO patients using DNA purified from blood. PCR
products were sent for Sanger sequencing. Only rare (global MAF
< 2%), coding variants detected were taken into account. Clinical
evaluation between patients with rare variants and those without
was performed. Fisher’ s exact test was used to compare categor-
ical and ordinal data, and Student’ s t test was used to analyze
continuous data.
Results: Ten out of 83 patients presented at least one rare coding
variant in FBLIM1 gene. One patient was a compound heterozygote
(rs114077715/rs146575757), while a patient carried an homozygous
mutation (rs540511146). Eight patients presented a heterozygous
variants never described before (Table 1). All patients presented clas-
sical features of CNO and statistical differences between patients
with presence of FBLMI1 and those without genetic mutations were
not found in terms of gender prevalence, positive family history, age
at onset, number of sites involved, presence of fever, arthritis and
skin involvement as well as remission prevalence at the end of
follow-up.
Conclusion: Our data seem to confirm a possible role of FBLIM1 in
the pathogenesis of CNO suggesting that CNO is a disorder of
chronic inflammation and imbalanced bone remodeling.
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Patient Variant MAF Amino Acid change
2 rs41310367 0.01 c.250+32 C>A Heterozygote
3 rs41310367 0.01 c.250+32 C>A Heterozygote
4 rs114077715 0.011 c.931G>A Heterozygote
6 rs 187479896 0.0008 c.717+14 A>G Heterozygote
7 rs144567113 0.01 c.718-29 C>T Heterozygote
8 rs144567113 0.01 c.718-29 C>T Heterozygote
9 rs144567113 0.01 c.718-29 C>T Heterozygote
10 rs766409425 0.00002 c.541+13G>A HeterozygoteAutoinflammatory diseases II
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Introduction: Children and adults with clinically and genetically de-
fined autoinflammatory diseases (AID) including CAPS, TRAPS and
HIDS can receive expensive Interleukin-1 (IL-1) inhibitors in many
countries around the world. However, patients suffering from unclas-
sified autoinflammatory conditions characterized by recurrent fevers
and organ dysfunction and the absence of a known pathogenic mu-
tation commonly have no access to these treatment options.
Objectives: The aim of this study was to explore the efficacy and
safety of colchicine treatment in children and adults with autoin-
flammatory diseases without pathogenic mutations.
Methods: Consecutive children and adults with autoinflammatory
diseases without pathogenic mutations treated with colchicine were
included in this single centre study and observed for a median of
12,94 months (range 1,25 – 66,73). Clinical features, autoinflamma-
tory disease activity indices (AIDAI), inflammatory markers ESR, CRP,
SAA and S100, frequency and duration of flares and physician global
assessment of disease activity (VAS) were recorded serially and com-
pared at baseline and while receiving Colchicine therapy.
Results: A total of 39 patients were included in the study. These were
16 girls and 23 boys, median age at start of colchicine therapy was 4
years (range 1 – 54). The diagnoses included PFAPA in 15, mutation-
negative FMF in 11, autoinflammation with low-penetrance variants in
nine (all NLRP3) and other unclassified AID in four patients. Recurrent
fever was the leading symptom, mostly associated with arthralgia and
myalgia. The mean disease activity decreased from 4.4 at baseline to
2.2 on colchicine. Mean SAA-levels decreased from 159 to 63.3mg/l,
CRP levels from 6.4 to 2.3mg/dl. Flare frequency was reduced in 72%
and remained unchanged in 28% of patients. Flare duration was re-
duced in 82%, unchanged in 14% and increased in only 4% of patients.
Most common adverse events were abdominal pain and nausea in
50% of patients and appeared to be dose dependent.
Conclusion: Children and adults with unclassified autoinflammatory
diseases may benefit significantly for colchicine therapy. Control of clin-
ical disease activity and improved inflammatory markers were docu-
mented in 59% of patients. Colchicine should be considered in patients
with active inflammatory disease with no access to IL-1 inhibitors. Con-
trolled trials are needed to further explore this approach.
Disclosure of Interest
None Declared
P317
NEW VARIANT IN THE IL1RN-GENE ASSOCIATED WITH LATE ONSET
AND ATYPICAL PRESENTATION OF DIRA
Jasmin B. Kuemmerle-Deschner1, Konstanze Hoertnagel2, Susanne
Schlipf3, Sandra Hansmann1, Anton Hospach4, Susanne M. Benseler5,
Xiao Liu6, Alexander Weber6
1Department of Pediatrics, Division of Pediatric Rheumatology,
UNIVERSITY HOSPITAL TUEBINGEN; 2Praxis für Humangenetik, Tuebingen;
3Kinderarztpraxis Dr. Lakner, Schwäbisch-Gmünd; 4Zentrum für
pädiatrische Rheumatologie, Klinikum Stuttgart, Olgahospital, Stuttgart,
Germany; 5Rheumatology, Department of Paediatrics, Alberta Children's
Hospital, University of Calgary, Calgary, Alberta, Canada; 6Department of
Immunology, University of Tübingen, Tübingen, Germany
Correspondence: Jasmin B. Kuemmerle-Deschner
Pediatric Rheumatology 2018, 16(Suppl 2):P317
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 165 of 243Introduction: Deficiency of the interleukin-1 receptor antagonist (DIRA)
is an autoinflammatory disease characterized by severe systemic inflam-
mation with bone and skin involvement present in the first days of life.
Objectives: We report a novel variant in the IL1RN-gene associated
an atypical phenotype of DIRA.
Methods: A 3 year-old Caucasian boy presented with recurrent
monthly episodes of fever and fatigue, associated with lymphaden-
opathy, pericarditis, pleuritis, pancreatitis, and arthritis involving
sacroiliac, hip, knee and ankle joints in the absence of any skin in-
volvement. Symptoms had started at age one and had progressed
over time to life-threatening episodes requiring intensive care ther-
apy. Throughout, inflammatory parameters including ESR, CRP, SAA,
S100A8/9, leukocytes, and platelets were highly elevated. Treatment
with colchicine and steroids improved symptoms, however did not
prevent flares. Immune deficiencies were ruled out; genetic testing
for FMF, CAPS, TRAPS, HIDS and DITRA did not reveal variants in the
associated genes.
Results: Whole exome sequencing detected a novel homozygous
stop variant c.62C>G; p.Ser21* in the ILRN gene (NM_173842.2).
Mother, father and brother are heterozygous for the same variant. In
addition, three variants of unknown significance were identified in
the patient's PCGF5, CPA1 and SPTA1 genes. Functional studies re-
vealed only marginal secretion of IL-1RA in the patient’s unstimulated
leucocytes and after stimulation with IL-1β and LPS, confirming the
disease-causing nature of the variant. Subsequently, IL-1 inhibition
with anakinra at 2mg/kg/d was started resulting in complete reso-
lution of clinical symptoms, normal inflammatory markers and dra-
matically improved energy levels. Intolerance to daily subcutaneous
injections prompted a switch to canakinumab at 4mg/kg/4 weeks.
However patient’s and mother’s assessment of disease activity was
inferior on canakinumab compared to anakinra. After four months a
flare appeared and lead to return to anakinra.
Conclusion: This is the first report of the novel c.62C>G; p.Ser21*
variant in the IL1RN-gene primarily causing severe serositis in a
homozygous carrier, while heterozygous family members were com-
pletely symptom free. Skin disease, one of the most prominent fea-
tures in other patients with DIRA was not observed in this patient,
while Il-1 inhibition was likewise effective.
Pathogenic variants in all reported DIRA patients so far affect all 4
isoforms of IL-1RA [1]. The different phenotype in the patient re-
ported here, may be due to the selective loss of secreted IL1RN. In-
formed consent to publish had been obtained.
1 Aksentijevich et al. N Engl J Med 2009; 360:2426-2437
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Introduction: SAPHO (Synovitis, Acne, Pustulosis, Hyperostosis and
Osteitis) syndrome is a rare disease and sufficient data on its
prevalence are unavailable. Usually it occurs in patients with aver-
age ages of 30 and 50 years, while is uncommon in pediatric
age, where is prevalent among adolescents. Due to its insidious
presentation, often it remains unrecognized or misdiagnosed.
Objectives: To assess clinical features, laboratory and radiological
findings in our patients affected by SAPHO syndrome and to
evaluate the response to different therapies.
Methods: Clinical, laboratory, radiological data, and treatments
were collected from all patients presenting to Meyer Children's
Hospital of Florence from 2015 to March 2018 diagnosed withSAPHO syndrome. Informed consent was obtained by the patients
and their family.
Results: Four patients (2 female and 2 male) with a mean age of
14 years and 9 months (range 140-179 months) were collected.
The median time between disease onset and diagnosis was 9,5
months, with a range of 3-22 months. All four patients had
osteoarticular symptoms and skin involvement. Two patients had
already been diagnosed with Crohn disease (CD) one, and Ulcera-
tive colitis (UC) the other and were both under infliximab treat-
ment at the time of SAPHO diagnosis. Skin involvement in these
two cases was characterized by psoriasis vulgaris and palmoplan-
tar pustulosis psoriasis. The other two patients were under iso-
tretinoin therapy for a severe acne. All patients suffered from
back pain, 3 of them complained with pain at sternoclavicular
joints, 2 at coxofemoral joints, 1 at shoulders and 1 in the costal,
tibial and mandibular bones. Two patients displayed a persistent,
low fever. Three patients showed increased ESR and the two CRP.
Whole body MRI was performed in three patients and it showed
signs of osteitis and synovitis, while bone scintigraphy was per-
formed only in one patient and exhibited an increased uptake in
affected bone with the typical “bull’s head” appearance in the
sternoclavicular region. All patients received NSAID and succes-
sively corticosteroid without clinical and radiological response;
one was treated with cyclosporine with partial response. All pa-
tients finally received an anti-TNFα treatment (3 Adalimumab and
1 Etanercept) with a complete clinical and laboratory recovery in
three of them, while one only had a partial improvement be-
cause of the brief follow-up. Moreover, two of them received
intravenous bisphosphonate (Pamidronate 1mg/kg/day for 3 days)
in consideration of a serious involvement of vertebral bodies, but
in one of them it was discontinued for side effects.
Conclusion: SAPHO syndrome, as we observed in our patients,
has a high impact on general health and quality of life. In two
cases we evaluated the association with IBDs, and we observed
the disease onset under treatment with anti-TNFα. While in the
others two cases the disease onset was under isotretinoin. There
is a lively debate if these drugs may be considered triggers or
cure. Whole body MRI and bone scintigraphy have been useful
tools to define the diagnosis, while no patients needed bone bi-
opsy. Anti-TNFα agents have proven to be effective in our pa-
tients, and they could be considered as a standard treatment to
control this disease.
Trial registration identifying number:
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Introduction: Pyoderma Gangrenosum (PG) is a sterile neutrophilic
disorder, rarely described in children and adolescents, and fre-
quently it is known as secondary to other chronic inflammatory
diseases. However, epidemiological, clinical and therapeutic data
on paediatric PG are numerically limited and no randomized con-
trolled trials have been published. Associated diseases in paediat-
ric cases are inflammatory bowel diseases, vasculitis, immune
deficiencies, PAPA Syndrome.
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 166 of 243The treatment with systemic steroids and cyclosporine is well
documented in the literature as the first-line treatment. In non-
responders, other treatment lines are indicated, as: corticosteroids
and mycophenolate mofetil, mycophenolate mofetil and cyclo-
sporine, tacrolimus, dapsone, infliximab, plasmapheresis. In case
reports adalimumab has been used as the treatment for patients
who did not respond to other drugs.
Objectives: We evaluated the efficacy of adalimumab in PG non-
responder to steroids, steroids plus cyclosporine, dapsone plus
cyclosporine.
Methods: We describe the clinical course of a 16-years-old female
affected by PG at the left leg since age 13. Autoimmune tests
were negative, as abdominal US with evaluation of the thickness
of bowel wall, tTG, AGA, IgA, IgG, IgM, IgE, C3, C4, transaminases,
ocular study with slit lamp were negative. She showed HLA DQ8,
as the mother affected by Celiac disease. Two biopsies studies
confirmed the diagnosis of PG, and the treatment with steroids
and antibiotics was started.
However, the disease gone on and cyclosporine was associated to
steroids. In a further line of treatment, she was treated with dapsone
plus cyclosporine. PG extended to the right leg and worsened with
acute lesions. She was treated with topic steroids and antibiotics,
with a further extension of the lesions. We proposed to start adali-
mumab (40 mg s.c. /14 days) and the tapering of topic steroids.
Results: Skin injuries progressively improved, and after 3 doses of
adalimumab PG is limited to the atrophic lesions in the zones of
previous ulcerative lesions.
Conclusion: Adalimumab is a safe and promising treatment in iso-
lated paediatric PG and can reduce the use of steroids or other
immune suppressive drugs. We highlight the role of accurate
diagnostic procedures to primary exclude associated diseases. In-
formed consent to publish had been obtained from the parents.Disclosure of Interest
None Declared
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Introduction: Chronic Non-Infective Osteitis (CNO), is a rare autoin-
flammatory condition which results in one or more sterile inflamma-
tory lesions of the bony skeleton. The most common presenting
complaints are bony pain and swelling. Clinical course varies and
diagnostic delay is common, often resulting in significant pain for
those affected. It is characterised by a relapsing and remitting course,
and long-term outcome is unclear. It is a diagnosis of exclusion with
a wide differential including infection and malignancy. It can affect
any part of the skeleton but most often affects the metaphyses of
long bones, clavicle, pelvis and vertebrae1. It has previously been re-
ported that the skull is almost never involved2. We report a rare case
of multifocal CNO with a large lytic skull lesion which healed follow-
ing a course of ibuprofen.
Objectives: To describe a rare case of multifocal CNO with a large
lytic skull lesion which healed following a course of ibuprofen.
Methods: Retrospective case review.
Results: A previously well 9 year old girl presented with a one month
history of pain and swelling of the forehead, with associated head-
aches and lethargy. There was no evidence of rash or fever.
Past medical history included two discrete episodes of right foot pain
and swelling 10 months previously. X-rays showed expansion and
sclerosis of the 2nd metatarsal, with corresponding cortical thickeningwith oedema on MRI. Her symptoms resolved spontaneously without
treatment and she was kept under clinical surveillance.
There was a strong family history of psoriasis affecting her father,
maternal aunt and maternal grandmother. There were autoimmune
problems including lichen sclerosis, Sjogren’s and thyroid problems
on her maternal side.
On examination she had an obvious soft tissue swelling over the
bridge of her nose, which was tender on palpation. Vision, eye move-
ments and cranial nerves were intact.
Initial investigations showed mildly raised inflammatory markers (CRP
11 and ESR 45). Further investigations included normal lymphocyte
subsets, complement and neutrophil burst suppression test. RF, ANA
and ANCA were negative. MRI showed evidence of frontal osteitis
with perforation of the external table of the skull vault. CT head with
contrast showed the appearance of osteitis of the frontal/nasal
bones. She received 7 days of empirical IV antibiotics to cover for in-
fection without improvement. Blood cultures were negative.
High dose Ibuprofen was commenced (10mg/kg QDS) pending bi-
opsy of the lesion. Whole body MRI was performed, which showed
high signal lesions in both 2nd metatarsals, left greater trochanter
and the sternum.
Endoscopic biopsy showed a non-specific, broadly reactive process,
with areas of monocytic inflammation, vascular granulation tissue
and neutrophilic inflammation, with giant cells in all areas. There was
no evidence of sarcoma or Langerhan’s cell histiocytosis. Bone biopsy
culture was negative.
Following extensive MDT discussion, a diagnosis of CNO was
made and ibuprofen was commenced as first line treatment. 1
month post-discharge, the forehead lesion was less swollen and
headaches less frequent.
3 months after starting ibuprofen CT of her facial bones and sinuses
showed significant improvement with healing of the previous frontal
and nasal bony destruction. Although she has subsequently reported
further pain at the site of her original right second metatarsal lesion.
Conclusion: We report an atypical case of CNO with skull involve-
ment in a 9 year old girl. As this is an unusual location for CNO this
led to a wide differential diagnosis including infection, LCH and
osteosarcoma. Pathological exclusion of these and the presence of
multiple other lesions on whole body MRI allowed the diagnosis of
CNO to be made. Informed consent to publish had been obtained
from the parents.
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Introduction: Pyoderma gangrenosum (PG) and Sweet's syndrome
(SS) were initially described independently according to their cu-
taneous elemental lesions. Based on observations in adult pa-
tients it was subsequently shown that PG and SS share many
diseases characteristics. This led to the development of the
current "modern" classification. In this classification PG is consid-
ered as the prototypical deep ND, SS as the prototypical dermal
ND and sub-corneal pustular dermatosis as the prototypical
superficial ND. Furthermore, association of clinical and histological
features of two different types of prototypic ND simultaneously
or successively in the same patient were called "atypical" forms
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 167 of 243ND. The validity of these "modern" classifications systems of ND
has not been studied in pediatric patients.
Objectives: We conducted a retrospective French cohort study to
describe ND and neutrophilic disease occurring in children and to
determine age-dependent particularities.
Methods: Patients were recruited via the members of the French
Society of Pediatric Inflammatory Diseases (SOFREMIP) and the
French Society of Pediatric Dermatology (SFDP).
Results: Twenty-seven patients diagnosed between 1998 and 2017
with PG or SS were included in this study. Children with SS were
younger than children with PG (2.7 months [0.9-7.8] versus 12.4 [3.4-
15]; p = 0.03. The number of multiple skin lesions was higher in pa-
tients diagnosed with PG than in patients with SS. No differences
were found with respect to all other studied From these results we
concluded that PG and SS in children share many clinical features.
Typical PG and SS were observed in 11/27 (41%) patients whereas
atypical forms were observed in 16/27 (59%) patients. We ob-
served overlapping forms of ND in 3/27 (11%) patients and associ-
ation of two different ND in 7/27 (26%) patients. No differences with
regard to the distribution of typical/atypical forms was found when
comparing patients diagnosed with PG versus SS.
Extracutaneous clinical manifestations were observed in 22/27 (81%)
children.Neutrophilic disease was observed in 17/27 (63%) patients; it
was confirmed in 4/27 (15%) patients and probable in 15/27 (55%)
patients. The presence of neutrophilic disease was similar in patients
diagnosed with PG when compared to patients diagnosed with SS,
though there was a trend (p=0.01) to more neutrophilic disease in
patients diagnosed with SS. The frequency of neutrophilic disease
was comparable in infants (8/10;80%), young children (2/5;40%), and
adolescents (7/12;58%). The location of extra-cutaneous of neutro-
philic disease was similar in infants, young children and adolescents.
However, neutrophilic disease of the upper respiratory tract, as well
as cardiac neutrophilic disease were specific to infants.
An association to another disease was observed in 19/27 (70,4%) pa-
tients. The proportion of patients with associated diseases was similar
in patients diagnosed with PG and patients diagnosed with SS. In in-
fants and young children, a large spectrum of diseases was associ-
ated to ND. In adolescents only IBD and Behçet's disease were
associated to ND, with IBD being by far the most frequent associated
disease (9/10 patients).
Conclusion: Pediatric patients diagnosed with PG and SS share many
clinical features. Atypical forms of ND, as well as overlap and simul-
taneous occurrence of different types of ND can be observed in chil-
dren, especially in infants. Finally, ND can be associated to a broad
spectrum of diseases in young children. Our study suggests that
modern classification systems of ND from adults can be applied to
children and that ND occurring in infants requires careful diagnostic
follow up and clinical management.
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Introduction: STING-associated vasculopathy with onset in infancy
(SAVI) is a newly described type I interferonopathy, caused by auto-
somal dominant gain-of-function mutations in Transmembrane Pro-
tein 173 (TMEM173) gene. It is characterized by early-onset systemic
inflammation with increased levels of acute phase reactants, a severe
cutaneous vasculopathy, leading to extensive tissue loss, and a se-
vere interstitial lung disease (ILD).Objectives: to describe an atypical clinical phenotype.
Methods: A 4 year-old young girl presented since the first months of
life with recurrent fevers, arthralgia, persistent cough and failure to
thrive (below the 5th percentiles). She never showed skin rash. At
the age of 3, she was admitted to our hospital for persistent fever
and arthritis of left knee and right ankle; she started ibuprofen with-
out any benefit. Laboratory tests showed persistently elevated
CRP and serum amyloid A levels, persistent microcytic anemia and
increased IgG levels, highly positive antinuclear antibody (title 1:640,
homogeneous pattern) with positive p-ANCA. Immunological and
cytogenetic studies performed on bone marrow were normal; both
sweat test and genetic test for cystic fibrosis were negative. She
started low-dose glucocorticoids with incomplete response, persist-
ent cough and polyarthritis in small joints. Chest radiograph and CT
showed features of severe interstitial lung disease (ILD) with bronchi-
ectasis and small nodules. Extensive investigations for bacteria, virus
and fungi and cytological tests on blood and bronchoalveolar lavage
were negative. A lung biopsy showed desquamative interstitial pneu-
monia. So, she started high-dose methylprednisolone, subcutane-
ously methotrexate and rituximab. Whole blood of the patient and
healthy donors (HD) (n = 10) were collected into PAXgene tubes. The
type I IFN signature was defined by the expression levels of six IFN-
regulated genes (IFI27, IFI44L, IFIT1, ISG15, RSAD2, SIGLEC1),
measured by quantitative polymerase chain reaction (qPCR). As pre-
viously described by Rice GI, the median fold change of each IFN-
induced gene, when compared with the median of the combined
HD, was used to calculate the type I IFN score. The mean type IFN
score of the HD plus two SD was calculated; we considered as posi-
tive a type IFN score higher of 1,42.
Results: Because of a persistent inflammatory state, ILD and polyar-
thritis, an autoinflammatory syndrome was considered and, in par-
ticular, Copa syndrome was suspected; however, sequencing of
coatomer associated protein subunit alpha (COPα) gene showed no
mutations. Molecular analysis of the TMEM173 gene by NGS showed
the presence of c.463G>A (p.Val155Met) variant in heterozygotic sta-
tus. Whole-blood gene expression studies demonstrated increased
IFN signature (182,2), well in the range for those reported in the lit-
erature in patients with SAVI and other interferonopathies. Elevated
levels of CXCL-10 (>1000 pg/ml) were also found.
Conclusion: The clinical picture of SAVI syndrome is characterized by
early-onset (before 8 weeks of age) cutaneous vasculitis, recurrent fe-
vers, ILD, and systemic inflammation. Our patient never developed
skin rash unlike the cases described in literature. Therefore, lack of
typical skin lesions should not exclude this clinical suspicion. The re-
spiratory and systemic inflammatory component of the disease may
predominate. In the context of early age of onset, ILD, failure to
thrive and recurrent fevers, SAVI must be considered as a differential
diagnosis. A better understanding of the genotype–phenotype cor-
relation is needed to improve SAVI management and prognosis.
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Introduction: Chronic non-infectious osteitis (CNO) predominantly af-
fects patients < 18 years of age. We have previously described short-
term outcome of consecutive pediatric CNO patients treated with
intravenous pamidronate (IV-PAM).
Objectives: We now present the long-term clinical, magnetic reson-
ance imaging (MRI), and bone resorption data in this same cohort.
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 168 of 243Methods: Patients: All consecutive pediatric CNO patients initially
treated with IV-PAM between 2003-2008 at a single tertiary pediatric
centre were prospectively followed until 2017.
Intravenous Pamidronate (IV-PAM) dosing: 0.5 mg/kg (maximum 30
mg) for the first dose and 1 mg/kg (maximum 60 mg) for all subse-
quent doses (maximum annual dose 11.5 mg/kg). IV-PAM was admin-
istered either as 1 day/month x 9, or as 3-day cycles every 1-3
months if the patient lived far away. Whole body MRI (WBMRI) was
performed at baseline, at pain resolution and at 6 and 12 months
during the first year, and also at time of suspected flare. In case of
WBMRI-confirmed flare unresponsive to non-steroidal anti-
inflammatory agents (NSAIDs), the patient received a repeat treat-
ment with IV-PAM (discontinued when pain resolved with follow-up
MRI at 6 months).
Visual analog scale for pain (VAS, 0=no pain; 10=maximum pain) and
bone resorption marker urine N-telopeptide/urine creatinine (uNTX/
uCr) were measured at baseline, preceding each IV-PAM, at 12
months, and also at time of WBMRI-confirmed CNO flare. Each pa-
tient’s uNTX/uCr level was compared to age and sex specific norms.
Results: Patient cohort: Nine patients (5 F: 4 M) were treated initially
between 2003-2008, with a median (range) age at treatment of 12.9
(4.5-16.3) years, and median (range) duration of symptoms of 18 (6-
36) months. All patients had multifocal disease: 2/9 with spinal dis-
ease, one of which presented with several vertebral compression
fractures at baseline.
Initial response: VAS decreased from 10/10 to 0-3/10 by the end
of first 3-day treatment for all patients. The mean (range) time to
complete MRI resolution of bone inflammation was 6.0 (2-12)
months. The mean [confidence interval (CI)] baseline uNTX/uCr
was 738.83 (CI 464.25, 1013.42) nmol/mmol/creatinine with all
uNTX/uCr levels decreasing below age-and sex specific normal
levels after the first IV-PAM.
Long-term follow-up: Median (range) of follow-up was 13 (11-14)
years: 5/9 patients had MRI confirmed CNO recurrence, 4 patients
flared within 12-18 months after 1st IV-PAM dose and responded to
one-day IV-PAM, 1 patient flared after 72 months and responded to
3 once-monthly 1-day IV-PAM, and 2 patients had a second flare at
18 months following the second IV-PAM treatment, which responded
to NSAIDS. The VAS ranged from 3-6/10 with each flare. No patients
flared while their uNTX/uCr was suppressed below age and sex ap-
propriate levels. No spinal CNO patient developed new vertebral frac-
tures during follow-up: 1 patient developed chronic back pain
despite no active disease on MRI and no compression fractures. Two
patients developed arthritis 10 and 12 years after CNO diagnosis. At
final follow-up, 7/9 patients were on no medications and 2/9 re-
quired NSAIDS and/or sulfasalazine for arthritis only with inactive
CNO. No patient developed osteonecrosis of the jaw.
Conclusion: Pamidronate resulted in initial resolution of pain and
MRI documented inflammation in all patients; with equal efficacy
with disease flares. No new spinal compression fractures nor new
spinal lesions developed after IV-PAM was initiated. No patient flared
while his/her uNTX/uCr remained suppressed. We propose that IV-
PAM is an effective and safe second-line therapy in difficult to treat
CNO. We recommend a MRI documentation of suspected flare, as
non-inflammatory pain can occur.Disclosure of Interest
None Declared
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Pediatric Rheumatology 2018, 16(Suppl 2):P324Introduction: Autoinflammatory diseases have revolutionized the
concept of classical rheumatic disease. Most of them are produced
by a “novo” mutation (only 10% have family history of disease). Hap-
loinsufficiency of A20 was described in 2016, it has dominant inherit-
ance and it is caused by mutations in the TNFAIP3 gene. A20 protein
is an inhibitor of transcription factor NF-kB signaling pathway, which
is key to inflammatory responses. This new autoinflammatory disease
presents high penetration and patients present clinical symptoms at
early age with similar phenotypes to Behçet's disease.
Objectives: We present a clinical case diagnosed of Haploinsuffi-
ciency of A20 with a mutation not described in the literature.
Methods: 7-year-old boy with histamine intolerance and non-IgE-
mediated food allergies. At the age of 4, pain begins in lower limbs,
reason why he attended a Paediatric Rheumatologist. He associated
perineal irritation and frequent conjunctivitis, as well as episodes of
oral aphthae and recurrent headaches. In addition, he presented
abdominal pain, diarrhea, genital aphthae, 3 day self-limiting febrile
episodes, asthenia, arthralgia, increased irritability and aggressive-
ness. Prior to diagnosis, it was considered as an autoinflammatory
process and treated with colchicine with partial response. He pre-
cised dose increase and association of subcutaneous methotrexate.
Among others, Behçet's disease and familial Mediterranean fever
were considered as differential diagnosis. He presented normal
serum levels of immunoglobulins and complement, negative antinu-
clear and anticardiolipin antibodies and negative HLA-B51. No muta-
tions in MEFV gene on genetic studies. Analysis of TNFAIP3 gene
detected heterozygosis the mutation p.W356R located in exon 7, that
confirmed diagnosis of haploinsufficiency of A20.
Throughout family history, we found years of evolution of similar
symptoms in a sister, his mother and grandmother. Genetic study
showed that the mutation p.W356R is segregated with disease be-
cause it was only detected in the three affected relatives.
Results: We report an haploinsufficiency of A20 case with a new mu-
tation p.W365R, which not described in literature or registered in the
database of genome diversity Exome Aggregation Consortium
(EXAC). In silic studies of functional damage of the mutation with
SIFT applications show a deleterious effect and with Polyphen appli-
cations a possible damage. We emphasize that family study was car-
ried out in 3 generations and shows that the mutation is segregated
with the autoinflammatory disease.
Conclusion: It is important to consider autoinflammatory diseases in
differential diagnosis when recurrent symptoms of this type appear,
since only its suspicion will enable adequate diagnosis and treat-
ment. Informed consent to publish had been obtained.
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Introduction: The diagnosis of autoinflammatory diseases (AID) relies
on careful interpretation of the clinical phenotype and results from
molecular genetic analysis.
Objectives: To investigate diagnostic rate of AID by fever pattern in
two onset-age groups, childhood and adult onset patients.
Methods: Final diagnosis of patients suspected to have AID in the
two groups with polymorphisms of AID responsible genes analyzed
from 2005 to 2016 in our institute was evaluated by fever pattern
with information of clinical manifestations and course. Genomic DNA
was isolated from the patients’ peripheral blood and a polymerase
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 169 of 243chain reaction (PCR) was used to amplify the indicated exons of 10
genes [MEFV (exons 1-10), TNFRSF1A (exons 2-4), MVK (exons 9-11),
NLRP3 (exon 3-6), NOD2 (exon 4), LI1RN (exons 2-4), IL36RN (exons 2-5),
PSMB8 (exons 2, 3, and 5), NALP12 (exons 3 and 9), PSTPIP1 (exons 10
and 11), TNFAIP3, and NLRC4.] After cleaning the PCR products, cycle
sequencing was carried out using the Big Dye® Terminator v3.1 kit and
analyzed with an ABI 3130xl Prism Genetic Analyzer. Genetic polymor-
phisms within above genes were examined.
Results: All 227 individuals(140 childhood-onset: 0.3~15 (median
5.0) years and 87 adult onset: 16~64 (median 30.5) years of onset
age)were classified into following four subgroups: 1. Periodic
fever (n=72 and 27 in childhood and adult onset, respectively), 2.
Recurrent fever lacking of regular period (n=47 and 41), 3. Per-
sistent fever (n=12 and 11), 4. No fever, but with probable mani-
festations of AID (n=9 and 8). Diagnostic rate of AID was highest
in Subgroups 1 (69.4% and 40.1% in childhood and adult onset,
respectively), followed by Subgroup2(29.8% and 17.1%)including
PFAPA (n=34 and 1) , FMF (n=20 and 15), CAPS (n=6 and 1),
TRAPS (n=3 and 1) in the two subgroups. No one was diagnosed
as AID in Subgroup 3 and 4 except 4 adult onset cases with
hydroarthopathy diagnosed as FMF.Childhood-onset Adult onset
n=140 (M:F=79:61) n=87 (M:F=27:60)
n Diagnosis
of AID
n Diagnosis
of AID
1.Periodic fever 72
(51.4%)
50 (69.4%) 27
(31.4%)
11 (40.1%)
2.Recurrent fever lacking of regular
period
47
(33.6%)
14 (29.8%) 41
(47.1%)
7 (17.1%)
3.Persistent fever 12
(8.6%)
0 11
(12.6%)
0
4.No fever, but with probable
manifestations of AID
9
(6.3%)
0 8
(9.2%)
4 (50%)
Total 140 64 (45.7%) 87 22 (25.3%)Conclusion: Conclusion: AID was identified higher in childhood-
onset patients compared with adult-onset. In both onset age groups,
AID was mostly identified in patients with periodic fever and never
diagnosed in patients with persistent fever. Fever pattern is one of
useful factors to estimate probability of AID.
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aphthous stomatitis, pharyngitis and adenitis and is
the most prevalent autoinflamatory disease.
PFAPA syndrome is characterized by periodic fever, aphthous stoma-
titis, pharyngitis and adenitis and is the most prevalent autoinflama-
tory disease.
Objectives: To describe the initial presentation, clinical course and
therapeutic response of PFAPA and PFAPA-like children visited in
the HSJD, and to assess if there are differences between both
groups and to compare it with the clinical manifestations of
PFAPA described in the published studies.
Methods: Children with clinical manifestations of PFAPA or
PFAPA-like visited from January 2004 to December 2015 were en-
rolled. Data were gathered from medical records.
Results: 85 patients with PFAPA syndrome evaluated. Onset of
symptoms was 27.6 months and the symptomatology stopped at
7.2 years. In 24.1% of the patients a positive familiar history of
periodic fever of unknown origin was reported. At disease onset
the episodes of fever have a regular recurrence every 3- 6 weeks.
Pharyngitis (85.9%), cervical adenitis (70.6%) and aphthous stoma-
titis (60%) were frequently described with the fever. Other associ-
ated symptoms were abdominal pain, headache, arthralgia,
myalgia, rash and diarrhea. Clinical symptoms of PFAPA-like
group were similar unless age of onset and end, 6 years and 9,5
years, respectively. The fever decreased in severity, duration and
frequency with corticosteroids in both groups. A single dose of
prednisone (1 mg/kg/day) was enough for clinical abortion in
most patients. Tonsillectomy was a successful option in the pre-
vention of recurrences in selected patients.
Conclusion: There are no important clinical differences between our
PFAPA patients and the published PFAPA data. PFAPA-like group
have similar clinical manifestations compared to PFAPA, except the
onset and the end ages.
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Introduction: Autoinflammatory diseases are a group of diseases charac-
terized by inflammatory attacks in the absence of infectious, neoplastic or
autoimmune etiology. In many of them mutations in single genes have
been identified being called monogenic or hereditary periodic fever syn-
dromes Since 1999, when this term was proposed by Don Kastner for the
first time, new entities previously unknown are progressively being
described.
Objectives: Principal: To review the demographic data, clinical character-
istics and response to treatment of all patients included in the Spanish
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 170 of 243registry of autoinflammatory diseases (SpRAD). Secondary: To identify pa-
tients not currently included in the Eurofever registry and enroll them.
Methods: Retrospective cross-sectional study was performed. The study
was approved by the ethics committees of all hospitals and, accordingly,
the participants had to sign an informed consent prior to inclusion in the
registry.
Results: 287 patients from 14 centres in 9 different Spanish regions were
identified, 144 were males (50%). Genetic study had been performed in
144 individuals (50%), and 18 inconclusive mutations belonging to 14 pa-
tients were found. 106 had a clinical diagnosis of monogenic disease, be-
ing the most frequent: familiar Mediterranean fever (FMF) (40%), hyper Ig
D syndrome (HIDS) (25%), cryopyrinopathies (11%) and tumor necrosis
factor receptor-associated periodic syndrome (TRAPS) (8.5%). As ex-
pected, the most common identified mutation among TRAPS patients
was p.R92Q (67%). Three patients diagnosed with deficiency of adeno-
sine deaminase 2 (DADA2) were included, all of them with symptoms re-
sembling polyarteritis nodosa. The rest of cohort, 180 patients, were
classified as suspected polygenic diseases, including systemic-onset ju-
venile idiophatic arthritis (34%), periodic fever, aphtous stomatitis, pha-
ryngitis and adenopathy syndrome (PFAPA) (23%), chronic multifocal
recurrent osteomyelitis (CMRO) (25.5%), Behçet syndrome (12%) and non-
specific recurrent fever (5.5%). Globally, the most frequent clinical mani-
festations at onset were fever, cutaneous symptoms, arthritis or
arthralgia, lymphadenopathies and abdominalgia. One patient, who was
finally diagnosed with chronic infantile neurological, cutaneous, and ar-
ticular (CINCA) syndrome, showed deafness. Two HIDS patients presented
advanced kidney failure due to amyloidosis. 118 patients were still on
treatment at the time of the study cut: corticosteroids (46.5%), colchicine
(40%), anti IL1 (43%), anti IL6 (23%), anti TNF (23%) and JAK inhibitor in
one patient.
Conclusion: Autoinflammatory diseases are infrequent diseases. For
this reason, registries are necessary in order to gather as many pa-
tients as possible, with the aim of improving these diseases descrip-
tion, avoiding misdiagnosis and developing therapy strategies.
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Introduction: ISG15 is a type I interferon (IFN)-inducible gene, encod-
ing an ubiquitin-like protein which is an effector of IFN-α/β-
dependent antiviral immunity in mice. Previous reports, based on
only 6 reported patients, have suggested that this deficiency does
not lead to increased viral infections in humans, but do promote
autoinflammation.
Objectives: We present a 6 year old girl, recently diagnosed with this
rare disease. We describe the striking presentation of this case, its
diagnostic/therapeutic approaches, and clinical outcome.
Methods: Medical chart was reviewed.
Results: At the age of six months, the patient showed spontaneous
and severe deep and necrotizing ulcerations involving groins, genital
area and proximal thighs; with associated fever, increased acute
phase reactants, and strabismus corresponding to sequelae of chor-
iorretinitis. After exhaustive study, no infectious/traumatic etiology
was found. The biopsy showed necrosis of the epidermis, dermis and
upper subcutis and vascular thrombosis in one margin. Despite par-
enteral antibiotics, surgical debridement and vacuum-assisted wound
closure therapy, healing was achieved only after oral steroids treat-
ment. Firstly considered an early onset Behçet disease, etanercept
was started with incomplete response, since systemic flares stillappeared albeit milder. IL-1 blockade was initiated (anakinra) with
persistence of systemic symptoms, and was thus withdrawn. Adali-
mumab was subsequently started and had to be retired, due to a
rapid development of anti-adalimumab antibodies at high levels. The
patient had recurrent systemic inflammation flares, becoming
steroid-dependent. At the age of 4, a deep and severe necrosis
followed by ulceration appeared on her neck, which led to hospital
admission for metilprednisolone intravenous pulses. Finally, IL-6
blockade was started with quick and complete response of systemic
symptoms. Nevertheless, mild skin flares have appeared twice, being
controlled with short courses of oral steroids. In September 2017, a
broader genetic study by next generation sequencing (NGS) panel
was performed, and two heterozygous mutations affecting ISG15
gene were discovered. After literature review involving 6 patients,
skin lesions were interpreted as affecting skin areas specifically above
lymphadenopathies. Moreover, the basal ganglia brain calcifications
that some of the previously reported patients exhibited led to per-
form brain CT scan, which demonstrated the presence of striking cal-
cifications. At present, the patient is still on tocilizumab, her growth
is normal, and has not presented serious infections.
Conclusion: Data reported so far show that ISG15 deficiency behaves
as an autoinflammatory disease but also as an immunodeficiency,
due to its involvement in type-I and type-II IFN regulation pathways.
Thus, affected individuals exhibit higher IFNα and lower IFNγ re-
sponses in comparison with healthy donors. This condition upholds
the growing evidence supporting the existence of a “continuum” be-
tween autoimmune/autoinflammatory diseases and immunodefi-
ciency conditions. IL-6 blockade has been effective in this single
patient, being to our knowledge the only ISG15 deficiency case who
has been reported as respondent to tocilizumab.
This patient’s parents have given their consent for presenting the
case to this congress and for further publication.
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Introduction: Childhood onset gouty tophus is a very rare
phenomenon. The conventional pharmacotherapy using for ad-
equate hyperuricemia control and acute gouty arthritis treatment are
limited in cases of severe tubulointersitial nephritis. Our experience
of single injection of Canakinumab in adolescent patient seems to be
very successful. Such experience has not been described earlier in
available literature.
Objectives: Presentation of our experience with Canakinumab ther-
apy in an adolescent patient with an early onset severe tophac-
eous gout and severe chronic kidney disease.
Methods: Case report.
Results: A 13 yo male patient with normal physical, psychosocial and
cognitive development presented with acute onset arthritis in the
right elbow (intensive pain, swelling, hyperemia and local hyperther-
mia) without potential triggering factors in November 2015. Because
of the provisional diagnosis of acute hematogenous osteomyelitis
the patient was hospitalized for surgical procedure (osteoperforation
of right humerus) and antibacterial therapy. For the next several
months he suffered from multiple episodes of acute arthritis in meta-
tarsophalangeal joint of the left toe, left ankle joint, left elbow joint,
interphalangeal joints of 3 and 5 fingers on the right hand. Diagnosis
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 171 of 243JRA, polyarthritis was established in April 2016. The patient was
treated by NSAIDs (i/m and per os) and sulfasalazine without any ef-
fect. Joints’ deformities and numerous tophies developed very rap-
idly. The diagnosis of tophaceous gout was suspected in June 2017.
The highest documented serum level of uric acid was 990.0 μmol/L.
Allopurinol therapy 200 mg/day started. By October 2017 lab findings
were as follows: serum creatinine 152 μmol/L, urea 8.1 mMol/L, uric
acid 397.1 μmol/L. Schwartz estimate glomerular filtration rate (GFR)
was 63.2 ml/min, diurnal proteinuria -0.1 g/day. Ultrasound and
scintigraphic findings confirmed chronic urate tubulointerstitial neph-
ritis. Imaging modalities (US, radiography, MRI) identified severe
bones destructions typical for chronic tophaceous gout. Acute arth-
ritis in the right ankle with significant intra-articular effusion and in-
flammatory changes in the synovial fluid and formation of crystals of
monurate sodium broke out in November 2017. Molecular-genetic
testing confirmed the syndrome of Kelley-Seegmiller (the hemizygo-
tic mutation in the gene HPRT1). A single 150 mg dose of Canakinu-
mab was injected in order to gain some control over disease activity
with excellent result. Its sustainable effect provided the possibility of
urate-lowering therapy. Febuxostat at 80 mg/day was administered
instead of allopurinol. The patient didn’t have attacks of acute arth-
ritis during 4 next months. Lab findings in April 2018 were as follows:
serum level of uric acid – 297 μmol/L, creatinine - 161.0 μmol/L.
Conclusion: Canakinumab injection provided rapid reverse of gouty
arthritis acute attack, and subsequent achievement of target serum
uric acid levels after administration of febuxostat in an adolescent
patient with severe tophaceous gout and chronic urate tubulointer-
stitial nephritis, which limited the allopurinol, NSAIDs and colchicine
using. Informed consent to publish had been obtained from the
parent.
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Introduction: Chronic recurrent multifocal osteomyelitis (CRMO) is a
rare autoinflammatory disease affecting bone. Untreated CRMO can re-
sult in complications such as vertebral compression fractures and leg
length discrepancy. First line treatment is with non-steroidal anti-
inflammatory drugs (NSAIDs) with a reported response rate of 50-
80%. Limited data is available on the efficacy of second-line treatments
which include methotrexate, bisphosphonates and biologic agents.
Objectives: To describe the experience of the National Centre for
Paediatric Rheumatology (NCPR) treating currently attending CRMO
patients with second-line agents.
Methods: Retrospective chart review of current patients requiring
second-line agents attending the National Centre for Paediatric
Rheumatology. Persistent active disease on NSAIDs was defined as
persistent pain with tenderness/warmth or persistent bone oedema
on MRI in at least one lesion site after >4 weeks treatment (CARRA
consensus treatment guidelines). Response to treatment was de-
fined as clinical and/or radiological improvement without complete
resolution. Remission was defined as normal ESR, absence of inflam-
matory pain or clinically active lesions, resolution of marrow oedema
on MRI and absence of new lesions on whole-body MRI (modified
CARRA criteria for treatment failure).
Results: Clinical charts of 30 patients with CRMO were reviewed. The
median age at onset was 8.5 years, and median follow-up was 3 years.
The median number of sites 3 (1-21), 87% had multifocal disease.
Second-line treatment was required in 60%. The indications for second-line treatment were persistent active disease on NSAIDS or the pres-
ence of spinal lesions or cosmetically significant mandibular lesion.
A total of 19 patients received methotrexate, either alone (n=8 )or in
combination with a biologic agent (n=11). Three received pamidro-
nate and 11 received a biologic agent with methotrexate. None of
the patients who received pamidronate achieved remission and all
subsequently received methotrexate +/- a biologic. Of those who re-
ceived methotrexate monotherapy, 1 is in remission on treatment, 1
remains in remission off treatment, 4 have responded but not
achieved remission and 2 have received <2 months treatment.
Of those on biologic combination therapy, 2 patients are in remission
on anti-TNF combination treatment, 1 discontinued biologic treat-
ment due to a hypersensitivity reaction. The remaining patients have
responded but have yet to achieve remission.
Conclusion: Treatment with second-line agents has led to a symp-
tomatic improvement in all patients but remission in only 4 patients.
Combination therapy of methotrexate and a biologic agent may be
the most favourable option but randomised controlled trials with
clearly defined response and remission criteria are required.
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Introduction: TRNT1 is a nuclear gene encoding a ubiquitous enzyme
(CCA-adding tRNA nucleotidyl transferase enzyme) necessary for ami-
noacylation of both mitochondrial and cytosolic tRNA. TRNT1 muta-
tions are associated to heterogeneous phenotypes and multisystem
involvement of variable severity and progression.
Objectives: to characterize clinical features, laboratory assessment
and treatment strategies in 2 patients affected by TRNT1 mutations
referred to our pediatric rheumatology unit.
Methods: The patient 1 (P1) is a twenty years old female. From the first
month of life she experienced recurrent fever associated to painful cu-
taneous lesions, edema of the hands, raised inflammatory markers and
anemia. The symptoms were moderately controlled by corticosteroid
therapy. One of these episodes was characterized by severe anemia
(Hb 6.6 g/dl), requiring blood transfusion. At the age of 8 months she
was found to have mild hypogammaglobulinemia, but no other alter-
ations were found on immunological investigations. She showed
normalization of the immunoglobulin levels at the age of 22 months.
The physical examination found facial dysmorphisms, brittle hair, devel-
opmental delay and microcephaly. Splenomegaly was reported by ab-
domen ultrasound. Isolated Growth Hormone Deficiency (GHD) was
diagnosticated at the age of 3 years and it was treated with recombin-
ant human GH (rhGH) for the next 4 years, without improvement. At
the age of 8 years she was diagnosed with bilateral sensorineural hear-
ing loss. At the age of 10 she was diagnosticated with posterior subcap-
sular cataract, probably related to chronic steroid treatment. The
patient 2 (P2) is a ten years old female. From four months of age she
suffered from recurrent fever, associated from the age of 11 months to
painful cutaneous lesions. Laboratory assessment showed elevated
serum inflammatory markers, mild anaemia, hypogammaglobulinemia
and reduced levels of B-cells. Growing up, she showed failure to thrive,
developmental delay, facial dysmorphisms, brittle, microcephaly,
hepato-splenomegaly and swelling of the right ankle. At the age of two
she was diagnosticated with sensorineural hearing loss and bilateral
cataract. At the age of 5 she started therapy with rhGH for GHD.
Results: Suspecting Chronic Infantile Neurologic Cutaneous and ar-
ticular (CINCA) syndrome,even though negativity of molecular ana-
lysis of CIAS1, they started treatment with anti-IL1 (Anakinra) at the
age of 9 (P1) and 2 (P2). Due to the partial response, P1 shifted to
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 172 of 243anti-TNFa therapy (Etanercept) at the age of 11 with significant im-
provement. P2 showed nonresponse to Anakinra so she shifted to
Etanercept after four months. Whole exome sequencing was per-
formed resulting in two mutation of TNRT1: P1 c.608G>A
(p.Arg203Lys), c.1246A>G (p.Lys416Glu); P2 c.938delT (p.Leu313fs),
c.1246A>G (p.Lys416Glu). During the 9 years follow-up the patients
underwent six-month clinical and laboratory assessment, showing
normalization of inflammatory index and resolution of recurrent fever
and associated symptoms.
Conclusion: Recently, treatment with Etanercept was reported in
three patients, showing steady improvement of clinical and labora-
tory parameters. In this study we extend the cohort of patients de-
scribed with TRNT1 mutations, we report a new mutation (c.938delT)
and the longest follow up in patients treated with Etanercept, con-
firming efficacy and safety of this treatment.
Informed consent for the publication was obteined from the parents.
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Introduction: The MEFV gene, which causes autosomal recessive Famil-
ial Mediterranean fever (FMF) disease, encodes pyrin protein to control
inflammation, and mutations in this gene can cause fail to function and
control the inflammation. Therefore, it has been reported that various
inflammatory diseases are associated with FMF disease.
Objectives: The aim of this study is to investigate the frequency of
FMF associated inflammatory diseases in children.
Methods: FMF patients who were followed at department of
pediatric rheumatology in Pamukkale University in the last five years
had been retrospectively reviewed. 26 of 322 FMF patients (7.8%)
were diagnosed with FMF and inflamatory diseases.
Results: İnflamatory diseases were as followings: 10 sacroiliitis
(38.5%), 5 vasculitis (19.2%), 2 oligoarticular juvenile idiopathic arth-
ritis (7.7%), 1 polyarticular juvenile idiopathic arthritis (3.8%), 1 juven-
ile psoriatic arthritis (3.8%), 3 P-FAPA (11.5%), 1 inflammatory bowel
disease (3.8%), and 1 celiac disease (3.8%). Five patients (19.2%) who
were diagnosed FMF and vasculitis were diagnosed with 4 henoch
schonlein purpura (HSP) and 1 hypocomplementemic urticarial vas-
culitis syndrome. Erythema nodosum developed during follow-up in
2 patients. M694V mutation in the MEFV gene was detected in 15
(57.6%) of 26 FMF patients with concomitant disease. 11.5% of
M694V mutation was homozygous (1 patient polyarticular JIA, 1 pa-
tient sacroileitis, 1 patient HSP). All of the patients were receiving
additional medication due to comorbidities while they were receiving
colchicine treatment. These treatments were 4 methotrexate, 4 sulfa-
salazine, 2 etanercept, 1 tosilizumab, 1 intraarticular steroid.
Conclusion: Some inflammatory diseases including juvenile idio-
pathic arthritis, P-FAPA, vasculitis, celiac and inflammatory bowel dis-
ease were more common with FMF. M694V mutation in childhood
FMF patients may be a susceptibility factor for related diseases. It
should be routinely monitored in terms of other inflammatory dis-
eases in our country where FMF is common.
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Introduction: Chronic recurrent multifocal osteomyelitis (CRMO) is an
idiopathic, auto inflammatory disease characterized by exacerbations
and healing periods.
Objectives: We aimed to present two siblings diagnosed as CRMO
who were resistant to nonsteroidal anti-inflammatory drugs and ster-
oid treatments. Their parents were first-degree cousins.
Methods: We reviewed the records of clinical symptoms, treatment
modality and clinical course in those siblings and analyzed to data.
Results: Case 1:
A 13-year-old boy was admitted to our clinic with swelling on jaw and
gait disturbance. Past medical history revealed that he was diagnosed
with juvenile idiopathic arthritis at two years old in another rheumatology
clinic and treated with some anti- inflammatory drugs such as steroid
and naproxen. However he could not visit regularly. On physical examin-
ation at first presentation he suffered from limitation of mandibular
movement and pain of right leg. There was no arthritis. Acute phase
markers were higher (C reactive protein: 6.6 mg/dl and erythrocyte sedi-
mentation rate: 74 mm/hour). MR imaging revealed contrast enhance-
ment in the right mandibular and ramus bones, right ramus erosion. It
was diagnosed as chronic osteomyelitis in his pathology and tissue cul-
ture was negative. Firstly the symptoms were controlled with short-term
steroid therapy, then the steroid was gradually reduced and ceased.
Meanwhile, methotrexate 15 mg / m2 /week was started. Since there was
no response, etanercept 50 mg / week was commenced at third month.
Although etanercept was administered for 6 months and no response
was obtained, biologic treatment was switched to adalimumab (40 mg
every two weeks). Significant clinical improvement was seen after a
months of the adalimumab treatment and high acute phase markers de-
creased within six months (C reactive protein:0.22 mg/dl and erythrocyte
sedimentation rate:38 mm/hour). He has no complaints for 10 months.
Case 2:
A 18-year-old boy presented with a swollen and painful right posterior
leg following a minor trauma. Ten years ago he was admitted to an-
other center with this the same complaint and biopsy was performed
since it was presumed osteosarcoma. The pathology was found to be
compatible with chronic osteomyelitis and also tissue culture was nega-
tive. He did not visit regularly the polyclinic like his brother, and he had
complaints as irregular consume of steroid and sulfasalazine drug treat-
ment for a long time. On physical examination, right femur and tibia
sensitivities were observed. Acute phase reactants were high (C reactive
protein: 4.1 mg/dl and erythrocyte sedimentation rate: 80 mm/hour).
The whole body MR detected chronic multifocal osteomyelitis in the re-
gion extending from the right femur and proximal tibia shafts to the
distal metaphyseal region. Methotrexate 15 mg / m2 / week and adali-
mumab 40 mg / 2 weeks was commenced. The clinical response was
complete at 3 months of treatment and acute phase reactants de-
creased within 9 months of treatment (C reactive protein:0.02 mg/dl
and erythrocyte sedimentation rate:27 mm/hour). The genetic screen-
ing of patients was planned. Informed consent to publish had been ob-
tained from the patient.
Conclusion: CRMO treatment should be individualized. Therapy choice
can be variable such as only nonsteroidal anti-inflammatory drugs or
steroid or anti-TNF therapy. These CRMO brothers thought to us that
there is a strongly probable genetic basis in the etiology of the disease.
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Introduction: Although familial Mediterranean fever (FMF) is the most
common autoinflammatory disease in the world, many problems of
FMF management are not standardised for optimal disease control and
follow-up. A standardised assessment of disease severity is required for
therapeutic decisions in managing patients with FMF. There are several
severity scoring systems for FMF. Because there is no consensus on any
of them and they were not consistent with each other, an international
group of FMF experts developed and initially validated a new severity
scoring system for FMF, which was called “international severity scor-
ing system for FMF” (ISSF). It is an easily applicable and widely accept-
able scoring system for research and clinical practice.
Objectives: To evaluate the disease severity scores of our patients by
using ISSF and compare them with literature data.
Methods: The patients who were diagnosed as FMF according to the
Tel-Hashomer criteria and being followed at Department of Rheuma-
tology in Behçet Uz Children’s Hospital for at least 6 months were
consecutively enrolled in this cross-sectional study. Demographic
data, FMF symptoms, MEFV mutation, disease duration, time to delay
for diagnosis, duration of follow-up, duration of attacks, and disease
severity score were recorded for each patient. Patients were classified
as mild, moderate and severe according to ISSF. The study protocol
was approved by the local ethical committee.
Results: A total of 160 patients (88 females and 72 males) were en-
rolled. The mean age of the patients was 12 ± 4.3 years. Thirty four
(%21.3) patients have mild, 113 (%70.5) patients moderate, 13(% 8.2)
patients have severe score according to ISSF. The most frequently
identified mutations in our study population were M694V (%54.3)
and E148Q (%18). Homozygous patients (M694V, M694I, M680I, and
V726A) had more severe disease. The disease severity score was posi-
tively correlated with the duration and dose of colchicine. There was
not a significant correlation between age at disease onset and ISSF
scores. When the patients were evaluated according to the age
groups, the duration of the attack was shorter in older patients (p<
0.05). Besides, different organ involvement during attacks was higher
in patients older than 7 years.
Conclusion: The compatibility of the data obtained from our study
with the literature in general indicates that ISSF is a suitable tool for
assessing disease severity. Furthermore, the results of this study sug-
gests that addition of “existence of some pathological MEFV muta-
tions” as a criterion of ISSF may be useful.
Trial registration identifying number: FMF, ISSF
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Introduction: In a recent series of 486 cases of Chronic Non-
bacterial Osteomyelitis (CNO) from the Eurofever international
registry, association between psoriasis and CNO was observed in
4% of the patients. The tumor necrosis factor-alpha (TNF-α) inhib-
itors drugs are increasingly used in treating psoriasis. In theConsensus Treatment Plans for Chronic Non-bacterial Osteomye-
litis anti-TNF-αare also a therapeutic option for patients with re-
fractory CNO. Based on these considerations we decided to treat
3 patients with CNO and psoriasis with etanercept but we ob-
served a worsening of skin involvement.
Objectives: To report the worsening of psoriasis in patients with
CNO in relation to use of etanercept.
Methods: Children with diagnosis of CNO associated with psoriasis
and treated with etanercept were included. Subsequent response to
this therapy was recorded.
Results: Pt1: caucasian female with diagnosis, at age of 10 years, of CNO
(long bones and vertebral lesions) and psoriasis (scalp and left plantar).
Due to clinical and radiological worsening of bone involvement after
non-steroidal anti-inflammatory drugs (NSAIDs) and 2 cycles of pamidro-
nate (1 mg/kg/day for 3 consecutive days every 3 months), we decided
to start etanercept. After 3 months of therapy psoriasis got significantly
worse. We discontinued etanercept with initial improvement of skin le-
sions. Pt2: 17 year-old caucasian female with CNO (long bones, vertebral
and pelvic lesions) and psoriasis (scalp and plaque psoriasis on the legs)
treated at the onset of the disease with IV cycles of pamidronate and
sulfasalazine. Despite an initial and persistent good response, after 2
years of treatment with sulfasalazine the patient showed clear evidence
of lack response. We started etanercept and we observed, after 3
months of therapy, an improvement of clinical and radiological bones in-
volvement but a worsening of psoriasis. The patient refused to discon-
tinue etanercept. After 6 months of therapy she had persistent remission
of CNO and stable skin lesions. Pt3: caucasian female with diagnosis, at
age of 8 years, of CNO (vertebral, pelvic and long bones lesions) and
psoriasis (scalp and periauricular lesions). Due to D6 and D9 vertebral
wedge deformities patient was treated with glucocorticoids and pami-
dronate. After 3 months she had a persistent polyarthralgia associated
with radiological increase in the number of bone lesions. We started eta-
nercept and we complete pamidronate cycles (a total of 4 cycles). She
had good clinical response without pain or functional impairment and
with decrease of bone lesions. After starting etanercept we observed a
severe exacerbation of psoriasis with increase in the number of skin le-
sions (scalp, plaque on the legs and nails). After 6 months of therapy we
decided to discontinue etanercept. At the last follow up visit, 2 months
later, skin and bone lesions were stable.
Conclusion: We report three cases of CNO and psoriasis treated with
etanercept with worsening of skin lesions. It is unclear the mechan-
ism that leads to exacerbation of previous psoriasis during the course
of treatment with etanercept. Further studies with a larger number
of patients are needed to clarify this mechanism and the manage-
ment of the patients. Should be discontinued etanercept, switched
to another anti-TNF-α or combined with another systemic treatment
such as methotrexate or cyclosporine? Informed consent to publish
had been obtained from the parents.
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Introduction: Majeed syndrome is a very rare autosomal recessive,
autoinflammatory disorder characterized by a triad of chronic recur-
rent multifocal osteomyelitis, congenital dyserythropoietic anemia
and neutrophilic dermatosis caused by LPIN2 gene mutation. 12/13
mutation positive cases identified till 2017 have been reported from
the Middle East.
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 174 of 243Objectives: We describe our brief experience with the second family
with a child afflicted with Majeed syndrome from India.
Methods: A 3 year old male child born of a consanguineous mar-
riage, presented with recurrent irregular episodes of fever with irrit-
ability and failure to thrive since 5 months of age . At 9 months of
age parents noticed, small skin ‘boils’ over the trunk and limbs,
which recurred every 15-20 days along with the fever and stayed for
4-5 days. At 18 months, parents noticed that he refused to bear
weight and walk and would cry on handling.
Gradually the episodes of painful small skin boils, limb pains which
the parents could not localize and fever increased in frequency and
after multiple pediatric, orthopaedic consults he was referred to us
by a pediatric neurologist who had been referred the case to rule
out Fabry disease. The pediatric neurologist had asked for whole ex-
ome sequencing and referred the case to us for clinical evaluation
sensing a musculoskeletal rather than neurological disease.
Results: On examination the weight (10 kg) and height (83 cm) were
below 3rd centile. He had pallor, painful swelling over the left tibia,
motor delay with hamstring tightness and mild bilateral knee contrac-
tures. Language and social milestones were normal. There were no skin
lesions at the time of evaluation and systemic examination was normal.
Review of his past investigations revealed a persistent, microcytic hy-
pochromic anemia (Hemoglobin 8.3-10.6 gm/dl) with raised erythro-
cyte sedimentation rate (54-105 mm/hr), C-reactive protein (37-98
mg/l) and platelets (4.3-8.9 x103 cu mm).
His genetic mutation for LPIN 2 returned positive with homozygous
missense variation in exon 17 of the LPIN2 gene resulting in amino
acid substitution of cysteine to arginine at codon 736 (p.Arg736Cy-
s;ENST00000261596). Meanwhile a bone scintigraphy done, showed
increased vascularity and osseous activity in proximal shaft of left
tibia with mild osseous activity at D9 and D10 vertebrae. A bone
marrow examination was not performed as a conclusive mutation
diagnosis was obtained.
He showed a dramatic response to Ibuprofen with abatement of fever,
no skin boils and improvement of general mood and playfulness. With
a view to attempt to omit NSAIDs intravenous Pamidronate was com-
menced. After the first course at 10 weeks follow up, he has gained
weight (11kg), is afebrile, walks with support with no new skin lesions.
Conclusion: Paucity of awareness amongst the medical community
about these rare illnesses are responsible for diagnostic delays and
complex referral pathways. With the high rates of consanguinity in sev-
eral parts of our country we believe that we are seeing just the tip of
the iceberg of monogenic autoinflammatory diseases. Due to non avail-
ability of Interleukin-1 inhibitors in India, which are highly effective at
controlling osseous and systemic inflammation in Majeed syndrome,
we have limited treatment options to offer to our patient. We have of-
fered educational resource and genetic counselling to the family. Writ-
ten informed consent was obtained from the patients for publication.
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Pediatric Rheumatology 2018, 16(Suppl 2):P338Introduction: PFAPA is an autoinflammatory disease characterized
by recurrent febrile episodes with associated symptoms from the
mouth and throat, with a typical onset before 5 years of age.
Tonsillectomy has been shown to be curative in a majority of pa-
tients, but remains debated as PFAPA is self-limiting and usually
resolves spontaneously before adulthood. However, the conse-
quences of the recurring fevers in terms of health-related quality
of life and family impact have not been previously studied.
Objectives: The aim of this pilot study was to investigate health-
related quality of life in children with PFAPA and the impact of the
disease on their families before and after tonsillectomy.
- Is the health-related quality of life affected in children with PFAPA,
and does it improve after tonsillectomy, as measured by Pediatric
Quality of Life Inventory™ 4.0 Generic Core Scales (PedsQL™ 4.0 GCS) ?
- What impact does PFAPA have on the family of patients and does
it change after tonsillectomy, as measured by PedsQL™ Family
Impact Module (PedsQL™ FIM)?
Methods: Children with typical PFAPA referred for tonsillectomy
in our clinics were enrolled consecutively. Parents to these pa-
tients answered PedsQL™ 4.0 GCS to measure health-related qual-
ity of life during fever episodes, between episodes and six
months after tonsillectomy. Family impact of PFAPA was mea-
sured by PedsQL™ FIM filled in by the parents before and six
months after tonsillectomy. Parents were also asked to keep a
diary of fever episodes during the study period. The PedsQL™
scales were scored according to The PedsQL™ Scoring Algorithm,
were items are reversely scored and linearly transformed to a 0-
100 scale, so that higher scores indicate better outcome. The
total scale score for each patient was obtained by computing the
mean of all items on the scale.
Results: In this pilot, six patients and their parents have completed
the study. The patients had a median of 7,5 episodes (range 5-9) dur-
ing the six months prior to tonsillectomy. After tonsillectomy, all pa-
tients were free of symptoms during the six months of follow-up.
Total scale scores on PedsQL™ 4.0 GCS were low during fever epi-
sodes with a median of 51,1 (range 43,5-55,4) and improved mark-
edly between episodes to a median of 88,1 (range 67,4-96,6) and
after tonsillectomy to a median of 93,9 (range 82,6-99). This also
showed a tendency to lower scores between fever episodes before
tonsillectomy compared to after tonsillectomy, although no further
statistical analysis was made due to the low number of patients.
Total scale scores on PedsQL™ FIM had a median of 61,5 (range 42,4-
74,3) before tonsillectomy and improved to a median of 93,8 (range
52,1-100) after tonsillectomy. One family stood out with a low and
unchanged score on the family impact module after tonsillectomy. In
this family, a younger sibling of the patient was diagnosed with
PFAPA during the study period.
Conclusion: Even though PFAPA syndrome is a benign disease with
a good long-term prognosis, this small pilot study indicates that it
has considerable negative impact on the child affected by the dis-
ease and the entire family. Tonsillectomy may be beneficial as ceas-
ing of the fever episodes improves the wellbeing of the child and
the family. There is a plan to continue this study with inclusion of a
greater number of patients.
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Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 175 of 243Introduction: Chronic recurrent multifocal osteomyelitis (CRMO) is a
rare disease characterized by sterile bone inflammation. It is an
orphan disease with many unclear aspects in diagnosis, treatment
and follow-up.
Objectives: The aim of this study is to report our experiences of
pediatric CRMO patients, as a tertiary pediatric rheumatology center,
regarding clinical and laboratory findings, treatments, disease activity
and treatment responses.
Methods: Children who were diagnosed with chronic recurrent multi-
focal osteomyelitis (CRMO), and were followed-up in the Pediatric
Rheumatology Unit of Hacettepe University between January 2008
and January 2017, were included in this study. Clinical characteristics
and laboratory findings (including radiological and pathological
evaluation) were reviewed from medical charts and electronic files of
the patients. In addition, treatments, treatment responses and dis-
ease activity were documented retrospectively.
Results: There were 15 CRMO patients (8M/7F) with a median age at
diagnosis of 10.5 yrs. Bone pain was the most common presenting
symptom. All of the patients had multifocal bone lesions. Vertebra
(66%) and femur (66%) were the most commonly affected bones. 8
of the patients also had sacroiliitis however only one of them was
HLA-B27 positive. Whole-body MRI used as a diagnostic tool in 13
patients revealing bone marrow edema (84.6%), osteitis (69.2%) and
periosteal reaction (61.5%). Bone biopsy was performed in 6 patients
showing sterile osteomyelitis with mixed inflammatory infiltration
and sclerosis. All patients were initially treated with NSAIDs, however
DMARDs, anti-TNF agents or pamidronate were added to therapy
due to inadequate treatment response. Clinical remission was
achieved in 12 patients (1 with NSAID, 3 with methotrexate, 1 with
pamidronate and 7 with an anti-TNF agent). During the follow-up
period, relapses were observed in four patients presented with pain
and/or a newly formed bone lesion on MRI. However, finally all of
these patients also reached remission. Three patients continued to
have clinical and radiologic active disease despite anti-TNF treatment
in two patients and pamidronate in one patient.
Conclusion: CRMO is a chronic disease which may have a progressive
or relapsing-remitting course. NSAIDs and anti-TNF drugs are the most
efficacious treatment, however pamidronate may also be used for re-
fractory cases. Although there is no consensus on follow-up parameters,
WB-MRI is a very useful tool to show active disease even the patient is
in clinical remission. Improvement of the knowledge about this rare dis-
ease may help to enlighten the unknowns of the disease.
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Introduction: Cryopyrin-associated periodic syndrome (CAPS) is a
rare group of monogenic autoinflammatory diseases (AIDs) associ-
ated with a mutation in the gene NLRP3.
Objectives: To characterize clinical and laboratory manifestations,
genetic features, therapy options, the course of the disease in pa-
tients with CAPS in the practice of pediatric rheumatologist.
Methods: It was an observational study of pediatric and adult pa-
tients with clinical diagnosis CAPS according to the Russian FederalRheumatology Center from 2007 to 2017. All patients passed the
examination generally accepted in rheumatology including molecular
genetic tests of NLRP3 gene.
Results: The study included 25 patients with CAPS (17 children, 8
adults), there were 11 males and 14 females. A total of 22 pts were
diagnosed with MWS and 3 pts had CINCA/NOMID. The aged of pts
were from 6 months up to 57 years, the duration of the disease was
from 1 month up to 44 years. Fever was noted in all patients, skin
rashes in 92%, eye symptoms in 52%, sensorineural hearing loss in
one third of patients, arthralgia/arthritis in 60%, neurological disor-
ders in 40%. All patients except one (with CINCA/NOMID) showed
mutations in the gene NLRP3, all in heterozygous state. The muta-
tions were p.T348M in 7 pts, Q703K in 13, V198M in 4, other muta-
tions in 6. 11 out of 25 pts received canakinumab (Il-1 inhibitor) for 1
- 5 years. The complete response to therapy was received in 9, partial
response-in 2 pts previously treated by anakinra. There were no
major adverse events (AE) or serious AE (SAE).
Conclusion: Despite the rarity, the patients with CAPS are found in
the practice of pediatric rheumatologist. Canakinumab is very effect-
ive and save treatment for CAPS pts. But the final diagnosis and ap-
pointment of therapy should be carried out with the participation of
experts in the field of AID.
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Introduction: Sweet Syndrome (Acute Febrile Neutrophilic Derma-
tosis) is an uncommon disease, extremely rare in children, where it
accounts 5% - 8% of all cases. The clinical suspicion is usually con-
firmed by the presence of a diffuse infiltrate of mature neutrophils in
the upper dermis at biopsy. On the bases of recent researches that
suggest an aberrant hyperproduction of interleukin‐1 in the patho-
genesis of this dermatosis, Anakinra, human interleukin 1 receptor
antagonist protein, has been used with success in some adults.
Objectives: We report our experience with Canakinumab (human anti-
IL-1β monoclonal antibody) in a paediatric case of Sweet Syndrome.
Methods: A five-years old male was admitted to our hospital for an
abrupt onset of fever, multiple, indurated painful red papules, and
plaques, associated with increased values of CRP, and ESR and neu-
trophilia. On histopathological examination, neutrophilic and lympho-
histiocytic infiltrate and edema were observed.
Results: On the basis of anamnestic, clinical, hystophtologic data and
laboratory tests the diagnosis of Sweet’s Syndrome was made and
prednisone was started. Despite a clear cutanous improvement, le-
sions apperared to flear at each attempted steroid withdrawal. Ana-
kinra was than introduced with a gradual good response. Because of
the scarce compliance due to the inconvenience of daily injections,
three months later, Anakinra was switched to Canakinumab (1 injec-
tion every 28 days). At a 4-months follow-up visit the patient’s cuta-
neous lesions were nearly resolved with minimal intervention.
Conclusion: To our knowledge, this is the first report of anti-IL-1β
monoclonal antibody treatment in Sweet syndrome. In our experi-
ence Canakinumab proved to be safe and effective. Informed con-
sent had been obtained from the parent.
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Introduction: Recurrent pericarditis (RP) is a common complication
of acute pericarditis (15–30%). Treatment regimen consists of a com-
bination of non-steroidal anti-inflammatory drugs (NSAIDs) with col-
chicine with the addition of corticosteroids in resistant or intolerant
cases. Anakinra is a therapeutic option as steroid-sparing agent. Ana-
kinra neutralises the biologic activity of interleukin-1α (IL-1α) and
interleukin-1β (IL-1β) by inhibiting their binding to IL-1 type I recep-
tor, while Canakinumab is a monoclonal antibody against IL-1β only.
Objectives: To describe two cases of refractory recurrent pericarditis
with a divergent response to two different IL-1 blockers.
Methods: The first patient is a 8-years old girl with recurrent pericarditis
started in April 2015 (6 years old), after surgical correction of an atrial
septal defect. NSAIDs and oral steroids were started and then gradually
tapered, with prompt relapse after the steroid suspension requiring a
pericardiocentesis. The child showed a steroid-dependent recurrent
pericarditis, with several relapses if tapering was attempted and no
benefit from colchicine and NSAIDs. After five relapses Anakinra was
started with a fast and complete clinical response, but discontinued
after 2 weeks for severe local injection reactions. She was firstly evalu-
ated in our Centre in April 2016 and in July 2016 therapy with canaki-
numab 150 mg (approximately 4 mg/kg) every 4 weeks was started,
together with steroids (then gradually tapered) and NSAIDs.
The second patient is a 10-years-old girl with a history of idiopathic
recurrent pericarditis, started in April 2017 with typical clinical pic-
ture, need of an urgent pericardiocentesis at onset and initial benefit
from NSAIDs and colchicine. However, ten days after the first episode
a relapse occurred and therapy with anakinra was established with
dramatic and complete clinical response. Two months later, while be-
ing in complete remission, anakinra was replaced with canakinumab
(2.5 mg/kg/dose) due to patient’s poor compliance to daily
injections.
Results: Patient 1: She experienced four relapses during Canakinumab
therapy (July 2016 -December 2017), despite the modification of the
schedule (4 mg/kg every three weeks) associated with the reintroduc-
tion of colchicine since April 2017 and continuous steroid treatment
with repeated flares at every attempt of tapering. In January 2018 a
procedure of desensitization from anakinra was performed, with suc-
cess. Anakinra therapy is currently ongoing (12 weeks follow up), in as-
sociation with low-dose colchicine. An almost complete withdrawn of
steroid is currently undergoing with no signs of flare.
Patients 2:Ten days after the first Canakinumab injection she experi-
enced a relapse requiring oral steroids. Anakinra (2 mg/kg/day) was
subsequently re-started allowing steroid tapering in few days. The
patient showed complete remission in anakinra as monotherapy with
a good tolerance. After further 6 months follow-up under anakinra,
the patient did not show any clinical, laboratory or echocardio-
graphic signs of relapse.
Conclusion: We describe two cases of substantial failure of the treat-
ment with anti-IL-1b monoclonal antibodies treatment in steroid-
dependent idiopathic RP. In both case a good response to the treat-
ment with recombinant IL-1 receptor antagonist was achieved. These
anecdotal and preliminary observations suggest a different efficacy
of the two IL-1 blockers in the management of recurrent pericarditis
and support a possible pivotal role of IL-1α in the pathogenesis of
this condition. Informed consent to publish had been obtained from
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Introduction: PAPA syndrome (Pyogenic arthritis, Acne and Pyo-
derma gangrenosum) is a rare autosomal dominant autoinflamma-
tory disorder. To our knowledge it has not been described in
Bulgarian patients before.
Objectives: To describe the phenotype of five family members with
PAPA syndrome from Bulgaria; to report one novel mutation of exon 11
of the PSTPIP1 gene, and a second one not previously associated with
PAPA syndrome, and to share our experience with different treatments.
Methods: We present five family members from three generations. The
children have recurrent pyogenic arthritis, one with Pyoderma gangre-
nosum as well. Their father and paternal grandmother have suffered
similar, although less frequent, episodes as children, developed severe
acne as adolescents and started suffering from Pyoderma gangreno-
sum as adults. Genetic tests confirmed mutations in exon 11 of the
PSTPIP1 gene. One (c.766C>A) had been previously described in pa-
tients with hyperzincemia and hypercalprotectinaemia, but not in PAPA
syndrome, the second was a novel mutation, c.766C>A.
Results: We established earlier onset of arthritis in subsequent gener-
ations (the youngest of our patients had his first episode at 7 months
of age). Pyoderma gangrenosum which usually appears in adulthood
started at the age of 4 years in the same patient.
Intraarticular steroids provided mixed results. Treatment with Salazo-
pirine in one patient with active arthritis, and with Resochin in
another was unsuccessful. Oral steroid therapy for Pyoderma gangre-
nosum had variable, but mostly unsatisfactory results.
Conclusion: We report 2 mutations in the PSTPIP1 gene – one novel
and one not previously associated with PAPA syndrome. Treatment
with some of the standard DMARDs, used in JIA, does not seem to
be effective. Informed consent to publish had been obtained from
the parents and patients.
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Introduction: Diffuse sclerosing osteomyelitis of the manidble
(DSMO) is a unifocal form of chronic non-bacterial osteitis (CNO)
and predominantly affects patients < 18 years. Intravenous pami-
dronate (IV-PAM) has been reported to be effective in multifocal
CNO in short term.
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 177 of 243Objectives: To describe a long-term clinical and radiologic outcome
of a DSMO patient following treatment with IV-PAM.
Methods: A 4-year old Caucasian female was diagnosed with DSMO
and prospectively followed from 2007-2017. She presented with a
20-month history of facial asymmetry and painful bony expansion
of the left hemimandible. Imaging (radiographs, CT) showed an ex-
pansile lesion with radiolucency, some ground-glass appearance,
periosteal reaction and soft-tissue swelling. Infectious osteomyelitis
was ruled out, due to negative blood cultures and inefficacy of IV
and oral antibiotics. Fibrous dysplasia was then considered. She
remained symptomatic despite ibuprofen (10 mg/kg/dose 4 times
daily) and a jaw replacement surgery was planned due to progres-
sive symptoms. Bone biopsy was performed and histopathology
demonstrated paucity of the spindle cells characteristic to fibrous
dysplasia, and revealed multiple osteoblasts and inflammatory
plasma cells. Whole-body MRI confirmed an isolated lesion in the
left hemimandible with soft tissue edema and the diagnosis of
DSOM was made at age 4 years. She was referred to rheumatology
after failing NSAIDs and analgesics. Examination revealed marked
swelling to the left mandibular area. Laboratory investigations
showed elevated erythrocyte sedimentation rate [28mm/hr (normal
<10 mm/hr)] and platelet count [606 109/L (normal 150-400 109/L)].
C-reactive protein was normal. She was started on monthly 1-day
IV-PAM infusions (1st dose 0.5mg/kg; each subsequent dose: 1mg/
kg). The response to treatment was assessed according to visual
analogue score for pain (VAS, 0=no pain; 10=maximum pain), se-
quential MRIs and clinical photos.
Results: She received 8 monthly IV-PAM infusions. The base-line
VAS was “10”, which decreased to “0” after the first infusion and
VAS remained “0” throughout the remainder of treatment. MRI doc-
umented resolution of abnormal signal at 5 months with gradual
mandibular remodeling and sustained improvement at 12 months.
Clinical photographs documented the gradual improvement of fa-
cial symmetry and improved affect, which was sustained during
follow-up. She had no side effects to IV-PAM apart from nausea fol-
lowing the first infusion.
She had three MRI confirmed flares at 22, 67 and at 120 months at
the identical site with pain and decreased mouth opening. Her pain
VAS ranged from 4-6/10 during flares. Each flare responded to Na-
proxen monotherapy both clinically and by MRI and she required
no further IV-PAM. She required dental braces at age 10-years. She
remains asymptomatic at 120 month follow-up with excellent func-
tional and cosmetic outcome.
Conclusion: DSMO is challenging to diagnose and treat due to its rare-
ness and lack of uniformly effective treatment. IV-PAM was effective in
this young refractory patient in resolution of pain, mandibular remodel-
ing and cosmetic improvement that was sustained during long-
termfollow-up. We recommend a bone biopsy of mandibular CNO/
DSMO to help confirm the diagnosis to differentiate it from fibrous dys-
plasia of the jaw. Informed consent to publish had been obtained.
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Introduction: A type I interferonopathy due to DNase II deficiency
has ben recently described in three cases with multi-organ diseases.
Objectives: To describe the case of an italian 14-year-old girl with a
complex clinical phenotype in which an autoinflammatory diseasewas suspected and a new deleterious heterozygous DNase II muta-
tion was found.
Methods: The most meaningful clinical aspects of our patient are:
 severe hemolytic anemia detected at six weeks of age,
requiring red blood cell transfusions and finally resolved at
three years of age
 cholestatic hepatitis beginning at age 8 months; markers of
cholestasis normalized at age 2 years but she developed an
inactive liver cirrhosis with stable hepatosplenomegaly and
mild thrombocytopenia
 failure to thrive and recurrent hypoglycemia with need of
enteral feeding till age of 6 years
 antibody-negative insulin dependent diabetes mellitus with
onset at 10 years of age
 normal early psychomotor development with subsequent
learning difficulties at school. Brain MRI at age 11 showed
multiple alterations of signal intensity in the subcortical and
periventricular white matter
 recurrent episodes of enteritis and keratitis
 normal erythrocyte sedimentation rate and C-reactive protein
with fluctuating hypergammaglobulinemia and antinuclear
antibodies
Results: The major classes of inborn errors of metabolism, cirrhosis
and autoimmune diseases were investigated and ruled out.
The peculiar clinical picture put together signs that taken overall can
be reminiscent of a rare DNAse II deficiency.
In particular, early onset and self-healing anemia and cholestatic
hepatopathy, subcortical white matter dystrophy, non-autoimmune
insulin dependent diabetes and hypergammaglobulinemia are all de-
scribed in the recent report about DNAse II deficiency. Moreover, we
describe an increased interferon signature and thus decided to se-
quence DNAse II gene. The analysis revealed a heterozygous muta-
tion (c.621delC deletion on the exon five) predicted to be
deleterious. However, the same deletion was found in patient’s
father, prompting us to perform whole-exome sequencing in the
search for other genetic anomalies. So far, the analysis didn’t held
any definite explanation for the disease.
Conclusion: Several evidence support a role for the mutation in
DNAse II in the disease of the patient but other yet unknown genetic
and environmental factors have to be investigated. Informed consent
to publish had been obtained.
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Introduction: Chronic Non-Bacterial Osteomyelitis (CNO) is a non-
infectious inflammatory disease characterized by uni- or multifocal
Table 1 (abstract P347). VOUS and VUS associated with AIF diseases
that have been detected in our patients
MEFV MVK NOD2 TNFRSF1A NLRP12 LPIN2 PLCG2 IL10RA IL10RB
p.Glu148Gln
‡‡
p.Pro369Ser
p.Ser339Phe
p.Thr356Met* p.Met950Leu**
p.Met513Thr†
p.Arg791Gln †
p.Asn145Ser
p.Arg568His
p.Arg121Gln‡
p.Thr861Ser*** p.Cys874Phe
p.Pro149Leu
p.Pro626Ser
p.Lys387Glu
p.Glu601Lys
p.Glu601Lys
p.Asn798Ser
p.Ala313Gly
p.Pro522Arg
p.Ala420Thr
p.Glu58Lys
P.Arg412Trp††
p.Val148Met
AP1S3 CARD14 CECR1 NLRP7 RBCK1 SH3BP2 SLC29A3 TMEM173
p.Phe4Cys p.Met931Lys
p.Ser200Asn
p.Arg826Tr
p.Met267Ile p.Arg156Gln
Cys399Tyr
p.Gly242Val
p.Pro347Arg
p.Ala212Val
p.Arg534Trp
p.Arg83His
p.Glu331Lys
p.Ala313Thr
p.Gly192Val
No variants were detected in the following tested genes: IL1RN, NLRP3, PSMB8, PSTPIP1, IL10, IL36RN, NLRC4
‡‡ 2 patients with FMF, 2 patients with resolved PF; *HIDS; **IBD; †Blau, same patient; ‡TRAPS; ***infantile Raynaud’s Phenomenon; ††IBD
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warmth. CNO mainly affects the metaphyses of the long bones, the
pelvis, shoulder girdle and, less commonly, the spine and the man-
dible. Only four cases of CNO involving the cranium have been re-
ported so far [1]
Objectives: To describe the prevalence and the clinical manifesta-
tions of CNO patients with neurocranium involvement among an Ital-
ian cohort of CNO patients.
Methods: This is a retrospective study. Charts of patients with CNO
admitted to eight Pediatric Rheumatology centres were reviewed.
Data collection included patient and family history, age at diagnosis,
sex, number and location of bone lesions at onset, diagnostic im-
aging, laboratory data at presentation and at last visit, histological
findings, comorbidity and response to treatments.
Results: Eighty-six patients were enrolled in the study. 31 were males
and 55 were females. The mean age at diagnosis was 9.4 years (SD ±
3.3). Only 11 patients presented a monofocal involvement while 75
patients presented a multifocal disease at onset. 3 out of 86 patients
(3.5%) presented a cranial involvement at onset. These three patients
were females; the age of presentation was 2 years old for one patient
and 12 for the last two. All of them presented multifocal lesions at
onset (12, 20 and 13 lesions respectively) but none of them com-
plained clinical symptoms attributable to skull involvement (head-
ache, vomiting, visual impairment, focal neurological involvement,
etc). Cranial involvement were detected only with bone scintigraphy
and then confirmed by magnetic resonance imaging and/or com-
puted tomography. 2 patients presented fever and two skin manifes-
tations. Laboratory inflammatory indeces were increased in two
patients. All underwent bone biopsy in another bone site confirming
the diagnosis. All patients received NSAIDs, without response. Two
patients received corticosteroid and then methotrexate reaching clin-
ical remission. One patient received pamidronate without benefit
and she still presents an active disease at the end of follow-up.
Conclusion: This is the first report of cranial involvement in a cohort
of patients affected by CNO. Cranial involvement confirms to be a
rare localisation and it seems to be associated with multifocal in-
volvement. In our cohort, in contrast with the 4 patients reported in
literature, all patients were asymptomatic. In case of cranial involve-
ment radiological control may be needed during follow-up.
Reference
1. Foley MR, Moshfeghi DM, Wilson MW et al. Orbital inflammatory
syndromes with systemic involvement may mimic metastatic disease.
Ophthal Plast Reconstr Surg. 2003;19:324-7
Disclosure of Interest
None Declared
P347
EXPANDING THE GENOTYPING OF PATIENTS WITH
AUTOINFLAMMATORY SYNDROMES
Maria Tsinti1, Maria Zamanakou2, Gedeon Loules2, Vasiliki
Dermentzoglou1, Elena Tsitsami1
1Pediatric Rheumatology Unit, First Department of Pediatrics, University
of Athens, Medical School, Children's Hospital Aghia Sophia, Athens;
2CeMIA SA, Larissa, Greece
Correspondence: Maria Tsinti
Pediatric Rheumatology 2018, 16(Suppl 2):P347
Introduction: Presentation of monogenic autoinflammatory (AIF)
diseases is markedly heterogenous. Next Generation Sequencing
(NGS) increases the possibility for the detection of variants associ-
ated with AIF manifestations. However, interpretation of NGS re-
sults in everyday clinical practice is difficult.
Objectives: To detect variants of inflammatory genes possibly associ-
ated with AIF diseases.
Methods: 41 children with symptoms compatible with AIF disease
were genotyped by a custom NGS protocol analyzing 25 genes asso-
ciated with monogenic AIF diseases (mean coverage >92%). Infec-
tions, immunodeficiencies and autoimmune diseases were excluded.Variants are reported according to the HGVS and the guidelines for
the genetic diagnosis of hereditary recurrent fevers.
Results: Variants of uncertain or unknown significance (VOUS - VUS) de-
tected in AIF genes are reported in Table 1. In 13/41 patients either com-
mon or benign, or no variants were detected. All 13 had been referred
for Periodic Fever (PF) unresolved posttonsillectomy and unresponsive
to steroids. In 9/13 fever eventually resolved, 1 is treated with colchicine
and in 3/13 symptoms recur. In 16/41 patients with unspecific PF, vari-
ants of uncertain or unknown significance (VOUS - VUS) were detected
(Table 1). In 10 out of the latter 16 patients fever resolved after >2 years
follow-up; the other 6 are diagnosed with PFAPA. In 2/41 patients (5%)
pathogenic variants were detected: (1) the p.Val726Ala MEFV variant was
detected (along with a TNFRSF1A VUS) in a 4 year old male with recur-
rence of fever post tonsillectomy, who responded to colchicine. (2) the
p.Val377Ile MVK variant was detected in a 4 year old male with recurrent
fever, rash, failure to thrive, dutch ancestry, elevated urinary mevalonic
acid and good response to steroids, (along with PLCG2, NLRP7 & IL10RB
VUS). In the rest 10/41 patients VOUS and/or VUS were detected, alone
or in combination, in genes correlated with their clinical phenotypes
(FMF, HIDS, TRAPS, Blau, Inflammatory Bowel Disease, Table 1).
Conclusion: Expanding the genotyping of patients with AIF clin-
ical phenotypes uncovers not yet reported or extremely rare vari-
ants of genes associated with AIF diseases. Our results provide
evidence in favor of the pathogenicity of some of these variants.
Combined expression of AIF variants observed in two patients
with typical clinical picture carrying pathogenic MEFV and MVK
variants along with VUS in other inflammatory genes indicate the
complex genetic associations of these initially regarded as men-
delian disorders.
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Introduction: Blau syndrome is a rare granulomatous autoinflamma-
tory disorder. Optimal response to anti-TNFa treatment has been re-
ported, however therapeutic outcomes are diverse probably due to
functional differences in NOD2 mutations.
Objectives: To report the clinical picture of Blau syndrome in a pa-
tient carrying 2 NOD2 variants and the response to anti-TNFa treat-
ment with adalimumab.
Methods: Case Report.
Results: A 19 month old girl was referred to the pediatric rheumatology
department from the dermatology department for an 8-month history of
generalized ichthyasiform skin eruption. The rash appeared on the age of
11 months on the shoulders and then spread to the knees trunk and
face. Multiple coalescing generalized slightly scaly red to violaceous flat-
FMF cases with
only arthritis
n=15
Typical FMF cases
n=890
p value
Sex %33.3 m (n=5)
%66.6 f (n=10)
%51.3 (456) m
%49.7 (434) f
p>0.05
Onset age of symptoms (year) 8.16 (1.16-15) 4.5 (0.16-16.6) p<0.05
Age of Diagnosis (year) 10.8 (2.66-15) 5.05 (1-17.5) p>0.05
Delay Times (year) 1.08 (0-9.33) 1.25 (0-17) p>0.05
Exon-10 Mutation %66.7 %66.6 p>0.05
M694V Mutation homozygous %13.3
(n=2)
heterozygous %33.3
(n=5)
homozygous %12.9
(n=113)
heterozygous %38.1
(n=333)
p>0.05
Colchicine Responsiveness and indication
for Biological Agents
0 %2.5 p>0.05
NLR 1,33 (0,1-6,8) 1,23 (0,1-23,46) p>0.05
MPV 8,30 (7,6-10,40) 8,20 (5,80-12,60) p>0.05
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injected. Skin biopsy had already been performed revealing granuloma-
tous dermal inflammation; granulomas contained epithelioid cells,
langerhans-type multinucleated giant cells, a few lymphoid cells, without
evidence of necrosis and perivascular lymphomononuclear infiltration
around dermal vasculature. Other causes of granulomatous inflammation
i.e fungal and mycobacterial infections, CVID, CGD and Jobb’s syndrome
were excluded. Clinical examination revealed significant boggy edema of
her wrists and ankles, knees and fingers and contractures of both elbows.
Meticulous history revealed the presence of morning stiffness since 6
months. Musculoskeletal ultrasonography corroborated the presence of
arthritis in these sites and revealed the presence of tenosynovitis in the
wrists and ankles. Onycholysis on the 4th and 5th right and the 4th left fin-
ger was noticed. The presence of granulomatous skin inflammation and
polyarthritis raised the suspicion of BLAU syndrome; ophthalmologic
examination revealed nummular keratiris with subepithelial opacities but
absence of anterior or posterior chamber inflammation. Her growth and
development were normal. Family history was negative. Laboratory find-
ings were: mild leukocytosis (WBC=17040/uL), mild anemia (Hb=9,6 mg/
dl), mild increase of inflammatory markers (ESR=40 mm/hr, CRP= 19mg/
dl), elevated IgG (1470 mg/dl) and IgE (271 IU/ml), normal SACE (37,4 IU/
L) and absence of autoandibodies and RF. Serum calcium and urine Ca/
Cr ratio were normal. Direct and Indirect Agglutination Tests were posi-
tive (for IgG). Chest XRay and abdominal US were normal. Next gener-
ation sequencing for genes of inherited autoinflammatory diseases
revealed the presence of 2 Variants of NOD2 (both of Uncertain Signifi-
cance): c.1538T>C (p.Met513Thr) and c.2372G>A (p.Arg791Gln). Treat-
ment with intravenous methylprednisolone pulse (30 mg/kg/3days)
followed by oral prednisolone gradually tapered over 4 months and top-
ical eye steroids were given. Subcutaneous Methotrexate-MTX was initi-
ated. Rash waned in the 1st month of treatment. Due to persistence of
polyarthritis after 3 months of MTX treatment adalimumab 24mg/m2/
2weeks was added. After 8 months of MTX and 5 months of adalimumab
treatment and 4 months after discontinuation of steroids arthritis, keratitis
and rash have remitted; mild elevation of ESR=45mm/hr persists.
Conclusion: This female toddler with Blau syndrome with onset in in-
fancy had optimal response to methotrexate and adalimumab treat-
ment and no severe eye involvement. The concomitant presence of
2 NOD2 variants is not frequently reported in Blau patients. The
1538T>C (p.Met513Thr) has been previously detected in heterozygo-
city in a patient with Blau syndrome and found to cause constitutive
NFκB activation whereas the c.2372G>A (p.Arg791Gln) that has been
associated with spondyloarthropathy possibly explains the presence
of onycholysis on hand nails, a manifestation not characteristic of
Blau syndrome. Informed consent to publis had been obtained.
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Introduction: Familial Mediterranean Fever (FMF) is the most frequent
autoinflammatory disease in eastern Mediterranean. It is mostly pre-
sented with recurrent fever, peritonitis, pleuritis and arthritis. Some pa-
tients might present with only arthritis during episodes.
Objectives: This study aimed to examine the differences between
typical FMF attacks and cases with only arthritis.Methods: The charts of 890 pediatric FMF cases were reviewed.
There were 15 cases presented with only arthritis. Demographic
and laboratory data were compared between the 2 groups.
Results: The mean age of 15 cases presenting with only arthritis was
13.83 (5.41-17.91) years, 5 were male (33.3%) and 10 were female
(66.6%). At onset of symptoms, the mean age of cases with arthritis
was 8.16 (1.16-15) years and was statistically higher than the control
group (p<0.05). There were no statistically significant differences in age
at diagnosis, delay at diagnosis and family history between two groups.
The mean platelet volume (MPV) and neutrophil / lymphocyte ratio
(NLR) values reflecting subclinical inflammation in attack-free period
also did not differ statistically between the two groups. The groups did
not differ in having either M694V or exon 10 mutations. Patients with
only arthritis did not have proteinuria, colchicine unresponsiveness and
indication for biologics.Conclusion: Recurrent fever, abdominal pain, chest pain, and arth-
ritis are major clinical symptoms of FMF. However; there is a cer-
tain group presenting only with arthritis, and continue to have
only articular symptoms throughout the disease. They have a
milder disease course without proteinuria, colchicine unrespon-
siveness and indication for biologics. They have different origins
from all over the Anatolia, but they live in the Aegean region.
Previous studies done with monozygotic twins born in Anatolia
who have same MEFV mutations showed that the ones raised in
Europe had milder disease course. The difference between pa-
tients only with arthritis and the other group could be attributed
to living in western Anatolia, and having Mediterranean type diet.
Further studies with larger group of patients all over the country
are needed to support this hypothesis.
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Introduction: Differential diagnosis of autoinflammatory syndrommes
may include solid tumours. Malignant peritoneal mesotheliomas rep-
resent less tan 10% of mesotheliomas, and they are exceptional in
younger tan 40 years.
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 180 of 243Objectives: We present a specially challenging case of a malignant
peritoneal mesothelioma diagnosed in a 17 year old boy with clinical
presentation and genetic compatible with autoinflammatory syn-
drome, its management and outcome.
Methods: Review of his medical chart and literature search
Results: At 12 years of age the patient presented with a two month
history of evening fever, loss of weight, elevation of acute phase re-
actants and captation of multiple supra and infra diafragmatic ade-
nopathies in PET-TC. Infectious and malignant causes were discarded
initially. Genetic testing of hereditary autoinflammatory syndrommes
was performed, showing heterozygose V-198-M mutation in NLRP3
gene – compatible with CAPS syndromme, and he initially responded
well to corticosteroids. IL-1 blockade (anakinra) was administered
without any success. He was then empirically treated with intraven-
ous IL-6 blockade (tocilizumab) with complete response, and
remained asymptomatic for 5 years. Treatment was then switched to
subcutaneous IL-6 blockade with reappearance of his symptoms.
PET-TC revealed multiple adenopathies and addition of retroperiton-
eal nodules. Exploratory laparotomy and biopsies were performed,
showing methastatic peritoneal mesotelioma. BAP-1 gene was tested
showing no mutation. The patient is still under chemotherapy follow-
ing our hospital protocoles.
Conclusion: The differential diagnosis of CAPS syndrome is wide, in-
cluding rare solid tumors among other conditions. There are some
peculiarities that made this specially challenging, such as the age of
the patient, fever and adenopathies at onset, indolent clinical course
and genetic testing supporting the diagnostic of presumption of
CAPS syndrome. This is the first published case of malignant periton-
eal mesothelioma with the presence of V-198-M mutation in NRLP3
gene. The absence of response to IL-1 blockade (anakinra) was
against the diagnosis of CAPS. IL-6 blockade has been effective in
this single patient, being to our knowledge the only malignant peri-
toneal mesothelioma case who has been reported as respondent to
tocilizumab. Informed consent to publish had been obtained from
the parent.
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Introduction: Familial Mediterranean fever (FMF) is an autosomal
recessive disease, characterised by recurrent, self-limited attacks
of fever and serositis. In addition to the Pras and Mor disease
severity scoring systems defined for adult FMF patients, the
International Severity Scoring System (ISSF), recently described
for children, is also used to assess disease severity.
Objectives: To determine the disease severity of our patients accord-
ing to Pras, Mor and (ISSF) scoring system , and to evaluate the
consistency of these three systems.
Methods: The clinical and demographic data of 205 patients who
met the FMF diagnostic criteria were evaluated retrospectively.
All patients screened for MEFV mutations. Patients grouped ashomozygous for M694V mutation, homozygous for other than
M694V, or compound heterozygous, heterozygous for any mutant
alleles, and with no mutation. The disease severity scores of all
patients and each groups were assessed by Pras, Mor and ISSF
scoring systems. The compatibility of the disease severity scoring
systems was investigated.
Results: According to Pras, Mor and ISSF scores 29.8%, 44.4% and 6.3%
of the patients had severe disease respectively. While the majority of
patients (66% and 64%) had moderate disease severity according to
Pras and ISSF scores, this rate was low in the Mor (17%). Pras, Mor and
ISSF scores were inconsistent with each other, and it was a poor fit be-
tween them (generalized Kappa: 0,140 ± 0,029; p <0,001).
When the disease severity were evaluated according to mutations,
M694V homozygous patients had higher disease severity score than
the other groups in all scoring systems (p<0.001). According to Pras,
Mor and ISSF scoring systems 58%, 62% and 12% of the patients
with homozygous M694V mutations had severe disease, respectively.
Findings, such as leg pain, elevated acute phase reactants at attack
free period, pyuria and proteinuria which was used in ISSF-score,
were found 39%, 18%, 13% and 5% of patients respectively.
Conclusion: Pras, Mor and ISSF scores determine the disease severity
by evaluating different aspects of the disease. Unlike the others, ISSF
Scoring system evaluate chronic sequelaes like as growth retardation,
anemia and splenomegalia besides amyloidosis, organ dysfunction,
duration of attacks, prolonged elevated acute fase reactants after at-
tacks, leg pain and etc. The benefit of the assessment of disease se-
verity according to ISSF scoring system for the treatment planning of
FMF patients should be supported by further clinical trials.
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Introduction: Tumor necrosis factor receptor-associated periodic syn-
drome (TRAPS) is an autosomal dominantly inherited autoinflamma-
tory syndrome caused by mutations in TNFRSF1A. Symptoms of
TRAPS are recurrent fever, abdominal pain, myalgia, exanthema,
arthralgia/arthritis, and ocular involvement. The clinical features and
laboratory parameters of patients with TRAPS and other autoinflam-
matory syndromes including systemic juvenile idiopathic arthritis (s-
JIA) tend to overlap, particularly in patients with atypical genetic mu-
tations and symptoms. Although the pathogenesis of TRAPS remains
unknown, one of possible mechanisms of TRAPS is impaired TNFR1
proteolytic cleavage and receptor shedding.
Objectives: To investigate clinical significance of serum soluble TNF
receptor I level and soluble TNF receptor I/II ratio for the differential
diagnosis of TRAPS and other autoinflammatory syndromes.
Methods: Thirteen active episodes from 4 patients with TRAPS, 156 pa-
tients with active s-JIA, and 63 with active Kawasaki disease (KD), 23 ac-
tive episodes from 15 patients with Familial Mediterranean fever (FMF),
along with 18 healthy controls (HC) were analyzed. Serum soluble tumor
necrosis factor receptor (sTNFR) I and II levels were measured using
enzyme-linked immunosorbent assay.
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 181 of 243Results: Serum sTNFRI levels in patients with s-JIA (median 2760 pg/
ml, range 900-8250 pg/ml) and KD (2520, 1240-6200) were signifi-
cantly elevated compared to TRAPS (920, 540-1900), FMF (1230, 580-
11000) and HC (835, 600-1280). Those levels in patients with TRAPS
and FMF were not elevated compared to HC. sTNFRI/II ratio in pa-
tients with s-JIA (0.392, 0.127-1.169), KD (0.333, 0.161-0.681) and FMF
(0.382, 0.252-0.618) were significantly elevated compared to TRAPS
(0.276, 0.126-0.391) and HC (0.275, 0.210-0.356). The receiver operat-
ing characteristic curve analysis indicated that the cutoff for sTNFRI/II
ratio to differentiate TRAPS from other autoinflammatory diseases
was 0.305 with a sensitivity of 73.6% and a specificity of 76.9%.
Conclusion: These findings indicate that sTNFRI/II ratio <0.305 might
be useful for the differential diagnosis of TRAPS and other autoinflam-
matory diseases. Low level of serum sTNFRI and sTNFRI/II ratio in TRAPS
might be associated with impaired TNFR1 proteolytic cleavage.
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Introduction: Behçet's disease (BD) is a chronic and recurrent inflamma-
tory disease of unknown etiology, classified into polygenic autoinflamma-
tory diseases or variable vessel vasculitis. It has a wide spectrum of
symptoms with a very variable range of severity, from mucocutaneous in-
volvement to neurological manifestations, systemic vascular or severe
ocular manifestations. About 5.4 – 7.6% of Behçet's cases have a pediatric
debut.
Objectives: To evaluate and compare the clinical and laboratory mani-
festations of a series of 52 patients, adults and children, diagnosed with
BD according to the classification criteria of the International Study Group
of BD (ISGBD-1990).
Methods: Retrospective cross-sectional observational study, which in-
cluded 43 adult patients and 9 pediatric patients diagnosed with EB in
the Rheumatology Department of a Madrid tertiary hospital. The clinical-
analytical characteristics of both groups were evaluated, as well as the
correlation of HLA-B51 with the described symptomatology.
Results: The mean age at diagnosis of BD was 36.9 ± 11.8 years in adults
and 11.4 ± 5.1 years in children. 27.3% of adults and 11.1% of children
with BD were male, with oral ulcers close to 90% in both groups. Contrary
to what was reported in other series, genital ulcers were more frequent in
children (77.8% versus 65.9% of adults), as was the presence of uveitis
(44.4% in children compared to 22.7% in adults) and neurological mani-
festations (22.2% in children versus 6.8% in adults). Joint involvement was
also more frequent in children (88.9% versus 52.3% in adults), as well as
fever (44% in children versus 14% in adults); being these two manifesta-
tions the only parameters that were associated in a statistically significant
way with their presentation in the pediatric age in BD. In contrast, skin in-
volvement and vascular manifestations were more frequent in adults. The
positivity of HLA-B51 did not correlate statistically with any clinical mani-
festation, but those who had it had a mean age at diagnosis of 26.5 years
compared to a mean of 39 years in those who did not present this gen-
etic marker.
Conclusion: Behçet's disease presents with a wide spectrum of clinical
manifestations, potentially serious, ranging from skin lesions to neuro-
logical or vascular manifestations. In our series, patients diagnosed at
pediatric age most frequently had systemic manifestations (fever), arth-
ritis or severe clinical manifestations such as neurological involvement or
uveitis. Limitations: a small number of pediatric cases included in our
study.
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Introduction: Adherence to DMARDs such as methotrexate and biologics
is critical for patients with Juvenile Idiopathic Arthritis (JIA). Notwithstand-
ing, few studies exists on that topic and we lack information to under-
stand the grounds for adherence.
Objectives: The RUMAJI study aims, among others, to understand and
decipher the parents and children adherence mechanisms and practices.
Methods: Qualitative methods were chosen in order to investigate par-
ents’ and children’s everyday life with JIA and its treatment. An ethno-
graphic study was designed by a multidisciplinary team including
rheumatologists, pediatricians, patient associations members and anthro-
pologists. Parents, children and doctors were interviewed. The study in-
volved 6 doctors (3 paediatricians and 3 rheumatologists) and 15 families
(enough to reach saturation), recruited from 5 centers, by diversity of clin-
ical and sociological profiles. The panel included 17 children with JIA, 11
girls and 6 boys, median age 10 [3 ; 17], median disease duration 2.5 [1 ;
15]. 4 children were treated with conventional DMARDs in monotherapy,
4 with biologic DMARDs in monotherapy, 5 with cDMARD-bDMARD asso-
ciation and 4 with NSAIDs only.
Doctors interviews were conducted first. Parents and children interviews
were conducted by anthropologists at family’s home using in-depth semi
directive and biographic methods. 3 fields were explored: organization of
everyday life with JIA, treatment practices, impact on school and social
activities. Interviews were recorded and transcribed for analysis.
Results: Adherence results from an appropriation process of the JIA
and treatment that require both an active role from parents and chil-
dren, even before the transition. The setting of a partnership-based
doctor-children-and-parents relationship has also a positive effect in
the family active role. The active role played by children could be ei-
ther stimulated or inhibited at home according to the family’s struc-
ture, social background, parents’ attitudes toward their child
(participation to the decision, explanation of the disease).
Children’s active role includes in particular: 1) negotiations with parents
and physicians, 2) experiments with the treatment (forgetting or involun-
tary switch from the parents, changing the dosage on their own initiative)
and 3) participation to the treatment administration and ritualization.
The manner children consider and manage their DMARDs is the result
of an arbitration depending on the positive (a) and side effects (b) they
felt in their body and the effects noted by the doctors (c) during the ex-
aminations and test results. Dealing with these 3 dimensions requires
to link together both a theoretical and practical knowledge of JIA. Thus,
children build their own and singular knowledge of their disease and
treatment, which is a source of control of their body and their life.
Conclusion: Qualitative methods, through an ethnographic study
starting from children, parents and doctors point of view, underline
the active role they played by children in their care. Adherence to
DMARDs could be improved by supporting children’s implication as
soon as the beginning of JIA.
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Table 1 (abstract P355). See text for description
Biological naïve
(n=45)
Switched from a non-originator
(n=19)
Switched from originator
(n=7)
Biosimilar
infliximab 30 (67%) 19 (100%) 4 (57%)
etanercept 15 (33%) 0 (0%) 3 (43%)
Age (years) at biosimilar
start
13 (10-15) 14 (11-15) 15 (12-16)
Disease duration (years) 2 (1-5) 9 (3-12) 7 (2-13)
Active Joints (71 joints) 4 (1-7) 1 (0-2) 0 (0-0)
Limited Joints (71 joints) 4 (1-7) 2 (0-4) 0 (0-1)
Patient Global (0-10cm) 7 (4-8) 2 (0-4) 2 ( 1-5)
CHAQ (0-3) 2 (1-3) 0 (0-1) 0 (0-1)
Active uveitis at start of
therapy
0 (0%) 10 (56%) 1 (17%)
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Introduction: Most research concerning biosimilar use in muscu-
loskeletal diseases has been done in adults. Little to no data re-
garding the use of biosimilars in Children and Young People
(CYP) with juvenile idiopathic arthritis (JIA) exist.
Objectives: To describe the characteristics of CYP with JIA starting
biosimilars in the United Kingdom (UK) following their approval in
the UK with musculoskeletal diseases.
Methods: The Biologics for Children with Rheumatic Diseases (BCRD) is
an ongoing prospective UK study recruiting CYP with JIA starting bio-
logic therapies other than Enbrel (followed in a separate parallel study)
from 2010 onwards. Baseline information is collected via questionnaires
completed by the treating physician or affiliated clinical research nurse.
Follow-up data including disease activity measures and changes in
drug therapy are collected at 6 months, 1 year and annually thereafter.
From 30-Sept-2015, data has been captured on infliximab and etaner-
cept biosimilars available in the UK.
Results: To 15 April 2018, 71 patients in total were identified in the
BCRD study starting a biosimilarof which 53 (74%) starting an infliximab
biosimilar and 18 (25%) an etanercept biosimilar (Table 1). Of these, 45
(63%) started a biosimilar as their first biologic therapy. Seven (10%) pa-
tients switched from their originator. The median (IQR) time on origin-
ator before switch was 1.6 (0.7-4.1) years. Nineteen (27%) switched to
an infliximab biosimilar from a non-originator biologic with 12 switch-
ing for efficacy reasons and 7 for safety reasons. The majority (n=14)
switched from adalimumab. Active uveitis was present in 10 patients at
the point of starting a biosimilar. Follow-up data out to 2 years were
available in 26 patients. Seven patients switched to another biologic in
this period: four infliximab biosimilar patients switched to tocilizumab
and 2 infliximab biosimilar patients switched to adalimumab. One pa-
tient switched back from etanercept biosimilar to originator due to in-
creased pain. Infliximab biosimilars were interchanged in 6 patients
due to changes in hospital procurement. No serious adverse events
were reported. Two cases of recurrent uveitis in patients on an inflixi-
mab biosimilar switching from a non-originator biologic were noted.
Conclusion: Biosimilars in children and young people with JIA are being
used as both first-line and subsequent-line biologic therapy. Currently
few UK children have been switched directly from an originator product.
Whether a move towards switching all children receiving originator prod-
ucts to biosimilar products, as has been seen in rheumatoid arthritis, will
occur is currently unknown but it is imperative that the safety of these
treatment decisions are captured in patient registers.
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Introduction: The Biker registry aims to provide long term sur-
veillance of biologic drugs which is particularly important in
pediatric patients (pts) who may require prolonged treatment
Objectives: To evaluate long-term rates of serious adverse events
(AE) and AEs of special interest (AESI) in clinical practice in
pediatric pts with juvenile idiopathic arthritis (JIA).
Methods: Safety data from pts treated with biologics and registered
in the German BIKER registry were analyzed. In addition to serious-
ness of AE, 25 AESI were defined including malignancy, serious and
medically important infection, uveitis, chronic inflammatory bowel
disease, cytopenia, hepatic event, anaphylaxis, depression, macro-
phage activation syndrome, pregnancy and death. Events per 100
patient-years (PY) of exposure were calculated using AEs reported
after first dose through 70 days after last dose. Rates were compared
by Wald test.
Results: A total of 3975 courses of biologics with a total exposure
time of 7592 PY were identified with Etanercept (ETA, 5376 PY), Ada-
limumab (ADA, 1334 PY), Tocilizumab (TOC,435 PY), Abatacept (ABA,
109 PY), Infliximab (INF, 99 PY ), Anakinra (ANA, 96 PY), Canakinumab
(CAN, 71 PY) and Golimumab (GOL, 67 PY). Differences in JIA cat-
egory distribution and concomitant treatment between these cohorts
were noted. A total of 3586 (47.2/100 years) AE, 461 (6.1) SAE and
629 (8.3) AESI were reported. The most common AESI were uveitis
(194(2.6)) followed by medically important infections (155(2.0)), cyto-
penias (62(0.8)), hepatic events 39(0.5), anaphylaxis (28 (0.4))), other
autoimmunopathies (25 (0.3)), chronic inflammatory bowel disease
(CED, 23 (0.3)), depression (17 (0.2)), macrophage activation syn-
drome )12 (0.2)), malignancies (8(0.1)) and pregnancies (8(0.1)). There
were marked differences in the rate of AESI in the cohorts with differ-
ent biologics. Uveitis reports were most common in TNF-antibody
treated cohorts, infections upon GOL, TOC and ANA, cytopenias upon
TOC and CAN, hepatic events upon TOC, anaphylaxis upon INF and
TOC, CED upon ETA and INF (Table 1). One case of latent TB but no
further opportunistic infections were reported. There was a single
death upon treatment due to sepsis in a ETA patient.
Conclusion: Surveillance of pharmacotherapy as provided by
BIKER is an import approach especially in the case of long term
treatment of children. These data provide support for the long-
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 183 of 243term and comparative safety of biologics in JIA pts. Overall, toler-
ance is acceptable. Differences between several biologics were
noted and should be considered in daily patient care.
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AESI ETA 5376
PY
ADA
1334
PY
GOL /
2PY
INF
99PY
ABA
109 PY
TOC
435 PY
ANA
97 PY
CAN 71
PY
All
7592
PY
Uveitis, n; RR;
p
106;2,01;
p<0,0001
70;2.64;
p<0.0001
5;2,77;
p=0.025
9;3,69;
p=0,0001
2;0,71;
n.s.
2;0,17;
p=0,013
0 0 194
Infection,
n;RR; p
90;0.57;
p=0,0005
32;1,22;
n.s.
6;4.21;
p=0.0005
3;1,5; n.s. 1,0,44;
n.s.
18;2.17;
p=0.002
4;2,06;
n.s.
1;0,68;
n.s.
155
Cytopenia,
n ; RR; p
30;0.39;
p=0,0002
1;0,07;
0=0,011
0 1,1,24;
n.s.
0 22,9.07;
p<0.0001
2,2,59;
n.s.
6;11.35;
p<0.0001
62
Hepatic
Event, n ;
RR; p
17;0.32;
p=0.0004
6,0,85;n.s. 0 1,2,0;n.s. 1,1,8;n.s. 13;8.25;
p<0.0001
0 1,2,78;n.s. 39
Anaphylaxis,
n ; RR; p
3;.05
[;p<0.0001
3,0,52;n.s. 1;3,62;
n.s.
5,15.1;
p<0.0001
2,4.90;
p=0.030
15;16.49;
p<0.0001
0 1;3,65;n.s. 30
Autoimmunopathy,
n ; RR; p
8,0.19;
p=0,0001
10;3.13;
p=0,005
1;4,37;
n.s.
1;3,17;n.s. 2,5.97;
p=0.015
3,2,24;n.s. 0 0 25
CED, n;
RR; p
19;1.96;n.s. 2;0,45;n.s. 0 2;7.21;
p=0.008
0 0 0 0 23
MAS, n ;
RR; p
2,0.08;
p=0.001
0 0 0 0 616.49;
p<0.0001
17,05;
n.s.
335.3;
p<0.0001
12
Malignancy,
n; RR ;p
6,1.23;n.s. 0 0 1,10,9;
p=0,026
0 1,2,35;n.s. 0 0 8P357
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Introduction: Corticosteroid joint injections are a routine procedure
in pediatric rheumatology. There is a dearth of existing literature on
joint injection practices. The authors conducted an online survey
targeting pediatric rheumatologists across the globe, to highlight
variations and areas of consensus in joint injection practices.
Objectives: 1. To describe global variations in intra-articular injection
practices.
2. To explore the relation of these variations with physician demo-
graphic features
Methods: An electronic survey consisting of 22 questions, divided in
two sections based on patient age (0-5 years, > 5 years) was designed
on the web app – Survey Monkey. The questions addressed practices
related to pre-procedural sedation, choice of anesthetic agent, dose
and type of steroid molecule, number of joints injected, use of ultra-
sound, and post procedure complications. The survey was distributed
via email to physicians registered in the PRINTO and CARRA/PRCSG net-
works. Analysis was performed using GraphPad Prism version 6.
Results: 310/358 respondents (87%) routinely performed intraarticular
injections. Majority performed the procedure in an outpatient procedure
room, day care or minor operation theatre (85%). Almost 80% injected
more than one joint per sitting (median:4, mode:2). 52% used ultra-
sound to guide joint injections either routinely or selectively. Ultrasound
was reported to be most useful for the hip joint. Ignoring availability,
the molecule of choice for joint injections was Triamcinolone hexaceto-
nide (78%). More than 50% respondents reported that Triamcinolone
hexacetonide was either not available or sporadically available in theircountry. The dose of steroid used for large and small joint injections
was 1 mg/kg and 0.5 mg/kg respectively (64% and 55% respectively).
68% of respondents used pre-procedure local anesthesia (LA): either
EMLA cream, subcutaneous lidocaine, or a combination. Additionally,
short anesthesia (49%) and oral sedation (19%) were offered. 80% stated
that the most commonly observed complication was local subcutaneous
atrophy. Post-procedure, most respondents monitored the patient in
the hospital until the effect of anesthesia subsided (77%). Less than half
the respondents (47%) reported following significantly different prac-
tices for the <5year age group. The commonest age dependent practice
was choice of anesthesia in 72%. With regards to the physician charac-
teristics, 60% had received a formal training in joint injections, and 49%
had more than 15 years of pediatric rheumatology clinical practice.
The variations in practices based on geographical location of the re-
spondents and years of training was analysed with chi-square and
Fishers exact tests. In the USA 47% of respondents used pre-
procedure LA, compared to 75% in the UK, and this difference was
significant (Chi-square=4.540, df=1, p=0.033). None of the other prac-
tices varied significantly by geographical location. The practices were
not significantly different in physicians with differing number of
years of clinical experience. 67% of physicians who had received for-
mal training followed different practices for 0-5-year age group
whereas none of those without formal training did. This difference
was statistically significant with Fishers exact test (p<0.0001).
Conclusion: There was consensus (about 80%) in some joint injection
practices like location of joint injection, multiple joints being injected
in one sitting, and choice of steroid molecule. However, the dose of
steroid, choice of sedation, post procedure activity limitation, and
use of Ultrasound was highly variable. Some of these variations may
be attributed to geographical location of training and presence or
absence of formal training. There is a definite need for developing
uniform global consensus plans for intraarticular joint injection
practices.
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Introduction: The Childhood Arthritis and Rheumatology Research
Alliance (CARRA) developed consensus treatment plans (CTPs) for
new-onset polyarticular JIA (pJIA). These CTPs represent commonly
used strategies for starting biologic medications to treat pJIA. The
CARRA Start Time Optimization of Biologic Therapy in Polyarticular
JIA (STOP-JIA) study is an observational and prospective study that
will assess the effectiveness of the various CARRA CTPs.
Objectives: The proportion of patients achieving Clinical Inactive Dis-
ease (CID) off of glucocorticoids and patient-reported outcomes at
12 months will be compared.
Methods: Untreated pJIA patients are enrolled in the CARRA Registry,
and prescribed treatment as outlined in one of the CTPs. The CTPs
follow the 3 most common treatment strategies for pJIA: 1) Step-Up
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 184 of 243(start DMARD only, and a biologic added later only if needed); 2)
Early Combination (both a DMARD and a biologic are started ini-
tially); and 3) Biologic First (a biologic is started alone without a
DMARD). Follow-up visits are performed at 3, 6, 9 and 12 months fol-
lowing enrollment and data are recorded in the Registry. The CTP
used is chosen by the provider and patients/families at baseline. All
treatment and follow-up visits are standard of care. There is no
randomization or blinding.
Results: Three hundred and fifty-three patients were enrolled in STOP-
JIA between 1 Nov 2015 and 27 April 2018, at 55 US and Canadian sites.
Table 1 shows baseline characteristics for the 320 patients with com-
pleted data entry. 65% started the Step-Up CTP, 33% the Early Combin-
ation CTP and 10% the Biologic First CTP. The JIA categories enrolled,
by descending frequency were: RF negative polyarticular (63%), RF posi-
tive polyarticular (17%), enthesitis related (8%), psoriatic (6%), extended
oligoarticular (3%), and undifferentiated (2%). 1,215 total visits have
been entered, with 152 patients completing the 12-month visit.
Twenty-one Serious Adverse Events (SAE) or Events of Special Interest
(ESI) were reported. These included 9 infections (including one case of
septic shock), 4 uveitis (new-onset) and 3 hepatitis.
Conclusion: Completion of enrollment (400 patients) in STOP-JIA is
expected by July 2018. All CTP choices are being used, but the Step
Up strategy is the most common. Baseline characteristics are similar
between groups, except for some differences in gender, the number
of active joints, JADAS and the percentage of patients prescribed oral
steroids. Comparative effectiveness of these 3 strategies will be
assessed following completion of the 12-month visit data collection
for the full cohort.
Trial registration identifying number: NCT02593006
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Total
(n= 320)
Step up
(n= 211)
Early
Combination
(n=77)
Biologic
First
(n=32)
Female N (%) 232 (72) 156 (74) 55 (71) 21 (66)
White N (%) 218 (68) 152 (72) 48 (65) 18 (56)
Age in yrs – mean (range) 10
(1-18)
10 (1-18) 11 (1-18) 11 (1-18)
Number of Active joints - mean
(range)
13
(5-50)
12 (5-49) 16 (5-50) 11 (5-41)
Physician Global Assessment of
Disease Activity - mean (range)
5 (0-10) 5 (0-10) 6 (1-10) 6 (1-10)
Juvenile Arthritis Disease Activity
Score - mean (range)
18 (5-
29)
17 (5-29) 20 (6-29) 20 (14-28)
CHAQ Score - mean (range) 1 (0-3) 1 (0-3) 1 (0-3) 1 (0-3)
Oral steroids prescribed at
baseline - N (%)
84 (26) 57 (27) 22 (29) 5 (16)P359
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Introduction: Biologics are the most effective drugs for treatment of
juvenile idiopathic arthritis (JIA) in the cases of methotrexate (MTX)
inefficacy or intolerance. The question about superiority of combin-
ation therapy (biologics+MTX) above monotherapy is still open. In
some studies were shown that combination therapy is more effect-
ive, but others did not show any differences. The problem of MTX in-
tolerance has been still actually, especially in adolescent patients.
Several studies confirm that MTX can prevent development anti-drug
antibodies avoiding to loss their efficacy. In patients with remission
the MTX discontinuation leads to flare of JIA in 10-15%.
Objectives: to evaluate the role of MTX discontinuation in flare
risk and survival of first biologic medication in non-systemic JIA.
Methods: in the study were included 692 non-systemic JIA patients,
whom biologic therapy was prescribed. Inclusion criteria: patient
whom first biologic was administrated with or without MTX or MTX
was discontinued after start of biologics due to different reasons (re-
mission, intolerance, adverse events). Exclusion criteria: treatment
with current systemic corticosteroids, infliximab, rituximab. After se-
lection 175 patients were eligible to analysis. We evaluate achieve-
ment of the remission, according C. Wallace criteria, flare, time to
flare, change to biologics due to inefficacy and time to change. We
compare two groups: i) patients with biologics with ongoing metho-
trexate and ii) patients with biologics alone, whom MTX was discon-
tinued or not prescribed. For statistical analysis we Cox’s regression
models, Log-Rank test, x2 test and Mann-Whitny test.
Results: there were no differences in initial data of studied popula-
tion between groups, despite the MTX therapy. The flares were de-
tected in 21.8% in whole group, 21.1% in MTX+biologics and 23.9 in
biologics alone group (p=0.69), and time to flare was 20.8 (8,8; 34.5)
and 19.3 (8.5; 21.0) months, respectively (p=0.37). There were no dif-
ferences in cumulative probability of flare in both groups (LogRank
test, p=0.7; RR=0.73 (95%CI: 0.28; 1,9), p=0.53). In 14.4% patients bio-
logic was change due to inefficacy: 14.8% in MTX+biologic and
13.0% in biologic group (p=0.77), time to switch first biologics was
17.1 (6.8; 37.7) and 16.8 (4.0; 40.0) months, respectively (p=0.68).
There were no differences in cumulative probability of biologic
switch in both groups (LogRank test, p=0.63; RR=1.38 (95%CI: 0.36;
5.2), p=0.63). There were no differences of flare rate and biologic sur-
vive in etanercept, adalimumab, abatacept and tocilizumab sub-
groups despite on ongoing MTX. There were no differences in flare
probability (p=0.4) and probability of switching biologics (p=0.46) be-
tween subgroup of TNFa inhibitors: etanercept mono; etanercept
+MTX, adalimumab mono, adalimumab+MTX.
Conclusion: we suppose that discontinuation of MTX due to remission
or intolerance does not increase the flare rate and probability of flare,
switching the first biologics and probability to switch in non-systemic
JIA patients with first administered biologics. Further trials are required.
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Table 1 (abstract P361). Submaximal treadmill test in patients and
controls
JIA total
(n=60)
Controls
(n=60)
p-
value
JIA oligo
(n=30)
JIA poly
(n=30)
p-
value
Estimated
VO2peak (ml/
kg/min)
43.2 (10.3) 44.8 (8.0) 0.35 44.0 (7.8) 42.4 (12.3) 0.53
Walking
distance, m
747 (97) 740 (70) 0.68 756 (73) 737 (117) 0.45
Speed km/h 6.1 (0.8) 6.1 (0.7) 0.67 6.2 (0.6) 6.0 (1.0) 0.33
3
min
HR 134 (9) 132 (9) 0.67 132 (9) 136 (9) 0.08
Borg
6-20
9.6 (2.0) 9.5 (2.2) 0.76 9.9 (2.0) 9.3 (2.0) 0.23
8
min
HR 163 (14) 159 (14) 0.17 163 (14) 163 (13) 0.98
Borg
6-20
13.0 (2.2) 12.5 (2.3) 0.34 13.2 (1.9) 12.8 (2.5) 0.45
Numbers are mean (SD). HR=heart rate
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Introduction: Juvenile idiopathic arthritis (JIA) is the most prevalent
pediatric rheumatic disease [1]. Long term complications include phys-
ical disability and a decreased quality of life [2]. Since the introduction
of anti-TNF drugs for JIA, its prognosis has improved significantly [1, 3].
Personalized medicine is the next step to improve treatment in JIA.
Anti-TNF trough levels and demonstration of the presence of anti-drug
antibodies (ADA) could help individualize treatment decisions in JIA pa-
tients, but evidence supporting this is missing.
Objectives: To describe cross-sectional data of anti-TNF trough levels
and ADA, combined with decision effects, in children with JIA.
Methods: Patients' records in children with JIA using etanercept, ada-
limumab or infliximab were retrospectively checked for measure-
ments of anti-TNF trough levels and ADA. Anti-TNF trough
concentrations and ADA were measured using an enzyme-linked im-
munosorbent assay (ELISA) and antigen-binding test. Data on age,
sex, JIA subtype, reason for testing and the decision effect of trough
level or presence of ADA on the current therapy were collected.
Results: Eighty-one anti-TNF trough levels were measured in 45 chil-
dren with JIA. A wide variety of anti-TNF trough levels was found.
Therapeutic drug concentrations, according to adult ranges in RA
and IBD [4,5,6], were found in 11 (58%) patients on etanercept
(n=19), 2 (14%) on adalimumab (n=14) and 8 (17%) on infliximab
(n=48). Four patients on adalimumab and one patient on infliximab
showed ADA. All of these five patients had non-detectable drug
trough levels. Reasons for testing trough level and/or presence of
ADA were loss of response (20%), partial or no response (40%), meas-
urement after dosage increase (2%), remission (17%), uveitis flare
(9%) and allergic reaction (11%). Treatment decisions were influ-
enced by trough levels in 70/81 (86.4%) of measurements and in 5/5
(100%) of patients with ADA.
Conclusion: Measuring anti-TNF trough levels and ADA was a valu-
able tool in making personalized treatment decisions in JIA. Treat-
ment changes included dose/frequency increase, or stopping and
switching treatment in the presence of ADA combined with un-
detectable drug levels. Variation in anti-TNF trough levels seems
even greater in children than in adults. More data are needed to ac-
cess optimal therapeutic drug levels in anti-TNF treatment in JIA and
to implement this strategy more widely.
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Introduction: Poor submaximal capacity is previously reported in ju-
venile idiopathic arthritis (JIA) patients, and is often assessed by the
6 minute walking test. However, due to improved management ofJIA, there is a need for a more physically challenging submaximal
test to measure submaximal capacity in JIA patients, and also to esti-
mate peak oxygen uptake (VO2 peak).
Objectives: To estimate VO2peak and measure submaximal parame-
ters using an eight-minute submaximal treadmill test1 in oligo- and
polyarticular JIA patients and controls. Further, to study associations
between disease variables and estimated VO2peak and walking dis-
tance in patients. The submaximal treadmill test has shown good val-
idity at group level in JIA patients.
Methods: Patients with persistent arthritis or polyarticular disease
were recruited consecutively at Oslo University Hospital. Age- and
sex-matched controls were selected randomly from the National
Registry. In all participants, VO2peak was estimated using the eight-
minute submaximal treadmill test. Submaximal parameters included
heart rate and rating of perceived exertion (Borg 6-20) at 3 and 8 mi-
nutes, speed and walking distance. Current pain, and pain and fa-
tigue during the previous week were assessed by a Numeric Rating
Scale. Disease activity, functional ability, disease duration and current
medication were registered in patients. Differences between groups
were tested with t-tests and correlations with Spearman’s rho correl-
ation coefficients.
Results: Sixty JIA patients (50 girls), 30 with persistent oligoarthritis
and 30 with polyarticular disease (extended oligoarthritis and polyar-
ticular RF +/-) aged 10-16 years and 60 controls were included. Bio-
logic drugs were used by 25 (42 %) patients. No significant
differences were found in estimated VO2peak (ml/kg/min) in patients
vs controls or in patients with persistent oligoarthritis vs polyarthritis
(Table 1). Submaximal parameters did not differ significantly between
patients and controls or between JIA subsets. In patients, there were
no correlations between any disease variables and estimated VO2peak
or walking distance (all r’s<-0.3, p=NS).
Conclusion: Estimated VO2peak and submaximal responses from a
submaximal treadmill test are comparable between JIA patients and
controls, and also comparable between patients with persistent oligo
arthritis and polyarticular disease. The encouraging results may pos-
sibly be explained by advances in the multidisciplinary management
of JIA, including biologic therapy and individualized tailored patient
education about physical activity.
Reference
1. Ebbeling CB, Ward A, Puleo EM, Widrick J, Rippe JM. Development of a
single-stage submaximal treadmill walking test. Med Sci Sports Exerc.
1991;23(8):966-73.
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Table 1 (abstract P362). Overview of the observational adverse events
per 100 PYs
Fixed-dosing
ADA±MTX
(N=272)
BSA-dosing
ADA±MTX
(N=263)
PYs=1076 PYs=940.8
E (E/100 PYs) E (E/100 PYs)
Any AE 453 (42.1) 358 (38.1)
AE at least “possibly drug related”
per the investigator
155 (14.4) 101 (10.7)
Severe AE 47 (4.4) 26 (2.8)
Serious AE 56 (5.2) 92 (9.8)
AE leading to discontinuation of
study drug or study
27 (2.5) 34 (3.6)
Infectious AE 160 (14.9) 119 (12.6)
Serious infectious AE 24 (2.2) 20 (2.1)
Injection site-related AE 18 (1.7) 20 (2.1)
E, events; PYs, patient years (Observation time, irrespective of study drug
treatment duration)
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Introduction: Adalimumab (ADA) has been approved for the treat-
ment of polyarticular juvenile idiopathic arthritis (pJIA) with long-
term use often required to maintain disease control.
Objectives: To describe the safety of ADA among children with pJIA
treated in current clinical practice with fixed-dosing (F-D, by weight
category, in the United States [US] and Australia) or body surface
area-dosing (BSA-D, in European countries).
Methods: This is a year (yr) 8 interim analysis of an ongoing,
multicenter, observational registry of patients (pts) with pJIA
with up to 10 yr safety follow-up. Pts included in the registry
were treated with ADA, alone or in combination with metho-
trexate (ADA±MTX), or MTX alone as a comparison arm, accord-
ing to routine clinical care in PRINTO/PRCSG centres in the US,
Australia, and Europe. This analysis included only ADA±MTX-
treated pts who were sub-grouped according to enrolling site
into two groups: F-D (10 - <15 kg, 10 mg every other week
[eow]; 15 - <30 kg, 20 mg eow; ≥30 kg, 40 mg eow) or BSA-D
(24 mg/m2 [maximum of 40 mg] eow). MedDRA observational
adverse events (AEs) were recorded from registry entry through
last contact, irrespective of duration of registry treatment with
ADA±MTX.
Results: Of the 537 pts enrolled in the ADA±MTX arm, 272 and
263 received F-D and BSA-D, respectively. At registry entry, F-D
and BSA-D groups were similar for mean JIA duration (3.5 yrs vs.
3.9 yrs), JADAS27(CRP) (10.8 vs. 12.2), and CHAQ-DI (0.6 for both).
Registry follow-up in the F-D and BSA-D groups were comparable
[mean (range) in yrs: 3.96 (0.00–8.92) vs. 3.58 (0.00–7.01)]. Overall,
166 pts (61%) in the F-D and 128 (49%) in the BSA-D group dis-
continued registry drug. Frequencies and rates of observational
AEs per 100 pt years of observation time (from registry entry up
to last contact, irrespective of drug treatment duration) were
comparable between groups (Table 1), including rates of serious
infection. Two pts from the BSA-D group reported latent TB, al-
though there were no cases of active TB across enrolling sites.
One pt (0.2%) from the BSA-D group reported an event of oppor-
tunistic infection (fungal oesophagitis). There were no reports of
death, malignancy, oral candidiasis, demyelination, or congestive
heart failure.
Conclusion: Overall, ADA±MTX was well-tolerated in pts with pJIA
where administration has been with a fixed dose, per weight cat-
egory, or based on BSA, respectively.Disclosure of Interest
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Introduction: Juvenile idiopathic arthritis (JIA) is most common
chronic rheumatic disease in childhood. The upper extremity involve-
ment in JIA causes muscle imbalance, joint destruction, pain, stiffness
and limitations on activities of daily living in varying degrees. It has
been reported that improvements of upper extremity functions were
achieved by exergame training in various disease groups.
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 187 of 243Objectives: The aim of this study was to investigate effects of indi-
vidualized exergame training on upper extremity problems in adoles-
cents with JIA.
Methods: 18 patients (15 girls, 3 boys) with JIA (8 oligoarticular, 18
polyarticular) who have at least one involvement upper extremity joint,
participated in this study. Muscular strength of upper extremity was
measured by using a portable digital handheld dynamometer. Also,
Range of Motion (ROM) of upper extremity was evaluated with a uni-
versal goniometer. Severity of pain (during exercise, activity and rest),
fatigue and stiffness were measured by Numeric Rating Scale (NRS). Be-
sides, CHAQ was used for assessing functional ability. Training was
structured in two 4-weeks phases with Xbox KinectTM Games, allowing
to adapt the training according to individual training progress. In the
first four weeks, games included movement patterns with low fre-
quency were preferred (Volleyball, Darts and Bowling). In the second
phase, games with fast movements for endurance were preferred (Fruit
Ninja, Table Tennis, Boxing). The games were set as Individualized for
45-60 minutes by the physiotherapist. All the participants completed an
8 weeks (3 times in a week) individualized exergame training program.
Results: The mean age and duration of disease was 13.89±2.13 (age
range 12-18), 7.50±4.27 years, respectively. 16 of patients had bilaterally
involvement of wrist joint and 15 of them involvement elbow joint (7
bilaterally, 8 unilaterally) and 11 of them also had finger involvement.
Statistically significant differences of pre and post-treatment were
found for almost all the scores of ROM, CHAQ and NRS, except some
scores of finger ROMs (p<0.05). And also, all muscles strength of upper
extremities were statistically significant increased (p<0.001).
Conclusion: Our exergaming protocol that included Xbox
KinectTM Games has showed improvements on pain, fatigue, stiffness
and upper extremity functions in adolescents with JIA. The results of
this study that the integration of exergame with Xbox KinectTM
Games seems to have positive effects on upper extremity and is thus
potentially beneficial for the long-term effectiveness of rehabilitation
programs in adolescents with JIA.
Disclosure of Interest
None Declared
P364
TUTTI ALLA PARI - SENSITIZATION PATH FOR SOCIAL INCLUSION
OF CHILDREN WITH CHRONIC AND RARE RHEUMATIC DISEASES
Antonella Celano, Francesco La Torre, Adele Civino, Raffaella Arnesano,
Annalisa Sticchi
Italian national Association people with rheumatic and rare diseases,
lecce, Italy
Correspondence: Antonella Celano
Pediatric Rheumatology 2018, 16(Suppl 2):P364
Introduction: “Tutti alla pari” is a project made by Apmar Onlus. From
the analysis of family and kids needs, it comes out that it’s difficult for a
kid to feel himself involved in the society system. It is not rare that the
kid with a rheumatic disease is socially excluded and sometimes bullied.
Involve kids with disabilities is a challenge that can be won focusing on
competence and collaboration. Differences must be accepted at school
first by the activation of inclusive paths.
Objectives: Developing an empowerment path, starting from young
people, to build up a most respectful and inclusive society; defining a
common strategy to fight social exclusion of people with chronic dis-
eases, especially children.
Methods: Create a participative process and an active involvement of so-
cial and institutional actors that take care of border risking minors. It in-
volved pediatricians, parents, formers and journalists, through punctual,
sensitizing and informative actions. 15 communication experts, 20 pediatri-
cians, 18 formers and 25 parents took part in 3 participative labs. After
those workshops a handbook that collects the “best practices for social in-
clusion” was realized and It was spread in 20 school and in 25 regional as-
sociations of patients with chronic and rare pathologies. The identified
method aims to create a participative process and an active involvement of
all social and institutional actors, that take care of border risking minors. It’sbeen involved paediatricians, parents, formers and journalists, through
punctual, sensitizing and informative actions. 15 communication experts, 20
paediatricians, 18 formers and 25 parents have been involved in 3 participa-
tive labs. Their participation gave birth to the realization of a handbook that
collects the “best practices for social inclusion”, that was spreaded in 20
school and in 25 regional associations of patients with chronic an
Results: Involving the youngest: experience labs organized in 16
schools through which kids could put themselves in a peer with rheuma-
toid arthritis’ shoes. By wearing gloves and special suits they experienced
all the functional limitations of the disease. The action had important
feedbacks, collected in written witnesses and videos elaborated by kids.
Formers involvement: 3 didactic seminars were realized about the
social inclusion and the involvement of kids with chronic and rare
pathologies. Bullism and cyber bullism and other topics were treated
during those meetings dedicated to family and teachers. The semi-
nars, attended by 200 people, have been developed by qualified pro-
fessionals (psychologists, communication experts, journalists).
Activities monitoring: It aimed to measure the efficiency of the in-
volved resources and the effectiveness of interventions related to the
targets. It all started from the logistics of the intervention and the
analysis of activities to elaborate monitoring schedules, addressed to
the internal staff of the project, and questionnaires addressed to
both direct and indirect targets.
Conclusion: To modify cultural attitude towards disability we must
know what it means, through empathy, positive inclusion and re-
spect. This kind of engagement is a priority in schools, in extra famil-
iar, work and extra scholastic contexts. It must involve specialized
staff to stay in touch with families, doctors and associations. “Tutti
alla pari” showed how this target should be reached, through hetero-
geneous competences and multi-skilled professional resources.
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Introduction: Adolescence is a critical period in lifetime when pa-
tients with a rheumatic condition (RC) has to deal with disease ac-
ceptance; therefore, an uninterrupted and adequate attention must
be provided to this population. Different transition programs (TP) are
currently working around the world however, a minority of those in-
clude a multidisciplinary team to conduct transition.
Objectives: To describe a program that provide an uninterrupted,
multidisciplinary and coordinated attention to adolescents with RC
during transition from pediatric to adult services in Mexico.
Methods: During January 2017, a multidisciplinary group of specialist
from our hospital were invited to participate in TP. Disciplines included in
the team were decided by consensus of pediatric and adult rheumatolo-
gist with the aim of cover the most important issues that affects outcome
in adolescents with RC.
From February to June 2017, we conducted systematic meetings to
discuss logistic/organizational aspects, evaluation tools, and estab-
lished goals and time that patients should stay in the program. A
transition strategy was created based on literature, general TP and
reports from other transition clinics.
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iatrist, nutritionist, clinical psychologist, nurse, and social services in-
tegrated the team. Got Transition questionnaire evaluated transition
skills of adolescents during TP.
TP beginning at Pediatric Rheumatology Clinic (PedRh, pre-transition),
following by a Transition Clinic (TC) where skills (Sk), counseling (Co),
multidisciplinary attention (MA), workshops (Wo), and psychosocial sup-
port (Psy) are offered to adolescents and families. Finally, post-
transition follow-up at Adult Rheumatology Clinic once the patient
were ready to transfer (Table 1).
During TC, visits are planned to be every 3 months unless closer fol-
low-up where necessary. All specialists evaluate the patient every
visit and meetings are conducted once a month to discuss cases and
established strategies/goals for each patient.
Despite planned period to stay in TC are two years, it depends on skills
that each patient demonstrate during TP, therefore, some could maintain
at the same phase more than one visit to assure success of program.
Conclusion: Here we shown the structure of an organized, special-
ized, multidisciplinary, integrated, and reproducible TP for adoles-
cents with RC.
Disclosure of Interest
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Phase Facility Physician Attendee Centered Age Goal
1 PedRh Ped Rheum Patient and
Caregiver
Caregiver 12
to
15
Co, Explain the
program
2 TC Ped and
Adult Rheum
Patient and
Caregiver
Patient 16
to
18
Sk, Co, MA,
Wo, Psy
3 TC Ped and
Adult Rheum
Patient Patient 16
to
18
Sk, Co, MA,
Wo, Psy
4 TC Ped and
Adult Rheum
Patient Patient 16
to
18
Sk, Co, MA,
Wo, Psy
5 TC Adult Rheum Patient Patient 16
to
18
Sk, Co, MA,
Wo, Psy
6 Adult
Clinic
Adult Rheum Patient Patient 18
to
22
Sk, Co, MA,
Wo, Psy
7 Adult
Clinic
Adult Rheum Patient Patient 18
to
22
Post-transition
f/u
8 Adult
Clinic
Adult Rheum Patient Patient 18
to
22
Post-transition
f/uP366
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Introduction: Through their lifetime, young people with chronic
conditions will experience a transition from pediatric care to
adult care facilities; this is an important period for the patients
since now they will have to take care of themselves.The main goal of transition is to maximize lifelong functioning
through the provision of high-quality, developmentally appropriate
healthcare services that continue uninterrupted as the individual
moves from adolescence to adulthood.
In pediatric clinics, care is provided to patients accompanied by
their tutors; therefore, the sense of preparation for independence
varies between one part and the other. To our knowledge, there
are no reports that identified differences in self-care skills be-
tween patients and caregivers, and no information on variables
that could influence on that perception has been To compare
the perception of self-care skills for transition between adoles-
cents and their caregivers and analyze clinical, familiar and socio-
economic factors that could influence on that perception.
Methods: Between January and April 2018 we included patients
with rheumatic diseases that were diagnosed during childhood
(under 16 years old) and at the time of their participation were
between 12 and 22 years old. We excluded patients with more
than one condition, neurological disabilities, or refuse to partici-
pate (patient or tutor). Patients were recruited from Outpatient
Clinics from University Hospital “Dr. Jose E. González” at Monter-
rey, Mexico.
We collected clinical (age, gender, disease onset, activity status, med-
ications, complications, and adverse events), familial (family compos-
ition), and socioeconomic (household characteristics, available
services) variables. Self-care abilities and perceptions were evaluated
with the Transition Readiness Assessment for Youth Questionnaire
Spanish Version 2.0 (2014, 25729) and Transition Readiness Assess-
ment for Parents/Caregivers Questionnaire Spanish Version 2.0 (2014,
25729). Variables were described with frequencies, means, medians,
and were analyzed with Chi Square, Mann-Whitney, t test, and correl-
ation tests as convenience.
Results: Perception in 31 patients and their parents were evaluated.
Most of them were female (70%), median age 17 (12 - 21) years, and ju-
venile idiopathic arthritis (JIA) as the most prevalent disease (48%). A
high part of our patients was classified as low and median low income
families and a few proportion of the parents have superior education.
Among transitions questionaires, “Need to change to adult centered
care” was answered with a median of 9 (5 - 10) by caregivers, that
was similar to answer by patient (9, 1 – 10, P = 0.42). On “Perception
of capability of adult-centered health care”, the answers were also
similar (9 vs 8). Despite this, other specific areas of “disease know-
ledge” and “use of health-care services knowledge” were overesti-
mated by caregivers when compared with patients.
No differences were seen when results by disease were analyzed.
Conclusion: Both patients and tutors are aware of the importance of
a adequate transition preparation, also both have the same percep-
tion of preparedness of the patient. Both sides think they aren’t pre-
pared enough for self care in emergency situations and the use of
medications by themselves. Based on the results of this question-
naire we should focus our efforts in educating patients on how to
react on an emergency situations as well as the self administration of
the medications they use on their daily life.
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Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 189 of 243Introduction: Diseases of poverty remain the dominating health pri-
ority in South Africa and other Low- and Middle Income Countries
(LMIC). Recent efforts towards strategic planning on the prevention
and control of non-communicable diseases (NCDs) reflect the grow-
ing relevance of NCD’s in LMIC’s where infectious diseases burden is
on the decline.
Objectives: We set out to identify barriers and drivers that influence
access for children and adolescents presenting with musculoskeletal
(MSK) symptoms with the aim to use this information to improve
MSK care outcomes trough the development of models of care and
deliver appropriate and applicable service improvement strategies. In
doing so we hope to develop a model that can be replicated in other
NCD’s and in other LMIC healthcare systems.
Methods: Five focus group interviews were done over a period of
two weeks. The focus group participants consisted of Community
Service Medical Officers (COSMO’s), Medical Officers (MO’s), Family
Physician Consultants and Registered Nurses in the Eden and Central
Karoo districts within the Western Cape Province of South
Africa. There were forty-one participants. 25 of the 41 participants
completed the questionnaire exploring their training with regard to
the MSK system and their own perceived confidence in identifying
and treating children with a MSK presentation.
Results: Twenty of the 25 participants were general practitioners, two
where specialist family physicians (consultants) and 3 participants did
not specify. The average level of experience was 8.8 years. Eight-eight
percent (n=22) had undergraduate training in the examination of the
paediatric MSK. 8% (n=2) had training in the paediatric gait, arms, legs
and spine (pGALS), but did not use it in day-to-day practice. Teaching
of the paediatric MSK system in children was predominantly delivered
by paediatricians and paediatric orthopedic surgeons. 84% of the par-
ticipants felt confident in some, but not all aspects of the MSK examin-
ation. Using short case studies the participants had to rate their
confidence on a scale of 0-10. The confidence score for the MSK cases
had a mean of 4.16-5.52 (SD 1.93-2.63), compared to communicable
disease case that had a mean of 7.2 (SD 1.68).
Good relationship fostered by the secondary hospital paediatricians
was identified as the biggest driver. Other drivers were, electronic plat-
form for note keeping, communication via certain social media applica-
tions and gained knowledge of system and disease by an intern first
working in a secondary hospital prior working in a peripheral hos-
pital. Barriers were the healthcare providers own perceived limitation
and exposure/knowledge to MSK diseases, poor history given by the
person accompanying the patient, limitations in after hour investiga-
tions, unpredictable availability of ambulance services and socioeco-
nomic factors of the patient population.
Conclusion: The focus groups identified barriers and drivers that play
a role in whether children and adolescents presenting with MSK
symptoms receive the “right care, delivered at the right time, by the
right team, in the right place, with the right resources” these insights
will direct further investigation into the drivers and barriers in the
other districts of South Africa and other LMICs. The results could give
direction in developing policies and Models of Care to improve MSK
care outcomes for children and adolescents.
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Mean SD
Case 1 (Limp) 5,52 1,93
Case 2 (Delayed Walking) 4,72 2,26
Case 3 (Shortness of breath and difficulty breathing) 7,2 1,68
Case 4 (Fever and arthritis) 4,52 2,63
Case 5 (Swollen joint) 4,16 2,26P368
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Introduction: Chronic pain disorder is a common and under-
recognized problem who is increasing in the pediatric population.Os-
teoarticular pain is one of the most common symptoms.This is a signifi-
cant problem leading to a decrease in quality of life,school absenteeism
and social withdrawal.A multidisciplinary approach is essential to evalu-
ate and manage those patients whom have an unsatisfactory evolution
despite primary medical care.Starting In 2014,a group of 4 medical spe-
cialists(pediatric rheumatologist, pediatric orthopedist, child psychiatrist
and pediatrician specialist in adolescent)and one physiotherapist
started a joint outpatient clinic assessing such children.
Objectives: The aim of this study was to describe and outline some
characteristics of all patients seen at this platform up to now.
Methods: A retrospective descriptive study was performed based on
medical records of patients seen at our center in Lausanne between
November 2014 and January 2018.Epidemiological,clinical and thera-
peutic data was collected and analyzed accordingly.
Results: A total of 35 patients were reviewed.The patients were in
most cases(82%)referred by the pediatric rheumatologic or ortho-
pedic surgeon.The sex ratio F/H was 3.3 (27 girls for 8 boys).The aver-
age age at the time of consultation was 12.8 years(9 to 18 years).A
triggering event was found in 48% of our patients with the notion of
trauma in 35% of these cases.The average duration of symptoms was
3.6 years prior to referral to the platform (1-11 years).Chronic pain af-
fected more than 5 joints in 75% of the cases.School absenteeism
was noted in 22% of the children with 2 cases of withdrawal.The
platform revealed in 52% a primary paindisorder,in 28% an associ-
ated orthopedic problem,in 25% a difficult psychosocial situation and
in 5% a rheumatologic problem.Therapeutic proposals were mainly
personalized physiotherapy or mind body approaches such as hyp-
noses and depending on the findings,follow-up in orthopedics,rheu-
matology,child psychiatry or adolescent specialist consultation.
Conclusion: A long delay before children with chronic pain reach the
platform was noticed.This could explain the severity of the presenta-
tion and the significant impact on school attendance and social life.-
The integrative clinical approach highlighted the multifactorial
aspects of chronic pain and led to the development of an adapted
multidimensional treatment to improve the prognosis and reduce
the negative impact of chronic pain.We encourage pediatricians to
detect and refer such patients early.
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Introduction: The paediatric rheumatology and paediatric chronic pain
teams in Oxford provide highly specialised rehabilitation services with
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 190 of 243interventions ranging from one-to-one therapy to intensive inpatient
rehabilitation programmes. It was identified that further ongoing com-
munity based support would be beneficial for the maintenance of
physical fitness and wellbeing once the input of the specialist teams
was no longer indicated.
Objectives: An opportunity to develop an innovative approach to
community based self-management group aquatic therapy was iden-
tified by bringing together the expertese of Fluid Motion, a social en-
terprise group with establised success in delivering community
group aquatic therapy for adults using artificial intelligence technol-
ogy, the clinical teams from the paediatric rheumatology and peadia-
tric chronic pain services in Oxford, and the research experience of
the musculoskeletal team at Oxford Brookes University.
We aimed to develop a self-management aquatic therapy programme
for adolescents with musculoskeletal pain and disability using indivi-
dualised digital progragrammes, enhanced with AI technology.
Methods: The specialist physiotherapists identified patients that were
actively under their care between the ages of 12-18 year.
The group had a range of diagnoses but all had the common finding
of ongoing musculoskeletal pain and disability.
It was recognised that a higher proportion would have a chronic pain
condition.
The level of function required to take part was agreed as, independ-
ently mobile, able to get in and out of pool without assistance, inde-
pendent dressing (parents will not be permitted to stay at pool side).
It was acknowledged that some patients may be inappropriate for
group work including those with specific behavioural difficulties.
Results: Outline of the programme:
Patients were invited to attend a 7 week aquatic self management
group under the supervision of our physiotherapists.
The patients had all been assessed by the specialist physiotherapists
and identified as being appropriate for the programme.
The physiotherapists selected exercises from the digital rehabilitation pack-
age in order to create an individualised programme for each participant.
The paediatric rheumatology hydrotherapy pool was used. This was
identified as an appropriate place to assess the initial intervention
with a view to hosting future programmes in community pools.
5-6 patients were in each group.
The physiotherapist was in the pool for each session to provide sup-
port with the physiotherapy assistant on poolside.
Patients were introduced to their programme on the tablet before
entering the pool.
The the patients used the tablets during each session and provided
real time feedback on their experiences to inform development of
their programme using AI technology.
Reassessment was carried out in the final session.
All patients had to commit to 6 out of 7 sessions including the final
session.
Assessing the intervention:
Rheumatology patients completed CHAQ assessments before and
after the programme.
Chronic pain patients completed the Oxford pain questionnaire in-
cluding a pain map before and after the programme.
Physical tests, were completed in clinic before the intervention and
in the 7th session of the programme
Conclusion: We identified a need to provide ongoing support for
young people with musculoskeletal pain and disability once the in-
put of highly specialised services was no longer indicated and recog-
nised the potential for supervised self management group aquatic
therapy. We present our experience of designing a programme using
digital technology that can be easily utilised by young people during
their therapy sessions and provide real time feedback to progress
their therapy using AI technology.
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Introduction: Physiotherapy (PT) and occupational therapy (OT) are
widely accepted as mainstay treatments for Paediatric rheumatological
conditions. Historically in Qatar children with rheumatological illness were
referred to a paediatric rheumatologist, then to general outpatient ther-
apy services hosted in separate sites. There were no formal feedback
mechanisms between therapy services and the pediatric rheumatologist.
Objectives: This study reviews the patterns of referral to PT and OT
services since opening the Pediatric Rheumatology clinic at Sidra
Medicine. The study also presents specific outcomes; range of move-
ment and goal attainment.
Methods: Patients referred for OT or PT were identified through Sidra
Medicine’s electronic medical records system. All patients referred for
OT or PT were identified between June 2017 and March 2018. A
retrospective review of the EMR was conducted by the therapists. Pas-
sive range of movement measurements and goal ratings were com-
pared at baseline and at the final assessment within the designated
timeframe of the review.
Results: A total of 88 patients were referred to the rheumatology ser-
vice. Of these 15(18%) were referred for therapy. Seven (39%) of these
were seen jointly by OT and PT while 7(39%) were seen by PT alone. One
patient was seen for OT assessment and intervention only.
There were 4 Qatari nationals and 11 non-nationals. Juvenile Idio-
pathic Arthritis (JIA) was the most frequent diagnosis with 9 pa-
tients. There were 3 patients with scleroderma and 2 patients with
Juvenile Dermatomyositis (JDM).
Five patients with restricted range of movement and functional limi-
tations were seen for therapy. The remaining 10 patients were seen
for strengthening only. Range of movement measurements were
taken at commencement of therapy and at the end of the period in-
cluded in the data. All patients set goals for therapy in conjunction
with their treating therapist and these were reviewed at every ses-
sion to assess progress.
The results of the initial and final range of motion measurements
and goal attainment are summarized below in Table 1.2.
All patients demonstrated an improvement in passive range of
movement in the joints assessed. Two of the patients continued to
experience an uncontrolled disease flare (patient 3 and patient 5)
however despite this demonstrated improvements in passive range
of movement following therapy intervention.
At Sidra Medicine goals are set with the patient and family and re-
flect the functional goals that the patient and/or their family are hop-
ing to achieve by attending therapy. Four of the 8 patients met all of
their established goals. Two patients met 66% of their goals and are
continuing with therapy to meet these remaining goals. A final two
patients did not meet their goals however both continued to have
active disease. These are the same two patients who experienced the
smallest improvements in passive range of motion of their joints.
Conclusion: Although only a small number of patients have been
seen for specialist OT and PT treatment at Sidra the review suggests
that outcomes for these patients in terms of improved range of mo-
tion and attainment of treatment goals is positive. The pediatric
rheumatologists report that the increase in communication with
treating therapists has positively affected their ability to manage dis-
ease flares ensuring improved care.
Disclosure of Interest
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Table 1.2 (abstract P370). See text for description
Patient Diagnosis Mean PROM
Improvement
(in degrees)
Median PROM
Improvement
(in degrees)
Goals
set
Goals Met
in time
frame
Goals
Continuing
%
Met
One JIA-ERA 16.75 13 2 2 0 100%
Two Scleroderma 11.66 10 6 4 2 66%
Three Scleroderma 7.77 5 5 0 5 0%
Four Scleroderma 10.71 7.5 3 2 1 66%
Five JIA-Poly-
Articular
13.75 15 2 0 2 0%
Six JIA-ERA NA NA 1 1 0 100%
Seven JIA-Oligo NA NA 1 1 0 100%
Eight JDM NA NA 2 2 0 100%
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Introduction: It is important for adolescents with a chronic disease
as Juvenile Idiopathic Arthritis (JIA) to get acquainted with their con-
dition. This allows the young people to take responsibility for their
own disease and medication. Health care professional’s knowledge
about the adolescents knowledge regarding their illness and treat-
ment is very limited.
Objectives: To examine the level of knowledge adolescents has
about their illness and treatment and to clarify in which area they
need education from health care professionals. As to examine diffi-
culties with procedures as join injections and blood samples.
Methods: To map the knowledge of patients who are 18 years old
and are to be transferred to adult care. The patients have received
and responded to the Medical, Exercise, Pain and Social Support
Questionnaire (MEPS). The questionnaire consists of four dimensions,
medical domain, exercise domain, pain domain and social domain
with varying number of subheadings. The questions are answered
using a VAS scale, between zero and one hundred.
Results: : All Thirty patients that was invited to participate, answered
the questionnaire. The results will be illustrated with examples from
each domain. In the medical domain the result shows that patients
have poor knowledge of juvenile idiopathic arthritis (JIA) and treat-
ment. The median value of the question: How much knowledge do
you have about the medical background to childhood rheumatism,
was 54,5. Only a few patients have a great deal of fear of sampling
and cortisone injections. Results from the exercise domain showed
that the median value for joining the school gymnastics was 89. Fur-
thermore, the question; Do you know how to reduce your pain sig-
nificantly, from the pain domain resulted in a median value of 46.
The questions about the social domain are about how valuable the
patients think it is to meet others with the same diagnosis and if it is
considered worthwhile with a patient association. The answers
showed that the patient did not think this had any difference.
Conclusion: This study of patients' knowledge illustrates that their
knowledge of their disease and treatment varies. The range is from
lowest to highest score on almost every question. In general, thestudy reveal that a large portion of the young patients have surpris-
ingly poor knowledge of their illness and treatment. However, we
thought that several of these patients would find it difficult to have
joint injections and take blood samples, which they didn´t. We see
this as a very pleasing result.
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Introduction: In 2014 Department of Rheumatology at Odense Univer-
sity Hospital experienced that their young patients had a lack of know-
ledge about their own disease, treatment and insight into life as an
adult patient. Health professionals from both the adult and pediatric
department participated in a brainstorm process, also including the
young patients and their families. They found, as expected, that the
young patients had very little knowledge about their own disease and
what to expect as an adult patient. The pediatric team decided to take
action in improving the standard for transition.
Objectives: To help identify and strengthen the young patients level
of self-care and improving their understanding of their own disease.
To inform and prepare them for the transition from the children’s
hospital to adult medicine. Here they will be expected to take a more
independent and active part in their treatment.
Methods: 1) More focus was given in the pediatric consultations
about living with JIA and going to consultations as an adult. This was
begun well in advance before the actual transition.
2) The patients were guided to the location of the adult department
of Rheumatology and welcomed by a nurse there at the end of their
last pediatric consultation. This was only an option if the patient
chose to receive further treatment at the same hospital. Others chose
hospitals closer to their home.
3) Development of an application for smartphones that contains in-
formation regarding the disease; medication and the organization of
the outpatient clinic at both departments with an option to write dir-
ectly to the nurses.
Results: These different methods were well received by both patients
and parents, although there was still in most instances a parent-
guided tendency in the consultations.
It was evident that there were still hurdles for the patients to climb
in regards to making direct contact and starting to take ownership of
their own disease and treatment. Several patients got the application
on their phone; none has used it to write directly in to the nurses, in-
stead their parents called the nurses as usual.
Conclusion: The feedback from the department of Rheumatology is
positive as they are encountering more prepared patients that have
a better understanding of the way the consultations and treatments
will be handled.
Further efforts are needed in supporting the young patients to take
a more active role in their treatment and in the understanding of
their disease.
Many, especially among the ones that have been diagnosed at an
early age, have very little insight into their own disease and
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 192 of 243treatment, while their parents are often fully understanding of the
different aspects.
The team has started to plan a group session of 4-6 young patients
to get them together, without parents, for a couple of hours one
afternoon where the focus would be JIA, and the treatment thereof.
A board game about JIA has been developed in an effort to make
talking to others about their disease easier, without having to share
personal details about themselves.
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Introduction: Juvenile Idiopathic Arthritis (JIA) is the most common
childhood rheumatic disease. The chronic disease, and specifically
the rheumatic one, is characterized by a varied symptomatology,
with an alternation between acute, remission and reactivation phases
of the disease that may induce disability, functional and social im-
pairments of variable importance on the basis of medical (clinical
subtype, late diagnosis, adequacy of the treatment) and non-medical
factors (attachment styles, Life events, pain coping strategies, emo-
tional state of child and parent).
There are scientific evidences that Cognitive Behavioral Therapy
(CBT) is a treatment that improves coping skills and reduces pain,
joint inflammation, physical disability and secondary depressive
symptoms in patients affected by cronic pain.
Objectives: The study investigates the psychological factors of chil-
dren with Juvenile Idiopathic Arthritis (JIA) at the onset of the disease
and its association with physician’s functional and pain assessment in
the follow-up.
The secondary aim was to evaluate the efficacy of an individual cog-
nitive behavioral treatment for children with JIA on the global pa-
tient’s outcome and their parents both in terms of functional and
pain assessment.
Methods: We performed an open longitudinal study on consecu-
tive onset JIA patients (any type of JIA as per the International
League of Associations for Rheumatology). Children underwent a
psychological interview, they were submitted questionnaires
evaluating the attachment with the caregiver (Separation Anxiety
Test, SAT), psychopathology (Child Behavior CheckList, CBCL),
strategies of pain facing (Coping) for children; anxiety and emo-
tional state (STAI-Y 1 STAI-Y 2) for caregivers and life-events in
children and caregivers.
Physician’s assessment was extracted from physical examination (dis-
ease activity, active joint count), laboratory variables (antinuclear
antibodies, hemoglobin, C-reactive protein and erythrocyte sedimen-
tation rate) and Child Health Assessment Questionnaire (CHAQ),
given at the same time.
Children and parents in the treatment condition completed question-
naires prior to treatment and directly after treatment.
Some children were also assigned to an individual psychological
cognitive-behavioral treatment of 8 sessions, based on psycho-
educating children and parents on pain and anxiety mechanisms,
teaching children to restructure pain related negative automatic
thinking, assertiveness training and relaxtion training. Results weremeasured from self-reported scales. Clinical data was collected by a
rheumatologist.
Results: Data from 40 patients with JIA (24 females; 16 man). At
baseline, median age was 8.5 years (3-16 years); 12 patients do not
report life events; 22 report life events one at baseline (64.7%); care-
givers state-anxiety are not significantly associated with a type of ju-
venile arthritis.
Results show a trend in the reduction of anxiety and emotional state
from children and parents who have carried out the CBT intervention
but this decrease does not reach a statistical significance (p= .44).
Conclusion: Preliminary analysis showed that stressful life events
that may promote the slatentization of AIG are: new education clas-
ses, illness of a family member, parents’ separation, grief in family.
This findings from suggest that Cognitive Behavioral intervention
for JIA may help patients and their parents in reduction the burden
of their illness.
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Introduction: Summer camps for children with chronic conditions
like Juvenile Idiopathic Arthritis (JIA) seem to have a positive im-
pact on physical, psychological, emotional and social aspects. The
first Portuguese Summer Camp for Children with JIA was an ini-
tiative of the Pediatric Rheumatology Unit of Hospital de Santa
Maria, in Lisbon. There have been 2 editions (Ed): the 1st in 2016
and the 2nd in 2017, with one-week duration and 19 participants
each.
Objectives: The goal of this prospective pre-post study was to
evaluate the impact of the Summer Camp for children with JIA.
Methods: Inclusion criteria were all children who participated in the
1st or 2nd Ed of the JIA Summer Camp and completed the 4 ques-
tionnaires: the Childhood Health Assessment Questionnaire (CHAQ),
the Functional Assessment of Chronic Illness Therapy (FACIT), the
KIDSCREEN-52 and the “Emotional and Social Competence Evaluation
Scale” (EACSE) questionnaires. These were done at 2 separate time
periods: "pre-camp", in the 3 months that preceded the camp; and
"post-camp", within 3 months after camp. Informed consent was ob-
tained from parents. Questionnaires with missing answers were ex-
cluded, as were children that only responded pre or post camp.
Results: A total of 33 questionnaires were completed by 20 chil-
dren who participated in one or both editions. Table 1 shows the
demographic characteristics.
The median CHAQ result was 0.125 (IQ 0—0.312) pre-camp and 0 (IQ
0—0.25) post-camp. There was a negative variation in pre and post
camp CHAQ with statistical significance difference (SSD) (p-value
0.035). The median FACIT result pre-camp was 46 (IQ 43-50) and
post-camp was 45 (IQ 42.5-49), with no SSD. In the KIDSCREEN ques-
tionnaire, the domain of Parent Relations and Home Life and the do-
main of Social Support and Peers had a positive SSD of 0.33 and 0.45
(p-value 0.47 and 0.45, respectively). Other domains did not have
SSD. The median global score was 3.60 (IQ 3.47 – 3.78) pre-camp and
of 3.54 (IQ 3.50 – 3.83) post-camp, with no SSD observed. In the
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 193 of 243EACSE Score, the Emotional Regulation domain had a positive SSD of
0.8 (p-value 0.34). The median global score pre-camp was 4.0 (IQ 3.0-
5.0) with no variation in post-camp score. There was also no SSD ob-
served in other domains.
Conclusion: The Summer Camp for children with JIA was a pion-
eer activity in Portugal, as was the analysis of Camp impact in
these children. The domain of Parent Relations and Home Life
and the domain of Social Support and Peers in KIDSCREEN and
the Emotional Regulation domain of the EACSE questionnaires
showed a positive SSD, which represents an improvement in
these domains. Similarly, the negative SSD in CHAQ also substan-
tiates the positive functional impact of this Summer Camp for
children with JIA. These results corroborate the idea that Summer
Camps have a positive impact in children with JIA.
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Male (%) 10 (50%)
Median age in years (IQ) 12 (10-14)
JIA category
Persistent oligoarticular 9 (45%)
Extended oligoarticular 3 (15%)
Polyarticular rheumatoid factor negative 3 (15%)
Enthesitis-related arthritis 3 (15%)
Psoriathic arthritis 2 (10%)
Prednisolone / Methotrexate / Biologic therapy (%) 1 (5%) / 14 (70%) / 2 (10%)P375
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Introduction: Juvenile idiopathic arthritis (JIA) is the most common
chronic pediatric rheumatic disease. Depending on the underlying
pathologies, the common symptoms of this disorder are the limitations
of the upper extremity joint movement angles, muscle imbalance and
the functional limitations caused by the contracture due to these pa-
tients. Wrist joint is the most affected joint in the upper extremity and
daily life activities such as feeding, personal care, and self mobility activ-
ities that use upper extremity are commonly limited with these chil-
dren. Ergotherapy can help to reduce a child's pain. It can help to
maximize their strength, endurance, and physical function. Ergotherapy
can make them more independent in their activities of daily living.
Objectives: The aim of this study was to investigation of effective-
ness of individual ergotherapy intervention for rehabilitation in pa-
tients with JIA who have involvement wrist joint.
Methods: 21 patients with JIA (17 girls and 4 boys), age range 6-18 par-
ticipated in this study. The patients were recruited from the pediatric
rheumatology outpatient clinic of the Department of Pediatric Rheuma-
tology of the Istanbul University Faculty of Cerrahpasa Medicine.
Range of motions (ROMs) of hand, grip strength, functional ability, fa-
tigue and quality of life were assessed with a goniometer, handdynamometer, Childhood Health Assessment Questionnaire (CHAQ),
Numeric Rating Scale (NRS), and the Pediatric Quality of Life Inven-
tory (PedsQL), respectively. The ergotherapy sessions were designed
according to the needs of the individual. The sessions consisted of
activities that improved fine motor skills and increased joint mobility,
hand-eye coordination, and daily life skills training. The patients com-
pleted an 8 week individually planned ergotherapy program 3 times
a week at the department of physical therapy and rehabilitation. Dur-
ation of the each therapy session was 30-45 minutes.
Results: The mean age and duration of disease was 13.48±3.50 (age
range 8-18), 4.95±3.59 years, respectively. The means of the pre/post
treatment scores of NRS fatigue were 5.33±1.88/2.00±1.54, PedsQL-
patients; 63.39±18.48/83.40±13.81, PedsQL-parents; 58.23±16.76,
CHAQ-total; 1.11±0.60/0.25±0.36, CHAQ-pain; 46.67±29.51/10.48
±18.83 and CHAQ-well being; 61.67±25.11/30.95±19.27, respectively.
Also, statistically significant differences were found between pre and
post-treatment of ROMs of wrist flexion and extension, hand grip
and pinch grips scores (p<0.05).
Conclusion: The study demonstrated that participating in an 8-week in-
dividually planned ergotherapy program improves ROMs of hand, grip
strength, fatigue, physical function and the quality of life in patients
with JIA. We think that patients with JIA who have affected wrist joint
may live independently through individualized ergotherapy program.
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Introduction: Published treatment recommendations state to
change biologic medications when the goal of inactive disease sta-
tus is not attained, but the switching of biologic agents has not been
well-studied.
Objectives: To examine the frequency of switching of biologic agents
in the treatment of JIA in clinical practice in North America.
Methods: Using retrospective and prospective data from the Child-
hood Arthritis & Rheumatology Research Alliance(CARRA) Registry,
we identified patients with JIA categories other than systemic arth-
ritis who newly started a biologic agent after 1 January 2008 and
had at least 12 months of observable time following medication
start. “Switchers” were defined by stopping the first biologic agent
and starting a different biologic agent within 6 months of the discon-
tinuation. “Delayed switchers” were defined by stopping the first bio-
logic agent and starting a different biologic agent more than 6
months after the discontinuation. “Non-switchers” were defined by
no use of any other biologic agent. Chi-square and Wilcoxon rank
sum were used to compare patient characteristics among the differ-
ent switching patterns.
Results: 708 children with JIA newly started a biologic agent during
the study period and had sufficient data available for ana-
lysis. 146 (21%) were switchers, 45 (6%) were delayed switchers, and
517 (73%) were non-switchers. Among switchers, the median time be-
tween starting the first biologic agent and switching biologic
agents was 309 days (interquartile range (IQR) 151 - 630) and the
median time between the first and second biologic medications
was 0 days (IQR 0 – 31). Among delayed switchers, the median
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 194 of 243time between starting the first biologic agent was 1184 days
(IQR 669-1442) and the median time between the first and second
biologic medications was 587 days (IQR 335-858). Etanercept was the
most commonly initiated first biologic agent (N=476,67%). The pro-
portion of patients who used etanercept as the first biologic agent
was greater among all switchers (73%) compared to non-
switchers (65%; p=0.04). The proportion of patients who took concur-
rent methotrexate was greater among all switchers (84%) compared
to non-switchers (76%; p=0.03). The prevalence of chronic uveitis
and inflammatory bowel disease was similar between switchers and
non-switchers. Medication ineffectiveness (N=77, 52%), flare of dis-
ease (N=19, 13%), and medication intolerance (N=16, 11%) were the
most commonly reported reasons for discontinuing the first biologic
agent among all switchers.All biologic
initiators
N= 708
Non switchers
n=517
Switchers
n=146
Delayed
switchers
n=45
Age (years) median,
range, IQR
10 (IQR 6, 13) 10 (6, 13) 10.5 (8, 14) 8 (4, 11)
RF+ poly 90 (13%) 69 (13%) 16 (11%) 5 (11%)
RF- poly 376 (53%) 278 (54%) 71 (49%) 27 (60%)
Persistent Oligo 66 (10%) 51 (10%) 11 (8%) 4 (9%)
Extended oligo 44 (6%) 32 (6%) 10 (7%) 2 (4%)
ERA 72 (10%) 49 (10%) 21 (14%) 2 (4%)
psoriatic 44 (6%) 27 (5%) 14 (10%) 3 (7%)
etanercept 476 (67%) 336 (65%) 103 (71%) 37(82%)
adalimumab 152 (21%) 118 (23%) 29 (20%) 5 (11%)Conclusion: Following first initiation of biologic agent use for
JIA, nearly 30% of children switched to a second biologic medica-
tion after a median of 14 months. All switchers were more likely to
have initiated etanercept and more likely to have taken concurrent
methotrexate compared to non-switchers. Future studies are needed
to examine the short- and medium-term clinical outcomes follow-
ing biologic switching to help identify the optimal timing of switch-
ing and the most effective second-line biologic agent.
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Introduction: The efficacy of intra-articular (IA) steroid injections
in patients with JIA has already been demonstrated. However,
the value of IA steroid injection into hip joint remains uncertain,
since in very few studies systematic imaging follow-up was con-
ducted with conventional radiography (CR) or magnetic reson-
ance imaging (MRI).
Objectives: To evaluate the effect of hip steroid injection in terms of
reducing synovitis and preventing joint damage progression in pa-
tients with JIA.Methods: All JIA patients who received ultrasound guided intra-
articular triamcinolone hexacetonide (IATH) injection for the treatment
of coxitis at the Study Unit between 2013 and 2018 and underwent im-
aging assessment before and after local treatment were included in the
present study. Pre- and post-therapeutic assessment included: clinical
work-up, bilateral hip radiographs (median duration of the interval be-
tween the two radiographs 1.5 years) and bilateral hip MRIs (median
duration of the interval between the two MRIs 1 year). Joint damage
progression was assessed according to the Childhood Arthritis Radio-
graphic Score of the Hip (CARSH). MRIs were assessed by using the Out-
come Measure in Arthritis Clinical Trials (OMERACT) Rheumatoid
Arthritis Scoring System (RAMRIS) synovitis score. Descriptive statistics
were reported in terms of absolute frequencies or percentages for cat-
egorical data, while in terms of medians, first and third quartiles (1st -
3rd q) for continuous quantitative data. Comparison of categorical data
was performed by means of the Fisher’s Exact test.
Results: A total of 13 patients (10 F, 3 M; 6 systemic, 3 polyarticular
and 4 oligoarticular -onset JIA patients; median age at the time of
IATH 16.2 years; median disease duration 8.8 years) received IATH in
17 arthritic hips. Nine patients had unilateral coxitis, while 4 had bi-
lateral hip involvement. Immediate pain relief and improved hip mo-
bility occurred in 13 out of 17 hip joints (76.5%). Nine out of 17 hips
(53%) were in clinical remission at 3 months follow-up visit. Follow-
up MRI showed an improvement of synovitis in 4 out of 17 hips
(23.5%) and a complete resolution of synovitis in 3 out of 17 hips
(17.6%). In the remaining 10 hip joints (58,8%) synovitis didn't im-
prove. Joint damage progression was assessed in 14/17 hips. Struc-
tural deterioration was observed in 5 out of 14 hips (35.7%). Four out
of 9 hips (44.4 %) with persistent synovitis experienced joint damage
progression versus 1 out of 5 hips (20%) that had an improvement or
complete resolution of synovitis (p=0,58). None of the hips that
achieved complete resolution of the synovitis experienced damage
progression. Notably, all cases of structural deterioration occurred in
patients with diagnosis of systemic JIA. Any avascular necrosis of the
femoral heads (FHN) or other complications were not observed.
Conclusion: IATH treatment of coxitis in JIA is a safe therapy yielding
a high remission rate from a clinical point of view. Clinical improve-
ment however does not equate to imaging resolution of synovitis.
The group of non-responders, with long-term persistent synovitis as
detected by imaging, experienced a higher frequency of joint dam-
age progression compared to patients with complete remission or
improvement of coxitis after IATH. None of the patients that
achieved complete resolution of the synovitis experienced structural
deterioration. It is important to highlight that most of our patients
had polyarticular or systemic JIA with long disease duration, thus jus-
tifying a more severe disease course.Disclosure of Interest
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Introduction: Favorable outcomes in the inflammatory state are ex-
pected without carrying over organ failure to adulthood if the
principle of early diagnosis and early therapeutic interventions are
maintained, and it is not too much to say that the advent of bio-
logics brought us this improvement. In pediatric rheumatology field,
four biologics (tocilizumab, etanercept, adalimumab, palivizumab and
abatacept) have been approved in Japan by April 2018. Especially,
new approval of pediatric indication for tocilizumab, etanercept and
adalimumab that are anti-rheumatic agents have greatly changed
the medical treatment in pediatric rheumatology field, by which
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 195 of 243many clinicians have realized the change of the time from “CARE” to
“CURE”
Objectives: For the development, approval and early introduction
into clinical practice of biologics in pediatric field, we need to grasp
the pesent situation of the development to approval of biologics as
anti-rheumatic agents for children in Japan, and visualize the pesent
problems and give a proposal for the future.
Methods: We reviewed the time lag from the development to ap-
proval between inside and outside of Japan and between adult use
and pediatric use using each Application document.
Results: As results of analysis in various directions, it is apparent that
the duration of a review period required for the preparation of clin-
ical trials and the approval in PMDA clearly reduced compared with
the past. Thus, it was speculated that a rate limiting step in the
process from development to approval was the duration of clinical
trials between its start to end. Therefore, it is necessary to consider
about the following 3 keywords to promote the development of bio-
logics and their early practical use: they were “Registry”,
“Centralization” and “Global cooperation”, all of which are related to
the reduction of duration of a clinical trial.
Conclusion: To reduce the duration of clinical trial, it is essential to
complete “a world-scale registry system” by developing the registry
system established by Pediatric Rheumatology Association of Japan.
Then, it is important to carefully plan to participate into the inter-
national network using “the world-scale registry system”, and aim at
global cooperative trials in which we can ensure the sufficient num-
ber of entries from Japan.
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Introduction: With the advent of targeted therapy as biologics for
the treatment of juvenile idiopathic arthritis (JIA) and other pediatric
rheumatic diseases outcome has improved considerably. However, a
major concern in patients treated with these immune-modulators
has been the increased risk of opportunistic infections.
Objectives: To explore the clinical and paraclinical findings following
serious opportunistic lower respiratory tract infection (LRTI) observed
in rheumatic children treated with immune-modulating therapy.
Methods: Single center study of consecutive cases with severe LRTI
observed during a two-year period from January 1st 2016 to Decem-
ber 31st 2017 in the Pediatric Rheumatology Clinic, Aarhus. Clinical
data, as well as imaging and laboratory results were extracted from
the medical records.
Results: We collected 4 patients (3 girls, 1 boy) diagnosed with se-
vere opportunistic LRTI: Two with JIA (1 with systemic JIA and recur-
rent macrophage activating syndrome (MAS), 1 with rheumatoid
factor negative polyarticular JIA, 1 with hypereosinophilic syndrome,
1 with mixed connective tissue disease (MCTD). Mean age at diagno-
sis was 115 months (range 50-186), disease duration at time of diag-
nosis of LRTI was 69 months (range 7-150). All had been treated with
biologics (2 with 1 and 2 with 3 different drugs) for 23 months
(range 2-63), all being pre-tested negative for latent tuberculosis in-
fection. In addition, three patients received corticosteroids at time of
LRTI diagnosis, duration of treatment was 30 months (range 5-66).
Clinical symptoms were rather sparse. Mild cough was observed in
two patients, but none had fever, tachypnea? or dyspnea. Ausculta-
tion of the lungs were normal in all patients. Elevation of the acute
phase reactants (mean ESR 58 (range 8-103), mean CRP 71 mg/L(range 0.6 – 141)) was seen in 3 patients, which was not related to
the activity of the rheumatic disease. Pulmonary abscess was de-
tected in one patient by FDG-PET-CT. Aspirate from the abscess gave
positive cultures with Staphylococcus aureus. In two of three patients
high-resolution-CT scan of the lungs revealed multiple bilateral infil-
trates, the third being normal. Bronchial alveolar lavage was per-
formed in three patients resulting in the detection of Pneumocystis
jiroveci in all three and in addition in one of these patients cultures
with Staphylococcus aureus and Aspergillus galactomannan antigen
(DNA) was found, but in neither of the three aspirates cultures with
Mycobacterium tuberculosis were found. All patients recovered after
receiving relevant antimicrobial therapy.
Conclusion: Children with rheumatic diseases treated with biologics
with or without the combination of corticosteroids may have a rather
asymptomatic course when infected with opportunistic lower respira-
tory tract infections. Comprehensive investigations of a possible in-
fectious cause must be undertaken even if symptoms are mild or
incongruent with abnormalities in ESR or other inflammatory
parameters.
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Introduction: Methotrexate (MTX) is the “gold standard” treatment of ju-
venile idiopathic arthritis (JIA); however, this therapy is not always effect-
ive and predictable, most often in connection with toxicity.The aim of
our study was to identify the relationship between inefficient assignment
of MTX and the presence of folate exchange genes polymorphism.
Objectives: In the period between 2016 and 2017 in the Department
of Pediatrics of the hospital “OKHMATDYT” 79 children between the
ages of 5 and 18 (mediane 12.8 years old) were diagnosed with JIA.
All children were initially treated with MTX. 15 children were also
given biological therapy during the first year of treatment.
Methods: Due to the ineffectiveness of basic therapy and toxic ef-
fects of MTX(nausea, vomiting, toxic hepatitis), 11 children were fur-
ther studied for the molecular genetic study of folate exchange
genes polymorphism (MTHFR C677T, rs1801133 and A1298C,
rs1801131; MTR1 A2756G; rs1805087; MTRR A66G; rs1801394; RFC1
G80A; rs1051266), homocysteine levels, folic acid and vitamin B12 in
the serum. Of the 11 children examined, 4 had a systemic variant of
JIA with the active arthritis, and 7 of them had a polyarticular variant,
which was complicated by uveitis in 4 patients.
Results: Among the examined children, the frequency of polymorph-
ous variants of the folate exchange genes were: for the MTHFR gene:
677CC - 55.56%, 677CT - 44.44% and 1298AA - 55.56% 1298AC -
33.33%, 1298CC - 11.11%. The genes of MTR1: 2756AA - 55.56%,
2756AG - 33.33%, 2756GG - 11.11%, and MTRR: 66AA - 44.44%, 66AG
- 33.33%, 66GG - 22.22%. Distribution of polymorphous variants of
the folate transporter gene RFC: 80GG -22,22 %%, 80GA-66,67%,
80AA-11,11%. 4 children had showed an increase in homocysteine
levels: 5.9-8.6 μmol/l(norm-5 μmol / L), 2-increasing the level of vita-
min В 12: 980-1530 pg/ml (norm-174-878 pg/ml), the level of folic
acid in serum was within regulatory limits (normal 3-17 ng/ml).
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 196 of 243Children with higher level of homocysteine and vitamin B12 had sys-
temic JIA.
Conclusion: Our research shows that when genes polymorphism of
folate exchange is present, there is a high likelihood that MTX will be
toxic and it can use as prognostic factor. The prognosis of efficacy is
discretionary, since the side effects of MTX are dose-dependent and
the working dose is probably not achieved due to early toxic effects.
Further studies are needed to assess the importance of these
markers to predict the effectiveness of MTX treatment.
Trial registration identifying number:
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Introduction: It is being recognized that serologic response to vac-
cines may be impaired in pediatric patients with rheumatic diseases
(pedRD), related to the disease and immunosuppression. In 2017,
Portuguese National Vaccination Programme (PNV) postponed tet-
anus and diphtheria immunization from 20 to 25 years and may pose
these patients at even higher risk. At the moment, there are no pub-
lished data in Portuguese pedRd
Objectives: Evaluate serologic response to vaccines in Portuguese
pedRD receiving immunosuppressive treatment (IT).
Methods: Thirty children with RD attended in a Pediatric Rheumatol-
ogy Unit, under immunosuppression, were recruited between January
to March of 2018. Blood analyses were processed in the same labora-
tory. Serum samples for Diphtheria-Tetanus (DT) antitoxin antibodies
were obtained on the date of recruitment. Laboratory reference
values for tetanus and diphtheria antitoxin antibodies (TAA and DAA)
recommends: vaccination for values under 0.1 UI/mL (TAA and DAA),
and booster for values under 0.5 (TAA) and 1 UI/mL (DAA). Anti-
hepatitis A and anti-HBs antibodies were evaluated in different times
before and along the treatment. Pos-vaccination anti-varicella-zoster
virus (anti-VZV) IgG antibodies were measured during the first three
months of IT. All had the PNV for the vaccines (V) analyzed, updated,
previously and during IT. HBV and Tetanus-Diphtheria (TD) V were ad-
ministrated, according the PNV (HBV:3 doses in the first year; TD: 3
doses in the first year, 18 months, 5 and 10 years). HAV and VZV are
not included in the PNV. VZV was administrated in susceptible patients
before starting IT. All had normal previous immunoglobulins and com-
plement evaluation and no history of frequent or severe infections.
Results: 30 children (13±5 years); 19 female (63%) with diagnosis in-
cluding juvenile idiopathic arthritis (JIA, n=18), SLE/others connective
tissue disease (n=6), vasculitis (n=2), auto-inflammatory diseases
(n=1), chronic uveitis (1); with mean disease duration of 42±37
months and total IT of 27±28 months. Almost all (n=27) had history
of high IT for longer than 3 months. IT included biologics (anti-TNF)
(n=8); Glucocorticoids (GC) (n=7), methotrexate (MTX) (n=19); Cyclo-
sporine (n=2) and Ciclophosphamide (n=1). In the last three months
17/30 have been under high IT (of which 8 with anti-TNF). TAA was
evaluated in 28/30, of those 7 (25%) revealed unprotected values
(<0.5), in patients with ages ranging from 3 to 16 years (median 11
±5 years). Six were on high IT (anti-TNF in 3; MTX+GC in 2; MTX alone
in one), and one in “low” MTX dose (a 16-year-old). DAA was ob-
tained in 27/30; with unprotected values (<1UI/mL) in 67%(n=18); of
those, three had results under 0.1 UI/mL (16 year old under MTX
“high”; 17 year-old with GC and MTX “low”; 8 year-old with MTX
“high”). Pre-treatment AcHBs evaluation was negative in 15/30 (mean
ages 16+/-3 years). Booster doses were administrated during IT in 6of these; of those, 3 persisted negative (all under anti-TNF). HAV was
administrated in 21/30 (nine one dose only; twelve two doses). Anti-
HA persisted negative in 5/18 evaluated; 2 in the two doses group.
VZV was administered in 9 patients, all 5 with subsequent serologic
evaluation had protective values.
Conclusion: Even being a small sample, this is for the best of our know-
ledge, the first evaluation in Portuguese pedRD. These patients demon-
strated impaired responses to the V evaluated and alerts to the real
necessity of routine investigation of the humoral response and adminis-
tration of booster V, even in younger ages. Also it does not seem very
cautious to postpone Td vaccination from 20 to 25 years in these pa-
tients. More and better designed studies are needed.
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Introduction: Children with rheumatic diseases (RD) are at increased
risk of infections, due to the immunosuppressive effect of the disease
or its treatment. Effective and safe vaccination is key in reducing the
burden of infections in this population. However, data on vaccination
status in Portuguese children with RD remains scarce.
Objectives: Evaluate the vaccination status of Portuguese children
with RD receiving immunosuppressive treatment (IT).
Methods: Multicentre study of consecutive patients with RD under-
going IT observed at a Pediatric Rheumatology Clinic, from January
to March of 2018. Patients were evaluated regarding vaccination sta-
tus and reasons for potential dropout. Demographic data and infor-
mation about the disease, drug treatments and vaccinations were
collected. Chi-squared test was used to study categorical variables.
The Portuguese National Vaccination Program (PNV) includes Hep B,
IPV, DTaP, Hib, MenC, MMR, HPV for girls and PCV13 for children
born after 2015. HPV for boys, varicella, other meningococcal and flu
vaccines are not included. In 2015, children receiving IT became eli-
gible for free pneumoccocal vaccines (PCV13 and PPV23).
Results: We studied 120 patients (66% female), mean age 8±5
years, from seven Portuguese Pediatric Rheumatology Units, with a
diagnosis of JIA (n=82), uveitis (n=10), jSLE (n=10), other connective
tissue diseases (n=7), vasculitis (n=5) and autoinflammatory dis-
eases (n=2). Most patients had been on high dose IT (82%), includ-
ing biologics (34%).
Before initiating IT 98% had an updated PNV and 73% had received
one dose of PCV13. At least one dose of Flu and MenB vaccines was
given in 12 and 5% of the patients, respectively.
Time elapsed between diagnosis and IT (> or < 3 months) was not
associated with the prescription of extra-PNV vaccines before treat-
ment, namely varicella.
During IT, immunizations were in accordance to the PNV in 91% of
the patients. Also, 28 patients were eligible for MMR vaccination (eg,
low dose methotrexate), but 11 did not receive it. MMR was adminis-
tered in six patients under high dose IT (including three with biologics),
but no complications were reported. Adequate pneumococcal vaccin-
ation was performed in 30%; 74% of patients received flu vaccine be-
fore or during IT. No boys received HPV.
Patients on high-dose IT did not receive more extra-PNV vaccines
than patients with low-dose IT.
Six cases of varicella in unvaccinated patients were reported during
treatment, and three required hospitalization.
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 197 of 243Conclusion: Vaccination rates in Portuguese children with RD are
sub-optimal.
The low prevalence of extra-PNV safe recommended vaccines (such as
other meningococcal) can be partially explained by their high cost.
Despite the small sample, MMR vaccination during high-dose IT pa-
tients was not associated with complications. Large controlled stud-
ies are required to evaluate the safety of live attenuated vaccines,
especially with high IT and/or during outbreaks.
Since primary health care services in Portugal are overall responsible
for vaccinations, optimal communication with tertiary services is in-
dispensable to ensure that the best care is provided.
It is essential to promote compliance with recommendations about
vaccination of children with RD and provide free recommended vac-
cines to this group of patients.
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Introduction: In our clinical practice, once the remission with a bio-
logical agent is reached, we try to withdraw the medication, but we
have 82% of relapses.
Objectives: To analyze the response to the reintroduction of anti-TNF
treatment in patients with Juvenile Idiopathic Arthritis (JIA).
Methods: Unicentric, retrospective study, through review of clin-
ical history, of the years 2015 and 2016.
The Wallace criteria were used to measure inactivity and the disease
was classified as inactive, remission with treatment and remission
without treatment. Through JADAS-71 we defined remission, minimal
disease activity and acceptable symptoms.
Results: 633 patients with JIA were visited, of which 31.3% were
treated with a biological agent. Of the patients with non-systemic JIA
treated with anti-TNF, 24 patients restarted administration after sus-
pension because of remission. The JADAS-71 at relapse was 7.8 ± 6.6
(median 6.1, range: 1.8-32.2). Time to reach inactivity after restart
was 5.26 ± 3.55 months (median 4.83 months, range: 0.93-12.17). An
87.5% reached inactivity upon reintroduction. Patients who did not
reach inactivity, had a reduction in JADAS-71 of 72.27% compared to
the time of reintroduction of anti-TNF.
Conclusion: Patients who restart treatment with anti-TNF after remis-
sion have a good response. More studies are needed to identify
which factors are associated with a worse response to reintroduction.Disclosure of Interest: None Declared
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Pediatric Rheumatology 2018, 16(Suppl 2):P384Introduction: Abatacept (ABA) is a selective T-cell co-stimulation
modulator approved for use in juvenile idiopathic arthritis (JIA). Effi-
cacy and safety of ABA in patients (pts) with JIA has been demon-
strated in two Phase III studies.1,2 This ongoing study provides
additional monitoring in a real-world setting.
Objectives: Describe the longitudinal effectiveness of ABA in pts with
JIA using registry data.
Methods: Using a standardized protocol, clinical sites in the Pediatric
Rheumatology Collaborative Study Group and Paediatric Rheumatology
International Trial Organization enrolled pts with JIA currently taking/
starting ABA in this longitudinal registry. Planned duration of follow-up
is 10 years (yrs); data shown were collected up to March 31, 2017 (3.5
yrs of follow-up). Follow-up effectiveness of ABA was assessed based
on disease activity at baseline (BL), 3 and 6 months (mths), and 1, 2, 3
and 3.5 yrs. Safety data were collected at each visit.
Results: 367 pts with JIA were enrolled; 354 were included in this
analysis. Total ABA exposure was 364.5 pt-yrs (median); ABA treat-
ment duration was 6.5 mths. At BL, 281 (79%) pts were female, age
was 13.6 yrs (median), 15 (4%) pts were aged 2–5 yrs, JIA duration
was 4.3 yrs and active joint count was 0 (mean 2.9). JIA categories
were systemic (2%), oligoarticular (22%), polyarticular RF– (57%),
polyarticular RF+ (9%), psoriatic (3%), enthesitis-related (3%) and un-
differentiated (4%). At 1-yr follow-up, pts had low Physician Global
Assessment of Disease Activity, low Juvenile Arthritis Multidimen-
sional Assessment Report (JAMAR) scores and improved joint assess-
ment (Table 1). A higher percentage of pts achieved clinical inactive
disease after 1 yr of follow-up vs BL (Table 1). This trend continued
despite low numbers of pts with 3 and 3.5 yrs of follow-up. During
the last 6 mths of follow-up (3–3.5 yrs), seven new serious AEs were
reported, but no new cases of treatment-related serious infection,
malignancy or tuberculosis were observed.3
Conclusion: In this JIA cohort, abatacept was safe and well tolerated
with no new safety risks identified.1-3 This longitudinal analysis further
supports the persistent effectiveness of abatacept in pts with JIA.1-3
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Table 1 (abstract P384). Assessment of Disease Activity
Endpoint BL
(n=354)
3 mths
(n=286)
6 mths
(n=252)
1 yr
(n=231)
2 yrs
(n=81)
3 yrs
(n=27)
3.5 yrs
(n=14)
Physician Global
Assessment of Disease
Activity*3
2.0 (0.1) 1.5 (0.1) 1.5 (0.1) 1.2 (0.1) 0.8
(0.1)
1.2
(0.3)
1.1
(0.4)
Clinical inactive disease
(Wallace criteria), %3,4
33 32 38 48 52 37 29
Joint assessment 3.1 (0.4) 2.7 (0.4) 2.8 (0.4) 2.1 (0.4) 1.1
(0.3)
1.9
(1.0)
2.1
(0.9)
Tenderness/pain
On motion 2.9 (0.3)
Active 2.0 (0.3) 2.2 (0.3) 1.8 (0.3) 1.2
(0.4)
3.0
(1.2)
2.6
(1.2)
JAMAR functional†
Child3 5.4 (0.4) 4.7 (0.4) 4.1 (0.4) 4.1 (0.4) 3.0
(0.5)
3.5
(0.9)
4.6
(1.5)
Parent 7.2 (0.7) 5.7 (0.5) 4.4 (0.4) 4.9 (0.9) 2.9
(0.5)
4.1
(1.2)
5.3
(1.8)
JAMAR HRQoL‡
Child3 7.0 (0.3) 6.0 (0.4) 5.5 (0.3) 5.1 (0.4) 4.5
(0.6)
6.5
(1.1)
7.0
(1.5)
Parent 8.3 (0.7) 7.0 (0.6) 6.8 (0.7) 6.3 (0.9) 6.4
(1.7)
4.4
(1.1)
7.1
(2.9)
Data are mean (SE), unless otherwise indicated
*Visual analogue scale 0–10; 0=inactive; †range 0–15, 0=no functional limitation; ‡range
0–15, 0=best possible HRQoL
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Introduction: Children with juvenile idiopathic arthritis (JIA) appear to
have an increased rate of incident malignancy compared to children
without JIA, although data are inconsistent.1,4 The relationship between
JIA and malignancy is uncertain. High incidence risk of new autoimmune
disease in patients affected with JIA was established.2 Childhood cancer
survivors are at increased risk for certain types of autoimmune diseases
(AID)3 and there is lack of data of JIA in those patients.
Objectives: To evaluate the frequency of malignant disease in a cohort
of patients included in JIA Registry in single tertiary center, to assess
the time of manifestation onset with respect to the time of diagnosis of
JIA and to assess presence of another autoimmune disease in the same
patient.
Methods: medical records of registered patients were reviewed. Data on
JIA diagnosis, malignant and autoimmune disease were analyzed. The
time of each manifestation onset was determined and compared with
the time of JIA diagnosis.
Results: as of the May 2018, 176 patients were registered in er
JIA Registry in single tertiary cent (females 118 (67%), males 58
(33%)). Three patients (1,7%) were identified with malignancy in
biological naive patients. Patient 1, boy, with unremarkable per-
sonal and family history regarding autoimmune and malignant
disease, was diagnosed as systemic onset JIA and synovial sar-
coma at the same time. Treated accordingly for SoJIA and malig-
nancy (surgery, followed with hemotherapy (CWS 2012 Protocol:
iphosphamide, vincristin, actinomicin) and radiotherapy. Onmonth 10th of therapy (while receiving radiotherapy) developed
macrophage activation sy as well as diagnosed as autoimmune thyroid-
itis (AIT). Patient 2, girl 15,5y, developed hard to treat enthesitis-related
arthritis while on maintenance therapy (MTX 50 mg/weekly) for T-cell
Non – Hodgkin lymphoma (ALL BFM 2009 Protocol) previously diag-
nosed also as AIT. Patient 3, boy 15y, diagnosed as juvenile spondiloar-
thropaty, with history of allogeneic bone marrow transplantation (BMT)
at age 6y for acute myeloid leukemia, AIT and hyperinsulinemia. Pa-
tients were not receiving biologics.
Conclusion: In JIA, cancer is a relatively rare event, which is reassuring
for patients and physicians. Registry data revealed 3 patients with JIA,
malignancy and hypothyreosis at the same time. Synovial sarcoma and
systemic onset JIA is quite rare comorbidity. Two other patients devel-
oped JIA during of after treatment for hematological malignancy – we
don't know if it could be atribute to genetic instability or something
else. Persistent immune abnormalities after treatment with chemother-
apy predispose to the development of autoantibodies, which are cen-
tral to the pathogenesis of many autoimmune diseases, probably
including JIA . Long-term follow up and large sample in JIA registry are
warranted.
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Introduction: Rituximab (RTX) is a chimeric monoclonal antibody di-
rected against the CD20 antigen on the surface of B lymphocytes. It
binds to CD20 and causes B cells death by different mechanisms. In
what concerns rheumatic diseases, RTX is only approved for the
treatment of rheumatoid arthritis and ANCA-associated vasculitis in
adults. However, there is growing evidence of its utility in other dis-
eases, including in pediatric patients.
Objectives: We aim to report the efficacy and safety of rituximab in
pediatric patients diagnosed with juvenile onset rheumatic diseases
refractory to conventional treatment.
Methods: A retrospective review was made of all medical records of
patients under 18 years old treated with RTX in two pediatric
rheumatology units in Lisbon.
Results: Ten patients, 8 girls, 8 Caucasian/2 African, mean age of
diagnosis 13.8 (min 8-max 18) years, were treated with RTX: 6 with
systemic lupus erythematosus (JSLE), 2 with juvenile dermatomyo-
sitis (JDM), 1 with polyarteritis nodosa (PN) and 1 with ANCA-
associated vasculitis (AAV). All of them were refractory to previous
treatments that included oral prednisolone (n=10), methylpredniso-
lone pulses (n=3, 2 JSLE, 1 AAV), cyclophosphamide pulses (n=5, 2
JSLE; 1 PN, 2 JDM), methotrexate (n=2, 1 JSLE, 1 JDM), hydroxychlor-
oquine (n=5, 4 JSLE, 1 JDM), mycophenolate mofetil (n=3, 3 JSLE),
azathioprine (n=9, all except 1 JDM), IvIg (n=3, 2 JSLE, 1 JDM) and
infliximab (n=1, 1 JDM).
The mean disease duration until receiving RTX was 26 (min 5-max
68) months. Renal involvement (3 class IV lupus nephritis and 1 pauci
immune glomerulonephritis) was the main indication for RTX.
In total, they received 21 cycles of RTX (min 1-max 4). The scheme of
RTX frequently used was 1000 mg two weeks apart, except for the
PN and 2 JDM that used 375 mg/m2 four weeks and 575 mg/m2 in
two weeks apart, respectively. The average time between cycles was
12 (min 6-max 26) months.
In all but one patient, disease activity improved when comparing the
period before and after RTX. The SLEDAI score for JSLE, decreased from a
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 199 of 243mean of 10.8 (min 8–max 17) to 3.8 (min 2–max 5); the BVAS score for
AAV decreased from 17 to 0, and the CMAS score for JDM also improved
from a mean of 20 to 51, as well as the MMT8 score from a mean of 54 to
75. The patient with PN patient did not respond to RTX, the BVAS score
got worse from 5 to 30 and the patient was switched to infliximab with
good response until nowadays.
Adverse events occurred in 1 patient who had hypogammaglobulinemia
without the need of immunoglobulin replacement.
Conclusion: Rituximab might have a role in the treatment of refrac-
tory pediatric rheumatic diseases. However controlled studies and
long term follow-up are needed to evaluate its safety and efficacy.
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Introduction: Methotrexate (MTX) is the only disease modifying drug
used in the treatment of Juvenile idiopathic Arthritis (JIA), other than bio-
logics. Its oral administration is mostly associated with nausea and vomit-
ing. The alternative subcutaneous injections are painful and very stressful
for children causing considerable anxiety [1]. In previous studies, we have
reported a novel polyvinyl alcohol (PVA)- based hydrogel-forming micro-
needle patch as a minimally invasive, pain-free drug delivery system
which was able to deliver MTX transdermally in a controlled and a sus-
tained manner in both in vitro and in vivo settings [2,3].
Objectives: To evaluate the robustness, relative bioavailability and
pharmacokinetics of MTX transdermally delivered from its PVA-based
hydrogel-forming microneedle patch (HFM-patch) after single and
multiple dose in comparison with oral and subcutaneous administra-
tion in hairless Sprague Dawley rats.
Methods: A total of 24 hairless Sprague Dawley rats were randomly
divided into 4 cohorts (6 per cohort). A dose of 2.56 ± 0.1 mg/kg
MTX was orally administrated to cohort 1. A dose of 2.56 ± 0.1 mg/
kg MTX was subcutaneously administered into the back of each rat
in the second cohort. Two HFM- patches containing MTX dose of 5.2
± 0.5 mg/kg was applied onto the back of each animal in the third
cohort. These were applied once weekly for three weeks. The forth
cohort was used as a negative control. Blood samples were collected
at predetermined time intervals over 21 days. MTX and its polygluta-
mates (MTX-PGs 2-5) were quantified by a developed and validated
HPLC-MS method.
Results: Following the first dose, the maximum blood concentration
for MTX after SC, oral and transdermal administration, 373.4 ± 37.5,
62.10 ± 3.4, and 33.8 ± 5.9 nM/mL, respectively and this was
achieved at 0.5, 1 and 24hrs, respectively after dosing. The AUC 0→
48 was, 1136, 588 and 1103 nM/mL/hr, respectively. The relative bio-
availability of MTX after oral administration in comparison with SC
was 51.8%, while it was 44.2% after transdermal dosing, correcting
for the dose difference.
HFM-patch delivered MTX in a controlled and sustained manner over
the patch application period i.e. 24 hrs with no high bolus blood
concentrations. This is essentially important in reducing the drug re-
lated side effects such as nausea and vomiting.
Nearly similar pharmacokinetic profile trend were also produced after
the 2nd and 3rd dose. This suggests that the HFM-patch can deliver
MTX at fairly consistent rates.
The other MTX polyglutamates (MTX-PGs2-5) appeared after the first
dose at various rates and increased gradually over the study period.Conclusion: PVA-based HFM-patch is an efficient, minimally invasive
and robust transdermal drug delivery system can reliably deliver a
reasonably consistent doses of MTX in a controlled and sustained
manner. This delivery system for MTX could to be used in treatment
of JIA and other diseases. Further studies is needed to evaluate its
safety and efficiency in a long term studies.
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Introduction: Acute arthritis, a common cause of consultation in
paediatric emergency wards, can be categorized as septic (SA),
juvenile idiopathic arthritis (JIA), and undetermined arthritis (UA).
An early accurate diagnosis is essential to provide appropriate
treatment and follow-up.
Objectives: The aim of this study was to determine whether clin-
ical and biological data may allow early differentiation between
septic and non-septic arthritis.
Methods: We retrospectively analysed clinical and biological data
corresponding to a joint aspiration collection from patients
treated at the Robert-Debré University Hospital in Paris between
9/2015 and 9/2017. The initial and final diagnoses were recorded.
Patients were classified as having SA, JIA defined according to
ILAR criteria, UA or other diagnoses. If no follow up was available,
final diagnosis of SA was considered if bacteria were identified
on culture or PCR, otherwise diagnosis of UA remained.
Results: 129 joint aspiration samples from 118 patients were ana-
lysed. The final diagnosis of acute arthritis was SA for 45 patients
(38.1%), UA for 39 patients (33%), JIA for 23 patients (19.5%) and
10 patients (8.5%) had other diagnoses. Clinical and biological
findings did not show major differences between the three
groups. Antibiotics were administered in 97.8% of patients with
SA, as well as in 39.1% of patients with a final diagnosis of JIA
and 84.2% with UA. Arthrotomy was performed in 62.2% patients
having SA, 30.4% of patients with JIA, 46.1% of patients with UA
and 50% patients with other diagnosis.
Conclusion: We did not identify any clinical or biological parame-
ters allowing us to distinguish SA versus arthritis of other causes.
However, this study shows that a large proportion of patients
with non-septic arthritis receive unnecessary invasive treatments,
highlighting the urgent need for identification of new diagnosis
markers.
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Introduction: Patients with Pediatric Rheumatic Diseases (PRD) due
to their immunomodulatory treatment are at risk for infections.
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 200 of 243Objectives: Primary: To study the vaccination coverage of children
and adolescents with PRD due to the lack of relative Greek studies.
Secondary: To investigate the reasons of incomplete vaccinations.
Methods: In this case-control prospective study, all patients of the
Referral Center with PRD were enrolled, following a patient/parent
consent over a 6-mo period (1/2017 -7/2017). Demographics and dis-
ease characteristics were recorded in a pre-formatted registry along
with their vaccination status according to their personal Child Health
Booklet. Additionally, the vaccinations of age-matched healthy stu-
dents (HS) were collected. The vaccination coverage was estimated
according to the National Immunization Program for the relevant
age group.
Results: The vaccination status of 101 children/adolescents (Male: Fe-
male 32:69) with PRD and a mean age of 11 years was recorded. The
control group was a population of 66 HS (Male: Female 25:41), with a
mean age of 9.76 years. 45.5% of patients with PRD and 42.40% of
HS were found with missing immunizations, mainly due to their phy-
sician’s recommendation (p=0.81). In respect to the type of vaccin-
ation administered, complete vaccination for DTP-Hib was recorded
in 60% of the PRD patients and 68.2% of the HS (p=0.32); for
pneumococcus the relevant percentages of the studied groups were
90% and 92. 4%, respectively (p=0.65). One dose for measles’s pro-
tection with MMR had 97% of the PRD and 100% of HS (p=0.26) and
for HPV 18.18% and 0%, respectively (p=0.21). As for the influenza
vaccination, at least one dose was recorded in 40% of the PRD and
15.15% of the HS (p=0.001).
Conclusion: Vaccination coverage of Greek pediatric patients with
PRD is not inferior to the relevant of HS, indicating the acceptance
and compliance to the recommended National Immunization Pro-
gram, especially for pathogens leading to invasive infections. About
half of the PRD patients comply with the EULAR influenza vaccination
recommendation. In HS, the absence of regarding HPV and lower level
of influenza immunization is in alliance to the National Immunization
Program regarding age and disease indications.
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Introduction: Nowadays a lot of patients, who are suffering from
juvenile idiopathic arthritis (JIA), are treated with anti-TNF ther-
apy. The issues of duration of anti-TNF therapy in children with
JIA, receiving anti-TNF therapy and reached remission on it, are
relevant and debatable.
Objectives: To evaluate the efficiency of anti-TNF therapy after 3
years of treatment with TNF-alpha inhibitors in children suffering
from JIA and having a remission of at least one year, which was
achieved on anti-TNF therapy, in 2 compared groups on different
treatment regimens.
Methods: This prospective study included 40 children (mean age
12.7±2.4) suffering from JIA (mean disease duration 5.2±1.4), re-
ceiving anti-TNF-therapy for 3 consecutive years (20(50%) children
were treated with adalimumab(ADA), 20(50%) – with etanercep-
t(ETA)). All children also received methotrexate(MTX) (mean dur-
ation of MTX therapy was 4.6±0.5) and had a remission (mean
duration of remission was 1.4±0.3). The first group included pa-
tients who after 3 years of anti-TNF therapy continued anti-TNF
therapy for another 6 months in standard dose and in standard
scheme (this group included 10(25%) children who were treatedwith ADA and 10(25%) children who were treated with ETA). The
second group included children who after 3 years of anti-TNF
therapy continued anti-TNF therapy for the next 6 months in
standard dose, but the intervals between injections of TNF-alpha
inhibitors were doubled (this group also included 10(25%) chil-
dren who were treated with ADA and 10(25%) children who were
treated with ETA). Both groups were comparable in age, disease
duration, and duration of treatment with both MTX and TNF-alfa
inhibitors. Efficacy was determined using the American College of
Rheumatology (ACR) Pediatric (Pedi) response criteria at the time
of inclusion in this study and after 12 and 24 weeks.
Results: At the time of inclusion in our study 90% improvement
according to ACR pedi criteria were registered in both groups.
After 12 weeks of treatment all children in the first group main-
tained 90% improvement according to ACR pedi criteria, in the
comparison group in 100% of children were registered 70% im-
provement according to ACR pedi criteria, and 18(90%) children
had 90% improvement according to ACR pedi criteria. After 24
weeks of treatment in all children (100%) in the first group
remained 90% improvement according to ACR pedi criteria, in
the comparison group 4(20%) children didn’t achieve 30% im-
provement according to ACR pedi criteria (2 children were
treated with ADA, 2 – with ETA), 16(80%) patients had 70% im-
provement according to ACR pedi criteria, and 15 (75%) children
– 90% improvement according to ACR pedi criteria.
Conclusion: According to the obtained data, we can conclude that
after 3 years of therapy with TNF-alpha inhibitors (ADA or ETA) in the
standard dose, standard scheme and with the presence of remission
for at least one year, it is possible to correct anti-TNF therapy by in-
creasing the intervals between the injections of ADA or ETA.
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Introduction: Nowadays awareness about rates of latent tuberculosis
infection (LTBI) in patients with juvenile idiopathic arthritis preceding
anti-TNF therapy for a long period of time is very relevant.
Objectives: To evaluate rates of LTBI in patients with juvenile idio-
pathic arthritis preceding anti-TNF therapy for more than 2 years.
Methods: This was a retrospective study that included JIA patients
treated with anti-TNF therapy for more than 2 years. 43 JIA patients
with current age of 10.1±3.4 years, mean disease duration of 3.8±1.9
years were included. All patients received a single anti-TNF:
24(55.8%) patients were treated with etanercept, another 19(44.2%)
patients were treated with adalimumab. All patients were screened
for LTBI prior to anti-TNF using tuberculin skin test (TST), chest com-
puter tomography (CT) and history of exposure to tuberculosis. Pa-
tients were regularly followed at 6-month intervals. Before patients
started receive anti-TNF therapy, LTBI screening (solely TST-positive)
was positive in 7(16.2%) patients: 4(9.3%) patients in group of etaner-
cept and 3(6.9%) - in group of adalimumab, no one had active tuber-
culosis (TB) or history of TB exposure. All this patients were treated
with standard course of anti-TB therapy before the beginning of anti-
TNF therapy.
Results: Through more than 2 years duration anti-TNF therapy in pa-
tients with JIA, LTBI screening was positive in 11(25.5%) patients:
2(4.6%) had TST-positive (1(2.3%) patient was treated with adalimu-
mab and 1(2.3%) with etanercept) and history of TB exposure,
Table 1 (abstract P392). Cases with receiving biological treatments
(n=80)
Sex %48.8 male (n=39) %51.2 female
(n=41)
Onset of Symptoms (year) 4.41 (0.16-17)
Diagnosis time (year) 7 (0.66-16)
Family History of Rheumatic
Disorders
%26.25 (n=21)
Receiving Steroid Treatment %37.5 (n=30)
Types of MEFV mutations 27.5% (n=22) MEFV mutation (+)
63.6% (n= 14) exon-10 mutations
54.5% (n=12) have M694V mutations
31.8% (n=7) have M694V homozygous
ANA positivity 27.5 (n=22)
Infection and malignancy after
treatment
Tuberculosis infection (n=1)
Varicella zoster (n=1)
Recurrent upper respiratory tract
infections (n=2)
Acute Lymphoblastic Leukaemia (n=1)
Need of Tuberculosis Prophylaxis %26.25 (n=21)
Mean Remission Time (months) 2.00 (1-18)
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 201 of 2437(16.2%) had solely TST-positive (3(6.9%) patients were treated with
etanercept and 4(9.3%) with adalimumab), 1(2.3%) patient had active
TB which was diagnosed with positive TST and changes on chest CT
(patient was treated with adalimumab).
Conclusion: According to our research LTBI appears to be prevalent
among patients treated with adalimumab. Screening for LTBI in pa-
tients on anti-TNF therapy may reduce risk of active tuberculosis,
however, current methods may not be fully effective.
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Introduction: Controlling of systemic inflammation is possible by
blockage of some specific proteins and cells in inflammatory steps
that play a role in the etiopathogenesis of rheumatic diseases.
Objectives: Our clinical experiments with biological agents such as
etanercept, canakinumab, adalimumab and tocilizumab, which are
used to inhibit TNF-α, IL-1 and IL-6, are presented in this study.
Methods: Demographic, clinical and laboratory data of 80 children
with rheumatic diseases were reviewed. Tuberculosis incidence
and other side effects were noted.
Results: Study population consisted of 80 cases, include 39
(48.8%) male and 41 (51.2%) female. Twelve cases had (15%) sys-
temic juvenile idiopathic arthritis (S.JIA), 24 (30%) polyarticular JIA
(P.JIA), 11 (17.5%) oligoarticular JIA (EIA), 22 (27.7%) familial Medi-
terranean fever (FMF), 3 (3.75%) hyper immunoglobulin D syn-
drome (HIDS), 1 (1.25%) Cryoprin-associated periodic syndrome
(CAPS) and one case of psoriatic arthritis (JPsA). There was a spe-
cial case with Farber disease receiving tocilizumab. Fourteen
cases (17.5%) were on canakinumab, 17 (21.25%) on etanercept,
17 (21.25%) on tocilizumab , and 32 (40%) were on adalimumab.
In addition, 23 cases needed to switch from one biologic to an-
other in order to control the disease. . Demographic, clinical and
laboratory evaluation of cases with receiving biological treatments
are presented in table.
Conclusion: The use of biological agents in paediatric rheumatology
practice is increasing in order to better control of the disease with
much less damage and increased quality of life. This study results
support this fact, and cases resistant to conventional DMARDs went
into remission following biologic treatment. In this evaluation, we
noticed clinical and laboratory remission in our resistant cases in a
short time after biological treatment. Although upper and lower re-
spiratory tract infections, tuberculosis and malignancy have been
observed in some cases, the relationship between treatment and in-
fections has not been fully documented. Since the use of biological
agents increases to suppress inflammation in uncontrolled rheum-
atic diseases day by day, there is a need for studies and evaluations
in wider case series across the national spectrum in case of efficacy
and side effect profiles.
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Introduction: Rituximab is a genetically engineered chimeric
monoclonal antibody that depletes the B-cell population by tar-
geting cells bearing the CD20 surface marker. Common adverse
effects of rituximab therapy include infusion reactions and infec-
tions. Although hypogammaglobulinemia post Rituximab therapy
has been reported, there is no clear evidence on the incidence
of hypogammaglobulinemia and the trend of the serum immuno-
globulin(Ig) levels over time in paediatric patients.
Objectives: To analyse the incidence of hypogammaglobulinemia
post rituximab therapy in children treated with Rituximab in a ter-
tiary paediatric rheumatology centre.
Methods: An initial audit was carried out reviewing the case
notes of children (<18 years of age) who received Rituximab for
a rheumatological indication from 2001 to 2016.This has been re-
ported previously, highlighting 26% of patients with hypogamma-
globulinaemia secondary to Rituximab therapy. A further review
was carried out to analyse the course and trends of immuno-
globulin levels till January 2018.
Results: With the extended review 9 out 19 patients (47%) were
noted to develop secondary hypogammaglobulinemia. One
patient's immunoglobulin had reverted back to normal following
cessation of Rituximab therapy. Overall 14/19 patients have
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 202 of 243suffered recurrent infections, of which 8 had hypogammaglobulinae-
mia. During the extension phase of the study,2 patients died. Patient 1
collapsed with respiratory arrest following acute epiglottitis (enterovirus
on throat swab) and subsequent cardiac arrest; patient 2 had died from
ARDS following Pneumocystis jirovecii pneumonia and CMV viraemia.4/
9 (44%) of the patients with hypogammaglobulinemia required im-
munoglobulin replacement therapy and a further 3 (33%) are under
the consideration of the immunology team.
Conclusion: In our cohort of patients, the incidence of hypogamma-
globulinemia was 47%( 9/19). This appears to have increased over
time with the number of cycles patients received. Reversal of hypo-
gammaglobulinaemia was observed only in 5% on cessation of Ritux-
imab therapy.
The results highlight the need for close monitoring of patients while
on and after Rituximab therapy for hypogammaglobulinemia and ap-
propriate management with multidisciplinary input involving the
immunologist.
The limitations for this study are the small number of patients, the
effect of previous and concomitant therapy with other immunosup-
pressive medications including cyclophosphamide and loss of few
patients to follow up.
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Types No of knees
injected
Number of knees having flare
3
month
6
month
12
month
18
month
24
month
Oligoarticular 84 2 9 12 2 4
Extended
oligoarticular
24 1 1 5 3
Polyarticular 43 1 5 5 2 2
Systemic JIA 6 3
Juvenile
spondyloarthropathy
1 1
Total 158 4 15 23 10 6
Percentage 2.53% 9.49% 14.55% 6.32% 3.79Poster walk 9: JIA clinical 2
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Introduction: Intra-articular knee injection is a common procedure in
paediatric rheumatology. However unlike adults, in children it is
mostly carried out under general anaesthesia which has its own risks.
Thus the effect of the intra-articular injection has to be optimal and
long lasting. We undertook this study to find out whether ultrasound
(US)assessment and guided intraarticular knee injections leads to a
better outcome.
Objectives: 1 To evaluate the outcome following ultrasound assessed
and guided intra-articular knee injection in patients with juvenile idio-
pathic arthritis (JIA)
2 To determine whether the base demographic, clinical, laboratory
and ultrasonographic findings can predict the outcome.
Methods: We followed consecutive patients who fulfilled the criterion for
diagnosis of JIA and required an intraarticular steroid injection to knees.
We recorded demographics; disease subtype. Clinical assessments in-
cluded; pain, swelling and limitation of movement. Classified as mild, mod-
erate and marked. Patients underwent US assessment using a MyLab70.
Joint effusion and synovial hypertrophy (SH) were classified as mild, mod-
erate and marked. Standard blood tests were performed.
Under GA, US-guided IACI of the affected knee/s was performed
using Triamcinolone Hexacetonide 20-40mg. Patients were followed
up every 3 months for 2 years. Statistical analysis included Kaplan
Meier survival analysis and ANOVA.
Study was approved by ORECNI 10/NIR01/11
Results: 112 patients underwent 158 ultrasound guided knee injec-
tions. Sixty four had oligo; 29 had poly; 14 had extended oligo; 4 sys-
temic JIA and one juvenile Sp. Median disease duration 6 months
(Range 1-145 months). Median age at injection 90 months (range 15-
261 months). Median ESR was 13 mm Hg (range 2-117), median CRP
2.7 mg/dl (range 0.3-183 mg/dl). 50 patients had positive antinuclear
antibody. 6patients received steroids; 33 patients received metho-
trexate; 14 patients received biologics.Kaplan Meier survival analysis, demonstrated that overall, 64% of
joints remained clinically quiet at 2 years.
There were 58 flares in 158 knees by 2 years. The number of flares according
to type of JIA and at end of 3, 6, 12, 18 and 24 months is given in Table 1.
Those with minimal SH pre injection had significantly better outcome
at 2 yrs. ( 72% remission) compared to those with marked SH, where
just 51% were in remission.
There was no significant difference in flare rates between oligoarticu-
lar and polyarticular subtypes. Concomitant steroid or methotrex-
ate did not alter the rates of flares. Longer duration of current
episode, higher ESR and CRP and lower total steroid dose were found
to predict flares.
Conclusion: This is the first study in paediatric rheumatology to use
ultrasound guidance in all intra-articular injections. Our outcomes are
significantly better than those previously published1 where 69% were
in remission at 6 months compared to our 88%. Whilst another retro-
spective study2 observed 49% were still in remission after approxi-
mately 2 years compared to our 64%.
IACI performed under US control appears to improve the outcome in
JIA and MSUS informs the clinician regarding the long term outcome
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Introduction: Patient’s perspective of disease status is a critical, yet diffi-
cult to capture component of outcome in Juvenile Idiopathic Arthritis
(JIA). Some patients exhibit high perceived disease activity, pain levels
and impaired health-related quality of life despite current inactive disease.
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 203 of 243Objectives: 1) To examine the relation between pain, physical func-
tioning, quality of life, damage measures and perception of activity
in different disease states.
2) To identify determinants of disease activity perception in patients
classified in remission.
Methods: Patients enrolled in The EPidemiology, treatment and Out-
come of Childhood Arthritis (EPOCA) study were included in this ana-
lysis. Data from an unselected of 2102 patients with oligoarticular
(n=352) and polyarticular (n=1750) were considered. Evaluated vari-
ables included the quantitative items of the Juvenile Arthritis Multidi-
mensional Assessment Report - VAS Pain, VAS Disease Activity, VAS
Well Being, Juvenile Arthritis Functional Score (JAFS), physical health
(JQLPsH) and psychosocial health (JQLPhH) Quality of Life Scale - and
the Juvenile Arthritis Damage Index. Interactions among patient-
reported physical disability, physical and psychosocial life quality,
damage, global well-being and activity perception were explored
using network analysis; clustering and centrality indexes were esti-
mated as measures of the strength of connections and relevance of
specific items, then compared across patients in activity and remis-
sion states. In addition, Pearson’s correlation and recursive partition-
ing were used to identify determinants of patient ‘activity perception
and global well-being VAS scores in the remission group (n=546).
Results: Network analysis revealed a highly clustered structure, with spe-
cific physical function and participation-related items connected to psy-
chological components through pain score. Clusters appeared stable
across activity and remission groups; walking and items related to cervical
limitations revealed higher centrality in active patients, while impaired
hand function was more central in patients in remission. In patients with
active disease, pain, difficulties in energy-consuming activities, walking and
impaired hand function showed the highest closeness centrality, indicating
a high ability to predict other items. After adjusting for disease activity
(JADAS10), pain, sadness, anxiety, difficulties in energy-consuming and so-
cial activities remained tightly interconnected, exhibiting the highest de-
gree centrality; no substantial differences in the structure were found
between polyarticular and oligoarticular patients. In the remission group,
patient-perceived disease activity correlated well with well-being (r= 0.81,
p<0,001) and pain (r= 0.73, p<0,001) scales. Recursive partitioning identi-
fied pain VAS > 4 (p<0.001), JQLPhH score > 6 (p=0.001), pain VAS < 1
(p<0.001) and difficulty in energy-consuming activities (p<0.001) as predic-
tors defining 5 subgroups with different levels of VAS disease activity in
patients in remission.
Conclusion: Network analysis revealed the connection between pain
and specific psycho-functional domains and their impact on patient-
perceived disease activity. These findings may inform the develop-
ment of patient-centered disease assessment tools and the thera-
peutic targeting of symptoms that are likely to have the greatest
impact on patient’s perception of treatment effectiveness and global
health status.
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Introduction: “Children with arthritis at school” is a brief text accompan-
ied by illustration spread by APMAR Onlus to give psychological support
to children that suffer from juvenile idiopathic arthritis and to their families
and teachers.
Objectives: The main goal of the book is spotlighting necessities of
children who are forced to live with juvenile idiopathic arthritis and
raise awareness of these diseases in teachers and school staff in gen-
eral. The aim is helping teachers and families to give a proper psycho-
logical support to children with arthritis. Furthermore, the publication
tries to show how to take care of kids according to their needs.
Methods: The book - realized with the contribution of Adele Civino,
a pediatrician at the “Cardinal Panico” Hospital of Tricase (LE), Gilda
Panzera primary school teacher, the psychologist Silvia Taccone and
the illustrator Salvatore Santuccio – was diffused by APMAR in
schools and pediatrician’s offices.
Results: With the book “Children with arthritis at school” APMAR
Onlus reached the purpose of focusing people's attention on
rheumatic diseases. In particular, the association spread information
about juvenile idiopathic arthritis (Juvenile" in this context refers to
an onset before age 16 and "idiopathic" refers to a condition with
no defined cause) and gave guidelines that allow teachers and fam-
ilies to make easier for the youngsters to attend school and make
the best of it.
“Children with arthritis at school” provide information about drugs
and teach how to recognize symptoms. It also promotes the import-
ance of communication: primarily between teachers and the family,
but also between the school staff and the pediatrician that attends
the child. Create a dialogue is fundamental to help kids enjoying
their school career, improve their quality of life and avoid them to
feel different or sink into depression.
Children well-being pass through the acceptance of the pathology.
To manage this achievement, they need the psychological support of
their families, their classmates and their teachers. The book gives
some practical advice addressed to adults.
In the book teachers will find very practical recommendations. For
example, tables useful for learning how to intervene in a proper way
depending on the situation and on the needs or pains showed by
the kid. “Children with arthritis at school” also provide a chart that
helps physical education teachers to know which activities can be
easily done by the children and which not.
Together with “Children with arthritis at school” APMAR created a
comic that illustrates how to deal with these diseases and how to
recognize the most common symptoms. A comic allows to communi-
cate with children in a language that they know and that is adequate
Table 1 (abstract P397). Selected outcomes at last clinic visit for
patients recruited at one ReACCh-Out center
Group Age in
years
Years
since
diagnosis
Active
disease
Remission
on meds
Remission
off meds
Still on
treatment
X-ray
damage
Uveitis
complications.
Oligoarthritis
(n=93)
14.1 (11.8,
17.1)
7.8 (2.8,
10.1)
19
(20%)
26
(28%)
46
(49%)
45
(48%)
8
(9%)
2
(2%)
ERA (n=51) 17.9 (16.9,
18.1)
4.6 (3.0,
6.2)
17
(33%)
7
(14%)
27
(53%)
24
(47%)
9
(18%)
0
Poly RF-Neg
(n=39)
17.7 (12.8,
18.1)
5.4 (3.8,
8.1)
16
(41%)
10
(26%)
12
(31%)
24
(62%)
6
(15%)
0
Systemic
(n=22)
17.1 (15.5,
17.6)
5.8 (3.7,
8.1)
2
(9%)
5
(23%)
15
(68%)
7
(32%)
4
(18%)
0
Psoriatic
(n=9)
18.1 (17.1,
18.2)
5.4 (4.3,
5.7)
2
(22%)
2
(22%)
5
(56%)
4
(44%)
5
(56%)
0
Poly-RF-Pos
(n=9)
17.9 (16.2,
18.6)
6.0 (5.6,
8.1)
4
(44%)
4
(44%)
1
(11%)
7
(78%)
4
(44%)
0
Undifferentiated
(n=13)
17.1 (9.7,
17.7)
6.3 (4.7,
7.7)
4
(31%)
2
(15%)
7
(54%)
6
(46%)
4
(31%)
0
All (n=236) 17.0 (13.0,
18.0)
5.6 (3.4,
8.2)
64
(27%)
56
(24%)
113
(48%)
117
(50%)
40
(17%)
2
(0.9%)
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 204 of 243for their age. The project also leads to a Youtube version of the
comic called “A new challenge to live together. Rheumatic diseases
explained to children”. The video is in Italian subtitled in English and
is visible at this link: https://youtu.be/o12g3Zz3N-g.
Furthermore, as part of the same communication campaign, APMAR
realized a video with the popular Italian singer Alessandra Amoroso
(https://www.youtube.com/watch?v=8mZSirhXo8U) focused on the
disease awareness.
Conclusion: The diffusion of the short text “Children with arthritis at
school” was welcomed with approval by families and teachers.
School fulfils the essential role of educate but also it allows kids to
grow both at a psychological and social level. This is the reason why
running an informative campaign among teachers is very important.
The book raise awareness and allow many children who suffer from
juvenile idiopathic arthritis to feel more comfortable at school. It also
turns on the debate about these diseases and spread the knowledge
of their symptoms matching the APMAR mission of sensitise public
opinion towards rheumatic pathologies.
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Introduction: Long term outcomes and clinical course of patients
with JIA may have improved since the pre-methotrexate era when
by early adulthood many patients had persistent active disease and
deformities.
Objectives: To assess long-term outcomes of patients with JIA re-
cruited at one centre in the Research in Arthritis in Canadian
Children Emphasizing Outcomes (ReACCh-Out) prospective incep-
tion cohort.
Methods: Clinical charts of patients with JIA recruited at one of the
16 centres in the ReACCh–Out cohort (diagnosed 2005-2010) were
assessed at the last available follow-up visit for disease activity, clin-
ical remission on or off medications (Wallace criteria), and articular
and extra articular damage
Results: From the identified eligible cohort 236 subjects
(97.5%) had follow-up information until discharged or transferred
to adult care; 135(57.2%) were females and the median age was
17.2y (IQR 13, 18). Median follow-up period since diagnosis was
5.6 y (IQR 3.4, 8.2) with maximum follow up of 13.1 years; 64 pa-
tients (27%) had active disease at last follow up visit and 56 (24
%) were in remission on medications. Nearly half of the patients
were off medications (119, 50.4%). Twenty patients (8.4%) had
uveitis during their disease course while 7 (2.9%) had active uve-
itis at last visit. Growth related complications included micro-
gnathia (11, 5%), and leg length discrepancy (11, 5%).
Radiographic joint damage was uncommon: 40 patients (17%)
had at least one erosion or joint space narrowing, 2 (1%) had
avascular necrosis and 5 (2%) required joint surgery. Table 1 de-
picts outcomes at last visit for each JIA category. Patients with
systemic JIA had the highest frequency of remission off medica-
tions (68%). Most patients with RF-positive polyarticular JIA were
still on treatment (78%). Half of the patients were on at least one
anti-rheumatic medication with approximately 20% on each of
NSAID, DMARD or Biologic. Raised inflammatory markers were
rare (4%). Changes in ILAR category were observed in 29(12.2%)
patients, including 9 who changed from unclassified to a specific
category by the last clinic visit and 12 oligo- persistent who be-
came oligo-extended.Numbers are median and IQR, unless otherwise indicated
Conclusion: This long-term follow-up of an inception cohort di-
agnosed early in the biologic era suggests a reduction in per-
manent damage, good prognosis for systemic JIA and a much
lower progression to an oligoarthritis extended category than
previously reported. Considerable disease activity persists in a
quarter of the patients. Extension of this study to the entire co-
hort will help confirm findings and identify predictors of long-
term outcome.Disclosure of Interest
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Introduction: The risk of malignancies, in particular malignant lymphomas,
in Juvenile Idiopathic Arthritis (JIA) patients is low but has been reported to
be elevated compared to the general population.
Objectives: To assess the risk of cancer in patients with JIA in comparison
to non-JIA individuals both in the pediatric age range and in adulthood.
Methods: Register-based cohort study of patients with a first JIA diagnosis
recorded from 1987 to 2016, based on data retrieved from the Swedish
Patient Register (with information on hospitalizations (1987 and onwards)
and outpatients visits (2001 and onwards)), and the Swedish Cancer
Register. JIA patients were matched (on sex and age) to five non-JIA indi-
viduals sampled from the Swedish child population. All participants were
followed up from six months after date of 2nd visit with a JIA diagnosis
(for JIA patients) or the corresponding date (for non-JIA individuals) until
the first date of the following events: cancer diagnosis, migration, death,
18 years of age, or 31 Dec. 2016. The occurrence of malignancies was
compared through standardized incidence rates (SIR). The same analysis
was rerun allowing participants to be followed up through adult ages
(age at 31 Dec. 2016).
Results: 7988 JIA patients and 39714 non-JIA individuals were identified
and followed up, with a median follow-up time until 18 years old of 4,7
years and a median follow-up time into adulthood of 9.5 years. Fourteen
malignancies (among which 6 lymphomas) until the age of 18, were re-
corded among the JIA patients and 37 (4 lymphomas) among the non-JIA
individuals. Allowing the follow-up to cover ages above 18, identified 37
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 205 of 243malignancies (11 lymphomas) among the JIA patients and 132 (15 lymph-
omas) among the non-JIA individuals.
Conclusion: JIA patients are at increased risk to develop cancer and espe-
cially malignant lymphoma compared to the general population. There is no
signal that the risk of cancer in JIA patients has been increasing over the last
years. The low numbers of cancer cases in JIA patients underscores that the
absolute risk is low.
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as compared with a general population comparator group by calendar
period of first identification of JIA versus all JIA, stratified by age at time
of cancer diagnosis
JIA by year of identification
1987–1998 1999-2016 All
Age 0–17 years
All cancers
Rate/100000 person-years
JIA 86,7 26,6 32,0
Non-JIA 0 18,7 17,2
RR (95% CI) – 1.43 (0.71-2.88) 1.86 (1.01 -3.44)
Lymphomas
Rate/100000 person-years
JIA 57,8 8,0 13,7
Non-JIA 0 2,1 1,9
RR (95% CI) – 3.75 (0.84-16.76) 7.39 (2.08 -26.19)
All ages-into adulthood
All cancers
Rate/100000 person-years
JIA 62,8 34,2 46,8
Non-JIA 4,8 30,2 34,2
RR (95% CI) 13.03 (1.36 -125.3) 1.13 (0.70 -1.82) 1.34 (0.93 -1.93)
Lymphomas
Rate/100000 person- years
JIA 41,9 9.8 13,9
Non-JIA 0 3,2 3,9
RR (95% CI) – 3.01 (1.09- 8.28) 3.53 (1.62-7.69)
Table 1 (abstract P399). Data is reported as median (minimum;
maximum)
Number of patients 57
Girls/Boys 42/15
Age (years) 12.7(6.1; 16.8)
Patients on DMARDs and/or biological medication 43
sJIA, poly RF+, poly RF-, oligo, enthesitis, PsA,
Undifferentiated
8%, 0, 15%, 38%, 7%, 7%, 15%
Pain intensity VAS 0-10 1.75 (0;7.7)
JADAS 27 (Range 0-57) 1.8 (0;16.3)
CSHQ (Range 33-99) 43 (36-61)P399
ANXIETY SYMPTOMS PREDICT POOR SLEEP QUALITY IN CHILDREN
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Introduction: Poor sleep quality is common in children with ju-
venile idiopathic arthritis (JIA). Sleep quality is affected by the
child’s activity in disease and experience of pain. Psychological
variables seem to have an impact on the sleep quality as well.
Objectives: The aim of this study was to examine how pain, dis-
ease activity, and psychological wellbeing differs in children withJIA with poor or normal sleep quality, and the likelihood of these
variables on having poor sleep quality.
Methods: In the outpatient clinic patients diagnosed with JIA age 6-
16 were included. Child and a parent completed questionnaires re-
garding the child’s sleep quality in The Children’s Sleep Habits Ques-
tionnaire (CSHQ), anxiety symptoms in Spence Children’s Anxiety
Scale (SCAS), wellbeing in WHO-5 Wellbeing Index (WHO-5)), positive
and negative mood in The Positive and Negative Affect Schedule
(PANAS). Pain intensity was measured using the VAS 1-10 scale from
the Juvenile Arthritis Multidimensional Assessment Report (JAMAR).
Disease activity was calculated as JADAS-27. Exclusion criteria were
JIA in remission off medication, co-morbidity, non- Danish speaking
patients.
Results: In total 62 patients were included. Results indicated that 55%
of the children reported poor sleep quality (CSHQ>41). Children with
poor sleep quality reported significant lower level of wellbeing and
higher levels of anxiety, negative mood, and pain intensity, and
showed higher level of disease activity (p =.02-.001). A logistic regres-
sion was performed to ascertain the effect of pain, disease activity,
wellbeing, anxiety, and negative mood on the likelihood, that the chil-
dren had poor sleep quality. The model was statistically significant
(chi2 (4) = 16.50, p=.006) and explained 36.4% of the variance in poor
sleep quality and correctly classified 75.5% of cases. Increasing level of
anxiety symptoms was significantly associated with an increased likeli-
hood of poor sleep quality (p=.01). None of the other predictor vari-
ables made a unique, significant contribution.
Conclusion: Disease activity, pain, and psychological wellbeing
were negatively affected in children with poor sleep quality. Es-
pecially the level of anxiety symptoms were a significant pre-
dictor of having poor sleep quality, which highlights the
importance of focusing on the impact of anxiety and worry on
children’s sleep quality.
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Introduction: The Transition Readiness Assessment Questionnaire
(TRAQ) was developed to evaluate the transition process of
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 206 of 243young people, with chronic pathology, into adult medicine. It
consists of 20 items grouped in 5 subscales (Medication Manage-
ment, Management of the consultations, Monitoring of Health
Problems, Communication with Health Technicians and Manage-
ment of Daily Activities), and the answers fit into a Likert scale of
5 points (increasing scale). The scores result from the sum of the
items of each subscale, with larger values indicating a greater de-
gree of preparation for the transition.
Objectives: To identify points of greater fragility in the transition to
adult care in order to develop strategies for a proper planning.
Methods: Cross-sectional study including adolescents and young
adults with chronic rheumatic conditions followed in the transition
clinic of our Paediatric Rheumatology Unit, with ages between 16
and 22 years in whom the recently validated Portuguese version of
TRAQ was applied. Demographic, clinical data and the responses to
the TRAQ questionnaire were analysed.
Results: 27 participants were interviewed. Of these, 19 (70.4%)
were female, with a mean age of 17.9 ± 1.2 years, 23 were in
school (85.2%), with an average schooling of 11.1 years. In the
population studied, 41% were able to perform their therapy with-
out help and, in this group, about half were using non-biological
or biological disease-modifying antirheumatic drugs. In the overall
evaluation of each topic of the questionnaire, the one with the
highest score refers to Communication with Health Technicians
with an average score of 4.81, with the lowest score correspond-
ing to Consultation Management (3,30). In this topic, the points
related to Money Management and Health Insurance are the
areas with a greater lack of knowledge. For the remaining topics
in ascending order we found: Monitoring of health problems
(3.44), Medication Management (4.12) and Daily Activities Man-
agement (4.31).
Conclusion: The transition to adult care is a crucial process of
emerging adolescents / adults with chronic diseases. The applica-
tion of this questionnaire proves to be fundamental in the prep-
aration for the transition, namely in the orientation of the
educational interventions provided by the health professionals.
Therefore, the scores of each topic are useful in identifying the
areas that require a higher level of intervention and thus contrib-
ute to better prepare the adolescents with chronic diseases to
enter the adult system. In our Paediatric unit we conclude that
the Consultation Management is the area where the results are
lower and thus a greater degree of investment in this area is
needed.
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Introduction: Vocational development is an integral component of
adolescence with several key educational transitions occurring during
this stage of life. In the context of long term health conditions and/
or disability including rheumatic disease, vocational morbidities are
increasingly recognised. However, only a few studies to date have
used qualitative methods to report on the perspective of young
people with arthritis [1,2].
Objectives: To understand the experiences of education and employ-
ment of educational and vocational outcomes for young people with
arthritis, from the perspective of young people themselves.Methods: We used secondary analysis of narrative and semi-
structured interviews (n=49) which had been video or audio re-
corded from a primary qualitative study on the experiences and in-
formation and support needs of young people with arthritis [3]. A
purposive, maximum variation sampling strategy had been employed.
The dataset consisted of 40 young people. The dataset consisted of 39
young people (median age at interview 20, range 10 to 28 years; me-
dian age at diagnosis 11, range 2 months to 22 years) and 10 carers of
young people who had been diagnosed with arthritis in childhood,
adolescence or young adulthood. Data analysis for the primary study
combined a thematic approach with the grounded theory technique of
constant comparison. NVivo software was used to assist data manage-
ment and coding. The secondary analysis process aligned with Heaton’s
categories of supra and supplementary analysis [4]. All 49 original tran-
scripts were re-coded with the overarching aim to identify all material
relevant to vocational experiences. We also undertook a series of work-
shop meetings in which the re-coded data were discussed and
reviewed jointly by the authorship group to add a further layer of scru-
tiny, and debate and refine the emerging findings.
Results: Three key themes were identified: (i) The impact of the unpre-
dictability of arthritis symptoms on education and vocation; (ii) the ne-
gotiation of disclosure, understanding, support and flexibility in the
workplace or educational setting; and (iii) the appraisal and reappraisal
of life’s goals in the context of an uncertain prognosis.
Findings illustrated how young people with arthritis are faced with a
range of challenges and disruptions in their everyday life at a time when
key developmental tasks occur, including the educational and vocational
aspects of their development. Appropriate support and flexibility in the
workplace or educational setting were identified as enablers to success-
ful educational and vocational outcomes. However, negotiating disclos-
ure was not a straightforward process for such young people, with a
range of concerns and expectations acting as barriers to disclosure. Fur-
thermore, participants’ accounts revealed how disclosure is a necessary
but not always sufficient step towards achieving an understanding and
supportive environment in school or the workplace.
Conclusion: There is a need to strengthen the health-school/work
interface to improve the educational and vocational outcomes for
young people with arthritis. Addressing disclosure with the young
person and employing effective interventions to improve communi-
cation, understanding and awareness beyond the clinical domain
and across workplace/educational settings are key challenges for
health professionals and important areas for further research.
[1] Hanson H, Hart RI, Thompson B et al. Disabil Rehabil. 2017 ; 13:1-8
[2]. Shaw KL, Hackett J, Southwood TR, McDonagh JE . Br J Occupa-
tional Therapy 2006;69(3): 98-105.
[3] McDonagh JE, Simmons B, Raisanen U, Zeibland S. Rheumatology
(2014) 53 (suppl 3): iii18
[4] Heaton, J., 2004. Reworking qualitative data. Sage, London.
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Introduction: Delayed puberty and reduced adult height have been
reported in JIA before the era of biologicals. Long-term conse-
quences of delayed puberty are among others growth disturbances,
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 207 of 243low bone mineral mass and decreased fertility. Treatment with anti-
TNF restores growth, but data on puberty are unknown
Objectives: We evaluated onset and course of puberty and growth, in
JIA-patients who are treated intensively, including the possibility of bio-
logicals, and identified variables related with puberty and growth
Methods: In a longitudinal JIA-cohort, all consecutive patients (10
-21yrs) were followed for three years. Annual examinations were per-
formed regarding demographic and disease-related items as well as
Tanner pubertal stages and anthropometric measurements. Median
ages at reaching each stage were estimated by Kaplan-Meier curves.
Parametric tests were used to determine differences between pa-
tients and healthy controls, non-parametric tests between patient-
groups. Univariate analyses and mixed models were used to identify
associated variables
Results: 138 patients were included (66% girls). Median disease-
duration was 7,8 years (IQR 3.7-10.5), median JADAS-27 3,7 (IQR 1,3-
8,0), DAS-28 2,16 (1,5-2,8). Puberty onset was 1,2yrs delayed in girls
(p<0,01), in boys 0,6 yrs (ns). The progression was also delayed: end-
stage (Tanner-5) in girls was 3,3yrs delayed (p<0,01), in boys 1,7 yrs
(p<0,01). A positive association was found for longer disease-
duration and a lower BMI. Biological-use was not associated. Both for
girls and boys, standardized height was not different at the onset
and at the end of pubertyTanner
stage
Breast stage (A) Genital stage (B) Pubic hair girls (C) Pubic hair boys (D)
JIA Controls JIA Controls JIA Controls JIA Controls
2 11.9
(10.6-13.3)*
10.7
(9.0-12.2)
12.1
(10.5-13.7)
11.5
(..-13.0)
11.9
(10.6-14.1)*
11.0
( 9.4-12.5)
12.5
(10.6-13.8)*
11.7
(9,2 -13.4
3 13.4
(11.9-16.1)*
11.9
(10.5-13.1)
13.3
(11.6-15.3)
12.9
(11.3-14.5)
12.8
(11.7-15.5)*
11.9
(10.6-13.2)
13.1
(11.4-15.1)
12.9
(11.6-14.5
4 15.0
(13.4-18.5)*
12.8
(11.5-14.5)
15.1
(13.1-16.8)*
13.9
(12.5-15.7)
14.8
(12.9-17.9)*
12.7
(11.4-14.3)
15.2
(13.4-17.1)*
13.8
(12.5-15.2
5 17.7
(14.8-20.2)*
14.3
(12.5-19.5)
17.0
(13.9-20.7)*
15.3
(13.6-19.5)
17.2
(14.2-20.2)*
13.8
(12.1-17.7)
16.6
(13.9-20.6)*
15.0
(13.3-17.4)
)
)
)Conclusion: In contrast to normalized longitudinal growth, we
found in JIA-patients in disease remission or with low disease
activity a delayed onset and progression of puberty despite in-
tensive treatment including biologicals. Eventually, puberty was
completed and normal adult height was reached. The effects on
bone mass and fertility will have to be evaluated in cohort
studies
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Pediatric Rheumatology 2018, 16(Suppl 2):P403Introduction: Musculoskeletal ultrasound (MSUS) is non-invasive, highly
patient acceptable, easy to perform and repeatable imaging method in
pediatric rheumatology. Yet, it is dependent on sensitivity of the machine
used and the skills of the operator. Additional specificities are unique fea-
tures of the growing skeleton, which include age-related variation of the
thickness of the articular cartilage (due to incomplete ossification) and
the presence of physiologically detected vascularization even in healthy
children.
Objectives: EULAR/PReS task force objective was to develop EULAR/
PReS Standardized Procedures for Ultrasound Imaging in Pediatric
Rheumatology through a consensus process among rheumatologists,
paediatric rheumatologists, and radiologists highly experienced in
the performance, teaching and research in paediatric MSUS in rheu-
matologic diseases.
Methods: In the first phase we performed a systematic literature re-
view (SLR) on guidelines for MSUS for children published by inter-
national societies and articles on how to perform MSUS scanning in
children. Based on the SLR results, project conveners (JV and PC) for-
mulated a Delphi survey by selecting the items to be included (i.e.
musculoskeletal anatomic structures evaluable by ultrasound, scan-
ning technique, and their lesions/abnormalities detectable by ultra-
sound at the principal joint areas). The Delphi survey was distributed
among a broad panel of experts in MSUS (i.e. rheumatologists, paedi-
atric rheumatologists, radiologists), selected by their high experience
in the performance, teaching and research in MSUS in children.
Based on the Delphi results main anatomical structures (for defini-
tions, photo and video recordings) were selected to be used in the
final phase organized as an exercise (lasting 4 days) on live healthy
children models. The meeting involved: 16 project participants (13
pediatric US experts, fellow, as well as, AHP and PARE representative), 16
healthy children models (representing four different age groups) accom-
panied by their parents (who has signed informed consent to partici-
pate), 4 photo/imaging technicians, 2 expert US machine technicians.
Results: Structures from nine musculoskeletal areas (i.e. shoulder,
elbow, wrist and hand, hip, knee, ankle and foot) in four age groups
of children were selected. Detailed scanning procedures (i.e. patient
position, probe placement, scanning method and bony/other land-
marks) were used to produce the photo and video records of the
scanning procedures. As a result, we obtained photo and video
image library with a detailed description of the standardized proce-
dures, which can be used as EULAR/PReS web-based educational
application.
Conclusion: This task force has produced a consensus-based compre-
hensive and practical framework on standardized procedures for
MSUS imaging in pediatric rheumatology.
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Introduction: Transitional care is a purposeful, planed movement
of adolescence and young adults with chronic condition from
childhood- to adult-oriented health care systems. Well-organized,
systematic transitional health care is of high importance for pro-
viding the continuous medical treatment and for reaching opti-
mal outcomes. Up to date, there is no unique, consensus-based
model for patients’ transition from childhood- to adult oriented
health care centers in Turkey.
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 208 of 243Objectives: We aimed to assess the transitional care among patients with
juvenile onset rheumatologic disease in referral tertiary center in Turkey.
Methods: The transitional policlinic is held once per month at the de-
partment for pediatric rheumatology, consisting of 2 adult rheumatolo-
gist, 4 pediatric rheumatologist and 1 adult rheumatology nurse. Patients
who have undergone the transitional care in the time period from May
2014 to December 2017 were called by telephone, by two different in-
vestigators (EP,OK). Thirty-three (22%) patients were not reached and 17
(11%) of theme were excluded from the study due to short post-
transitional period (<6 months). Consequently, 97 (66%) patients have
been reached and included in the study. Data on demographic, clinical
and socio-economic features and experience with transitional practice
were collected by using a structured questionnaire, which was fulfilled
during the phone conversation between investigator and patient.
Results: A total of 147 patients (79 (54%) females) underwent transi-
tion process and 97 of them were included in the study (Table 1).
There was no statistically significant difference between different pa-
tients groups regarding the age of transition. The education levels of
patients were as following: university 60 (61.9%), high-school 21
(21.6%), middle-school 13 (13.4%), primary school 3 (3.1%). Majority
of patients was single at the time of study (79 (81.4%) patients) while
only 18 (18.6%) patients were married; half of them being child
owner. At the time of study, 44 (30%) patients were employed and
mean age at employment was 19.06±3.1 years. Most of patients had
health insurance at the time of study (94 (96.9%)). Seventy-one
(73.2%) patients continued their regular follow up at adult depart-
ment while 26 (25.8%) patients discontinued medical treatment. The
most common reasons for cessation of follow up were the work/
school absence (20 (76.9%)), followed by patients’ personal reasons
(2(7.6%)) and dissatisfaction with adult clinic services (4(15.5%)). Most
of patients reported satisfaction with transition process: 96 (99%).
Conclusion: Well-organized transitional health care is of crucial
importance for the continuous and optimal health care of adoles-
cents and young adults with chronic rheumatic disease. Further
studies with higher number of patients would reveal the rele-
vance of described transitional care model.Disclosure of Interest
None DeclaredTable 1 (abstract P404). See text for description
Patients that were included in the study
N=97
Female, n (%) 58 (59.7%)
Age at transition, mean±SD 21.4±1.4 years
Age at study mean±SD 22.8±1.8 years
JIA, n(%) 26 (26.8%)
Oligoarticular JIA 2 (2%)
Polyarticular JIA 10 (10%)
Systemic JIA 2 (2%)
JSPA 11 (11%)
Psoriatic arthritis 1 (1%)
FMF 60 (61.8%)
Connective Tissue Disease, n(%) 7 (7%)
jSLE 5 (5%)
JDM 1 (1%)
Mixed cryoglobulinemia 1 (1%)
Vasculitis, n(%) 4 (4%)
Takayasu arteritis 1 (1%)
Behçet’s disease 3 (3%)P405
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Introduction: Many individuals, including adults, live with childhood-
onset (onset <18 years) systemic autoimmune rheumatic diseases
(ChildSARDs), which comprise of childhood-onset systemic lupus ery-
thematosus (SLE), Sjogren’s syndrome, idiopathic inflammatory myo-
sitis (IIM), systemic sclerosis, and vasculitides. With increasing survival
of these patients in the past few decades, many now live into adult-
hood with their disease. However, little is known about ChildSARD
outcomes in adulthood. Adult rheumatologists therefore have inad-
equate evidence to guide their management of these patients. Pa-
tients and their families also have little information about their
possible outcomes in adulthood.
Objectives: To systematically review prognosis studies performed on
adults with childhood-onset systemic autoimmune rheumatic dis-
eases (ChildSARD), examine for quality of studies (for risk-of-bias) and
the scope of outcomes studied, so as to identify gaps of knowledge
and methodological issues. To recommend future directions of re-
search in adulthood outcomes of ChildSARD and advice on common
pitfalls in study designs to avoid.
Methods: We developed a search strategy with an academic librarian
to identify all full-length English articles in MEDLINE and Embase (Janu-
ary 1990 – May 2017) reporting on any adulthood outcomes of Child-
SARDs. Our strategy was iteratively fine-tuned and finalized after peer-
review by librarians. Hand-searching supplemented the literature
search. We excluded case reports, case series, letters, editorials, and
short reports. If a study included both pediatric and adult subjects, we
assessed the study only if the median (or mean, assuming no skewed
distribution) age at outcome ascertainment was ≥ 18 years. Information
about outcomes, prognostic factors, and study designs was recorded.
All studies were graded independently by two reviewers (after prior
training for adequate agreement) using the Quality in Prognosis Studies
risk-of-bias tool.
Results: Of 14,100 articles, 26 publications met our inclusion criteria.
Two studies (7%) were longitudinal (repeat measures) while the re-
mainder assessed outcomes on a single occasion. Only 10 (36%)
studies focused exclusively on adults. Studies by publication times
were: 4% (1990-1999), 18% (2000-2009), and 79% (2010-2017). Most
studies (82%) were conducted in either North America or Europe.
The most commonly studied diseases were SLE (in 61% of studies),
IIM (18%), and systemic sclerosis (11%). The most commonly re-
ported primary outcomes were organ damage (29%), cardiovascular
outcomes (14%), and mortality (14%). The mean ages at outcome as-
sessment were 19.5 – 46.8 years for adult-only studies and 19.3 – 35
years for mixed studies. Moderate to high risk-of-bias was found in
100% of studies for study participation, 90% for study attrition, 61%
for prognostic factor measurement, 36% for outcome measurement,
89% for confounding, and 54% for statistical analysis.
Conclusion: There is clear need for more information about adulthood
outcomes of ChildSARDs. Longitudinal data collection and analyses
were especially lacking. We recommend that future studies on Child-
SARD outcomes be undertaken in the framework of a longitudinal co-
hort, have adulthood outcomes separately reported from outcomes in
childhood, and have study populations clearly defined to allow for ac-
curate MESH coding so as to facilitate easy searching for such informa-
tion and for knowledge dissemination. Careful attention should be paid
especially during study design to reduce bias in choice of study popula-
tions, accounting for attrition and confounding.
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Introduction: Many individuals, including adults, live with childhood-
onset systemic autoimmune rheumatic diseases (ChildSARDs), with
improved survival in recent decades. Employment is a major mile-
stone of independence in adulthood and has obvious impacts on so-
cioeconomic attainment and sense of achievement. Employment is
often associated with access to health insurance and healthcare.
Therefore, employment is an important outcome for adults with
ChildSARDs as they enter into adulthood.
Objectives: To systematically review current literature on employ-
ment outcomes of adults diagnosed with ChildSARDs.
Methods: Systemic autoimmune rheumatic diseases (SARDs) in our
study include: systemic lupus erythematosus (SLE), inflammatory
myositis, Sjogren’s syndrome, systemic sclerosis, and systemic vascu-
litides. We developed a search strategy with an academic librarian
and iteratively refined it by peer-review before finalization. MEDLINE,
Embase, and Scopus were searched for full-length English articles be-
tween January 1990 and November 2017. References of review arti-
cles were hand searched. Articles identified were screened by 1
reviewer to identify eligible studies; eligibility was confirmed by re-
view of the full-length articles. If a study contained adults with Child-
SARDs and adult-onset SARD patients, we contacted the corresponding
authors for clarification on the number of ChildSARD patients and re-
quested the employment outcomes of those individuals. We extracted
information on study design, employment outcome measures, prog-
nostic factors, and confounders using a standard data collection form.
Eligible studies were graded independently by 2 reviewers, after train-
ing to ensure acceptable agreement, using the Quality in Prognosis
Studies (QUIPS) risk-of-bias tool.
Results: Five publications arising from 4 studies from 2109 abstracts.
Four publications studied SLE and 1 studied juvenile dermatomyositis
(JDM). In total, there were 296 patients (257 SLE, 39 JDM). Study partici-
pants had a mean age of 23.3-29 years with a mean disease duration of
7.6-15 years. Of the 5 studies, only 1 was longitudinal (at least 3 re-
peated outcome measurements). 80% (4/5) of studies were from North
America. No study made comparisons between the study population
and corresponding age/sex-matched general population. Moderate to
high risks-of-bias were commonly found especially in study population
(100%), prognostic factor measurement (80%), and confounding (80%).
47% of the 296 total patients were working (full/ part-time), 21% were
studying, the remaining 32% were not working (for various reasons,
variably reported in different studies). Reasons for patients being in dif-
ferent work categories were not reported, and only 1 study made com-
parisons with the national average employment rate. Only 2 studies
assessed work productivity, and one measured work characteristics. In-
come was reported in two studies. Multiple prognostic factors for em-
ployment were identified in 3 studies; generally, these were either
disease characteristics or workplace support and satisfaction.
Conclusion: There is scarce information on employment outcomes of
adults with ChildSARDs. Other than SLE and JDM, no other SARDs were
represented. There was little information on work characteristics; studies
tended to focus on either sociodemographic or disease aspects but not
both. Important study domains, such as population and confounding, are
at moderate-high risk-of-bias. Future studies should aim to study other
ChildSARD diseases, with careful attention to study design, and investiga-
tors should collect more comprehensive information on employment be-
yond work status, compare patient outcomes to the general population,
and test both sociodemographic and disease related factors.
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Introduction: Among the causes of death in patients with rheumatic
diseases (RD) 38.1% are disorders of the cardiovascular system, which
can be caused by immune mechanisms and are often not detected.
Objectives: To investigate the possibility of revealing electrophysio-
logical changes in myocardium of children with RD using a new
software-hardware complex (SHC) with a 4-level estimate "Cardio
plus P".
Methods: With the help of the SHC 27 patients with RD during remis-
sion period, with no clinical, instrumental and laboratory signs of
heart disease were examined. 9 boys, 18 girls were examined, 10.1
±3.6 y old, duration of the disease 1.45±0.51 y. 54% of them received
low-dose GC. Their results were compared with healthy ones.
SHC registers a 12-channel ECG with a multi-level analysis of the
signal-averaged complex. It studies alternate parameters (standard
deviation, level of the overall adaptive potential, rapid rate of heart
rate, sympathetic and parasympathetic regulation, generalized signs
of heart failure, symmetry of the T wave), it takes into account the
variability of complexes, allows control of regulation and functional
state of the myocardium (by the form of ST, amplitude and waves
square indexes, angles of deviations), detects a violation of the
rhythm, indirectly assesses the psycho-emotional state. The monitor
demonstrates the graphical form of the 4-level estimate of ECG ana-
lysis and the integral index of the functional state of the cardiovascu-
lar system.
Results: Analysis of the data showed that only in 14.2% of cases for
HSC there were no violations of the heart rate. The comprehensive
assessment of regulation showed a significant decrease in patients
with RD (65.82±1.97 at a rate of 76-100), mostly due to vegetative
imbalance. The triangular index grew to 25525.2±27.6 (norm 9-100),
the voltage index up to 164.59±33.46 (0-120). Operational control of
the myocardium was also decreased to 55.5±2.41 (75-100). The de-
crease in the amplitude of the wave T in the leads I and AVL and its
increase in the leads of the III AVF with its asymmetry indicated the
presence of cardiometabolic changes. The integral indices of the ST-T
form were changed in all leads, the highest of I 60.36±3.74 (75-100),
the ratio of the amplitudes of the waves T and R increased 0.83±0.21
(0.14-0.33) The ratio of ECG phases in patients with RD was 27.82
±5.43 (75-100). The absence of a bias of the ST segment after 0.08 s
after the point J reflected the absence of hypoxia. The index of myo-
cardial reserve in RD decreased to 63.77±2.59 (75-100). The patients
noted a general insignificant psycho-emotional stress. The composite
index of myocardium state was 61.13±2.18%, and only 11.1% of pa-
tients had normal indexes. Dependence on anemia (r=0.35), thyroid
gland damage (r=0.72), ESR (r=0.45), LDH activity (r=0.86), phos-
phorus content (r=0,99), titers of antiphosphatidyl ethanolamine
(r=0.71) and dsDNA antibodies (r=0.33) were detected. It did not de-
pend on the previous carditis and the presence of foci of infection,
dysproteinemia, CRP.
Conclusion: The use of HSC allows to detect changes in the cardio-
vascular system in children with RD and latent heart rhythm distur-
bances three times more often. Electrocardiographic changes are
observed in 81% of patients with RD. They are mainly due to vegeta-
tive and metabolic disorders.
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Introduction: The lesions of the respiratory system, namely the pulmon-
ary tissue, are not specific for the development of poly- and oligoarticu-
lar juvenile arthritis. However, sclerotic damage to the mesenchymal
tissue is one of the complications of long-term therapy with methotrex-
ate and one of the factors determining the long-term prognosis of these
patients of adult age. Rheumatic diseases are characterized by frequent
involvement of respiratory organs. In children, pulmonary function disor-
ders often occur latently, with minimal clinical manifestations, which is
due to the high compensatory abilities of the child's organism.
Objectives: For the timely diagnosis and prevention of pulmonary
complications the ventilatory lung function in children with rheum-
atic diseases was assessed.
Methods: Spirometry was performed in 129 children from 5 to 18 years
with rheumatic diseases, among them 35 boys and 94 girls. In the
structure of diagnoses were patients with JIA - 89 people (69%), with
SLE - 18 people (13.95%), with scleroderma 12.40% (16 people), derm-
atomyositis - 4 people (3.1%), nodular polyarteritis - 2 people (1.55%).
Results: 29 children showed a violation of the ventilation function of
the lungs (which amounted to 22.8% of the total number of pa-
tients). In all cases, the violations were as a restrictive type. Among
them lung lesions were noted more often in patients with SLE (up to
44%), in patients with JIA to 21%, with systemic scleroderma - 12%.
Among children with dermatomyositis and nodular polyarteritis,
there were no abnormalities, which is probably due to the small
number in the structure of the subjects. An analysis based on gender
were carried out , it showed that girls made up 84% with JIA, and
with SLE - 75%, with systemic scleroderma, violations were detected
only in girls. In most patients, external respiratory function impair-
ments were mild or moderate severity, and severe respiratory ventila-
tion dysfunction was detected only in patients with JIA. A correlation
analysis was made of the relationship between the spirogram score
and individual patient parameters, such as gender, age, physical de-
velopment by BMI. There were not reveal a reliable relationship be-
tween these parameters. An additional analysis of the correlation
was made with the duration of the disease in patients with JIA. As a
result, a weak positive relationship was found with the duration of
the disease (r = 0.36, p <0.05).
Conclusion: In children with juvenile idiopathic arthritis before the age
of 18 we found signs of a violation of the respiratory function of a re-
strictive type, which is indicate of a lesion of the pulmonary paren-
chyma. The revealed changes depend on the duration of the disease
and do not depend on the clinical parameters of the patients.
Trial registration identifying number:
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Pediatric Rheumatology 2018, 16(Suppl 2):P409Introduction: Immunoglobulin G4-related disease (IgG4-RD) is a
chronic systemic inflammatory condition with an unclear pathophysi-
ology and IgG4-positive plasma cells infiltration of various organs
and parts of the body.
Objectives: If untreated, the disease can lead to fibrosis and irrevers-
ible organ damage. IgG4-RD mostly has been described in adults,
hence it is generally unknown among pediatricians.
Methods: We conducted a retrospective analysis of clinical features
and response to therapy of five patients (one female, four males, me-
dian age 13,6 years) with IgG4-related disease, treated in our Center.
The diagnosis was confirmed by detection of lymphoplasmacytoid
infilatration with >30% of cells expressing IgG4 in all, and elevated
IgG4 serum concentration in 4 cases.
Results: Three patients had localized lesions (orbit, hip muscle, peri-
rancreatic tissue, respectively), two – multiorgan disease with poly-
lymphadenopathy, pulmonary, renal and hepatic foci, dacryoadenitis
with edema of the eyelids. Autoimmune thrombocytopenia (70 х109/l),
neutropenia (0,79 х109/l) were present in one patient. Rituximab ther-
apy was successful in 2 cases (one patient received monotherapy with
rituximab, another one – Rituximab and Sirolimus). Two other patients
received JAK inhibitor therapy (ruxolitinib) with good effect. No side ef-
fects were noted. One patient underwent surgery - the infiltration in
the abdominal cavity was removed with positive effect without specific
therapy.
Conclusion: IgG4-RD symptoms can be diverse and sometimes
atypical, so dealing with this pathology requires physician’s aware-
ness. Rituximab was effective in patients with multi-organ manifes-
tations, and JAK inhibitor (Ruxolitinib) was effective in patients with
mono-focal disease. Steroids are routinely used in IgG4-RD as a first
line of treatment with significant side effects. We propose that al-
ternative drugs could be used in IgG4-RD, especially in pediatric
patients to achieve fast remission with significan morbidity
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Introduction: The approach to the rheumatological patient often
takes to the individuation of pathognomonic clinical and laboratory
signs. Nevertheless, their presence should not exempt the physician
from the search of differential diagnostic elements, mostly in onco-
hematological purview.
Objectives: To describe the workup of two cases misdiagnosed as
rheumatic disease.
Methods: Report of two clinical cases referred to the pediatric
rheumatology unit of the University of Naples Federico II.
Results: The first patient is a 15-year old girl suffering from pale
skin and fatigue from 3 months. At the admission to the local hos-
pital, the laboratory investigations revealed microcytic anemia (Hb
7.5 g/dl), raised ESR (120 mm) and CRP (143.6 mg/L); no
thrombocytopenia and no leukopenia were found. Infectious dis-
eases were excluded as well as inflammatory bowel disease. Auto-
immune panel was performed and a slight increase of ANA and
Lupus Anticoagulant was found. A Systemic Lupus Erythematosus
(SLE) onset was suspected. The girl was referred to our center and
laboratory examinations were performed: slight increase of Anti
Histone Antibodies, positive Direct Coombs Test, weakly increase
of ANA, non-hemolytic anemia and hypergammaglobulinemia
were found. During the clinical examination, no skin involvement
was noticed, but a supraclavicular lymphadenopathy and hepatos-
plenomegaly were evidenced. Clinical and immunologic criteria
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 211 of 243were not sufficient for SLE diagnosis. An ultrasound of lymph node
was performed and showed an inhomogeneous and hypoechoic
structure, richly vascularized. Total body PET was performed,
showing hyperaccumulation of lymph node sites above the dia-
phragm. Lymph node biopsy led to the diagnosis of Hodgkin’s
Lymphoma (nodular sclerosis subtype). Chemotherapy and radio-
therapy were performed and 3 months later, the total body PET
was completely negative.
The second case report is about a previously well 8-year-old boy,
with 1-month history of multiple subcutaneous plaques and nodules,
involving the extremities, trunk and face, onset after a trauma. Panni-
culitis was diagnosed based on skin biopsy and the child was treated
with low doses of steroids. After 6 months, he was admitted to our
Unit with high fever, malaise, myalgia and extended cutaneous le-
sions. Clinical examination revealed liver and spleen enlargement; la-
boratory data showed anemia, leukopenia and elevated levels of ERS,
CRP, AST, ALT, LDH, ferritin and low level of albumin. He was nega-
tive to screening of EBV and tuberculosis infection. By the review of
the first skin biopsy, Subcutaneous Panniculitis T-cell lymphoma
(SPTCL), an unusual type of peripheral T-cell lymphoma, was sus-
pected. Another surgical skin biopsy was performed. The histopatho-
logical picture showed a pleomorphic cellular infiltrate and cell
surface markers consistent with the diagnosis of SPTLC. Liver biopsy
revealed systemic hemophagocitic syndrome, while bone marrow
examination and bone biopsy were normal; after a week the boy ex-
perienced disseminated intravascular coagulation. He was admitted
to the Pediatric Hematology and Oncology Unit and initially treated
with chemotherapy and local radiotherapy, then autologous bone
marrow transplantation was performed and now he is completely
recovered.
Conclusion: The isolated finding of positive autoimmune laboratory
data, without suggestive clinical features, should not immediately
lead to the diagnosis of rheumatologic disorders, but requires more
investigations to exclude oncohematological disease. Likewise, sug-
gestive clinical signs should in any case, lead to differential diagnosis, if
the clinical course is atypical or if the response to therapy is inadequate.
Informed consents for the publication were obteined from the
parents.
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Introduction: The association of two or more autoimmune diseases
(AIDs) in a single patient may be explained due the fact that those
diseases share pathogenic mechanisms, many clinical manifestations
are common and the profile of autoantibodies is unspecific for sev-
eral AIDs and those associations may cause significant morbidity .
There are limited information about polyautoimmunity on juvenile
patients. Three years ago was started a registry of patients with poly-
autoimmunity documented during the follow up at a pediatricrheumatology clinics ( 17 centers on 5 Colombian cities). A prelimin-
ary report was presented a PRES meeting 2016. We continue this
registry, including new patients and updating the information.
Objectives: Identify the clusters of polyautoimmunity observed on
those patients and describe the clinical, laboratory, histopathological
features and treatment in juvenile patients with polyautoimmu-
nity (2 AIDs) and multiple autoimmune syndrome (≥3 AIDS) and
analyze the clusters of AIDs observed.
Methods: Multi-center, retrospective and prospective study. Medical
records were reviewed and the information was recollected using a
data collection format. Statistical analysis performed using SPSS 20.
Results: N = 313 Sex ratio F22: M1, mean age was 11,3 years (1-16). The
first AIDs documented was named as “chaperone” disease followed by
the additional AIDs at a variable of time needed to confirm the diagnosis
and classified as simultaneous when the interval was less than 6 months
or sequential if that interval was longer. Those intervals varied widely be-
tween associations. 28 AIDs were identified. The shorter interval was for
AIDs associated to SLE and the longer was for Sjogren Syndrome ( con-
firmed by minor salivary gland biopsy). Some were re classified because
developed additional AIDs since their entrance to the registry to the last
cut point. 40 patient developed multiple autoimmune syndrome
Thyroid was the most common organ-specific AID and SLE was the
most frequent systemic AID with polyautoimmunity. SLE preceded,
diagnosed simultaneously or followed by other 7 AIDs correspond to
the biggest cluster followed by Hashimoto, JIA and Sjogren in associ-
ation to another AIDs. Other 16 types of associations were
documented.
Conclusion: What we have learn??
First: Polyautoimmunity is not an uncommon event on juvenile pa-
tients and patients with a AID are at risk of additional AIDs as it has
been confirmed on adult patients but the type of associations may
vary between populations (ethnicity).
Second: Some associations must be searched at the time of diagnosis
and during the follow up because may determine severe complications
and immunomodulation, hormone supplementation and additional
prophylatic and therapeutic measures may benefit the prognosis of the
patients.
Third: If an atypical clinical course or changes of the symptoms and
clinical signs on a patient with AIDs are observed, to check the func-
tional tests of the potential target organs and autoantibody profile is
indicated in order to rule out polyautoimmunity.
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Introduction: Osteoarticular pain can not only be the sign of arthritis
and musculoskeletal syndromes, but also of benign or malignant
tumors.
Objectives: We describe four paradigmatic cases of acute lympho-
blastic leukemia (ALL), osteoid osteomas (OO), Ewing Sarcoma (ES),
pigmented villonodular synovitis (PVS).
Methods: Diagnostic hypotheses were based on the medical history,
physical examination, blood and imaging tests.
Results: Case report 1. Since about a month, a six-year-old male child
complained of nocturnal pain in the lower limbs with awakening,
intermittent fever, asthenia, loss of appetite, headache, weight loss
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 212 of 243and reported upper airway infection in the last two months. Physical
examination showed cutaneous pallor, apathy but absence of hepa-
tosplenomegaly, lymphadenopathy, petechiae, ecchymoses, scrotal
swelling and signs of arthritis. Ocular fundus examination was nor-
mal. Blood tests showed mild anemia, neutrophilic leukocytosis,
thrombocytopenia, increased erythrocyte sedimentation rate (ESR)
and C-reactive protein (CRP), increased lactic dehydrogenase and
urate. Search for homovanillic and vanillylmandelic acid in the urine
was negative. Microscopic observation of peripheral blood
highlighted the presence of blasts. Bone marrow needle aspiration
and biopsy confirmed the suspicion of ALL.
Case report 2. Since about two months, a 14-year-old teenage boy
reported pain in the right lower limb, more intense at night, not as-
sociated with fever and increased in intensity despite oral administra-
tion of ibuprofen. Clinical examination showed lameness and
functional limitation of the right coxo-femoral joint. Blood tests were
all normal, while radiograph at the proximal femur showed an oval
radiolucent lesion of about one centimeter in diameter, surrounded
by a sclerotic ring. Computerized tomography (CT) was performed
and scintigraphy showed an increased uptake with technetium 99m.
Diagnostic suspicion of OO was confirmed following the removal of
the lesion.
Case report 3. A 15-year-old teenage boy since about a month com-
plained of pain referred to the anterior surface of the left thigh, asso-
ciated with fever and which resulted in nighttime awakening. At
physical examination the patient was limping; laboratory tests
showed increased ESR and CRP. Radiological examinations revealed
an elongated lytic bone lesion, disrupting the cortex and surrounded
by onion-skin periosteal reaction. Bone biopsy confirmed the diagno-
sis of ES.
Case report 4. A 16-year-old teenage girl came to our observation for
joint pain in her right knee since more than six months. Physical
examination showed swelling, pain and functional limitation of the
knee joint. Blood tests turned out to be normal, ultrasonography
showed signs of synovial hypertrophy and intra-articular effusion;
joint aspiration highlighted dark-brown synovial fluid. Magnetic res-
onance imaging (MRI) revealed a hypertrophic synovial membrane
with a villonodular appearance. Diagnosis of PVS was confirmed fol-
lowing surgical excision.
Conclusion: In the clinical suspicion of an osteoarticular tumor, blood
tests do not provide specific diagnostic indications and radiography
can show if the lesion is osteolytic or osteogenic. CT and MRI evalu-
ate the extent of the lesion, while scintigraphy may be useful in the
location of the tumor. Definitive diagnosis of a benign or malignant
tumor rests on the histological evaluation of an open or fine-needle
biopsy. Informed consent to publish had been obtained.
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Pediatric Rheumatology 2018, 16(Suppl 2):P413Introduction: Osteoarticular manifestations may be the first sign of
non malignant hematological diseases, such as hemophilia and
hemoglobinopathies.
Objectives: We describe in sequence three paradigmatic case reports
on sickle cell anemia, beta thalassemia minor and hemophilia A man-
ifested at onset with osteoarticular symptomatology.
Methods: Diagnosis were formulated in consideration of reported
clinical history, signs highlighted at the physical examination and re-
sults of laboratory tests.
Results: Case report 1. Two year old black male child, whose parents
were both african, presented inconsolable afebrile crying, macro-
scopic haematuria and acute swelling of the fingers of both hands
and feets. Physical examination showed dactylitis of hands and feet,
scleral jaundice, splenomegaly and absence of focal neurological
signs. Blood tests showed moderate anemia, hyperbilirubinemia, reticu-
locytosis and increased lactic dehydrogenase, while chest radiography
and abdomen ultrasound were normal. Microscopic observation of the
peripheral blood smear showed sickle-shaped red cells; the suspected
diagnosis of sickle cell anemia was confirmed by high-performance li-
quid chromatography, sickle cell test and search for genetic mutation.
Case report 2. Seven year old girl came for widespread joint pains
without fever since several months. Physical examination revealed mild
scleral jaundice, hepatosplenomegaly and pain in the mobilization of
hips, ankles, wrists, knees and elbows without signs of joint limitation.
Blood tests showed mild hyperbilirubinemia and moderate microcytic
and hypochromic anemia with sideremia, transferrin, ferritin and in-
flammatory indices in the norm. Radiological examinations were nor-
mal, while the hemoglobin electrophoresis showed a percentage
increase in hemoglobin A2, confirming in association with DNA analysis
the suspicion of beta thalassemia minor.
Case report 3. Sixteen months old male child, came to our observa-
tion for the swelling of both ankles and knees in the absence of
fever. Physical examination revealed several hematomas on the skin
surface and considerable swelling of ankles and knees with reduced
joint mobility. Blood tests showed a lengthening of the activated par-
tial thromboplastin time (APTT). In the suspicion of hemophilia A, the
factor VIII dosage was performed, which was reduced thus confirm-
ing the diagnostic hypothesis.
Conclusion: Sickle cell anemia occurs almost exclusively in black chil-
dren and the joint symptomatology of hands and feet is usually sym-
metrical. Thalassemias are a heterogeneous group of syndromes in
which bone pain is often reported. Non-steroidal anti-inflammatory
drugs (NSAIDs) should be avoided in patients with haemophilia; joint
aspiration has a limited therapeutic role, but should be preceded by
the administration of factor VIII. Finally, research of the etiology of
osteoarticular clinical signs must include these haematological diseases
if there are suggestive clues that justify the request for targeted diag-
nostic tests. Informed consent to publish had been obtained.
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Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 213 of 243Introduction: Often forgotten in the developed world, vitamin C defi-
ciency occasionally presents to rheumatology. With non-specific mul-
tisystem presentation, children can pose a diagnostic challenge and
often have extensive investigations to rule out malignancies, neuro-
muscular disorders or arthritis.
Objectives: To describe cases referred to rheumatology with muscu-
loskeletal symptoms explained by vitamin C deficiency over previous
6 years, with serum vitamin C level <15umol/L.
Methods: Retrospective case review
Results: We present a series of 4 autistic children whose wide variety
of phenotypes were explained by vitamin C deficiency and responded
to supplementation.
Case 1: 12 year old boy, background Fragile X and autism, with 5
weeks nocturnal hand pain and reduced function, unresponsive to
simple analgesia. Joint examination revealed hypermobile fingers
only. Subsequent review identified limited diet and bleeding gums.
Vitamin C level was 12umol/L and symptoms completely resolved
with vitamin C treatment.
Case 2: 3 year old autistic girl, with 4 months intermittent limp, finger
swelling with morning stiffness; diagnosis of juvenile idiopathic
arthritis(JIA) had been considered. Diet was very restricted. No evi-
dence of synovitis on rheumatology review. Ankle X-ray showed
osteopenic bones. Vitamin C level was 4umol/L and she was treated
with vitamin C.
Case 3: 13 year old autistic boy, previously diagnosed with Henoch-
Schonlein Purpura, with 1 month limp, painful legs, right knee and
ankle swelling and vasculitic rash. Diet was poor with no fruit or veg-
etables. Rheumatology review identified he was non-weight bearing,
thickened left ankle, with pain on hip movement. Dermatology re-
view elicited follicular hyperkeratosis, with coiled follicular hairs. Vita-
min C level was <1umol/L and he was successfully treated with
vitamin C, with rapid resolution of symptoms, with only some mild
residual joint contractures.
Case 4: 6 year old autistic boy, thought to have JIA, with 4 months
painful legs, lower limb rash and then progressive stiffness and pain.
He had a limited diet but reported to take daily multivitamins. On
examination, non-blanching follicular rash on lower limbs, painful
hips on internal rotation and warm, full ankles. He had brisk reflexes,
truncal and proximal weakness. He was investigated thoroughly by
Neurology, including lumbar puncture and MRI brain and spine
which was essentially normal. After 10 day admission on hospital
diet, symptoms improved. Vitamin C level subsequently returned at
<1umol/L and he responded well to treatment.
Conclusion: We present a series of 4 autistic children with restricted
diets, 3 of whom had been given other diagnoses, and several had
extensive investigations. Increased awareness following the herald
case facilitated earlier diagnosis in the subsequent patients and rec-
ognition of other patient groups at potential risk, including those
with inflammatory bowel disease. As well as classical perifollicular pe-
techiae, hyperkeratosis, gingival bleeding, bony manifestations may
precede in the paediatric population. Pathophysiology includes defect-
ive bone structure; degradation of bone trabeculae, haemorrhages
within the subperiosteal layer and osteoporosis. Musculoskeletal
phenotypic and radiographic variability amongst vitamin C deficient
paediatric patients should not dissuade clinicians from the diagnosis.
Awareness of this seldom recognised condition, in any child, but
especially autistic children, along with the phenotypic variability
is necessary to prevent consequent morbidity and unnecessary
investigations and treatment. Informed consent to publish had
been obtained.
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Introduction: With just over 100 cases reported in the literature, KBG
syndrome is a rare genetic condition with characteristic developmental
delay, dysmorphic features, macrodontia and skeletal anomalies. Arthritis
has not previously been described in individuals with KBG syndrome.
Objectives: To describe the clinical course of this case of KBG
syndrome.
Methods: Retrospective case note review.
Results: Case description:
This 17 year old girl, presented aged 20 months with bilaterally swol-
len knees and elbow stiffness. She had a background of global devel-
opmental delay (speech and motor), with significant behavioural
issues and learning difficulties. Examination elicited bilateral knee
flexion contractures and left wrist pain. Initial management included
non-steroidal anti-inflammatories, physiotherapy and splints. Over
the subsequent few years she developed wrist and 3rd proximal in-
terphalangeal (PIP) joint restriction. She was noted to have relative
short stature (9-25th centile) and some dysmorphic features, with a
prominent forehead, hypertelorism, brachydactyly and 5th finger clin-
odactyly and single palmar crease on right hand. Paediatric psych-
iatry assessment was requested aged 4, due to her unusual
behaviour and social interaction, and she was diagnosed with an
atypical autistic disorder.
By age 6, when she was first seen in paediatric rheumatology, her
joint symptoms had progressed. Clinical examination confirmed in-
flammatory polyarthritis especially of her wrists, knees, ankles and
PIP joints. She had short-lived benefit from multiple intra-articular
joint injections. She had a partial response to methotrexate but
stopped this due to poor tolerance. She had various biological ther-
apies all with limited response; etanercept for 6 months aged 10,
infliximab aged 12 stopped after 8 months due to an infusion reac-
tion, tocilizumab for 18 months from age 13 which was stopped as it
was ineffective. She has now been on abatacept for 4 years with rea-
sonable control of her arthritis.
She developed increasing back pain and stiffness with unusual radio-
graphic appearances: elongated vertebral bodies on x-ray and MRI
with endplate changes and loss of anterior vertebral body height.
She subsequently developed dystrophic toe nails. Aged 14 years she
developed seizures.
She had an extensive genetic and metabolic diagnostic work-up with
normal karyotype, normal organic and amino acids. Possible diagno-
ses including Rett’s syndrome, Smith Magenic syndrome and muco-
polysaccharidoses were excluded. Chronic infantile neurological
cutaneous and articular syndrome (CINCA), was considered but clin-
ical picture and investigations were not thought to be consistent and
no mutation in NLRP3 was identified.
At the age of 14, a genetic mutation in ANKRD11 gene, diagnostic of
KBG syndrome was identified. KBG is an autosomal dominant condi-
tion cause by mutations in ANKRD11, which has an essential role in
controlling acetylation and expression of genes during development
of the nervous system. Mutations of this gene occur at 16q24.3.
Phenotype typically includes learning difficulties and developmental
delay, macrodontia, with short stature, seizures, feeding difficulties
and autism all prominent features. Recognised skeletal features in-
clude short stature, costovertebral abnormalities, clinodactyly, but to
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 214 of 243our knowledge there are no previous descriptions of inflammatory
arthritis as a feature.
Conclusion: We describe a case of KBG syndrome with arthritis being
a key feature in her clinical picture. We suggest consideration of this
diagnosis in children presenting with arthritis in the context of devel-
opmental delay and other characteristic clinical features.
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Introduction: Immune-mediated necrotising myopathy (IMNM) is a rare
and severe subtype of Idiopathic inflammatory myopathy (IIM). It results
from an immune reaction that promotes muscle destruction with con-
sequent necrosis and regeneration, causing proximal muscle weakness.
IMNM can be idiopathic, secondary to viral infections, malignancy and
connective tissue diseases or be associated with statin administration.
Objectives: To present a clinical case of rare association of IMNM
and Autoimmune liver disease.
Methods: Description of a case report.
Results: A 15-years-old healthy boy was admitted to the Liver Unit in
April 2017 due to epistaxis and increased liver enzymes levels. A type 1
Autoimmune Hepatitis (AIH) was diagnosed (hypergammaglobulinemia,
positive antinuclear and anti-smooth muscle antibodies and histological
interface hepatitis) and he started immunosuppressive protocol with ste-
roids and azathioprine. In June 2017 he begun generalized lower limbs
myalgia. During the following months the patient had a fluctuating
pattern of muscle pain without weakness or cutaneous abnormalities. In
parallel, he maintained an oscillating increased liver enzymes and creat-
ine kinase (CK) levels (range: 100-4 610 U/L). The immunosuppressive
schedule was modified (steroid, mycophenolate and cyclosporine) but
was unsuccessful in inducing remission. In January 2018, after clinical
worsening with a limitative mechanical back pain, he was admitted for
further investigation and a clinical evaluation by paediatric rheumatolo-
gist was performed. The patient presented an extensive 12 cm right lum-
bar pain that got worsen with muscle masses palpation, without trigger
points to myofascial syndrome, and with a normal osteoarticular examin-
ation including sacroiliac manoeuvres. A muscle limb ultrasound was per-
formed disclosing muscle oedema. The anti-actine and anti-centromere
antibodies were positive, the myositis specific antibodies panel was nega-
tive. Muscle histology was compatible with IMNM as well as the electro-
myography. At present, the patient is under steroids and high doses of
mycophenolate and there were notice some improvement in muscle
complaints as well as decreased of liver enzymes' and CK levels.
Conclusion: There are only few reported adult cases about the associ-
ation of autoimmune liver diseases with IIM. In contrast to the present
case report, IMNM typically presents with a pronounced acute/subacute
symmetrical muscle weakness associated to an increased CK levels, and
myalgia may or may not be present. The finding of predominant necro-
sis with scarce inflammation in the muscle histology is a critical tool in
the diagnosis. These patients often require intensive immunomodula-
tion and are prone to relapse.
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Introduction: Sacroiliitis and spondylodiscitis of infectious origin
are uncommon. Together, they account for approximately 2-4%
of total osteoarticular infections (OAI). They usually occurs in chil-
dren with fewer than 5 years of age. The clinical presentation is
insidious, which can cause a long diagnostic delay.
Objectives: To describe the clinical characteristic and outcome of
these OAI.
Methods: Descriptive, retrospective study of the last 12 years (Janu-
ary / 2005 - December / 2017) of children <18 years diagnosed of
infectious sacroiliitis or spondylodiscitis in a tertiary hospital. Epi-
demiological, clinical and analytical variables were analyzed.
Results: During the study period 382 children were diagnosed of
osteoarticular infection, affecting axial axis in 25 patients ( 6.5%, 13
spondylodiscitis and 12 sacroiliitis), 17 were females (68%). The mean
age at onset was 25.5 ± 10 months, all of them younger than 4 years.
The mean delay time until diagnosis was 15.6 ± 8 days (3-32). Eleven
patients (44%) presented fever at some point in the evolution, being
other reasons for consultation: rejection of sitting (44%), limp (36%), pain
(28%), immobility (24%), irritability (20%) and abdominalgia or hyperlor-
dosis (both 8%). In addition, 9 patients (36%) associated previous or con-
comitant upper respiratory infection. Blood test was performed in all
patients, obtaining erythrocyte sedimentation rate (ESR) and C reactive
protein (CRP) in 22 and 23 cases, respectively. In 20 patients (80%), ESR
was over than 20 mm/h (mean 61,4 ± 28.7). On the other hand, only 8
patients (32%) had CRP higher than 20 mg/L (median 20, IQR= 28-4). The
leukocyte count was normal, and 13 patients (52%) had thrombocytosis
> 400,000. Blood cultures were negative in all patients.
Bone scan was performed in 23 patients, confirming the diagnosis in
22. The remaining 2 cases were diagnosed by magnetic resonance.
Spondylodiscitis were all located at the lumbosacral level (4 L5-S1, 3
L4-L5, 2 L3- L4, 1 L2, 1 L2-L3, 1 S1). All were treated with antibiotics
(cefuroxime axetil in 20 cases, amoxicillin clavulanic acid in 4, and 1
clindamycin). Eleven patients received intravenous treatment (mean
duration 2.5 days, IQR 3-5). The total duration of antibiotic treatment
was median 28 days (IQR 21-28). All the children had a good re-
sponse to the treatment and did not present follow-up sequelae.
Conclusion: Osteoarticular infections affecting the axial axis were in-
frequent in our hospital. Moreover, the symptoms at onset was non-
specific and without accompanying fever in more than half cases. For
those reasons, high index of suspicion is needed. The rejection of sit-
ting or irritability were complains that should put us on alert. Correct
diagnosis is essential to start treatment early, avoiding possible com-
plications. In our series the outcome was good in all cases, without
complications or sequelae.
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Introduction: Mixed Connective Tissue Disease (MCTD) is a clinical entity
characterized by a combination of signs and symptoms of Systemic
Lupus Erythematosus (SLE), Systemic Sclerosis (SSC) and polymyositis/
dermatomyositis (PM/DM) with high titers of antibodies targeting the U1
small nuclear ribonucleoprotein particle (U1 snRNP) in peripheral blood.
Pediatric Mixed Connective Tissue Disease (pMCTD), in terms of rheumatic
disease, is rare. Multiple studies have reported a frequency of 0.1 -0.5 %,
with no ethnic predisposition. Median age of onset is 11 years, with fe-
male predominance of 6:1. Only 23% of MCTD cases present in childhood.
Objectives: This study aims to describe the epidemiological, clinical
and immunological features of pMCTD in a Mexican pediatric hos-
pital in the last 5 years.
Methods: We conducted a retrospective study by reviewing the
medical records of pediatric patients treated for mixed connective
tissue disease (Kasukawa´s criteria) between January 2013 and March
2018. For each case of pMCTD the parameters studied were epi-
demiological, clinical and immunological features.
Results: We found a cohort of 7 patients with a mean age at diagnosis of
13 ± 1.2 years old, six (85.7%) patients were female. The range in the diag-
nosis delay was 2 to 60 months. The most common clinical manifestations
were arthritis (100%), Raynaud (85.7%), hand edema (71%), sclerodactyly
(71%), Pulmonary Arterial hypertension (42.9%), lung restriction (28.6%),
gastroesophageal reflux (28%), delay in voiding (14%), neurological alter-
ation (28.6%), muscle weakness (28%) and vasculitis (85.7%). Respect the
immunological features we found that hiper IgG (100%), antinuclear anti-
bodies (100%) and anti RNP/Sm (100%) were present in all the patients
while double-stranded anti-DNA antibodies were positive in 57% patients.
During follow-up, the management consisted of systemic steroids in 100%,
methotrexate in 66%, nifedipine in 57%, and ciclophosphamide in 57%.
During the evolution of the patients we identified that a patient died
secondary to an infectious process related to immunosuppressive
therapy, a patient is on induction therapy with monthly cyclophos-
phamide for pulmonary arterial hypertension and the rest of the pa-
tients are without clinical activity with therapy maintenance.
Conclusion: The EMTC is a very uncommon disease in pediatrics,
with a very variable clinical presentation, uncertain and potentially
fatal prognosis. This study suggests that, in mexican children, the ex-
pression pattern of the observed disease is similar to what has been
described in patients with pMCTD from other series.
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Introduction: Kimura’s disease, syn : eosinophilic lymphogranuloma
is a chronic inflammatory disorder of unknown aetiology with angio-
lymphatic proliferation. It is a disease of middle aged Asian males
and is seen less frequently in children.
Objectives: We describe a seven year old with steroid-dependent
Kimura disease, who responded dramatically to cetirizine (histamine H1
receptor-blocker) and montelukast (leukotriene receptor antagonist).Methods: A seven year old boy , weight 17 kg and height 111 cm, pre-
sented with complaints of multiple axillary and inguinal lymph node
swellings and fever since 2 years of age, for which he was evaluated
elsewhere and diagnosed as a case of Kimura disease. He was initially
started on oral steroids to which he responded well but lymph node
swelling and fever would recur as soon as steroids were tapered to
10mg (0.6 mg/kg/day). He was thus constantly on steroids for about
five years and showed significant growth retardation. Azathioprine was
attempted as a steroid-sparer, but was discontinued since he devel-
oped transaminitis. He was then referred to us for further management.
Results: The clinical details were reviewed and diagnosis reconfirmed
by a review of the earlier biopsy. The child was started on cetirizine
and montelukast (available as a combination) after a literature search
showed scattered reports favouring these agents as steroid-sparers in
this condition. Steroid taper was initiated. On first follow up after 6
weeks, he was afebrile and there was no adenopathy on examination.
Parent VAS was 10/10. He was continued on cetirizine and montelukast,
steroids progressively tapered and stopped in three months. He started
gaining weight (18 kg) and height (112.5 cm). Two months have
elapsed since cessation of steroids and he continues to remain asymp-
tomatic as per a recent telephonic interview with parents. We propose
to discontinue montelukast and observe him in the coming weeks.
Conclusion: Cetirizine and Montelukast should be considered as initial
steroid-sparing options in Kimura disease, especially in the pediatric age
group where they have a much safer adverse effect profile compared to
other immunosuppressives. Response to these drugs whose mechanism of
action is known should help to provide a clue to the pathogenesis of this
mysterious illness. Informed consent for publication had been obtained
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Introduction: Mutations in the ASAH1 gene cause acid ceramidase defi-
ciency (Farber disease), accumulation of the pro-inflammatory and pro-
apoptotic lipid ceramide, and a distinct set of clinical features, which can
vary greatly in severity. Typically, Farber disease presents in childhood
with polyarticular arthritis or joint contractures, subcutaneous nodules
and a hoarse or weak voice due laryngeal nodules. The prevalence of Far-
ber disease is currently unknown, but it is likely underdiagnosed due to
lack of awareness of the clinical presentation and of the availability of
diagnostic testing. Acid ceramidase enzyme replacement therapy is cur-
rently under development.
Objectives: The primary purpose of the study is to establish the nat-
ural history of Farber disease, through analysis of retrospective and
prospective data on patients, including living patients who have and
have not undergone hematopoietic stem cell transplantation (HSCT)
and deceased patients. Additionally, the goal is to establish a set of
clinical, laboratory (biomarkers), and functional data characterizing
distinct groups within this population.
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Natural History and Phenotypic Spectrum of Farber Disease” was initi-
ated in November 2017. 19 patients have been enrolled in the study to
date (9 living, 10 deceased), from 11 sites in 7 countries. Demographic
and epidemiologic data is available in these patients, as is information
about the onset of symptoms and time to diagnosis in most cases.
Results: The ratio of females to males is 8:11. 68% (13/19) of the pa-
tients enrolled were born in 2008 or later. The ages of the living pa-
tients, who may be able to participate in the prospective portion of the
study, range from 2-28 years (mean: 12.2 years), with 5/9 (55.5%) living
patients currently under the age of 12 years. All patients enrolled to
date developed joint disease (arthritis and/or contractures) and sub-
cutaneous nodules at some point over the course of their disease. In
the patients for whom this data is available, subcutaneous nodule size
ranges from 1-50mm in diameter, and the current number of nodules
per patient ranges from 1-68.
Conclusion: This is the first study to systematically collect both retro-
spective and prospective data in both transplanted and non-
transplanted patients with Farber disease. Further patients are expected
to be enrolled from additional countries and centers in 2018. The data
currently available supports clinical evidence indicating that Farber dis-
ease has a broad clinical spectrum, with symptoms and age at onset
overlapping with polyarticular JIA. It may take years for typical symp-
toms to appear together, indicating that additional awareness of Farber
disease symptoms and phenotypes among pediatric rheumatologists
may allow earlier and more efficient diagnosis.
Trial registration identifying number: NCT03233841
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Pediatric Rheumatology 2018, 16(Suppl 2):P421Introduction: Due to the paucity of randomised controlled studies
concerning vaccination in children with rheumatic diseases, the level
of evidence for recommendations for vaccinations in these children
is low. Booster doses of live attenuated vaccines might be considered
in children with rheumatic diseases treated with immunosuppressive
therapy, but data from multicentre studies are lacking. Moreover, na-
tional vaccination programs, parental obligation to vaccinate their
children and vaccine coverage rates vary greatly among countries.
Objectives: To highlight differences in the current national vaccin-
ation policies, and to develop a platform for future multicentre initia-
tives for uniform vaccination practices for children with rheumatic
diseases treated with immunosuppressive drugs.
Methods: The PReS Vaccination working group was formed during
the 2017 PReS meeting in Athens. Paediatric rheumatologists from
34 countries were invited to participate.
Results: Data were collected from 25 countries who responded. Vac-
cinations are mandatory in 12/21 European countries (Croatia, Czech
Republic, France, Greece, Hungary, Italy, Latvia, Poland, Serbia,
Slovakia, Slovenia, Ukraine). The vaccination schedules and coverage
differ among countries. The first MMR vaccine is recommended at
11-15 months-of-age in all countries and most recommend the sec-
ond dose before 2 years-of-age or at 6 years; however in Spain it is
at 2-4 years, in the UK at 3-5 years, and in Hungary, The Netherlands,
Estonia, Norway, Poland and Slovakia at the age of 9 years or later.
Mandatory programs, as compared to optional vaccination, do not al-
ways ensure higher coverage. For example, in Australia, Israel, The
Netherlands and Norway where vaccinations are optional, the vaccin-
ation rate is high, at around 95%. However, coverage for MMR fell
below 95% in Croatia, Czech Republic, Serbia and Slovenia, where
vaccination is mandatory. Vaccinations were optional in France and
Italy; however, due to low coverage, they are now mandatory.
Conclusion: There are considerable differences amongst countries in
vaccination programmes, coverage, and in parental obligation to vaccin-
ate their child. A powerful anti-vaccine campaign has gained momentum
in many countries and has resulted in a significant drop in vaccination
coverage to a level that is no longer sufficient for herd immunity. This is
especially dangerous for children with rheumatic diseases on immuno-
suppressive therapy. Our future goals are to prospectively examine the
outcomes of live vaccination in children with rheumatic diseases who are
treated with immunosuppressive drugs and hopefully to demonstrate
that booster doses of live attenuated vaccines are safe and protective.
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Introduction: Pericarditis is the inflammation of pericard and may
occur following infections, malignancy, autoimmune and autoinflam-
matory diseases. It might be acute, chronic and recurrent. It might be
life threatening by altering the hemodynamics of the heart and caus-
ing constructive pericarditis.
Objectives: The patient with TRAPS was reported.
Methods: The patient's file rewieved retrospectively. Phsical examin-
ation, laboratory test, imaging and genetic analyses results evaluated.
Results: CASE: A fifteen-year-old girl was consulted to the emergency
department with high fever and chest pain. She was then transferred
to intensive care unit due to severe pleural effusion with tachypnea
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 217 of 243and tachycardia. The pleural fluid was exudative, she had fibrinous
pericarditis. The bacterial cultures including tuberculosis were negative.
She continued to have severe respiratory distress despite pericardiotomy,
and pericardiectomy was performed. Fibrinous pericarditis was confirmed
by histochemical study of pericardiectomy material and neither malig-
nancy nor tuberculosis were detected. Histopathological examination of
pleura consisted of mainly neutrophils. In laboratory, hemoglobin was 9.4
g/dl, leukocytes were 12300/mm3, (76% neutrophil, 14% lymphocyte),
thrombocytes were 427000/mm3, C-reactive protein was 126 mg/L,
erythrocyte sedimentation rate was 89 mm/h, procalcitonin was
0.28 ng/ml, troponin was <0,01 ng/ml, and liver and renal func-
tion tests, immunoglobulin levels were normal. Anti-nuclear anti-
bodies and anti-neutrophilic cytoplasmic antibodies were found
as negative and C3, C4 levels were normal. No malignancy was
detected in the bone marrow. High dose IV prednisolone success-
fully controlled the disease. Colchicine was added due to pericar-
ditis protocol. Detailed history revealed recurrent chest pain and
fever attacks. TRAPS was suspected, and p.arg121Gln mutation in
TNFRSF1A gene was detected which was recorded as patho-
logical. She was discharged with colchicine, but had another simi-
lar attack, which was controlled by anti IL-1 treatment.
Conclusion: TRAPS, also known as Hibernian fever, is an autosomal
dominant inherited autoinflammatory disease, which is localized in
12p13 chromosome. TRAPS presents with recurrent attacks of fever
lasting up to 1-4 weeks, myalgia, periorbital edema, and serosal in-
flammation (peritonitis, pleuritis). Rarely, pericarditis is reported dur-
ing the attacks1. A study indicates that TRAPS constituted 6% of the
idiopathic recurrent pericarditis2. TRAPS and other rare autoinflam-
matory diseases should be kept in mind in the differential diagnosis
of recurrent pericarditis. Informed consent for publication had been
obtained from the parents.
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Introduction: Hyperimmunoglobulin D syndrome (HIDS) is an auto-
somal recessive periodic fever syndrome presenting with fever,
vomiting, diarrhea, abdominal pain, rash, arthralgia, and arthritis.
Objectives: Herein, we describe 4 HIDS cases in the same family.
Methods: Case 1: A 6 year old boy who applied with recurrent fever,
abdominal pain, vomiting, joint swelling and rash every month for 4
years. There was no mutation in the MEFV gene, and colchicine treat-
ment did not prevent his attacks. G18R heterozygote mutation was
detected on the MVK genome. The patient is followed without at-
tack by treatment with anti-IL-1 (canakinumab).
Case 2: A 3 year old girl, with complaints of fever, vomiting, leg pain
for 2 to 3 days every 2-3 months was using colchicine with FMF diag-
nosis but no improvement in her attacks.
Genetic analysis revealed a G18R heterozygote mutation in the MVK
gene. After the anti-IL-1 therapy attacks resolved.
Case 3: A 2 year old girl, was admitted with episodes of fever, diar-
rhea and vomiting that lasted 3-4 days, which was observed 4 times
in the last 2 months. Genetic analysis revealed a G18R heterozygote
mutation in the MVK gene. The patient is followed without attack by
treatment with anti-IL-1.
Case 4: A 8 year old girl was admitted with complaints of recurrent
fever, abdominal pain and headache. Genetic analysis revealed aG18R heterozygote mutation in the MVK gene. Following the initi-
ation of anti-IL-1 therapy, the complaints were resolved.
Results: With anti-IL1 therapy, 4 siblings are followed without attacks.
Conclusion: Symptoms may be different in patients with HIDS even
if they are the members of the same family or carrying the same mu-
tation. HIDS should be considered when recurrent fever episodes are
accompanied by rash, arthritis, vomiting and diarrhea. Anti-IL1 treat-
ment is very effective in reducing symptoms and prevention of amyl-
oidosis. Informed consent to publish had been obtained.
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Introduction: Cryopyrin-associated periodic syndromes (CAPS) are a
group of rare congenital auto-inflammatory diseases with onset in
the first year of life with the advent of fever, urticarial rash and vari-
ous options for joint removal - from arthralgia to recurrent and per-
sistent arthritis in severe cases, as well as damage to the nervous
system.
Objectives: Consider the clinical case of the child with cryopirin-
associated periodic syndrome.
Methods: The laboratory - instrumental examination was conducted
of 1 year and 8 months old boy, who entered the rheumatological
department of the National Medical Research Center of Children’s
Health with the systemic juvenile idiopathic arthritis.
Results: The patient A. entered the rheumatological department with
diagnosis systemic JIA. Complaints: fever up to 39.0°C, a rash, pain
and limitation of movements in the joints. On examination: urticarial
rash all over the body, hepatosplenomegaly, lymphadenopathy, poly-
arthritis with involvement of interphalangeal joints of hands and feet,
wrists, elbows, hips, knees, ankles, temporomandibular joints and the
cervical spine. Blood tests: hypochromic anemia (Hb 82 g/l), throm-
bocytosis (platelets 650 x 109/l), ESR - 45 mm/h, CRP level - 96.88
mg/l, ferritin - 2334.86 ng/ml (norm of 15 - 80 ng/ml). The child was
consulted by the audiologist and ophthalmologist - the pathology of
hearing and vision was not presented. The child is suspected of an
auto-inflammatory syndrome, because of the severe condition,
debuting in first year and the resistance to the standard anti-
rheumatic therapy (prednisolone 13 mg/day, tocilizumab 12 mg/kg
once every 14 days within one month). Exon 04 of the NLRP3 gene
with adjacent intron regions were examined by the method of direct
automatic sequencing. A mutation c.943A> G in the heterozygous
state, resulting in the amino acid substitution p.I315V, was detected.
A previously prescribed topic was described in patients with
cryopyrin-associated periodic syndrome. The "Cryopyrin - associated
periodic syndrome” diagnosis was confirmed by the previous re-
search study results, pathogenetic therapy was prescribed by giving
the genetically engineered biological agent - canakinumab (interleu-
kin 1 inhibitor) for subcutaneous injection at a dose of 4 mg/kg (52
mg) once every 4 weeks. After the first injection of canakinumab, the
rash disappeared, but fever, hepatosplenomegaly, lymphadenopathy
persisted, macrophage activation syndrome developed (ferritin -
3318.01 ng/ml, white blood cells 6.71 x 109/l). The child was given
glucocorticoids for oral administration (prednisolone at a dose of 2
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 218 of 243mg/kg, 25 mg per day) and for injection (dexamethasone 20 mg
/m2 / day in 2 divided doses). The therapy was effective, patient`s
condition improved significantly - fever, rash, hepatosplenomegaly,
lymphadenopathy, arthritis resolved (Hb 111 g/l, ESR - 3 mm/h, CRP
level – 1.48 mg/l, ferritin – 25.55 ng/ml). The second and third injec-
tion of canakinumab gave no reaction. Intravenous glucocorticoids
were withdrawn the dose of oral GK was reduce to 18.75 mg/day. At
the moment, the patient is on therapy (canakinumab 52 mg once
every 4 weeks, prednisolone 5 mg per day) for more than six months
without signs of systemic inflammation.
Conclusion: Cryopyrin - associated periodic syndrome, with onset at
an early age, characterised by an aggressive course and inefficiency
of glucocorticoid therapy. To verify the diagnosis and to provide tar-
geted therapy to children with a clinical picture of systemic juvenile
arthritis, a molecular genetic study should be performed to exclude
or confirm a monogenic autoimmune syndrome. Informed consent
to publish had been obtained from the parent.
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Introduction: Early onset sarcoidosis (EOS) is characterized by a triad of
polyarthritis, uveitis and rash. The familial cases, manifesting the classic
clinical triad and an autosomal transmission pattern, have been termed
Blau syndrome (BS). Mutations involve the NOD2 gene.
Objectives: To describe clinical presentation and treatment strategies
in a patient affected by EOS.
Methods: Case report of a patient affected by pediatric sarcoidosis re-
ferred to Pediatric Rheumatology Unit of Federico II University of Naples.
Results: The patient (female, six years old) was referred to our Unit at
the age of 2 years. The family history revealed a mother with rheuma-
toid arthritis and visual loss due to panuveitis. The clinical history dis-
closed that at the age of 12 and 15 months the patient had two
episodes of diffused rash spontaneously resolved in two weeks. From
the age of 18 months recurrent hip pain, defined as transient synovitis
of the hip, was reported. It was treated successfully with non-steroideal
antinflammatory drugs (NSAID) but pain would reappear once stopped
the treatment. Clinical evaluation showed polyarticular symmetrical
arthritis of wrists, elbows, knees, proximal interphalangeal (PIP) joints.
Polyarticular Juvenile Idiopathic Arthritis (JIA) diagnosis was made
and treatment with NSAID and Methotrexate was started without
significant improvement, therefore Etanercept was added and
NSAID stopped. Screening of uveitis was performed every six
months. Persisting arthritis of right wrist after 7 months of ther-
apy, ultrasound was performed showing tenosynovitis. Therefore,
she underwent intra-articular injection of glucocorticoids with par-
tial response. At the age of 4 years, she presented papuloerythe-
matous rash, mainly on the trunk, infiltrated and confluent in
plaques, so skin biopsy was performed resulting consistent with
sarcoid-like granulomatous disease . Suspecting BS molecular ana-
lysis was done. At the age of 5 years, she presented scotoma
and visual loss; the ocular assessment found bilateral anterior
uveitis and posterior bilateral synechiae. She started systemic
glucocorticoid therapy and shifted from Etanercept to Adalimu-
mab with improvement of both ocular and articular disease. The
molecular analysis of NOD2 showed missense mutation R334W
consistent with BS. The ocular disease evolved into iridolenticular
synechiae and band keratopathy. She started topical treatment
with improvement. Currently, the articular and cutaneousmanifestations are controlled by the combined therapy with Ada-
limumab and Methotrexate. The ocular disease is steady.
Conclusion: The patient presents typical clinical manifestations of
pediatric sarcoidosis, confirmed by skin biopsy. R334W is one of
the most common mutations reported in the international Blau
registry. The presence of typical clinical manifestations, NOD2
mutation and family history led to the diagnosis of Blau Syn-
drome. The molecular analysis of NOD2 gene in the mother is
ongoing.
Informed consent for the publication was obteined from the parents.
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Introduction: Sacroiliitis has rarely been reported in patients with familial
Mediterranean fever (FMF), especially in the pediatric population.
Objectives: In this report we present patients with FMF related
sacroiliitis who had very early disease onset.
Methods: Two cases with documented sacroiliitis at 3 and 4.5 years
of age were presented.
Results: A 5-year-old male patient had the complaints of intermittent
hip pain and limping attacks with duration of 15 days, started at 2
years of age. He had also recurrent fever attacks and his father has
FMF. At 3 years of age sacroiliac joint magnetic resonance imaging
(MRI) showed left sided sacroiliitis and MEFV gene analysis was com-
patible with homozygous p.M694V mutation. HLA-B27 was negative.
Colchicine was commenced and his complaints improved. Seven
months later hip pain and limping attacks started again and de-
scribed partial improvement with ibuprofen. At the age of 5 years,
control MRI revealed bilateral sacroiliitis. Salazopyrin was added to
his treatment.
The second patient is a 7 year old boy who had the diagnosis of ul-
cerative colitis at the age of 14 months. He was referred to rheuma-
tology clinic due to hip pain, low back pain and gait disturbance at 3
years of age. He had family history of FMF and ongoing elevated
acute phase reactants but no typical FMF attacks. HLA-B27 was nega-
tive. Mutation analysis revealed p.M694V/p.M680I, sacroiliac joint MRI
showed pelvic enthesitis and colchicine was started. His complaints
improved. At the age age of 4.5 years, due to intermittent complaints
and elevated acute phase reactants, control MRI was performed and
showed bilateral sacroiliitis. Adalimumab was commenced. He had
no complaints thereafter.
Conclusion: Familial Mediterranean fever related sacroiliitis can be
seen in very small children. Furthermore, in patients with early
onset sacroiliitis FMF should be investigated in the differential
diagnosis. Written consent for publication was obtained from the
parents
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gression of proteinuria due to amyloidosis secondary to familial
Mediterranean fever (FMF) by colchicine and/or anti-interleukin 1
treatment, there is no study about response to therapy at tissue level
of amyloidosis secondary to FMF (1,2).
Objectives: We aimed to evaluate the influence of colchicine and
anti-interleukin 1 treatment at tissue level in a case of FMF with
amyloidosis.
Methods: A 10-year-old boy presented with nephrotic range pro-
teinuria (83.5 mg/m2/hour, 2 g/day) and high level acute phase
reactants in May 2011. First kidney biopsy revealed renal amyloid-
osis. Mediterranean fever mutation test showed homozygous for
M694V, R202Q and E148Q mutations. Colchicine (1.5 mg/day) and
enalapril (7.5 mg/day) was commenced. Although the proteinuria
was reduced to 10 mg/m2/hour within 2 years by this treatment,
acute phase reactants did not return to normal values. Therefore,
second kidney biopsy was performed in July 2013, since ongoing
amyloidosis and subclinical inflammation, anti-interleukin 1 (ana-
kinra 2mg/kg/day) was commenced as an additional treatment to
colchicine and enalapril. Two months later, proteinuria (<4mg/m2/
hour) and acute phase reactants were normal. In Semptember
2015 anakinra was switched to canakinumab (2mg/kg/month). Re-
mission was successfully maintained, he didn’t experience attacks,
after switching to canakinumab. After obtaining from parental
and the patient consents, third kidney biopsy was performed in
April 2017. Creatinine clearance never deteriorated during follow-
up period. Three renal biopsies were re-evaluated and compared
according to the hystopathological classification, scoring and
grading system established by Sen et al. (4).
Results:The renal amyloidosis
scoring and grading
system items
First Biopsy
(May 2011)
Second Biopsy
(July 2013)
Third Biopsy
(April 2017)
Class of glomerular
amyloid deposition
(GAP)
Class II
Mesangial minimal
amyloid deposition
+ 2
Class III
Focal
mesangiocapillary
amyloid deposition
(including nodular
amyloidosis)
+3
Class III
Focal mesangiocapillary
amyloid deposition
(including nodular
amyloidosis)
+3
Percentage of
glomerular amyloid
deposition (GA%)
%10-25
+2
%25-50
+3
%25-50
+3
Vascular amyloid
deposition (VA)
Moderate
+3
Focal
+2
Minimal
+1
Interstitial amyloid
deposition (IA)
Minimal
+1
Absent
0
Minimal
+1
Interstitial fibrosis
and tubular
atrophy (Ifib)
Absent
0
%10-25
+2
%10-25
+2
Interstitial
inflammatory
infiltration (Iinf)
%1-10
+1
%1-10
+1
%1-10
+1
Glomerular
sclerosis (GS)
Absent
0
Absent
0
Absent
0
The renal amyloid
prognostic score
(RAPS)
9 11 12
Amyloid grade II II IIAlthough the renal amyloid grade remained stable, RAPS progressed
slowly.
Conclusion: We concluded that anti-interleukin 1 treatment in patient
with amyloidosis secondary to FMF could not stop progression at tissue
level, but it could lead to clinical improvement. We need to new treatment
strategies that not only to remove the inflammation, but also to dissolve
amyloid deposits. Informed consent for publication had been obtained.
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Introduction: The modern period of studying different pathogenetic
links of the course of JIA is characterized by a special attention to the
formation of changes in bone tissue. Violations of the bone tissue due
to a decline in mineral bone density can be registered as the first signs
of arthritis and in later stages of the disease.
Objectives: To evaluate the possibility of non-drug correction of
vitamin d deficiency for the prevention of bone metabolism dis-
orders in children with articular form of JIA.
Methods: The study included 32 patients with articular JIA and 28 chil-
dren with other arthritis, which were divided into three equal and com-
parable groups. In each of the groups applied different methods of
correction of vitamin D deficiency, namely: subgroup A – children re-
ceive a balanced diet and a specialized product for enteral of food con-
taining 52 IU of vitamin D3 100 ml (non-medicament correction of
deficiency/insufficiency of vitamin D); subgroup B – children only re-
ceived nutrition, subgroup С - children were on medical correction of
deficiency/insufficiency of vitamin D officinal drugs.
Results: In subgroup "А" all children before correction were in deficit
(75 %) or deficiency (25%) of vitamin D. After correction, the proportion
of children with a level of 25(OH)D below 30 ng/ml did not exceed
30%. Before the beginning of the correction in all children with oligoar-
ticular variants (OAV) of JIA from subgroup “A” vitamin D deficiency
was registered (below 20 ng/ml), after correction more than 62% of the
examined children reached the level of 25(OH)D more than 30ng/ml in
serum. With polyarticular variant (PAV) JIA succeeded in all children
with vitamin D insufficiency increase its level in blood serum above 30
ng/ml, while 50% of children with a deficiency to increase the level of
vitamin D in the blood serum before 21-29 ng/ml. The use of non-
pharmacological correction of vitamin D deficiency in children with
other arthritis in history has allowed more than 80 % of patients to
achieve normal values of 25(Oh)D in serum (more than 30 ng/ml). In
subgroup "B" 95% of children at the beginning of the study had a level
of 25(OH)D in serum below 30 ng/ml. After 4 weeks of observation,
there was a slight improvement in the indicators 25(OH)D in serum,
and the proportion of children who have overcome the threshold of 30
ng/ml, increased to 10%. Among children with other arthritis in the
anamnesis it was possible to achieve a twofold increase in the pro-
portion of patients with a level of 25(OH)D in serum more than 30
ng/ml. In subgroup "C" 90% of children at the time of the study
had vitamin D deficiency (serum 25(OH)D level below 20 ng/ml),
only 2 patients had vitamin D level in the zone of insufficiency (21-
29 ng/ml). After 4 weeks of medical correction in patients of this
subgroup, the proportion of children who overcame the threshold
of 30 ng/ml was 85%. In the subgroup "C" after 4 weeks of medical
correction in all patients with polyarthritis, in 90% of children with
oligoarthritis and in 87,5% of cases in children with other arthritis
in the history noted a positive result-the concentration of 25 (OH)D
in serum levels above 30 ng/ml.
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 220 of 243Conclusion: The increase in the subgroups "A" and "C" after the 4-
week course as a non-pharmacological and pharmacological correc-
tion of deficit of 25(Oh)D in serum in the proportion of children with
a normal supply of vitamin D is from 0 to 75%, and 90% of cases, re-
spectively, demonstrates the effectiveness of the applied methods,
and the lack of significant differences in the achieved level of
25(Oh)D in the serum of patients in these subgroups confirms the
possibility of using non-pharmacological correction of vitamin D defi-
ciency for the prevention of osteopenia, based on the use of special-
ized products for enteral nutrition.
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Introduction: Important advances in management of JIA have been
made over the last few decades. However, there are still differences
with regard to outcomes across European countries.
Objectives: To assess disease activity, functional status and damage
in JIA patients of all subtypes followed in a southeastern Pediatric
Rheumatology tertiary center (Greece).
Methods: JIA patients consecutively seen in a Pediatric Rheumatology
reference center between January and April 2018 were enrolled in this
observational cross-sectional study. Outcome measures included num-
bers of active and limited joints, physician’s VAS of overall disease activ-
ity, parent’s VAS of global wellbeing and pain, CHAQ, articular and
extra-articular damage. Criteria for inactive, low, moderate and high dis-
ease activity were applied [1; 2]; for patients with enthesitis-related
arthritis, (ERA) the absence of enthesitis was an additional criterion.
CHAQ score, overall wellbeing and pain scores were divided into 4 cat-
egories: 0 (no disability), >0 and ≤0.5 (mild disability), >0.5 and ≤1.5
(moderate disability), and >1.5 (severe disability), as previously de-
scribed [3]. For statistical analysis, non-parametrical tests were used.
Results: A total of 24 JIA patients were included. Our cohort comprised
67% oligoarticular JIA, 12% polyarticular RF-negative JIA and 21% ERA
patients with median disease duration of 1 year (range 1 month - 15
years). Treatment comprised NSAIDs (54%), MTX (71%), intra-articular
corticosteroids (50%), systemic corticosteroids (25%) and biotherapy
(38%). Criteria for inactive disease and low, moderate and high disease
activity were met by 13% and 8%, 50%, 29% of patients, respectively.
Uveitis developed in 13% of patients, all with oligoarticular JIA. The me-
dian value of CHAQ score was 0 (range 0-1.875). The majority of pa-
tients had no or mild functional disability (88%) and pain (63%);
however moderate or severe overall well being impairment was
present in more then half of the patients (58%). Within JIA subgroups,
ERA patients had significantly worse scores for CHAQ, VAS wellbeing
and pain. CHAQ significantly correlated with disease activity (p<0.0001),
physician’s global VAS (p<0.0001) and with VAS scores for overall well-
being (p=0.0009) in altogether JIA patients. Articular and extra-articular
damage were found in 8% and 13% of patients, respectively.
Conclusion: Conclusion. In the present cohort, the majority of patients
had moderate disease activity but good functional scores, probablyrelated to the short disease duration. ERA patients still represent a man-
agement challenge. A good control of disease is essential in order to pre-
serve the functional abilities and the overall wellbeing of JIA patients.
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Introduction: Cystic ganglionosis is a benign condition whereby
multifocal soft tissue masses arise adjacent to joints and tendons.
Management is conservative unless there is damage to underlying
bone in which case surgical resection is rarely indicated.
Objectives: We present the case of an 18-month old girl, who pre-
sented for assessment of multiple soft tissue masses on her hands
and feet that had developed over the preceding 4months.
Methods: She was otherwise well and there was no family history of
note. Blood tests including full blood count, inflammatory markers,
thyroid function, renal and bone profile were normal. On examin-
ation, she was noted to have painless multiple soft tissue swellings,
varying in size from 0.5cm to 4cm across her phalanxes and the dor-
sum of her feet. These were raised with no overlying skin changes.
An xray of her foot showed no evidence of bone or joint space ab-
normality. She went on to have an ultrasound of her right foot,
where multiple well defined simple fluid structures consistent with
ganglion cysts were evident. This was confirmed with a MRI of her
right foot, which showed multiple simple cysts adjacent to and com-
municating with the joints of the foot, predominantly the tarus.
Results: A diagnosis of cystic ganglionosis was made and she has been
referred to the National Centre of Rheumatology for further review.
Conclusion: Cystic ganglionosis is rare in children and to our know-
ledge this case is only the third such case reported in a child less
than 12yrs of age.[i] [ii] Informed consent to publish had been ob-
tained from the parent.
[i] Meyer, N.P., Meyers, A.B., Szabo, S. et al. A rare case of cystic gang-
lionosis in a child with associated imaging findings. Skeletal Radiol.
2016 Mar45(30: 419-26.
[ii] Shinawi M, Hicks J, Guillerman RP, et al. Multiple ganglion cyst
(‘cystic ganglionosis’): an unusual presentation in a child. Scand J
Rheumatol. 2007 Mar-Apr;36(2):145-8.
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Introduction: Hyperimmunoglobulin E syndrome (HIES) is a rare pri-
mary immunodeficiency disease characterized by elevated serum im-
munoglobulin E levels, recurrent skin and lung infections, chronic
dermatitis and various connective tissue and skeletal abnormalities.
Objectives: To investigate the effectiveness of orthosis and cilinical pila-
tes exercises for eliminating knee joint deficits in the presence of HIES.
Methods: 12,5 years old boy with HIES, applied to the rheumatology de-
partment with complaints of the weakness and stiffness of the gastrocne-
mius muscles and effusion on the knees for the last 2 months. It was
reported that the complaints were relieved by removal of fluid from the
patient's knees, but there was an abnormality in the direction of the genu
valgus in the knee and the development of walking difficulty due to it.
The patient was directed to physiotherapy at this stage. A goniometric
measurement was made for knee joint positional sensation while lying on
the back of the patient and antropometric measurement was made for
the edema. For functional evaluation, observational walking analysis, 10 m
walking test, time up and go test (TUG) were performed. The Childhood
Health Assessment Questionnaire (CHAQ) was administered for activities of
daily living and pain. Exercise training was given once a week for 8 weeks.
The home exercise program was given for other days. Clinical Pilates exer-
cises were given for the proprioception and muscle strength. It was de-
cided to support the knee with a double articulated orthosis covering the
knee and ankle to increase medial-lateral control. The skin was followed
up frequently and edema-related orthosis adaptations were made.
Results: After 8 weeks of training, improvement in knee position sensa-
tion, TUG, CHAQ scores was observed (Table 1). However, the improve-
ment observed until the sixth week was delayed due to the effusion on
the knees in the seventh week. This decline was reflected in the results
of anthropometric measurements and changes in pain scores at week 8.
Conclusion: In the case of HIES, selected clinical pilates exercises for
ankle and knee joints and orthosis practice was found to be benefi-
cial for the patient's walking. Considering the attacks of the disease,
it was concluded that the patient should be evaluated at frequent in-
tervals. Informed consent to publish had been obtained.
Disclosure of Interest
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scores
First Assessment Second Assessment
Edema:
Antropometric measurements
Right Left Right Left
Middle of the knee (cm) 38,5 41,5 43 43
Middle of the calf (cm) 24,8 26,4 27 36
Ankle (cm) 28 20,5 29,5 23
Perception of knee position:
Femur-tibia angle (degree)
30o 25o 11o 13o
TUG (sec) 13,3 9,3
10 m walk (sec) 11,93 18,73
CHAQ 1,125 0,875
Pain (cm) 5,1 5Immunoregulation and basic science
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Introduction: Pericarditis, pleuritis and/or peritonitis can be
present in infectious, malignant or inflammatory processes. In-
flammatory serositis are common associated with rheumatologic
and auto-inflammatory diseases. There are other conditions that
may be complicated by a transitory autoimmune reaction respon-
sible by reactive inflammatory serositis: Inflammatory Serositis not
Rheumatologic nor Infectious (ISnRnI).
Objectives: To describe the different etiologies, treatment and evolu-
tion of ISnRnI.
Methods: Retrospective study of inflammatory serositis observed
in the Pediatric Intensive Care Unit and/or the Pediatric Rheuma-
tology Department of our hospital in the last 30 years.
Exclusion criteria: Chronic rheumatologic, auto-inflammatory and in-
fectious diseases.
Results: Twenty-two cases of ISnRnI were selected: 62,5% male,
with a median age of 9 years. Thirty-six per cent had pericardial
effusion only, 46% had both pericardial and pleural effusions and
18% had poliserositis (pericardial, pleural and peritoneal). Seven
were idiopathic, and 15 were considered postpericardiotomy syn-
drome: 7 post cardiac surgery, 2 post cardiac catheterization, 3
related to chest trauma, 1 following surgery for pectus excavatum
and 2 were diagnosed with an anterior mediastinal mass.
Fever, chest pain and respiratory signs were the most frequent
symptoms and 3 patients had cardiac tamponade at presentation.
The median of days at the beginning of the symptoms, in “post-
pericardiotomy syndrome” cases, was 33 days (min. 0 days; max.
180 days).
The median diagnostic delay was 2 days (min. 0 days; max. 120
days). Eighty-six per cent of the patients was admitted in the In-
tensive Care Unit. Antibiotics were initiated in 86% of the pa-
tients. Nonsteroidal anti-inflammatory drugs (NSAIDs) were used
in 14 patients, 5 were managed with NSAIDs and colchicine and
5 patients received corticosteroids. Pericardiocentesis was per-
formed in 46% of the patients, thoracentesis in 9% and both
techniques in 27% of the patients. Recurrence was observed in 8
(36%) patients, median days after the first episode being 35 days. One
patient died with cardiorespiratory arrest during pericardial drain
replacement.
Conclusion: Different conditions from rheumatologic and auto-in-
flammatory diseases can cause serositis. Any anterior mediasti-
num procedure or trauma can induce an immunologic reaction
with inflammatory serositis, such as postpericadiotomy syndrome.
Both diagnostic delay and unnecessary antibiotic use are frequent
in these cases. NSAIDs and colchicine are essential in the man-
agement of inflammatory serositis, with oral corticosteroids re-
served for complicated cases. Colchicine is useful in preventing
the frequent relapses.References
1. Castellani C, Saxena AK. Pleural and Pericardial Associations After Minimal
Pectus Repair. In: Saxena AK. Chest Wall Deformities. Springer-Verlag Hei-
delberg, 2017:383-387.
2. Gouriet F, Levy PY, Casalta JP. Etiology of Pericarditis Cohort of 1162
Cases. Am J Med. 2015;128(7):784.e1-8.
3. Yukumi S, Suzuki H, Kashu Y. Postpericardiotomy syndrome after
thymothymectomy: report of two cases. Gen Thorac Cardiovasc Surg.
2012;60(7):462-4.
TURKISH (n=13) BRITISH (n=13) p
Age 12,9±1,38 12,9±1,38 1,000
BMI 21,07±3,05 20,63±6,31 0,309
Sex 9F/4M 9F/4M 1,000
CHAQ 0,33±0,34 0,87±0,87 0,202
Active Joints 0,54±0,87 1,17±1,52 0,324
Limited Joints 0,33±0,65 1,83±2,55 0,045
Parental VAS 1,38±2,06 5,46±2,87 0,001
Physician VAS 1±2,08 4,09±2,58 0,003
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 222 of 2434. Imazio M, Hoit BD. Post-cardiac injury syndromes. An emerging cause of
pericardial diseases. Int J Cardiol. 2013;168(2):648-52.
5. Raval J, Nagaraja V, Eslick GD. The Role of Colchicine in Pericarditis – A
Systematic Review and Meta-analysis of Randomised Trials. Heart Lung Circ.
2015;24(7):660-6.
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Introduction: Acute rheumatic fever (ARF) is an autoimmune disease
following group A streptococcal (GAS) infection. Despite being rare,
in Latvia new cases still occur. RF remains a clinical syndrome which
has variable manifestations according to genetic predisposition,
prevalence of GAS strains, and socio economical conditions. There
are data that genetic susceptibility to RF is linked to HLA class II al-
leles. However, studies in different populations have given conflicting
results of susceptibility and/or protective alleles [1]. In Latvian pa-
tients diagnosed with RF between 1995 and 2001, DRB1*07 allele
was associated with the disease [2]. Since 2001, 27 newly diagnosed
RF cases have been reported in Latvia. Therefore, a thorough under-
standing of immunological mechanisms involved in the development
of RF is required.
Objectives: To describe the clinical characteristics of ARF in children in
Latvia between 1995 and 2016 and to investigate immunogenetic
markers of HLA-DRB1; -DQB1; -DQA1 in patients diagnosed with RF since
2001.
Methods: Part A: A retrospective study included 96 children diagnosed
with RF between 1995 and 2016 at Children’s Clinical University Hospital
(CCUH). We analysed medical case reports, evaluating clinical and labora-
tory data and compliance with the Jones criteria. Statistical analysis was
performed using SPSS Statistics.
Part B: A prospective study included 21 out of 27 patients diagnosed with
RF between 2001 and 2016, and 100 healthy controls. Patients were ge-
notyped for HLA-DRB1; -DQB1; -DQA1 using RT-PCR with sequence-
specific primers. Statistical analysis was performed using DOS StatCalc
program, Cochran-Mantel-Haenszel test and Fisher’s exact correction.
Results: Part A: Among 96 RF patients 64.6% (n=62) were boys. The age
of patents at time of diagnosis varied between 4 and 17 years, the me-
dian age was 10 years (IQR 5-15). Carditis (85.4%) and polyarthritis
(42.7%) were the most frequent Jones criteria. Most commonly (in 41.5%
of cases) patients had either mitral valve or multivalvular (MV+AV) lesions.
Sydenham's chorea occurred in significantly fewer patients (16.7%). Ery-
thema marginatum and subcutaneous nodules were rarely observed
(10.4%, 1% respectively). Of the minor Jones criteria the most common
were arthralgia (81.3%), elevated inflammatory markers (79.2%) and fever
(61.5%).
Part B: Significant associations were found between the RF and control
groups. Alleles DRB1*04:01 (OR=1.28, p=0.027), *07:01 (OR=9.8, p=0.001)
and *11:01 (OR=1.38, p=0.029) were more often observed in the group
with RF and described as risk alleles. The risk variants were also
DQB1*03:01 (OR=1.13, p=0.01), *03:02 (OR=2.12, p=0.017), *04:01-2
(OR=1.6, p=0.01) and DQA1*02:01 (OR=1.90, p=0.015), *03:01 (OR=1.75,
p=0.018) alleles. The frequencies of DQB1*06:02-8 (OR=0.46, p=0.019)
and DQA1*05:01 (OR=0.99, p=0.001), *06:01 (OR=0.67, p=0.01) alleles
were decreased and described as protective for RF.
Conclusion: ARF most commonly occured in school-aged children, and
boys were more affected by the disease. Clinical presentation was typical
with cardiac (85.4%), polyarticular (42.7%) and neurological involvement(16.7%). Our study confirms that certain HLA class II alleles are associated
with risk or protection from RF.
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Introduction: Juvenile Idiopatic Arthritis (JIA) is one of the most com-
mon chronic, rheumatic diseases in children. The prevalence of disease in
a systematic study is reported to be 1,6-23/100,000 in Europe. In Turkey,
this ratio has been reported as 6.4/100.00.
Objectives: The aim of this study is to compare the characteristics of
children with JIA in the Turkish and British communities.
Methods: The study included children of the same age and sex, diag-
nosed with JIA who were followed in the Pediatric Rheumatology De-
partment of the Hacettepe University İhsan Doğramacı Children's
Hospital and the Great Ormond Street Hospital for Children. The Child
Health Assessment Questionnaire (CHAQ) was used to assess the general
health status of children, the visual analogue scale of the clinician and
the family was used to assess the general condition of the child. Demo-
graphic data and active and limited joint numbers were recorded.
Results: A total of 26 children participated in the study (n=13 for Brit-
ish, n?13 for Turkish). There was no difference in age, diagnosis, sex,
CHAQ, and number of active joints in the two groups (p>0,05). How-
ever, there was a difference between limited joints and general
health assessments from family and clinician (p<0,05).Conclusion: As a result of this pilot study, there was no difference in
the CHAQ scores of children with JIA when age and gender matched,
but there were differences in the general situation assessment be-
tween the family and the clinician. This study will be continued by
increasing the number.
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Introduction: Harlequin ichthyosis (HI) is the most severe variant of
autosomal recessive congenital icthyosis and it is due to mutations
in ABCA12 gene. HI is clinically characterized at birth by hyperkera-
totic plates covering the entire body, ectropion, eclabium, poorly de-
veloped ears, and joint contractures. Inflammatory joint involvement
has been rarely described. [1] The management of polyarthritis in pa-
tients with HI is challenging, due to the difficult balance with an in-
creased infectious risk and with disease’s progression. Moreover little is
known about effects of conventional DMARDs and biologics on dermato-
logical manifestations.
Objectives: We report the case of young boy with HI who developed
a polyarthritis successfully treated with intra-articular steroid injec-
tions and methotrexate.
Methods: We present cinical details of young boy with HI who devel-
oped a polyarthritis. Written informed consent for publication of his
clinical details and clinical images was obtained from the patient.
Results: A 6 year-old male with HI was referred to our rheumatology
centre because of chronic polyarthritis. The child was born at term
with classical features of HI. During his first years of life he was hospi-
talised several times due to severe infections. At 4 years of age he
developed chronic arthritis with symmetrical involvement of knees;
suspecting a septic arthritis associated with HI, he was unsuccessfully
treated with antibiotics. Two years later he presented to our centre
with erythrodermic skin, joint contractures, severe ectropion. Swell-
ing, pain and severe limitation of motion of hips, knees, ankles, mid-
feet, wrists, elbows and left shoulder was detected. The patient was
unable to walk since 2 years. Laboratory examinations showed micro-
cytic anemia, mild leukocytosis, thrombocytosis and mild elevation of
C-reactive protein (0.79 mg/dl). Antibodies to nuclear antigens, ex-
tractable nuclear antigens, cyclic citrullinated peptide and rheuma-
toid factor were negative. Uveitis screening was negative. He was
treated with multiple intra-articular corticosteroid injections (IACI) in
both knees, wrists, elbows, and ankles and he was started on metho-
trexate; due to his severe dermatological involvement oral route was
preferred. One month later a dramatic response to treatment was ob-
served and the child started walking again. A limitation of motion at
the mid-feet and ankles persisted. Considering the brilliant response to
injective treatment, a multiple ultrasound-guided IACI in the mid-feet
(previously not injected) is going to be performed at this time. We did
not observe any adverse events or infections related to the treatment so
far (almost two months follow up).
Conclusion: To the best of our knowledge this is the youngest HI
patient with polyarthritis described so far, [2,3] and the first one
treated with IACI. The increased susceptibility to infection and
the growth retardation reported in children with HI make sys-
temic glucocorticoid therapy and global immunosuppression un-
desirable. IACI allows to avoid most of the systemic side effects
of glucocorticoid treatment and results in a more effective and
rapid improvement of articular function. In our patient, combined
treatment with IACI and methotrexate, successfully controlled ar-
ticular symptoms and improved his quality of life. Informed con-
sent to publish had been obtianed.
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Introduction: HLA-B27 plays an important role in the classification of Ju-
venile idiopathic arthritis (JIA) and it is associated with enthesitis related
arthritis1, .spondyloarthropathies and reactive arthritis.2
Objectives: Our objective is to investigate associations of HLA-B27
and the joint involvement in JIA patients and to determine which of
the JIA subtypes most frequently has positive HLA-B27.
Methods: The retrospective analysis included 21 HLA-B27 positive JIA
patient hospitalized in a referral rheumatology centre in the period of
two years Patients were followed for sixth months. The diagnosis of
JIA was based on criteria by the International League of Association for
Rheumatology (ILAR).3 Detection of HLA –B27 was done by using a
DNA-based PCR-SSP test.
Results: In our group of 21 HLA B27 positive JIA patients, there were
14 boys (66%) versus 7 girls (33%)
The age of JIA onset was 8.4 years (range: 3.2-15 y). Most frequently in-
volved joint was ankle in 12 patients (57.1 %), followed by knee joint (9
patients -42.8%). Small joints of hands were inflamed in 7 patients (33%)
and feet and as well as hip joint in 6 children (28.5%). Sacroileitis was de-
tected in 5 patients (23.8%). Uveitis was diagnosed in 2 children (9.5%)
and both of them were boys.
Most frequently diagnosed JIA subtype was enthesitis related arthritis
(ERA) in 8 patients (38.1%), followed by an oligoarticular JIA in 7 patients
(33%) and polyarticular JIA in 5 children (23.8%). One patient could not fit
any JIA category so he was diagnosed as having undifferentiated JIA.
Conclusion: HLA-B27 antigen can predict development of ERA in chil-
dren. ERA is usually treatment resistant so knowing HLA B27 status
could help in more aggressive therapy approach.
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Introduction: There are multifactorial causes of decrease in bone
mass in JIA patients which correlate with the duration of active disea-
se.By measuring the vitamin D level we can assess the deficiency or
insufficiency earlier and can predict the risk of osteoporotic bone
fracture and give appropriate supplementation of vitamin D and
calcium.
Objectives: This study was done to determine the status of serum
25(OH)D in patients with JIA and to see the relationship among vari-
ous subtypes and disease duration.
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 224 of 243Methods:
It was a cross sectional study. Thirty newly diagnosed cases ofJIA at-
tending the pediatric rheumatologyclinicof Bangabandhu Sheikh
Mujib Medical University (BSMMU), Dhaka, BangladeshfromJuly 2014
to December 2015 were included. Thirty age and sex matched con-
trol were selected. Serum 25(OH)D was measured in cases and
controls.
Results: Among JIA patients, 60 % and among controls 33% had
hypovitaminosis D. In JIA group the mean level of serum 25 (OH) D
was lower than control group and the result is statistically significant
in cases of polyarticular JIA and systemic JIA(SJIA).There is significant
difference of the mean values of vitamin D levels in JIA and control
groups for the cases of hypovitaminosis D. Level of 25(OH)D was de-
creased as disease duration increased.
Conclusion: More than half of JIA patients had hypovitaminosis D.It
is more significant in cases of polyarticular JIA (RF negative) and sys-
temic JIA(SJIA).There was negative relationship between 25(OH)D
level and disease duration.
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*p-value JIA(n=30)
Mean±SD
Control(n=30)
Mean±SD
Oligoarticular (n=4) 34.83±8.27
0.37
ERA (n =7) 29.38±11.57
0.58
Polyarticular RF + (n =2) 26.66±16.26
31.47±6.11
0.39
Polyarticular RF – (n=9) 24.5±8.31
0.02
Systemic JIA(SJIA) (n = 8) 23.22±13.13
0.05
S.25(OH)D(ng/ml) (n= 30) 26.86±10.97
31.47±6.11
0.135
*unpaired student t-testB19
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Introduction: Juvenile Idiopathic Arthritis (JIA) is a group of diseases of
unknown origin, lasting more than 6 weeks, beginning before the age of
16 years. It is the most frequent rheumatic disease in childhood, affecting
predominantly girls, especially in the oligoarticular subtype (the most fre-
quent, corresponding to 50% of cases). Treatment is based on a pharma-
cological combination, rehabilitation and psychosocial support. The
manifestation of the disease is demonstrated by the inflammatory activity.
The implication of the inflammatory activity in the daily life activities is a
focal point of the evaluation.
Objectives: The aim of this study is to characterize patients with JIA
followed at the Multidisciplinary Clinic of Pediatric Rheumatology of
the University Hospital Center of the Algarve (CHUA).Methods: Descriptive observational study based on the clinical rec-
ord and the national registry of rheumatic patients (Reuma.pt) of all
patients with JIA, followed during 2017, at the Multidisciplinary Clinic
of Pediatric Rheumatic Diseases of CHUA. Sociodemographic, clinical,
analytical and therapeutic data were analysed. We have included the
reference to Physical Medicine and Rehabilitation (MFR). Statistical
analysis was performed using Microsoft Excel 2010.
Results: Sample of 10 patients (total of 32), 6 boys and 4 girls. The
average age of onset was 6.6 years (1-15); age at diagnosis 6.8 years
and duration of illness 4.2 years (1-10). The distribution of the ILAR
classification was: persistent oligoarticular 60%, arthritis / entesitis
30% and systemic 10%. Analytically we noted ANA and HLA B27
positive in 30% of the cases; the RF and anti-CCP were always nega-
tive. 60% of the patients had active disease and 40% were in remis-
sion; in relation to CHAQ / HAQ, we obtained a mean score of 0.28
points, with only 2 patients presenting values different from zero; on
the JADI A and E scale we obtained an average score of 0.1 and 0.2
points, respectively. 50% of patients had already been exposed to
corticosteroids (CE), 60% to synthetic DMARDs and 10% to biological
DMARDs; currently only 10% are under CE, remaining 60% with syn-
thetic DMARDs (Methotrexate) and 10% with biological DMARDs (Eta-
nercept). The cumulative exposure to therapy was 0.76 years for CE,
3.11 years for synthetic DMARDs and 0.1 years for biological
DMARDs. 20% of patients already had (at some point during the
course of the disease) been referred to the MFR consultation, both
for elbow flexion deformity.
Conclusion: The high frequency of JIA justifies the 31% of patients
found; there was no predominance of expected gender, despite the
dominance of the oligoarticular category. This category occurs prefer-
entially in girls and before the age of 6; in our sample we found 4 (in
this category), with onset of the disease before 6 years old. Two of
the 3 patients with HLA B27 positive belonged to the arthritis /
enthesitis category, as expected. This category occurs predominantly
in boys, after 7-8 years; the 3 cases obtained fit these characteristics.
Positive evolution is expected, given negativity for RF and anti-CCP,
as well as absence of polyarticular and systemic variants. Although
60% of the patients still have active disease, in 50% of them the dur-
ation of the disease and the follow-up is less than 2 years, which
may explain this percentage. The main purposes of the treatment
are pain control, preservation of joint amplitudes, management and
prevention of complications and facilitation of adequate psycho-
motor development. Thereby, MFR will play a predominant role in
the multidisciplinary team responsible for the support provided to
these patients, as seen by the 20% of patients referred to this clinic.
Disclosure of Interest
None Declared
B20
STRUCTURE OF JUVENILE IDIOPATHIC ARTHRITIS ACCORDING TO
THE REGISTER OF CHILDREN WITH RHEUMATIC DISEASES IN THE
CITY OF MOSCOW
Vladislav Sevostyanov1, Elena Zholobova2
1The Research Institute for health organization and medical
management, Moscow; 2I.M. Sechenov First Moscow State Medical
University, Moscow, Russian Federation
Correspondence: Vladislav Sevostyanov
Pediatric Rheumatology 2018, 16(Suppl 2):B20
Introduction: In recent decades, there has been a tendency to increase
the number of diagnosed systemic diseases, including juvenile idio-
pathic arthritis (JIA). The working group on pediatric rheumatology
established the register of children with rheumatic diseases in Moscow.
The tasks of the register include the study of clinical and epidemio-
logical features of the course of JIA in Moscow, the calculation of the
need for basic and genetically engineered biological drugs .
Objectives: To analyze the structure of juvenile idiopathic arthritis, as
well as the structure of Antirheumatic therapy.
Methods: Observational descriptive study. The study included 752
patients living in Moscow between the ages of 1 and 17 years,
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 225 of 243including 480 females (63.8%) and 272 males (36.2%) suffering from
JIA.
Results: 752 patients at the age of 1-17 years with various options of
juvenile idiopathic arthritis were enrolled in the study (male - 272
(36.2%), female - 480 (63.8%)). Among them 283 (37,6%) suffer from
polyarticular seronegative JIA, 269 (35,7%) oligoartiсular JIA, 82 (11%)
the JIA systemic form, 15,7% are the share of other JIA forms. Aver-
age age of patients was 10,8 years, average age of a debut of a dis-
ease of 68,5 months (5 years 7 months). The interval between a
debut of a disease and establishment of the diagnosis averages 9,2
months, an interval from a disease debut prior to specific therapy of
12,5 months. An age of a debut of a disease for male patients was
significantly higher. Female patients had uveitis more often (р
=0.0011). DMARD therapy was received by 73,7% of patients (84,1%
of cases it was Methotrexate. Biological therapy was received by
43,1% of patients. In structure of biological therapy inhibitors the
TNFα prevail (etanercept and adalimumab – 71%). Etanercept was re-
ceived - 41,7% of all children who are on biological therapy, adalimu-
mab– 29,3%.
Conclusion: The problem of studying of JIA is one of the actual areas
of Pediatrics. The register of children suffering from rheumatic dis-
eases was established first in Moscow. The work to be done to iden-
tify patients with the debut of JIA, as well as patients consisting on
the account in the pediatric rheumatologist with the purpose of set-
ting the dispensary record and inclusion in the register.
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Introduction: JIA severe disabling disease, which leads to motor dis-
orders and disrupts the daily activity of a sick child. and preserving
the functionality of the child Exercise therapy is easy method phys-
ical activation patients with JIA.
Objectives: Analysis of the functional status of patients with JIA in
specializedpediatric rheumatology department and the results of the
rehabilitation of inpatient and outpatient treatment.
Methods: 306 patients aged 2 to 17 years with various JIA-types(a
systemic - 7 %,poly-57%,oligo-36%,); 118pts not have problems with
function of joints only weakness of musculature, 154 have functional
problem in joint without disorder walking and self-service, 34 have
problems with walking. There were used: 306 Card of patients with
register variant exercise-therapy-in group, individually with instructor,
self-dependent. In the functional treatment of patients, general re-
storative, mobilizing and corrective complexes of physiotherapy exer-
cises were used.
Results:Days of exercise therapy % patients>10days(full course) 36%6-9days(not full course) 25%<6 days (Teaching exercises) 39%Middle 6daysConclusion: Term exercise-therapy in pediatric department is not
long, but all patients must have recommendations on exercise-
therapy for home. Only regular exercise by the patient with the sup-
port of parents and with regular supervision by a physiotherapist can
achieve satisfactory results in terms of functional status.
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Introduction: It is known that chronic non-specific inflammation in
rheumatoid arthritis (RA) acts as an inducer of activation of the coagulation
link of hemostasis, contributes to the deficiency of physiological anticoagu-
lants, as well as to the decrease of fibrinolytic activity, which creates patho-
genic preconditions for the occurrence of hemocoagulation disorders.
Objectives: It was considered necessary to determine the features of
the hemostasis system in children with juvenile idiopathic arthritis (UIA)
with comorbid pathology.
Methods: 97 children (5-18 years) of patients with UIA with oligo and
polyarticular variants of the disease were examined. Patients were
divided into two groups. The first group consisted of 38 children
(39.2%) without symptoms of comorbidity, and the second group,
with signs of comorbidity, included 59 children (60.8%). In the group
with the presence of comorbidity, the signs of high activity of the
rheumatoid process, such as C-reactive protein and circulating im-
mune complexes, were significantly more often recorded. The com-
ponents of the blood coagulation system were determined from the
data of the coagulogram, which included determination of the level
of fibrinogen (FG, g / l), prothrombin index (PTI,%), thrombin time
(PM, c), activated partial thromboplastic time (AFTV, c), international
normalized the ratio (MNF, U.S.), D-dimer, y. at. Statistical processing
was performed using the Statgrafics 16.0 application package.
Results: In the group of children with signs of comorbidity, an increase
in the prothrombin index (p <0,05) was found, as well as a probable
prolongation of thrombin time (p <0,03) indicating the probability of
thrombotic formation. The parameters of the study of the coagulation
system were also studied in a group of patients with signs of kidney
damage. There is a probable increase in the prothrombin index (p <0.05),
which may indicate a possible development of thrombosis. As for
atherosclerosis and thrombosis, inflammation is the main binding factor;
we analyzed parameters of hemostasis in a group of children with UIA
with signs of atherogenic orientation changes in the lipid spectrum.
Signs of the development of thrombocytopenia development were
revealed by parameters of PTI (p <0,05). Only in this group of patients a
probable increase in the level of D-dimer, the main marker of thrombotic
readiness (p <0,05), was established.
Conclusion: Thus, in children with UIA, with signs of comorbid pathology,
signs of thrombophilic formation have been identified, as evidenced by
an increase in both the prothrombin index and the main marker of
thrombotic readiness - the D-dimer. Thus, precisely inflammation is the
most important factor that supports the threat of development of athero-
sclerosis, atherothrombosis and venous thrombosis in children with SLE,
and it is dangerous not only the process of inflammation in the vascular
wall itself, but also the pathological influence on the endothelium of the
cells of the immune system and products of the systemic inflammatory re-
sponses - acute phase proteins and circulating immune complexes.
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(JIA), different rare diseases that mimic chronic arthritis, should be
considered. Our article describes the case, where the rare disease -
Synovial chondromatosis had to be excluded in spite of findings by
imaging methods.
Objectives: A 4 year old female patient presents with complaints
of walking difficulties, morning stiffness, swelling of right knee, and
limitation of movement. Blood results did not show increased
inflammatory activity. The patient was RF and ANA negative. Slit-lamp
examination excluded uveitis. Based on signs and symptoms, the diagno-
sis of Juvenile idiopathic arthritis was considered. Plain radiograph of the
knee showed soft tissue swelling. Findings of MRI examination revealed
the diagnosis of primary synovial chondromatosis (Reichel´s syndrome).
However, the musculoskeletal sonography showed a typical image of
proliferative synovitis with high power doppler signal and small amount
of anechoic fluid. Inflammatory etiology was confirmed by analysis of the
synovial fluid. The diagnosis of JIA was confirmed and the patient was
treated by intra-articular application of triamcinolone hexacetonide.
Synovial chondromatosis (Reichel´s syndrome or Reichel-Jones- Hen-
derson syndrome) is a benign cartilaginous metaplasia of the synovium,
which may affect any synovial joint. Typically, free fragments of cartil-
age originating from the synovium of the joint are seen in the joint cav-
ities. The disease is usually monoarticular, it affects most commonly the
knee, hip, or elbow and less commonly the wrist, ankle, and shoulder. It
involves rarely the TMJ. The joint most commonly involved is the knee
joint. The condition is connected with pain, swelling and limitation of
movement. It typically affects adults between 30 to 50 years old, and
occurs extremely rarely in children. Synovial chondromatosis exists as
primary and secondary. In primary form the cause is unknown, fre-
quently without known prior trauma or inflammation. Diagnosis is
made by radiographs, computed tomography (CT), magnetic resonance
imaging (MRI) , by surgery and histology. The prognosis of this disease
is good. Asymptomatic patients do not require therapy. Symptomatic
patients should undergo arthroscopic or surgical removal of intra-
articular bodies. There have been documented very rare cases of malig-
nant transformation. Written consent of the legal guardian has been
obtanied to publish this case study.
Methods: Case report.
Results: Six months after administration of triamcinolone hexacetonide
to the right knee, the patient is asymptomatic with complete clinical and
ultrasound remission.
Conclusion: Although MRI confirmed the diagnosis of Reicheľs
syndrome, due to the age of the patient and clinical and ultrasound
findings we decided to treat the patient according to the guidelines for
JIA. Treatment of the patient was successful without surgical intervention.
Imaging methods can be helpful in differential diagnosis of JIA, however,
findings might sometimes be confusing or misleading.
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Introduction: Although the sternoclavicular joint (SCJ) is a real synovial
articulation that can be affected actively during systemic inflammatory
disease such as juvenile or adult rheumatoid arthritis (RA), there were no
reports of SCJ arthritis in juvenile idiopathic arthritis (JIA).
Objectives: In this article, we report a case of a boy who is newly
diagnosed with oligoarticular JIA with unexpected joint involvement.
Methods: Case ReportResults: A formerly healthy 11-year-old boy with a month history of left
ankle swelling and pain with morning stiffness was admitted to our clinic
with SCJ pain and swelling for one week.
He reported no hospitalization and regular use of medication in his
previous medical history.
Family history was not remarkable for rheumatological disease.
At presentation, the child had pain and limitation of movement of the
left ankle. The SCJ was warm, effused and painful when pressure was
applied. There was no enthesitis or complaints in other peripheral joints.
The other organ systems were healthy upon physical examination.
Laboratory evaluation revealed significantly elevated erythrocyte
sedimentation rate and C-reactive protein levels, and an ANA test
was positive. According to the physical, laboratory and imaging eval-
uations, and bone marrow aspiration, there was no evidence for ma-
lignancy and infectious disorders.
After the evaluation of clinical and radiological findings, the child
was diagnosed with oligoarticular JIA without uveitis and was started
on 10 mg of weekly subcutaneous methotrexate in addition to oral
prednisolone 2 mg/kg daily. Prednisolone was tapered and ceased
within 4 weeks.
Two weeks after stopping steroids, despide efficient methotrexate
treatment the patient presented at our department with re-
exacerbation of pain and swelling in the SCJ. Acute phase reactants
were risen again and the MRI of the left SCJ was consistent with
marked bone marrow edema, joint effusion, synovial thickening and
bone erosion. Meanwhile etanercept (0.8 mg/kg/week subcutaneous)
was added. The responses to treatment in the third and sixth month
were optimal according to the American College of Rheumatology
(ACR) Paediatric 30/70. It was observed that the patient had significant
healing after a year without any adverse reaction to treatment.
We report a case study of a boy with oligoarticular JIA who presented
with arthritis of unexpected joint involvement. Oligoarticular JIA is the
most prevalent chronic inflammatory arthritis of childhood. SCJ
involvement in JIA has not been reported yet. However, symptomatic
SCJ involvements in adult RA were reported at varying rates. Recently,
Rodríguez-Henríquez et al. reported that 15% of RA patients had
synovitis in the SCJ according to ultrasound. If the patient has no
complaint, SCJ involvement might be missed upon routine
rheumatological examination.
Conclusion: We concluded that SCJ involvement in JIA is very rare,
but it may actively participate in the inflammatory process, as do
other peripheral synovial joints. Careful clinical examination of the
musculoskeletal system is essential for early diagnosis, and advanced
radiological tools simplify the evaluation of joints in early phases
effectively. In addition, biologic agents particularly seem to be more
useful in early phase. Informed consent for publication had been
obtained from the parent.
Disclosure of Interest
None DeclaredMacrophage activation syndrome
B25
PARVOVIRUS B19 INDUCED MACROPHAGE ACTIVATION
SYNDROME IN A CHILD WITH JUVENILE PSORIATIC ARTHRITIS
UNDER SULPHASALAZINE TREATMENT
Nuray Aktay Ayaz, Ayşe Zopçuk, Gül Karadağ
Pediatric Rheumatology, Sağlık Bilimleri University KSSEAH, Istanbul,
Turkey
Correspondence: Nuray Aktay Ayaz
Pediatric Rheumatology 2018, 16(Suppl 2):B25
Introduction: Juvenile idiopathic arthritis (JIA) is the most common
chronic rheumatic disease in childhood, macrophage activation
syndrome (MAS) is a rare and potentially fatal complication of JIA. It can
be triggered by drugs, malignancies, infections, and rheumatic diseases.
Time point/
treatment given
Variable
(Normal Value)
At diagnosis
IVIG 2 g/kg
After
3 days
Remsina
5 mg/kg
After
9 days
IVIG 2g/kg
After
11 days
Methylpred.
2 doses +
prednisolone
After
16 days
Anakinra
8 mg/kg
After
3 weeks
After
7 weeks
Haemoglobin,
mmol/l (6-8,4)
5,9 5,5 5,9 5,8 6,4 6,5 7
White cell
count x 109/l
(3-14)
36 28,1 38,7 33,1 45,2 35,5 20,1
Platelets
x 109/l
(175-565)
1360 699 1466 1618 1988 1409 924
Ferritin, μg/l
(22-400)
837 823 731 724 3349 481 88
ALT, U/l
(5-45)
101 75 17 23 457 136 40
CRP mg/l
(<6)
116 116 117 100 55 1,1
Fibrinogen
mmol/l
(5,5-11,5)
12 24,6 8,4
Triglyceride
mmol/l (<2)
1,0 5,6 2,6 2,5
Pericardial
effusion
(yes/no)
yes yes (no) no no
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 227 of 243Objectives: Herein, we describe Parvovirus B19 Induced MAS in a
child with Juvenile Psoriatic Arthritis under sulphasalazine (SAZ)
treatment
Methods: A 14 year old boy with a 3 years diagnosis of JPsA (arthritis
together with a psoriatic rash, dactylitis, nail pitting and psoriasis in a
first-degree relative) was SAZ, because of unresponsive to NSAID, ste-
roids, intraarticular steroids, oral and subcutaneous methotrexate and
leflunomide treatments. During the third week of SAZ, the patient
complained of fever, fatigue, nausea, vomiting, rash, diffuculty in
breathing. In his physical examination, the general condition was
poor, tachypneic, dyspneic, body temperature: 39.4 ° C, pulse rate:
120 min, respiration rate: 25 / min, blood pressure: 160/80 mm/Hg.
An indurated, confluent erythema over the cheeks(‘’slapped-cheek”
appearence) and a symmetric maculopapuler rash on his arms, legs
and trunk, sparing the palms and soles were detected. There was pe-
techia on hard palate. Respiration and heart sounds were normal.
The liver and spleen was not palpable. In the laboratory review;
hemoglobin: 12.1 g/dL, hematocrit: 36.3%, leukocyte count: 21 000/
mm3, eosinophil: 1590/mm3, platelet count: 108 000/mm3, C-
reactive protein (CRP): 8.06 mg/dL (n=<0.79), erythrocyte sedimenta-
tion rate (ESR): 1 mm/1st hour, procalcitonin: 0.59 ng/mL, BUN: 8 mg/
dL, creatinin: 0.52 mg/dL, AST: 694 U/L, ALT: 749 U/L, gamma gluta-
myl transferase (GGT): 143 IU/L, lactate dehydrogenase (LDH):851 IU/
L, total bilirubin: 3.9 mg/dl, direct bilirubin: 3.1 mg/dl, albumin: 2.5 g/
dl, cholesterol: 89 mg/dL, triglyceride: 178 mg/dL, HDL cholesterol:
13 mg/dL, LDL cholesterol: 57 mg/dL, fibrinogen: 159 mg/dL, D-
dimer: 2.89 mg/L and ferritin: 840 ng/mL. Eosinophilia, atypical lym-
phocytes and monocytes were observed in peripheral blood smear.
Abdominal ultrasonography revealed splenomegaly and liver size
was at the upper border. The serum was positive for anti-parvovirus
B19 IgM and negative for anti-parvovirus B19 IgG. Echocardiography
was normal. Bone marrow aspiration showed an increased number
of macrophages with prominent hemophagocytosis. From these find-
ings, we considered that he had sulfasalazine-induced MAS associ-
ated with possible active Parvovirus B19 infection.
Results: Treatment with sulfasalazine was discontinued. He was treated
by plasmapheresis, methylprednisolone pulse therapy and intravenous
immunoglobulin (IVIG) therapy. Thereafter, oral prednisolone was
tapered with dramatic improvement of the clinical symptoms and
laboratory findings.
Conclusion: The present case demonstrated that combining steroid,
IVIG and plasmapheresis is an effective therapeutic strategy for MAS,
complicated by hypercytokinemia, in patients with juvenile idipathic
arthritis
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Introduction: Macrophage activation syndrome (MAS) is a potentially
life-threatening condition featuring fever and organ failure. Its patho-
genesis is poorly understood. It occurs as a complication of severe in-
flammatory diseases and/ or is triggered by infections, particularly due
to Epstein-Barr virus. Diagnosis in patients with systemic juvenile arth-
ritis (sJIA) is based on the classification criteria published by Ravelli
et al. in 2005, and edited in 2016.
Objectives: We performed an analysis of cases of MAS, using the Ravelli
criteria.
Methods: We evaluated 13 episodes of MAS treated in our
Department of Pediatric Rheumatology over a period of 12 years.
Results: There were no fatal outcomes. Five girls and five boys aged 6,3
– 16,3 years were affected, three patients showed two episodes of MAS.
Of the 10 episodes in patients with sJIA, five began at the time ofdiagnosis, or immediately afterwards. One case occurred in a patient
with suspected sJIA (without arthritis), and two were associated with
infections. The Ravelli criteria were met in eight cases. In another three
cases the criteria valid at the time (prior to 2016) were fulfilled. Two
cases were interpreted as MAS without fulfilling the criteria.
There was considerable variation in laboratory findings and clinical courses
among the patients. The cases occurring under therapy with tocilizumab
showed milder clinical symptoms and lower ferritin concentrations. The
episodes occurring under high-dose steroid therapy tended to have fewer
abnormal laboratory findings, other than elevated ferritin.
Conclusion: The current diagnostic criteria for MAS in patients with sJIA
do not encompass well patients treated with biological medications.
Therefore they should be reevaluated.
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Introduction: A 12-week-old boy presenting with atypical Kawasaki
disease (KD) complicated with macrophage activation syndrome
(MAS) is reported.
Objectives: -
Methods: The infant presented with cerebral irritability, pain, takypnea
and vomiting during 10 days. He had no history of fever or rash. Ad
admittance mild pleiocytosis (37 x 10E6/L) in the cerebrospinal fluid (CSF)
was found. Antibiotic treatment was initiated without any clinical
response. No bacteria or viral DNA was detected in CSF, blood, urine, or
airways. Pericardial effusion was seen on echocardiogram in addition to
severe dilatation of coronary arteries (LAD: 4.2 mm Z-score 12,68; RCA:
4,2 mm Z-score 9,3). Treatment with intravenous Immunoglobulin (IVIG)
and aspirin was initiated for KD without any response. Addition of inflixi-
mab reduced the pericardial effusion but otherwise the condition was
unchanged. High dose methylprednisolone was initiated followed by
prednisolone but 5 days later criteria for MAS were fulfilled. High dose
Anakinra was started resulting in dramatically improvement in his clinical
condition.
Results:
Table 1 (abstract B28). See text for description.
ESR
mmHg
Hemoglobin
g/L
Platelets
No
AST U/L Ferritin
ng/ml
Triglycerides
U/L
68 94 g/L 60 x10/9 L 288 3500 2,8
36 71 g/L 20 x10/9 L 296 3946 4,8
After the treatment with 3mg/kg of cyclosporine
20 130 g/L 241 23 <500 2,8
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 228 of 243Conclusion: This case shows benefit of interleukin-1 receptor block-
ade for refractory kawasaki disease complicated by MAS in an infant.
Trial registration identifying number: Written informed consent for
publication is obtain from the parents.
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Introduction: Macrophage activation syndrome (MAS) is potentially
life-threatening complication of systemic inflammatory disorders,
which occurs most commonly in systemic juvenile idiopathic arthritis
(sJIA), its adult equivalent, as well as in with other autoimmune or
autoinflammatory conditions. It is being reported with increased fre-
quency. It is potentially fatal condition which can results with death
of 8% of patients. MAS is characterized by an over-whelming inflam-
matory reaction due to an uncontrolled and dysfunctional immune
response involving the continual activation and expansion of T lym-
phocytes and macrophages, which results in massive hypersecretion
of pro-inflammatory cytokine.
Objectives: We are presenting the case of 22 year old patient who is
suffering from sJIA since he was 4 years old, who developed MAS
because of acute hepatitis A infection.
Methods: The patient was prone to different infections like cutaneous,
upper respiratory tract, urinary infections because of the long term
immunosuppressive treatment, glucocorticoid use and insufficient
water supply in his village. He was also treated for septic sacroiliitis,
have chronic Q fever and many other infective complications to his
sJIA. He presented with 2 weeks history of high fever 39,5 degrees
Celsius, salmon colored rash on his back coinciding with the fever,
arthralgia and arthritis of 12 joints, dark colored urine, low appetite and
exhaustion. Few days later he had yellow colored skin and sclera. The
diagnostic tests for hepatitis A IgM antibodies were positive. He also
had positive IgM and IgG antibodies against Ebstein Barr Virus.
The laboratory results are presented in Table 1. He fulfilled EULAR
classification criteria for
sJIA associated MAS from 2016.
The other laboratory results were as follow: ALT 1990 U/L, LDH >2234 U/L
, GGT 1000 U/L, Albumins 25 , total bilirubin 108 (ref 20 Mmol/L), direct
bilirubin 90 Mmol/L, APTT shortened 22 sec. D-dimers >5000 ng/ml CRP
60 mg/L.
The patient was immediately put on high-dose 1mg/kg glucocorticos-
teroids and immunosuppressants- we used 3 mg/kg of cyclosporine.
MAS was successfully treated and his sJIA is now in 6 months remission
with only 50 mg of cyclosporine daily and low dose prednisone.
Results:
Conclusion: Fulminant viral hepatitis may cause MAS, with hepatitis A virus
being more frequently associated with MAS than the other hepatotrope
viruses. Fifteen cases (including children) have been described, mainly in
Asia: three of these patients also had a concurrent rheumatological disease
including sJIA. Hepatitis A can mimic MAS as well, but high awareness and
immediate immunosuppressive treatment could prevent the potentially
fatal consequences of MAS in patients with sJIA. Informed consetn to
publish had been obtained from the patient.
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Introduction: Severe MAS(Macrophage Activation Syndrome) with
neurological,renal & bleeding complications is challenging to manage
Objectives: To describe life-threatening MAS responding to high
dose iv Anakinra
Methods: A 9 year old Caucasian girl presented with high fevers for 3
weeks,severe abdominal/leg pains,no rashes & no infectious focus.Past/
family history non-contributory.She underwent an appendicectomy(nor-
mal appendix & abdominal MRI).Fevers continued with high nflamma-
tory markers(ferritin 5000)& rising Creatinine.Upon transfer to our
centre, she was febrile/delirious & collapsed with rapid deterior-
ation & multi organ dysfunction. She was ventilated,needing ino-
tropes for profound hypotension/poor cardiac output(with resultant
ischaemic necrotic patches on limbs).Severe renal failure needed
haemofiltration.Concurrent ferritin was 192549,CRP 180,ESR<1,Creati-
nine 257,falling Haemoglobin/platelets(necessitating transfusions),fibri-
nogen<0.3,Triglycerides 3.9,ALT 242,LDH 3218,prolonged PT/aPTT,bone
marrow showed haemophagocytosis,all these confirming MAS/HLH.1
Results: She was given pulsed IV methyl Prednisolone & IV Anakinra
0.5mg/kg/hour, IV Immunoglobulin,antibiotics,antivirals. Dexamethasone
was added with Candida/PCP prophylaxis.MAS parameters slightly
improved with ferritin plateauing at 35000.Inotropes were gradually
discontinued but she remained on maximal ventilation & haemofiltration.
Bleeding dyscrasias necessitated multiple platelet/cryoprecipitate
transfusions. She developed unreactive pupils & clonus.A CT brain
showed no focal findings. She was too unstable for a lumbar puncture.
Cerebral Function Monitoring tracing was equivalent to a flat EEG.As
for neuroHLH,immunosuppression was intensified and Dexamethasone
was doubled.2 Simultaneously Anakinra was steeply escalated to 2mg/
kg/hour(48mg/kg/day) for 3 days, the rationale for this being the role
of IL1 blockade in reducing mortality in sepsis associated MAS.3 In
addition, IL1 inhibitors are highly neuroprotective experimentally,
inhibiting systemic acute phase response to stroke and have been
shown to be safe in acute Sub Arachnoid haemorrhage, reducing
peripheral inflammation with proposed neuroprotection.4
1 dose of Etoposide as per creatinine clearance was also
administered. Within 40 hours of this regimen,clear signs of life were
obvious. A 2nd pulse of Methyl prednisolone was administered
whilst weaning Anakinra. Haemofiltration was discontinued within 3
days & ventilation within a week. Dexamethasone was changed to
oral Prednisolone & Ciclosporine added. Her hospital stay was
complicated by respiratory aspergillosis & bacterial line
infection,both appropriately treated. All initial infectious serology
was negative as was autoimmune serology, malignancy screen &
HLH genetics. Due to knee synovitis on followup,she is being
treated as presumed systemic JIA with MAS.Recently gene
sequencing has shown an intronic variation for TRAPS,of unknown
significance. Remarkably she is neurologically intact,apart from
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 229 of 243psychology support for longstanding anxiety & is on daily Anakinra,
Ciclosporine & weaning Prednisolone.
Conclusion: Conclusion:
Severe MAS/HLH requires close collaborative working between
multiple specialties including paediatric intensivists, rheumatologists,
haematologists and infectious disease specialists
High dose IV Anakinra contributed to reversing severe neurological
obtundation in our patient & is a therapeutic option in neuroHLH,
given its potential neuroprotective role
Trial registration identifying number:
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Introduction: We report a clinical case of a 9-year old girl diagnosed
with juvenile dermatomyositis, complicated with macrophage activa-
tion syndrome , probably triggered by Herpes simplex infection.
Objectives: Our objective is to describe the presentation of
macrophage activation syndrome in a child with newly diagnosed
juvenile dermatomyositis
Methods: Our patient is 9-year old girl who presented to a Pediatric
Department with a 6-month history of abnormal gait and lower limbs
pain, which appeared mainly in the evening and after physical activ-
ities. On admission she had polyarthritis, maculopapular rash over the
cheeks and erythema over the nasal tip. The lab studies revealed leuco-
penia with lymphopenia, mild anemia, slightly elevated ESR, positive
ANA titer and negative anti-dsDNA. Treatment with NSAIDs and Metho-
trexate was prescribed, but the parents decided to try alternative ther-
apy - homeopathy, and refused the treatment.
In the following months the child deteriorated with progressive muscle
weakness, difficulty walking, skin rash, alopecia, persistent fever,
progressive weight loss and abdominal pain. On examination there was
marked symmetrical proximal muscle weakness and the girl was
unable to perform the usual daily activities on her own. Characteristic
cutaneous changes were observed - heliotrope discoloration of the
eyelids with periorbital edema and a malar rash.She had also
hyperpigmented lesions around the elbows, knees and ankles,
Gottron's papules and aphtous stomatitis. Due to the clinical signs adiagnosis of JDM was suspected,but was inconclusive due to the
normal lab studies with normal creatine phosphokinase levels, normal
inflammatory and immunology markers and the technical inability to
perform electromyography.Finally the diagnosis was supported by
magnetic resonance imaging of the thigh muscles revealing the
characteristic pattern of muscle involvement in JDM. What made the
case more perplexing were the additional overlap clinical signs of
subtle arthritis with flexion contractures at the elbows and knees,
alopecia, butterfly-like rash and aphtous stomatitis. For the latter, a
positive result for HSV infection was received . In addition we observed
jaundice with enlarged liver and spleen, lab studies revealed hepatitis
and cholestasis, so an exclusion of underlying reasons for the develop-
ment of hepatitis (viruses, autoimmune hepatitis, drug induced, meta-
bolic diseases) was required.
Overall, a diagnosis of JDM complicated with MAS (the lab studies
revealed pancytopenia, normal ESR, elevated liver enzymes,
increased bilirubin levels, elevated LDH levels, decreased levels of
albumin and total protein, hypertryglyceridemia, hyperferritinemia)
was established.
Results: Pulse therapy with high‐dose intravenous methylprednisolone
and intravenous immunoglobulin was initiated. After almost two months
of hospital stay, the girl was discharged with great improvement in the
range of motions and normal laboratory markers
Conclusion: MAS is a rare and life-threatening complication of JDM,
most commonly triggered by infections.In our case the triggering
factor might be the HSV infection .JDM can present with inconclusive
lab studies and our challenge was also associated with the differen-
tial diagnosis of liver involvement in MAS. Informed consent to pub-
lish had been obtained from the parent.
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Introduction: Macrophage Activation Syndrome (MAS) is a critical,
overinflammatory condition complicating Systemic onset Juvenile
Idiopathic Arthritis (SoJIA), Systemic Lupus Erythematosus (SLE) or it can
be triggered by other factors such as infections, malignancies or drugs.
Objectives: The final diagnosis and outcome of children diagnosed
with MAS at a tertiary referral center
Methods: Patients who were hospitalized from 1990-2017 at a teach-
ing Athens Pediatric Hospital Department and met the HLH 2004 or
the EULAR/ACR/PRINTO 2016 criteria for MAS (ferritin >684 ng/ml
and any 2 of the following platelet count ≤181 x 109/litre, Aspartate
aminotransferase >48 units/litre, triglycerides > 156 mg/dl, fibrinogen
≤360mg/dl) or exhibited macrophage hemophagocytosis in bone
marrow biopsy specimens.
Results: 11 children were included in our study with a female
predominance (6 girls and 5 boys). The mean age at diagnosis was
8.5 years (range:3.5–16years). Only one patient had a diagnosis of
SoJIA, which was recognized several days before the diagnosis of
MAS. The mean duration of their symptoms prior to diagnosis was 20
days (range: 9-44 days), while the mean duration of hospitalization prior
to diagnosis was 8 days (range: 1-24 days). All patients presented with
fever, 7 presented with rash and joint paint and 2 with arthritis. Regard-
ing the laboratory investigation which correlates with the MAS criteria,
mean ferritin was 16.714 ng/ml (range 150-44.000), mean platelet count
was 170 x 109/ liter (range 48-459 x 109/liter), aspartate aminotransfer-
ase was 172 U/l (range 24-621), mean triglycerides 260 mg/dl (range
79-700) and mean fibrinogen 309 mg/dl (range 70-577). 7 patients re-
vealed macrophage hemophagocytosis in bone marrow biopsy. 4 pa-
tients were admitted to the Intensive care Unit. Furthermore, 6 patients
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 230 of 243developed neurologic complications. All patients received systemic cor-
ticosteroids (prednisolone, pulses of methylprednisolone or dexametha-
sone), 4 patients were treated with biologic agents, 4 patients with
etoposide, whereas 5 patiens initially were treated with intravenous im-
munoglobulin. All patients survived and clinically recovered. One pa-
tient presented with relapse of MAS, 1 year after the first episode. 9
patients were diagnosed with SoJIA and 2 with possible SoJIA, with
mean time of follow up: 62.4 months (range 4-146 months).
Conclusion: High suspicion with subtle clinical or laboratory changes
in a protracted febrile patient is necessary for prompt diagnosis and
management of MAS. Validated classification criteria have been
published in 2016, but treatment guidelines have only developed for
primary HLH. Our patients were treated with different therapeutic
protocols, according to the severity of their clinical status and their
response. Although biologics have rarely implicated as triggering
factors in single case reports, in our case, as in others, they worked
perfectly well. Prompt diagnosis, judicious use of corticosteroids,
immunosuppressants, biologics and supportive therapy, ends to a
favorable outcome even in this life threatening syndrome.
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Introduction: Mesenteric panniculitis is a rare inflammatory process
leading to fibrosis. It involves the mesenteric adipose tissue with an
unknown etiology. Malignancy, tuberculosis, trauma, drugs, and
surgery are considered as the predisposing factors. Three cases with
different etiology are presented.
Objectives: In this article three pediatric cases of mesenteric
panniculitis with different etiologies were presented.
Methods: The files of the three MP cases were reviewed and clinical,
laboratory, imaging results, treatment and outcomes were assessed.
Results: Case 1:
A five-month-old girl was hospitalized following her consultation to
the emergency department with discomfort and vomiting. She had
dehydration with abdominal distention with no bowel sounds. Com-
puterized tomography revealed generalize fluid in the abdominal
cavity. Exploratory laparotomy demonstrated intense lipoid deposits
in the mesenteric of the small and large intestines and the appendix.
Histopathological examination showed necrotic foci, suppurative in-
flammation and fibrinous exudate of the omentum, compatible with
mesenteric panniculitis.
Case 2:
A ten-year-old boy was consulted to emergency department with ab-
dominal pain and nausea for two weeks. There was rebound tender-
ness in the right lower quadrant. The abdominal ultrasonography
revealed appendicitis and the patient was operated. The omentum
tissue was compatible with mesenteric panniculitis, and lymphoid
hyperplasia with fibrolipomatous appearance was detected in the
histopathologic investigation. The patient recovered following the
operation. Consent had been obtained from the parents.
Case 3:
A fifteen-year-old girl with RF negative polyarticular JIA was in remis-
sion for three years. She had a progressive worsening of general condi-
tion with vomiting. Bilateral hydronephrosis was detected in abdominal
ultrasonography, and a further MRI revealed retroperitoneal fibrosis sur-
rounding perirenal tissue and ureters. Histopathologic examination, adi-
pose tissue necrosis and septal fibrosis, but there was no amyloid
deposition. IgG4 related disease was excluded. She was diagnosed asmesenteric panniculitis. Initial therapy with high dose steroids was suc-
cessful. The maintenance therapy was provided with methotrexate and
azathioprine. Tocilizumab therapy was started due to recurrence. She is
still under remission for the last year.
Conclusion: Mesenteric panniculitis is characterized by chronic
nonspecific inflammation of the mesenteric adipose tissue of the small
intestine and colon. It is reported as a very rare condition in children.
Also, mesenteric panniculitis was characterized with different findings
in these three cases and came up in an early age as 5-month old. It
should be in the differential diagnosis of children with acute abdomen.
Consent had been obtained from the parents.
Disclosure of Interest
None Declared
B33
PEDIATRIC AUTOIMMUNE BULLOUS DISORDERS DIFFERENTIAL
DIAGNOSIS IN RHEUMATOLOGY
Marinabiondina Amico1, Francesca Orlando2, Roberta Naddei2,
Carolina Porfito2, Teresa Lastella2, Maria Alessio2
1Mother and Child Department; 2Mother and Child Departement,
Federico II University of Naples, Naples, Italy
Correspondence: Marinabiondina Amico
Pediatric Rheumatology 2018, 16(Suppl 2):B33
Introduction: Autoimmune blistering diseases (AIBDs) are a group of
disorders mostly affecting the skin and mucous membranes. Occasionally,
other organ systems may be involved, such as eye.
Objectives: We present two cases of severe childhood AIBDs referred
to our Department with diagnosis of Rheumatic diseases.
Methods: Case report
Results: A 9-year-old girl with three years history of conjunctivitis with
conjunctival scarring evolved in ocular sicca syndrome, was referred to
our Department with diagnosis of Sjögren's syndrome, treated with high
doses of steroids. Clinical history revealed also mucocutaneous involve-
ment, with oral and anovulvar ulceration. Laboratory data showed
anemia, elevated serum levels of ERS and CPR, normal serum levels of
autoantibodies (ANA, anti-dsDNA, ENA). Biopsies of buccal mucosa, vulval
skin, parotid and colon were performed. The histopathological study
showed an infiltrate of lymphocytes, plasma cells and eosinophils; the dir-
ect immunofluorescence (DIF) showed linear deposition of IgG and C3 at
the mucosal/submucosal junction. These findings were considered con-
sistent with Sjögren's syndrome, and inflammatory bowel disease. Six
months later the girl was admitted to our Department: the clinical exam-
ination revealed bilateral fornix foreshortening, symblepharon, entropion,
corneal scarring, blisters around the nails, oral ulcerations; the vulval mu-
cosa was completely denuded and adhesions were developing between
the anterior aspects of the labia majora. The airway examination showed
bilateral choanal atresia and laryngeal stenosis due to scarring. She
started corticosteroid and she underwent surgery to remove cicatricial
lesions of eyes, vulval area and choanae. Immunofluorescence findings
of the surgical biopsies reveals the presence of linear homogeneous
deposits of IgG and C3 along the epithelial basement membrane zone,
therefore diagnosis of cicatricial pemphigoid (CP) was made. Ciclospor-
ine was introduced without improvement, therefore after one month
on the therapy was shifted to tacrolimus with initial response but wors-
ening of ocular disease after two months. Many therapeutic trials were
performed (thalidomide, cyclophosphamide and etanercept) without
improvement. The patient was admitted to Intensive Care Unit, she
underwent tracheostomy and died after 4 months. The second case is
a 15-year-old girl with recent onset of oral e genital ulcers, referred to
our Unit with suspect of Behçet’s disease. She was on prednisone and
cyclosporine. Laboratory data showed raised inflammatory markers and
ANA positivity. At the admission the clinical examination revealed facies
cushingoide, strie rubrae, multiple eruptions and blisters was found in
her face, trunk, genital area and proximal limbs. Skin biopsy showed
intraepidermal suprabasal acantholysis with infiltrate of lymphocytes
and eosinophilis. Direct immunofluerescence showed IgG deposits at
the surface of epidermal keratinocytes and confirmed the diagnosis of
pemphigus vulgaris (PV). Oral prednisone combined with mycopheno-
late mofetil (MMF) resulted in complete clinical remission off therapy.
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 231 of 243Conclusion: Cicatricial pemphigoid and pemphigus vulgaris are
autoimmune disorders, rare in pediatric age. Both could involve skin and
eyes. Immunohistopathologic evaluation with direct immunofluorescence
are essential for diagnosis and repeat biopsies may be useful in patients
with atypical disease courses. Corticosteroids and immunosuppressants
were the mainstay of treatment. The inclusion of these disorders in
differential diagnosis of rheumathologic diseases with dermatologic and
ocular manifestations is important to start an appropriate and early
treatment. Informed consent to publish had been obtained.
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Introduction: Causes of weakness in children include disorders that
involve any component of the lower motor neuron: anterior horn
cell, peripheral nerve, neuromuscular junction or muscle; sometimes
differential diagnosis can be challenging.
Objectives: Report of a patient with a rare combination of two
autoimmune diseases both contributing to muscle weakness.
Methods: A 7-year-old boy presented to the emergency department
with a three-week evolution of left knee pain and upper and lower
limbs weakness. Parents denied previous episodes of muscle weak-
ness, frequent falls or choking, fever or previous infections. Personal
and family background were irrelevant.
Physical examination showed myopathic gait with axial and appendicular
hypotonia, predominant proximal muscle weakness with normal deep
tendon reflexes. No skin rash, dyspnea or dysphonia were noted.
During hospital stay clinical worsening was noted with reduced
muscle strength and fluctuation of symptoms such as ptosis and
episodes of dysphonia. Childhood myositis assessment scale (CMAS)
total score was 8/52.
Results: Blood tests revealed slightly elevated creatine kinase (534,15UI/L)
and myoglobin (209 UI/L); aldolase, calcium and phosphorus were normal.
ANAs were 1/320 with positive anti-dsDNA antibodies. Anti-PL 12 and
anti-acetylcholine receptors (AchR) antibodies were both positive.
Reactive C-Protein, erythrocyte sedimentation rate, RNA synthetase
antibodies and other immunologic markers were normal/negative. In-
vestigation for infectious and metabolic diseases was negative. Cardi-
ology, Ophtalmology and Ear, Nose and Throat evaluations were
normal.
Electromyography was suggestive of primary muscle disease.
Repetitive nerve stimulation was not performed due to non-
compliance. Chest CT scan was normal and lower limbs MRI showed
no evidence of myositis.
Biopsy from lateral vastus muscle revealed T-cell infiltrates with
muscle fiber necrosis and healthy muscle fibers expressing MHC class
I antigen, all typical pathological features of polymyositis.
The patient started Pyridostigmine (1mg/Kg/dose qid) and intravenous
Immunoglobulin (1g/Kg in two doses). He additionally started a
physiotherapy program. Partial clinical improvement was noted 48
hours after initial dose with a CMAS score of 21/52.
After biopsy results came to knowledge, he was started on
Methylprednisolone (5 pulses of 30mg/Kg) followed by Prednisolone
(2mg/Kg/d) and Methotrexate (17mg/m2/week).
At 3-weeks follow-up he recovered to almost normal strength with a
CMAS total score of 44/52.Conclusion: Polymyositis and Myasthenia Gravis are rare autoimmune
disorders of childhood affecting muscle and neuromuscular junction,
and constitute a great diagnostic challenge.
The diagnostic approach to our patient was difficult owing to clinical
overlap of both autoimmune disorders and an absence of typical
features: sudden onset of weakness with rapid progression in the
absence of cutaneous features, ptosis, diplopia, bulbar symptoms at
presentation. Serologic testing, biopsy and clinical improvement with a
trial of Pyridostigmine and immunosuppressants allowed confirmation
of both diagnoses and appropriate management of both conditions.
Written informed consent for publication of his clinical details and/or
clinical images was obtained from the patient’s parent.
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Introduction: Sjögren's Syndrome (SS) is a chronic autoimmune
disease characterized by inflammation of the lacrimal and salivary
glands, secondary to infiltration of lymphocytes and in the presence
of auto antibodies (Anti-Ro and Anti-La). Primary SS occurs with-
out association of other systemic autoimmune diseases, and is more
often in women of medium to advanced age, being rare in child-
hood. It presents as dry mucosa surfaces of the mouth and eyes. In
addition, 40% of the patients have extraglandular involvement, such
as skin manifestations, musculoskeletal and neurological disor-
ders. Systemic vasculitis manifestations of SS occur in approximately
5 to 10% of adult patients, however, the incidence decreases with
age. Half of the individuals that develop vasculitis presents with a
single episode, and histologically findings of leukocytoclastic vascu-
litis or necrotizing arteritis. These patients develop a more serious ill-
ness and have a worse prognosis.
Objectives: We describe a pediatric patient with leukocytoclastic
vasculitis as the initial clinical manifestation of Sjögren's Syndrome.
Methods: Descriptive. Clinical case presentation.
Results: A 13 year old female, referred to the Pediatric Rheumatology
Department, with a year of palpable purpuric lesions, in both lower
extremities, limited to the knees, and associated with painful edema
of the ankles. The manifestations became recurrent, being treated
with low dose oral steroid for two months without remission.
Subsequently the patient developed dry eye, with recurrent episodes
of conjunctivitis and arthralgia in both ankles and knees. Laboratory
finding include elevated ESR 43mm/hr, and FR, 37.1 Ul/ml, anti-SS-A
(Ro) 198.74 RU/ml and anti-SS-B (La) 200 RU/ml, IgA 411 mg/dl
and IgG 2410 mg/dl, IgG1 11600 mg/dl, ANA fine speckled 1:640.
The rest of immunological and serology profile was negative. Minor
salivary gland biopsy reported chronic sialodenitis with inflammatory
lymphoplasmocytic infiltrate and intralobular infiltrate around the
ducts and the rest of the lobules, compatible with SS. Skin biopsy re-
ported leukocytoclastic vasculitis. With this finding we integrated pri-
mary SS and we started high dose steroid for ten days and
immunomodulation with hydroxychloroquine, in addition to sun-
screen and eye lubricant. The patient responded to this treatment,
with remission of cutaneous manifestations and improvement of
ocular symptomatology.
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nosis of primary SS, fulfilling the clinical, laboratory and histology
ACR-SICCA 2012 criteria, having as primary manifestation leukocyto-
clastic vasculitis. Leukocytoclastic vasculitis is a very rare systemic
manifestation of SS, reported in 5 to 10% of adults. There are no data
of the prevalence of this vasculitis in pediatric population with SS,
since the wide spectrum of cutaneous disease is yet to be described.
Pediatric presentation of SS is different from that of the adults, mak-
ing it a diagnosis challenge. It is important to acknowledge that leu-
kocytoclastic vasculitis can be the initial manifestation of pediatric
SS. A prompt identification assures an early treatment allowing an
improvement in quality of life and preventing the development of
secondary complications. Informed consent to publish had been ob-
tained from the parents.
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Introduction: The Fabry’s disease (FD) is a lysosomal storage disease,
X linked, that may affect both men and women. Mutations in alpha
Gal A gene carry a partial or total deficiency of the Galactosidase A alpha
enzyme with secondary globotriaosylceramide (Gb3) accumulation in the
skin, eyes, kidney, heart, brain and peripheral nervous system. It
generates clinical heterogeneous profiles with some specific features
according to the age groups.
Objectives: To describe a Fabry’s disease pediatric clinical case
confirmed whose clinical manifestation was the neuropathic pain.
Methods: A report about a Fabry’s disease case in a pediatric patient
is submitted
Results: 12-year old male patient, with no pathological personal ante-
cedents. Two-year evolution clinical profile showing fever episodes
each 4 months without associated infectious symptoms with a duration
of 3 to 5 days and spontaneous improvement. He has been admitted
in hospital, infectious processes discarded. In addition, he presents
burning pain episodes, described as “burning sensation” in soles and
palms with an approximate 10-minute duration, which spontaneously
or when dipping his hands in cold water get better, followed by a hand
redness and then paleness, without cyanosis. These episodes occur
each 2 to 3 months and are not related to fever. During the last 6
months, said episodes have been more frequent. No other symptoms.
No alterations found when submitted to the physical exam. Routinely
labs tests such as creatinine, ureic nitrogen, glomerular filtration rate
and transaminases, normal. Urinalysis without microalbuminuria or pro-
teinuria. Serology for cytomegalovirus, Epstein barr, toxoplasma and
HIV, negative; 0 mm tuberculin. Medical imaging studies on abdomen
and thorax with no alterations. Electromyography and nerve conduc-
tion studies on the four extremities, normal. Because of FD suspicion,
alpha galatosidase A studies were performed in a drop of blood in filter
paper, reporting in 0,48 nmol/ml/hour (reference for males with FD 0,0
– 03 nmol/ml/hour). Serum complement (C3, C4, Ch50), ferritin, albu-
min, immunoglobulin A, G, M, Normal. Immunoglobulin E elevated for
his age. He was assessed by pediatric ophthalmology confirming the
presence of cornea verticillata. Molecular study performed evidencing a
GLA sequence analysis abnormal: exon 1, c.128delG, pGly43Alafs*78
previously reported in the database as a pathological mutation.
LysoGB3 levels: 112 ng/ml (<0,8 ng/ml) by high-resolution liquid chro-
matography. Sent to genetics where family tree and counselling arecarried out and starting a therapy of enzymatic replace with alpha-
galactosidase beta each 2 weeks. Levels of enzymatic antibodies taken,
negative.
Conclusion: FD is the second more frequent lysosomal storage
disease because among its pathophysiological aspects, the abnormal
Gb3 storage in multiple tissues endothelium, triggers structural
alterations which alter the normal function thereof resulting in a
large set of clinical manifestations. The neurological compromise,
typical of an early damage of both the little somatic peripheral
nervous fibers and the autonomic ones is one of the earliest
observed symptoms predominantly in males. The neuropathic pain
of the case presented was the only clinical manifestation, and it
teaches us to highly suspect of the large variety of symptoms, which
must be timely recognized by the clinician in order to make an early
diagnosis and thus to initiate the enzymatic supply therapy to
improve both the prognosis and the patient’ life quality. Informed
consent to publish had been obtained from the parent.
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Introduction: IgG4-related disease (IgG4-RD) is a wide spectrum of
fibro-inflammatory diseases that affect many organ systems and
characterized by storiform fibrosis, mild to moderate tumor-like eosi-
nophile and significant IgG4- producing plasma cell infiltration in
histopathology, and the high level of serum IgG4 concentration. Its
pathophysiological mechanism is unclear; however, when untreated
may lead to fibrosis and irreversible organ damage. This rare disease
mostly has been described in middle-aged adults and more rarely in
children. Enlargment of lacrimal and salivary glands, cervical lymph-
adenopathy, retro-orbital and other organ pseudotumors, pancrea-
titis, sclerosing cholangitis and mesenteritis,retroperitoneal fibrosis,
pulmonary and aortic inflammatory disease, thyroiditis, and joint dis-
ease are some aspects of the disease.
Objectives: To report a boy with orbital mass with final diagnosis of
IgG4-related disease
Methods: -
Results: Case report: Herein, a 12-year-old boy is reported which pre-
sented with orbital mass. He had high IgG4 serum level (175 mg/dl)
and histopathologic manifestation of pseudotumor compatible with
IgG4-RD. Investigation for other organ involvements as part of the
IgG4-RD spectrum was normal. After resection of tumor and treat-
ment with an oral corticosteroid, 9 months follow-up has not been
shown flare.
Conclusion: Recognition of IgG4-RD spectrum condition leads to
early diagnosis and treatment of the disease and so is important be-
cause it is usually responsive and prevent fibrosis and organ dam-
ages. Informed consent to publish had been obtained from the
parent.
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Introduction: Fever is the most common reason for pediatric
counseling and when it becomes persistent, even the most rare
causes need to be considered.
Objectives: We present the diagnostic approach to persistent fevers
in pediatric patients by describing 5 exemplary case reports.
Methods: Diagnostic hypotheses were formulated according to the
medical history, detection of pathological signs at the physical
examination and the results of laboratory and imaging tests.
Results: Case report 1. 3-year-old girl with high fever recurrent every
month since a year, lasting about 5 days and associated with pharyn-
gitis, aphthous stomatitis, cervical lymphadenitis with neutrophilic
leukocytosis and increased erythrocyte sedimentation rate (ESR) and C-
reactive protein (CRP). Between episodes, the patient was asymptom-
atic and laboratory tests were normal. With the passing of the years,
these episodes were reduced in intensity and frequency until they dis-
appeared completely 6 years later. The patient, nowaday adult, has
grown up normally thus confirming PFAPA syndrome diagnosis.
Case report 2. In the last 6 months, 8-year-old male child reported 5 epi-
sodes of periodic fever, lasting about 3 days and associated with abdom-
inal and thoracic pain, arthralgia and myalgia particularly in the lower
limbs. Laboratory tests showed neutrophilic leukocytosis and increased
ESR and CRP, while diagnostic imaging tests were negative. Suspected
diagnosis of FMF was confirmed by genetic analysis and satisfactory re-
sponse to colchicine therapy.
Case report 3. 14-year-old girl with intermittent fever (37,5°C- 37,8°C)
since 2 month, associated with asthenia and pains in the lower limbs.
Physical examination showed arthritis of the knees. Diagnostic tests
showed anemia, increased ESR and CRP, presence of antinuclear anti-
bodies (ANA), anti-native DNA and anti-Sm antibodies confirming the
diagnosis of SLE.
Case report 4. 10-year-old girl reported muscle weakness associated with
low-grade fever since about a month. Physical examination showed mus-
cular hypostenia in the upper and lower limbs and in the neck muscles,
Gottron papules in the metacarpophalangeal joints and eyelid rash.
Blood tests showed an increase in ESR, CRP, muscle enzymes (LDH, aldol-
ase, CK and transaminases) and presence of ANA. Electromyography re-
vealed reduction in amplitude and duration of action potentials;
magnetic resonance imaging revealed signs of muscular inflammation
confirmed at biopsy, thus supporting JDM diagnosis.
Case report 5. 13-year-old girl reported several episodes of persistent
fever lasting 3 - 4 consecutive days since at least 1 year. Physical
examination revealed maculo-erythematosus rash, splenomegaly and
asymmetric polyarthritis of the knee, hip, ankle, wrist and hip, while
blood tests showed anemia, increased ESR and CRP, leukocytosis and
thrombocytosis. Blood culture, bone marrow needle aspiration, the
research of vanilmandelic and homovanillic acid in the urine all
turned out to be normal. Radiological examinations of the jointsaffected by signs of arthritis highlighted just joint space narrowing
and erosions, thus finally confirming s-JIA diagnosis.
Conclusion: Persistent fevers in pediatric patients may have not only
an infectious, vasculitic or oncologic etiology, but also autoimmune
or autoinflammatory causes. Informed consent to publish had been
obtained.
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Introduction: Longitudinal evaluation of the pediatric rheumatology
practice help to establish the spectrum of childhood rheumatic
diseases and the role of pediatric rheumatology programs in
evaluating children rheumatic diseases and conditions that mimic
rheumatic diseases, exposing the difficulties to achieve some
diagnosis.
Objectives: To analyze a longitudinal maintained pediatric rheumatology
clinic disease prospective registry.
Methods: A total of 3.451consecutive referrals to Coimbra’s Pediatric
Rheumatology Department during the period 1987–2017 (31 years)
were analyzed. The main diagnosis, 1 to 4 per patient, were prospectively
analyzed. The diagnostic criteria of each disease or syndrome were those
used in recent textbooks of Pediatric Rheumatology1,2. Patients were
classified in 25 large groups. The non-classifiable conditions were
grouped into symptomatic groups.
The main diagnosis (no more than four per patient) were
recorded.The diagnostic criteria of each disease were those used in
recent textbooks of Pediatric Rheumatology1,2. Patients were
classified in 25 large groups. The non-classifiable conditions were
grouped into symptomatic groups.
Results: Among the 3.451 patients we established 4.147 different
diagnosis: average 1,2 diagnosis/child, justifying 120% of diagnosis
comparatively to the number of patients.
The distribution of the 25 groups was: 1. Pediatric Juvenile arthritis
(JIA) 15,9%; 2. Nonspecific musculoskeletal pain 15,5%; 3. Amplified
pain syndromes 8,9%; 4. Connectivitis (systemic lupus erythematous,
neontal lupus erythematous, juvenile dermatomyositis, sclerodermas,
mixed connective disease an undifferentiated connective tissue,
Sjogren syndrome) more Arthropaties (Chronic inflammatory bowel
disease, Immunodeficiencies, Erythema pernium, Celiac disease,
Hypertrophic osteoarthropathy, Paraneoplasic arthritis) 8,5%; 5.
Orthopedic conditions 6.0%; 6. Laboratory diagnostic investigation
unduly valued for excess 5,5%; 7. Systemic vasculitis 5,2%; 8. Uveitis
(5,0%); 9; Reactive arthritis, Recurrent transient synovitis of the hip and
Palindromic rheumatism 4,9%; 10. Vascular acrosyndomes 4,8%; 11.
Infections 3,8%; 12. Nonspecific arthritis 3,7%; 13. Dermatologic
conditions including Erithema nodosum 3,5%; 14. Rheumatic fever and
Poststreptococcal arthritis 3,4%; 15. Recurrent oral aphthous 3,3%; 16.
Allergic conditions, mainly serum-like disease and Idiopathic Chronic
Urticaria 2,7%; 17. Autoinflammatory diseases 2,5% (CRMO and PFAPA
2,1%) ; 18. Degenerative conditions, including skeletal dysplasias 1,7%;
19. Prolonged or recurrent fever 1,4%; 20. Autoimmune thyroiditis,
autoimmune hepatitis and celiac disease 1,3%; 21. Malignant diseases
Table 1 (abstract B43). See text for description.
Variable Description No. (%)
Sex Women 10 (32.3)
Men 21 (67.7)
Vital status at the time of review Alive 30 (96.7)
Dead 1 (3.3)
Patients who received some treatment Yes 22 (71)
No 9 (29)
Number of medications received One 10 (32.3)
More than one 12 (38.7)
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 234 of 2431,2%; 22. Others ophthalmologic conditions 1,1%, 23. Normal variants
1,0%; 24. Vascular malformations 1,0% (primary and secondary lymph-
edema 0,6%); 25. Miscellaneous conditions 9,9%.
Globally, “Rheumatic Diseases” represent 45,4% (Groups 1, 4, 7, 8, 9,
14, 17) and “Non Rheumatic Diseases” 54,6%.
Conclusion: The many differential diagnosis of the rheumatic diseases
justifies the reason for the many different pathologies observed in
pediatric rheumatology units. It also justify that less than half of the
patienets observed in our unit had the classic “Reumatic Diseases”.
The sum of Nonspecific musculoskeletal pain, Amplified pain
syndromes and excess Laboratory diagnostic investigation
represents 30% of patients observed, also justifying the need of
training in basic issues of pediatric rheumatology.
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Introduction: Herein we describe an unusual finding of raghib
syndrome(an unroofed left superior vena cava) in a case of
autoimmune pancreatitis with IgG4 related disease(AIP/IgG4RD) .
Objectives: Autoimmune pancreatitis (AIP) is a rare form of chronic
pancreatitis with characteristic clinical, histologic, and morphologic
findings rarely reported in children which clinically present with
abdominal pain, weight loss, and jaundice also introduced by
Kamisawa as a syndrome characterized by elevated serum IgG4
levels, prominent lymphoplasmacytic infiltrates with increased IgG4+
plasma cells, and dense sclerosis.time is still needed till its cardiac
complications and assosiation be declared.
Methods: after thorough history taking and physical examination
a standard transthoracic echocardiography performed by expert
pediatric cardiologist.
Results: after visualization of a dilated coronary sinus,contrast
echocardiography by injecting agitated salin via left antecubital vein
performed at first, which revealed entrance of bubbles into left atrium
that is charactristic of unroofed LSVC.then it was confirmed with a
more accurate procedure of transesophageal echocardiography.
Conclusion: Raghib syndrome is an extremely rare congenital
heart defect characterized by persistent left superior vena cava
(LSVC) draining into the left atrium and absence of the coronary
sinus.An unroofed left superior vena cava (LSVC) is usually
asymptomatic and diagnosed incidentally although it gives rise to
increased risk of paradoxical embolism. The standard technique
for the diagnosis is echocardiography, either transthoracic or
transoesophageal.Up to now some cardiac complications like
lymphoplasmacytic aortitis is described in association with AIP
but best of our knowledge occurrence of raghib syndrome or
unroofed LSVC in a case of AIP hasnt been reported yet
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Introduction: The Autoimmune Lymphoproliferative Syndrome (ALPS) is
a disease associated to alterations in apoptosis due to a genetic defect
(mutations of the FAS, FASLG and CASP10 genes), characterized by a non-
neoplasic lymphoproliferative state and fever for more than 6 months.
Objectives: Describe clinical presentation, treatment and outcomes of
ALPS patients followed at a Pediatric Hospital Center in Colombia.
Methods: A retrospective observational study was conducted, 2300
clinical records of children attended at Fundación HOMI between
2010 and 2016 . Based CIE-10 codes 31 cases met clinical criteria of
NIH for ALPSDemographic characteristics, clinical presentation and la-
boratories were recollected in a Microsoft Excel® sheet. Stata 8® soft-
ware was used to statistical analysis
Results: Of the 31 patients , 67.7% were male, Average age at diagnosis
was 6 years old (6 months to 15 years old). Among the reasons for
consultation we found that fever and lymphadenopathy was the most
frequent symptom (96.7%), followed by hepatomegaly (58%),
splenomegaly (54%), exanthema (25.8%) and arthritis 2(2.6%). Doubly
negative lymphocytes high count was founded in in all cases (values
between 1.5% and 16.2%). B12 vitamin average was 987.5 ng/L (range
237-2000ng/L) and total immunoglobulin G levels was found 240 – 5104
mg/dl. Molecular studies for mutations in the FAS, FASLG y CASP10 genes
were negatives in 9 cases, in 7 patients was pending at moment of this
revision, and was not possible to do in 15 due to administrative limita-
tions from insurances.Table 1 summarizes the characteristics of the pa-
tients. About treatment in acute phase, 20 patients received oral
corticosteroids, 7 patients with thrombocytopenia received intravenous
immunoglobulin (IVIg) , and 8 children with hemolytic anemia received
methylprednisolone. Maintenance medications include: Cyclosporine A
in 6 patients, methotrexate in 5 cases with joint manifestations, myco-
phenolate mofetil in 3 children, sirolimus in 2 cases with refractory
thrombocytopenia and rituximab in 1 patient.
Conclusion: All patients this study configure probable diagnosis
of ALPS since none has positive genetic test for apoptosis
mutations, although 40% of the cases do not have any mutation
according to the literature. The ALPS is confused with other
hematology, oncology and autoimmune diseases for its
presentation. The ALPS is a non-prevalent genetic disease that
should be considered in patients with signs of chronic lympho-
proliferation without neoplasic pathology.
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Table 1 (abstract B44). Demografics of patients undergoing IAS
and results of the survey
Individual patients 63, 19 male*
Disease subtype
Systemic -
Oligoarticular 45
Polyarticular 10
Psoriatic 1
ERA 2
Undifferentiated 1
Juvenile dermatomyositis 1
Seropositive RA 1
Purulent arthritis 1
Joint pain 1
Appointments for IAS 93*
Injections 174*
Relevant for physio: appointments for IAC/patients 75/ 49 (14 male)
Follow ups within time 40 (53%)
Total number of follow ups 69 (92%)**
Median time to follow up 27 (range 8-119)
Effect at follow up when documented ***
+ (good) 32 (46%)
+/- (major effect but not complete) 14 (20%)
- (no or minor effect) 18 (26%)
*4 patients (2 male); 7 appointments; 10 injections: only have their doctor at DSBUS rest
of team at local hospital. **100% were offered follow up, 6 appointments cancelled by
patient/family. ***Effect was not well documented in charts at all follow ups
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Introduction: Background:
When treating active arthritis in juvenile idiopathic arthritis (JIA)
intra-articular corticosteroid injections (IAS) are an action of im-
portance (1-4). IAS has been proven a safe and efficacious treat-
ment for active arthritis either as single treatment or in
combination with medicine therapy. IAS have been shown to
drastically relieve pain, swelling and to increase mobility in the
injected joint (1-4). At our clinic the patients who receive IAS
are to be offered a follow up at the physiotherapy department
or occupational therapy department (depending on the joint
injected) within two to four weeks following the injection, ac-
cording to the care program. As to this date there has been no
survey at our clinic to show how many patients are followed up
as agreed.
Objectives: 1) How many of the patients are offered follow up at the
physiotherapy clinic within two to four weeks after IAS? 2) What is
the time between the injection and the actual follow up? 3) What
was the effect of the IAS?
Methods: A retrospective review of the patient registry and charts
at the rheumatology clinic at Queen Silvia Children's Hospital,
during January 1st - December 31st 2017.
Results: The total number of individual patients who received IAS
during 2017 at the rheumatology clinic was 63. The number of
appointments for IAS was 93 and the number of injections given
was 174. The department of physiotherapy followed up a total of
92% the patients relevant for physiotherapy. Out of these, 53%
were followed up within 28 days. Of the patients followed up
46% experienced good effect of the injection, though the effect
was not always well documented in the charts. See Table 1 for
details.
Conclusion: All patients were offered follow up, however not
always in time. Of patients 92% were followed up and 46%
received good effect from the injection. This retrospective study
has lead to a further development of the post-injection assess-
ment of the patients with a more structured guide how to evalu-
ate the effect of injections. A further question to evaluate is the
actual care programme, if it functions as intended, with an effi-
cient communication within the team, and as to what happens in
case of no effect of the injection, are the patients offered a doc-
tor’s appointment earlier or even another injection? Another im-
portant matter is if the care programme is relevant for the
patient.
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Introduction: Rheumatic diseases in children are a multisystemic,
heterogeneous group of diseases involving mainly the muscoloskeletal
system resulting in disability. The multidisciplinary approach is essential
in the management of rheumatic diseases in children.
Objectives: Aim of this study is to evaluate the rehabilitation aspect of
the child with chronic rheumatic disease in a more holistic view of his care
and his recovery. Rehabilitation must be based not only on diagnostic and
prognostic evaluation of the damage but also the awareness of the
repercussions of the motor impairment on the psychomotor, intellectual,
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 236 of 243and emotional development. Equestrian rehabilitation (ER) is not a
method but a rehabilitative practice using the horse as a mean of
rehabilitation, the horse facilitates postural, motorial, perceptive and
relational-motivational reeducation; ER is therefore a therapeutic interven-
tion methodology that is an individual rehabilitation project.
Methods: Besides clinical assessment of different types of arthritis, the
specific rehabilitative aspects (joint evaluation, muscular strength,
CHAQ, VAS dolor) must be evalueted, around which must organizing
the intervention and the objectives. ER consists of 3 levels of
intervention:1.horse therapy (hippotherapy), uses bodily features of the
horse to the gait where the horse transmits to the child over three
levels (longitudinal, transverse and sagittal plane) the correct human
gait, playing a physiological pattern movement. At this level you are
working on fine motor movements, balance, laterality, body image and
cognitive aspects of attention-perception; 2.re-education trought horse
riding, aims to achieve autonomy in the conduct of the horse; at this
level you are working on the body pattern, lateralization movements
with the use of the reins in the conduct of the horse, the balance on
the saddle with stirrups, on fine motor coordination, on taking the
reins, and space-time continuity, both sensory and motor; at this level
we can introduce the trotting gait stimulating the adaptive, coordina-
tive capacities in the relationship with the horse. The motivational as-
pect are so stimulated that leads to the pattern of movement;
3.equestrian rehabilitation therapeutic group (disability group).
Results: In horse-assisted therapy observations are made on the ef-
fects on the neuromuscular system of the patient caused by the
mechanical influence of the horse walk. Specific to the horse therapy
is that the patient continuously receives impulses from the horse
walk, which lead to a relaxed perception of the body, equilibrium,
and coordination of movement.
Conclusion: In horse-assisted therapy observations are made on the
effects on the neuromuscular system of the patient caused by the
mechanical influence of the horse walk. Specific to the horse therapy
is that the patient continuously receives impulses from the horse
walk, which lead to a relaxed perception of the body, equilibrium,
and coordination of movement.
Trial registration identifying number: Rehabilitative therapy during
childhood and adolescence is aimed primarily to prevent primary
damage effects produced by sensory-motor development. The child
with a disability due to chronic rheumatologic disease must follow a
rehabilitation program aimed to the functional motor recovery and
also psycho-affective recovery in which the horse is the rehabilitation
mean.
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Introduction: Previous studies have linked maternal Rheumatoid
Arthritis, Systemic Lupus Erytematosus, and other rheumatic
diseases with preterm birth and low birthweight. Now a growing
evidence suggest increased rates of learning delays among offspring
of mothers with rheumatic diseases and associations between autism
spectrum disorders, dyslexia and other neurocognitive dysfunction.
There is a lack of evidence about neurological maturational changes
and behavioral functioning the first year of life of children born to
women with rheumatic diseases, and the relation betweenmaturational abnormalities and their mothers disease diagnosis,
evolution and treatment.
Objectives: To describe the neurological assessment and birth
outcomes of children born to women with rheumatic diseases.
Methods: Children born between July 2017 and April 2018 of
mothers attended at Hospital Universitario “José Eleuterio González” in
Monterrey, Nuevo León, México with rheumatic diseases were included
in this cross-sectional study. Descriptive data, demographic, clinical and
laboratory results were collected form mothers and offspring. Amiel-Tison
Neurological Assessment at Term (ATNAT), a 35 item test was used to
evaluate the maturity of the children.
Results: Nine children were evaluated, the median of gestational
birth age was 38.6 (33.4-43.4) weeks, the birth of female gender was
more frequent (n=7), the mean of birth weight was 2,990 grams
(S.D ± 105.2 grams) , the mean of length was 48.8 ± 2.47cm ,
cephalic perimeter median 33.07 (34-36) cm.
The median of mothers age was 32 years (19 – 42), Rheumatoid
Arthritis was the most frequent rheumatic disease (55.7%), the
disease was considered active in 71.4%, with only 2 patients were
without medication and the most frequently received treatment
was sulfasalazine. The neurological assessment showed alteration
in 88.8%, with predominance in muscle tone as spontaneous motor
activity (n=7), the 57% showed hypertonia in neck flexors. When
directed, there were alterations in the way of loading the child,
which was modified predominantly by pain in the upper
extremities, position which would explain the alterations in the
tone found in the patients evaluated.
Conclusion: This study showed an important relation between the
mother diagnoses, its activity degree, and neurological maturity
abnormalities in their children. The musculoskeletal affection in
rheumatic diseases especially the upper extremities apparently
affects the maturity of the children due to the erroneous racing
way. We propose the realization of prospective studies that
evaluate the response to interventions and the modification in
neuronal maturation in these patients. In addition to reporting
evidence of alterations in the neurodevelopment of children of
mothers with musculoskeletal involvement, secondary probably to
changes in the way of parenting.
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Introduction: Juvenile scleroderma is a rare multisystemic
autoimmune disease. The two main forms of the disease
are localized scleroderma (LS) and systemic sclerosis (SSc). In juvenile
LS fibrosis involves limited areas of the skin.
Objectives: This study was established as a retrospective review of
the patients diagnosed and followed-up in Sağlık Bilimleri University
KSSEAH Pediatric Rheumatology outpatient-clinic as JS between the
years 2012 and 2018. Our purpose was to report our single-center
experince with JS.
Methods: The medical charts of patients diagnosed and followed-up
as JS between the years 2012–2018 retrospectively. Totally 24 pa-
tients were enrolled to the study. Data recorded included age, sex,
age at disease-onset, age at-diagnosis, delay to the diagnosis, pres-
ence of consanguinity, laboratory data, family history of both sclero-
derma and any other autoimmune disease, treatment modalities and
outcomes.
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were reviewed. One patient (a boy, 4.17 %) had SSc and 23 patients
(%95.83) had LS. The ratio of female (n: 19) to male (n: 5) was 3.8:1.
The mean age 12.38±3.97, mean age at the onset of symptoms was
9.13 ± 4.13 years. All patients were treated with oral prednisolone
and oral or subcutaneous MTX. The treatment of 4 patients (16.67 %)
were changed to mycophenolate mofetil and 1 (4.17 %) was
changed to cyclosporine because of unresponsiveness or intolerance.
Eight patients (33.33 %) were treated with local steroids and 4 were
treated with topical tacrolimus (16.67 %) in addition to systemic
treatment. Two generalized scleroderma patients treated with IVIG
(8.33%).Capillaroscopic findings [n (%)] 4 (16.67%)Raynaud’s phenomenon [n (%)] 3 (12.50%)Arthralgia [n (%)] 6 (25.00%)Arthritis [n (%)] 4 (16.67%)Contracture [n (%)] 7 (29.17%)Uveitis 0 (0%)Conclusion: SSc is very rare in children. The incidence of juvenile SSc
is around 0.05 per 100,000 children. In our study the ratio of SSc to
LS was 1/23. Juvenile LS (JLS) is more common in girls (female to
male ratio 2.4: 1) with mean age-at onset of 7.3 years. According to
our results, female-to-male ratio of LS was 3.8/1 and the mean age-
at-onset of LS was similar to literature as 9.13±4.13 years. Laboratory
results are suggestive, but not specific enough for diagnosis of
scleroderma. There is no single therapy for JS. MTX had been suc-
cessfully used both in adults and in children with localized sclero-
derma. MTX and/or corticosteroids (oral or intravenous) are accepted
as first line treatment.
In conclusion, juvenile scleroderma is very rare in children, and
characterized by the thickening and hardening of the skin. Most
presented as a localized form of the disease. Close monitoring of the
disease status and treatment response is important for clinical
evaluation and early clarification of disease complication. The
prognosis of LS in children is
better than in adults. If disease showed progressing clinically, it
should be treated aggressively even when the skin lesion are
localized initially. There is a need for new studies for better
understanding of the prognosis, evaluation of the disease and new
treatment modalities.
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Introduction: SAPHO syndrome (synovitis, acne, pustulosis, hyperostosis,
osteitis) belongs to autoinflammatory diseases without genetic
correlation. The incidence of the disease is very low, and the
disease is classified as an orphan disease. In addition to skin
manifestation, clinical manifestation includes musculoskeletal symptoms,
with a dominant affection of the axial skeleton, therefore the SAPHO
syndrome is currently classified as juvenile spondylartropathy. A frequent
location of aseptic inflammation, in addition to axial involvement, is the
area of the anterior wall of the chest – sternoclavicular and sternocostal
joints. The syndrome may not be fully expressed – skin manifestations
often occur independently, and only after several months, synovitis andosteitis develop, or vice versa. In the active stage of the disease,
increased inflammatory parameters (erythrocyte sedimentation, CRP) can
be observed. Imaging examinations (magnetic resonance imaging and
scintigraphy) have an irreplaceable role in diagnosis. Differential
diagnosis is necessary to exclude particularly an infectious process and
neoplasia, therefore biopsy examination is a “gold standard”. Current
treatment options include the use of disease-modifying anti-
inflammatory drugs (NSAIDs, antibiotics, corticosteroids, sulfasalazine,
methotrexate). For relapsing and high-activity forms of the disease, there
is sufficient data on the use of biological treatment (adalimumab, inflixi-
mab). The response to the treatment determines the prognosis of the pa-
tients; with the good response to DMARDs, the prognosis is optimal.
Objectives: We present the case of a 17-year-old patient initially ad-
mitted with back pain in the lumbosacral region. In the course of
two weeks, the condition progressed into a spastic triparesis with the
impossibility of independent walking. The patient had a history of a
total and local acne conglobata treatment lasting for several months.
Laboratory parameters showed high inflammatory activity with insuf-
ficient response to broad-spectrum antibiotic therapy. Cerebrospinal
fluid analysis and imaging examination of brain, C, Th, LS spinal cord
without pathology. Due to oedema and tenderness of the sternocos-
tal joint to the left, the MR examination was carried out with the
finding of an inflammatory process – osteitis; the SAPHO syndrome
is considered for the first time. Scintigraphy with a picture of high re-
arrangement and increased perfusion in the clavicle, in the sternocla-
vicular joints, sacroiliac articulations, in both ischial bones. Biopsy of
the sternoclavicular joint confirmed chronic non-specific synovitis.
Based on both clinical and laboratory findings, the patient met the
SAPHO syndrome criteria.
Methods: Case report.
Results: The purpose of the case report was to point to differential
diagnostic pitfalls, which led to a definitive diagnosis of autoinflammatory
disease. At the same time, we provide an overview of the current
therapeutic options for this rare disease , especially the effectiveness of
biologic drugs in our case.
Conclusion: The purpose of the case report was to point to
differential diagnostic pitfalls, which led to a definitive diagnosis of
autoinflammatory disease. At the same time, we provide an overview
of the current therapeutic options for this rare disease , especially
the effectiveness of biologic drugs in our case. Informed consent to
publish has been obtained from the patient.
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Introduction: Systemic juvenile idiopathic arthritis (sJIA) has a special
place among childhood arthritis with a broad spectrum of mild to
severe joint problems and significant extraarticular features.
Objectives: It is aimed to present the characteristics of sJIA patients
who are followed in Izmir Dr. Behcet Uz Children’s Hospital.
Methods: The medical files of 12 sJIA patients who are followed in Izmir
Dr. Behcet Uz Children’s Hospital were investigated retrospectively.
Results: Six girls and six boys with sJIA were included in the study.
The median age was 115.5 months (min-max: 15-195 months), me-
dian diagnosis age was 74,5 months (min-max: 10-122 months), and
median follow-up time was 20 months (min-max: 1-84 months). The
median delay for the diagnosis was 12 days (min-max: 7-30 days). All
the cases had intermittent fever. The half of the patients showed
rashes and/or joint involvement. Serositis was present in only one
Table 1 (abstract B51). Correlation between spot protein/creatinine
ratio and 24 hour urine protein
Spot protein/
creatinine ratio
n 24 hour urine protein Significance
(p value)r value
overall 209 0.669 0.001
<0.5 65 -0.083 0.51
0.5-1 45 0.347 0.019
>1 99 0.579 0.01
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 238 of 243patient (8.3%). The complications were as follows: macrophage acti-
vation syndrome (MAS) in 4 patients, and severe growth retardation
due to long-term corticosteroid use in 1 patient. Lymphadenopathy,
HSM, and uveitis were not present in any cases. The cases were using
the following medications: NSAID (8.3%), steroid (41.7%), methotrex-
ate (66.7%), anakinra (8.3%), canakinumab (25%), tocilizumab (33.3%).
While no remission was achieved in 1 case, 9 cases achieved remis-
sion under medical treatment. Two patients (16.7%) have achieved
remission without need of medications. The laboratory findings
regressed to the normal levels following the treatment (p<0.05).
Conclusion: sJIA is a differential diagnosis and it might take a while to
diagnose a patient with sJIA. This delay might lead unwanted situations
as MAS. sJIA might be controlled with proper treatment plans.
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Introduction: In children with lupus nephritis, 24 hour estimation of
urinary protein measurement is considered as gold standard. But it is
fraught with difficulties of collection.This study was undertaken to
find out if a random urine spot protein/creatinine is reliable and can
be interchanged with a 24 hour urine protein estimation
Objectives:
1. To find out the correlation of spot protein/creatinine
estimation and 24 hour urine protein estimation
2. To find the value of spot protein/creatinine ratio that best
correlates with the 24 hour protein value
Methods: 209 paired samples of spot protein/creatinine ratio and 24
hour urine protein were retrospectively recorded from charts of 64
children with lupus nephritis.
Statistical analysis was done using SPSS version 16.1.
Results: Spot protein creatinine ratio showed a good correlation with
24 hour urine protein values with p value <0.01.The correlation was
poor for spot protein/creatinine ratio <0.5(p value=0.5).
Using ROC, the cut off value of spot protein creatinine ratio to predict
nephrotic range proteinuria (>1gram) was 1.81 with area under curve
95%(0.875). 95% confidence interval(0.817-0.932). Sensitivity 73.1%,
specificity 90.8%. Positive predictive value is 0.79, negative predictive
value 0.87.
Conclusion: The spot protein/creatinine ratio in ranges>0.5 correlate
well with 24 hour protein values and can be reliably used in routine
clinical practice.The urine spot protein/creatinine ratio can thus be
utilised fairly accurately as a guideline to determine whether child
has nephrotic range proteinuria or not.It however cannot be used
interchangeably in higher values of spot protein/creatinine ratio.
References
Christopher-Stine L, Petri M, Astor BC, Fine D. Urine protein-to-creatinine ratio is
a reliable measure of proteinuria in lupus.J Rheumatol 2004;31;1557-1559Lane C,Brown M,Dunsmuir W,Kelly J,Mangos G. Can spot urine protein/
creatinine ratio replace 24 h urine protein in usual clinical nephrology?
Nephrology 2006; 11, 245–249
Disclosure of Interest
None DeclaredB52
DIFFICULTIES IN DIAGNOSING LUPUS-LIKE SYNDROMES
Olena A. Oshlyanska1, Agar G. Artsymovych2
1Department of Pediatrics № 1, Shupyk National Medical Academy of
postgraduate education; 2Department of connective tissue disorders in
children, State Institute of Pediatrics, Obstetrics and Gynecology,
Academy of Medical Sciences of Ukraine, Kyiv, Ukraine
Correspondence: Agar G. Artsymovych
Pediatric Rheumatology 2018, 16(Suppl 2):B52
Introduction: The symptom complex of some rheumatic diseases
develops gradually. Various combinations and overlop-syndromes are
described. In recent years, more scholars have focused on the devel-
opment of genetically determined forms of autoimmune diseases, in-
cluding lupus, an analysis of the peculiarities of their clinical course
and treatment.
Objectives: To analyze the features of the pediatric case of systemic
lupus erythematosus (SLE).
Methods: analysis of data of medical documentation
Results: Boy 14 y old. From birth, there was a rash on the skin. At
1,5 y he had thrombocytopenia. Frequent infectious diseases. At 3
y. episodes of bronchoconstriction. At 12 y. edema of the ankle
joint, hyperthermia, hepatolienal syndrome, carditis, positive
antinuclear antibodies. Diagnosed sJIA: GC, methotrexate. The
effectiveness of therapy was partial: pain syndrome and temporary
synovitis persisted, pericarditis was detected. GC was increased
periodically. At 13 y. rescribed tocilizumab. At 14 y. cramps of limbs
were added, polyneuropathy was registered on EMG. Antibodies to
MPO, PT3, glomerular membrane, APL were negative. At MRI of the
brain, pathological changes were not detected at that time. At
14.5 y., bullous changes of the skin. At 15 y. daily loss of
consciousness, convulsions in the limbs, pain in the joint, gait
disturbance. Child had exogenous hypercorticism, malar rash, erythema
on the elbow and popliteal, livedo on the lower limbs, keloid scars on
the lumbar cluster. Leg and foot were paste. Weakening of breathing in
the lower parts of the lungs, tachycardia 115, liver +2 cm. No synovitis
found. Left tongue deviation. Weakness in the left leg. Increase of
tendon reflexes and positive plantar reflex on the left, knees and ankles
clonus. EEG the predominance of slow-wave paroxysms in the mid-
back segments of the cerebral hemispheres. Blood leukopenia,
thrombocytopenia, ESR 2 mm/h. Significant changes in the biochemical
study were not detected. Calcium, kalium, Ck were normal, LDH 335U/l.
Results of immunological studies: IgG 5.0, IgA 0.43, IgM 0.31 g/l, ANA,
APLAb, lupus anticoagulant, anti-dsDNA negative. Complement level is
normal. Blood lymphocyte subpopulation: lymphopenia, deficiency of
B-lymphocytes 2.58%. US-examination: hepatomegaly. Spirography: dis-
turbance of ventilation capacity of the lungs by obstructive type. CT of
chest: exudative pericarditis, inflammatory fibrosis S1-3 on the left, S3
on the right. Head MRI: cerebrovascular accident ischemic type in the
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Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 239 of 243basin of the right posterior cerebral artery. In order to clarify the nature
of the inflammation, a skin biopsy was performed: lymphocytic infiltra-
tion around the vascular bundles, vascular walls with microvessel
thickening, fibrinoid swelling, endothelium with manifestations of dys-
trophy. A part of vessels are with obliteration of lumens, vacuolic dys-
trophy of the epidermis, focal fibrinoid swelling. These changes
allowed to completely eliminate sarcoidosis and treat the disease as
SLE. Due to the impossibility of conducting genetic studies, clinical dif-
ferential diagnosis was performed between the forms of the congenital
lupus. The presence with an early onset, infectious syndrome, lung in-
jury, CNS, hematologic and lymphoproliferative syndrome, cold
changes, absence of antibodies to DNA, ANCA, normal level of comple-
ment and IgM, indicated the possibility of interferonopathy. Correction
of therapy has been performed: the dose of GС was increased to 1.5
mg/kg/d, DMARD has been changed to cyclophosphamide, anti-
convulsant and antihypertensive drugs have been added.
Conclusion: Possibility of development of identic symptoms in
rheumatic diseases can lead to the appointment of therapy
before establishing the final diagnosis. Improving the possibilities
of in-depth examination of the child will promote the appoint-
ment of effective therapy. Informed consent to publish has been
obtained.
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Introduction: Antiphospholipid syndrome (APS) is an autoimmune
disease that presents with recurrent arteriovenous thrombosis, repeated
pregnancy loss and elevated titers of antiphospholipid antibodies. APS
may occur as an isolated clinical entity (primary APS) or in association
with other diseases, mainly systemic lupus erythematosus (SLE). The
incidence of thrombosis in children is significantly lower than in adults
but the rate of APS-associated thrombosis in children appears to be
higher than in adults with other common prothrombotic risk factors. We
presented 16-year-old, female with SLE secondary to APS with deep vein
thrombosis as initial sign.
Objectives: .
Methods: Case reports
Results: A 16-year-old girl who was admitted to the emergency room
with the cause of pain and swelling of the left leg, hospitalized with
left-sided popliteal vascular thrombosis in Doppler USG findings. Her
medical and family history is unremarkable. In physical examination,
she was obese with a BMI 34 (>95p) and her left leg was swollen,
hyperemic and painful. Vital signs were normal. She had no rash in
her body except the discoid rash on her cheek. Blood cell counts,
liver and kidney function and urinary tests were normal, CRP: 61.08
mg / L, ESR: 6 mm / hr. In the investigations performed with the
cause of obesity, insulin resistance was shown and abdominal USG
was normal. Coagulation parameters was found as aPTT: 48,2 secs,
PT: 12,7 secs, INR: 1,16 INR, D-dimer 550 [mu] g / L. First, the anti-
factor Xa was given and then replaced by warfarin. Metformin treat-
ment was added for insulin resistance. Investigations were carried
out by the Department of pediatric hematology for thrombosis eti-
ology. Lupus anticoagulant was highly presence. Factor V Leiden,
MTHFR, prothrombin, PAI genetic analyzes were performed (Tests are
pending). She was consulted to department of pediatric rheumatol-
ogy with the reason of discoid rash. Complement C4 (6,9 mg/dl) was
decreased. Immunological tests show presence of antinuclear anti-
bodies, anti-double stranded DNA antibodies, a positive direct
Coombs test and presence of anti-phospholipid antibodies (Lupus
Anti-Coagulant high positive, anticardiolipine antibodies IgM: 69 andanti-B2-glycoprotein I IgM: >200). In the light of clinical and labora-
tory findings, diagnosis of secondary antiphospholipid syndrome to
systemic lupus erythematosus was made.
Conclusion: Venous thrombosis in children is uncommon. In most cases
several clinical risk factors for thrombosis are present. In adolescents it
may be the first manifestation of SLE. Therefore, SLE and APS should be
kept in mind in and investigated in children with thrombosis.
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Introduction: Antinuclear antibodies (ANA) are important for diagnosis
of rheumatic diseases. However, a positive ANA test is obtained
different conditions and healthy people. So routine antibody screening
is not recommended if there aren’t appropriate clinical signs.
Objectives: This study aimed to evaluate the ANA positivity rate
detected in Erciyes University laboratories.
Methods: In Erciyes University Hospitals ANA tests requested by
different specialties in 2013-2017 years assessed retrospectively. ANA
have been determined by indirect immunofluorescence (IIF). ANA
test results obtained from medical records of serology laboratory.
ANA have been determined by indirect immunofluorescence (IIF)
Results: 5999 tests requested by different specialties obtained. There
were 4940 patients when recurrent tests removed. 1323 (26,8%) of
tests were positive and 3617 (73,2%) of tests were negative. 684
(51,7%) of positive tests had ≥1/1000 antibody titers, 628 (47,5%)
had ≤1/100, 6 (0,4%) had 1/320 titers. 917 patients (69,3%) were
female, 1695 patients (46,9%) were male in positive results, and 1921
patients (53,1%) were female, 1695 patients (46,9%) were male in
negative results. 3812 patients were requested from different
pediatric clinics. 1670 (43,8%) patients were requested from pediatric
rheumatology clinic and 1229 (32,2%) patients were requested from
other pediatric clinics. When ANA assessed according to date 637
(12,9%) patients were requested in 2013, 953 (19,3%) in 2014, 1154
(23,3%) in 2015, 1038 (21%) in 2016, 1158 (23,4%) in 2017.
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 240 of 243Conclusion: In the recent years, the frequency of test requests has
increased, since the determination of ANA is more available. It is
considered that also requested ANA by other pediatric departments
besides the pediatric rheumatology department. Compared to pediatric
rheumatology department, other departments have a higher negative
test result rates. Clinical findings of patients need to be evaluated in
detail while ANA requesting.
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Introduction: Although effective in all subtypes of JIA, intraarticular
steroid injection is most frequently used in children with arthritis
where non-steroidal anti-inflammatory drugs (NSAIDs) have been in-
effective in controlling the disease and early in the disease to rapidly
resolve synovitis, provide pain relief, facilitate or obviate physiother-
apy and rehabilitation, and allow the withdrawal or avoidance of
regular systemic treatment. However, intraarticular steroids may be
used to treat an arthritis flare in children already maintained on sec-
ond line agents
Objectives: to evaluate the therapeutic response to intraarticular
triamcinolone hexacetonide (TH) injections in patients with juvenile
idiopathic arthritis
Methods: Among 17 patients with JIA (15 oligoarticular, 2 polyarticular)
included in the study, 14 girls and 3 boys. Mean age was 7.3 years, age
of diseases onset was 5.4±1.4 years. Triamcinolon hexacetonide was
administered (1mg/kg body weight ) in the knee joints. Prior to
triamcinolon hexacetonide administration 4/17 children recived NSAID,
11/17 NSAID and two children recived anti TNF inhibitor. For most
children activity of arthritis was a moderate, mean ESR was 13.4±9.3
mm/h; CRP 22±8.1mg/dl (ref <3.0mg/dl).
Results: After administration of TH, the remission of the joint
inflammation lasting three months had four children (2 oligoarticular,
2 polyarticular forme of JIA), while complete remission at least 6
months was obtained in 11/17 (64.7%) children. For two children, with
oligoarticular arthritis, remission was achieved lasting 13 months after
intraarticular TH, those children also recived anti TNF-α inhibitor.
Conclusion: Our modest experience has confirmed that the triamcinolone
hexacetonide is an effective and safe therapy for inflammatory joint
disease in JIA, particularly in the oligoarticular form
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Introduction: Biological agents (BA) against proinflammatory
cytokines (TNF alpha, IL-6, IL-1), which play a role in juvenileidiopathic arthritis (JIA) pathogenesis have become more frequently
used treatment option in recent years. Many adverse events related
to BA have been reported, but long term results are not sufficient for
pediatric patients. In addition, the switch of BA is required due to
many reasons during follow-up.
Objectives: This study aimed evaluate the adverse events and switch
reasons of biological agents based on patient follow-up data in JIA.
Methods: This was a retrospective study in Erciyes University
Hospital, Department of pediatric rheumatology, Kayseri, Turkey. In
2008-2017, 115 patients who received biological treatment with JIA
were included in the study. Adverse events and switch reasons dur-
ing the treatment were obtained from the medical records.
Results: There were 115 patients treated with BA. 43 patients (37.4%)
had enthesitis related arthritis (ERA), 30 patients (26.1%)
oligoarthritis, 21 paitents (18.3%) RF negative polyarthritis, 4 patients
(3.5%) RF positive polyarthritis, 12 patients (10.4%) systemic JIA, 2
patients (1.7%) juvenile psoriatic arthritis and 3 patients (2.6%)
undifferentiated arthritis. Mean age of diagnosis was 9,05±4,56 years.
Cumulative follow-up duration was 569,87 years (mean: 4,95±2,82
years, min-max: 0,54-14,21 years) and cumulative follow up on BA
was 298,04 years (mean: 2,59±1,77 years, min-max: 0,09-7,46 years).
Sixty patients (52.17%) were treated with only one BA. In this pa-
tients, etanercept in 26 patients, adalimumab in 28 patients, inflixi-
mab in 3 patients, tocilizumab in 3 patients were given as the first
BA. Thirty-one patients with inactive disease, 19 patients with active
disease were still treated with first BA. Biological agents were stopped
in 9 patients treated with one BA (clinical remission: 6, adverse event: 2,
lack of effectiveness: 1). Twenty-nine patients had once, 7 patients had
twice, 2 patients had three times, 1 patients had five times, 1 patient
seven times switches. For all BA switches (total n=61), the reasons were
lack of effectiveness in 36 (59%), disease activation in 9 (14.8%), adverse
event (AE) in 8 (13.1%), noncompliance to treatment in 6 (9.8%) and
macrophage activation syndrome in 2 (3.3%). In follow-up on BA, 0.67
AE/patient-year and 0,18 SAE/patient-year were recorded. Death and
malignancy were not seen. Sixty-one percent of the adverse events (n
= 122) were infections. Most common infections were respiratory tract
system infections (44.7%). Ten local reactions, 4 allergic reactions, 3
anaphylaxes were documented.
Conclusion: In JIA, biological agents are switched for many reasons
such as lack of effectiveness, disease activation, adverse event and
noncompliance to treatment. In our study, most common reason of
switch was the lack of effectiveness. Also, many adverse events such
as infections are frequently seen during treatment with these agents.
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Introduction: Behçet Disease (BD) is described as a vasculitis that can
affect arteries or veins of any size, and is characterized by recurrent oral
and/or genital aphtous ulcers accompanied by cutaneous, ocular, articular,
gastrointestinal, and/or central nervous system inflammatory lesions.
BD is extremely rare in pediatric population and children only consist
of 5.3-7.6% of all the Behçet patients. Neurologic involvement is 5-
15% in pediatric Behçet.
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 241 of 243Objectives: The aim of study, pediatric Behçet patients with neurologic
involvement evaluate that demografic datas and clinical features,
nerological finding and treatments.
Methods: Four pediatric Behçet patients with neurologic involvement
according to International Study Group Criteria who are followed in
Dokuz Eylul University, Faculty of Medicine, Pediatric Rheumatology
Unit was included in the study.
Results: There were 2 female and 2 male patients. The ages were
between 11.5 and 14.5 years (average age: 13.4 years) in the time of
the diagnosis. The delay in the diagnosis was 10.5 months (1-27
months). Average follow-up time was detected as 41.2 months.
Headache was present in all patients, while a patient reported blur-
ring of vision, a patient reported orbital pain and other two patients
reported nausea and vomiting. The prediagnosis was pseudotumor
cerebri in two patients, thrombophilia in one patient and multiple
sclerosis in one patient. Behçet family history and recurrent aphthous
lesions in the family were present in one patient. All patients had
oral aphthous lesions and one patient had genital aphthous lesions.
Three patients presented with papilla edema. Pathergy test was
negative in all patients. Lumbar puncture was performed in three pa-
tients for diagnostic and therapeutic purposes. HLA B51 was
screened in two patients and both were positive. MRI revealed ven-
ous sinus thrombosis in three patients, optic nerve thickening was
observed in two patients and demyelination plaques were found in
one patient without thrombosis. ANA and ANCA tests were found as
negative, and thrombosis tests were normal in all patients. All pa-
tients were receiving azathioprine, there patients were using steroids
and low molecular weight heparin additionally. A patient with severe
apthous lesion was using colchicine, another patient was using
methotrexate and sulfasalazine due to sacoiliitis Adalimumab was
started to patient with unresponsive optic nerve compression and
sinus venous thrombosis. While three patients who had thrombosis
were followed in the remission clinically and radiologically, but the
patient with the parenchymal lesion did not reach to remission. Re-
mission was achieved following 8.6 months in average.
Conclusion: Neurological involvement of Behçet disease is rare in the
childhood. Neurological involvement is classified in two groups as
parenchymal involvement due to inflammatory meningo-encephalitis
process and non-parenchymal involvement due to vascular process.
While meningo-encephalitis is more common in adult patients, children
have cerebral venous thrombosis more commonly. In a study which
covers both adult and pediatric cases, thrombosis was reported 88.5%
of the pediatric cases, only three cases had parenchymal involvement.
Three of the four cases in our study also presented vascular involve-
ment. The same study reported the average diagnosis age as 13.0 for
Behçet disease, and 13.5 for NeuroBehçet disease. Our results are simi-
lar (average Neuro Behçet diagnosis age: 13.4 years) to this study.
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Introduction: IgA vasculitis could present rarely with hematemesis. In a
proportion of patients IgA vasculitis is preceeded by respiratory infection.
Objectives: A report of a 6 year old girl with IgA vasculitis (rash, arthritis,
gastrointestinal symptoms including hematemesis) is presented.
Methods: case report
Results: The girl presented with arthritis, and rash on extremities
with history of mild bronchitis. No fever, normal urine and stool werefound. Clinical examination revealed palpable purpura on
extremities, arthritis of wrists and insteps. Inflammatory markers were
elevated (CRP 49 mg/l, leucocytosis 15.6 x10to9/l, neutrophilia 74%,
thrombocytosis 493 x10to9/l), and borderline erythrocyturia was
present. Further urine tests were normal. Analgetics, rutin plus
vitamin C, and rest were recommended. Since the rash worsened,
and bullous morphs appeared on instep on day 6, the girl was
admitted to the clinic, and topical treatment using betamethasone
and gentamycine cream was recommended by dermatologist.
Serology revealed active Chlamydia sp. infection, thus clarithromycin
was added. Later, flebothrombois of right cephalic vein led to
initiation of anticoagulation therapy. Antiphospholipid antibodies
were negative. Furthermore, gastrointestinal symptoms appeared on
day 10, including abdominal pain and mild hematemesis (once).
Ultrasonography excluded intussusception, and prednison 1mg/kg/
day was prescribed. Her clinical status improved, and corticosteroid
detraction is performed at the time of abstract submission (day 34).
Conclusion: To our best knowledge, there are only few IgA vasculitis
cases with hematemesis described in literature. Chlamydia species are
frequent causes of respiratory infection. Here, this infection represented a
trigger of IgA vasculitis. The treatment using antibiotics and prednisone
led to early improvement of clinical status.
Parents agreed with presentation of patient´case, including
photodocumentation.
Grants: KB was supported by National Sustainability Programme
(LO1304).
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Introduction: Takayasu arteritis(TA) is a large vessels vasculitis
characterized by intramural granulomatous inflammation of the
pulmonary arteries, aorta and its major branches, leading to wall
thickening, stenosis, occlusion and thrombus formation(1). Relapsing
polychondritis(RP) is a rare disease characterized by recurrent flares
of destructive inflammation of cartilage. To date, only one case of a
pediatric patient with recurrent polychondritis and TA has been
reported in literature(2).
Objectives: To describe an atypical clinical presentation of TA.
Methods: Case report.
Results: We report the case of a 13-year-old caucasian girl who pre-
sented with stridor and respiratory distress at the age of 11. The
naso-pharyngo-laryngoscopy showed an isolated subglottic swelling.
Infectious researches were negative; no evidence for granulomatosis
with polyangiitis nor sarcoidosis was found. She was treated with a
one-month course of oral prednisone leading to complete resolution
and then a quick tapering of the steroid therapy, with no relapse
ever since.
After one uneventful year, she complained of low-grade intermittent
fever and transient erythematous rash, with no other symptom. Clin-
ical examination was normal. Blood tests showed a moderate inflam-
mation with elevated CRP, ESR and IgG as well as a slight
inflammatory anemia; otherwise complete blood count, blood smear,
Pediatric Rheumatology 2018, 16(Suppl 2):52 Page 242 of 243liver and renal functions and urinalysis were normal; auto-antibodies
were negative. Thoracic x-ray, pulmonary fonction, cardiac and ab-
dominal US and large infectious researches were negative. After 10
months of unchanged symptoms, she presented with arterial hyper-
tension and a pathologic Doppler on renal arteries. A thoraco-
abdominal CT-scan was performed showing wall thickening, stenosis
and enlargement of the descending thoracic and abdominal aorta,
renal and mesenteric arteries, the coeliac trunk and lobar and seg-
mental pulmonary arteries. The total body angio-MRI showed similar
findings, without involvement of cerebral and cervical arteries. The
diagnosis of TA was confirmed and a therapy with steroids, infliximab
and methotrexate was started on March 2018.
Conclusion: The diagnosis of TA can be very challenging in the
absence of specific symptoms, as in our patient. As an early diagnosis
can possibly reduce the risk of permanent vascular complications, TA
should be considered in the presence of persistent and unexplained
biologic inflammation, particularly in adolescent girls.
Regarding the subglottic swelling, its origin is not completely
understood, but a non-infectious chondritis seems to be the most
reasonable explanation. Even if our patient did not meet the criteria
for the RP, a possible association between the chondritis and TA
should be considered, as they could both be the consequence of a
unique dysimmune process.
Written informed consent obtained from the parents.
1)Aeschlimann et al. Arthritis Res Ther 2017;19:255.
2)Ghosn et al. J Am Acad Dermatol 2008;59:S84-7.
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Introduction: Kawasaki disease is one of the most frequent vasculitis
and the main cause of acquired heart disease in childhood; the cause is
still unknown and affects mainly children under 5 years old. Timely
treatment with intravenous immunoglobulin (IVIG) has succeeded in
decreasing the incidence of coronary aneurysms from 25% to
approximately 4%, with the risk of developing future thrombosis,
stenosis, myocardial ischemia or involution of aneurysms.
Objectives: Presentation of the case and treatment initiated in the
presence of giant coronary aneurysms as well as systemic aneurysms
in a 3-month-old girl.
Methods: Description of the clinical case of a patient outside the age
range for Kawasaki disease with formation of giant aneurysms of the
coronary arteries, iliac arteries and abdominal artery.
Results: We present the case of a female patient of 3 months of age,
with no relevant history, who comes to our institution for 16 days
with fever as well as irritability, treated with antipyretic and multiple
antibiotic schemes without clinical response.
At hospital admission, an approach was made to rule out an
infectious process, requesting an echocardiogram, which reported:
right coronary artery with a 6 x 11mm aneurysm (z 11.7) before the
bifurcation and right coronary artery with a 4 x 6mm saccular
aneurysm (z 10.2). Physical examination with fever, conjunctival non-
exudative erythema, cleft lip, generalized maculopapular rash andBCGitis, which integrates the definitive diagnosis. Subsequently, man-
agement was started with intravenous immunoglobulin 2 g/kg,
methylprednisolone bolus 30 mg/kg, acetyl salicylic acid 80 mg/kg
and enoxaparin 1 mg/kg/ per dose. The control echocardiogram re-
ported a decrease in the right coronary aneurysm, which was now
medium but an increase in the giant aneurysm of the left coronary
artery, added to the increase of inflammatory markers, we decided a
second dose of IVIG followed by 7 days with full dose of prednisone
(2 mg/kg).
Angiotomography was performed three days later reporting fusiform
aneurysms in the abdominal artery and common iliac arteries but
without fever and normalization of C-reactive protein (CRP), so de-
cided decrease of acetyl salicylic acid to 4 mg/kg, continue with
anticoagulation and hospital discharge.
Conclusion: The incidence of systemic aneurysms is not well
described with series that report between 0.6 to 2.5%, developing
giant aneurysms up to 10%, and an age range of 1 to 20 months
with an average of 6 months as the case of our patient. The sites
mainly affected are brachial artery, common iliac artery, internal iliac
artery, subclavian artery, axillary artery, lateral thoracic artery, femoral
artery, and renal artery. Informed consent to publish had been
obtained from the parent.
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Introduction:
Background: Granulomatosis with polyangiitis (GPA) or Wegener's
granulomatosis (WG) is a chronic systemic vasculitis involving
small to medium sized arteries characterized by granulomatous
inflammation of the upper and lower airways, necrotizing and
pauci-immune glomerulonephritis and vasculitis that affects many
other vital organs. Clinical manifestations are inflammation of
upper and lower respiratory tract and renal involvement.
Objectives: Patient is an 11-year-old boy complaining of fever, pain
and swelling of the ankles and ecchymotic skin lesions on the legs
and buttock, and purpuric lesions resembling erythema multiform on
the elbows and dorsal side of forearms.One day after admission, pe-
techiae presented on the surface of his mouth and patient had
hemoptysis for several times. Microscopic hematuria was detected in
urine analysis. The next day due to massive hemoptysis, evidence of
pulmonary hemorrhage in CT scan of the lungs and patient’s respira-
tory distress, he was candidate to be admitted in the ICU. According
to the presentation and physical examination of the patient and C-
ANCA titer which has been reported more than 300, the diagnosis of
AAV (Wegener) was made with Printo’s criteria.
Methods:
case report
Results: case report
Conclusion: This case was an 11-year-old boy presenting with pur-
puric rashes on the limbs and arthritis who has been diagnosed with
WG by the result of C-ANCA titer and ruling other diagnosis out such
as infectious diseases, immune disorders, neoplastic disorders, Anti
GBM disease, ANCA positive ulcerative colitis and other autoimmune
diseases. Patient has been treated with methylprednisolone pulse for
three days with 30mg/Kg/day dosage and after that cyclophospha-
mide pulse and 2mg/Kg/day of prednisolone as maintenance ther-
apy. Informed consent for publication had been obtained.
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Introduction: We present a 4 years old girl with prolonged fever
who was diagnosed as perforated appendicitis at the same time
with coronary artery dilation as a complication of Kawasaki
disorder
Objectives: Atypical presentations of the kawasaki disease can pose
a diagnostic dilemma. The prevalence of incomplete or atypical
disease that do not meet the classical presentation of the disease is
relatively high(13.8 percent in Japan). It is important to know other
significant, though not diagnostic, findings that raise a suspicion of
the disease in absence of the classical criteria.
Methods: Our patient is a 4 years old girl with no prior positive
medical history who presented to our emergency department with
prolonged fever and a febrile seizure on the first day of her
feve.Three days after the fever began she started having generalized
colicky abdominal pain .Her initial lab results showed a WBC count of
19500 per mm3 with 73% Neutrophils, a hemoglobin of 9.2 with
normal MCV and MCHC, normal platelet count and an elevated ESR
and CRP at 81 and 116 respectively. Serum Albumin and liver
function tests were normal.
Results: To diagnose the source of her prolonged fever an
echocardiogram and abdominal ultrasound was ordered.
Abdominal ultrasound showed a collection in the right lower
quadrant compatible with a diagnosis of perforated appendicitis.
Echocardiogram showed dilation of LAD with a Z score of 4(small
aneurysm).CT Angiography of abdominal aorta and femoral
arteries revealed no dilation or narrowing.
Conclusion: upto now just two cases similar to ours has been
previously described. Our case provides the third example of this
extremely rare presentation of the disease.In every person with
prolonged fever and abdominal pain vasculitides like kawasaki
disease must be ruled out. Informed consent to publish had been
obtained.
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Introduction: Kawasaki disease is an acute vasculitis characterized by
fever, bilateral non purulent conjunctivitis, erythema of the mouth,
rash and cervical lymphadenopathy. In 15 to 20% of untreated
children, ectasia or coronary artery aneurysms may develop. The most
difficult complications are ischemic heart disease and sudden death.
Objectives: The aim of this study is to describe clinical manifestations,
laboratory investigations, therapeutic approach, complications and
outcome in children with Kawasaki disease.
Methods: Medical records of all children with Kawasaki disease during 8
years period (between 2009 and 2017) at the Pediatric Clinic Banja
Luka were retrospectively reviewed. 20 children, 12 girls and 8 boys were
analyzed.
Results: The youngest child was 4 months old, and the oldest
child was 7 years old. The most common clinical manifestations were:
fever 20/20(100%), rush 15/20 (75%), conjunctivitis 12/20 (60%), lips
and buccal mucosa hyperaemia 13/20(65%), gastrointestinal 9/20(45%),
cervical lymphadenopathy 8/20 (40%) and renal involvement 8/20
(40%). In 8/20 ( 40%) of patients had coronary ivovement. Coronary
aneurysm occurred in 5/20( 25 %) of children. 15/20 (75% ) of
children had elevated parameters of inflammation. All 20 children
were treated with i.v. immunoglobulins (IG) with acetyl salicylic
acid. In 2 children, a second dose of IG and methylprednisolone
were administered. Two patients required administration of Anti-
TNF alpfa monoclonal antybodies-infliximab, given as a single dose,
with favourable outcome. During follow-up period 4 children ( 20%)
had persistent aneurysmal enlargement of the coronary arter-
ies. During the study period no death was recorded.
Conclusion: In eight children 8/20 (40%) who developed coronary
involvement , the therapy was started late, after the seventh day of the
onset of the disease. The most complicated patient was 4 months
old infant who received therapy at the latest from all patients (Day 13).
There was no significant difference in clinical manifestations, laboratory
results, therapeutic approach and outcome in children with Kawasaki
disease compared to other studies.
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